paclitaxel has been researched along with Breast Neoplasms in 4452 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 680 (15.27) | 18.2507 |
| 2000's | 1559 (35.02) | 29.6817 |
| 2010's | 1701 (38.21) | 24.3611 |
| 2020's | 512 (11.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bernacki, RJ; Bissery, MC; Bounaud, PY; Kuduk, SD; Michaud, E; Ojima, I; Pera, P; Slater, JC; Veith, JM; Vrignaud, P | 1 |
| Bernacki, RJ; Kuduk, SD; Ojima, I; Pera, P; Veith, JM | 1 |
| Deng, Y; Jiang, TY; Sheng, S; Snyder, JK; Tianasoa-Ramamonjy, M | 1 |
| Alaoui-Jamali, MA; Batist, G; Mamer, O; Sauriol, F; You, XL; Zamir, LO; Zhang, J | 1 |
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| Au, JL; Jang, SH; Wientjes, MG | 1 |
| Bernacki, RJ; Chibale, K; Geng, X; Haupt, H; Ojima, I; Pera, P | 1 |
| Bane, S; Chatterjee, SK; Kingston, DG; Liu, C; McCracken, M; Rahim-Bata, R; Schilling, JK; Strobl, JS | 1 |
| Bacherikov, VA; Chen, CH; Chou, TC; Dong, HJ; Lin, YW; Su, TL; Tsai, TJ | 1 |
| Avery, MA; Desai, PV; Feller, DR; Jones, DK; Mora, FD; Nagle, DG; Patny, A; Smillie, T; Zhou, YD | 1 |
| Aránega, A; Campos, JM; Conejo-García, A; Espinosa, A; Gallo, MA; Marchal, JA; Núñez, MC; Rodríguez-Serrano, F | 1 |
| Brodsky, JL; Chovatiya, RJ; Day, BW; Huryn, DM; Jameson, NE; Pipas, JM; Turner, DM; Werner, S; Wipf, P; Wright, CM; Zhu, G | 1 |
| Biggerstaff, J; Kabalka, G; Le Puil, M; Miao, W; Townsend, D; Wall, J; Yao, ML; Zeng, W | 1 |
| Bai, L; Curran, DP; Day, BW; Eiseman, JL; Jung, WH; Moura-Letts, G | 1 |
| Arya, KR; Bid, HK; Chaturvedi, JP; Chaudhary, P; Konwar, R; Narender, T; Nayak, VL; Reddy, KP | 1 |
| Chou, TC; Dong, H; Kakadiya, R; Kapuriya, K; Kapuriya, N; Lee, PC; Lee, TC; Shah, A; Su, TL; Zhang, X | 1 |
| Bastow, KF; Brossi, A; Dong, Y; Hsu, JL; Hung, MC; Lang, JY; Lee, EY; Lee, KH; Liu, YN; Morris-Natschke, SL; Nakagawa-Goto, K; Pai, HC; Pan, SL; Peng, CY; Shi, Q; Teng, CM; Wu, PC; Yu, D | 1 |
| Agrawal, SK; Rani, R; Roy, P; Saxena, AK; Singh, J; Sondhi, SM | 1 |
| Liu, G; Ma, Y; Zhao, N | 1 |
| Brown, ML; Dakshanamurthy, S; Deb, TB; Grindrod, SC; Paige, M; Yang, Y; Yenugonda, VM | 1 |
| Alaoui-Jamali, M; Bijian, K; Jiang, T; Li, G; Sun, X; Wan, S; Xu, B; Zhang, P | 1 |
| Chen, JW; Han, HY; Kuo, SC; Liao, WY; Liaw, CC; Lin, LH; Shen, CN; Wu, SH; Yang, YL | 1 |
| Huang, Y; Jin, HZ; Nag, S; Qin, JJ; Shan, L; Voruganti, S; Wang, W; Zhang, R; Zhang, SD; Zhang, WD | 1 |
| Chow, LM; Jiang, T; Wan, S; Wong, IL; Zhang, N; Zhang, Z | 1 |
| Madala, HR; Mikelis, C; Punganuru, SR; Samala, R; Srivenugopal, KS; Venugopal, SN | 1 |
| Chen, JP; Meng, CW; Peng, F; Xiong, L; Zhou, QM | 1 |
| Cichewicz, RH; Du, L; Mooberry, SL; Robles, AJ | 1 |
| Meegan, MJ; Nathwani, S; O'Boyle, NM; Twamley, B; Zisterer, DM | 1 |
| Al-Khdhairawi, AAQ; Chong, KW; Chung, FF; Kam, TS; Krishnan, P; Leong, CO; Lim, KH; Low, YY; Mai, CW; Yong, KT | 1 |
| Arun, A; Chourasia, MK; Karade, SS; Konwar, R; Patel, OPS; Saini, D; Singh, PK; Yadav, PP | 1 |
| Alpaugh, ML; Althufairi, BD; Chantarasriwong, O; Milcarek, AT; Morales, TH; Rezende, CO; Settle, AL; Theodoraki, MA; Theodorakis, EA | 1 |
| Barbarossa, A; Caruso, A; Ceramella, J; Dallemagne, P; El-Kashef, H; Grande, F; Iacopetta, D; Occhiuzzi, MA; Rault, S; Rizzuti, B; Saturnino, C; Sinicropi, MS | 1 |
| Jana, K; Manna, T; Misra, AK; Pal, K | 1 |
| Albadari, N; Chen, H; Deng, S; Kumar, G; Li, W; Ma, D; Miller, DD; Wang, Y; White, SW | 1 |
| Dubrovskyi, O; Dye, K; Gutgesell, LM; Huang, F; Li, Y; Ratia, K; Shen, Z; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Chang, TT; Chen, CL; Chen, WS; Fu, CW; Hsiao, PW; Li, WS; Tsai, HE | 1 |
| Arya, GC; Jaitak, V; Kaur, K | 1 |
| Faull, KF; Janzen, C; Kawahara, B; Mascharak, PK | 1 |
| Chanda, D; Das, S; Dwivedi, A; Gautam, Y; Iqbal, H; Khan, F; Khan, H; Khan, S; Konwar, R; Negi, AS; Pathak, N; Raghuvanshi, DS; Shanker, K; Sirohi, VK; Yadav, P | 1 |
| Ahmed, U; Anwar, A; Eugin Simon, S; Khan, KM; Saad, SM; Tan, EW; Tan, KO | 1 |
| Ahmed, MS; Al-Enazy, S; Albekairi, NA; Ali, S; Nanovskaya, TN; Patrikeeva, S; Rytting, E; Shah, M | 1 |
| Han, X; Lu, C; Qiao, P; Ren, C; Sun, Y; Yang, T; Yu, Z | 1 |
| Amaya, C; Baigorri, J; Baucells, R; Luo, S; Smith, ER; Xu, XX | 1 |
| Barroso-Sousa, R; Block, C; Briccetti, F; Burstein, H; Constantine, M; Di Meglio, A; Faggen, M; Hassett, MJ; Hu, J; Leone, JP; Li, T; Lin, NU; Milisits, L; Partridge, A; Rees, R; Sinclair, N; Tayob, N; Tolaney, SM; Trippa, L; Vaz-Luis, I; Waks, AG; Winer, EP | 1 |
| Ban, M; Belac Lovasić, I; Boraska Jelavić, T; Curić, Z; Podrug, M; Vrdoljak, E | 1 |
| Hamid, SBS; Kaus, NHM; Noor, NS; Szewczuk, MR | 1 |
| Bugni, TS; Burkard, ME; Chappell, RJ; Correia-Staudt, K; Esbona, K; Fitzgerald, J; Fowler, AM; Laffin, JJ; Lager, AM; Lasek, A; McGregor, SM; Molini, R; O'Regan, R; Scribano, CM; Tevaarwerk, AJ; Tucker, JB; Wan, J; Weaver, BA; Wisinski, KB; Zasadil, LM; Zhou, AS | 1 |
| Atrafi, F; Boix, O; Bruns, I; Chawla, SP; Diamond, JR; Eder, JP; Genvresse, I; Gutierrez, M; Langer, S; Lolkema, MP; LoRusso, PM; Mathijssen, RHJ; Rajagopalan, P; Sankhala, K; Subbiah, V; Tolcher, AW; Verweij, J | 1 |
| Delaloge, S; Ezzalfani, M; Filleron, T; Pérol, D; Porcher, R; Robain, M; Savignoni, A | 1 |
| Dai, H; Fu, C; Han, X; Liu, Y; Pan, Y; Wang, H; Wang, HQ; Yang, W | 1 |
| Ghazanfari, L; Kabanov, AV; Master, A; Seo, Y; Sokolsky-Papkov, M; Vishwasrao, HM; Wan, X | 1 |
| Alsherbiny, MA; Bhuyan, DJ; Chang, D; Li, CG; Low, MN | 1 |
| Babal, P; Bohac, M; Burikova, M; Cihova, M; Danisovic, L; Drahosova, S; Janega, P; Krivosikova, L; Kucerova, L; Miklikova, S; Plava, J; Rojikova, L; Smolkova, B; Trnkova, L | 1 |
| Cui, Y; Fu, S; Leng, Q; Li, Y; Lu, Y; Wang, B; Wu, Z; Xiong, K; Zhao, L; Zhou, P | 1 |
| Argyriou, AA; Bruna, J; Cavaletti, G; Ferrari, S; Kalofonos, HP; Kalofonou, F; Karteri, S; Mariotto, S; Simo, M; Velissaris, D | 1 |
| Cheng, G; Li, J; Liu, S; Lv, H; Zhang, R | 1 |
| Chablani, L; Gupta, U; Jeswani, G; Nakhate, KT; Sahoo, RK | 1 |
| Gok Metin, Z; Gokce Ceylan, G | 1 |
| Barenholz-Cohen, T; Cooper, TJ; Devarasetty, M; Haj-Shomaly, J; Hasson, P; Levi-Galibov, O; Raviv, Z; Scherz-Shouval, R; Shaked, Y; Soker, S; Timaner, M; Vorontsova, A; Weihs, D | 1 |
| Ligtenberg, M; Steegers, M; van den Heuvel, S; van Haren, F; Vissers, K | 1 |
| Fu, J; Huang, T; Lin, L; Tang, L; Wang, H | 1 |
| Adetunji, CO; Ayatollahi, SA; Butnariu, M; Calina, D; Choudhary, MI; Cruz-Martins, N; Das, G; Daştan, SD; Ekiert, H; Grozea, I; Klimek-Szczykutowicz, M; Kobarfard, F; Michael, OS; Muntean, AC; Panda, MK; Patra, JK; Polito, L; Quispe, C; Sharifi-Rad, J; Singh, YD; Sytar, O; Szopa, A; Tynybekov, B; Živković, J | 1 |
| Cao, J; Gong, C; Hu, S; Hu, X; Li, T; Li, Y; Tao, Z; Wang, B; Wang, L; Xie, Y; Zhang, J; Zhao, Y | 1 |
| Ikeda, M; Morita, S; Nakamoto, S; Ohtani, S; Watanabe, J | 1 |
| Ak, R; Aksoy, S; Aktas, BY; Bas, O; Diker, O; Dizdar, O; Guven, DC; Kertmen, N; Koylu, B; Oksuzoglu, B; Olgun, P; Taban, H | 1 |
| Amini, M; Asl, ER; Azarbarzin, S; Baghbani, E; Baghbanzadeh, A; Baradaran, B; Dastmalchi, N; Khojasteh, SMB; Lotfinejad, P; Safaralizadeh, R; Shadbad, MA | 1 |
| Ait-Oudhia, S; Vaidya, TR | 1 |
| Morita, A; Nohara, Y; Ono, S; Sato, T; Takagi, S; Tanaka, M; Yamashita, S; Yoshinaga, Y | 1 |
| Chiu, CC; Hou, MF; Hsieh, TH; Hsu, CY; Kan, JY; Liang, SS; Ou-Yang, F; Tsai, EM; Wang, TN; Yang, PJ | 1 |
| Feng, G; Guo, Q; Hao, YN; Liu, H; Liu, J; Liu, Y; Sun, X; Yang, L; Zhang, CG; Zhao, CC | 1 |
| Barrios, C; Bondarenko, I; Dent, RA; Hinton, H; Isakoff, SJ; Kim, SB; Kovic, B; Lian, Q; Mani, A; Nowecki, Z; O'Shaughnessy, J; Oliveira, M; Reilly, SJ; Saji, S; Turner, N; Wongchenko, MJ | 1 |
| Arun, BK; Ayoub, JP; Bach, BA; Bhattacharya, S; Diéras, V; Feng, D; Friedlander, M; Han, HS; Kaufman, B; Khandelwal, N; Kundu, MG; Maag, D; Puhalla, SL; Ratajczak, CK; Wildiers, H | 1 |
| Adámková Krákorová, D; Demlová, R; Halámková, J | 1 |
| Abd-Alhaseeb, MM; Mahmoud, MA; Okda, TM; Omran, GA | 1 |
| Chen, B; Guo, J; Jiang, J; Li, D; Li, Y; Sui, Y; Xu, H | 1 |
| Chen, D; Chen, Q; Guo, C; Guo, H; Kong, M; Su, Y; Wang, B | 1 |
| Dong, J; Sun, M; Zhang, F; Zhou, Z; Zhu, C | 1 |
| He, F; Li, G; Li, Q; Liu, J; Shen, X; Wang, Z | 1 |
| Asano, H; Hiramoto, S; Kawabata, A; Miyamoto, T; Takegami, M | 1 |
| Bellon, JR; Burstein, HJ; Dang, CT; DeMeo, M; Isakoff, SJ; Krop, IE; Partridge, AH; Tayob, N; Tolaney, SM; Tralins, J; Winer, EP; Yang, DD | 1 |
| Hanamura, N; Ishitobi, M; Kashikura, Y; Kozuka, Y; Mizuno, T; Noro, A; Ogawa, T; Saito, K; Yamashita, M | 1 |
| Adhav, R; An, T; Chan, UI; Deng, CX; Lei, JH; Li, J; Liu, J; Miao, K; Mo, L; Shu, X; Su, SM; Wang, Y; Xu, J; Xu, X; Zhang, X | 1 |
| Di, S; Fu, JJ; Gong, J; Gong, L; Lin, Z; Lu, D; Ma, Q; Wang, Y; Xiao, S; Zhang, L; Zhang, Q; Zhu, C | 1 |
| Ballman, K; Bellon, JR; Campbell, JD; Carey, LA; Collyar, D; Fan, C; Fernandez-Martinez, A; Golshan, M; Hahn, OM; Hoadley, KA; Hu, Z; Hudis, CA; Hyslop, T; Kuzma, C; Li, Y; Ma, C; Mamounas, E; Parker, JS; Partridge, A; Perou, CM; Polley, MC; Port, ER; Selitsky, S; Shepherd, JH; Sikov, WM; Singh, B; Soloway, MG; Somlo, G; Spears, PA; Tolaney, SM; Winer, EP | 1 |
| Jue, MY; Nisar, T; Shah, D; Stiles, A | 1 |
| Chen, S; Hu, X; Li, Y; Liang, L; Peng, H; Wang, B; Xu, Y; Zhao, Y | 1 |
| Chen, L; Derstine, BA; Griggs, JJ; Hayes, DF; Henry, NL; Hertz, DL; Pai, MP; Su, GL; Wang, SC | 1 |
| Li, Y; Liu, M; Zhang, C; Zhang, Q | 1 |
| Alexandri, C; Demeestere, I; Lambertini, M; Ntemou, E; Van den Steen, G; Vidal, PD | 1 |
| Adelaïde, J; Bertucci, F; Carbuccia, N; Chaffanet, M; Dalenc, F; Garnier, S; Goncalves, A; Guille, A; Isambert, N; Levy, C; Mamessier, E; Pakradouni, J; Robert, M; Sabatier, R; Sfumato, P; Vicier, C | 1 |
| Harbeck, N | 1 |
| Jin, J; Liang, M; Wang, M; Zhu, B | 1 |
| Chen, T; He, Y; Lu, H; Pang, Z; Wang, Y | 1 |
| Candiani, M; Cioffi, R; Gentilini, O; Girardelli, S; Mangili, G; Mauro, F; Peccatori, FA; Rabaiotti, E; Valsecchi, L; Zucchinelli, P | 1 |
| Chandrasekhar, V; Kalachaveedu, M; Kalluru, H; Kondaveeti, SS; Mallayasamy, SR | 1 |
| Chee, CE; Goh, BC; Lee, MX; Lee, SC; Lim, JSJ; Lim, SE; Ow, S; Soo, RA; Sundar, R; Tan, DSP; Wang, L; Wong, ALA; Yong, WP | 1 |
| Chen, Y; Fang, Y; Li, X; Liang, W; Shi, J; Tang, C; Wang, H; Xiao, H; Xu, J; Zhu, X | 1 |
| Amorim, I; Duarte, D; Rêma, A; Vale, N | 1 |
| Chen, N; Hou, X; Kang, C; Li, L; Li, X; Yang, S; Yi, K; Yuan, X; Zhan, Q; Zhao, J | 1 |
| Becherini, C; Calosi, L; Ciccone, LP; Desideri, I; Francolini, G; Livi, L; Loi, M; Mangoni, M; Meattini, I; Salvatore, G; Salvestrini, V; Sottili, M; Stocchi, G | 1 |
| Ali, J; Fahad, MS; Ikram, S; Malik, I; Rahat, A; Sajjad, M; Siddiqui, N | 1 |
| Badmasti, F; Beram, FM; Hejabi, F; Kazempour, R; Larijani, SF; Mirzaie, A; Pourmoghadasiyan, B; Rahimi, S; Sedaghatnia, K; Tavakkoli, F | 1 |
| Antary, TMA; Duraisamy, V; Li, J; Qian, Y; Sun, Y; Wang, L; Wang, Z | 1 |
| Guo, N; Jia, L; Li, H; Li, M; Li, S; Li, X; Li, Y; Ma, W; Su, W; Wu, J; Xie, Y; Yang, G; Yu, P | 1 |
| Cai, ZW; He, LY; Liang, L; Liu, SY; Luo, J; Lv, ML; Sun, WL | 1 |
| Huang, X; Ni, J; Xi, X; Yang, F; Yuan, H | 1 |
| Chen, L; Xu, Y; Ye, X | 1 |
| Cao, X; Guan, J; Lin, Y; Mao, F; Pan, B; Peng, L; Shen, S; Sun, Q; Wang, C; Wang, X; Xu, C; Xu, Y; Yao, R; Zhang, X; Zhang, Y; Zhong, Y; Zhou, X; Zhou, Y | 1 |
| Okines, A; Turner, N | 1 |
| Badau, LM; Ciocoiu, AD; Gheju, A; Oprean, CM; Segarceanu, NA; Vlaicu, B | 1 |
| Bui, QA; Huynh, PD; Nguyen, DT; Nguyen, NT; Nguyen, QH; Tran, NQ; Viet, NT | 1 |
| Bai, Y; Blenman, KRM; Denkert, C; Foldi, J; Gunasekharan, V; Ibrahim, EY; Karn, T; Li, X; Loibl, S; Marczyk, M; Park, T; Pusztai, L; Qing, T; Reisenbichler, E; Rimm, DL; Rozenblit, M; Silber, A; Sinn, BV; Wolf, DM; Yaghoobi, V | 1 |
| Alberti, P; Alemany, M; Argyriou, AA; Bruna, J; Cavaletti, G; Dinoto, A; Ferrari, S; Kalofonos, HP; Kalofonou, F; Karteri, S; Mariotto, S; Stradella, A; Velasco, R; Velissaris, D | 1 |
| Chen, R; He, J; Huang, X; Li, C; Shi, W; Shi, X; Wan, X; Wang, J; Wang, Y; Xu, H; Xu, Y; Zha, X; Zhang, W | 1 |
| Andrikopoulou, A; Chatzinikolaou, S; Dimopoulos, MA; Kaparelou, M; Liontos, M; Panourgias, E; Zagouri, F | 1 |
| Eckert, D; Joshi, R; Menon, R; Mensing, S; Nuthalapati, S; Ratajczak, CK; Stodtmann, S; Xiong, H | 1 |
| Fujisawa, T; Hasegawa, Y; Ishida, T; Iwata, H; Kashiwaba, M; Kikawa, Y; Kitada, M; Masuda, N; Morita, S; Nakamura, R; Ohno, S; Ohtake, T; Saji, S; Taira, N; Takada, M; Takano, T; Toh, U; Toi, M; Toyama, T; Yamamoto, Y | 1 |
| Augustin, D; Braun, M; Christgen, M; Fischer, HH; Forstbauer, H; Gluz, O; Graeser, M; Grischke, EM; Harbeck, N; Kates, R; Krauss, K; Kreipe, HH; Kuemmel, S; Nitz, U; Pelz, E; Potenberg, J; Reimer, T; Schumacher, C; Stefek, A; Wuerstlein, R; Zu Eulenburg, C | 1 |
| Czerwonka, A; Luszczki, J; Okon, E; Stepulak, A; Wawruszak, A | 1 |
| He, J; He, Q; Li, J; Li, M; Long, Y; Qiu, Y; Ren, K; Wang, X; Xu, Z; Yang, Y; Zang, S; Zhang, Z | 1 |
| Agassi, R; Ariad, S; Bayme, M; Belochitski, O; Delgado, B; Dredze, LM; Dyomin, V; Friger, M; Geffen, DB; Koretz, M; Libson, S; Mizrahi, T; Rosenthal, M; Shaco-Levy, R; Tokar, M | 1 |
| Chawla, SP; Dewnani, K; Goldfarb, SB; Iacobucci, M; Lacouture, ME; Lang, JE; Markova, A | 1 |
| Fan, R; Li, J; Song, S; Sun, W; Tian, Y; Wang, R; Zhang, H; Zhang, T; Zheng, A | 1 |
| Fu, L; Gu, F; Guo, X; Li, S; Li, W; Qian, X; Wang, S; Zhang, X | 1 |
| Deursen, MAGDH; Gelderblom, H; Houtsma, D; Kaptein, AA; Kroep, JR; Lugtenberg, RT; Mosch, L; Smorenburg, CH; van den Hurk, CJG | 1 |
| Bugada, L; Gao, W; Hu, H; Li, C; Li, R; Rajanayake, KK; Song, Y; Sun, D; Truchan, NA; Wen, F; Yuan, H; Zhang, L | 1 |
| Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A | 1 |
| Holotiuk, IS; Holotiuk, SI; Holotiuk, VV; Kryzhanivska, AY; Maliborska, SV | 2 |
| Ahmed, AU; Amidei, C; Arrieta, VA; Castro, B; Chang, CL; Chen, L; Cordero, A; Dmello, C; Gould, A; Győrffy, B; Horbinski, C; Hsu, P; Kang, SJ; Kanojia, D; Lesniak, MS; Sonabend, A; Sonabend, AM; Stupp, R; Winter, J; Zhang, DY; Zhang, J | 1 |
| Baczyńska, D; Kasperkiewicz-Wasilewska, P; Kulbacka, J; Rembiałkowska, N; Saczko, J; Sauer, N; Szewczyk, A; Szlasa, W; Wala, K | 1 |
| Maravajjala, KS; Roy, A; Swetha, KL | 1 |
| Blohmer, JU; Denkert, C; Engels, K; Fasching, PA; Hanusch, C; Huober, J; Jackisch, C; Just, M; Link, T; Loibl, S; Nekljudova, V; Reinisch, M; Rhiem, K; Schneeweiss, A; Seiler, S; Seither, F; Solbach, C; Stötzer, O; Thill, M; Untch, M; Wimberger, P | 1 |
| Ghosh, C; Pal, K; Roy, P; Singh, S | 1 |
| Ding, L; Li, C; Xu, Y; Zhang, Y | 1 |
| Akingbesote, ND; Foldi, J; Halberstam, AA; Lustberg, MB; Norman, A; Perry, RJ; Zhang, X; Zhu, W | 1 |
| Elshafiey, RA; Elzawawy, S; Ghoneim, A; Mostafa, TM; Werida, RH | 1 |
| Elancheran, R; Maruthanila, VL; Mirunalini, S | 1 |
| Lu, X; Lv, H; Yang, P; Zhang, Z | 1 |
| Ding, Z; Fan, Z; Guan, Q; Han, J; Li, Y; Liu, M; Liu, S; Wang, Q; Wang, Z; Zhang, H; Zhao, Y | 1 |
| Liu, X; Lv, H; Shen, H | 1 |
| Ariyanto, EF; Atmaja, H; Aulia, Y; Bashari, MH; Fadhil, M; Indrati, AR; Putri, T; Qomarilla, N; Rohmawaty, E; Sari, AK; Sudji, IR | 1 |
| Cao, X; Chen, T; Wang, X; Wu, Y | 1 |
| Mellerick, A; Nicolae, R; Siderov, J; Uccellini, A; Wong, V; Yeo, B | 1 |
| Dupré, DJ; O'Leary, LF; Tomko, AM; Whynot, EG | 1 |
| Futamura, M; Iwasa, T; Kawabata, H; Kitano, S; Masuda, N; Matsumoto, K; Minami, H; Mukohara, T; Ozaki, Y; Takahashi, M; Takano, T; Tanabe, Y; Tsurutani, J; Yoshimura, K | 1 |
| Huang, Q; Li, J; Li, L; Liu, D; Wang, Q; Wu, H; Ye, M; Yu, Z; Zeng, J; Zhang, J | 1 |
| Chang, S; Chen, SJ; Chen, ST; Dai, MS; Huang, CS; Kuo, SH; Lee, YH; Lin, PH; Liu, LC; Lo, C; Tan, KT; Tseng, LM; Wang, MY; Yeh, DC | 1 |
| Chen, CS; Henry, NL; Hertz, DL; Smith, EML; Stringer, KA | 1 |
| Cao, S; Dong, P; Hu, J; Huang, X; Li, X; Liu, J; Lv, H; Shi, Y; Wang, D; Wang, Q; Wang, S; Xie, L; Yang, H | 1 |
| Al Shareef, ZM; Al-Humaidi, RB; Fayed, B; Haider, M; Jagal, J; Jayakumar, MN; Noreddin, A; Omar, HA; Semreen, MH; Shakartalla, SB; Sharif, SI; Soliman, SSM | 1 |
| Fukuma, Y; Jo, A; Kawano, S; Kishino, E; Koike, Y; Kurebayashi, J; Mikami, T; Nomura, T; Ogata, R; Saito, W; Soda, M; Tanaka, K; Yamamoto, Y | 1 |
| Huang, P; Jiang, S; Lin, J; Zhang, Y | 1 |
| Ishikawa, T; Kanbayashi, Y; Katoh, N; Sakaguchi, K; Tabuchi, Y; Taguchi, T; Takagi, R; Takayama, K; Yokota, I | 1 |
| Martín Del Valle, EM; Nieto, C; Pérez-Esteban, P; Rodríguez, V; Vega, MA | 1 |
| Antonio-Aguirre, B; Armenta-Quiroga, AS; Catalán, R; Espinosa-Fernandez, JR; Estrada-Mena, FJ; Freyria, A; Guijosa, A; Ortega-Treviño, MF; Perez-Ortiz, AC; Villarreal-Garza, C | 1 |
| Czerwonka, A; Luszczki, J; Okon, E; Telejko, I; Wawruszak, A | 1 |
| Chen, K; Sun, L; Zhang, Y; Zhou, Y | 1 |
| Adrada, BE; Boge, M; Candelaria, RP; Elshafeey, N; Huo, L; Jarrett, AM; Litton, JK; Ma, J; Mohamed, RMM; Rauch, GM; Son, JB; Tripathy, D; Valero, V; White, JB; Wu, C; Yam, C; Yankeelov, TE; Zhou, Z | 1 |
| Khajah, MA; Khushaish, S; Luqmani, YA | 1 |
| Gao, C; Li, J; Liu, L; Liu, Y; Yang, C; Zhang, G; Zhang, S; Zhang, Y | 1 |
| Chen, R; Fan, L; Lei, L; Wang, X; Zheng, W | 1 |
| Bentley, R; Cheng, C; Guo, X; Li, N; Liang, M; Liang, Q; Lowe, S; Song, Q; Su, W; Sun, C; Wang, H; Zhou, Q; Zhou, Z; Zhu, Y | 1 |
| Chakrabarti, P; Dehghani, M; Gholamzadeh, MJ; Kamali, AM; Mousavi, SZ; Nami, M; Owrangi, M; Vasaghi Gharamaleki, M | 1 |
| Etminan, M; Maberley, D; Mikelberg, F; Sodhi, M; Yeung, SN | 1 |
| Chen, CY; Pai, HC; Yang, TT | 1 |
| Beijnen, JH; Huitema, ADR; Lin, L; Soesan, M; van Balen, DEM | 1 |
| Hu, W; Li, L; Song, M | 1 |
| Golalipour, M; Hashemi, M | 1 |
| Cao, H; Dang, C; Feng, P; Hou, P; Liu, Z; Meng, D; Wang, J; Wang, N; Wu, S; Xia, P | 1 |
| Drier, SW; Ekwueme, DU; Fairley, TL; Gogate, A; Reeder-Hayes, KE; Rocque, GB; Rotter, J; Trogdon, JG; Wheeler, SB | 1 |
| Aktas, B; Büdi, L; Gluz, O; Klare, P; Magdolna, D; Mangel, L; Morita, S; Müller, V; Ohno, S; Pikó, B; Schneeweiss, A; Toi, M; Yamamoto, Y; Yamashiro, H | 1 |
| Bagchi, A; Banerjee, A; Bhattacharya, A; Biswas, A; Chatterji, U; Mukherjee, P; Roy, H | 1 |
| Ding, M; Guo, K; Liu, Y; Shubhra, QTH; Tang, Z; Wang, Z; Xiao, N; Zhang, B; Zhang, C | 1 |
| Argyriou, AA; Bruna, J; Ferrari, S; Hernández, J; Marco, C; Mariotto, S; Pernas, S; Stradella, A; Velasco, R | 1 |
| Chen, M; Ge, X; Liu, J; Ma, Q; Tang, Y; Wen, Q; Zhang, L; Zhao, M; Zhu, L | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kohno, N; Kubota, T; Miura, D; Miyashita, M; Narui, K; Suzuki, M; Tachibana, A; Yamada, A; Yamada, K | 1 |
| Bödecker, J; Follo, M; Lerner, B; Mertelsmann, R; Pattarone, G; Peñaherera, A; Perez, M; Pilz, J; Rosero, G | 1 |
| Behroozaghdam, M; Bishayee, A; De Greef, D; Dehghani, M; Hasani Sadi, F; Hashemi, M; Javanshir, S; Kamali, D; Mirzaei, S; Rashidi, M; Tabari, T; Zabolian, A; Zarepour, A; Zarrabi, A | 1 |
| Aruga, T; Koibuchi, Y; Kosaka, Y; Masuda, N; Osaki, A; Saeki, T; Suzuki, R; Takano, T; Watanabe, J; Yamashita, T | 1 |
| Atlı Şekeroğlu, Z; Aydın, B; Kontaş Yedier, S; Şekeroğlu, V | 1 |
| Fan, Z; Jin, C; Jin, Y; Li, L; Li, S; Liu, C; Miao, QR; Zhang, X; Zhao, B | 1 |
| Arani, HZ; Entezari, M; Fallah, S; Ghorbani, A; Hashemi, M; Heidari, H; Hushmandi, K; Kakavand, A; Khaledabadi, M; Orouei, S; Saebfar, H; Salimimoghadam, S; Taheriazam, A; Tavakolpournegari, A | 1 |
| Dilawari, A; Graham, D; Isaacs, C; Kurian, S; Lynce, F; Mainor, C; McNamara, D; Mohebtash, M; Ottaviano, Y; Pohlmann, PR; Rao, S; Swain, SM; Swanson, N; Tan, M; Warren, R; Wu, T | 1 |
| Accetta, C; Carbognin, L; D'Angelo, T; Di Giorgio, D; Di Leone, A; Fabi, A; Franceschini, G; Fuso, P; Garganese, G; Giannarelli, D; Magno, S; Masetti, R; Muratore, M; Paris, I; Pavese, F; Sanchez, AM; Scambia, G; Terribile, DA; Tiberi, G | 1 |
| Duarte, D; Nunes, M; Ricardo, S; Vale, N | 1 |
| Barette, C; Bouazza, L; Daunizeau, T; Houssin, A; Ichim, G; Peyruchaud, O; Ribeiro, J; Saier, L | 1 |
| Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Song, G; Sun, X; Teng, Y; Xu, B; Yan, X; Zhai, J; Zhao, F; Zhao, J | 1 |
| Ludmir, EB; McCaw, ZR; Wei, LJ | 1 |
| Alečković, M; Almendro, V; Clement, K; Egri, SB; Fassl, A; Frank, DA; Geck, RC; Harper, NW; Jaffe, JD; Jovanović, B; Kingston, NL; Li, Z; Long, HW; Meissner, A; Michor, F; Overmoyer, BA; Papanastasiou, M; Park, SY; Peluffo, G; Polyak, K; Pyke, AL; Qiu, X; Salas, J; Seehawer, M; Shu, S; Sicinski, P; Stevens, LE; Temko, D; Toker, A; Trinh, A; Walker, S; Wilde, CM; Zhou, N | 1 |
| Hamada-Nishimoto, M; Kang, Y; Katayama, T; Tsuyuki, S | 1 |
| Alba, E; Antolin, S; Barnadas, A; Bonfill, X; Lluch, A; Martin, M; Rodriguez-Lescure, A; Ruiz-Borrego, M; Sanchez-Rovira, P; Servitja, S; Sola, I; Urrutia, G; Vazquez, JC | 1 |
| Dong, Q; Du, F; Gao, L; Huo, X; Li, Z; Liu, Z; Ren, D; Shen, G; Wang, M; Xie, Q; Xin, Y; Zhao, F; Zhao, J; Zhao, Y | 1 |
| Augustin, D; Biehl, C; Braun, M; Christgen, M; Feuerhake, F; Fischer, HH; Forstbauer, H; Gluz, O; Graeser, M; Grischke, EM; Harbeck, N; Kates, R; Kolberg-Liedtke, C; Krauss, K; Kreipe, HH; Kuemmel, S; Ni, H; Nitz, U; Palatty, J; Pelz, E; Potenberg, J; Reimer, T; Schumacher, C; Stefek, A; Ulbrich-Gebauer, D; Wuerstlein, R; Zu Eulenburg, C | 1 |
| Apala, JV; Bueno, MJ; Caleiras, E; Calvo, I; Cejalvo, JM; Colomer, R; Cortes, J; Fustero-Torre, C; Garcia-Saenz, JA; Gil-Gil, M; Gómez-López, G; Gonzalez-Cortijo, L; Lluch, A; Malats, N; Malumbres, M; Manso, L; Martinez, M; Martinez-Janez, N; Megias, D; Moreno, A; Mouron, S; Muñoz, J; Murillo, R; Quintela-Fandino, M; Sabroso-Lasa, S; Sánchez-Bayona, R; Ximénez-Embún, P | 1 |
| Chablani, L; Gupta, U; Jeswani, G; Nakhate, KT; Sahoo, RK; Taksande, AG | 1 |
| Caner, A; Cumaoğlu, A; Önal, MG; Sezer, G | 1 |
| Ge, L; Li, C; Li, S; Liu, L; Sheng, R; Tan, X; Zhang, Q; Zhang, Y | 1 |
| Cui, Y; Frankel, PH; Kruper, L; Lavasani, SM; Martinez, N; Mortimer, J; Murga, M; Ruel, C; Schmolze, D; Somlo, G; Tang, A; Tumyan, L; Waisman, JR; Yeon, C; Yost, SE; Yuan, Y | 1 |
| Dong, S; He, Z; Li, L; Li, S; Li, SD; Lin, G; Liu, H; Liu, Y; Meng, F; Qiu, S; Wang, Y; Wang, Z; Ye, J; Yu, J; Zhang, C; Zhou, S | 1 |
| Abdullah, MI; Abed, MN; Ibrahim, SL; Mohamed, G; Price, JC; Richardson, A | 1 |
| Cheng, C; Mao, L; Shi, X; Shi, Y; Tao, S; Wang, J; Wang, W; Yang, Q; Zhang, S | 1 |
| Cheng, Y; Jiang, T; Lan, H; Li, Y; Sun, X; Wan, X | 1 |
| Ao, X; Cui, L; He, ZM; Jiang, M; Jin, H; Li, HS; Liang, HL; Qiu, N; Xia, HM; Zhan, YT; Zhou, J | 1 |
| Cao, M; Li, H; Lv, Z; Ma, F; Mo, H; Pan, B; Sun, X; Xu, B; Zhai, J; Zhao, F; Zhao, J | 1 |
| Fang, C; Feng, J; Gong, T; Li, J; Tan, Y; Wu, Q; Xiang, L; Zhou, X | 1 |
| Ballman, KV; Brasó-Maristany, F; Campbell, JD; Carey, LA; Chic, N; Cortés, J; Fernandez-Martinez, A; Hoadley, KA; Krop, I; Llombart-Cussac, A; Nuciforo, P; Pare, L; Partridge, A; Pascual, T; Perou, CM; Prat, A; Rashid, NU; Singh, B; Spears, PA | 1 |
| Asano, Y; Futamura, M; Hosono, Y; Ikawa, A; Ishihara, K; Katagiri, Y; Kawaguchi, Y; Kawajiri, M; Kitazawa, M; Kumazawa, I; Kuno, M; Matsuhasih, N; Mori, R; Morikawa, A; Mushika, Y; Nagao, Y; Nakada, T; Nakakami, A; Niwa, Y; Ogiso, A; Shimokawa, T; Takeuchi, M; Tokumaru, Y | 1 |
| Anderson, RA; Arecco, L; Ballestrero, A; Bruzzone, M; Cameron, DA; Ceppi, M; de Azambuja, E; Del Mastro, L; Demeestere, I; Di Cosimo, S; El-Abed, S; Franzoi, MA; Lambertini, M; Latocca, MM; Lecocq, C; Massarotti, C; Nuciforo, P; Partridge, AH; Peccatori, FA; Piccart, M; Pistilli, B; Pusztai, L; Rolyance, R; Ruddy, KJ; Saura, C; Sohn, J; Untch, M; Wang, Y | 1 |
| Cólus, IMS; da Rocha, CQ; Okuyama, NCM; Pereira, ÉR; Ribeiro, DL; Serpeloni, JM | 1 |
| Asano, Y; Goto, W; Iimori, N; Kashiwagi, S; Kouhashi, R; Maeda, K; Morisaki, T; Ogisawa, K; Shibutani, M; Takada, K; Tanaka, H; Tauchi, Y; Yabumoto, A | 1 |
| Bao, X; Gao, Y; Li, Y; Lu, GL; Wen, J; Wu, Y; Xie, H; Zhang, Z | 1 |
| Abadi, PG; Banihashem, S; Bybordi, S; Faraji Dizaji, B; Farrokh-Eslamlou, N; Hasanbegloo, K; Irani, M; Jazi, FS | 1 |
| Chen, C; Mao, H; Mao, L; Pang, S; Pei, W; Shi, X; Shi, Y; Tao, S; Wang, J; Wang, W; Wei, K; Wei, X; Wu, Y; Yang, Q; Zhang, S; Zhu, H | 1 |
| Du, X; Feng, Z; Huang, P; Peng, Y; Song, X; Wang, W; Xing, J; Yu, S | 1 |
| Aghabozorgi, R; Babaee, M; Hashemi, M; Hesam, M; Rayegani, SM; Zahed, G | 1 |
| Hata, T; Hiraki, M; Hori, A; Ikeshima, R; Katsuyama, S; Kikumori, K; Masuzawa, T; Mitsuyoshi, A; Murata, K; Ohmura, Y; Oshima, K; Shinke, G; Sugimura, K; Takeda, Y; Yanagawa, T | 2 |
| Acconcia, F; Battocchio, C; Ciccone, L; Cracco, P; Fiocchetti, M; Iucci, G; Marino, M; Montalesi, E; Moreno, S; Muzzi, M; Nencetti, S; Orlandini, E; Venditti, I | 1 |
| Chen, X; Feng, W; Mao, C; Wang, R; Wang, T; Wu, C; Zhang, H; Zhong, Q | 1 |
| Fan, Y; Kang, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Wang, X; Xu, B; Yuan, P; Yue, J; Zhang, P | 1 |
| Attaran, N; Kharazmi, A | 1 |
| Appleman, LJ; Belani, CP; Beumer, JH; Chen, AP; Chu, E; Ding, F; Emens, LA; Giranda, VL; Ivy, SP; Kiesel, BF; Lee, JJ; Lin, Y; Malhotra, MK; Pahuja, S; Puhalla, S; Shepherd, SP; Stoller, RG; Tawbi, HA | 1 |
| Chatelut, E; Dalenc, F; De Maio, E; Koning, MW; Lacaze, JL; Le Louedec, F; Montastruc, M; Pacher, S; Perriat, S; Puisset, F; Ung, M; Verguet, L; Vinson, C | 1 |
| Albain, KS; Barroso-Sousa, R; Burstein, HJ; Carey, LA; Dang, CT; DeMeo, M; DiLullo, M; Ellis, MJ; Graham, N; Hudis, CA; Krop, IE; Marcom, PK; Moy, B; Parè, L; Partridge, AH; Prat, A; Rugo, HS; Shapira, I; Tarantino, P; Tayob, N; Tolaney, SM; Villacampa, G; Villagrasa, P; Wagle, N; Waks, AG; Weiss, J; Winer, EP; Wolff, AC; Yardley, DA; Zanudo, JGT | 1 |
| Fang, P; Gong, W; Leng, M; Shi, Y | 1 |
| Belleville, E; Brucker, SY; Erber, R; Fasching, PA; Fehm, TN; Häberle, L; Hack, CC; Hartkopf, AD; Hartmann, A; Hein, A; Janni, W; Kolberg, HC; Rübner, M; Theuser, AK; Uhrig, S; Untch, M | 1 |
| Cartwright, MS; Portland, TE; Strowd, RE | 1 |
| Chen, R; He, J; Huang, X; Li, X; Ma, L; Shi, W; Wan, X; Wang, J; Wang, L; Wang, Y; Xu, L; Xu, Y; Zha, X; Zhang, W; Zheng, R | 1 |
| Cai, Y; Chen, G; Liu, C; Zhang, T | 1 |
| Azar, CA; Baez-Diaz, L; Bandos, H; Bear, HD; Boileau, JF; Brufsky, AM; Geyer, CE; Hassan, S; Magrinat, GC; Mamounas, EP; Paik, S; Rastogi, P; Sarwar, S; Shibata, HR; Suga, JM; Swain, SM; Tang, G; Wolmark, N; Yothers, G | 1 |
| Du, J; Hu, W; Li, J; Tian, Z; Zhao, P; Zhao, Y; Zheng, W | 1 |
| Bao, T; Dreyfus, N; Galantino, M; Kot, KL; Lessing, A; Li, S; Piulson, L; Zhi, WI | 1 |
| Bay, JO; El-Ghazzi, N | 1 |
| Dai, Y; Song, Z; Zhang, L; Zhang, Y | 1 |
| Fan, Z; He, Y; Li, J; Ouyang, T; Wang, J; Wang, T; Wang, X | 1 |
| Bartoletti, M; Mazzega-Fabbro, C; Meneghetti, L; Montagner, D; Polesel, J; Puglisi, F; Spazzapan, S; Tabaro, G | 1 |
| Benz, S; Budczies, J; Denkert, C; Fasching, PA; Heinmöller, E; Jackisch, C; Karn, T; Loibl, S; Marmé, F; Mueller, V; Nekljudova, V; Rabizadeh, S; Schem, C; Schmatloch, S; Schneeweiss, A; Sinn, HP; Soon-Shiong, P; Spilman, P; Stickeler, E; Szeto, C; Untch, M; van Mackelenbergh, M; Warm, M; Weber, K | 1 |
| Cathcart-Rake, EJ; Friday, BB; Lacouture, M; Loprinzi, CL; McCue, S; O'Connor, A; Piens, J; Register, T; Smith, D; Thomé, S; Young, S; Zahrieh, D | 2 |
| Chen, C; Feng, J; He, Z; Sun, J; Sun, M; Zhang, X; Zhao, F | 1 |
| Adrada, BE; Candelaria, RP; Clayborn, A; Damodaran, S; Ding, QQ; Garber, HR; Huo, L; Ibrahim, N; Karuturi, M; Layman, RM; Litton, JK; Mittendorf, EA; Moulder, SL; Murthy, RK; Prabhakaran, S; Ramirez, D; Rauch, GM; Ravenberg, E; Sun, R; Symmans, WF; Thompson, AM; Tripathy, D; Valero, V; White, JB; Yam, C | 1 |
| Kamo, N; Konishi, J; Nozaki, Y; Tanaka, N; Yamamuro, M | 1 |
| Heibloem, RE; Ilozumba, OUC; Komen, MMC; van den Hurk, CJG | 1 |
| Aldana, M; Brunette-Masi, LL; Ciccone, MA; Dong, T; Facio, G; Garcia, AA; Garcia-Sayre, J; Groshen, SG; Lin, YG; Louie, S; Matsuo, K; Mhawech-Fauceglia, P; Muderspach, LI; Pham, HQ; Roman, LD; Tsao-Wei, DD; Yessaian, AA | 1 |
| Aksoy, S; Arslan, C; Basaran, G; Bilici, A; Cakar, B; Cicin, I; Cubukcu, E; Demirci, U; Erdem, D; Gumus, M; Harputluoglu, H; Kaplan, MA; Karadag, I; Karadurmus, N; Oksuzoglu, B; Olmez, OF; Selcukbiricik, F; Sendur, MAN; Sezer, A; Sezgin Goksu, S; Shbair, ATM; Sumbul, AT | 1 |
| Itagaki, T; Kimura, Y; Shigematsu, H; Yasui, D | 1 |
| Deng, T; Guo, R; He, Q; He, X; Li, J; Li, M; Li, T; Wang, Y; Zang, S; Zhang, L | 1 |
| Dziegiel, P; Jablonska, K; Maciejczyk, A; Matkowski, R; Partynska, A; Suchanski, J; Szymczak-Kulus, K; Ugorski, M; Urbaniak, A | 1 |
| Ijichi, H; Kawaguchi, K; Oki, E; Omori, S; Shigechi, T; Yoshizumi, T | 1 |
| Brasó-Maristany, F; Castillo, O; Desai, N; Galván, P; Guerriero, J; Krop, IE; Marín-Aguilera, M; Martínez-Sáez, O; Metzger, O; Mittendorf, EA; Ogayo, ER; Paré, L; Parker, JS; Perou, CM; Prat, A; Tarantino, P; Tolaney, SM; Tung, NM; Villacampa, G; Villagrasa, P; Vivancos, A; Waks, AG; Winer, EP | 1 |
| Ashrafichoobdar, E; Ayalew, L; Gorbanwand, V; Monroy, J; Perez, T; Slowinska, K | 1 |
| Choueiri, MA; Dietz, MD; Zelmanski, MH | 1 |
| Abolhassani, H; Ashrafnia Menarbazari, A; Bidaki, A; Farmani, AR; Hosseini, F; Mirzaei Chegeni, M; Moeinzadeh, A; Nabipoorashrafi, SA; Seyedi, SA; Tavakkoli Yaraki, M; Zaer, M | 1 |
| Christgen, M; Eulenburg, CZ; Gluz, O; Graeser, M; Harbeck, N; Hartkopf, A; Holtschmidt, J; Just, M; Kates, RE; Kolberg-Liedtke, C; Kreipe, HH; Kuemmel, S; Lüedtke-Heckenkamp, K; Nitz, UA; Potenberg, J; Schem, C; Schinköthe, T; Schumacher, J; von Schumann, R; Wuerstlein, R | 1 |
| Dang, CT; Du Toit, Y; Hurvitz, SA; Knott, A; Polito, L; Restuccia, E; Sanglier, T; Shim, J; Swain, SM | 1 |
| Ao, H; Fu, J; Guo, Y; Han, M; Li, M; Lu, L; Shi, R; Wang, X | 1 |
| Feng, E; Han, Q; Kong, Z; Wan, L; Zhu, B | 1 |
| Alberti, J; Chikarmane, S; Constantine, M; DeMeo, M; Desai, NV; Dominici, L; Faggen, M; King, TA; Krop, IE; Li, T; Mittendorf, EA; Nakhlis, F; Partridge, AH; Poorvu, PD; Sinclair, N; Spring, LM; Tayob, N; Tolaney, SM; Tung, NM; Waks, AG; Weiss, A; Winer, EP; Wrabel, E | 1 |
| Eltantawy, A; Haroun, EA; Mansour, NO; Shams, MEE | 1 |
| Huang, M; Qi, M; Xiong, J; Yi, X; Yue, B; Zhou, S | 1 |
| Abreu Ribeiro, L; Aguado-Lobo, M; Carreira, N; Correia, C; Costa, L; Damaso, S; Esperanca-Martins, M; Espinosa-Lara, P; Pena, B; Soares-de-Almeida, L | 1 |
| Antoine, A; Delaloge, S; Drouet, Y; Lasset, C; Pérol, D; Robain, M | 1 |
| Beaufort, CM; Bos, MK; Boven, E; de Jonge, E; Helmijr, JCA; Jager, A; Jansen, MPHM; Lam, SW; Martens, JWM; Motta, G; Sleijfer, S | 1 |
| Hou, W; Wang, H; Wang, Y; Xue, C; Yang, S; Zhang, Y; Zheng, Q | 1 |
| Adorno-Cruz, V; Almubarak, HF; Azadi, P; Cobb, BA; Colley, KJ; Cristofanilli, M; D'Amico, P; Dandar, T; Dashzeveg, NK; El-Shennawy, L; Gerratana, L; Gradishar, WJ; Hoffmann, AD; Jia, Y; Liu, H; Manai, M; Muller, WA; Patel, P; Platanias, LC; Ramos, EK; Reduzzi, C; Scholten, D; Schuster, EJ; Shah, AN; Shajahan, A; Sokolowski, MT; Taftaf, R; Zhang, Q; Zhang, Y | 1 |
| Dang, W; He, J; Jia, B; Jia, X; Li, H; Li, Z; Liu, Z; Xing, B; Yu, C; Zhang, Y | 1 |
| Baek, JM; Jeon, YW; Kang, YJ; Kim, D; Kim, YS; Oh, SJ; Rhu, J; Yang, YJ; Yi, JP; Yoon, CI | 1 |
| Adams, KN; Ahmed, SJ; Akaputra, R; Akosman, I; Akya, A; Ali, S; Aminuddin, A; An, B; An, X; Anana, EV; Ao, L; Arany, Z; Arena, R; Azhar, A; Azhar, W; Baasankhuu, A; Bae, WK; Bahar, B; Balaji, L; Barbosa, M; Batchu, UR; Berg, KM; Berlin, N; Berthier, E; Bettiol, AA; Bi, B; Bodie, D; Borges, VF; Borghi-Silva, A; Bowman, CE; Brantly, M; Budhathoki, L; Bukhari, A; Cabeza, M; Cao, J; Cao, Q; Cao, S; Carrasco-Nuñes, N; Caruso, FR; Carvalho, C; Chakrabarty, D; Chandra Mondal, P; Chandran, V; Chang, P; Chase, M; Chauhan, AS; Chauhan, PS; Che, J; Cheemalamarri, C; Chen, D; Chen, H; Chen, J; Chen, Q; Chen, X; Chen, Z; Chetri, BK; Cho, SW; Choi, TI; Chung, HC; Cocchi, MN; Collins, LC; Colombo, N; Come, SE; Custodio, JM; Dai, TY; De La Garza Ramos, R; de Oliveira, CR; Dębczak, A; DeMuri, GP; Deng, J; Deng, K; Dhanani, LY; Diaz, S; Djaharuddin, I; Dong, G; Dong, Q; Donnino, MW; Dwiyanti, R; Elango, KP; Eleswarapu, A; Evans, EGB; Fachri, M; Fang, Y; Fantappiè, G; Farasat, A; Farsida, F; Fathimah, A; Febrianti, A; Feng, S; Fernandes, V; Fernandez Garcia, E; Fleming, GF; Foskett, JK; Fourman, MS; Fu, M; Fu, W; Fukushima, S; Gahlay, GK; Gai, S; Gao, R; Gao, W; Gilbert, DM; Gong, J; Gong, MN; Gong, Z; González-Cavieres, L; Gordon, SE; Goudarzi, F; Goulart, CDL; Greenstein, AE; Grigg, ARC; Grilli, D; Grisham, RN; Grossestreuer, AV; Grzęda, A; Grzegorczyk, A; Gu, J; Guo, H; Gupta, R; Haldar, A; Hamid, Y; Han, HJ; Hancock, CN; Hassan, GW; Hatta, M; He, D; He, F; He, J; Heidarinia, H; Helmchen, G; Herrera-Lavados, C; Hieber, DL; Hoehr, C; Hou, L; Huang, C; Huang, J; Hussain, S; Imaoka, S; Indoliya, Y; Jain, E; Jana, S; Jang, H; Jang, HS; Jara-Quijada, E; Jeacopello, I; Jeung, HC; Jiang, B; Jiang, D; Jiang, G; Jiang, L; Jiang, Q; Jiang, Y; Jiang, Z; Jiao, Z; Jr, JCB; Jung, M; Jung, S; Junita, AR; Kalavathi, A; Kang, X; Kannan, R; Kato, K; Khadka, M; Khan, AR; Khan, I; Khodayari, N; Kim, BJ; Kim, CG; Kim, CH; Kim, D; Kim, H; Kim, HS; Kim, HT; Kim, TS; Kim, YT; King, R; Koh, K; Konkol, M; Koo, DH; Kretzschmar, R; Krop, IE; Kuang, Y; Kubeneck, LJ; Kulkarni, K; Kumar, N; Kunjan, C; Kwon, WS; Lai, C; Lans, A; Lascano, J; Lavania, UC; Lee, CK; Lee, DA; Lee, HS; Lee, J; Lee, KH; Lee, MS; Lee, SW; Lee, UN; Lemus-Mondaca, R; Li, HR; Li, J; Li, Q; Li, X; Li, Y; Li, Z; Liang, H; Liang, Y; Lin, L; Lin, Y; Lipsyc-Sharf, M; Liu, B; Liu, C; Liu, DX; Liu, H; Liu, J; Liu, K; Liu, S; Liu, X; Liu, Z; Locknane, MP; Lorusso, D; Lü, H; Luo, Z; Lv, X; Ma, Y; Mandava, K; Manfrinetti, P; Mao, W; Marques-Sá, J; Masaki, T; Massi, MN; Matsuse, M; Matulonis, UA; Maxwell, CA; McAssey, EV; McManamen, AM; Mehl, RA; Mendes, RG; Meng, Z; Miao, Z; Miller, S; Milovanovic, S; Mishra, SK; Mitra, S; Mitsutake, N; Miyazaki, Y; Moriwaki, S; Mortenson, R; Moskowitz, A; Mudring, AV; Mues Genannt Koers, L; Muhammad, S; Muhimpundu, S; Murapaka, C; Murota, H; Mv, S; Nakazawa, Y; Nam, CM; Natzir, R; Ngo, L; Nguyen, DD; Nie, Y; Nishigori, C; Noji, MC; Notini, L; Oaknin, A; Ogi, T; Oguro, A; Okukawa, K; Olawaiye, AB; Omble, AD; Oso, T; Page, CA; Palma-Acevedo, A; Pani, M; Parikh, SM; Park, J; Park, S; Partridge, AH; Pashova, HI; Paudel, U; Paulssen, E; Payero, L; Peng, M; Peppercorn, JM; Pérez-Won, M; Pitarresi, JR; Pradhan, J; Prevost, D; Primaguna, MR; Puvvada, N; Qian, D; Rajaure, YS; Rajca, A; Rajput, N; Rana, SR; Rangan, L; Ranjbarian, P; Redd, PS; Ren, T; Rha, SY; Riley, L; Romano, M; Rong, X; Rosenberg, SM; Rostamian, M; Rothwell, KA; Ru, S; Ruddy, KJ; Rustgi, AK; Salam, A; Sankaran, S; Santoso, A; Saravanakumar, P; Satheeshkumar, K; Schapira, L; Schulz, K; Senapati, A; Senju, C; Sharma, P; Shelke, RG; Shen, F; Shen, X; Shen, Y; Sheteiwy, MS; Shetty, PR; Shi, L; Shi, MM; Shiigi, H; Shimada, M; Shinkawa, VAM; Shtender, V; Siswanto, FM; Smetana, V; Snow, C; Sridiana, E; Stephenson, MW; Stoll, S; Su, X; Sun, S; Sun, XF; Surapaneni, JR; Suri, K; Świątek, Ł; Syukri, A; Tabilo-Munizaga, G; Takezawa, MG; Tamimi, RM; Tamura, A; Tanaka, K; Tang, M; Tao, Y; Tateishi, S; Thapa, B; Theberge, AB; ThomasArrigo, LK; Thongpang, S; Tiwari, M; Tong, Q; Totton, RR; Tripathi, RD; Tsujimoto, M; Tu, WC; Tudor, IC; Tyskiewicz, K; Ubaidah, FM; Ulhassan, Z; Utani, A; Van Gorp, T; Veerapandian, V; Vennila, KN; von Gunten, U; Wagle, N; Waks, AG; Wald, ER; Wang, B; Wang, D; Wang, H; Wang, L; Wang, W; Wang, X; Wang, Y; Wang, Z; Warner, E; Waterhouse, GIN; Weiss, J; Weissenrieder, JS; Wellen, KE; Wu, JY; Xiang, W; Xiao, S; Xie, Q; Xu, F; Xu, TW; Xu, Y; Yan, B; Yan, JM; Yang, D; Yang, P; Yang, S; Yang, W; Yao, Y; Yassari, R; Yong, Q; Yu, H; Yu, Z; Yun, UJ; Zagotta, WN; Zang, DY; Zanudo, JGT; Zeng, A; Zhang, H; Zhang, R; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YT; Zhao, C; Zhao, J; Zhong, S; Zhou, F; Zhou, W; Zhou, Y | 1 |
| Chen, X; Guo, X; He, H; Hong, W; Hou, M; Li, S; Li, W; Wang, C; Zhang, X; Zhao, G | 1 |
| Hao, L; Li, N; Li, Z; Qi, G; Shi, G; Wang, S; Yin, Q; Zhang, Z | 1 |
| Olivier, T; Prasad, V | 1 |
| Denkert, C; Fasching, PA; Furlanetto, J; Heinmöller, E; Jackisch, C; Karn, T; Loibl, S; Mairinger, T; Marme, F; Müller, V; Nekljudova, V; Schem, C; Schmatloch, S; Schneeweiss, A; Shen, C; Soon-Shiong, P; Stickeler, E; Szeto, CW; Untch, M; van Mackelenbergh, MT; Weber, KE; Williams, TM | 1 |
| Bengala, C; Campadelli, E; Chini, C; Cinieri, S; Colleoni, M; Collovà, E; Cretella, E; Generali, D; Gianni, L; Loi, S; Montagna, E; Munzone, E; Orlando, L; Palleschi, M; Petrelli, F; Puglisi, F; Regan, MM; Ruepp, B; Shi, R; Zamagni, C | 1 |
| Amjad, ZS; Babaei, F; Bayat, M; Doroudian, M; Haghighi, ZMS; Karampour, R; Moghoofei, M; Nahand, JS; Payandeh, M; Rafigh, M; Roozgari, M; Tabatabaei, T | 1 |
| Jin, L; Kang, X; Li, H; Sun, D; Wang, Z; Wu, F; Zhang, H; Zhang, X | 1 |
| Hedayat, M; Jafari, R; Khezri, MR; Majidi Zolbanin, N; Malekinejad, H | 1 |
| Agostinetto, E; Azambuja, E; Barchiesi, G; Botticelli, A; De Giorgi, U; Debien, V; Duhoux, FP; Jacobs, F; Lambertini, M; Marta, GN; Molinelli, C; Moreau, M; Paesmans, M; Piccart, M; Santoro, A; Sirico, M; Speranza, I; Taylor, D; Wildiers, H | 1 |
| Chen, H; Deng, Y; Zhang, M | 1 |
| Armstrong, AC; Behrouzi, R; Howell, SJ | 1 |
| Ernst, A; Kubik, M; Ladekarl, M; Nowicka-Matus, K; Salkus, G; Søkilde Pedersen, I; Sønderkær, M; Takacs-Szabo, Z | 1 |
| Ikeda, T; Isono, Y; Jinno, H; Maeda, Y; Matsumoto, A; Naruse, S; Sasajima, Y; Sato, A; Yamada, M | 1 |
| Banan-Khojasteh, SM; Baradaran, B; Hosseinpour Feizi, MA; Lotfinejad, P; Rasoolnezhad, M; Roshani Asl, E; Safaralizadeh, R | 1 |
| Kania, K; Marczak, A; Michlewska, S; Szczęch, M; Szczepanowicz, K; Szwed, M | 1 |
| Li, J; Liu, J; Meng, L; Sun, L; Wang, J; Zhang, H; Zhou, Q | 1 |
| Shan, J; Wang, C; Wang, Q; Wang, S; Wu, Y; Xu, L; Zhang, D; Zhu, H | 1 |
| Abd El-Sadek, I; Lichtenegger, A; Makita, S; Matsusaka, S; Mori, T; Mukherjee, P; Shen, LT; Yasuno, Y | 1 |
| Chen, R; He, J; Huang, X; Shi, W; Wan, X; Wang, J; Wang, Y; Xu, L; Xu, Y; Zha, X; Zhang, W | 1 |
| Bruque, CD; Bruzzone, A; Jabloñski, M; Lüthy, IA; Pérez Piñero, C; Rivero, EM; Rodríguez, MS; Vanzulli, S | 1 |
| Blohmer, JU; Denkert, C; Fasching, PA; Hanusch, C; Huober, J; Jackisch, C; Just, M; Kuhlmann, JD; Link, T; Loibl, S; Nekljudova, V; Reinisch, M; Rhiem, K; Schmitt, WD; Schneeweiss, A; Seiler, S; Sinn, BV; Stotzer, O; Thill, M; Untch, M; Wimberger, P | 1 |
| Chen, X; Hong, W; Hou, M; Li, W; Liu, H; Zhang, X | 1 |
| Clark, RF; Coombs, MRP; Fernando, W; Hoskin, DW; Rupasinghe, HPV | 1 |
| Barton, DL; Brown-Glaberman, UA; Dayao, ZR; Lafky, JM; Loprinzi, CL; Pankratz, VS; Tawfik, B | 1 |
| Bai, J; Li, A; Ma, J; Meng, F; Peng, F; Tang, S; Zhai, X; Zhou, B; Zou, X | 1 |
| Fu, L; Li, Z; Liao, M; Mou, Y; Wu, L; Ye, J; Zhen, Y; Zhou, Y | 1 |
| Albain, KS; Ambrosone, CB; Barlow, WE; Budd, GT; Chen, CS; Damaj, MI; Godwin, AK; Henry, NL; Hertz, DL; Hortobagyi, GN; McKiver, B; Pusztai, L; Stringer, KA; Thompson, A; Zirpoli, G | 1 |
| Chen, S; Cui, W; Dong, H; Xie, C; Yang, L; Zhang, A; Zhao, R | 1 |
| Besson, L; Bossennec, M; Campbell, DJ; Caux, C; Degletagne, C; Di Roio, A; Duhen, T; Grinberg-Bleyer, Y; Hubert, M; Lalle, G; Ménétrier-Caux, C; Metzger, S; Moudombi, L; Rodriguez, C; Schneider, R; Trédan, O; Treilleux, I | 1 |
| Giniatullin, R; Guo, Q; Jolkkonen, J; Li, Y; Lin, X; Liu, C; Liu, F; Liu, Z; Lv, C; Zhang, X; Zhao, C; Zhong, S; Zhou, Z | 1 |
| AbdulHameed Saeed, V; Mohammed, NAK | 1 |
| Abrams, G; Chesney, M; Conley, YP; Kober, KM; Levine, JD; Melisko, M; Miaskowski, C; Paul, SM; Schumacher, M; Topp, K | 1 |
| Chae, YS; Im, SA; Jung, KH; Kim, JH; Kim, JY; Kim, TY; Lee, E; Lee, KS; Park, K; Park, YH; Sohn, J | 1 |
| Bjermo, H; Borgå, O; Dediu, R; Hansson, F; Heldring, N; Lilienberg, E | 1 |
| Bao, W; Chen, J; Du, Z; Peng, J; Wang, H; Xie, F; Xu, H; Xu, Y | 1 |
| Menon, R; Mensing, S; Nuthalapati, S; Ratajczak, CK; Shepherd, SP; Stodtmann, S; Xiong, H | 1 |
| Burke, L; Ferguson, T; Ghersi, D; Nowak, AK; Wilcken, N; Willson, ML | 1 |
| Belcheva, A; Boone, T; Chang, JC; Creamer, SL; Darcourt, JG; Ensor, JE; Kaklamani, VG; Kuhn, JG; Li, X; Meisel, JL; Niravath, PA; Patel, TA; Qian, W; Rodriguez, AA; Rosato, RR; Schwartz, MR; Zhao, J | 1 |
| Kaul, R; Mooberry, SL; Risinger, AL | 1 |
| Chworos, A; Janaszewska, A; Klajnert-Maculewicz, B; Marcinkowska, M; Sobierajska, E; Stanczyk, M | 1 |
| Heeke, AL; Pan, TC; Read, WL; Switchenko, JM | 1 |
| Bayarmaa, B; Lu, J; Peng, J; Wang, Y; Wu, Z; Xu, S; Yan, T; Yin, W; Zhou, L | 1 |
| Anazodo, A; Dickinson, JE; Li, Z; Lui, K; Safi, N; Sullivan, EA; Wang, AY | 1 |
| Bloom, MJ; Hormuth, DA; Jarrett, AM; McKenna, MT; Shah, A; Sorace, AG; Yankeelov, TE | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Coraci, D; Fusco, A; Giovannini, S; Loreti, C; Padua, L | 1 |
| Bian, W; Chen, M; He, P; Li, Y; Lu, X; Ren, X; Vasilatos, SN; Yao, B; Yao, C; Zhang, X | 1 |
| Guo, J; Jia, R; Shao, J; Sun, Y; Yan, L | 1 |
| Tolaney, SM; Winer, EP | 1 |
| Chaudhary, P; Goel, AK; Sharma, G; Singh, D; Zamre, V | 1 |
| Fan, K; Gao, J; Jin, Y; Lin, D; Lin, J; Liu, Z; Tang, Y; Wang, Q; Wang, S; Xu, H; Zhao, L | 1 |
| Gao, M; Jiang, C; Jin, Q; Wang, F; Yao, N; Zhang, D; Zhang, J | 1 |
| Kang, Y; Shiraki, E; Tsuyuki, S | 1 |
| Huang, P; Huang, W; Su, Y; Wang, G; Yan, D; Zhang, R; Zhou, Y | 1 |
| Chan, YN; Chen, CY; Jheng, YW; Lin, MW; Wang, PJ; Wang, YJ | 1 |
| Ben Kridis, W; Khanfir, A | 2 |
| Chun, HJ; Hyun, H; Kim, SY; Ko, HS; Yang, DH; Yoo, YB | 1 |
| Jeon, M; Lin, G; Mu, Q; Stephen, ZR; Untoro, S; Welsh, P; Yen, TY; Zhang, M | 1 |
| Beutler, A; Dockter, T; Grosse-Perdekamp, MT; Lacouture, ME; Le-Rademacher, J; Loprinzi, CL; Onitilo, AA; Ruddy, KJ; Tan, AD; Vander Woude, AC; Wilkinson, M | 1 |
| Das, L; Sidhu, AS; Singh, AS | 1 |
| Cai, D; Han, C; Liu, L; Ma, X; Qian, J; Zhou, J; Zhu, W | 1 |
| Bland, KA; Bovard, J; Campbell, KL; Davis, MK; Gelmon, KA; Kirkham, AA; McKenzie, DC; Shenkier, T; Zucker, D | 1 |
| Chumsri, S; Colon-Otero, G; Gavin, PG; Li, Z; Mashadi-Hossein, A; Moreno-Aspitia, A; Paik, S; Perez, EA; Pogue-Geile, KL; Serie, DJ; Song, N; Thompson, EA | 1 |
| Andrade, MS; de Barros, ALB; Franco, MS; Leite, EA; Oliveira, MC; Roque, MC; Vilela, JMC | 1 |
| Adel, A; Al-Toukhy, GM; Ammar, RA; Attia, YM; El-Kersh, DM; Elmazar, MM; Eskander, K; Hamdy, M; Khalil, A; Mansour, MT; Mohsen, NE; Reda, N; Walid, H | 1 |
| Li, M; Lin, Y; Lu, J; Muhetaer, G; Situ, H; Wang, N; Wang, S; Wang, Z; Yang, B; Zhang, F; Zheng, Y | 1 |
| Ferhatoğlu, F; Gezer, U; Özgür, E; Saip, P; Şen, F | 1 |
| Chung, S; Cooper, J; Dadwal, S; Jung, J; Kruper, L; Mortimer, JE; Stewart, D; Wong, L; Yu, KW; Yuan, Y | 1 |
| Gong, W; Lu, L; Ren, J; Shi, Y; Wang, Y | 1 |
| Chen, F; Chen, Y; Luo, X; Zhang, K; Zhou, L | 1 |
| Bahar, I; Chi, JJ; Cristofanilli, M; Izquierdo-Ferrer, J; Li, H; Lu, X; Schiltz, GE; Wan, Y; Wavelet, CM; Xue, Y; Zhang, B; Zhou, Z | 1 |
| Bao, H; Chen, H; Chen, J; Cong, D; Jia, J; Li, Q; Li, Y; Liu, Z; Luan, X; Lv, Z; Meng, Q; Pei, J; Ren, Z; Sun, F; Tang, H; Wang, L; Yang, Y; Zhao, W; Zhou, X | 1 |
| Amillano, K; Arenas, M; Camps, J; Fernández-Arroyo, S; Gascón, M; Joven, J; Melé, M; Murria, Y; Rodríguez-Tomàs, E; Sabater, S | 1 |
| André, F; Arnedos, M; Asselain, B; Chateau-Joubert, S; de Cremoux, P; Dujaric, ME; Lacroix-Triki, M; Marangoni, E; Moindjie, H; Monchecourt, C; Nahmias, C; Nehlig, A; Pierga, JY; Rodrigues-Ferreira, S; Seiler, C; Servant, N | 1 |
| Ding, T; Dong, L; Jiang, YF; Li, JB; Xie, BJ; Zhu, LN; Zhu, ZN | 1 |
| Bago, JR; Batrakova, EV; Haney, MJ; Jin, YS; Kabanov, AV; Klyachko, NL; Li, SM; Zhao, Y | 1 |
| Fujii, T; Horiguchi, J; Inoue, K; Kurosumi, M; Kurozumi, S; Matsumoto, H; Oyama, T; Shirabe, K | 1 |
| Bighin, C; Bisagni, G; Bruzzone, M; Ceppi, M; Cognetti, F; Conte, B; de Azambuja, E; De Laurentiis, M; Del Mastro, L; Durando, A; Fabi, A; Garrone, O; Giuliano, M; Lambertini, M; Montemurro, F; Poggio, F; Puglisi, F; Turletti, A; Urracci, Y | 1 |
| Cai, C; Cai, Z; Qiao, L; Wu, C; Wu, P; Wu, X | 1 |
| Hanai, A | 1 |
| Abu Samaan, TM; Büsselberg, D; Kubatka, P; Liskova, A; Samec, M | 1 |
| Woodward, WA | 1 |
| Barry, WT; Gobburu, JV; Gray, E; Hudis, C; Lad, TE; Lyss, AP; Mehrotra, S; Moreno-Aspitia, A; Overmoyer, B; Ratain, MJ; Rugo, HS; Sharma, MR; Toppmeyer, DL; Velasco, M; Winer, EP; Wu, K | 1 |
| Fernández-Carballido, A; Fraguas-Sánchez, AI; Martin-Sabroso, C; Simancas-Herbada, R; Torres-Suárez, AI | 1 |
| Andrade, VP; Brentani, MM; Campos, AP; Encinas, G; Folgueira, MAAK; Katayama, MLH; Kerr, LM; Lima, LGCA; Maistro, S; Pereira, CAB; Petroni, MAL; Roela, RA; Serio, PAMP; Vieira, RADC | 1 |
| Du, WW; Fang, L; Hibberd, S; Ma, J; Wu, N; Yang, BB; Yang, Q | 1 |
| Beutler, AS; Burness, ML; Gersch, CL; Griggs, JJ; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Marcath, LA; Rae, JM; Smith, EML; Van Poznak, C; Vangipuram, K | 1 |
| Ewertz, M; Hjelmborg, JVB; Holm, HS; Jensen, JD; Rosenbaek, F | 1 |
| Li, F; Liu, J; Wei, L; Zhao, Y | 1 |
| Albain, KS; Ambrosone, CB; Barlow, WE; Budd, GT; Cannioto, R; Gralow, JR; Hershman, DL; Hobday, TJ; Hortobagyi, GN; Hutson, AD; Isaacs, C; Kelly, KM; McCann, SE; McCann, WE; Moore, HCF; Salim, M; Stewart, JA; Sucheston-Campbell, LE; Unger, JM; Zirpoli, GR | 1 |
| Alves, M; Chollet, C; Fougeray, T; Franchet, C; Garmy-Susini, B; Gomez-Brouchet, A; Guillermet-Guibert, J; Lacazette, E; Martinez, LO; Najib, S; Prats, AC; Tatin, F; Therville, N; Vaysse, C; Zamora, A | 1 |
| He, J; Ling, Z; Luo, J; Ran, H; Song, W; Wang, Z; Zhang, Q; Zhang, Y; Zhong, S; Zhou, Z | 1 |
| Figg, WD; Kindrick, J; Li, M; Nguyen, L; Peer, CJ; Rajaputra, P; Subramaniyan, B; Woo, S; You, Y | 1 |
| Al-Suhaimi, EA; Almatroudi, A; Alomary, MN; Alzohairy, MA; Ansari, MA; Chung, IM; Farooqui, Z; Rajakumar, G; Sajid Jamal, QM; Thiruvengadam, M | 1 |
| Barker, MR; Etz, RS; Farris, KB; Gonzalez, M; Henry, NL; Hertz, DL; Krumbach, EK; Quinn, CS; Reed, HL; Salgado, TM; Syverson, JG; Vangipuram, K; Wenceslao, I | 1 |
| Hiramatsu, M; Ishikawa, T; Kanbayashi, Y; Kanehisa, F; Katoh, N; Nakatsukasa, K; Ouchi, Y; Sakaguchi, K; Tabuchi, Y; Taguchi, T; Takagi, R; Yokota, I | 1 |
| Nguyen, TA; Shishido, S | 1 |
| Colleoni, M; Demetriou, GS; Fujiwara, Y; Hanes, V; Kolberg, HC; Santi, P; Tesch, H; Tomasevic, Z | 1 |
| Jang, H; Li, B; Wang, J; Yang, X; Zhao, H; Zhi, K | 1 |
| Barillé-Nion, S; Bourgeois, N; Campone, M; David, L; Dumont, A; Fétiveau, A; Frapin, M; Gautier, F; Jézéquel, P; Juin, PP; Kerdraon, O; Lasla, H; Lohard, S; Loussouarn, D; Maillet, L; Moreau-Aubry, A; Nguyen, F; Vuillier, C | 1 |
| Ajabnoor, GM; Al-Abd, AM; Alamoudi, AA; Bashmail, HA; Hegazy, GA; Noorwali, A | 1 |
| Chen, J; Chen, M; Wu, J; Ye, Z | 1 |
| Di Venere, D; Mardente, S; Miccadei, S; Mileo, AM | 1 |
| Ao, H; Fu, J; Guo, Y; Han, M; Huang, T; Li, H; Lu, L; Wang, X; Wang, Y; Yue, F | 1 |
| Elibol, B; Kilic, U; Orhan, C; Ozercan, IH; Qazi, S; Sahin, K; Sahin, TK; Tuzcu, M; Uckun, FM | 1 |
| Deng, M; Li, Z; Liu, B; Lv, Q; Xin, X; Zhang, Y; Zhang, Z; Zhao, Z | 1 |
| Bashash, D; Ghaffari, SH; Karimzadeh, MR; Kashani, B; Nasrollahzadeh, A; Zandi, Z | 1 |
| Albain, KS; Asare, SM; Berry, DA; Berry, S; Boughey, JC; Buxton, MB; Chien, AJ; Clark, AS; Clennell, J; DeMichele, A; Edmiston, KK; Elias, AD; Ellis, ED; Esserman, LJ; Forero-Torres, A; Godellas, C; Haley, BB; Helsten, T; Hirst, GL; Hylton, NM; Isaacs, C; Jaskowiak, N; Kaplan, HG; Kemmer, K; Korde, L; Lang, JE; Lu, J; Matthews, JB; Melisko, ME; Murthy, R; Nanda, R; Northfelt, DW; Paoloni, M; Perlmutter, J; Peterson, G; Rugo, HS; Sanil, A; Schwab, R; Singhrao, R; Steeg, K; Stringer-Reasor, E; Symmans, WF; Tripathy, D; Van't Veer, LJ; Viscusi, RK; Wallace, AM; Wilson, A; Yau, C; Yee, D | 1 |
| Hirata, T; Nishina, M; Ozaki, S; Shigematsu, H; Yasui, D | 1 |
| Fang, K; Guo, Y; Lan, M; Liu, D; Liu, Y; Peng, Y; Shen, D; Wang, L; Yu, Z; Zhu, L | 1 |
| Chen, CP; Chen, CT; Chen, YJ; Cheng, YM; Chiu, TY; Chou, LH; Ho, C; Liu, L; Liu, TW; Nieh, SW; Tsai, CY; Wang, MH; Yeh, TK | 1 |
| Audet-Walsh, E; Bourmeau, G; Dufour, CR; Giguère, V; Kuasne, H; Li, X; McGuirk, S; Park, M; Scholtes, C; St-Pierre, J; Vernier, M | 1 |
| Fujiwara-Tani, R; Goto, K; Kawahara, I; Kishi, S; Kondoh, M; Kuniyasu, H; Luo, Y; Mori, S; Mori, T; Nishiguchi, Y; Ohmori, H; Sasaki, T | 1 |
| Hou, S; Liu, D; Lv, Q; Qin, X; Sun, Z | 1 |
| Cheng, L; Li, L; Lu, Y; Majumdar, A; Stover, D; Wu, S | 1 |
| Assefa, M; Gadisa, DA; Wang, SH; Yimer, G | 1 |
| Bos, MEMM; Bouma, JM; Claessens, AKM; de Graaf, H; Erdkamp, FLG; Honkoop, AH; Lopez-Yurda, M; Rademaker-Lakhai, JM; Tjan-Heijnen, VCG | 1 |
| Griffin, JI; Ho, RJY; McConnachie, LA; Mu, Q; Wu, Y; Yu, J; Zhu, L | 1 |
| Chen, HH; Chen, SH; Chiang, WH; Chiu, HC; Chuang, CL; Liu, TI | 1 |
| Bao, Y; Chen, AT; Chen, J; Chen, Z; Deng, G; Ma, J; Xu, W; Yao, G; Yu, ZQ; Zhang, S; Zhou, J | 1 |
| Aburatani, T; Hanaoka, M; Hoshino, N; Kawamura, Y; Kawano, T; Miura, T; Nishioka, Y; Ogo, T; Sugimoto, H | 1 |
| Hasegawa, T; Hirakawa, K; Kinoshita, H; Mori, T; Noda, E; Ohira, M; Takashima, T; Teraoka, H | 1 |
| Chen, J; Cong, D; Han, B; Li, Q; Li, Y; Liu, Z; Luan, X; Meng, Q; Pei, J; Ren, Z; Sun, F; Sun, Y; Tang, H; Wang, Z; Yang, Y; Zhang, Z; Zhou, X | 1 |
| Mutlu-Agardan, NB; Sarisozen, C; Torchilin, VP | 1 |
| Burness, ML; Fang, F; Griggs, JJ; Hayes, DF; Henry, NL; Hertz, DL; Jennaro, TS; Kidwell, KM; Smith, EML; Van Poznak, C; Vangipuram, K | 1 |
| Li, Q; Liao, W; Wang, F; Wang, X; Wu, Q; Zhang, M | 1 |
| Beutler, AS; Farris, KB; Henry, NL; Hertz, DL; Le-Rademacher, J; Liu, J; Lopez, CL; Loprinzi, CL; Quinn, CS; Reed, HL; Salgado, TM; Smith, EML; Syverson, JG; Vangipuram, K | 1 |
| Ishii, T; Itou, J; Sato, F; Tanaka, S; Toi, M | 1 |
| Akabane, H; Fujii, S; Fujisawa, T; Hozumi, Y; Imoto, S; Mizuno, T; Mukai, H; Nishimura, R; Ohsumi, S; Park, Y; Sagara, Y; Takahashi, M; Takashima, T; Toyama, T; Uemura, Y; Yamaguchi, T; Yamashita, S | 1 |
| Dille, S; Hansen, R; Harde, J; Marschner, N; Nusch, A; Potthoff, K; Söling, U; Stötzer, O | 1 |
| Chen, H; Li, J; Li, P; Liu, J; Liu, P; Miao, Y; Wang, R | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Fujiwara, Y; Hasegawa, J; Hashimoto, K; Ikeda, K; Kawabata, H; Nishizawa, D; Ozaki, Y; Shimizu, C; Shimomura, A; Shiraishi, S; Takano, T; Tamura, K; Tamura, N; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Lipovetzki, J; Lubin, I; Raiter, A; Yerushalmi, R | 1 |
| Fu, Q; Guo, L; Huang, M; Peng, Y; Pu, Y; Wu, Y; Zheng, Y | 1 |
| Bottinor, W; Das, S; Nunnery, S | 1 |
| Guo, X; Han, L; Mu, D; Xiao, Y; Xu, Y; Yuan, C | 1 |
| Allouache, D; DA Silva, A; Damaj, G; Emile, G; Faveyrial, A; Gunzer, K; Hrab, I; Johnson, A; Levy, C; Licaj, I; Morel, A; Segura, C | 1 |
| Eguchi, H; Hayashi, N; Kuroda, Y; Masuda, T; Mimori, K; Natsugoe, S; Noda, M; Otsu, H; Tanaka, F; Tsuruda, Y | 1 |
| Chan, LL; Kessel, SL | 1 |
| Ghahremani, S; Jusu, SM; Obayemi, JD; Salifu, AA; Soboyejo, WO; Tadesse, M; Uzonwanne, VO | 1 |
| Cha, C; Lee, D | 1 |
| Guan, X; Guan, Y | 1 |
| Alexopoulos, A; Andreadis, C; Aravantinos, G; Ardavanis, A; Bafaloukos, D; Baka, S; Bompolaki, I; Christodoulou, C; Christopoulou, A; Kampoli, Κ; Karvounis, K; Koumarianou, A; Liori, S; Makrantonakis, P; Papadimitriou, C; Papakotoulas, P; Psyrri, A; Samantas, E; Zagouri, F | 1 |
| Chitra, K; Jeyaraj, M; Karthikeyan, K; Mehnath, S | 1 |
| Aieta, M; Bordonaro, R; Borsellino, N; Bozza, G; Ciccarese, M; Cilenti, G; Cinieri, S; Colucci, G; Febbraro, A; Fedele, P; Forcignanò, R; Lorusso, V; Maiello, E; Orlando, L; Pisconti, S; Riccardi, F; Rinaldi, A; Romito, S; Saracino, V; Schiavone, P; Surico, G | 1 |
| Huang, G; Li, Y; Zang, H; Zhang, X | 1 |
| Li, M; Liu, Y; Piao, H; Sun, T; Yu, H | 1 |
| Hara, F; Iwamoto, T; Mukai, H; Ohashi, Y; Uemura, Y; Watanabe, T | 1 |
| Doğan, HH; Gündüz, U; Kars, MD; Özdemir, Ö | 1 |
| Albany, C; Costello, BA; Dockter, T; Einhorn, L; Lafky, JM; Le-Rademacher, J; Loprinzi, CL; Ma, C; Pachman, D; Smith, E; Staff, N; Wagner-Johnston, N; Wolfe, E | 1 |
| Fan, Z; He, Y; Li, J; Li, Y; Ouyang, T; Wang, L; Wang, T; Xie, Y | 1 |
| Almehdi, AM; Alniss, H; Cacciatore, S; El-Awady, R; El-Huneidi, W; Mousa, M; Semreen, MH; Soares, NC; Zerbini, L | 1 |
| Alasino, RV; Beltramo, DM; Cremonezzi, DC; García, NH; Leonhard, V; Pasqualini, ME | 1 |
| Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C | 1 |
| Aboelhassan, R; El Wakeel, LM; Khalefa, HG; Shawki, MA | 1 |
| Hinds, B; Marsch, AF; Shakhbazova, A | 1 |
| Rugo, HS | 2 |
| Cao, LP; Gao, Y; Shan, WG; Shen, M; Tang, L; Tu, CJ; Zhang, ZH; Zhu, ZF | 1 |
| Franchi, GC; Gomes, AM; Martins, ML; Parra, JPRLL; Pinto, TS; Rodrigues, CG; Zambuzzi, WF | 1 |
| Cheng, W; Gu, J; Wang, Q; Wang, X; Wang, Y; Wu, H; Zhou, D | 1 |
| Azam, S; Irani, S; Paknejad, M; Soleimani, M | 1 |
| Chen, Y; Du, B; Li, J; Li, Z; Luo, F; Song, N; Tan, H; Yin, H | 1 |
| Hagio, K; Nara, M; Oshino, T; Takazaki, E; Yamashita, H | 1 |
| Barenholz-Cohen, T; Haj, J; Kirchmeier, D; Merkher, Y; Shaked, Y; Shechter, D; Weihs, D | 1 |
| Fujisawa, T; Ishikawa, T; Kashiwaba, M; Kawaguchi, H; Kondo, N; Mashino, K; Morita, S; Nakamura, R; Nakayama, T; Ohno, S; Ohtani, S; Takahashi, M; Takano, T; Tanino, Y; Toh, U; Toi, M; Toyama, T; Tsugawa, K; Yamamoto, Y; Yamashiro, H | 1 |
| Farhan, H; Guo, W; Liu, D; Liu, Y; Momen Ali, SA; Ojima, I; Rong, D; Taouil, A; Wang, C; Wang, H; Wang, Y; Wei, Y; Yang, S; Zhang, M; Zhang, X | 1 |
| Jošt, M; Kopač, P; Koren, A; Korošec, P; Lainščak, M; Mangaroski, D | 1 |
| Chan, AHP; Cox, TR; Feng, N; Filipe, EC; Hung, J; Lam, YT; Lee, BSL; Michael, P; Santos, M; Tan, RP; Wise, SG | 1 |
| He, Z; Kan, Q; Lu, Q; Luo, C; Sun, J; Wang, K; Wang, X; Wang, Y; Yang, B; Ye, H; Zhang, H; Zhang, X; Zhao, J; Zhao, Z | 1 |
| Li, W; Li, Y; Lin, Q; Lu, X | 1 |
| Kacem, M; Nahmias, C; Nehlig, A; Rodrigues-Ferreira, S | 1 |
| Fu, M; Ji, J; Jia, G; Liu, M; Liu, X; Shi, X; Yang, X; Zhai, G | 1 |
| Dong, K; Gao, H; Geng, W; Lv, Y; Pu, Q; Song, H; Zhao, Q | 1 |
| Bi, Z; Chen, P; Liu, YB; Song, XR; Sun, X; Wang, YS; Zhao, T | 1 |
| Bao, C; Chen, D; Chen, J; Ding, B; Fan, W; Lou, W; Lu, Y; Xu, L | 1 |
| Becerra, C; Brachmann, RK; Diamond, JR; Farooki, A; Henner, R; Kapoun, AM; Mita, A; Mita, M; O'Shaughnessy, J; Osborne, C; Richards, D; Stagg, B; Uttamsingh, S; Xu, L; Zhang, C | 1 |
| Fraguas-Sánchez, AI; Martín-Sabroso, C; Raposo-González, R; Torres-Suárez, AI | 1 |
| Alexeev, SM; Burdaeva, ON; Ivanov, RA; Khorinko, AV; Kryukov, F; Kulik, SA; Mukhametshina, GZ; Paltusova, AN; Satheesh, CT; Shelepen, KG; Shustova, MS; Srivastava, K; Vikranth, M | 1 |
| Aibe, H; Hattori, M; Masuda, M; Mori, D; Nishihara, Y; Sakai, M; Sassa, Y; Shirahane, K | 1 |
| Cheng, J; Han, Y; Qiao, W; Wang, J; Yang, X; Zhao, H | 1 |
| Arun, BK; Ayoub, JP; Bondarenko, I; Campone, M; Diéras, V; Dudley, M; Friedlander, M; Han, HS; Jakobsen, EH; Jalving, M; Kaufman, B; Khandelwal, N; Kundu, MG; Maag, D; Oprean, C; Palácová, M; Park, YH; Puhalla, SL; Ratajczak, CK; Shparyk, Y; Wildiers, H; Yañez, E | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bloomquist, E; Goldberg, KB; Ibrahim, A; Pazdur, R; Sridhara, R; Tang, S; Theoret, MR; Tolaney, SM; Winer, EP; Xie, D | 1 |
| Hui, Y; Li, N; Liu, Z; Lu, P; Ma, Z; Pi, J; Zhang, B; Zhang, Y | 1 |
| Das, A; Narendran, V; Ranjan, R; Shah, PK | 1 |
| Chen, Y; Fu, S; Lu, Y; Luo, J; Wang, B; Wen, Q; Wu, Z; Xiong, K; Zhang, Y; Zhao, L | 1 |
| Davidson, NE; Dueck, AC; Halyard, MY; Hwang, ES; Martino, S; Perez, EA; Pisansky, TM; Pockaj, BA; Tenner, KS; Thorpe, CS; Vargas, CE | 1 |
| Akhtari, FS; Ash, J; Carey, LA; Havener, TM; Hertz, DL; Larson, A; McLeod, HL; Motsinger-Reif, AA | 1 |
| Cao, DS; Chen, XS; Cheng, Y; Guan, YD; Li, AX; Li, LY; Ren, XC; Sun, XY; Tao, YG; Wang, KS; Wang, XL; Wu, MH; Yang, JM; Yin, MZ; Zhang, Y | 1 |
| Di Cosimo, S | 1 |
| Griffin, JI; Ho, RJ; McConnachie, LA; Mu, Q; Perazzolo, S; Shen, DD; Yu, J; Zhu, L | 1 |
| Chen, L; Di, GH; Fan, L; Ge, LP; He, M; Jiang, YZ; Jin, X; Liu, GY; Liu, Y; Shao, ZM; Wang, ZH; Wu, J; Yu, KD; Zuo, WJ | 1 |
| Qiao, W; Wang, J; Yang, X; Zhao, H | 1 |
| Banerjee, P; Bose, C; Das, U; Ghosh, U; Kundu, J; Sinha, S | 1 |
| Li, M; Wu, J; Zhang, Y | 1 |
| Chen, J; Li, W; Liu, X; Qin, S; Wang, M; Zang, F | 1 |
| Aborehab, NM; Elnagar, MR; Waly, NE | 1 |
| Sidaway, P | 1 |
| Hass, R; Melzer, C; Ohe, JV | 1 |
| Holland, SP; Sekhon, A; Tan, JCH; Wang, JYF; Yeung, SN | 1 |
| Avraham, S; Geiger, T; Harel, M; Loven, D; Mukherjee, A; Orian-Rousseau, V; Prinz, E; Sagredo, LM; Shaked, Y; Shechter, D; Wolfenson, H | 1 |
| Lin, Y; Lu, J; Peng, J; Wang, Y; Wu, Z; Xu, S; Yin, W; Zhou, L | 1 |
| Chang, PM; Fang, CY; Hsiao, M; Hsieh, HL; Jan, YH; Lai, TC; Liu, CY; Yang, YF | 1 |
| Berry, D; Carey, LA; Dang, C; Fernandez-Martinez, A; Hahn, O; Harris, L; Henry, NL; Hillman, DW; Hoadley, KA; Hudis, C; Huebner, L; Krop, IE; Parker, JS; Partridge, A; Perou, CM; Polley, MY; Shepherd, J; Tolaney, S; Winer, E | 1 |
| Kalachaveedu, M; Kalluru, H; Kondaveeti, SS; Telapolu, S | 1 |
| Gu, Y; Han, M; Li, L; Mi, H; Wang, F; Wang, J; Zhu, M | 1 |
| Bao, B; Chen, Y; Lv, Y; Sun, D; Wang, J; Zhang, L; Zhao, W | 1 |
| Jia, L; Li, Z; Zhao, Z; Zheng, D | 1 |
| Ahn, JH; Cheon, DH; Chong, SE; Hyun, S; Jang, J; Lee, Y; Nam, SH; Yu, J | 1 |
| Alhudaithi, SS; Almuqbil, RM; Bielski, ER; Bos, PD; da Rocha, SRP; Du, W; Sunbul, FS; Zhang, H | 1 |
| Chen, D; Hu, H; Li, W; Song, B; Wu, S | 1 |
| Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV | 1 |
| Li, Q; Liu, P; Shi, C; Wang, X; Xu, T | 1 |
| Adelson, K; DiGiovanna, MP; Hood, A; Kunst, N; Mougalian, SS; Pusztai, L; Wang, SY | 1 |
| Joerger, M; Kloft, C; Muth, M; Ojara, FW | 1 |
| Guo, R; He, J; He, Q; Li, J; Li, M; Liu, Y; Mei, L; Qiu, Y; Ren, K; Tang, J; Wei, J; Xu, S; Yu, Q; Zhang, Z; Zhao, W | 1 |
| Alizadeh, MR; Amani, A; Nohtani, M; Yaghoubi, H | 1 |
| Fujimoto, A; Ichinose, Y; Matsuura, K; Nukui, A; Osaki, A; Saeki, T | 1 |
| Li, G; Sun, J; Xu, D; Zhao, S; Zheng, D | 1 |
| Chambers, TC; Huczyński, A; Piña-Oviedo, S; Urbaniak, A; Yuan, Y | 1 |
| Duarte, D; Vale, N | 1 |
| Ando, Y; Eto, M; Masuda, T; Mimori, K; Nonami, A; Tanaka, F | 1 |
| Gnanaprakasam, JNR; López-Bañuelos, L; Vega, L | 1 |
| Chen, K; Han, H; Liu, B; Wang, Q; Wang, W; Zhang, L; Zhao, Y; Zheng, H | 1 |
| Abdul Hamid, SS; Adam, Z; Mohd Janib, SN; Rohani, R; Salleh, MZ; Tajau, R | 1 |
| Gong, W; Gong, X; Shi, Y; Wang, P; Zhao, X | 1 |
| Fischbach, C; Kalish, M; Pabst, L; Petit, T; Pflumio, C; Pivot, X; Velten, M | 1 |
| Baby, S; Dan, VM; Raveendran, RS | 1 |
| Dora, CP; Ghadi, R; Jain, S; Katiyar, SS; Kushwah, V | 1 |
| Ji, J; Liu, M; Liu, Y; Qiu, N; Shi, X; Wang, R; Yang, H; Yang, X; Zhai, G | 1 |
| Bogestål, Y; Garre, E; Gustafsson, A; Håkansson, J; Landberg, G; Leiva, MC; Ståhlberg, A; Svanström, A | 1 |
| Chosokabe, M; Deura, I; Kawamoto, H; Koike, J; Kondo, H; Kuji, S; Maeda, I; Migita, O; Ohara, T; Suzuki, N; Tozawa-Ono, A; Tsugawa, K | 1 |
| Brady, BL; Chebili, CL; Cooper, C; Dokubo, I; Fox, KM; Lucci, M; Varker, H; Wilson, K; Wojtynek, J | 2 |
| Cooper, C; Dokubo, I; Fox, KM; Sharma, D; Wojtynek, J | 1 |
| Busatto, FF; Saffi, J; Schaefer, BT; Viero, VP | 1 |
| Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A | 1 |
| Chan, YS; Chen, FW; Chen, PS; Cheng, TL; Feng, SY; Hsu, HP; Hung, JH; Jiang, JZ; Lai, MD; Lin, FP; Liu, YW; Omar, HA; Phan, NN; Sun, Z; Wang, CY; Yeh, PH; Yen, MC | 1 |
| Ishikawa, S; Kano, S; Kayahara, M; Makita, N; Munemoto, M; Oonishi, I; Yagi, Y | 1 |
| Aksoy, F; Artac, H; Artac, M; Cakir, M; Emsen, A; Kars, MD; Koygun, GK; Tavli, L | 1 |
| Alves, VD; Carla-da-Silva, J; Dichi, I; Herrera, ACSA; Kern, R; Malanowski, J; Micheletti, PL; Panis, C; Rech, D; Scandolara, TB; Simão, ANC; Souza, JAO; Victorino, VJ | 1 |
| Giri, J; Iversen, TG; Mælandsmo, GM; Pandya, AD; Sandvig, K; Skotland, T; Szwed, M; Torgersen, ML; Valsalakumari, R; Yadava, SK | 1 |
| Amant, FCH; Beijnen, JH; Bekkers, R; Boere, I; Dorlo, TPC; Drochytek, V; Fruscio, R; Halaska, MJ; Huitema, ADR; Janssen, JM; Ottevanger, P; Painter, RC; Schröder, CP; Van Calsteren, K; Witteveen, PO | 1 |
| Akazawa, K; Endo, I; Hasegawa, Y; Ishikawa, T; Kohno, N; Nakazawa, K; Narui, K; Yamada, A | 1 |
| Boyle, F; Friedlander, M; Goldstein, D; Harrison, M; Kiernan, MC; Li, T; Park, SB; Timmins, HC; Trinh, T | 1 |
| Liu, M; Liu, S; Wang, S; Yang, L | 1 |
| Baradaran, B; Dastmalchi, N; Hosseinpourfeizi, MA; Khojasteh, SMB; Safaralizadeh, R | 1 |
| Dong, Y; Huang, S; Li, R; Li, X; Ma, Y; Wang, F; You, C; Zhang, Y | 1 |
| Bunnell, CA; Chen, WY; Freedman, RA; Lynce, F; Mayer, EL; Overmoyer, B; Partridge, AH; Regan, MM; Tolaney, SM; Williams, JT; Winer, EP | 1 |
| Au, K; Battaglini, E; Geelan-Small, P; Goldstein, D; Grimison, P; Henderson, RD; Ke, H; Li, T; Marker, J; Mizrahi, D; Park, SB; Timmins, HC; Trinh, T; Wall, B; Wyld, D | 1 |
| Feng, YJ; Huang, DF; Liang, XJ; Luo, B; Wu, XH; Xu, J; Zhang, Q; Zheng, HM | 1 |
| Hara, K; Mimata, A; Morikawa, N; Tsuji, H; Yoshitomi, S | 1 |
| Arpino, G; Baldini, E; Bernardo, A; Bruzzese, D; De Angelis, C; De Laurentiis, M; De Placido, P; De Placido, S; De Santo, I; Del Mastro, L; Fabi, A; Forestieri, V; Gamucci, T; Giuliano, M; Lauria, R; Leo, L; Michelotti, A; Poggio, F; Russo, S | 1 |
| Arabi, MS; Khodadadi, E; Mahjoub, S; Najafzadehvarzi, H; Nasirian, V | 1 |
| Imai, S; Iwamitsu, Y; Koyanagi, M; Matsubara, K; Matsumoto, M; Moriya, A; Nakagawa, S; Nakagawa, T; Nakazato, Y; Ogihara, T; Saigo, M; Yonezawa, A | 1 |
| An, N; Dong, Z; Du, J; Hu, X; Liu, Y; Wang, J; Zhao, J; Zhou, K | 1 |
| Ikeda, M; Kubo, S; Nakamoto, S; Notsu, A; Yamamoto, M; Yamashita, T | 1 |
| Chen, C; Dong, Z; Li, Y; Wang, W; Xu, H; Yan, L; Yang, Q; Zhang, L | 1 |
| Cecil, D; Corulli, L; Curtis, B; Disis, MN; Park, KH | 1 |
| Aruga, T; Bando, H; Haga, H; Ishiguro, H; Kadoya, T; Kasai, H; Kataoka, TR; Kawabata, H; Kikawa, Y; Masuda, N; Morita, S; Nagai, SE; Ohno, S; Ohtani, S; Suzuki, E; Takahashi, M; Toi, M; Uozumi, R; Yamanaka, T; Yasojima, H | 1 |
| Abedin, MR; Aiardo, R; Barua, D; Barua, S; Powers, K | 1 |
| Ge, JY; He, M; Liu, XY; Mo, M; Shao, ZM; Yu, KD | 1 |
| Chen, XJ; Fan, XD; Li, FZ; Piao, JG; Wang, BH; Wei, YH; Zhang, BB; Zheng, HS; Zheng, HY; Zhu, JJ | 1 |
| Chen, G; Li, X; Liu, J; Liu, Z; Ren, H; Xu, Y | 1 |
| Accordino, M; Crew, KD; Hershman, DL; Hopson, MB; Kalinsky, K; Lee, S; Maurer, M; Trivedi, M | 1 |
| Cruz, RAC; Díaz, SNG; González, RVV; Gutiérrez, OV; Quezada, CEL | 1 |
| Fujitani, M; Fukuyama, H; Hatanaka, S; Hiramoto, S; Kanto, A; Kawabata, A; Koizumi, Y; Miyamoto, T; Sekiguchi, F; Tsubota, M | 1 |
| Chun, HJ; Khang, G; Kim, HJ; Kim, KR; Lee, D; Yang, DH; You, SJ | 1 |
| Liu, S; Qian, J; Sun, J; Xiao, Y; Xie, Y; Yang, T; Zhang, Z; Zhao, J | 1 |
| Andorsky, D; Block, M; Danso, M; Locke, T; Ma, L; McIntyre, K; O'Shaughnessy, J; Scales, A; Wang, Y; Wilks, S | 1 |
| Fukasawa, Y; Funasaka, C; Harano, K; Hosono, A; Kawasaki, T; Kogawa, T; Komuro, A; Kondoh, C; Kusuhara, S; Mamishin, K; Matsubara, N; Mukohara, T; Naito, Y; Nakao, T; Okunaka, M | 1 |
| Lu, C; Qiao, P; Ren, C; Sun, Y; Yu, Z | 1 |
| Brown, JM; Coyle, KM; Cruickshank, BM; Dahn, ML; Fernando, W; Giacomantonio, CA; Huynh, TT; Lamoureaux, E; Langille, MGI; Marcato, P; Nearing, JT; Sultan, M; Vidovic, D | 1 |
| Lee, K; Reserva, J; Speiser, J; Zelman, B | 1 |
| Basu, SM; Giri, J; Singh, R; Yadava, SK | 1 |
| Bi, D; Feng, L; Fu, J; Guo, Y; Han, J; Han, M; Wang, X; Zou, Y | 1 |
| Annan, DA; Cong, L; Hida, K; Hida, Y; Maishi, N; Morimoto, H; Morimoto, M; Nam, JM; Young, MF | 1 |
| ArulJothi, KN; Blanckenberg, A; Chakraborty, S; Costa-Lotufo, LV; de la Mare, J; du Toit, A; Edkins, A; Irene, I; Kimani, S; Loos, B; Mapolie, S; Prince, S; Van Niekerk, A | 1 |
| Anders, CK; Barry, WT; Burstein, HJ; Carey, LA; Hudis, CA; Huebner, L; Ligibel, JA; Ma, C; Partridge, AH; Rugo, HS; Suman, V; Toppmeyer, DL; Winer, EP | 1 |
| Cang, J; Chen, X; Chen, Y; Du, J; Hu, Y; Miao, F; Muddassir, M; Pei, W; Shao, Y; Shen, Y; Teng, G; Zhang, J; Zhang, Y | 1 |
| Kim, EK; Shin, HC | 1 |
| Adachi, Y; Gondou, N; Hattori, M; Horisawa, N; Iwata, H; Kataoka, A; Kobara, M; Kotani, H; Mori, M; Sawaki, M; Sugino, K; Takahata, C; Terada, M; Yoshimura, A | 1 |
| Gao, Y; Hong, T; Li, R; Liu, J; Liu, K; Xu, T; Xu, ZP; Zhang, L; Zhang, R; Zhong, M | 1 |
| Attari, F; Hazim, H; Mazarei, Z; Rafati, H; Zandi, A | 1 |
| Huang, P; Huang, Y; Li, G; Shao, X; Shi, L; Zheng, Y | 1 |
| Gelat, B; Johar, K; Pandya, HA; Rathaur, P; Rawal, R; Soni, MN | 1 |
| Cao, L; Guan, F; Li, X; Lin, S; Tan, Z; Zhou, Y | 1 |
| Li, J; Luo, K; Wang, G; Xu, F; Yao, T; Yu, H; Zhu, J | 1 |
| Kurosaka, N; Nakajima, H; Nakaya, N; Obara, Y; Sato, I; Ueno, S | 1 |
| Choi, HJ; Fukui, M; Wang, P; Zhu, BT | 1 |
| Guo, R; He, Q; Li, J; Li, M; Li, T; Long, Y; Lu, Z; Sheng, Q; Zang, S; Zhang, Z; Zhao, W | 1 |
| Abramson, VG; Ayers, GD; Chen, SC; Mayer, IA; Richmond, A; Saleh, N; Yan, C; Yang, J | 1 |
| Abramson, V; Albain, K; Ardman, B; Barry, W; Bose, R; Briccetti, F; Burstein, H; Cheng, K; Constantine, M; Dang, C; DeFusco, P; DeMeo, M; Faggen, M; Forero-Torres, A; Gadi, VK; Garrett, AM; Gelber, RD; Hart, L; Hu, J; Isakoff, SJ; Jankowitz, RC; Krop, I; Liu, M; Marcom, K; Mulvey, T; Nanda, R; Partridge, A; Pohlmann, PR; Ramaswamy, B; Reeder-Hayes, K; Rimawi, M; Rosenberg, SM; Ruddy, K; Rugo, HS; Schneider, B; Tayob, N; Tolaney, SM; Trippa, L; Tung, N; Valero, V; Van Poznak, C; Weckstein, D; Winer, EP; Wolff, AC; Yardley, DA; Zheng, Y; Zuckerman, D | 1 |
| Hashimoto, H; Kawazoe, H; Nakamura, T; Shimanuki, Y; Terakado, H; Udagawa, R; Uozumi, R; Watabe, D; Yamaguchi, M | 1 |
| Bian, JJ; Cutitar, M; Dizon, DS; Edmondson, DA; Emmick, CM; Fenton, M; Gass, JS; Graves, TA; Legare, RD; Lopresti, ML; Olszewski, AJ; Pandya, SV; Sakr, BJ; Sikov, WM; Strenger, RS; Stuckey, AR; Witherby, SM | 1 |
| Chen, CS; Chen, L; Henry, NL; Hertz, DL; Stringer, KA; Sun, Y | 1 |
| Benner, EA; Cortes-Sanchez, E; Dos Santos, CO; Guillen, KP; Hagen, KM; Kerkvliet, CP; Lange, CA; Ostrander, JH; Pengo, T; Telang, S; Temiz, NA; Trousdell, MC; Truong, TH; Wang, Y; Welm, BE; Yang, CH | 1 |
| Abramson, V; Albain, KS; Ardman, BM; Bose, R; Briccetti, FM; Burstein, HJ; Cheng, KL; Constantine, M; Dang, CT; DeFusco, PA; DeMeo, MK; Faggen, MG; Forero-Torres, A; Gadi, VK; Hart, LL; Hu, J; Isakoff, SJ; Jankowitz, RC; Kelly Marcom, P; Krop, IE; Liu, MC; Merrill Garrett, A; Mulvey, TM; Nanda, R; Partridge, AH; Pohlmann, PR; Ramaswamy, B; Reeder-Hayes, KE; Rimawi, M; Rosenberg, S; Ruddy, KJ; Rugo, HS; Schneider, BP; Sella, T; Tayob, N; Tolaney, SM; Tung, NM; Valero, VV; Van Poznak, C; Weckstein, DJ; Winer, EP; Wolff, AC; Yardley, DA; Zheng, Y; Zuckerman, DS | 1 |
| Nycz, J; Wilczok, A; Zajdel, A | 1 |
| Albain, KS; Asare, AL; Asare, SM; Beckwith, H; Berry, DA; Berry, S; Boughey, JC; Brown-Swigart, L; Chien, AJ; Clark, AS; DeMichele, AM; Du, L; Elias, AD; Esserman, LJ; Forero-Torres, A; Han, HS; Helsten, TL; Hirst, GL; Hylton, NM; Isaacs, C; Kalinsky, K; Kemmer, K; Liu, MC; Matthews, JB; Melisko, M; Nanda, R; Perlmutter, J; Petricoin, EF; Pusztai, L; Rugo, HS; Sanil, A; Schwab, RB; Shatsky, R; Singhrao, R; Sit, L; String-Reasor, E; Symmans, WF; Thomas, A; Van't Veer, LJ; Wallace, AM; Wilson, A; Wolf, DM; Wulfkuhle, JD; Yau, C; Yee, D | 1 |
| Al-Amer, O; Alomar, S; Barnawi, I; Dash, P; Hawsawi, YM; Hussien, NA; Mansour, L; Mustafa, SK; Oyouni, AAA | 1 |
| Koukourakis, IM; Koukourakis, MI; Kouloulias, V; Zygogianni, A | 1 |
| Arun, BK; Ayoub, JP; Bach, BA; Bell-McGuinn, KM; Diéras, V; Friedlander, M; Han, HS; Kaufman, B; Kundu, MG; Maag, D; Puhalla, SL; Ratajczak, CK; Wildiers, H | 1 |
| Blau, S; Bradley, D; Dent, R; Espié, M; Im, SA; Isakoff, SJ; Kim, SB; Mani, A; Oliveira, M; Reilly, SJ; Saura, C; Tan, AR; Wongchenko, MJ; Xu, N | 1 |
| Jiang, D; Lu, H; Qiu, M; Shan, C; Wang, Q; Xu, X; Zha, S; Zhang, W; Zheng, X | 1 |
| Chen, J; Gu, C; Huang, J; Ni, K; Ni, Q; Wang, GH; Wang, XD | 1 |
| Abdelfattah, NM; Elnahass, Y; Sabri, NA; Solayman, MH | 1 |
| Fujii, T; Koibuchi, Y; Nakazawa, Y; Ogino, M; Shirabe, K; Takata, D | 1 |
| Cardoso, A; Duarte, D; Vale, N | 1 |
| Cleenewerk, L; Eijkelkamp, N; Hiensch, AE; May, AM; Vermeer, CJC | 1 |
| Feng, K; Liu, G; Liu, J; Wang, X; Xing, Z; Zhang, M | 1 |
| Fan, W; Jin, Z; Teng, C; Wang, F; Zhang, J; Zhu, L | 1 |
| Fujisaki, K; Miyoshi, T; Ootsubo, Y; Sai, G; Shiina, N; Wakabayashi, Y; Yokomizo, J | 1 |
| Abdelfattah, ON; Bakri, HM; Eid, S; Mohamed, RF | 1 |
| Han, SW; Im, SA; Kim, JH; Kim, JS; Kim, M; Kim, SH; Kim, TY; Lee, DW; Lee, KH; Park, IA; Park, SY; Ryu, HS; Suh, KJ; Woo, GU | 1 |
| Chen, L; Gao, Z; Hou, Y; Huang, W; Jin, M; Quan, X | 1 |
| Ahn, JH; Chae, YS; Cho, EH; Im, SA; Jang, JH; Jung, KH; Kim, JH; Kim, JY; Lee, KH; Lee, KS; Lee, SY; Park, MS; Park, YH; Sohn, J | 1 |
| Asselain, B; Berger, F; Beuzeboc, P; Bidard, FC; Cottu, PH; Dieras, V; Dujaric, ME; Escalup, L; Laurence, V; LE Tourneau, C; Pierga, JY; Piperno-Neumann, S; Pop, S; Robain, M | 1 |
| Clark, JL; Janusis, J; Mercado-Matos, J; Piper, AJ; Shaw, LM | 1 |
| Baker, E; Dang, CT; Miller, KD; Northfelt, DW; O'Neill, A; Partridge, AH; Schneider, B; Sepucha, K; Sledge, GW; Vaz-Luis, I; Winer, EP | 1 |
| Dong, W; Han, X; Hao, H; Jin, Y; Liao, H; Liu, Y; Wang, B; Xia, X; Yang, Y; Ye, J | 1 |
| Guo, D; Liu, X; Luo, J; Luo, Y; Ran, H; Song, W; Wang, Z; Zhang, Q; Zhao, J; Zhao, Y | 1 |
| Kasaei, A; Mahjoubi, F; Mobini-Dehkordi, M; Saffar, B | 1 |
| Dang, CT; Eaton, A; Hudis, CA; Liu, JE; Oeffinger, KC; Singh, JC; Steingart, RM; Wang, R; Yu, AF | 1 |
| Ali, S; Asaduzzaman, M; Constantinou, S; Coombes, RC; Gallon, J; Hu, Y; Lam, EW; Lin, ML; Min, H; Raguz, S; Shousha, S; Singh, P; Yagüe, E | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Foley, EA; Joyce, JA; Kim, H; Olson, OC; Quail, DF | 1 |
| Feng, J; Hurvitz, S; Jiang, Z; Lee, KS; Liu, D; Ng, TY; Noel-Baron, F; Ridolfi, A; Ringeisen, F; Shao, Z; Shen, K; Toi, M; Tseng, LM; Wang, X; Xu, B; Zhang, Q | 1 |
| Cai, R; Chen, S; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Barbolosi, D; Benzekry, S; Ciccolini, J; El Cheikh, R; Imbs, DC; Mollard, S | 1 |
| Adrover, E; Alba, E; Bermejo, B; Blasco, MA; Calvo, I; Campo, R; Carrasco, E; Colomer, R; Cortes, J; de Andres, R; Escudero, MJ; García-Saenz, JA; Gil-Gil, M; Gonzalez-Martin, A; Guerra, J; Llombart-Cussac, A; Lluch, A; Manso, L; Martinez-Jánez, N; Moreno-Antón, F; Mouron, S; Quintela-Fandino, M; Simon, SP; Soberon, N; Viñas, G; Zamora, E | 1 |
| Goto, H; Kawamura, S; Nakajima, T; Taniwaka, K | 1 |
| Chung, HC; Jeung, HC; Kim, TS; Kwon, WS; Rha, SY | 1 |
| Dave, JK; Eisenbrey, JR; Forsberg, AI; Forsberg, F; Fox, TB; Halldorsdottir, VG; Liu, JB; Machado, P; Marshall, A; Merton, DA | 1 |
| Hazama, S; Inoue, Y; Kanekiyo, S; Kubo, H; Maeda, N; Matsui, H; Nagano, H; Nagashima, Y; Oka, M; Sakamoto, K; Sato, Y; Shindo, Y; Suzuki, N; Takeda, S; Ueno, T; Yamamoto, S; Yoshino, S | 1 |
| Alhalili, Z; Auliya, NH; Sandersonb, B; Shapter, J | 1 |
| Fujiwara, Y; Hamada, A; Hasegawa, J; Hashimoto, K; Ikeda, K; Kawabata, H; Nishizawa, D; Ozaki, Y; Shimizu, C; Shimomura, A; Takano, T; Tamura, K; Tamura, N; Tanabe, Y; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Bauerfeind, I; Conrad, B; du Bois, A; Elling, D; Fehm, T; Harbeck, N; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Schneeweiss, A; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Emami, J; Hassanzadeh, F; Mohammadkhani, H; Rezazadeh, M; Rostami, M; Sadeghi, H | 1 |
| Liu, Z; Niu, Y; Shen, H; Wang, Y; Yin, Q; Zhang, T; Zhang, W | 1 |
| Badana, AK; Kumari, S; Malla, R; Mohan, GM; Shailender Naik, G | 1 |
| Bird, D; Brown, SA; Carpenter, JP; Chang, S; Fromer, MW; Gaughan, JP; Hagaman, AL; Koko, KR; Matthews, M; Nolan, RS; Zhang, P | 1 |
| Chen, WL; Li, F; Liu, Y; Qu, CX; Yang, SD; You, BG; Yuan, ZQ; Zhang, XN; Zhu, QL; Zhu, WJ | 1 |
| Freedman, RA; Gross, C; Haddad, TC; Hashmi, SK; Herrin, J; Jemal, A; Mougalian, S; Ruddy, KJ; Sangaralingham, LR; Shah, N; Thompson, CA; Van Houten, HK | 1 |
| Bossenmaier, B; Cejalvo, JM; Ceppi, M; Cervantes, A; Collins, D; Crown, J; Hasmann, M; Jacob, W; James, I; Weisser, M | 1 |
| Barroso-Sousa, R; Lin, NU | 1 |
| Asghari, F; Baradaran, B; Elieh Ali Komi, D; Haghnavaz, N; Kazemi, T; Shanehbandi, D | 1 |
| Hu, Y; Jiang, J; Liao, C; Wang, M | 1 |
| Aravantinos, G; Chrisafi, S; Fountzilas, G; Gavressea, T; Gogas, H; Kalofonos, HP; Kalogeras, KT; Karanikiotis, C; Koliou, GA; Koufopoulos, N; Koutras, A; Lazaridis, G; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pavlakis, K; Pazarli, E; Pectasides, D; Petraki, K; Tsigaridas, K; Zagouri, F | 1 |
| Dong, X; Gong, M; Han, X; He, R; Li, J; Li, Z; Lu, X; Luo, L; Wang, M; Xu, R | 1 |
| Bilensoy, E; Erdoğar, N; Erdoğdu, B; Eroğlu, H; Esendağlı, G; Esendağlı-Yılmaz, G; Nielsen, TT; Sargon, MF; Yöyen-Ermiş, D | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Bianchi, G; Capri, G; de Braud, F; Ferrari, B; Maggi, C; Mariani, G; Mennitto, A; Mennitto, R; Milano, M; Re, B; Rinaldi, L; Stefanetti, C; Vernieri, C | 1 |
| Barry, WT; Gobburu, JV; Gray, E; Hudis, C; Lad, TE; Lyss, AP; Mehrotra, S; Moreno-Aspitia, A; Overmoyer, B; Ratain, MJ; Rugo, H; Sharma, MR; Toppmeyer, DL; Valasco, M; Winer, EP; Wu, K | 1 |
| Huang, Q; Jiang, P; Li, D; Liu, M; Liu, X; Shi, X; Sun, X; Wang, C; Wang, Y; Zhang, Y; Zhou, J | 1 |
| Chen, X; Ju, C; Su, Z; Sun, Q; Tang, C; Tian, C; Xue, L; Yin, Y; Zhang, C; Zhang, Y | 1 |
| Adán-Ladrón de Guevara, A; Gallardo-Pérez, JC; Marín-Hernández, A; Moreno-Sánchez, R; Rodríguez-Enríquez, S | 1 |
| Feng, X; Li, Y; Liu, Q; Liu, X; Wang, P; Wang, X; Yan, F; Zheng, H | 1 |
| Abraham, I; Chacra, W; Danciu, OC; Kankanala, V; Remo, M | 1 |
| Chen, Y; Fan, Q; He, Y; Ji, W; Wang, B; Xu, C | 1 |
| Abdel-Rasoul, M; Byrd, JC; Caligiuri, MA; Carson, WE; Duggan, MC; Layman, R; Levine, KM; Lustberg, MB; Mace, TA; Macrae, ER; Markowitz, J; Mrozek, E; Ramaswamy, B; Reinbolt, RE; Schoenfield, L; Stiff, A; Trikha, P; Wesolowski, R | 1 |
| Abdelhay, E; Barbosa, DS; Binato, R; Cecchini, R; Correa, S; Dias-Alves, V; Herrera, ACSA; Panis, C; Pizzatti, L; Simão, ANC; Victorino, VJ | 1 |
| Allan, D; Andrew, S; Figeys, D; Gadde, S; Ji, G; Jia, D; Lee, J; Li, L; Li, X; Wang, L; Yao, Z | 1 |
| Fu, Y; Gong, T; Wang, Y; Zhang, ZR | 1 |
| Kim, JO; Nguyen, CN; Nguyen, HT; Tran, BN; Yong, CS | 2 |
| Carey, LA; Dusetzina, SB; Hinton, SP; Meng, K; Meyer, AM; Reeder-Hayes, KE | 1 |
| Chen, C; Chen, S; Ding, Y; Duan, K; Li, Y; Wang, H; Wang, W; Wang, Y; Wu, H; Yang, Q; Zhang, L; Zhou, J | 1 |
| Decker, T; Göhler, T; Indorf, M; Nusch, A; Overkamp, F; Rösel, S; Sahlmann, J; Trarbach, T | 1 |
| Burugu, S; Chen, B; Gao, D; Gelmon, KA; Kos, Z; Leung, S; Liu, S; Nielsen, TO; Parulekar, WR; Shepherd, L; Virk, S | 1 |
| Allison, SE; Bourget, K; Chen, Y; Mackenzie, PI; Murray, M; Petrovic, N; Zhang, J | 1 |
| Blohmer, JU; Burchardi, N; Denkert, C; Eiermann, W; Engels, K; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Klare, P; Kümmel, S; Loibl, S; Paepke, S; Schem, C; Schneeweiss, A; Untch, M; von Minckwitz, G | 1 |
| Huang, S; Huang, X; Ijaz, M; Shi, Y; Wang, D; Zhang, S | 1 |
| Chang, YS; Hai, T; Jalgaonkar, SP; Middleton, JD | 1 |
| Imai, S; Nio, Y; Sakamoto, M; Tamaoki, M; Uesugi, K | 1 |
| Ando, Y; Hato, Y; Ito, Y; Kawaguchi, Y; Nishikawa, S; Sugiura, H; Terada, M; Yoshimoto, N | 1 |
| Moeller, M; Moore, HCF; Mustafa Ali, M; Rybicki, L | 1 |
| Chatterji, U; Chattopadhyay, D; Gupta, A; Mukherjee, P | 1 |
| Deng, Y; He, C; Jin, Y; Li, X; Liu, Y; Qu, X; Wang, D; Wang, Z; Zhou, Y; Zou, Y | 1 |
| Cruz, JJ; Gomez, A; Lozano, R; Martin, T; Rodriguez, CA | 1 |
| Chen, J; Chen, X; Feng, Z; Li, Y; Tang, K; Zhou, W | 1 |
| Ge, L; Li, A; Li, P; Li, W; Li, Y | 1 |
| Asher, R; Baron-Hay, S; Gibbs, E; Giuffre, B; Khasraw, M; Mukaro, V; Murphy, C; Tobler, R; West, L | 1 |
| Bronich, TK; Cohen, SM; Desale, SS; Lei, F; Marky, LA; Soni, KS | 1 |
| Blessing, WA; Colson, YL; Grinstaff, MW; Reynolds, DS; Tevis, KM; Zaman, MH | 1 |
| Koay, EJ; Li, C; Li, T; Wen, X; Zhao, J | 1 |
| Akiyama, F; Fukada, I; Horii, R; Ito, Y; Iwase, T; Kobayashi, K; Ohno, S; Shibayama, T; Takahashi, S | 1 |
| Boughey, JC; Carpenter, JT; Connolly, RM; Fackler, MJ; Gabrielson, EW; Goetz, MP; Stearns, V; Storniolo, AM; Sukumar, S; Walsh, B; Watkins, SP; Zhang, Z; Zhou, XC | 1 |
| DeLuca, AN; Esserman, LJ; Melisko, ME; Rice, BA; Rugo, HS; Ver Hoeve, ES | 1 |
| Baselga, J; Bermejo, B; de la Pena, L; Denkert, C; Gombos, A; Kümmel, S; Lee, SC; Loi, S; Loibl, S; Lux, M; Michiels, S; Nekljudova, V; Piccart, MJ; Rezai, M; Steger, G; Turri, S; Untch, M; Urban, P; Von Minckwitz, G; Zardavas, D | 1 |
| Cheng, R; Li, X; Liu, J; Liu, Z; Sun, N; Tian, Z; Yang, Z; Zhao, C | 1 |
| Sugita, K; Tani, N; Yamamoto, O | 1 |
| Augustin, D; Braun, M; Christgen, M; Fischer, H; Forstbauer, H; Gluz, O; Grischke, EM; Harbeck, N; Kates, R; Kohls, A; Krauss, K; Kreipe, H; Kuemmel, S; Liedtke, C; Nitz, UA; Potenberg, J; Reimer, T; Schumacher, C; Schumacher, J; Stefek, A; Wuerstlein, R | 1 |
| Chen, C; Chen, S; Chen, T; Ding, Y; Duan, K; Li, Y; Wang, H; Wang, W; Wang, Y; Yang, Q; Zhang, L | 1 |
| Adachi, Y; Hattori, M; Iwata, H; Kikumori, T; Kodera, Y; Kondo, N; Nakanishi, H; Nishida, K; Shibata, K; Usuki, H; Yatabe, Y; Yoshimura, M | 1 |
| Bernstein, V; Chi, K; Clemons, M; Dent, SF; Dhesy-Thind, SK; Ellard, SL; Feilotter, H; Gelmon, KA; Hagerman, LJ; Ksienski, D; Lui, H; Mates, M; Panasci, L; Salim, M; Seymour, L; Simmons, C; Song, X; Tu, D; Verma, S | 1 |
| Liu, H; Song, Z; Wang, M; Wang, X; Yang, L; Yang, W | 1 |
| Baeyens, JM; Contreras-Cáceres, R; Leiva, MC; López-Romero, JM; Mayevych, I; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J; Sarabia, F | 1 |
| Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML | 1 |
| Freedman, RA; Gross, CP; Haddad, TC; Jemal, A; Keegan, THM; Leal, AD; Loprinzi, CL; Mougalian, SS; Mutter, RW; Neuman, HB; Ruddy, KJ; Sangaralingham, L; Shah, N; Van Houten, H | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| du Bois, A; Harbeck, N; Hinke, A; Huober, J; Jackisch, C; Konecny, GE; Kuhn, W; Kurbacher, C; Lück, HJ; Möbus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Atkins, JN; Biggs, DD; Brufsky, AM; Cecchini, RS; Fehrenbacher, L; Flynn, PJ; Ganz, PA; Geyer, CE; Gross, HM; Jeong, JH; Mamounas, EP; Polikoff, J; Rastogi, P; Romond, EH; Seay, TE; Swain, SM; Wade, JL; Wahl, TA; Wolmark, N; Zapas, JL | 1 |
| Anderson, NR; Araysi, LM; Berry, JL; Frost, AR; Goliwas, KF; Lobo-Ruppert, SM; Pruitt, HC; Richter, JR; Samant, RS | 1 |
| Boggiani, D; Musolino, A; Palli, D; Pellegrino, B; Tommasi, C | 1 |
| Cardoso, VN; de Barros, ALB; Fernandes, RS; Leite, EA; Lopes, SC; Monteiro, LOF; Oda, CMR; Oliveira, MC; Rubello, D; Townsend, DM | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, YH; Sohn, JH | 1 |
| Baehner, FL; Butler, SM; Cherbavaz, DB; Costantino, JP; Jamshidian, F; Jeong, JH; Julian, TB; Kim, SR; Lawrence Wickerham, D; Lembersky, BC; Liu, Q; Mamounas, EP; Paik, S; Shak, S; Sing, AP; Tang, G; Wolmark, N | 1 |
| Abe, A; Ito, J; Kato, H; Kubo, T; Suzushino, S; Ueno, N; Yasuda, M | 1 |
| He, J; Jin, S; Li, J; Lu, X; Xu, R | 1 |
| Jager, A; Kock, MCJM; Levin, MD; Rier, HN; Sleijfer, S; van Rosmalen, J | 1 |
| Chiu, L; Chiu, N; Chow, E; Chow, R; DeAngelis, C; Drost, L; Ganesh, V; Lao, N; Lee, J; Wan, BA; Zhang, L | 1 |
| Burney, M; Gaikwad, A; Gonzalez, AO; Mathew, L; Nugent, EK; Smith, JA | 1 |
| Badr El-Din, NK; Ghoneum, M; Hassan, TA; Mahmoud, AZ | 1 |
| Ge, X; Jiang, BH; Li, W; Liu, LZ; Liu, WT; Shi, ZM; Sun, HR; Wang, M; Wen, YY; Zhang, JY | 1 |
| Han, XD; Li, Z; Liu, MM; Qiu, XL; Ren, Y; Shi, JH; Song, W; Tu, DY; Zhang, J; Zhen, LL | 1 |
| Cameron, D; Garcia, J; Hilton, M; Miles, D; O'Shaughnessy, J | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kohno, N; Miura, D; Tanino, H | 1 |
| Kamal, MM; Nazzal, S | 1 |
| Chen, J; Chen, Y; Feng, Z; Li, Y; Liu, C; Tang, K; Tian, K | 1 |
| Cheng, G; Fang, Y; He, X; Tong, J; Wan, Y; Wang, G; Wang, L; Xia, Y; Zheng, Q; Zheng, SY; Zhu, C | 1 |
| Barbeaux, A; Bernhard, J; Borstnar, S; Colleoni, M; Cortés, J; Gennari, A; Hasler-Strub, U; Hennessy, B; Jerusalem, G; Kennedy, MJ; Maibach, R; Murillo, SM; Pagani, O; Parraga, KA; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Sun, Z; Vidal, MJ; Von Moos, R; Walshe, J | 1 |
| Bradley, D; Colomer, R; Dang, C; Delaloge, S; Douthwaite, H; Eng-Wong, J; Ewer, MS; Ferrero, JM; Kiermaier, A; Swain, SM; Verrill, M; Viale, G; Vieira, C; Waldron-Lynch, M; Werner, TL | 1 |
| Chen, C; Chen, S; Ding, Y; Li, Y; Wang, H; Wang, Y; Yang, Q; Zhang, L | 1 |
| Ameels, H; Baselga, J; Berghorn, M; Borrego, MR; Bozovic-Spasojevic, I; Bradbury, I; Campbell, C; Chen, DR; de Azambuja, E; Di Cosimo, S; Ewer, M; Fumagalli, D; Harbeck, N; Huober, J; Im, YH; Izquierdo, M; Lambertini, M; Maetens, M; Piccart, M; Ponde, N; Pusztai, L; Rodeheffer, R; Suter, T; Zardavas, D | 1 |
| Franco, L; McLellan, BN; Rzepecki, AK | 1 |
| Duan, XC; Guo, Y; Hao, YL; Li, H; Li, ZT; Xu, MQ; Yao, X; Yin, YF; Zhang, S; Zhang, X; Zheng, XC; Zhong, T | 1 |
| Tutt, A | 1 |
| Alvarez, I; Anton, A; Bermejo, B; Bisagni, G; Calvo, L; Chacon, JI; Chan, A; De Fato, R; Dent, RA; Dittrich, C; Gianni, L; Magazzù, D; Mansutti, M; Morales, S; Plazaola, A; Redfern, AD; Semiglazov, V; Thill, M; Tusquets, I; Valagussa, P; Zambetti, M | 1 |
| Sparano, JA | 5 |
| Li, X; Yang, B; Zhai, Z; Zhang, L; Zhang, Y; Zhao, J | 1 |
| Angelini, F; Astone, A; Barba, M; Bertolini, I; Botti, C; Botticelli, A; Cassano, A; Ciliberto, G; De Angelis, C; Fabbri, MA; Gamucci, T; Giordano, A; Grassadonia, A; Izzo, F; Lauro, LD; Magnolfi, E; Marchetti, L; Marchetti, P; Maugeri-Saccà, M; Mazzotta, M; Mentuccia, L; Michelotti, A; Moscetti, L; Natoli, C; Pizzuti, L; Rossi, E; Sarobba, MG; Sergi, D; Sini, V; Sperduti, I; Tomao, S; Vaccaro, A; Vici, P | 1 |
| Adessi, C; Albanell, J; Cejalvo, JM; Ceppi, M; Cervantes, A; Cortés, J; Dieras, V; Gonzalez, I; Hasmann, M; Jacob, W; James, I; Joly, F; Lassen, U; Levy, C; Lopez-Martin, J; Marmé, F; Martinez-Garcia, M; May, M; Meneses-Lorente, G; Michielin, F; Moisan, A; Park-Simon, TW; Racek, T; Schindler, C; Schneeweiss, A; Weisser, M; Welt, A | 1 |
| Han, X; He, W; Lin, C; Lv, Y; Qin, C; Xin, X; Xu, C; Yang, L; Yang, X; Yin, L; Zhang, L; Zhao, X | 1 |
| Albain, KS; Crew, KD; Fehrenbacher, L; Fisch, MJ; Greenlee, H; Hershman, DL; Lew, DL; Lynn Henry, N; Minasian, LM; Moinpour, CM; Till, C; Unger, JM; Wade, JL; Wong, SF | 1 |
| Bogenrieder, T; Campbell, F; Ellies, LG; Figueiredo, C; Hammond, D; Ireland, L; Mielgo, A; Santos, A; Schmid, M; Weyer-Czernilofsky, U | 1 |
| Cui, B; Li, S; Lin, H; Lin, Z; Xia, A; Xie, B; Zheng, L; Zhou, P | 1 |
| Chen, L; Huang, Y; Peng, J; Qian, Z; Tan, L; Wang, Y; Zhao, H | 1 |
| Bergh, J; Brage, SE; Carlsson, L; Einbeigi, Z; Fernö, M; Foukakis, T; Hatschek, T; Linderholm, B; Loman, N; Lorent, J; Lövrot, J; Malmberg, M; Matikas, A; Skoog, L; Suzuki, C; Tobin, N; Zerdes, I | 1 |
| Aguilera-Barrantes, I; Duan, Y; Fan, Z; Gao, P; Han, B; Hu, W; Jin, Y; Kong, A; Kumar, SN; Li, S; Liu, T; Miao, QR; Rana, U; Shi, A; Song, D; Wang, B; Wang, X; Yang, M; Zhao, G | 1 |
| Han, Y; Kim, YC; Park, JH; Rejinold, NS; Seok, HY; Yoo, J | 1 |
| Nakayama, I | 1 |
| Abu-Khalaf, M; Brandt, DS; Burrello, T; Chagpar, A; DiGiovanna, MP; Foldi, J; Frederick, C; Hatzis, C; Hofstatter, EW; Horowitz, N; Killelea, B; Lannin, D; Mougalian, S; Pusztai, L; Rispoli, L; Sabbath, K; Sanft, T; Silber, A | 1 |
| He, Z; Huang, J; Liu, B; Lyu, H; Wang, B; Wang, S | 1 |
| Lei, B; Pang, D; Wan, L; Wang, P; Wu, H; Xia, B; Xu, S; Zhang, D; Zhang, G; Zhang, J; Zhang, X | 1 |
| Bao, C; Chen, D; Du, C; Fan, W; Fu, P; Lou, W; Pan, J; Shen, J; Si, W; Xu, L; Zheng, H; Zhong, G | 1 |
| Laoitthi, P; Parinyanitikul, N; Poovorawan, N; Rattananupong, T; Sithidetphaiboon, P; Sriuranpong, V; Tanpipattanakul, W; Thanasanvimon, S | 1 |
| Cui, YN; Dian, LH; Hu, YJ; Lin, JY; Lu, WL; Su, ZB; Yan, Y; Zhang, JY | 1 |
| Ci, L; Huang, Z; Liu, Y; Liu, Z; Lu, L; Lu, W; Yan, X; Yan, Z; Yu, L | 1 |
| Bando, H; Inoue, K; Iwata, H; Kasai, H; Kuroi, K; Masuda, N; Morita, S; Ohno, S; Ohtani, S; Sakurai, T; Takano, T; Toi, M; Yamamoto, N; Yanagita, Y | 1 |
| Belum, VR; Blinder, VS; Goldfarb, SB; Gucalp, A; Kamboj, M; Lacouture, ME; Virgen, CA | 1 |
| Akiyama, K; Haku, E; Hayami, R; Kawamoto, H; Kojima, Y; Nishikawa, T; Shimo, A; Tsugawa, K | 1 |
| Cara, FE; El-Azem, N; Granados-Principal, S; Pulido-Moran, M; Quiles, JL; Ramirez-Tortosa, CL; Ramirez-Tortosa, M; Sanchez-Rovira, P | 1 |
| Baggio, C; Bhowmick, NA; Billet, S; Chen, JF; Gambini, L; Pellecchia, M; Posadas, EM; Salem, AF; Tseng, HR; Udompholkul, P; Wang, S | 1 |
| Cai, K; Chen, Q; Chen, X; Cheng, J; Guo, Q; He, X; Huang, Y; Jiang, C; Li, C; Liu, L; Lu, Y; Sun, T; Zhang, Y | 1 |
| Chantharasamee, J; Ithimakin, S; Singsuksawat, E; Sootichote, R; Thuwajit, C; Thuwajit, P; Warnnissorn, M; Yenchitsomanus, PT | 1 |
| Barzilay, R; Enzinger, A; Forsyth, AW; Hughes, KS; Lindvall, C; Lorenz, KA; Lui, D; Tulsky, JA | 1 |
| Cai, Q; Chen, Q; Hao, H; Wang, G; Wu, B; Zang, X; Zhang, J; Zheng, X; Zhou, F; Zhu, X | 1 |
| Hu, Y; Nie, G; Song, Y; Tang, H; Wang, J; Wang, Y; Zhao, R; Zhu, X | 1 |
| Cho, E; Ellis, G; Gadi, V; Gralow, J; Linden, H; Rubinstein, L; Specht, J; Wu, Q | 1 |
| Ji, J; Shi, X; Yang, X; Zhai, G | 1 |
| Baek, JS; Cho, CW; Han, SM; Hwang, SJ; Kim, MS | 1 |
| Chen, X; Dai, Y; Fan, W; Gao, G; Jacobson, O; Kiesewetter, DO; Ma, Y; Shan, L; Yung, BC; Zhai, K; Zhang, F; Zhu, G; Zhuo, X | 1 |
| Aguilar-Lemarroy, A; Barrón-Gallardo, CA; Carranza-Rosales, P; Carranza-Torres, IE; Garcia-Chagollan, M; Guzmán-Delgado, NE; Jave-Suárez, LF; Mariscal-Ramirez, I; Martínez-Silva, MG; Pereira-Suárez, AL; Ramírez-Montoya, H | 1 |
| Hu, S; Liu, X; Piao, Y; Shen, Y; Tang, J; Wang, G; Wu, B; Xiang, J; Zhou, Q; Zhou, Z | 1 |
| Alba, E; Álvarez, I; Amir, E; Caballero, R; Calvo, L; Carrasco, E; Casas, M; Crespo, C; Ethier, JL; Gracia Marco, J; Lluch, A; Martin, M; Ocaña, A; Ramos, M; Rodríguez Lescure, A; Rodríguez, CA; Ruíz, A; Ruíz-Borrego, M; Sánchez-Aragó, M; Santaballa, A | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Fujii, Y; Hirahara, N; Hyakudomi, R; Kaji, S; Tajima, Y; Taniura, T; Yamamoto, T | 1 |
| Chen, YZ; Kim, Y; Lee, JK; Soliman, HH; Ying, G | 1 |
| Duan, H; Ji, X; Jiang, L; Qiu, J; Wang, T; Wang, Y | 1 |
| Araki, K; Bun, A; Fujimoto, Y; Higuchi, T; Imamura, M; Kira, A; Miyagawa, Y; Miyoshi, Y; Nishimukai, A; Ozawa, H; Takatsuka, Y | 1 |
| Asakura, M; Houchi, H; Kontani, K; Kosaka, S; Motoki, T; Takahashi, K; Tanaka, H; Yamaguchi, K; Yokomise, H | 1 |
| Balušíková, K; Daniel, P; Jaček, M; Jelínek, M; Kirubakaran, P; Kovář, J; Němcová-Fürstová, V; Ojima, I; Vondrášek, J; Wang, X; Wei, L | 1 |
| Gao, H; Hu, C; Liu, R; Xiao, W; Xie, R | 1 |
| Li, K; Li, S; Wang, B; Wang, X; Yuan, S; Zhao, Q | 1 |
| Al-Arag, S; Cuisinier, F; Gergely, C; Middendorp, E; Orti, V; Salehi, H | 1 |
| Bromberg, J; Cadoo, K; D'Andrea, G; Dang, C; Dickler, M; Fornier, MN; Gilewski, T; Hudis, CA; Modi, S; Morris, PG; Norton, L; Patil, S; Rota, S; Seidman, AD; Sklarin, N; Zamora, S | 1 |
| Beaumont, JL; Griffiths, C; Kwon, N; Paice, JA | 1 |
| Allen, JA; Gradishar, W; Hodges, JS; Raizer, J; Robertson, J | 1 |
| Botteman, M; Cortes, J; Fandi, A; Ko, A; Margunato-Debay, S; Pérez-García, J; Solem, C; Tai, MH; Wan, Y; Whiting, S | 1 |
| Cai, P; Cao, J; Ouyang, B; Pan, T; Wen, X; Xiao, Z | 1 |
| Cai, Y; Chen, J; Dong, H; Fu, Y; Huang, L; Lan, X; Lin, R; Lin, T; Ren, Q; Tan, J; Wang, J; Wang, P; Wang, S; Yang, S; Zhao, H; Zhu, L; Zuo, W | 1 |
| Darrieux, FCDC; Hachul, DT; Hajjar, LA; Sacilotto, L; Scanavacca, MI; Veronese, C; Veronese, P; Wu, TC | 1 |
| Cun, X; He, Q; Li, M; Long, Y; Shi, K; Tang, X; Wei, J; Zhang, Z | 1 |
| Cai, Y; Fu, W; Gu, J; Wang, D; Wang, N; Wang, S; Wang, Z; Yang, B; Zhang, F; Zheng, Y | 1 |
| Bremner, DH; Li, H; Niu, S; Qian, Q; Wang, H; Wu, J; Zheng, H; Zhu, L | 1 |
| Allen, C; Evans, JC; Houdaihed, L | 1 |
| Wang, S; Xiao, Y; Yin, Z; Zong, Q | 1 |
| Chen, XG; Ji, M; Lai, FF; Li, J; Wang, LY; Zhou, Q | 1 |
| Alan, O; Ercelep, O; Hasanov, R; Kaya, H; Mutis, A; Ones, T; Simsek, ET; Telli, TA; Yumuk, PF | 1 |
| Deng, Z; Li, L; Liu, X; Tan, G; Wang, S; Yan, F; Zhang, J; Zheng, H | 1 |
| Chen, C; Cheng, S; Dong, X; Li, L; Liang, X; Liu, S; Liu, T; Sun, H; Wang, Y; Yang, Z; Yao, N; Zhao, X | 1 |
| Adessi, C; Dang, JS; Laurent, J; McIntyre, C; Meneses-Lorente, G; Mercier, F; Ravva, P; Xu, C | 1 |
| Arai, H; Hamabe, Y; Hanai, A; Imai, S; Ishiguro, H; Nakagawa, T; Sozu, T; Toi, M; Tsuboyama, T; Tsuda, M; Yano, I | 1 |
| Bauerschlag, D; Kratzenstein, S; Maass, N; Mundhenke, C; Röcken, C; Schmidt, T; Vollmers, PL | 1 |
| Hayes, DF; Henry, NL; Hertz, DL; Kim, JH; Smith, EML; Stringer, KA; Sun, Y; Vangipuram, K; Yeomans, L | 1 |
| Cao, Y; Chen, D; Chen, Y; Duan, S; Li, M; Pu, X; Wang, H; Wang, Y; Wei, Z; Yin, L; Yuan, Q; Zong, L | 1 |
| Hua, J; Li, L; Lu, J; Suo, S; Zhang, D; Zhang, Q; Zhuang, Z | 1 |
| Tanaka, T; Uchida, H | 1 |
| Jiang, C; Seng, J; Wang, R; Yang, Z; Zhang, T | 1 |
| Du, Y; Han, X; Liu, Z; Lv, S; Qiao, P; Ren, C; Sun, Y; Wang, L; Yang, T; Yu, Z | 1 |
| He, W; Xiao, Q; Yin, L; Yuan, Y; Zhu, X | 1 |
| Bao, T; Blinder, VS; Chen, X; Dickler, MN; Li, Q; Mao, JJ; Piulson, L; Robson, ME; Seidman, AD; Vahdat, LT; Vertosick, E; Vickers, AJ; Zhi, WI | 1 |
| Bae, S; Banchereau, J; Banchereau, R; Blankenship, D; Brookes, HM; Cepika, AM; Chung, CH; George, J; Kim, KI; Lavecchio, E; Levin, MK; Marches, F; Martinek, J; O'Shaughnessy, J; Obermoser, G; Oxley, KL; Palucka, AK; Pascual, V; Smith, JL; Snipes, GJ; Turner, J; Wang, X; Wu, TC; Xu, K; Young, RR; Zurawski, S | 1 |
| Chen, C; Chen, S; Chen, T; Li, Y; Wang, H; Wang, W; Wang, Y; Xu, H; Yan, L; Yang, Q; Zhang, L | 2 |
| Guan, J; He, Z; Kan, Q; Shang, L; Sun, J; Sun, M; Yang, B; Yang, J; Yang, R; Zhang, D; Zhang, H; Zhang, R; Zhang, S; Zhang, T | 1 |
| Asghari, F; Baradaran, B; Haghnavaz, N; Kazemi, T; Khaze, V; Shanehbandi, D | 1 |
| Cabello, C; Oliveira Botelho Ramalho, S; Resende, U; Zeferino, LC | 1 |
| Hazama, Y; Ishida, T; Kurebayashi, J; Matsumoto, K; Matsumoto, R; Moriya, T; Murata, S; Murata, T; Nakai, Y; Nakamura, T; Nomura, T; Shimoya, K; Sugawara, S; Sugihara, M | 1 |
| Chen, Q; Chen, Y; Gao, X; Ge, P; Jiang, X; Li, Z; Luo, S; Ma, J; Song, H; Subinuer, X; Wang, Y; Yang, H; Zhao, D; Zhao, X; Zhu, X | 1 |
| Akin, S; Kas Guner, C | 1 |
| Bloom, S; Brufsky, AM; Dang, CT; Goldstein, LJ; Gradishar, W; Hendricks, CB; Hobday, TJ; Le-Lindqwister, NA; Mayer, IA; Miller, KD; Northfelt, DW; O'Neill, A; Sledge, GW; Sparano, JA; Tevaarwerk, AJ | 1 |
| Higashi, T; Mase, K; Mizutani, M; Moriya, T; Onodera, Y; Ozawa, K; Takagi, S; Takeshita, A; Usuba, O; Yokoyama, M | 1 |
| Ebisui, C; Fukuchi, N; Furukawa, J; Kinuta, M; Kitahara, T; Minoji, T; Okamura, S; Tamai, K; Watanabe, N; Yamamura, N; Yokouchi, H | 1 |
| Aoki, R; Asai, H; Kamei, Y; Komatsu, S; Kusakabe, E; Mizuno, Y; Murakami, A; Nishiyama, K; Sugimori, W; Taguchi, K; Takada, Y; Yamasawa, H; Yamashita, M | 1 |
| Alpaugh, K; Dang, CT; Miller, KD; Northfelt, DW; O'Neill, A; Sledge, GW; Sparano, J; Wolff, AC | 1 |
| Calaf, GM; Carrión, F; Ponce-Cusi, R | 1 |
| Buckley, B; Caffrey, PB; Frenkel, GD; Gibbon, DG; Gounder, M; Hellmann, M; Kane, MP; Kumaran, MN; Nieves-Neira, W; Rodriguez-Rodriguez, L; Shih, W; Song, M; Vaidya, A | 1 |
| Castro, SN; de Castro Baccarin, AL; de Iracema Gomes Cubero, D; Del Giglio, A; Irene, MN; Luz, AS; Móz, LES; Sordi, R | 1 |
| Hayashi, N; Kitani, A; Kuwayama, T; Nakamura, S; Okuyama, H; Sato, T; Takano, T; Tsugawa, K; Yamauchi, H | 1 |
| Feng, L; Han, X; He, C; Jin, J; Liu, X; Ma, X; Mao, A; Wan, X; Wang, Y; Yu, F; Zhang, P; Zhou, T | 1 |
| Clements, D; Giacomantonio, M; Gujar, S; Kennedy, BE; Konda, P; Murphy, JP; Pathak, GP; Schlaepfer, IR; Shah, R; Xu, Z | 1 |
| Alspach, E; Burnette, B; Faget, DV; Flanagan, KC; Fu, Y; Gruosso, T; Johnson, RM; Leahy, K; Luo, X; Mbalaviele, G; Monahan, JB; Murali, B; Park, M; Ren, Q; Ross, MH; Stewart, SA; Su, X; Wang, C; Weilbaecher, KN | 1 |
| Chacko, AM; Chen, IW; Chen, SY; Choi, H; Hu, SH; Liu, T; Qiao, H; Zhou, R | 1 |
| Grebhardt, S; Hansen, R; Harde, J; Marschner, N; Nusch, A; Potthoff, K; Salat, C; Söling, U | 1 |
| Bos, MEMM; Bouma, JM; Claessens, AKM; de Graaf, H; Erdkamp, FLG; Honkoop, AH; Lopez-Yurda, M; Rademaker-Lakhai, JM; Tjan-Heijnen, VCG; van der Sangen, MJC; van Druten, E; van Warmerdam, LJC | 1 |
| Jin, Z; Lei, J; Li, Y; Liu, J; Meng, M; Sun, T; Wang, Q; Xu, H; Xue, H | 1 |
| Dong, W; Jin, D; Li, L; Liu, Y; Meng, Y; Wang, H; Xia, X; Yang, Y; Ye, J | 1 |
| Fang, K; Gao, D; Guo, Z; Li, L; Liu, B; Qi, X; Zhang, X | 1 |
| Diao, K; Dong, Y; Liu, Y; Mi, X; Su, L; Zhao, L | 1 |
| Chen, J; Chen, W; Chen, Y; Shi, J; Tang, C; Wei, J; Xu, Z; Yang, X; Zhang, H | 1 |
| Cresta, S; Damian, S; Gendreau, S; Mayer, IA; Morrissey, KM; Ng, VW; Rooney, I; Schöffski, P; Singel, SM; Spoerke, JM; Wildiers, H; Winer, E | 1 |
| Artuso, S; Bielli, A; Cervelli, V; D'Amico, F; D'Angelo, C; Gentile, P; Leonetti, C; Orlandi, A; Porru, M; Scioli, MG | 1 |
| Boughey, JC; Buzdar, AU; Ellis, MJ; Hunt, KK; Leitch, AM; Meric-Bernstam, F; Royce, ME; Suman, VJ; Unzeitig, GW | 1 |
| Goto, M; Konishi, E; Nakatsukasa, K; Ouchi, Y; Sakaguchi, K; Taguchi, T | 1 |
| Drucker, L; Fishman, A; Komemi, O; Lishner, M; Matalon, ST; Pasmanik-Chor, M; Pomeranz, M; Shochet, GE | 1 |
| Chiu-Lam, A; Ishov, AM; Morozov, VM; Rinaldi, C; Rivera-Rodriguez, A | 1 |
| Aluigi, A; Ballestri, M; Ferroni, C; Foglietta, F; Guerrini, A; Muraro, MG; Sotgiu, G; Spagnoli, GC; Varchi, G | 1 |
| Cha, EY; Lee, JS; Lee, MS; Lee, Y; Na, J; Park, JB; Sul, JY | 1 |
| Kong, J; Leong, WS; Shan, B; Song, H; Song, Z; Tian, Y; Wang, M; Wang, X; Yang, L; Yang, W | 1 |
| Ao, M; Chen, YL; Guo, Y; Liu, FQ; Ran, HT; Tan, MX; Wang, XY; Wang, ZX; Yu, JH | 1 |
| Bahmanzadeh, M; Firozian, F; Ghaffari, F; Nili-Ahmadabadi, A | 1 |
| El-Sokkary, GH; Ismail, IA; Saber, SH | 1 |
| Chen, F; Chen, J; Chen, Z; He, H; Huang, J; Tian, W; Wang, X | 1 |
| Ehrsam, D; Lengerke, C; Meyer Zu Schwabedissen, HE; Porta, F | 1 |
| Hoyt, K; Jashkaran, G; Javed, K; Khairalseed, M; Kim, JW; Parker, KJ | 1 |
| Asghari Jafarabadi, M; Esfahani, A; Fathifar, Z; Ghoreishi, Z; Goodman, KA; Keshavarz, S | 1 |
| Chauhan, SC; Chowdhury, P; Dan, N; Hafeez, BB; Hatami, E; Jaggi, M; Khan, S; Meibohm, B; Nagesh, PKB; Tripathi, MK; Wagh, S; Yallapu, MM | 1 |
| Guo, S; Hu, L; Li, M; Shen, Y; Zhang, Z | 1 |
| Araki, K; Egawa, C; Fukada, I; Imamura, M; Ito, Y; Kira, A; Kobayashi, K; Miyagawa, Y; Miyoshi, Y; Ohno, S; Suwa, H; Takatsuka, Y | 1 |
| Chen, J; Han, L; He, M; Liu, F; Olopade, OI; Wei, M; Yan, Y; Zhao, L | 1 |
| Behbakht, K; Buscema, J; Coleman, RL; Duska, LR; Fabbro, M; Falchook, G; Fu, S; Ghamande, S; Goff, B; Gray, HJ; Kurzrock, R; Leonard, EJ; Lesoin, A; Lin, HM; Lortholary, A; Martin, LP; Matulonis, U; Ray-Coquard, I; Roszak, A; Sawrycki, P; Schilder, RJ; Schwartz, PE; Sheldon-Waniga, E; Tew, W; Venkatakrishnan, K; Zhou, X | 1 |
| Chen, K; Li, M; Liu, Y; Su, Y; Wang, D; Wang, W; Xu, L; Xu, X; Zhou, J | 1 |
| El-Tabba', RM; Khajah, MA; Masocha, W; Mathew, P | 1 |
| Cheng, G; Fang, G; Gou, Y; Qian, Y; Tang, B | 1 |
| Armstrong, P; Gavino, AC; Reichenberg, JS; Woody, MM | 1 |
| Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF | 1 |
| Bian, ZJ; Song, YK; Wang, Y; Wen, YY; Zhao, P | 1 |
| Albrecht, TL; Beebe-Dimmer, JL; Greenwald, MK; Ruterbusch, JJ; Schwartz, AG; Simon, MS | 1 |
| Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M | 1 |
| Coletta, D; Formica, V; Gargano, L; Giuliano, G; Lucchetti, J; Morosetti, D; Palmieri, G; Roselli, M; Sileri, P | 1 |
| Fu, J; Jin, Y; Li, X; Liang, X; Luo, Y; Zhang, J; Zhang, P; Zou, Q | 1 |
| Firuzi, O; Mostoufi, H; Tamaddon, AM; Yousefi, G | 1 |
| Dueñas-Rodríguez, B; Martínez-Martos, JM; Ramírez-Exposito, MJ | 1 |
| Ji, J; Li, X; Lian, B; Liu, X; Xu, G; Zheng, N | 1 |
| Beaudoin, JJ; Bludau, H; Jordan, R; Kabanov, AV; Makita, N; Min, Y; Sokolsky, M; Vinod, N; Wan, X; Wang, A | 1 |
| Cass, AEG; Kobatake, E; Mashimo, Y; Matsumoto, R; Mie, M | 1 |
| Ascenzi, P; Cipolletti, M; Fiocchetti, M; Marino, M; Montalesi, E; Nuzzo, MT | 1 |
| Chen, Y; Han, H; He, Z; Le, Z; Leong, KW; Liu, L; Liu, Z; Mao, HQ; Tian, H; Yang, C; Zhao, P | 1 |
| Cazzaniga, ME; Ciruelos, E; Fabi, A; Garcia-Saenz, J; Lindman, H; Mavroudis, D; Schem, C; Steger, G; Timotheadou, E; Torri, V; Zaman, K | 1 |
| Chen, J; Chen, Z; Cui, X; Li, G; Li, J; Qiao, H; Wang, R; Wang, X; Yang, M; Zhang, Z | 1 |
| Apellaniz-Ruiz, M; Calsina, B; Calvo, I; Cascón, A; Castelo, B; Curras, M; García-Donas, J; Guerra, E; Gutiérrez-Gutiérrez, G; Inglada-Pérez, L; Letón, R; Merino, M; Montero-Conde, C; Remacha, L; Robledo, M; Rodríguez-Antona, C; Roldán-Romero, JM; Sánchez-Barroso, L; Santos, M; Sereno, M | 1 |
| Dang, D; Frost, JA; Li, J; Li, L; Yang, Q; Zuo, Y | 1 |
| Ishikawa, T; Kanbayashi, Y; Nakatsukasa, K; Ouchi, Y; Sakaguchi, K; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshioka, T | 1 |
| Arsenyan, A; Blanchard, S; Burhenn, P; Choi, J; Chung, S; Hurria, A; Katheria, V; Lee, T; Levi, A; Li, D; Luu, TH; Morrison, R; Mortimer, JE; Noonan, AM; Rotter, A; Rubalcava, A; Somlo, G; Soto-Perez-de-Celis, E; Sudan, N; Waisman, JR; Yeon, CH; Yuan, Y | 1 |
| Lang, T; Li, Y; Liu, Y; Ran, W; Yin, Q; Zhai, Y; Zhang, P; Zheng, Z | 1 |
| Li, Z; Lv, Q; Zhang, Y; Zhang, Z; Zhao, Z | 1 |
| Bae, EJ; Lee, MK; Xu, W | 1 |
| Chang, SJ; Choi, JM; Jeong, HJ; Jeong, SA; Kim, SH; Lee, JY; Lee, SJ; Lee, SY; Park, JM; Park, YA; Song, YC | 1 |
| Ghadi, R; Jain, S; Katiyar, SS; Kushwah, V; Rege, MD | 1 |
| Azoulay, D; Leibovici, A; Sharon, R | 1 |
| Cassali, GD; de Barros, ALB; de Oliveira Silva, J; Franco, MS; Oliveira, MC; Roque, MC | 1 |
| Anders, CK; Basch, E; Carey, LA; Choi, SK; Deal, AM; Dees, EC; Jolly, TA; Karuturi, MS; Kimmick, GG; Lee, JT; Muss, HB; Nyrop, KA; Reeder-Hayes, KE; Reeve, BB; Reinbolt, RE; Shachar, SS; Speca, JC; Wood, WA | 2 |
| Aggarwal, R; Bondarenko, I; Ewesuedo, R; Freyman, A; Hingmire, S; Iwase, H; Krivorotko, PV; Lee, KS; Li, R; Li, RK; Pegram, MD; Pikiel, J; Tan-Chiu, E; Vana, A; Yin, D; Zacharchuk, C; Zorzetto, MMC | 1 |
| Elumalai, N; Rajan, M; Rajendran, NK; Ramu, A; Vinothini, K | 1 |
| Chen, IC; Lu, YS; Yang, MH | 1 |
| Anastopoulou, GG; Argyriou, AA; Bikas, C; Dimitropoulou, D; Karanasios, P; Litsardopoulos, P; Lykoura, C; Makridou, A | 1 |
| Fan, S; Gui, R; Guo, J; Li, G; Li, X; Liu, F; Liu, Y; Luo, Y; Ma, J; Nie, X; Niu, W; Wang, H; Wang, X; Xiong, W; Zeng, Z; Zhou, M; Zhou, Y | 1 |
| Chao, TY; Chen, JH; Huang, CC; T H Wu, A; T W Tzeng, D; Tzeng, YM | 1 |
| Chandarlapaty, S; Dang, CT; Hudis, CA; Iyengar, N; Jochelson, M; Modi, S; Norton, L; Patil, S; Smyth, LM; Wang, R | 1 |
| Jiang, J; Li, Y; Piao, L; Zhang, H | 1 |
| Imanishi, S; Kagara, N; Kim, SJ; Miyake, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Tanei, T | 1 |
| Antolín, S; Atienza, M; Benito, S; Caballero, R; Carrasco, E; Escudero, MJ; Falcón, A; Gil-Martin, M; Montaño, Á; Montero, JC; Ocana, A; Orlando, J; Pandiella, A; Pernas, S; Ribelles, N; Rojo, F; Ruiz-Borrego, M; Urruticoechea, A | 1 |
| Alexiou, C; Draack, S; Eberbeck, D; Friedrich, RP; Janko, C; Ludwig, F; Lugert, S; Mühlberger, M; Unterweger, H | 1 |
| Andrés, R; Calvo, I; Canes, J; Ciruelos, E; Gavilá, J; Gonzàlez, X; Llombart-Cussac, A; Marín-Aguilera, M; Martínez, D; Martínez, J; Morales, S; Muñoz, M; Oliveira, M; Paré, L; Pascual, T; Perelló, A; Perez-Garcia, J; Prat, A; Quero, JC; Ruiz, I; Virizuela, JA | 1 |
| An, T; Gong, L; Gong, Y; Kong, L; Li, Y; Xu, X; Yan, J; Yang, X; Yu, C; Zhang, H; Zhou, H; Zhu, H | 1 |
| Bai, R; Huang, X; Jiang, X; Li, M; Li, X; Lin, D; Liu, Z; Mai, D; Pan, L; Su, J; Tan, L; Tan, W; Yang, J; Ye, Y; Zhang, B; Zhang, J; Zhao, Q; Zheng, J; Zheng, Y; Zuo, Z | 1 |
| Duan, XC; Feng, ZH; Hao, YL; Li, H; Li, ZT; Li, ZY; Liu, M; Wang, JR; Xu, MQ; Yao, X; Zhang, S; Zhang, X; Zheng, XC | 1 |
| Chaltiel, L; Clement, E; Dauvillier, S; Dumontet, C; Esteve, D; Fallone, F; Franchet, C; Geneste, A; Lazar, I; Le Gonidec, S; Lehuédé, C; Li, X; Longué, M; Muller, C; Nieto, L; Valet, P; Vaysse, C | 1 |
| Akcay, IM; Arisan, ED; Doganay, GD; Kilbas, PO | 1 |
| Chang, HJ; Chang, HS; Chang, JC; Chen, ST; Cheng, WL; Kuo, SJ; Lin, TT; Liu, CS; Wu, YC | 1 |
| Bhattacharya, A; Li, Y; Yang, L; Zhang, Y | 1 |
| Hirano, A; Inoue, H; Kinoshita, J; Kodera, A; Matsuoka, A; Naritaka, Y; Ogura, K; Sakaguchi, S; Tanaka, N; Yoshimatsu, K; Yukawa, H | 1 |
| Kars, MD; Yıldırım, G | 1 |
| Chen, XX; Fu, KF; Liu, JF; Liu, Y; Pu, Q; Wang, YX; Wu, CL; Yu, XJ; Zhou, LJ | 1 |
| Agapito, G; Altomare, E; Arbitrio, M; Arpino, G; Cannataro, M; Caracciolo, D; Di Martino, MT; Fabiani, F; Galeano, T; Grillone, F; Iuliano, E; Santini, D; Scionti, F; Staropoli, N; Tagliaferri, P; Tassone, P | 1 |
| Petitjean, A; Roze, S; Smith-Palmer, J; Tehard, B; Valentine, W | 1 |
| Baltay, M; Barroso-Sousa, R; Barry, WT; Dang, C; Dillon, D; Fuhrman, K; Getz, A; Guo, H; Krop, IE; Marcom, PK; Mittendorf, EA; Moy, B; Osmani, W; Tan, YB; Tolaney, SM; Winer, EP; Yardley, D | 1 |
| Chen, J; Feng, C; Ji, W; Qu, Y; Rui, M; Wang, S; Xin, Y; Xu, X; Yamashita, F; Zhang, H; Zhang, Q | 1 |
| Berger, T; Cappello, P; Cescon, DW; Chu, MF; Duncan, G; Garcia-Valero, M; Gorrini, C; Hodgson, K; Jafari, SM; Mak, TW; McGaha, TL; Palomero, L; Pujana, MA; Roux, C; Shinde, R; Silvester, J; Wakeham, A | 1 |
| Aghili, M; Akrami, S; Esmati, E; Ghalehtaki, R; Kalaghchi, B; Mousavi, N; Sotoudeh, S; Zare, M | 1 |
| Goodwin, A; O'Connell, DL; Wilcken, N; Willson, ML; Zaheed, M | 1 |
| Cai, ZW; Luo, J; Sun, WL; Wang, L; Zhu, HW | 1 |
| Kamata, H; Sadahiro, S; Yamori, T | 1 |
| Chumsri, S; Colon-Otero, G; Knutson, KL; Li, Z; Lou, Y; Mashadi-Hossein, A; Moreno-Aspitia, A; Perez, EA; Pogue-Geile, KL; Serie, DJ; Soyano-Muller, AE; Thompson, EA; Warren, S | 1 |
| Bhatt, H; Biswas, S; Ghosh, B; Kiran Rompicharla, SV | 1 |
| Le Tourneau, C; Ricci, F | 1 |
| Braunstein, LZ; Cahlon, O; Dang, CT; Eaton, A; Ho, AY; Lee Chuy, K; Liu, JE; Mara, E; Oeffinger, KC; Steingart, RM; Thor, ME; Yu, AF | 1 |
| Hu, Z; Lai, W; Li, R; Ma, Y; Shi, F; Yue, C; Zhao, M | 1 |
| Nakatsumi, H; Nakayama, KI; Shimizu, H; Takeishi, S | 1 |
| Chen, Q; Chen, Y; Han, X; He, W; Lu, E; Sha, X; Sun, Y | 1 |
| Amid, A; Daddiouaissa, D; Elnour, AM; Epandy, MAKMS; Fuad, FAA; Kabbashi, NA | 1 |
| Alarcón, E; Armstrong, AC; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Gómez Villanueva, A; Lindemann, JPO; López Chuken, YA; Maudsley, R; Moschetta, M; Oliveira, M; Outhwaite, E; Pass, M; Pérez-Fidalgo, JA; Philco, M; Rugman, P; Sablin, MP; Schiavon, G; Tamura, K; Turner, NC | 1 |
| Carr, TH; Citi, V; Cutts, R; de Bruin, EC; Fenwick, K; Garcia-Murillas, I; Hrebien, S; Kozarewa, I; Maudsley, R; McEwen, R; Oliveira, M; Ratnayake, J; Schiavon, G; Turner, N | 1 |
| Alsop, K; Beach, J; Bild, A; Bowtell, DDL; Brady, SL; Christie, EL; Copeland, A; deFazio, A; Fereday, S; Hendley, J; Lamb, G; Pandey, A; Pattnaik, S; Rashoo, N; Thorne, H | 1 |
| Gupta, N; Gupta, P; Srivastava, SK | 1 |
| Castanares, MA; Collins, DS; Park, J; Yeo, Y | 1 |
| Beith, J; De Boer, RH; Redfern, A; Truman, M; White, M; Woodward, N; Young, J | 1 |
| Huang, Y; Li, H; Li, Y; Su, X; Wang, X; Zhai, Z | 1 |
| Albain, KS; Baltay, M; Barry, WT; Burstein, HJ; Carey, LA; Dang, CT; Dillon, DA; Ellis, MJ; Fuhrman, K; Guo, H; Hudis, CA; Krop, IE; Marcom, PK; Moy, B; Overmoyer, B; Partridge, AH; Pernas, S; Ritterhouse, L; Rugo, HS; Schneider, BP; Shapira, I; Shen, F; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Horwitz, SB | 2 |
| Ali Hassan, A; Ibrahim, NY; Jassen, MAR | 1 |
| Callan, B; Callan, JF; Foglietta, F; Gao, J; Kamila, S; Logan, K; McHale, AP; McKaig, T; Nesbitt, H; Nomikou, N; Sheng, Y | 1 |
| Dirix, L; Triebel, F | 1 |
| El-Sayed, NS; Parang, K; Park, SE; Sajid, MI; Shirazi, AN; Tiwari, RK | 1 |
| Hu, X; Lian, B; Shao, ZM | 1 |
| Pang, D; Qiao, K; Sui, S; Wang, P; Wang, Q; Wu, H; Xu, H; Xu, S; Yang, W; Zhang, J | 1 |
| Kamata, T; Motono, N; Shimada, K; Uramoto, H | 1 |
| Hou, MF; Lee, YC; Wang, CH; Wang, YY; Yang, YF; Yuan, SF | 1 |
| Albain, KS; Barry, WT; Bellon, JR; Burstein, HJ; Carey, LA; Dang, CT; Ellis, M; Guo, H; Hudis, CA; Krop, I; Marcom, PK; Moy, B; Overmoyer, BA; Partridge, AH; Rugo, HS; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Chang, YC; Chen, SN; Cheng, SP; Lin, CH; Lin, JC; Liu, CL | 1 |
| Boloursaz, LA; Habibi Jouybari, M; Hosseini, S; Irani, M; Mahboobnia, K; Moradi, M | 1 |
| Khanal, P; Yang, X; Yeung, B; Zhao, Y | 1 |
| Coleman, RL; Falchook, G; Schilder, RJ | 1 |
| Benedetti Panici, P; Tomao, F; Tomao, S | 1 |
| Arasu, V; Esserman, LJ; Gibbs, J; Hylton, NM; Jones, EF; Kornak, J; La Yun, B; Li, E; Li, W; Newitt, DC; Partridge, SC; Wilmes, LJ | 1 |
| Atmaja, H; Bashari, MH; Huda, F; Meiyanto, E; Putri, T; Qomarilla, N; Shabrina, S; Subhan, B; Sudji, IR; Tartila, TS | 1 |
| Cai, H; Everett, RS; Thakker, DR | 1 |
| Baurain, JF; Danse, E; Derouane, F; Komuta, M; Yildiz, H; Yombi, JC | 1 |
| Chen, H; Chen, W; Huang, Q; Peng, C; Qiu, Z; Wang, H; Wang, L; Wang, P; Wu, Y; Yao, L | 1 |
| Wang, X; Yu, W; Zhang, F; Zhang, H; Zhao, B | 1 |
| Chen, X; Ewesuedo, R; Li, C; Yin, D | 1 |
| He, Z; Kan, Q; Li, N; Song, H; Sun, J; Wang, D; Wang, K; Wang, X; Wang, Y; Wei, L; Yang, B; Ye, H; Zhang, H; Zhang, X | 1 |
| Bi, X; Duan, S; Jiang, B; Lan, K; Wu, S; Yang, L; Yu, S; Yu, Y; Zhang, A | 1 |
| De Grève, J; Decoster, L; Fontaine, C; Joris, S; Schallier, D; Vanacker, L | 1 |
| Blask, DE; Dauchy, RT; Frasch, T; Hill, SM; Hoffman, AE; Pointer, D; Xiang, S | 1 |
| Kiyohara, T; Makimura, K; Miyamoto, M; Nagano, N; Nakamaru, S; Shijimaya, T; Tanimura, H | 1 |
| Alshreef, A; Chalkidou, K; Culyer, AJ; Dawkins, B; Dixon, S; Edoka, I; MacQuilkan, K; Meads, D; Riddin, J; Ruiz, F; Taylor, M; Ward, S | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, S; Park, YH; Sohn, J | 1 |
| Chen, M; Mu, X; Singh, S; Xiao, B; Yang, B; Zhang, B | 1 |
| Hara, M; Ishida, T; Miki, Y; Sasano, H; Sato, A; Suzuki, T; Takagi, K; Yoshimura, A | 1 |
| Alagoz, O; Ergun, MA; Hajjar, A; Rampurwala, M | 1 |
| Chumakova, A; Esakov, EL; Gullapalli, K; Hale, J; Jensen, J; Lathia, J; Reizes, O; Richards, EG; Torre-Healy, L; Trivedi, D; Wessely, O | 1 |
| Tao, L; Wu, YQ; Zhang, SP | 1 |
| Alvarado Miranda, A; Astudillo de la Vega, H; Bargalló Rocha, E; de la Rosa Oliva, F; Flores-Díaz, D; Gutiérrez-Salmeán, G; Ibarra, A; Lara-Medina, F; Matus-Santos, J; Meneses García, A; Oñate-Acuña, LF; Ruiz Calzada, H; Ruiz García, E | 1 |
| Chen, C; Cui, X; Guo, Z; Lin, D; Wang, S; Xie, C; Zhao, Y; Zhao, Z; Zhou, J | 1 |
| Gong, PY; Li, P; Zhong, D | 1 |
| Chen, L; Ding, N; Duan, Y; He, J; Li, W; Sun, LQ; Xiao, Z; Zhou, J | 1 |
| Bordallo, HN; Dinitzen, AB; Hartmann-Petersen, R; Herwig, KW; Mamontov, E; Martins, ML; Pereira, JEM; Rudić, S | 1 |
| Chen, CJ; Chen, SL; Chen, TT; Dong, ZY; Wang, WR; Wang, YY; Xu, HN; Yan, L; Yang, QL; Yang, S | 1 |
| Chen, X; Niu, S; Williams, GR; Wu, J; Zhang, X; Zheng, H; Zhu, LM | 1 |
| Li, H; Luo, J; Su, J; Wang, J | 1 |
| Çetin, N; Demirci, U; Izgu, N; Karadas, C; Metin, ZG; Ozdemir, L | 1 |
| Byrne, AT; Connor, K; Conroy, E; Crown, J; Dicker, P; Donovan, NO; Gallagher, WM; Kerbel, RS; Miller, IS; Shiels, LP | 1 |
| Balušíková, K; Daniel, P; Halada, P; Jelínek, M; Kovář, J | 1 |
| Branco de Barros, A; Cardoso, V; Cassali, GD; Castro, L; Evangelista, F; Fernandes, RS; Leite, EA; Loures, C; Monteiro, LOF; Oliveira, MC; Reis, D; Sabino, AP | 1 |
| Cai, G; Cao, L; Chen, JY; Feng, Y; Kirova, YM | 1 |
| Gupta, N; Srivastava, SK | 1 |
| Gao, H; He, X; Liu, R; Qin, L; Xiao, W; Xie, R; Yang, X; Yang, Z; Yu, W | 1 |
| Bachert, SE; Gibbs, R; Ginter, PS; Stewart, RL | 1 |
| Hashimoto, T; Inamoto, T; Katayama, T; Kato, H; Kato, T; Kikawa, Y; Mizuno, Y; Ogura, N; Okuno, T; Sugie, T; Takahara, S; Takuwa, H; Tanaka, S; Tsuyuki, S; Yamagami, K; Yamashiro, H; Yamauchi, A; Yoshibayashi, H | 1 |
| Geyer, CE; Ross, M | 1 |
| Gu, N; Hu, K; Huang, S; Liu, J; Sun, Y; Xie, J; Xiong, F; Yan, C; Yan, D; Zhang, Y | 1 |
| He, Z; Na, K; Song, Y; Sun, B; Sun, J; Wang, J; Wang, Y; Wei, W; Yang, L; Zhang, H | 1 |
| Dai, J; Dong, L; Qin, S; Wang, Y; Zhang, B; Zhang, Y; Zheng, P | 1 |
| Alp, D; Benovic, JL; Jacinto, AZ; Lagman, J; Lee, CS; Peng, N; Sayegh, P; So, CH; Sok, V; Sulon, SM | 1 |
| Arase, M; Hashimoto, K; Hirokaga, K; Matsumoto, K; Miki, M; Nishimura, M; Onoe, T; Sakai, H; Soyama, M; Takao, S; Tane, K; Watanabe, S | 1 |
| Aliyev, A; Baydas, T; Celik, RS; Coban, E; Demir, T; Kocyigit, A; Seker, M; Turk, HM | 1 |
| Adamchuk, H; Baselga, J; Boyle, F; Ciruelos, E; Dasappa, L; de Azambuja, E; de la Pena, L; Di Cosimo, S; Fumagalli, D; Gelber, RD; Hackman, J; Hickish, T; Holmes, E; Huober, J; Jackisch, C; Jouannaud, C; Lang, I; Lecocq, C; Piccart-Gebhart, M; Sarp, S; Smith, I; Toral Pena, JC; Untch, M; Wildiers, H; Xu, B | 1 |
| Buckner, CA; Conlon, MS; Lafrenie, RM; Pawelec, G; Shipp, C; Speigl, L | 1 |
| Carey, LA; Clark, LS; Dees, EC; Drobish, A; Hertz, DL; McLeod, HL; Motsinger-Reif, AA; Roy, S | 1 |
| Gollahon, L; Pan, Z | 1 |
| Arias Barquet, L; Caminal Mitjana, JM; Padrón Pérez, N; Rubio Caso, MJ | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HJ; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Oh, DY; Yoon, YK | 1 |
| Bastien, RR; Bernard, PS; Berry, DA; Caballero, R; Carrasco, E; Casas, M; Crespo, C; Davis, C; Ebbert, MT; Ellis, MJ; Furió, V; García, AM; Harris, L; Hudis, C; López-Vega, JM; Martín, M; Munárriz, B; Perou, CM; Pitcher, BN; Prat, A; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Stijleman, IJ; Tuck, DP; Winer, E | 1 |
| Chen, Y; Gao, X; Huang, Y; Li, J; Li, S; Lu, J; Stolz, DB; Sun, M; Venkataramanan, R; Zhang, L; Zhang, X; Zhao, W | 1 |
| Barshack, I; Benayoun, L; Clementi, C; Eldar-Boock, A; Miller, K; Pasut, G; Polyak, D; Satchi-Fainaro, R; Shaked, Y | 1 |
| Gilhuijs, KG; Koolen, BB; Rodenhuis, S; Rutgers, EJ; Valdés Olmos, RA; Vincent, AD; Vogel, WV; Vrancken Peeters, MJ; Wesseling, J | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Gonzalez-Angulo, AM; Hernandez-Aya, LF | 1 |
| Li, CJ; Shi, JF; Sun, YJ; Tao, W; Xue, B; Zhang, Q | 1 |
| Colon-Otero, G; Dakhil, S; Dueck, AC; Franco, S; Ghanem-Cañete, I; Jenkins, RB; Johnson, D; Kahanic, S; McCullough, AE; Moreno-Aspitia, A; Northfelt, D; Palmieri, FM; Patel, T; Perez, EA; Rodeheffer, R; Tenner, KS | 1 |
| Hosokawa, T; Kanbayashi, Y; Kitawaki, J; Taguchi, T | 1 |
| Xian, L; Xie, Y; Yang, Y | 1 |
| Fan, W; Huang, Y; Jiang, D; Sui, M; Zhong, W | 1 |
| Fan, S; Li, L; Mao, J; Shi, Y; Song, B; Tang, J; Wang, B; Yu, X | 1 |
| Han, W; Im, SA; Moon, HG; Moon, WK; Noh, DY; Park, IA; Park, SJ; Shin, HC | 1 |
| Arpornwirat, W; Chen, G; DeSilvio, ML; Gomez, H; Guan, Z; Jiang, Z; Leung, WL; Lorvidhaya, V; Makhson, A; Newstat, B; Oliva, C; Russo, MW; Shen, Z; Tong, Z; Wang, L; Xu, B; Yang, J | 1 |
| Loganathan, R; Nesaretnam, K; Radhakrishnan, AK; Selvaduray, KR | 1 |
| Cavaco, TB; Coombes, RC; Gomes, AR; Gong, C; Harada-Shoji, N; Khongkow, M; Khongkow, P; Khoo, US; Koo, CY; Lam, EW; Laohasinnarong, S; Man, EP; Monteiro, LJ; Olmos, Y; Schwer, B; Tsang, JW; Yagüe, E | 1 |
| Hu, P; Lei, L; Li, JJ; Liu, RB; Wang, JN; Zeng, WG | 1 |
| Alba, E; Ciruelos, E; Liria, MR; Lluch, A; López, R; López-Vega, JM; Martín, M; Muñoz, M; Pérez-Alcántara, F; Sánchez-Rovira, P; Seguí, MÁ | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Höß, C; Huober, J; Jackisch, C; Khandan, F; Kittel, K; Krabisch, P; Kümmel, S; Loibl, S; Mau, C; Minckwitz, Gv; Nekljudova, V; Rezai, M; Schwedler, K; Tesch, H; Untch, M | 1 |
| Feng, Z; Gao, Z; Ye, L; Yin, X; Zhang, A; Zhang, X; Zhou, Y | 1 |
| Hertz, DL; Krens, SD; McLeod, HL | 1 |
| Keegan, AD; Kingsley, C; Perry, A; Porter, HA; Tran, NL | 1 |
| Allen, P; Buchholz, TA; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Kim, MM; Kuerer, HM; Litton, JK; Meric-Bernstam, F; Mittendorf, EA; Woodward, WA | 1 |
| Bhar, P; Gradishar, WJ; Iglesias, J; O'Shaughnessy, J | 1 |
| Agbor-tarh, D; Azim, HA; Baselga, J; Bradbury, I; Criscitiello, C; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Piccart, M; Rubio, IT | 1 |
| Choi, H; Chow, RH; Hwang, JY; Kim, HH; Kisler, K; Lam, KH; Lee, C; Lee, NS; Lin, MY; Shung, KK; Woo, J; Zhou, Q | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH | 1 |
| Seidman, AD | 6 |
| Harada, H; Hicks, MA; Miller, AV; Nakajima, W; Richardson, AC; Windle, JJ | 1 |
| Coser, KR; McSweeney, KR; Rivizzigno, D; Shioda, K; Shioda, T; Yeh, WL | 1 |
| Ayadi, M; Boussen, H; Chraiet, N; Gligorov, J; Krimi, S; Labidi, S; Lagha, A | 1 |
| Colby, A; Colson, YL; Grinstaff, MW; Liu, R; Schulz, MD; Zubris, KA | 1 |
| Ballardini, P; Borghi, A; Corazza, M; Minghetti, S; Virgili, A | 1 |
| Krop, IE | 1 |
| Abbas, R; Bondarenko, I; Chow, LW; Freyman, A; Gupta, S; Vo Van, ML; Xu, B; Zhao, Y | 1 |
| Chen, CM; Li, JW; Liu, GY; Lu, JS; Shao, ZM; Shen, ZZ; Wu, J; Yu, KD | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Aldrighetti, D; Amadori, D; Campone, M; Conte, P; Lee, F; Liu, D; McHenry, MB; Melisko, M; Pivot, X; Rugo, HS; Villanueva, C; Wardley, A | 1 |
| Chen, B; Davidson, NE; Dueck, AC; Geiger, XJ; Gralow, JR; Harris, LN; Jenkins, RB; Kaufman, PA; Kutteh, LA; Lingle, WL; Martino, S; McCullough, AE; Perez, EA; Reinholz, MM; Sledge, GW | 1 |
| Di, GH; Hu, XC; Jia, Z; Lu, YH; Shao, ZM; Sun, S; Tang, LC; Wang, BY; Zhang, J | 1 |
| Haruta, M; Higuchi, T; Inoue, K; Kaneko, Y; Kasai, F; Kurosumi, M; Miyazaki, M; Ogawa, S; Sato-Otsubo, A; Takada, M; Takei, H; Tozuka, K; Watanabe, J | 1 |
| Arnould, T; Michiels, C; Ninane, N; Notte, A | 1 |
| Berger, M; Layman, R; Lustberg, M; Mrozek, E; Olson, E; Poi, MJ; Ramaswamy, B; Shapiro, CL; Wesolowski, R | 1 |
| Heimans, JJ; Postma, TJ; Reijneveld, JC | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Li, J; Liu, X; Miao, Z; Wang, Z; Wu, J; Xu, Y; You, Y; Zhao, T | 1 |
| Agustoni, F; Celio, L; Damian, S; De Benedictis, E; De Braud, F; Mariani, P; Ricchini, F | 1 |
| Rajput, S; Ran, S; Volk-Draper, LD | 1 |
| He, XM; Xiang, H; Yang, HJ; Yu, Y; Zong, XY | 1 |
| Álvarez, I; Andrés, R; Antón, A; Barnadas, A; Calvo, L; Carabantes, FJ; Carrasco, E; Chacón, JI; Crespo, C; Dorca Ribugent, J; Espinosa, E; González, S; Hernando, B; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz Borrego, M; Ruiz, A; Salvador Bofill, J; Sánchez-Rovira, P; Seguí-Palmer, MA; Servitja, S | 1 |
| Angarita, FA; Meek, E; Rodríguez, JL; Sánchez, JO; Tawil, M; Torregrosa, L | 1 |
| Amoroso, MR; Condelli, V; Esposito, F; La Torre, G; Landriscina, M; Lettini, G; Maddalena, F; Matassa, DS; Piscazzi, A; Sisinni, L | 1 |
| Ala-Luhtala, T; Asola, R; Elomaa, L; Heikkinen, M; Huusko, M; Järvenpää, R; Kaleva-Kerola, J; Kellokumpu-Lehtinen, P; Kokko, R; Lehtinen, I; Maiche, A; Möykkynen, K; Tuunanen, T | 1 |
| Gao, J; Guo, J; Li, L; Liu, M; Tang, H; Wu, M; Xie, X | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Crawford, J; Dale, DC; Lyman, GH; Tomita, D; Whittaker, S | 1 |
| Balletta, L; Bridges, A; Cheang, MC; Combest, A; Darr, D; Herschkowitz, JI; Jordan, J; Karginova, O; Liu, M; Perou, CM; Prat, A; Roberts, PJ; Rosen, JM; Sharpless, NE; Usary, J; Zamboni, W; Zhao, W | 1 |
| Bushman, J; Costache, M; Kohn, J; Sheihet, L; Vaughan, A; Zhang, Z | 1 |
| Dong, W; Feng, L; Giordano, SH; Hortobagyi, GN; Jiralerspong, S; Kim, ES | 1 |
| Kim, H; Kim, JH; Lee, JE; Park, GS | 1 |
| Baltazar, F; Moreira, R; Queirós, O; Tavares-Valente, D | 1 |
| Ambrogio, MW; Botros, YY; Chen, X; Cryns, VL; Frasconi, M; Lei, J; Liu, Z; Malin, D; Sauvage, JP; Stoddart, JF; Strekalova, E; Wu, Y | 1 |
| Bach, A; Clawson, A; Conlin, AK; Forero, A; Hackney, MH; Hudis, CA; Lake, D; Moynahan, ME; Norton, L; Seidman, AD; Wright, GS | 1 |
| Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Oya, M; Ueda, Y; Yamagishi, H | 1 |
| Campone, M; Chacko, RT; Chan, S; Dasappa, L; Fasching, PA; Horak, C; Hurtado de Mendoza, F; Leichman, CG; Liu, D; Manikhas, A; Mukhopadhyay, P; Nag, SM; Pusztai, L; Saura, C; Symmans, WF; Tseng, LM; Xing, G | 1 |
| du Bois, A; Hinke, A; Huober, J; Jackisch, C; Kreienberg, R; Kuhn, W; Kurbacher, C; Lueck, HJ; Moebus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M | 1 |
| Geng, J; He, X; Liu, T; Liu, X; Liu, Y; Pang, D; Sun, Q; Zhang, X | 1 |
| Biankin, AV; Caldon, CE; Clark, SJ; Cowley, MJ; Gallego-Ortega, D; Gee, JM; McCloy, RA; Musgrove, EA; Nicholson, RI; Ormandy, CJ; Print, CG; Sergio, CM; Stone, A; Valdes-Mora, F | 1 |
| Fujita, S; Katagata, N; Matsuzaki, M; Nomizu, T; Saito, M; Sakuma, T; Takenoshita, S; Watanabe, F | 1 |
| Ishiguro, H; Kato, H; Kawaguchi, K; Nakamura, K; Namura, M; Nishimura, T; Nishio, N; Ono, K; Shimada, K; Yamada, H; Yamoto, M; Yoshibayashi, H | 1 |
| Fujisawa, F; Hirano, M; Kojima, H; Mitsuhashi, S; Morishita, A | 1 |
| Kawamura, M; Kyoda, S; Nakano, S; Tabei, I; Takeyama, H; Yoshida, K | 1 |
| Agarwal, S; Beckman, J; Cotreau, MM; Dickler, MN; Duarte, A; Mayer, EL; Richly, H; Scheulen, ME; Steelman, L; Strahs, AL; Winer, EP | 1 |
| Graichen, ME; Lobert, S; Morris, K | 1 |
| Niu, L; Ohlfest, JR; Panyam, J; Roger, E; Swaminathan, SK; Toti, U | 1 |
| Chen, Q; Fan, L; Jiang, J; Qi, X; Wang, S; Yang, X; Zhang, Y | 1 |
| Cascini, GL; Evangelista, L; Luigi, M | 1 |
| Aigner, J; Jaeger, D; Marmé, F; Schneeweiss, A; Schuetz, F; Smetanay, K | 1 |
| Abi-Raad, R; Brachtel, EF; Corben, AD; Koerner, FC; Macklin, EA; Popa, I; Taghian, AG; Teo, CH | 1 |
| Chou, LC; Chung, CH; Huang, CH; Huang, LJ; Kuo, SC; Lee, FY; Lee, JC; Lien, JC; Way, TD; Wu, JC | 1 |
| Baş, AL; Gündüz, U; Kars, MD; Uney, K | 1 |
| Boffito, M; Ciardelli, G; Mattu, C; Pabari, RM; Ramtoola, Z; Sartori, S | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
| DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Sammel, MD; Speck, RM; Stineman, MG | 1 |
| Bae, YH; Hu, J; Miura, S; Na, K | 1 |
| Bergh, J; Carlsson, L; Einbeigi, Z; Hatschek, T; Lidbrink, E; Linderholm, BK; Norberg, B; Olsson, ME; Svensson, H; Tallroth, E; von Wachenfeldt, A; Wilking, N | 1 |
| Graichen, ME; Lobert, S | 1 |
| Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Ding, D; Li, D; Wang, H; Wang, L; Wei, J; Yang, Z; Yin, Z; Zhu, M | 1 |
| Banarji, A; Chauhan, PS; Chikati, R; Kumar, CS; Pandrangi, SL; Saxena, S | 1 |
| Hayashi, Y; Inoue, K; Kubo, K; Kurozumi, K; Matsumoto, H; Nagai, S; Ohkubo, F; Takei, H; Tsuboi, M | 1 |
| Adkins, CE; Bohn, KA; Geldenhuys, WJ; Liu, X; Lockman, PR; Mittapalli, RK; Nounou, MI; Palmieri, D; Qhattal, HS; Smith, QR; Steeg, PS; Terrell, TB | 1 |
| Armesilla, AL; Brown, S; Darling, JL; Jiang, W; Kannappan, V; Kumar, IS; Liu, P; Tang, JZ; Tawari, PE; Wang, W | 1 |
| Barbieri, E; Bettelli, S; Conte, PF; Dieci, MV; Ficarra, G; Guarneri, V; Omarini, C; Piacentini, F | 1 |
| Baby, T; Jayakumar, R; Nair, SV; Rejinold, NS | 1 |
| Chung, S; Kubo, M; Low, SK; Nakamura, Y; Sasa, M; Takahashi, A; Zembutsu, H | 1 |
| Choi, K; Jeong, SY; Kim, K; Koo, H; Kwon, IC; Lee, SC; Min, KH; Park, JH; Park, K | 1 |
| Abbruzzi, A; Chen, C; Come, SE; Dang, CT; Hudis, CA; Iyengar, NM; Lehman, R; Lin, N; Morris, PG; Moy, B; Norton, L; Oeffinger, KC; Patil, S; Steingart, R; Winer, EP | 1 |
| Bai, J; Cheng, Q; Fang, L; Li, LT; Liu, JJ; Qi, YD; Zheng, JN | 1 |
| Aksoy, S; Altundag, K; Sendur, MA; Zengin, N | 1 |
| Al-Sakaff, N; Bell, R; Chang, J; Feng, FY; Heinzmann, D; Jassem, J; Láng, I; Lopez, RI; Semiglazov, V | 1 |
| Ellervik, U; Frejd, T; Manner, S; Oltner, VT; Oredsson, S | 1 |
| Lee, C; Paul, A; Prakash, S; Rodes, L; Shao, W; Zhao, B | 1 |
| Aura, CM; Azim, HA; Baselga, J; Bavington, M; Cure, H; de Azambuja, E; Di Cosimo, S; Domont, J; Eidtmann, H; Ellis, C; Ferro, A; Gamez, C; Gebhart, G; Ignatiadis, M; Maetens, M; Piccart-Gebhart, M; Rothé, F; Rouas, G; Sotiriou, C; Toral-Peña, JC; Vuylsteke, P | 1 |
| Cai, DY; Gao, X; Hong, TT; Wu, XH | 1 |
| Alvarez, I; García-Estévez, L; Lluch, A; Muñoz, M; Seguí, MÁ; Tusquets, I | 1 |
| Cruz, P; Espinosa, E; Higuera, O; Torres, M | 1 |
| Abraham, J; Adamson, LM; Buyse, M; Jacobs, SA; Jankowitz, RC; Limentani, SA; Tan, AR; Tierno, MB; Wolmark, N | 1 |
| He, H; Jia, J; Li, Z; Liu, J; Wang, J; Zhang, W | 1 |
| Fan, T; Fan, Z; Li, J; Lin, B; Ouyang, T; Wang, T; Xie, Y | 1 |
| Balasubramanian, SU; Harfouche, R; Luchette, M; Papa, AL; Sarangi, S; Sengupta, S; Sidiqui, A | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Alcazar-González, GA; Barrera-Saldaña, HA; Calderón-Garcidueñas, AL; Castruita-Avila, AL; Cerda-Flores, RM; Escorza-Treviño, S; Garza-Rodríguez, ML; González-Guerrero, JF; le Brun, S; Olano-Martin, E; Rubio-Hernández, G; Simon-Buela, L | 1 |
| Atkins, JN; Azar, CA; Baez-Diaz, L; Bandos, H; Bear, HD; Brufsky, AM; Costantino, JP; Farrar, WB; Fehrenbacher, L; Geyer, CE; Mamounas, EP; Margolese, RG; Paik, S; Rastogi, P; Robidoux, A; Sarwar, S; Shibata, HR; Swain, SM; Tang, G; Wolmark, N | 1 |
| André, F; Campone, M; Dalenc, F; El-Hashimy, M; Gligorov, J; Hurvitz, SA; Jhangiani, H; Lincy, J; Llombart, A; Miao, S; Mirshahidi, HR; O'Regan, RM; Sahmoud, T; Soria, JC; Tan-Chiu, E; Taran, T; Tjan-Heijnen, VC | 1 |
| Kawamura, R; McAllister, SD; Murase, R; Neelakantan, H; Walker, EA; Ward, SJ | 1 |
| Ades, F | 1 |
| Guan, Z | 1 |
| Chaigneau, L; Chelly, J; Fiteni, F; Limat, S; Meneveau, N; Monnot, T; Montcuquet, P; Nerich, V; Perrin, S; Pivot, X; Villanueva, C; Voidey, A | 1 |
| Aliabadi, HM; Falamarzian, A; Lai, R; Lavasanifar, A; Molavi, O; Seubert, JM; Uludağ, H | 1 |
| Cai, B; Edgerton, SM; Huang, J; Lee, CK; Li, F; Liu, B; Lyu, H; Tan, J; Thor, AD; Wang, S; Yang, X | 1 |
| Chi, HD; Liu, Z; Orlando, M; Quinlivan, M; Xu, B; Zhang, XQ | 1 |
| Audhuy, B; Berdah, JF; Buyse, M; Delbaldo, C; Greget, S; Laplaige, P; Mousseau, M; Piedbois, P; Priou, F; Quinaux, E; Serin, D; Teissier, E; Zelek, L | 1 |
| Ang, WT; Ho, GH; Koh, QM; Koong, HN; Lin, VC; Sivaramakrishnan, G; Sun, Y | 1 |
| Chang, Y; Hu, X; Li, Z; Lv, F; Nan, F; Tian, T; Zhang, M; Zhang, X | 1 |
| Blanco, E; Ferrari, M | 1 |
| Li, Q; Luo, Y; Ma, D; Song, Q; Su, B; Tan, W; Wang, C; Wang, L; Zhang, Y | 1 |
| Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T | 1 |
| Boughey, JC; Buzdar, AU; Ellis, MJ; Ewer, MS; Hunt, KK; Leitch, AM; McCall, LM; Meric-Bernstam, F; Royce, M; Suman, VJ; Unzeitig, G | 1 |
| Agbor-Tarh, D; Aktas, B; Azim, HA; Baselga, J; Bradbury, I; de Azambuja, E; Di Cosimo, S; Dinh, P; Dreosti, L; Eidtmann, H; Greger, JG; Hsieh, RK; Huang, CS; Jackisch, C; Kim, SB; Piccart, M; Smith, I; Vuylsteke, P | 1 |
| Cao, Y; Chen, J; Hu, P; Huang, Q; Li, Z; Ouyang, Q; Wu, X | 1 |
| Gao, X; Huang, Y; Li, J; Li, S; Lu, J; Venkataramanan, R; Zhang, P; Zhang, X; Zhang, Y; Zhao, W | 1 |
| Cai, JX; Chen, SY; Dong, Q; Dong, YL; He, HR; Hu, SS; Lu, J; Sun, JY; Wang, TT; Xie, J; Xing, JF; Zhang, WP | 1 |
| Cai, J; Chen, S; Dong, Q; Dong, Y; He, H; Hu, S; Lu, J; Sun, J; Wang, T; Xie, J; Xing, J; Zhang, W | 1 |
| Carafa, M; Celia, C; Cilurzo, F; Di Marzio, L; Gentile, E; Paolino, D; Ventura, CA; Wolfram, J | 1 |
| Amiri-Kordestani, L; Liewehr, DJ; Lin, NU; Palmieri, D; Steeg, PS | 1 |
| Anderson, T; Blum, JL; Danso, M; Espina, V; Florance, A; Holmes, FA; Krekow, L; Liotta, LA; Mahoney, J; McIntyre, KJ; Nagarwala, YM; O'Shaughnessy, JA; Osborne, CR; Pippen, J | 1 |
| Day, JM; Foster, PA; Kasprzyk, PG; Meyer-Losic, F; Newman, SP; Purohit, A; Reed, MJ | 1 |
| Aharon, A; Alishekevitz, D; Brenner, B; Bril, R; Fremder, E; Gingis-Velitski, S; Loven, D; Miller, V; Munster, M; Scherer, SJ; Shaked, Y; Voloshin, T | 1 |
| Engel, N; Fuellen, G; Kerkhoff, C; Reimer, T; Struckmann, S; Warsow, G | 1 |
| Baba, Y; Kagara, N; Kim, SJ; Kishi, K; Maruyama, N; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y; Tsunashima, R | 1 |
| Abraham, J; Caldas, C; Chan, S; Dean, S; Dunn, J; Earl, HM; Fenwick, N; Gallagher, C; Gounaris, I; Harries, M; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; Iddawela, M; Laing, R; McAdam, K; Provenzano, E; Ritchie, D; Skene, A; Vallier, AL; Wishart, G; Young, J | 1 |
| Ahn, JS; Chang, W; Choi, MK; Im, SA; Im, YH; Kim, S; Lee, SY; Park, YH; Woo, SY | 1 |
| Amid, A; Fouz, N; Hashim, YZ | 1 |
| Ding, ZY; Guo, F; Han, YL; Liang, XF; Liu, L; Liu, ZZ; Ma, DC; Xie, XD; Yu, HY | 1 |
| Ishikawa, T; Mizuyama, Y; Nakagawa, H; Ohno, Y; Shinto, O; Takashima, T; Tamura, T | 1 |
| Enomoto, T; Kikuchi, M; Kosaka, Y; Minatani, N; Nishimiya, H; Sengoku, N; Tanino, H; Waraya, M; Watanabe, M | 1 |
| Nagahara, M; Nakagawa, T; Sato, T; Sato, Y; Sugihara, K | 1 |
| Aomatsu, N; Asano, Y; Hirakawa, K; Ishihara, S; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Morisaki, T; Noda, S; Onoda, N; Takashima, T; Watanabe, M | 1 |
| Enomoto, T; Habiro, T; Hatate, K; Hayashi, K; Oshida, S; Sengoku, N; Watanabe, M | 1 |
| Azarnia, N; Baselga, J; Byakhov, M; Cortés, J; Forenza, S; Goldfarb, RH; Hudis, CA; Llombart, A; Lokanatha, D; Manikhas, A; Matera, J; Roman, L; Rozencweig, M; Semiglazov, VF | 1 |
| Ali, DA; Badr El-Din, NK; El-Dein, MA; Ghoneum, M | 1 |
| Kashihara, H; Murata, T; Shimizu, Y; Taga, R; Tsuji, K; Yamada, C; Yonezawa, M; Yoshino, H | 1 |
| Abe, S; Goto, H; Kamei, T; Nakajima, T; Taniwaka, K; Yoshioka, T | 1 |
| Chang, TK; Chuang, YH; Li, PC; Lin, CJ; Wang, YH | 1 |
| Brindley, DN; Chen, X; Hajar, A; Li, S; Parissenti, AM; Vo, T; Wang, H; Wang, Z | 1 |
| Baldassarre, G; Barbareschi, M; Croce, CM; Fassan, M; Galligioni, E; Gasparini, P; Ishii, H; Lovat, F; Schiappacassi, M; Vecchione, A | 1 |
| Fu, L; Gu, F; Ma, Y; Zhao, L | 1 |
| Chen, ML; Li, K; Zhang, J; Zhu, ZL | 1 |
| Fan, W; Han, N; Huang, Y; Jiang, D; Wang, S; Xu, L; Xu, M; Zhou, L | 1 |
| Artemov, D; Kato, Y; Zhu, W | 1 |
| Ben-Ami, S; Friedman, E; Har-Zahav, G; Kaufman, B; Laitman, Y; Pud, D; Rubinek, T; Symon, Z; Wolf, I; Yeheskel, A | 1 |
| Andrade, CT; Andrade, DA; Costa, AM; Dal Lago, L; Monteiro, AJ; Nunes, JS; Vieira, RA; Zucca-Matthes, G | 1 |
| Liu, Z; Zhang, S; Zhang, XS | 1 |
| Craik, CS; Duriseti, S; King, ML; LeBeau, AM; Murphy, LL; Murphy, ST; Sevillano, N; VanBrocklin, HF | 1 |
| Baldwin, RM; Chhibber, A; Hudis, CA; Kroetz, DL; Kubo, M; Li, M; McLeod, HL; Mefford, J; Nakamura, Y; Owzar, K; Pendergrass, SA; Plenge, RM; Ratain, MJ; Ritchie, MD; Shulman, LN; Stahl, EA; Winer, EP; Witte, JS; Zembutsu, H | 1 |
| Chen, NF; Ho, WH; Lu, FJ; Tseng, TH; Wang, CJ; Yang, MY | 1 |
| Fan, P; Jordan, VC; Obiorah, I; Sengupta, S | 1 |
| Avila, A; Gollahon, L; Pan, Z | 1 |
| Hurvitz, SA; Megerdichian, C; Olimpiadi, Y | 1 |
| Cui, Y; Gu, Y; Huang, C; Li, M; Li, Y; Wang, X | 1 |
| Ciruelos, E; Jackisch, C | 1 |
| Chen, C; Cheng, Z; Gan, H; Jiang, C; Jiang, Z; Liu, H; Zhang, Q; Zhao, S | 1 |
| Budi, L; Cseh, J; Dank, M; Erfan, J; Landherr, L; Mangel, L; Piko, B; Ruzsa, A | 1 |
| Abraham, JE; Bowden, SJ; Burns, R; Caldas, C; Dorling, L; Dunn, JA; Earl, HM; Guo, Q; Hardy, R; Hiller, L; Ingle, S; Jones, L; Pharoah, PP; Poole, CJ; Tyrer, J; Vallier, AL | 1 |
| Baabur-Cohen, H; Blau, R; Epshtein, Y; Ferber, S; Kisin-Finfer, E; Redy, O; Satchi-Fainaro, R; Shabat, D | 1 |
| Mazzocato, C | 1 |
| Cai, Y; Chen, C; Chen, S; Huang, J; Lu, X; Wang, Z; Wu, Q; Yang, Q; Zhu, L | 1 |
| Railey, E; Sledge, GW; Smith, ML; White, CB | 1 |
| Andersen, KA; Burkard, ME; Raines, RT; Rocque, GB; Tevaarwerk, AJ; Weaver, BA; Wilke, LG; Yeum, D; Zasadil, LM | 1 |
| Hu, X; Jia, Z; Liu, G; Lu, Y; Lv, F; Qiu, L; Shao, Z; Sun, S; Tang, L; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, Q; Zheng, C | 1 |
| Du, LL; Feng, Q; Gao, LY; Hou, WJ; Liu, XY; Ma, XF; Niu, YJ; Pang, WH; Pei, XW; Qiu, C; Wang, JC; Yu, MZ; Zhang, Q | 1 |
| Cai, J; Chen, S; Dong, Y; Hu, S; Lu, J; Xing, J; Zhang, W | 1 |
| Chargari, C; Libert, N; Magne, N; Meillan, N; Tanz, R; Vedrine, L | 1 |
| Charalambous, E; Dimopoulos, MA; Dionysopoulos, D; Fountzilas, G; Kotoula, V; Koutras, A; Kouvatseas, G; Papandreou, CN; Papazisis, K; Pectasides, D; Pentheroudakis, G; Samantas, E; Zagouri, F | 1 |
| Knopp, MV; Layman, R; Lustberg, M; Mrózek, E; Ramaswamy, B; Shapiro, CL; Vecchione, A | 1 |
| Carey, LA; Clark, LS; Dees, EC; Drobish, A; Hertz, DL; Jack, J; McLeod, HL; Motsinger-Reif, AA; Roy, S | 1 |
| Arun, B; Cohen, L; Lam, CY; Ratcliff, CG; Valero, V | 1 |
| Jackson, K; Li, W; Liu, J; Shi, R; Zhao, Y | 1 |
| Amanpour, S; Behrouzi, B; Khorgami, Z; Muhammadnejad, S; Sadighi, S | 1 |
| Anwar, MF; Asif, M; Beg, MN; Garg, V; Gaur, S; Kardam, H; Suri, S; Yadav, D | 1 |
| Chen, A; Chen, S; Han, Q; Hu, C; Li, S; Yang, M; Zhang, Z | 1 |
| Alba, E; Brase, JC; Caballero, R; Calvo, L; Carrasco, E; Casas, M; Crespo, C; Fisch, K; Krappmann, K; Kronenwett, R; Martin, M; Munarriz, B; Petry, C; Rodriguez, CA; Rodriguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Weber, KE | 1 |
| Ando, M; Aogi, K; Fujiwara, Y; Hamano, T; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Ohono, S; Shimizu, S; Sukigara, T; Yamamoto, N; Yamauchi, H | 1 |
| Kudo, S; Makino, T; Ogata, T | 1 |
| Dolfi, SC; Haffty, BG; Hirshfield, KM; Jäger, AV; Medina, DJ; Yang, JM | 1 |
| Chen, J; Dong, X; Li, D; Liu, M; Liu, R; Liu, Z; Luo, Y; Ran, J; Yan, B; Zhou, J | 1 |
| Burbujo, J; Calderón-Komaromy, A; Córdoba, S; de Pablo, NP; Freites-Martínez, A; Martinez-Sánchez, D | 1 |
| Ding, HJ; Han, X; Hu, ML; Leng, Y; Shi, JF; Sun, YJ; Yang, N; Zhang, JX | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Glück, S | 1 |
| Di, GH; Jiang, YZ; Liu, GY; Peng, WT; Shao, ZM; Wu, J; Yu, KD | 1 |
| Bongaerts, AH; Brouwers, AH; de Jong, JR; de Vries, EG; Gaykema, SB; Lub-de Hooge, MN; Oude Munnink, TH; Perik, PJ; Schröder, CP | 1 |
| Arima, H; Eguchi, Y; Hirata, M; Ijichi, T; Ishigami, S; Kijima, Y; Kurahara, H; Nakajo, A; Natsugoe, S; Okumura, H; Shinden, Y; Uenosono, Y; Yoshinaka, H | 1 |
| Hardy, RW; Rezonzew, G; Siegal, GP; Wang, D; Zhao, X | 1 |
| Ong, JL; Roy, SS; Satsangi, A; Satsangi, RK; Vadlamudi, RK | 1 |
| Liang, F; Liu, J; Rayner, S; Xiong, J; Zhu, L | 1 |
| Blakely, T; Kvizhinadze, G; Rivalland, G; Webber-Foster, R | 1 |
| Guan, Y; Liu, J; Liu, S; Liu, X; Niu, Y; Wang, L; Wang, Y; Zhang, W | 1 |
| Alavi, SE; Ebrahimi Shahmabadi, H; Koohi Moftakhari Esfahani, M; Movahedi, F | 1 |
| Barcenas, CH; Buchholz, TA; Elting, LS; Giordano, SH; Hortobagyi, GN; Niu, J; Smith, BD; Zhang, N; Zhang, Y | 1 |
| Abu-Khalaf, MM; Bai, Y; Bossuyt, V; Cheng, H; Harris, LN; Rimm, DL; Sikov, W; Sinclair, N | 1 |
| Altieri, DC; Bosari, S; Faversani, A; Lopergolo, A; Moro, GP; Rivadeneira, D; Schultz, DC; Tosi, D; Vaira, V | 1 |
| Ding, C; Jia, L; Li, W; Li, Y; You, W; Zhai, B; Zhang, B; Zhi, H | 1 |
| Bartonova, I; Dincakova, L; Halada, P; Kovar, J; Pavlikova, N | 1 |
| Alpaugh, RK; Andreopoulou, E; Bhalla, K; Fehn, K; Fineberg, S; Fiskus, W; Hershman, DL; Huang, M; Kalinsky, K; Makower, D; Montgomery, LL; Negassa, A; Pellegrino, CM; Sparano, JA; Tu, Y; Wiechmann, LS | 1 |
| Colombo, L; Lamb, C; Lanari, C; May, M; Molinolo, A; Rojas, P; Sequeira, G; Vanzulli, SI | 1 |
| Maeda, T; Sakuma, H; Yagi, Y; Yoshimitsu, Y | 1 |
| Ishizuna, K; Kawashima, M; Kojima, M; Ninomiya, J; Nozaki, M; Ogawa, T; Ueda, Y; Yamagishi, H | 1 |
| Bao, J; Jiang, YZ; Peng, WT; Shao, ZM; Yu, KD | 1 |
| Ballman, KV; Goodwin, PJ; Levine, M | 1 |
| Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Hudis, CA; Kimmick, G; Martino, S; Muss, H; Norton, L; O'Regan, R; Perez, EA; Schneider, CJ; Shapiro, CL; Shulman, LN; Winer, EP | 1 |
| Cai, KQ; Domanitskaya, N; Egleston, B; Foster, K; Hopper-Borge, E; Jacobs, J; Mahdaviyeh, Y; Malofeeva, E; Paulose, C; Peiffer, E; Wangari-Talbot, J; Zhou, Y | 1 |
| Chander, SK; Day, JM; Ferrandis, E; Foster, PA; Jourdan, FL; Leese, MP; Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Regis-Lydi, S; Stengel, C | 1 |
| Adesina, SK; Akala, EO; Capala, J; Holly, A; Kramer-Marek, G | 1 |
| Cha, HJ; Choi, YH; Eo, JW; Kang, YJ; Kim, HS; Kim, WJ; Leem, SH; Ock, MS; Rhyu, DW; Yi, JM | 1 |
| Bondareva, A; Jirik, FR; Singla, AK | 1 |
| Chen, Y; Huang, Y; Li, J; Li, S; Venkataramanan, R; Zhang, P; Zhang, X; Zhao, W | 1 |
| Dai, MS; Tseng, YC | 1 |
| Conzen, SD; Di Rienzo, A; Fleming, GF; Maranville, JC; Nanda, R; Skor, MN | 1 |
| Camps, J; Carrascosa, M; Climent, MÁ; Fernández, A; Gavilá, J; Gozalbo, F; Guerrero, Á; Guillem, V; Ruiz, A | 1 |
| Cao, X; Fu, P; Li, L; Sun, L; Zhao, C | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| DeSilvio, M; Ellis, C; Guan, Z; Jiang, Z; Leigh, M; Russo, M; Shen, Z; Tong, Z; Xu, B; Yang, J | 1 |
| Bratos, R; Colomer, R; Escudero, MJ; Gil, M; Gil-Martin, M; Gonzalez-Martin, A; Guerra, J; Hernandez-Agudo, E; Hilberg, F; Marquez, R; Quintela-Fandino, M; Rodriguez-Martin, C; Urruticoechea, A; Vlassak, S | 1 |
| Jonas, W; Li, X; Liu, Y; Nikolinakos, P; O'Regan, RM; Pippas, A; Srinivasiah, J; Torres, M; Zelnak, AB | 1 |
| De Kerckhove, C; De Kerckhove, M; Haraguchi, M; Inoue, K; Irie, J; Izumida, R; Kitajima, M; Kosaka, M; Matsuda, S; Mine, T; Ohno, T; Shinichiro, I; Tanaka, T; Tokai, H; Yoshioka, H | 1 |
| Lei, N; Li, W; Li, Y; Liu, X; Peng, B; Zhang, JY | 1 |
| Cheng, X; Ding, L; Jia, Y; Lin, Q; Lu, Y; Wang, C; Wang, Y; Weng, Z; Wu, K; Zhu, M | 1 |
| Chen, X; Dai, J; Jin, J; Li, Y; Mei, M; Xie, D; You, F; Zhang, Y | 1 |
| Baena, JM; Bayo, J; Blancas, I; Casal, J; Ciruelos, E; de la Haba, J; de Villena, MC; Galan, A; Gil, M; Jaen, A; Jara, C; Manso, L; Mel, JR; Murias, A; Salvador, J; Sanchez Rvira, P | 1 |
| Cai, R; Li, Q; Liu, M; Luo, Y; Ma, F; Wang, L; Xu, B; Xu, N | 1 |
| Harder, BG; Lang, JE; Wong, PK; Wu, T; Zhang, DD | 1 |
| Banik, P; Kumar, BN; Mandal, M; Parida, S; Rajput, S | 1 |
| Arulvasu, C; Manikanadan, R; Pandi, M; Raj, KG; Sambantham, S | 1 |
| Agoulnik, S; Chow, J; Dezső, Z; Funahashi, Y; Oda, Y; Oestreicher, J; Santiago, S; Weaver, A | 1 |
| Acevedo, R; Vaidya, GN | 1 |
| Furuhata, Y; Miura, D; Shimizu, K; Yoneyama, K | 1 |
| Emami, J; Hasanzadeh, F; Lavasanifar, A; Minaiyan, M; Mostafavi, A; Rezazadeh, M; Rostami, M; Sadeghi, H | 1 |
| Gao, B; Mu, W | 1 |
| Chen, X; Chuan, X; Dai, W; He, B; Lin, J; Song, Q; Wang, X; Zhang, H; Zhang, Q | 1 |
| Ko, YT; Ruttala, HB | 1 |
| da Silva Lima, JM; Hoff, PM; Mano, MS; Oliveira, JA; Piato, JR; Santana, IA; Testa, L | 1 |
| Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A | 1 |
| Kontrogianni-Konstantopoulos, A; Martin, SS; Perry, NA; Vitolo, MI | 1 |
| DeNardo, D; Griggs, C; Hall, K; Kohio, P; Rajput, S; Ran, S; Volk-Draper, L | 1 |
| Herbert, BS; Sprouse, AA | 1 |
| He, H; Liu, H; Wang, J; Yan, X; Zhang, Q; Zou, K | 1 |
| Gireesh, KK; Gupta, H; Manna, TK; Sreeja, JS; Thomas, GE | 1 |
| Dranitsaris, G; Kaura, S; King, J; Sun, W; Wang, L; Yu, B; Yuan, P; Zhang, A; Zhou, Y | 1 |
| Masocha, W | 1 |
| Amano, S; Enomoto, K; Hara, Y; Makishima, M; Nagashima, S; Sakurai, K; Suzuki, S | 1 |
| Dayn, Y; Emerson, BM; Khan, SY; Kim, HJ; Lee, MC; Lopez-Diaz, FJ; Pourmand, N; Radenbaugh, AJ; Tariq, MA; Vaske, CJ | 1 |
| Nahta, R; O'Regan, RM; Paplomata, E | 1 |
| Ding, L; Gu, Y; Li, R; Shu, C; Yin, D; Yin, Y; Zhong, W | 1 |
| Bachinger, A; Jaeger, D; Marmé, F; Schneeweiss, A; Schuetz, F; Seitz, J; Sinn, HP; Smetanay, K; Zorn, M | 1 |
| Barar, J; Hejazi, MS; Samadi, N; Sharifi, S | 1 |
| Chen, F; Chen, Y; Cheng, B; Fang, Y; Qu, X; Wang, Z; Xiong, B | 1 |
| Iida, S; Iwamoto, M; Kurita, T; Saegusa, H; Takei, H; Uchida, E; Yamashita, K; Yanagihara, K | 1 |
| Apellániz-Ruiz, M; Calvo, I; Cascón, A; Castelo, B; García-Donás, J; García-Estévez, L; Guerra, E; Gutiérrez-Gutiérrez, G; Ingelman-Sundberg, M; Johansson, I; Leandro-García, LJ; Lee, MY; Robledo, M; Rodríguez-Antona, C; Sánchez-Barroso, L; Sereno, M | 1 |
| Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Makrantonakis, P; Malamos, N; Mavroudis, D; Polyzos, A; Saloustros, E; Ziras, N | 1 |
| Chen, BS; Feng, QZ; Huang, ZJ; Jiang, L; Luo, Q; Luo, WY; Wu, BL; You, J | 1 |
| Chen, Z; Erin, N; Gorczynski, RM; Khatri, I; Podnos, A | 1 |
| Cao, S; Jiang, X; Wang, F; Wang, Y; Wei, Y; Xiong, Y; Xu, S; Zhang, Q; Zhang, S; Zou, A | 1 |
| Albain, KS; Barlow, WE; Budd, GT; Burton, GV; Chew, HK; Cho, JK; Flaherty, LE; Gralow, JR; Hobday, TJ; Hortobagyi, GN; Isaacs, C; Lew, DL; Livingston, RB; McGregor, BA; Moore, HC; Moore, TD; Rinn, KJ; Salim, M; Srkalovic, G; Stewart, JA | 1 |
| Engel, JB; Gehrmann, M; Hengstler, S; Honig, A; Keller, D; Kranke, P; Schmidt, M | 1 |
| Abreu, GR; Amorim, MH; Borgo, MV; Carvalho, AL; Gouvea, SA; Romero, WG; Silva, FB | 1 |
| Alzouebi, M; Ramakrishnan, S; Rennie, I; Salvi, S | 1 |
| Dragun, AE; Dunlap, NE; Jain, D; Meena, RA; Quillo, AR; Riley, EC; Shaughnessy, JN | 1 |
| Bora, HK; Chourasia, MK; Datta, D; Meher, JG; Panchal, SB; Pawar, VK; Sharma, K; Singh, A; Singh, P; Singh, Y | 1 |
| Frankel, P; Kirschenbaum, M; Kruper, L; Luu, T; Shaw, S; Shinde, AM; Somlo, G; Vito, C; Vora, NL; Yim, JH; Yu, KW; Zhai, J | 1 |
| Boughey, JC; Carey, LA; Carpenter, J; Connolly, RM; Davidson, NE; Fetting, JH; Gabrielson, E; Goetz, MP; Jacobs, LK; Jeter, SC; Khouri, N; Leal, JP; Mhlanga, J; Miller, RS; O, JH; Powers, P; Sideras, K; Stearns, V; Storniolo, AM; Wahl, RL; Walsh, B; Watkins, S; Wolff, AC; Zhang, Z; Zhou, XC; Zorzi, J | 1 |
| Eustermann, H; Harich, HD; Hinke, A; Jackisch, C; Reichert, D; Schoenegg, W; Selbach, J; Tesch, H; Welslau, M; Wohlfarth, T | 1 |
| Augustin, HG; Besemfelder, E; Hu, J; Jugold, M; Kapel, SS; Korn, C; Pasparakis, M; Savant, S; Srivastava, K; Teichert, M; Thomas, M | 1 |
| Blanchard, MS; Brown, J; Choi, A; Chung, CT; Doan, CM; Feng, T; Hurria, A; Katheria, V; Luu, T; Mortimer, J; Ramani, R; Rotter, AJ; Somlo, G; Synold, TW; Wong, C | 1 |
| Aliño, SF; Bosó, V; de la Cueva, H; Herrero, MJ; Marqués, MR; Megias, JE; Montalar, J; Palomar, L; Poveda, JL; Rojas, L; Santaballa, A | 1 |
| Chen, Q; Liang, C; Liu, Z; Wang, C | 1 |
| Cheng, J; Huang, Y; Liu, Y; Luo, R; Ouyang, M; Sun, X; Tan, W; Xiao, Y; Yu, K; Zhao, X | 1 |
| Bidoli, E; Comaro, E; Crivellari, D; Dolcetti, R; Lombardi, D; Martorelli, D; Massarut, S; Miolo, G; Muraro, E; Perin, T; Scalone, S; Spazzapan, S; Talamini, R; Turchet, E; Viel, E | 1 |
| Amoroso, V; Berruti, A; Ferrari, L; Pedersini, R; Sharratt, P; Sigala, S; Simoncini, E; Vassalli, L | 1 |
| Berry, DA; Cirrincione, CT; Hudis, CA; Shulman, LN; Winer, EP | 1 |
| Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D | 1 |
| Berger, MJ; Layman, R; Lustberg, MB; Macrae, E; Mrozek, E; Phillips, G; Ramaswamy, B; Shapiro, CL; Shaver, K; Vargo, C; Vincent, M; Wesolowski, R | 1 |
| Allegrini, G; Amoroso, D; Arrighi, G; Bocci, G; Bona, E; Camerini, A; Casadei, V; Cazzaniga, M; Coltelli, L; Danesi, R; Del Re, M; Di Desidero, T; Di Lieto, M; Donati, S; Falcone, A; Ferrarini, I; Ferro, A; Finale, C; Fioravanti, A; Fontana, A; Goletti, O; Lucchesi, S; Marcucci, L; Molinaro, S; Orlandi, P; Pazzagli, I; Salvadori, B; Scalese, M; Triolo, R; Villa, F | 1 |
| Hwang, JY; Kim, SY; Seo, JW; Shin, US | 1 |
| Burris, H; Campana, F; Ciruelos, E; Garcia, AA; Gartner, E; Jiang, J; Krop, I; Maurer, M; Mayer, IA; Saura, C; Tolaney, S; Winer, E; Wu, B; Xu, Y | 1 |
| Chen, C; Chen, D; Chen, K; Hu, H; Qiao, M; Wang, Y; Zhao, X | 1 |
| Aldairy, W; Borin, MT; Chen, M; Chittenden, J; Mocci, S; Rubets, I; Stroh, M | 1 |
| Bhatt, K; Bury, MJ; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Goel, R; Jacobs, SA; Johannes, H; Julian, TB; Mamounas, EP; Provencher, L; Rastogi, P; Robidoux, A; Stella, PJ; Swain, SM; Tan, AR; Thirlwell, MP; Wolmark, N | 1 |
| Dai, W; Fu, J; Gao, W; He, B; Lin, Z; Lu, W; Ma, L; Mei, D; Wang, J; Wang, X; Zhang, H; Zhang, Q; Zhang, X; Zhou, D | 1 |
| Baselga, J; D'Andrea, G; Dang, C; Datko, F; Dickler, M; Fasano, J; Fornier, M; Gajria, D; Gilewski, T; Goldfarb, S; Hamilton, N; Hudis, C; Iyengar, N; Jochelson, M; Lake, D; Modi, S; Moynahan, ME; Norton, L; Patil, S; Theodoulou, M | 1 |
| Liang, XS; Liu, Y; Pang, D; Tao, WY; Wang, CY | 1 |
| Balušíková, K; Bartoňová, I; Halada, P; Kopperova, D; Kovář, J; Pavlíková, N | 1 |
| Albain, KS; Barry, WT; Burstein, HJ; Carey, LA; Dang, CT; Ellis, M; Guo, H; Hudis, CA; Krop, IE; Marcom, PK; Moy, B; Overmoyer, BA; Partridge, AH; Rugo, HS; Shapira, I; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Cao, C; Dong, WL; Tian, Y; Wang, XF; Yang, L; Zhang, XY; Zhang, ZQ; Zheng, LY | 1 |
| Brower, V | 1 |
| Chavez-MacGregor, M; Gonzalez-Angulo, AM; Hortobagyi, GN; Hunt, KK; Lei, X; Mittendorf, EA; Parinyanitikul, N; Valero, V; Zhang, H | 1 |
| Grzybowska, E; Kolosza, Z; Pamula-Pilat, J; Radlak, N; Tecza, K | 1 |
| Anan, K; Hayashi, M; Kamata, Y; Maeda, S; Mashino, K; Matsuo, S; Mitsuyama, S; Nishimura, J; Tamura, K; Tanaka, M; Toyoshima, S; Yamaguchi, Y; Yamamoto, Y; Yoshinaga, Y | 1 |
| Burki, TK | 1 |
| Corkery, DP; Dellaire, G; Le Page, C; Mes-Masson, AM; Meunier, L; Provencher, D | 1 |
| Dent, S; Earle, C; Eisen, A; Enright, K; Ghannam, M; Grunfeld, E; Kaizer, L; Krzyzanowska, MK; Moineddin, R; Trudeau, M; Yun, L | 1 |
| Chen, C; Chen, S; Lu, X; Wang, Y; Wang, Z; Wu, Q; Yang, Q; Zhao, Z; Zhu, L | 1 |
| Chen, C; Chen, D; Chen, K; Guo, X; Hu, H; Qiao, M; Wang, Y; Zhao, X | 1 |
| Fu, A; Song, Y; Yu, Z; Zhang, E | 1 |
| Amadori, D; Andreis, D; De Giorgi, U; Fabbri, F; Kopf, B; Menna, C; Pietri, E; Rocca, A; Schirone, A | 1 |
| Sun, CZ; Sun, YT; Wang, C; Wang, X; Wang, XH; Zhang, Y; Zhao, K | 1 |
| Choi, HG; Jeon, CK; Kim, SH; Lim, SJ | 1 |
| Sikov, WM | 1 |
| An, S; Guo, Y; He, X; Jiang, C; Jiang, X; Kuang, Y; Li, J; Ma, H | 1 |
| Bria, E; Brunelli, M; Carbognin, L; Giannarelli, D; Nortilli, R; Pellini, F; Pollini, GP; Sperduti, I; Tortora, G; Vicentini, C | 1 |
| Kong, D; Li, C; Li, P; Song, H; Wang, C; Wang, W; Zhang, J; Zhao, Q | 1 |
| Akcakanat, A; Chen, H; Culotta, KS; Do, KA; Doyle, LA; Gonzalez-Angulo, AM; Krop, I; Kurzrock, R; Li, Y; Liu, S; Meric-Bernstam, F; Mills, GB; Moulder-Thompson, S; Piha-Paul, S; Sahin, AA; Tarco, E; Velez-Bravo, V; Winer, EP | 1 |
| Chen, L; Chen, Y; Gu, W; Huang, Y; Li, Y; Meng, Q; Su, J; Sun, H; Tang, S; Xu, M; Yin, Q; Yu, H; Zhang, Z | 1 |
| Chang, JH; Kim, H; Lee, H; Moon, H; Sim, C | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Arnould, T; Fattaccioli, A; Fransolet, M; Genin, M; Michiels, C; Notte, A; Rebucci, M; Roegiers, E; Tellier, C; Watillon, K | 1 |
| Du, YZ; Hu, FQ; Li, WS; Liu, P; Shan, CL; Situ, JQ; You, J; Yuan, H | 1 |
| Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kim, SB; Koo, DH; Lee, HJ; Son, BH; Yoon, DH | 1 |
| Abe, Y; Hirai, R; Ikeda, E; Kashima, H; Kuroda, M; Kurosaki, T; Miyahara, K; Moriyama, S; Takagi, S; Tsuji, H; Yamano, T; Yoshitomi, S | 1 |
| Asano, Y; Hirakawa, K; Ishihara, S; Kashiwagi, S; Kawajiri, H; Kurata, K; Morisaki, T; Noda, S; Onoda, N; Sakimura, C; Takashima, T; Tauchi, Y; Tokumoto, M | 1 |
| Sueoka, N; Tsubota, Y; Yamamoto, D | 1 |
| Hirayama, S; Ishizaki, M; Kawai, H; Miyauchi, S; Nishi, H; Sugimoto, R; Waki, N; Yamashita, K; Yoshida, R | 1 |
| Fujita, Y; Ishikawa, F; Ito, H; Kamata, S; Nitta, H; Omoto, H; Yamada, C | 1 |
| Aschner, M; Bornhop, DJ; Carter, KJ; Dozier, EA; Fan, KH; Koyama, T; Matrisian, LM; McIntyre, JO; Samuelson, LE; Scherer, RL; Shyr, Y; Stanwood, GD; VanSaun, MN | 1 |
| Długosz, A; Gach, K; Janecka, A; Janecki, T; Modranka, J; Pomorska, D; Szymański, J | 1 |
| Ardizzoni, A; Barni, S; Bighin, C; Bisagni, G; Boni, C; Bruzzi, P; Cavazzini, G; Cognetti, F; Colantuoni, G; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Forestieri, V; Gamucci, T; Garrone, O; Giuliano, M; Gravina, A; Montemurro, F; Nisticò, C; Papaldo, P; Puglisi, F; Turletti, A; Valle, E | 1 |
| Aksoy, S; Altundag, K; Berk, V; Karaca, H; Ozdemir, N; Ozkan, M; Ozturk, B; Sendur, MA; Yazici, O; Yazilitas, D; Zengin, N | 1 |
| Bareggi, C; Blundo, C; Galassi, B; Gambini, D; Locatelli, E; Runza, L; Sosnovskikh, I; Tomirotti, M; Visintin, R | 1 |
| Bono, P; Diéras, V; Dirix, LY; Gonçalves, A; Guastalla, JP; Hurvitz, SA; Jassem, J; Jerusalem, G; Lakshmaiah, KC; Li, A; Limentani, SA; Pickett, CA; Pienkowski, T; Roché, H; Romieu, G; Sánchez-Rovira, P; Seguí Palmer, MÁ; Slamon, DJ; Sun, YN; Wildiers, H | 1 |
| Alba, E; Moreno, I; Navarro-Perez, V; Plata-Fernández, Y; Ribelles, N; Sánchez-Muñoz, A; Santonja, A | 1 |
| Moses, MA; Neckers, L | 1 |
| Brill, LM; Cardiff, RD; Feng, Y; Jeon, YJ; Jiang, T; Khelifa, S; Kim, H; Kluger, Y; Lau, E; Mills, GB; Osterman, AL; Parisi, F; Ratnikov, B; Rimm, DL; Ronai, ZA; Ruller, C; Scott, DA; Smith, JW | 1 |
| Andrade, F; Arai, RJ; Barroso-Sousa, R; Gagliato, DM; Hoff, PM; Leal, AI; Longo, E; Mano, MS; Petry, V; Piato, JR; Ricci, MD | 1 |
| Cai, J; Chen, S; Dong, W; Dong, Y; Hu, S; Lu, J; Xing, J; Zhang, W; Zheng, X | 1 |
| Bae, SB; Kim, HJ; Kim, K; Lee, KT; Lee, N; Lee, SC; Park, HS; Park, WY; Won, JH | 1 |
| Debeb, BG; Larson, R; Li, L; Smith, DL; Woodward, WA; Xu, W | 1 |
| Dash, S; Heidari, Z; Peralta, DV; Tarr, MA | 1 |
| Avery, VM; Lovitt, CJ; Shelper, TB | 1 |
| Kang, L; Li, J; Li, L; Lu, Y; Ma, W; Mao, J; Song, B; Tao, Y; Yang, B; Zhao, L | 1 |
| Biazar, E; Moslemin, MH; Pourshamsian, K; Tavakolifard, S | 1 |
| He, X; Jiang, X; Li, L; Song, H; Su, H; Wang, L; Zhou, D | 1 |
| Aruga, T; Iwasa, T; Komoike, Y; Kuroi, K; Makimura, C; Miyazaki, M; Nakagawa, K; Nishina, S; Okamoto, K; Saeki, T; Shigekawa, T; Tanizaki, J; Tsurutani, J; Yamashita, T | 1 |
| Chen, S; Huang, L; Liu, G; Shao, Z; Wu, J; Yao, L | 1 |
| Kagara, N; Kim, SJ; Maruyama, N; Michishita, S; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y | 1 |
| Fujita, Y; Nakatsukasa, K; Okamoto, A; Sakaguchi, K; Sugimoto, R; Taguchi, T | 1 |
| Ishiyama, T; Jinguu, A; Kikuchi, J; Matsumoto, H; Suzuki, T | 1 |
| Español, AJ; Rojo, D; Salem, A; Sales, ME | 1 |
| Chalasani, P; Clarke, K; Iannone, M; Livingston, RB; Marron, M; Roe, D; Shan, JS; Stopeck, AT | 1 |
| Han, L; Kang, CS; Liu, X; Mei, M; Ren, Y; Song, X; Tian, WP; Wang, QX; Yang, JJ; Zhang, L; Zhao, XH; Zhou, X; Zhu, ZY | 1 |
| Chen, J; Gao, H; He, Q; Liu, Y; Qiu, Y; Ruan, S; Tai, X; Wang, Y; Xia, T; Yang, Y; Zhang, L; Zhang, Q | 1 |
| Ge, Y; Li, L; Zhao, Y | 1 |
| Chen, Y; Chi, Y; Huang, S; Niu, J; Pfeffer, LM; Shao, ZM; Wang, W; Wu, J; Wu, ZH; Xue, J; Ye, X | 1 |
| Jiang, Y; Liang, X; Liu, T; Lu, X; Pang, D; Shi, Q; Song, Y; Sun, S; Wu, H; Zhang, X | 1 |
| Conesa, MÁ; de la Morena Barrio, P; de la Peña, FA; García-Garre, E; García-Martínez, E; González-Billalabeitia, E; Poves, MZ; Urrego, E; Vicente, V | 1 |
| Albarracin, C; Atkins, J; Booser, D; Gilcrease, M; Helgason, T; Janku, F; Koenig, K; Kurzrock, R; Moroney, J; Morrow, PK; Moulder, S; Wheler, J | 1 |
| Chandra, H; Chandra, S; Verma, SK | 1 |
| Koyakutty, M; Menon, D; Mony, U; Narayanan, S; Paul-Prasanth, B; Vijaykumar, DK | 1 |
| Espinoza, I; Lupu, R; Menendez, JA; Papadimitropoulou, A; Peirce, SK; Schroeder, B; Vellon, L | 1 |
| Hu, Y; Xu, K; Yagüe, E | 1 |
| Du, Y; Gao, F; He, Y; Liu, Y; Wang, W; Yang, C; Zhang, H | 1 |
| Andre, F; Arnould, L; Beuzeboc, P; Coeffic, D; Ferrero, JM; Lortholary, A; Spano, JP | 1 |
| Chen, G; Li, L; Shi, Y; Sun, L; Wei, W; Zheng, D | 1 |
| Bernardo, A; Ferzi, A; Gambaro, A; Palumbo, R; Piazza, E; Pozzi, E; Sottotetti, F; Spinapolice, EG; Tagliaferri, B; Teragni, C; Trifirò, G | 1 |
| Albarracin, C; Downs-Kelly, E; Gould, R; Hatzis, C; Morkowski, J; Peintinger, F; Sinn, B; Symmans, WF | 1 |
| Matsuo, T; Nakamura, Y; Suzuki, K | 1 |
| Garrone, O; Infante, L; Lattanzio, L; Lo Nigro, C; Merlano, MC; Tonissi, F | 1 |
| Goins, B; Ong, JL; Roy, SS; Satsangi, A; Satsangi, RK; Tolcher, AW; Vadlamudi, RK | 1 |
| Coombes, RC; Gomes, AR; Gong, C; Khongkow, P; Khoo, US; Lam, EW; Man, EP; Medema, RH; Monteiro, LJ; Tsang, JW; Zhao, F | 1 |
| Funato, Y; Ito, K; Ito, Y; Iwata, H; Nakamura, S | 1 |
| Kitamura, T; Tanaka, Y; Tsuboi, K; Tsuda, S; Tsujii, S; Yagi, K; Yamamoto, A | 1 |
| Aogi, K; Armour, A; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Nakayama, T; Nishimura, Y; Rai, Y; Sasaki, Y; Shimizu, S | 1 |
| Hayashi, K; Homma, S; Ishidao, T; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M | 1 |
| Bielopolski, D; Evron, E; Landes, M; Moreh-Rahav, O; Salamon, F; Stemmer, SM | 1 |
| Ichiba, Y; Kajiume, S; Kiba, T; Morii, N; Mura, T; Nagashima, S; Ogawa, Y; Okada, Y; Takahashi, H; Yamashiro, H | 1 |
| Baselga, J; Bellet, M; Blasco, C; Garcia-Martínez, E; Gil-Gil, MJ; Llombart, A; Manso, L; Martinez-Jáñez, N; Melé, M; Mesia, C; Morales, S; Ojeda, B; Pernas, S; Villagrasa, P | 1 |
| Albain, KS; Barry, W; Burstein, HJ; Carey, LA; Dang, CT; Ellis, MJ; Guo, H; Hudis, C; Krop, IE; Marcom, PK; Moy, B; Overmoyer, BA; Partridge, AH; Ruddy, KJ; Rugo, HS; Shapira, I; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Chang, JY; Chang, YW; Chen, HA; Chen, LT; Chen, PS; Hong, CC; Huang, MT; Jiang, SS; Su, CM; Su, JL; Su, YH; Sung, SY; Wang, MY; Wu, CH | 1 |
| Bekki, K; Haarmann-Stemmann, T; Ito, T; Li, W; Matsumura, F; Sweeney, C; Vogel, CF; Vogel, H | 1 |
| Hasebe, T; Hirokawa, E; Kuji, I; Matsuura, K; Osaki, A; Saeki, T; Shigekawa, T; Shimada, H; Sugitani, I; Sugiyama, M; Takahashi, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Huo, M; Wang, L; Yin, L; Yin, T; Zhou, J | 1 |
| André, T; Dumont, S; Lopez-Trabada Ataz, D | 1 |
| Ann, DK; Arif, M; Chen, CH; Cheng, CT; Fong, LW; Wu, R; Yuan, Y; Zhai, J | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Jung, SH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH; Woo, SY | 1 |
| Chen, Z; Dai, C; Fu, L; Huang, Z; Ma, S; To, K; Wang, F; Wu, X; Zhao, H | 1 |
| Dai, W; Hu, H; Wang, X; Zhang, H; Zhang, Q | 1 |
| Fan, Z; Hu, X; Jing, X; Wu, D; Zheng, Y | 1 |
| Bedalov, CO; Prosperi, JR; Soto, KF; VanKlompenberg, MK | 1 |
| Ali, FR; Fitzgerald, D; Yiu, ZZ | 1 |
| De Brabander, JK; Gellert, G; Krauth, M; Meyer, CJ; Miller, JH; Northcote, PT; Shay, JW; Wick, MJ | 1 |
| Barry, WT; Carey, LA; Cirrincione, C; Hudis, C; Leung, E; Lyss, AP; Mayer, EL; Moreno-Aspitia, A; Naughton, M; Perez, EA; Rugo, HS; Toppmeyer, D; Winer, EP | 1 |
| Chan, MM; Donoghue, E; Ghersi, D; Simes, J; Wilcken, N; Willson, ML | 1 |
| Martín, M | 2 |
| Chen, HZ; Fang, C; Gao, YG; Liu, HJ; Liu, YR; Luan, X; Wu, H; Yu, DH | 1 |
| Davidson, NE; Ligibel, JA; Martino, S; Perez, EA; Saphner, T; Sledge, GW; Sparano, JA; Wolff, AC; Wood, WC; Zhao, F | 1 |
| Chen, S; Cui, S; Geng, C; Huang, L; Huang, T; Lei, Y; Pang, D; Shao, Z; Song, E; Tang, L; Wang, Y; Xu, B; Yang, H; Yang, W; Zhang, J; Zheng, H | 1 |
| Chen, L; Hu, X; Kuang, XY; Li, S; Ling, H; Liu, YR; Qiao, F; Shao, ZM; Zhang, ZJ; Zheng, YZ | 1 |
| Andre, F; Burris, HA; Buyse, ME; Cabaribere, D; Dreosti, LM; Hurvitz, SA; Jiang, Z; Lindsay, MA; Liu, D; Mano, MS; Neciosup, SP; Pacaud, LB; Rao, S; Shao, Z; Shen, K; Slamon, D; Taran, T; Toi, M; Tseng, LM; Zhang, Q | 1 |
| López-Tarruella, S; Martin, M | 2 |
| Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
| Alfer, J; Burchardi, N; Conrad, B; Decker, T; Denkert, C; Eidtmann, H; Eiermann, W; Hackmann, J; Huober, J; Jackisch, C; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Potenberg, J; Reimer, T; Simon, E; Stickeler, E; Thomssen, C; von Minckwitz, G | 1 |
| Barry, WT; Berry, D; Cirrincione, CT; Citron, M; Ellis, M; Gradishar, W; Hudis, CA; Ingle, JN; Ligibel, JA; Liu, M; Mardis, E; Martino, S; Michaelson, R; Perou, CM; Sikov, W; Winer, E | 1 |
| Apellániz-Ruiz, M; Bergmann, TK; Brøsen, K; Green, H; Ingelman-Sundberg, M; Johansson, I; Lee, MY; Rodríguez-Antona, C; Vikingsson, S | 1 |
| Comaro, E; Crivellari, D; Dolcetti, R; Lombardi, D; Martorelli, D; Massarut, S; Militello, L; Miolo, G; Muraro, E; Perin, T; Scalone, S; Spazzapan, S; Talamini, R; Turchet, E | 1 |
| Abraham, J; Alcorn, H; Buyse, ME; Jacobs, SA; Limentani, S; Robidoux, A; Shalaby, I; Sturtz, K; Tan, AR; Wolmark, N | 1 |
| Basu, R; Brunt, KR; Das, SK; Fisher, PB; Konar, S; Kumar, BNP; Mandal, M; Mazumdar, A; Pathak, A; Puvvada, N; Rajput, S; Rao, RR; Sarkar, S | 1 |
| Blundell, C; Choi, Y; Huh, D; Hyun, E; Kim, HC; Lee, E; Lee, SH; Moon, A; Moon, WK; Seo, J | 1 |
| Bechi, B; Bennett, A; Cleveland, DW; Huels, D; Littler, S; Ly, P; Nelson, L; Procter, DJ; Ridgway, RA; Sansom, OJ; Schandl, C; Sloss, O; Sun, Y; Taylor, SS; Tighe, A; Topham, C | 1 |
| Cai, J; Chen, S; Dong, Y; Xing, J; Yang, Q; You, H; Zhang, W; Zheng, X | 1 |
| An, F; Qiu, RG; Tang, L; Zhao, WJ | 1 |
| Beijnen, JH; Harms, E; Marchetti, S; Mergui-Roelvink, MW; Rehorst, H; Schellens, JH; Sonke, GS; Steeghs, N; van der Noll, R | 1 |
| Wilks, ST | 1 |
| Artuso, E; Belausov, E; Ben-Harosh, S; Bier, A; Genin, O; Grivas, CF; Johnson, MD; Kapulnik, Y; Khalaila, I; Koltai, H; Laufer, D; Levi, O; Mayzlish-Gati, E; Pines, M; Prandi, C; Sananes, A; Shaknof, J; Yarden, RI | 1 |
| Alecu, I; Bielawski, J; Ernst, D; Hornemann, T; Kistner-Griffin, E; Kornhauser, D; Kramer, R; Othman, A; Spassieva, S | 1 |
| Hase, K; Hasegawa, S; Moriya, T; Sakaguchi, N; Tsuda, H; Yamagishi, Y; Yamamoto, J; Yamazaki, T | 1 |
| Chen, J; Cui, Z; Fu, L; Fu, Y; He, M; Jiang, Q; Jin, F; Mi, X; Wang, E; Wei, M; Wu, H; Xiao, Q; Yan, Y; Yao, W; Yu, Z; Zhao, H; Zhao, L | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, PA; Chevreau, C; Clisant, S; Collard, O; Cupissol, D; Delcambre, C; Domont, J; Isambert, N; Italiano, A; Le Cesne, A; Mir, O; Penel, N; Piperno-Neumann, S; Ray-Coquard, IL; Saada-Bouzid, E; Tresch-Bruneel, E | 1 |
| Armat, M; Bakhshaiesh, TO; Baradaran, B; Hejazi, MS; Samadi, N; Shanehbandi, D; Sharifi, S | 1 |
| Nadal-Serrano, M; Oliver, J; Pons, DG; Roca, P; Sastre-Serra, J; Torrens-Mas, M | 1 |
| Abasolo, I; Arango, D; Arranja, A; de Sousa Rafael, DF; Fernández, Y; Fort, NB; Gener, P; Gouveia, LP; Ortega, JS; Prieto, RM; Sabat, GR; Schwartz, S; Videira, M | 1 |
| Lee, H; McClure, R; Pundir, S; Solomon, VR; Vu, HY | 1 |
| Bade, D; Bicker, U; Bludszuweit-Philipp, C; Geltmeier, A; Maier, P; Meditz, K; Rinner, B; Witt, R | 1 |
| Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
| Gligorov, J; Richard, S | 1 |
| Azoulay, D; Braester, A; Goldberg, H; Gross, B; Leibovici, A; Shaoul, E; Sharoni, R | 1 |
| Alba, E; Álvarez, I; Andrés, R; Aramendía, JM; Barnadas, A; Batista, N; Calvo, L; Ciruelos, E; Cortés, J; de Dueñas, EM; de la Haba, J; de la Peña, FA; Galve, E; García-Palomo, A; García-Sáenz, JÁ; González-Martín, A; Llombart, A; Lluch, A; López, R; López-Vivanco, G; Martín, M; Martínez-Jáñez, N; Plazaola, A; Rodríguez-Lescure, Á; Ruiz, M; Sánchez-Rovira, P; Santaballa, A; Seguí, MÁ; Tusquets, I; Zamora, P | 1 |
| Cao, J; Gao, N; Li, M; Liu, X; Liu, Y; Peng, H; Ruan, Y; Sun, G; Tang, S; Tian, X; Wang, G; Wang, Q; Wang, R; Yang, W; Yu, Y; Zhou, C | 1 |
| Bao, Y; Chu, Q; Tan, S; Wu, T; Wu, Y; Zhang, Z; Zhuang, X | 1 |
| Abe, H; Hoshi, I; Nakai, Y; Watanabe, H; Yamasaki, K | 1 |
| Dai, Y; Ishibashi, O; Kondo, T; Maeda, M; Ohkohchi, N; Watanabe, M | 1 |
| Ashida, A; Koga, H; Minagawa, A; Ohashi, A; Okuyama, R; Uhara, H | 1 |
| Baek, JS; Cho, CW; Kim, JH; Park, JS | 1 |
| Bharti, R; Mandal, M; Parida, S; Prashanth Kumar, BN; Rajput, S | 1 |
| Karam, A; Kong, CS; O'Keefe, MC; Westhoff, GL; Wheeler, L | 1 |
| Baranova, K; Carcangiu, ML; Dorman, SN; Knoll, JH; Mariani, G; Rogan, PK; Urquhart, BL | 1 |
| Advani, PP; Ballman, KV; Colon-Otero, G; Dockter, TJ; Perez, EA | 1 |
| Kim, HI; Kim, HS; Kim, JH; Kim, N; Kim, SJ; Lee, HJ; Lee, JO; Lee, YW; Park, SH | 1 |
| Fan, S; Jiang, S; Li, G; Li, X; Liu, Y; Luo, Y; Ma, J; Peng, S; Phillips, JB; Tan, M; Wang, H; Wang, X; Wen, Q; Xiong, W; Xu, Y; Yang, J; Zeng, Z; Zhao, R; Zhou, M | 1 |
| Fernandez, RO; Iniesta, MD; Lu, KH; Malpica, A; Patrono, MG; Ramirez, PT; Salvo, G | 1 |
| Jordan, MA; Lopus, M; Miller, H; Oroudjev, E; Smiyun, G; Wilson, L | 1 |
| Farnie, G; Lisanti, MP; Sotgia, F | 1 |
| Dong, J; Fu, Y; Gong, T; Lian, X; Song, X; Wan, Z; Xia, C; Yi, X; Zhang, Z | 1 |
| da Cunha Bianchi, PK; Gebrim, LH; Kfoury, JR; Salvadori, ML; Silva, RS | 1 |
| Andrade, MS; Barbosa, MV; Carneiro, G; Carvalho-Junior, AD; Leite, EA; Malagutti, AR; Monteiro, LO; Oliveira, MC; Vilela, JM | 1 |
| Baselga, J; Chen, MF; Comen, EA; D'Andrea, GM; Dang, CT; Drullinsky, PR; Fornier, MN; Gajria, D; Goldfarb, SB; Hudis, CA; Iyengar, NM; Lacouture, ME; Lake, DE; Modi, S; Norton, L; Patil, S; Sugarman, SM; Theodoulou, M; Traina, TA; Troso-Sandoval, TA | 1 |
| Bass, JD; Bosserman, LD; Burris, HA; Hainsworth, JD; Harwin, WN; Morgan, SK; O'Shaughnessy, JA; Peacock, NW; Priego, VM; Yardley, DA | 1 |
| Ahmed-Zaïd, H; Baillet, A; Cantaloube, I; Froidevaux-Klipfel, L; Poüs, C; Targa, B | 1 |
| Kim, DK; Kim, JS; Kim, MJ; Lim, W; Min, KN; Nam, JS; Park, SA; Park, SY; Sheen, YY | 1 |
| Hao, X; Li, C; Su, W; Zhang, J; Zhang, S | 1 |
| Badve, SS; Baehner, FL; Bailey, H; Ballman, KV; Perez, EA; Tenner, KS; Thompson, EA | 1 |
| Jeon, M; Kant, RJ; Kievit, FM; Lin, G; Mu, Q; Zhang, M | 1 |
| Dai, W; He, B; Hu, H; Lin, Z; Wang, J; Wang, X; Zhang, H; Zhang, Q; Zhang, X | 1 |
| Adachi, K; Amano, S; Enomoto, K; Hara, Y; Makishima, M; Nagashima, S; Sakurai, K; Suzuki, S | 1 |
| Bao, Y; Cai, Y; Ditzel, HJ; Feng, M; Goh, JY; Hoon, DS; Kohlbauer, VK; Lee, PL; Lim, E; Tam, WL; Tan, EY; Wang, PP; Wee, ZN; Yatim, SM; Yi, B; Yu, Q; Zhang, S | 1 |
| Abasi, M; Abbasi, MM; Akbarzadeh, A; Jahanban-Esfahlan, R; Sani, HM | 1 |
| Gu, X; Guo, J; Li, JY; Li, PS; Zhang, WH | 1 |
| Alecci, M; Allegretti, M; Benedetti, E; Brandolini, L; Cifone, MG; Cimini, A; Cinque, B; Confalone, G; Cristiano, L; De Pizzol, M; Di Giacomo, E; Fidoamore, A; Florio, TM; Galante, A; Giordano, A; Ruffini, PA | 1 |
| Otsuka, S; Sasaki, Y; Shimada, K; Watanabe, N; Yuasa, T | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Fan, W; Jiang, D; Lei, J; Wang, S; Xu, L; Zhou, L | 1 |
| Albain, K; Burstein, HJ; Carey, LA; Dang, C; Ellis, M; Groarke, J; Guo, H; Hudis, C; Krop, I; Marcom, K; Miller, K; Moslehi, J; Moy, B; Najita, J; Rugo, H; Shapira, I; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, D | 1 |
| Casañas Pimentel, RG; Gómez García, C; Hinestroza, JP; Robles Botero, V; San Martín Martínez, E | 1 |
| Chamorey, E; Ferrero, JM; Milano, G | 1 |
| Cai, Y; Chen, CJ; Chen, SL; Li, CX; Wang, YY; Xia, CL; Yang, QL; Zhao, ZL | 1 |
| Fatatis, A; Jiao, X; Pestell, RG | 1 |
| Jiang, J; Kang, X; Kong, Q; Ni, Z; Wu, R; Xiang, F; Xu, J; Zhan, Y | 1 |
| Hara, F; Hozumi, Y; Imoto, S; Matsubara, N; Mukai, H; Nishimura, R; Ohashi, Y; Park, Y; Sagara, Y; Saito, T; Shimozuma, K; Takano, T; Takashima, T; Toyama, T; Tsurutani, J; Watanabe, T | 1 |
| Gao, Y; Li, Y; Teng, L; Yu, K; Zhang, Z; Zhao, J; Zhou, Y | 1 |
| Davidson, NE; Kahanic, SP; O'Neill, A; Schneider, BP; Shen, F; Sledge, GW; Thor, AD; Zander, PJ | 1 |
| Arcangeli, A; Bracci, L; Brunetti, J; Depau, L; Falciani, C; Lozzi, L; Menichetti, S; Pillozzi, S; Pini, A; Scali, S; Tenori, E | 1 |
| Shen, B; Yang, C; Zhang, J; Zhang, Q | 1 |
| Álvarez, I; Ballesteros, AI; Blanco, E; Bueno, C; Cassinello, J; Chacón López-Muñiz, I; Cortés-Funes, H; Fernández-Aramburo, A; Galán, A; Gallegos Sancho, I; Gálve, E; Garau, I; García, MJ; González, S; González, X; González-Santiago, S; Grávalos, C; Llorca, C; Llorente, R; Manso, L; Olier, C; Palomo, AG; Perelló, A; Pérez Carrión, R; Torregrosa, D | 1 |
| Arshad, A; Bahl, A; Holly, JM; Perks, CM; Shield, JP; Zeng, L; Zielinska, HA | 1 |
| Alvarez, RH; Chavez-MacGregor, M; Fouad, TM; Fujii, T; Hortobágyi, GN; Kogawa, T; Liu, DD; Masuda, H; Shen, Y; Ueno, NT; Valero, V; Wu, J | 1 |
| Accortanzo, V; Adami, F; Bighin, C; Bruzzi, P; Castiglione, F; Cavazzini, G; Conte, P; Danese, S; Del Mastro, L; Durando, A; Garrone, O; Landucci, E; Levaggi, A; Michelotti, A; Miglietta, L; Pastorino, S; Piras, M; Pronzato, P; Scotto, T | 1 |
| Bakos, T; Banerjee, A; Lee, JC; Ludueña, RF; Prasad, V; Tuszynski, JA; Weis, AL; Yeh, IT; Yeh, LC | 1 |
| Dang, C; Friedman, MD; Lacouture, M | 1 |
| Arpino, G; Cortés, J; Leonard, R; Llombart-Cussac, A; Marmé, F; Ricevuto, E | 1 |
| Corzo, D; Enger, C; Fraser, CD; Ko, A; Li, L; Liang, C; Patt, D | 1 |
| Dong, JT; Fu, L; Fu, X; He, Y; Zhang, B; Zhao, R; Zhu, Z | 1 |
| Ahmadloo, N; Askarian, M; Hatam, N; Javan-Noghabi, J; Mohammadianpanah, M | 1 |
| Atkins, GJ; DeNichilo, M; Evdokiou, A; Findlay, DM; Hay, S; Ingman, W; Labrinidis, A; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, AC; Zinonos, I; Zysk, A | 1 |
| Cun, X; Gao, H; He, Q; Lu, L; Wang, Y; Xia, T; Yang, Y; Yu, Q; Zhang, L; Zhang, Q; Zhang, Z | 1 |
| Armat, M; Mohammadian, J; Molavi, O; Oghabi Bakhshaiesh, T; Sabzichi, M; Saeid Hejazi, M; Samadi, N; Shanehbandi, D; Sharifi, S | 1 |
| Bernabeu, E; Cagel, M; Chiappetta, DA; Gergic, EP; Gonzalez, L; Moretton, MA | 1 |
| Gong, Y; Hao, XY; Li, BJ; Ren, GH | 1 |
| Saxena, S; Sharma, B; Singh, RK; Varney, ML; Wu, L | 1 |
| Choghaei, E; Falahati, M; Hasanpour, M; Hashemi, ZS; Khamisipour, G; Mossahebi-Mohammadi, M; Naeimi, B; Shamsian, S; Tahmasebi, R | 1 |
| Abe, Y; Hagiwara, H; Kamata, A; Kano, T; Koizumi, M; Miyamae, T; Natori, J; Sarukawa, H; Takahashi, K; Uchiyama, K; Wada, Y | 1 |
| Che, S; Li, J; Ou, Y; Wang, M; Wu, B; Zhao, X; Zhou, C | 1 |
| Al Faraj, A; Halwani, R; Ratemi, E; Shaik, AS | 1 |
| Kroes, MA; Pronzato, P; Puglisi, F; Rea, D | 1 |
| Abdel-Rahman, S; Awad, D; Bassiouny, A; Haggag, A; Shaban, N; Talaat, I | 1 |
| Cattin, S; Fellay, B; Fürstenberger, G; Pradervand, S; Rüegg, C; Ruhstaller, T; Trojan, A | 1 |
| Abu-Khalaf, MM; Awadallah, A; Bossuyt, V; Fenton, MA; Gilmore, H; Harris, LN; Krop, IE; Miskimen, KL; Parsai, S; Sikov, W; Somlo, G; Tuck, D; Varadan, V; Winer, EP | 1 |
| Cheng, L; Deng, C; Goltsche, K; Haag, R; Meng, F; Xie, F; Zhong, Y; Zhong, Z | 1 |
| Andre, F; Burris, HA; Buyse, M; Eiermann, W; Hurvitz, SA; Jiang, Z; Lindsay, MA; Slamon, D; Toi, M | 1 |
| Aktas, B; Blohmer, JU; Clemens, M; Conrad, B; Dan Costa, S; Darb-Esfahani, S; Denkert, C; Eidtmann, H; Engels, K; Gerber, B; Hackmann, J; Hanusch, C; Hilfrich, J; Jackisch, C; Just, M; Kümmel, S; Loibl, S; Nekljudova, V; Paepke, S; Schmitt, WD; Schneeweiss, A; Untch, M; von Minckwitz, G; Warm, M; Wiebringhaus, H | 1 |
| Chien, AJ; Cockerill, A; Esserman, LJ; Fancourt, C; Kelley, RK; Ko, AH; Korn, WM; Melisko, ME; Moasser, MM; Munster, PN; Rugo, HS; Schmidt, E; van't Veer, L; Wolf, DM; Yau, C | 1 |
| Alsharedi, M; Dotson, J; Elmsherghi, N; Gress, T; Tirona, MT | 1 |
| Nurcahyanti, AD; Wink, M | 1 |
| Ajorlou, E; Khosroushahi, AY; Yeganeh, H | 1 |
| Das, T; Enriquez-Navas, PM; Foroutan, P; Gatenby, RA; Gillies, RJ; Hassan, S; Kam, Y; Martinez, G; Minton, S; Ruiz, E; Silva, A | 1 |
| Sales, ME | 1 |
| Gagat, M; Grzanka, A; Grzanka, D; Hałas-Wiśniewska, M; Izdebska, M | 1 |
| Li, XR; Liao, N; Liu, CL; Liu, YH; Wang, K; Xu, FP; Zhang, GC; Zhang, YF; Zhu, T; Zu, J | 1 |
| Bajpai, J; Bakshi, AV; Bapsy, PP; Bhatt, N; Bhattacharya, GS; Bhowmik, S; Bondarde, SA; Chimote, G; Desai, CJ; Deshmukh, CD; Digumarti, R; Govind Babu, K; Gupte, SU; Haritha, C; Jain, MM; Khopade, A; Kumar, R; Pathak, AB; Patil, P; Patil, SG; Subramanian, S; Vaid, AK | 1 |
| Brown-Glaberman, U; Chalasani, P; Iannone, M; Livingston, R; Marron, M; Specht, J; Stopeck, AT | 1 |
| Cárpen, O; Chen, P; Davidson, B; Elgaaen, BV; Hautaniemi, S; Huhtinen, K; Kallio, MJ; Lønning, PE; Mäki-Jouppila, J; Pruikkonen, S; Straume, AH; Tambe, M | 1 |
| Amico, AL; Olopade, OI; Saha, P | 1 |
| Guo, F; Liang, W; Meng, J; Wang, C; Xu, H; Yang, XD | 1 |
| Abad-Sazatornil, MR; Agustín-Ferrández, MJ; Escolano-Pueyo, Á; Gimeno-Ballester, V; Pascual-Martínez, O; Uriarte-Pinto, M | 1 |
| Azami, S; Dehghankelishadi, P; Dorkoosh, FA; Gholami, M; Mahdavi, M; Ravar, F; Saadat, E | 1 |
| Aktas, B; Förster, F; Geberth, M; Gluz, O; Hertz-Eichenrode, MM; Kiewitz, C; Klawitter, S; Kutscheidt, A; Schmidt, M; Schneeweiss, A; Schönegg, W; Schumacher, C; Tesch, H | 1 |
| Althaus, B; Elias, A; Guardino, E; Krop, IE; LoRusso, PM; Lu, D; Modi, S; Pegram, M; Strasak, A | 1 |
| Chuttani, K; Ghanghoria, R; Jain, NK; Mishra, AK; Tekade, RK | 1 |
| Cheng, H; Ding, H; Han, X; Li, A; Liu, Y; Lv, J; Shao, L; Si, X; Sun, L; Sun, Y; Yang, N; Yang, Y; Zhang, XA; Zhu, D | 1 |
| Adams, S; Goldberg, NR; Park, E | 1 |
| Dang, CT; Fleisher, M; Hudis, CA; Jones, LW; Liu, JE; Manrique, C; Mara, E; Patil, S; Pun, S; Steingart, RM; Yu, AF | 1 |
| Castelo, B; Díaz, E; Espinosa, E; Fresno, JÁ; Gámez, A; Hardisson, D; Heredia, V; Herranz, J; Martínez-Marin, V; Mendiola, M; Miguel, M; Pinto, Á; Ramírez de Molina, A; Redondo, A; Yébenes, L; Zamora, P | 1 |
| Cao, K; Cao, P; Huang, C; Jin, L; Li, X; Luo, Y; Ma, J; Shen, S; Tan, M; Tang, X; Zhou, M | 1 |
| Lipkowitz, S; Polley, E; Yang, SX | 1 |
| Fidler, IJ; Hanibuchi, M; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Yu, H | 1 |
| Imamura, F; Ishitobi, M; Kittaka, N; Nakayama, T; Okuno, J; Sugimoto, N; Tamaki, Y; Yagi, T; Yoshinami, T | 1 |
| Bowman, L; John, W; Liepa, AM; Melemed, A; Peterson, P; Shen, W; Smyth, EN | 1 |
| Fang, W; Fu, T; Hua, ZC; Li, XF; Luo, R; Niu, L; Qiu, F; Wang, F; Zhang, YJ; Zhao, M | 1 |
| Bartlett, JM; Boutros, PC; Burnell, M; Chen, BE; D'Costa, A; Levine, MN; Lyttle, N; O'Brien, P; Shepherd, L; Spears, M; Yao, CQ | 1 |
| Kumar, PV; Prabaharan, S; Ravind, R | 1 |
| Chen, M; Dong, S; Jiang, ZX; Xia, G; Zhao, P | 1 |
| Ooe, A; Suganuma, Y | 1 |
| Mamounas, EP; Ueno, NT | 1 |
| Awada, A; Bachelot, T; Badwe, RA; Bondarenko, I; Bose, R; Bryce, R; Carey, LA; Colomer, R; Demetriou, G; Deo, S; Goswami, C; Inoue, K; Kim, SB; Lee, SC; Mehta, AO; Wong, A; Xu, F; Yao, B | 1 |
| Paul, A; Prakash, S; Rodes, L; Shao, W | 1 |
| Goodarzi, H; Nguyen, A; Tavazoie, SF; Yoshida, M | 1 |
| Kuji, I; Osaki, A; Saeki, T; Shigekawa, T; Takeuchi, H; Ueda, S; Yamane, T | 1 |
| Andronova, NV; Bonartsev, AP; Bonartseva, GA; Borisova, JA; Kalishjan, MS; Mahina, TK; Myshkina, VL; Shaitan, KV; Smirnova, GB; Treshalina, HM; Yakovlev, SG; Zernov, AL; Zharkova, II | 1 |
| Chen, W; Li, T; Liu, ZY; Weng, CX; Zhao, HY | 1 |
| Ozer, U | 1 |
| Bae, JK; Chae, HS; Chin, YW; Choi, HS; Choi, YH; Kim, DY; Kim, YJ | 1 |
| Ballman, K; Calfa, C; Clynes, R; Erskine, CL; Kemp, KP; Knutson, KL; Mittendorf, EA; Northfelt, D; Norton, N; Pegram, M; Perez, EA; Shreeder, B; Tan, W; Tenner, KS; Yeramian, P | 1 |
| Chang, TY; Chang, YW; Chen, HA; Chiu, CF; Hung, MC; Kuo, TC; Su, JL; Tseng, PC; Wang, W | 1 |
| Ash, A; Caruso, D; Corona, G; Crivellari, D; Giordano, A; Lombardi, D; Miolo, G; Muraro, E; Rizzolio, F; Scalone, S | 1 |
| Pugliano, L; Ryan, C; Tsoi, D; White, M; Woodward, N | 1 |
| Cao, Z; Ge, X; Gu, Y; Han, M; Li, J; Lyu, P; Wang, F; Xia, W; Yu, Z | 1 |
| Cui, S; Hu, X; Liao, N; Liu, D; Luo, R; Sun, Q; Wang, X; Xu, B; Yu, S; Zhang, Q; Zheng, H | 1 |
| Deng, C; Meng, F; Wu, J; Zhang, J; Zhong, Z | 1 |
| Argolo, DF; Baselga, J; Chandarlapaty, S; Chen, MF; Comen, EA; Dang, CT; Drullinsky, PR; Hudis, CA; Iyengar, NM; Norton, L; Patil, S; Popper, SM; Singh, JC; Smyth, LM; Sugarman, SM; Traina, TA; Troso-Sandoval, T; Wasserheit-Lieblich, C | 1 |
| Ishiguro, M; Iwamoto, A; Nishidoi, H; Shibata, S; Tada, Y; Takaya, S; Yamaguchi, Y; Yamashiro, Y | 1 |
| Kan, X; Li, Q; Li, Y; Liu, Y; Luo, Y; Ma, Z; Na, D; Su, B; Wang, C; Wang, L; Wang, P; Zhang, G; Zhang, Y; Zhu, X | 1 |
| Ascenzi, P; Cipolletti, M; Fiocchetti, M; Leone, S; Marino, M | 1 |
| Alakhova, D; Bludau, H; Darr, DB; Dobrovolskaia, MA; He, Z; Jordan, R; Kabanov, AV; Li, Z; Luxenhofer, R; Montgomery, SA; Perou, CM; Schulz, A; Sokolsky, M; Stern, ST; Wan, X; Yuan, H | 1 |
| de Graaf, H; de Groot, SM; Drooger, JC; Erdkamp, FL; Hamberg, P; Heijns, JB; Honkoop, A; Imholz, AL; Jager, A; Kroep, JR; Linn, SC; Portielje, JE; Sleijfer, S; Ten Tije, AJ; van Leeuwen-Stok, AE; van Rossum-Schornagel, QC; van Tinteren, H | 1 |
| Doihara, H; Iwamoto, T; Matsuoka, J; Mitsuhashi, T; Mizoo, T; Motoki, T; Nogami, T; Ogasawara, Y; Shien, T; Taira, N; Tsuji, H; Yoshitomi, S | 1 |
| Chaudhari, AMW; Loprinzi, CL; Lustberg, MB; Monfort, SM; Pan, X; Patrick, R; Singaravelu, J | 1 |
| Li, M; Wang, W; Wang, X; Xu, X; Zhang, F; Zhou, J | 1 |
| Li, Y; Liu, Y; Lu, G; Pan, J; Su, X; Su, Y; Tang, Y; Teng, Z; Tian, J; Tian, Y; Wang, C; Wang, S; Wu, J; Zhu, H | 1 |
| Hu, Y; Ji, W; Liu, J; Qiu, Y; Yagüe, E; Zhang, J | 1 |
| Cao, J; Chen, D; Deng, D; Gu, Y; Huang, S; Tang, L | 1 |
| Baabur-Cohen, H; Calderón, M; Eldar-Boock, A; Krüger, HR; Landa-Rouben, N; Leor, J; Markovsky, E; Satchi-Fainaro, R; Tiram, G; Vossen, LI; Wedepohl, S; Yeini, E | 1 |
| Aittokallio, T; Brück, O; Edgren, H; Eldfors, S; Hultsch, S; Jaiswal, A; Kallioniemi, O; Kangaspeska, S; Mpindi, JP | 1 |
| Chen, Y; Huang, R; Lin, Y; Sun, X; Yao, X | 1 |
| Barlow, WE; Chennuru, S; Corso, SW; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mirshahidi, HR; Nahleh, ZA; Perez, EA; Pusztai, L; Schott, AF; Sikov, WM | 1 |
| Albain, KS; Berry, DA; Boughey, JC; Buxton, MB; Chien, AJ; Chui, SY; Davis, SE; DeMichele, A; Edmiston, KK; Elias, AD; Esserman, LJ; Euhus, DM; Haddad, TC; Haley, BB; Helsten, T; Hirst, GL; Hogarth, M; Hylton, NM; Isaacs, C; Kaplan, HG; Kemmer, KA; Khan, QJ; Lang, JE; Liu, MC; Lyandres, J; Melisko, M; Moulder, SL; Nanda, R; Northfelt, DW; Paoloni, M; Park, JW; Perlmutter, J; Pusztai, L; Sanil, A; Schwab, R; Symmans, WF; Tripathy, D; van 't Veer, LJ; Viscusi, RK; Wallace, AM; Wood, WC; Yau, C; Yee, D | 1 |
| Flores, ML; Gasca, J; Giráldez, S; Japón, MA; Romero, F; Ruiz-Borrego, M; Sáez, C; Tortolero, M | 1 |
| Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kodaira, M; Koizumi, F; Komori, O; Nakatochi, M; Okuma, HS; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Alesse, E; Bafile, A; Cannita, K; Cocciolone, V; Ficorella, C; Irelli, A; Lanfiuti Baldi, P; Manetta, R; Paradisi, S; Ricevuto, E; Rinaldi, L; Zugaro, L | 1 |
| Chen, YH; Qin, J | 1 |
| Ikeda, M; Kubo, S; Nakamoto, S; Tsukioki, T; Yamamoto, M | 1 |
| Cefalì, K; Corvino, R; D'Aniello, D; De Iuliis, F; Lanza, R; Salerno, G; Scarpa, S; Taglieri, L | 1 |
| Boche, D; Bousquet, G; El Bouchtaoui, M; Gourmaud, S; Janin, A; Paquet, C | 1 |
| Lin, H; Tao, L; Wang, L; Xu, X; Yan, Y; Yu, Y; Zhang, J | 1 |
| Asselain, B; Bachelot, T; Brain, E; Cailliot, C; Campone, M; Chenuc, G; Courtinard, C; Dalenc, F; Debled, M; Delaloge, S; Dieras, V; Ferrero, JM; Goncalves, A; Guesmia, T; Jacot, W; Jouannaud, C; Kerbrat, P; Levy, C; Lorgis, V; Mouret-Reynier, MA; Pérol, D; Petit, T; Robain, M; Uwer, L; Vanlemmens, L; Veyret, C | 1 |
| Bisagni, G; Ciccarese, M; Fontanella, C; Gamucci, T; Leo, L; Marchetti, P; Molino, A; Puglisi, F; Silva, RR | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Mo, H; Wang, J; Wang, X; Xu, B; Yin, Y; Yuan, P; Zhang, B; Zhang, P; Zheng, S | 1 |
| Ameye, L; Awada, A; Bustin, F; D'Hondt, V; Dal Lago, L; De Azambuja, E; Gombos, A; Ignatiadis, M; Larsimont, D; Lebrun, F; Lemort, M; Maetens, M; Michiels, S; Nogaret, JM; Paesmans, M; Piccart, M; Sotiriou, C; Vanderbeeken, MC; Veys, I; Wilke, C; Zardavas, D | 1 |
| Asano, Y; Hirakawa, K; Kashiwagi, S; Kawajiri, H; Kitagawa, S; Noda, S; Ohsawa, M; Onoda, N; Takashima, T | 1 |
| Mehta, RS; Nangia, CI; Tran, PN; Zhuang, L | 1 |
| Bernal-Estévez, D; Parra-López, C; Sánchez, R; Tejada, RE | 1 |
| Hosotani, Y; Mimura, O; Morimatsu, T; Takata, M | 1 |
| Li, J; Ren, J; Sun, W | 1 |
| Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E | 1 |
| Aghapour, M; Baradaran, B; Mansoori, B; Mohammadi, A; Nami, S; Shirjang, S | 1 |
| Anghel, R; Beslija, S; Brodowicz, T; Dank, M; Eniu, A; Greil, R; Inbar, M; Kahán, Z; Láng, I; Melichar, B; Messinger, D; Nisenbaum, B; Petruzelka, L; Pienkowski, T; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Aitken, AS; Arulanandam, R; Bell, JC; Bourgeois-Daigneault, MC; Diallo, JS; Falls, T; Garcia, V; Pelin, A; Roy, DG; St-Germain, LE | 1 |
| Azad, N; Iyer, AKV; Venkatadri, R; Yakisich, JS | 1 |
| Brynychova, V; Ehrlichova, M; Gut, I; Hlavac, V; Kodet, R; Kovar, J; Leva, J; Mrhalova, M; Nemcova-Furstova, V; Pecha, V; Soucek, P; Trnkova, M; Vaclavikova, R; Vrana, D | 1 |
| Chen, Z; Du, F; He, D; Jin, J; Li, H; Lu, H; Ma, X; Pan, Q; Tang, C; Wang, Y; Yao, X; Zang, X; Zhang, P | 1 |
| Gao, M; Huang, D; Jiang, C; Jin, Q; Li, J; Peng, F; Song, S; Wang, C; Zhang, D; Zhang, J | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Chen, J; Cheng, R; Deng, C; Feijen, J; Meng, F; Wang, X; Zhang, J; Zhong, Z; Zhu, Y | 1 |
| Capelan, M; Lote, H; Mohammed, K; Papadimitraki, E; Redana, S; Ring, A; Sharp, A | 1 |
| Abell, F; Apt, D; Chan, S; Fehrenbacher, L; Gendreau, S; Huizing, M; Laing, R; Petrakova, K; Rooney, I; Roylance, R; Singel, S; Vuylsteke, P; Zhou, J | 1 |
| Gyawali, B; Prasad, V | 1 |
| Chen, S; Di, GH; Jiang, YZ; Jin, X; Shao, ZM | 1 |
| Beer, LA; Domchek, S; Kossenkov, AV; Ky, B; Liu, Q; Luning Prak, E; Speicher, DW | 1 |
| Justinger, JS; Mazur, TM; Moore, GL; Nguyen, PT; Nyabuto, GO; Tipton, AR; Trendel, JA; Vestal, DJ; Wadi, S; Wilson, JP | 1 |
| Li, W; Yu, D; Zhang, B; Zhang, Y | 1 |
| Dong, W; Jin, Y; Liu, Y; Ma, P; Meng, L; Xia, X; Yang, Y; Ye, J | 1 |
| Abubakar, IB; Bai, RG; Loh, HS; Manickam, S; Muthoosamy, K | 1 |
| Abdolahad, M; Amiri, MH; Gharooni, M; Khosravi, S; Namdar, N; Zanganeh, S | 1 |
| Amiri-Kordestani, L; Balasubramaniam, S; Bates, SE; Bryla, C; Burotto, M; Choyke, P; Davarpanah, N; Figg, WD; Fojo, T; Gonzalez, EM; Liewehr, DJ; Lindenberg, M; O'Sullivan, CC; Patronas, N; Peer, CJ; Steinberg, SM | 1 |
| Mendelsohn, J | 1 |
| Castro-Sánchez, A; Escobar-Arriaga, E; Esparza-López, J; Ibarra-Sánchez, Mde J; León-Rodríguez, E; Medina-Franco, H; Ramos-Elías, PA; Rocha-Zavaleta, L; Zentella-Dehesa, A | 1 |
| Balušíková, K; Brynychová, V; Daniel, P; Ehrlichová, M; Kopperová, D; Kovář, J; Němcová-Fürstová, V; Souček, P; Václavíková, R | 1 |
| Cao, J; Jung, Y; Kim, MS; Lee, EH; Naeem, M; Noh, JK; Yoo, JW | 1 |
| Gao, JJ; Pohlmann, PR; Swain, SM; Tan, M | 1 |
| Chaney, D; Elsoueidi, R; Gresham, C; Michael, L; Mourad, H | 1 |
| Asuncion, BR; Bandla, A; Fazreen, Z; Goh, BC; Ho, J; Hoppe, MM; Jeyasekharan, AD; Kumarakulasinghe, NB; Lee, SC; Lim, JS; Ow, SG; Pang, B; Poh, LM; Putti, TC; Soong, RC; Sundar, R; Tan, DS; Tan, SS; Wilder-Smith, EP | 1 |
| Barroso-Sousa, R; Batista, RB; Bunnell, CA; Camuso, K; Costa, RB; Golshan, M; Hughes, ME; Lin, NU; Losk, K; Metzger-Filho, O; Paes, FR; Vaz-Luis, I; Winer, EP | 1 |
| Anchisi, S; Bärtschi, D; Bernhard, J; Bigler, M; Borner, M; Cathomas, R; Hasler-Strub, U; Küng, M; Matter-Walstra, K; Müller, A; Na, KJ; Rauch, D; Rochlitz, C; Rordorf, T; Ruhstaller, T; Trojan, A; Vetter, M; von Moos, R; Wicki, A; Winterhalder, R; Zaman, K | 1 |
| Foroud, T; Gardner, L; Jiang, G; Lai, D; Li, L; Miller, KD; O'Neill, A; Radovich, M; Schneider, BP; Shen, F; Sledge, GW; Sparano, JA; Xue, G | 1 |
| Boven, E; Frederiks, CN; Guchelaar, HJ; Honkoop, AH; Lam, SW; van der Straaten, T | 1 |
| Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Giranda, VL; Han, HS; Isakoff, SJ; Johnson, EF; Kaufman, B; Maag, D; Puhalla, S; Qin, Q; Robson, M; Shepherd, SP; Telli, ML | 1 |
| Che, D; Jin, X; Lv, H; Zhang, Y; Zhang, Z | 1 |
| Feng, R; Tian, X; Yu, B; Zhang, L | 1 |
| Dawood, S; Rugo, HS | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Calaf, GM; Quispe-Soto, ET | 1 |
| Baehner, F; Ballman, KV; Carr, JM; Cheang, MC; Ferree, S; Kachergus, JM; Mashadi-Hossein, A; Necela, BM; Norton, N; Perez, EA; Perou, CM; Tenner, KS; Thompson, EA | 1 |
| Chen, J; Feng, J; Gao, X; Jiang, T; Kang, T; Wei, D; Wei, X; Yao, J; Zhu, Q | 1 |
| Hong, W; Huang, Y; Liu, Y; Wang, H; Wang, W; Yang, J; Zhou, C | 1 |
| Batista López, N; Beck, JT; Campone, M; Chan, A; Delaloge, S; Di Tomaso, E; Dirix, L; Goteti, S; Hegg, R; Khan, QJ; Krivorotko, P; Manikhas, A; Martín, M; Massacesi, C; O'Shaughnessy, J; Ramos Vázquez, M; Ruiz Borrego, M; Shtivelband, M; Urban, P | 1 |
| Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH | 1 |
| Gokoz-Dogu, G; Saricopur, A; Senol, H; Yaylali, YT; Yurtdas, M | 1 |
| Chen, Y; Fan, J; Huang, Y; Li, J; Li, S; Lu, B; Ma, X; Venkataramanan, R; Wang, P; Xia, R; Xie, W; Zhang, X; Zhao, W | 1 |
| Cheng, B; Hu, F; Hu, Y; Liu, N; Tan, Y; Wen, L; Yuan, H | 1 |
| Czerniecki, BJ; Datta, J; De La Cruz, LM; Fisher, CS; McDonald, ES; Mick, R; Nocera, NF; Xu, S | 1 |
| Aktas, B; Blohmer, JU; Clemens, M; Dan Costa, S; Denkert, C; Engels, K; Gerber, B; Hackmann, J; Hanusch, C; Jackisch, C; Just, M; Kümmel, S; Loibl, S; Nekljudova, V; Paepke, S; Schmatloch, S; Schneeweiss, A; Untch, M; von Minckwitz, G; Warm, M; Wiebringhaus, H | 1 |
| Ao, X; Chang, H; Nie, P; Wang, S; Wu, B; Xu, W; Zhang, T; Zou, Z | 1 |
| Ji, X; Li, X; Liu, Y; Peng, Z; Qiao, Z; Yan, Z; Yang, Y | 1 |
| Chen, L; Gu, W; Li, Y; Meng, Q; Su, J; Sun, H; Tang, S; Yin, Q; Yu, H; Zhang, Z | 1 |
| Jin, X; Li, M; Lv, H; Yin, L; Zhang, Z; Zhou, J | 1 |
| Greka, A; Jeselsohn, R; Popovtzer, M; Rennke, HG; Siddiqui, B | 1 |
| Han, X; Li, A; Liu, Y; Pan, B; Shao, L; Shi, X; Si, X; Sun, L; Sun, Y; Yang, N; Zang, R; Zhang, E; Zhang, Z | 1 |
| Elkhuizen, PH; Koolen, BB; Rodenhuis, S; Rutgers, EJ; Stokkel, MP; Teixeira, SC; Valdés Olmos, RA; van der Noort, V; Vrancken Peeters, MT | 1 |
| Aliper, A; Artemov, AV; Borisov, N; Buzdin, A; Camargo, ML; Cantor, CR; Irincheeva, I; Izumchenko, E; Khokhlovich, E; Labat, I; Lezhnina, KV; Medintsev, S; Nikolsky, Y; Osipov, AN; Ozerov, IV; Sidransky, D; Vanhaelen, Q; Vijg, J; West, MD; Zhavoronkov, A | 1 |
| Cho, SG; Choi, HS; Jang, HJ; Kim, MK; Ko, SG; Lee, HJ; Moon, SH | 1 |
| Chen, Y; De, G; Li, Z; Ma, H; Sui, F; Wang, J; Xiao, S; Yu, H; Yue, Q; Zhao, Q | 1 |
| Basavanna, LN; Karuppasamy, R; Sequeira, VM; Veerappapillai, S; Verma, K | 1 |
| Angelini, F; Astone, A; Barba, M; Bertolini, I; Buglioni, S; Cassano, A; De Angelis, C; Di Lauro, L; Fabi, A; Gamucci, T; Giordano, A; Grassadonia, A; Magnolfi, E; Marchetti, P; Maugeri-Saccà, M; Mentuccia, L; Michelotti, A; Moscetti, L; Natoli, C; Nisticò, C; Palleschi, M; Pellegrini, D; Pellegrino, A; Pizzuti, L; Rossi, E; Sarobba, MG; Sergi, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P | 1 |
| Akyol, Z; Arisan, ED; Çoker-Gürkan, A; Obakan-Yerlikaya, P; Palavan-Ünsal, N | 1 |
| Gao, H; He, Q; Liu, J; Ma, L; Shi, K; Wang, Y; Xia, T; Yu, Q; Zhang, L; Zhang, Q | 1 |
| Chen, CM; Chen, S; Jin, X; Shao, ZM; Wang, RX | 1 |
| Allegrini, G; Arrighi, G; Bocci, G; Bona, E; Coltelli, L; Falcone, A; Ferrarini, I; Filidei, M; Finale, C; Fontana, A; Ginocchi, L; Goletti, O; Lucchesi, S; Marcucci, L; Salvadori, B; Scalese, M | 1 |
| Alexeev, E; Benites, J; Brockunier, R; Brown, SA; Carpenter, JP; Chang, S; Harris, WM; Kappy, N; Ortiz, T; Plastini, M; Zhang, P | 1 |
| Ding, R; Fu, Y; Gong, T; Li, H; Luo, J; Zhang, T; Zhang, Z | 1 |
| Goto, Y; Kimura, M; Sakiyama, K; Yoshida, T | 1 |
| Abesamis-Tiambeng, ML; Akewanlop, C; Baczkowski, M; Baramidze, K; Barve, A; Bondarenko, I; Hernandez-Bronchud, M; Herson, J; Kothekar, M; Loganathan, S; Mamillapalli, G; Manikhas, A; Mukhametshina, G; Nemsadze, G; Parra, JD; Pennella, E; Ray, S; Rugo, HS; Sharma, R; Sriuranpong, V; Vynnychenko, I; Waller, CF; Yanez Ruiz, EP; Yuan, J | 1 |
| Ghosh, S; Graham, K; Katsetos, CD; Lee, JC; Ludueña, RF; Mackey, JR; Patterson, J; Tuszynski, JA; Wang, W; Wang, X; Winter, P; Wong, GK; Zhang, H | 1 |
| Garcia, J; Green, L; Morrow, PK | 1 |
| Atyabi, F; Dinarvand, R; Ebrahimi, SM; Esfandyari-Manesh, M; Ghahremani, MH; Mohammadi, A; Nabavi, SM; Shahmoradi, E; Varnamkhasti, BS | 1 |
| Ando, Y; Goto, H; Kikumori, T; Maeda, O; Matsuoka, A; Mizutani, T; Nakano, Y; Tsunoda, N | 1 |
| Chen, Z; Li, C; Li, L; Liu, B; Wang, F | 1 |
| Asiaee, F; Hejazi, M; Lai, R; Molavi, O; Narimani, F; Sharifi, S; Shayanfar, A; Tarhriz, V | 1 |
| Asano, M; Futamura, M; Ishihara, K; Kawaguchi, Y; Kumazawa, I; Mori, R; Morimitsu, K; Nagao, Y; Nakada, T; Nawa, M; Shimokawa, T; Shiroko, T; Takeuchi, M; Yoshida, K | 1 |
| Shen, K; Wu, J; Zong, Y | 1 |
| Amemiya, K; Hirotsu, Y; Inoue, M; Mochizuki, H; Nakada, H; Nakagomi, H; Omata, M; Oyama, T | 1 |
| Badeaux, M; Garkavtsev, I; Gupta, N; Jain, RK; Liu, Y; Munn, LL; Naxerova, K; Sgroi, D | 1 |
| Allison, KH; Childs, JS; Coveler, AL; Dang, Y; Disis, ML; Higgins, DM; Lu, H; Reichow, JL; Salazar, LG; Waisman, J | 1 |
| Baehner, FL; Butler, SM; Cherbavaz, DB; Costantino, JP; Jamshidian, F; Jeong, JH; Julian, TB; Kim, SR; Lembersky, BC; Liu, Q; Mamounas, EP; Paik, S; Shak, S; Sing, AP; Tang, G; Wickerham, DL; Wolmark, N | 1 |
| Fang, P | 1 |
| Baba, H; Hoshino, N; Kume, Y; Nishioka, Y; Orita, F; Sato, Y; Sugimoto, H | 1 |
| Aomatsu, N; Haraoka, G; Hirakawa, T; Iwauchi, T; Morimoto, J; Nagashima, D; Nakazawa, K; Nishii, T; Nonomura, A; Takeuchi, K; Tei, S; Tsujio, G; Uchima, Y; Wang, E; Yamakoshi, Y | 1 |
| Abe, N; Abe, S; Aoto, K; Kimijima, I; Ohtake, T; Okano, M; Tachibana, K; Takenoshita, S; Yasuda, M; Yoshida, S | 1 |
| Bousamra, A; Brewster, AM; Buchholz, TA; Buzdar, AU; Gould, R; Hatzis, C; Hortobagyi, GN; Hunt, K; Liu, M; Moulder, S; Pusztai, L; Ramineni, M; Sinn, B; Symmans, WF; Valero, V; Walls, A; Wei, C; Yang, W; Yu, X; Zhang, Y | 1 |
| Bi, Y; Chen, Q; Chen, X; He, X; Jiang, C; Liu, L; Ruan, C; Sun, T; Wang, H; Zhang, Y; Zhou, M | 1 |
| Kanatani, K; Kashiwaba, M; Masuda, N; Nakagami, K; Nakayama, T; Okumura, Y; Sato, N; Tajima, K; Takahashi, M | 1 |
| Cheng, R; Deng, C; Feijen, J; Meng, F; Wang, X; Zhang, J; Zhong, Z; Zhu, Y | 1 |
| Argolo, D; Barrio, A; Baselga, J; Boafo, C; Dang, C; Hudis, CA; Jones, LW; Mamtani, A; Modi, S; Morrow, M; Norton, L; Patil, S; Schweber, S; Singh, JC; Smyth, LM; Sugarman, S; Yu, AF | 1 |
| Hu, P; Li, H; Li, JP; Liao, XH; Nie, Q; Xiang, Y; Yu, CX; Zhang, TC; Zhou, J | 1 |
| Campos, J; Haidar, ZS; Varas-Godoy, M | 1 |
| Chourasia, MK; Gothwal, A; Gupta, U; Khan, I; Kumar, V; Sharma, AK; Sharma, S; Singh, Y | 1 |
| Button, B; Chu, D; Cidado, J; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Hurley, PJ; Kyker-Snowman, K; Lauring, J; Park, BH; Rosen, DM; Wong, HY; Zabransky, DJ | 1 |
| Chen, Q; Deng, H; Liu, J; Xu, M; Xu, T; Zheng, W | 1 |
| Bernabeu, E; Chiappetta, DA; Gonzalez, L; Grotz, E; Moretton, MA; Zubillaga, M | 1 |
| Chen, S; Dong, Y; Meng, T; Ojima, I; Wang, C; Xing, Y; You, H; Zheng, X | 1 |
| Bosukonda, A; Carlson, WD | 1 |
| Printz, C | 1 |
| Bojková, B; Demečková, V; Gancarčiková, S; Hrčková, G; Kassayová, M; Mudroňová, D; Solár, P | 1 |
| Kapoor, S; Kumar Santra, M; Naaz, A; Panda, D; Rai, A | 1 |
| Bharali, DJ; Darwish, NH; Davis, PJ; Debreli Coskun, M; Keating, KA; Lin, HY; Mousa, SA; Sudha, T; Yalcin, M | 1 |
| Chung, HC; Gho, SG; Kim, GM; Kim, SI; Paik, S; Park, HS; Park, S; Sohn, J | 1 |
| de Boer, M; Dercksen, MW; Joore, MA; Lobbezoo, DJA; Peters, FPJ; Peters, NAJB; Ramaekers, BLT; Smilde, TJ; Tjan-Heijnen, VCG; van de Wouw, AJ; van den Berkmortel, F; van Kampen, RJW; van Riel, JMG | 1 |
| Chen, J; Chen, Q; Liu, Z; Ning, P; Tian, L; Wang, G; Yang, K; Yi, X | 1 |
| Bou-Dargham, MJ; Liu, JS; Lively, T; Lung, PY; Sang, QA; Sheffield, C; Tan, W; Yu, K; Zhang, J | 1 |
| Cohen, L; Driver, L; Eng, C; Lopez, G; Lyle, R; McQuade, J; Novy, D; Prinsloo, S; Ramondetta, L | 1 |
| Chesca, DL; Eloy, JO; Lee, RJ; Marchetti, JM; Petrilli, R; Saggioro, FP | 1 |
| Gong, C; He, T; Nie, S; Song, L; Wang, N; Wang, Z; Wu, Q; Yang, S; Yang, X; Yi, C | 1 |
| Liang, Z; Xi, Y | 1 |
| Chen, J; He, P; Luo, T; Lv, Q; Tan, QW; Tian, TL; Zeng, HL; Zheng, H | 1 |
| Ehrlich, BE; England, A; Moore, LM; Rimm, DL | 1 |
| Bertalot, G; Di Fiore, PP; Ekalle Soppo, B; Pambianco, S; Pece, S; Pruneri, G; Tosoni, D; Viale, G; Zecchini, S | 1 |
| Aime, S; Cutrin, JC; Geninatti Crich, S; Ruggiero, MR; Stefanìa, R; Turino, LN | 1 |
| Gu, P; Margolick, JB; Yin, D; Zhang, H; Zhang, Y; Zhou, J | 1 |
| Han, HS; Kang, HS; Kim, SW; Lee, DH; Lee, ES; Lee, H; Lee, KS; Nam, BH; Ro, J; Seo, JA | 1 |
| Bakri, K; Berry, DA; Cirrincione, C; Fleming, GF; Hudis, C; Lake, D; Marcom, K; Muss, H; Norton, L; Polite, BN; Schwartz, JH; Seidman, A; Shapiro, C; Winer, EP | 1 |
| Blackwell, K; Bullock, K | 1 |
| Bivens, CM; Desai, N; Flister, MJ; Ran, S; Stutzman, A; Trieu, V; Volk, LD | 1 |
| Bachelot, T; Blay, JY; Dufresne, A | 1 |
| Ameshima, S; Demura, Y; Ishizaki, T; Mizuno, S; Morikawa, M; Okazawa, H | 1 |
| Aravantinos, G; Bamias, A; Fountzilas, G; Papadimitriou, CA; Papakostas, P; Timotheadou, E | 1 |
| Espirito, JL; Pusztai, L; Valero, V; Wilson, NM | 1 |
| Amler, LC; Cavet, G; Haydu, L; Hu, X; Lackner, MR; Modrusan, Z; Mohan, S; O'Brien, C; Pandita, A; Rivers, CS; Toy, K | 1 |
| Aragon-Ching, JB; Dahut, WL; Desai, N; Figg, WD; Gardner, ER; Hawkins, MJ; Jones, J; Scripture, CD; Sparreboom, A | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, G; Catalano, V; Ceccolini, M; Fedeli, SL; Giordani, P; Graziano, F; Rossi, D | 1 |
| Cameron, DA; Stein, S | 1 |
| Brase, JC; Gehrmann, M; Hengstler, JG; Roos, P; Schmidt, M | 1 |
| Baselga, J; Prat, A | 1 |
| Barsuk, D; Catane, R; Evron, E; Goldberg, H; Kaufman, B; Modiano, T; Paluch-Shimon, S; Papa, MZ; Shabtai, M; Wolf, I; Yosepovich, A | 1 |
| Hino, M; Homma, K; Sano, M; Sato, N | 1 |
| Basu, S; Chelala, C; Crook, T; Danovi, SA; Gangeswaran, R; Harada, T; Holliday, D; Jones, LJ; Lara, R; Lemoine, NR; Manson-Bishop, C; Mein, CA; Pardo, O; Smith, P; Tomlinson, V; Yuan, M | 1 |
| Huober, J; Spirig, C; Thürlimann, B | 1 |
| Ishiguro, K; Nishimura, M; Suda, T | 1 |
| Kami, M; Komatsu, T; Tsubokura, M | 1 |
| Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L | 1 |
| Cleator, S; Coombes, RC; Kim, SB; Palmieri, C | 1 |
| Aksoy, S; Altundag, K; Dizdar, O | 1 |
| Ansari, R; Geyer, CE; Hamm, JT; Kardinal, CG; Kim, W; Lembersky, BC; Paik, S; Rastogi, P; Raymond, JM; Robidoux, A; Shalaby, IA; Song, YK; Tseng, GC; Wilson, JW; Wolmark, N | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Balzarini, J; Berndsen, SC; Direcks, WG; Lammertsma, AA; Molthoff, CF; Peters, GJ; Proost, N; Spreeuwenberg, MD | 1 |
| Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF | 1 |
| Anderson, E; Clarke, RB; Farnie, G; Howell, SJ; Hunter, T | 1 |
| Guinan, P; Rubenstein, M; Tsui, P | 2 |
| Cao, XX; Chen, Q; Li, HX; Li, QQ; Liu, XP; Tang, F; Wang, WJ; Xu, JD; Xu, ZD; Yang, JM | 1 |
| Clark, DW; Fillmore, RA; Fodstad, O; Jiang, WG; Mitra, A; Samant, RS; Shevde, LA | 1 |
| Kong, K; Mehta, RS; Schubbert, T | 1 |
| Albain, KS; Calderillo-Ruiz, G; Jordaan, JP; Llombart, AC; Melemed, AS; Nag, SM; O'Shaughnessy, J; Pluzanska, A; Reyes-Vidal, JM; Rolski, J; Sekhon, JS; Simms, L | 1 |
| Heinrich, G; Loibl, S; Müller, L; Murmann, C; Nekljudova, V; Schwedler, K; von Minckwitz, G; Warm, M | 1 |
| Coglianese, M; D'Alassandro, A; D'Andrea, G; Drullinsky, P; Fornier, M; Fournier, M; George, R; Hodgman, E; Hudis, C; Lake, D; Mills, N; Moynahan, M; Norton, L; Panageas, K; Smith, J; Sugarman, S; Troso-Sandoval, T; Wasserheit, C | 1 |
| Burstein, HJ; Najita, J; Tolaney, SM; Winer, EP | 1 |
| Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y | 1 |
| Gokmen-Polar, Y; Miller, KD | 1 |
| Benezra, R; Bertolini, F; Colleoni, M; Daenen, LG; Emmenegger, U; Henke, E; Kerbel, RS; Langenberg, MH; Man, S; Mancuso, P; Roodhart, JM; Shaked, Y; Strieter, RM; Tang, T; Voest, EE; Witte, L; Xu, P; Zhu, Z | 1 |
| Bosnjak, SM; Radulovic, S; Susnjar, S | 1 |
| Kikuchi, Y; Kita, T; Kudoh, K; Sato, K; Takano, M | 1 |
| Fontana, JA; Liu, CY; Parsa, V; Srinivasan, S | 1 |
| Scorilas, A; Thomadaki, H | 1 |
| Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA | 1 |
| Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A | 1 |
| Harano, M; Higaki, K; Kagemoto, M; Kin, R; Masumura, K; Matsuura, H; Ohtani, S; Takada, S; Urashima, M | 1 |
| Anan, K; Hirose, N; Mitsuyama, S; Ogawa, S; Saimura, M; Shimada, K; Tamaki, N; Tamura, K; Tanaka, M; Tomisaki, S | 1 |
| Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Souda, M; Tanaka, K; Yamamoto, Y | 1 |
| Fujii, T; Ikejiri, K; Koike, K; Sasada, S; Takahashi, H; Yokoyama, G | 1 |
| Doi, K; Ishihara, A; Kudo, K; Maeda, T; Ogata, K; Ohchi, T; Suzuki, S | 1 |
| Blot, E; Ouvrier, MJ; Philippin-Lauridant, G; Thureau, S | 1 |
| Georgoulias, V; Mavroudis, D; Saloustros, E | 1 |
| Eskiocak, U; Gunduz, U; Iseri, OD; Kars, MD; Sakin, V | 1 |
| Bay, JO; Blay, JY; Bompas, E; Brain, EG; Bui, BN; Chevreau, C; Cupissol, D; Fournier, C; Isambert, N; Jimenez, M; Kerbrat, P; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I; Taieb, S | 1 |
| Badve, S; Cobleigh, M; Davidson, N; Dickler, M; Edgerton, S; Flockhart, DA; Gralow, J; Hancock, B; Miller, KD; Perez, EA; Radovich, M; Schneider, BP; Shenkier, T; Sledge, GW; Thor, A; Wang, M | 1 |
| Black, M; Karmali, PP; Kastantin, M; Kotamraju, VR; Missirlis, D; Ruoslahti, E; Tirrell, M | 1 |
| Kutuk, O; Letai, A | 2 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Ahn, JB; Chang, H; Chung, HC; Im, CK; Jeung, HC; Kwon, WS; Rha, SY; Roh, JK; Yoo, NC | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Bachelot, T; Colin, C; Fournel, C; Ganne, C; Jacquin, JP; Jaisson-Hot, I; Lenoir, VT; Marechal, F; Mechin-Cretinon, I; Orfeuvre, H; Peaud, PY; Poncet, B; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Bacci, C; Giovannoni, L; Hindle, S; Kaspar, M; Mårlind, J; Neri, D; Sommavilla, R; Trachsel, E | 1 |
| Aogi, K; Kakishita, T; Nishikawa, K; Ohama, Y; Okita, A; Okita, R; Saeki, T; Taira, N; Takashima, S | 1 |
| Chmielewski, J; Emmert, D; Hrycyna, CA; Pires, MM | 1 |
| D'Andrea, G; Dang, C; Dickler, M; Fornier, M; George, R; Gilewski, T; Hudis, CA; Hurria, A; Lake, D; Mills, N; Moynahan, ME; Norton, L; Panageas, KS; Robson, M; Smith, K; Sugarman, S; Troso-Sandoval, T | 1 |
| Agostara, B; Belfiglio, M; Bertetto, O; Bruzzi, P; Cascinu, S; Cognetti, F; Conte, P; Crinó, L; D'Amico, R; Di Leo, A; Frassoldati, A; Guarneri, V; Molino, A; Pronzato, P | 1 |
| Akashi-Tanaka, S; Ando, M; Doihara, H; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Miyakawa, K; Seki, K; Shien, T; Shimizu, C; Taira, N | 1 |
| Arbushites, MC; Aziz, Z; Bines, J; Dering, J; Di Leo, A; Finn, RS; Gomez, HL; Guerrera, SF; Koehler, M; Oliva, C; Press, MF; Stein, SH; Williams, LS; Zvirbule, Z | 1 |
| Benz, MS; Brown, DM; Smith, SV | 1 |
| Horiguchi, J; Iino, Y; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, R; Odawara, H; Rokutanda, N; Sato, A; Takeyoshi, I; Tokiniwa, H | 1 |
| El-Saghir, NS; Farhat, MH; Shamseddine, AI | 1 |
| Ando, M; Fujiwara, Y; Hasegawa, T; Hashizume, K; Hatanaka, Y; Katsumata, N; Kinoshita, T; Kouno, T; Ono, M; Shimizu, C; Tamura, K; Tsuta, K; Yonemori, K | 1 |
| Dewhirst, MW; Li, CY; Li, F; Provenzale, JM; Tashjian, J; Viola, RJ; Yuan, H | 1 |
| Jeon, E; Onyüksel, H; Rubinstein, I | 1 |
| Cottrell, W; Dranitsaris, G; Hopkins, S; Spirovski, B | 1 |
| Chakrabarty, S; Hu, X; Liu, G | 1 |
| Iwamoto, M; Kimura, K; Nohara, T; Sumiyoshi, K; Takahashi, Y; Tanaka, S; Tanigawa, N | 1 |
| Amore, C; Di Santo, A; Donati, MB; Iacoviello, L; Latella, MC; Lorenzet, R; Napoleone, E; Zurlo, F | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| Aulitzky, WE; Friedel, G; Fritz, P; Haubeis, S; Mürdter, TE; Schroth, W; Simon, W; Sonnenberg, M; van der Kuip, H | 1 |
| Brindley, DN; Gaetano, C; Goping, IS; Samadi, N | 1 |
| Jiang, LY; Liu, HT; Shi, P; Sun, JZ; Wang, MM | 1 |
| Bane, CL; Gross, GG; LaPlant, BR; Palmieri, FM; Roy, V | 1 |
| Aranishi, T; Hausheer, FH; Hisamatsu, K; Kuroi, K; Masuda, N; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Takeuchi, A | 1 |
| Kakuta, H; Kawahata, M; Makishima, M; Matsuura, N; Morishita, K; Ohsawa, F; Sasaki, K; Tai, A; Takamatsu, K; Yakushiji, N; Yamaguchi, K | 1 |
| Cao, XX; Chen, Q; Chen, ZQ; Li, QQ; Liu, XP; Tang, F; Wang, WJ; Xu, JD; Xu, ZD | 1 |
| Czernick, M; Goping, IS; Rieger, A | 1 |
| Amano, S; Enomoto, K; Kitajima, A; Sakurai, K; Shiono, M; Tani, M | 3 |
| Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Ogino, T | 1 |
| De Benedictis, E; Fasolo, A; Gianni, L; Mariani, G | 1 |
| Besson, P; Gillet, L; Le Guennec, JY; Roger, S; Tran, TA; White, E | 1 |
| Kawakami, I; Kobayashi, Y; Kohyama, N; Ohbayashi, M; Yamamoto, T; Yasuda, M | 1 |
| Androic, I; Gätje, R; Kaufmann, M; Krämer, A; Rödel, F; Strebhardt, K; Yan, R; Yuan, J | 1 |
| Baselga, J; Benavides, M; Cirera, L; Climent, MA; Cortes, J; Cortés-Funes, H; Di Cosimo, S; Dorado, JF; Gascón, P; Gil, M; Lluch, A; Mayordomo, JI; Ojeda, B; Regueiro, P; Rodríguez, CA; Trigo, JM; Vazquez, J | 1 |
| Chang, CC; Chang, JS; Chuang, SM; Feng, BL; Ho, TF; Lin, SC; Lu, CH; Peng, YT; Yu, WJ | 1 |
| Chalut, KJ; Giacomelli, MG; Ostrander, JH; Wax, A | 1 |
| Brauchli, P; Dedes, KJ; Fink, D; Matter-Walstra, K; Pestalozzi, BC; Schwenkglenks, M; Szucs, TD | 1 |
| Gunduz, M; Haisa, M; Imada, T; Ito, M; Jordan, VC; Kurebayashi, J; Matsuoka, J; Motoki, T; Naomoto, Y; Ono, R; Shirakawa, Y; Tabuchi, Y; Takaoka, M; Tanaka, N; Yamatsuji, T | 1 |
| Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Gresham, LJ; Izevbigie, EB; Ross, J | 1 |
| Katsuura, M; Kurokawa, N; Miwa, Y; Murai, T; Noguchi, S; Oishi, M; Okamoto, Y; Taguchi, T; Ueda, M; Uejima, E; Yamamoto, T | 1 |
| Kawakami, T; Soma, Y; Tsutsumi, Y | 1 |
| Chen, JL; He, BS; Jiang, HX; Pan, YQ; Wang, B; Wang, SK; Zeng, QD; Zhang, LR | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Cohen, PR | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Lim, WY; Min-Han, T; Seng, TC; Tan, CS; Tan, MH; Yen, LW | 1 |
| Cyjon, A; Evron, E; Kovel, S; Sella, A; Yachnin, A; Yarom, N | 1 |
| Fornier, MN; Morris, PG | 1 |
| Conyers, JL; Joshi, PP; Lyon, JL; Mitchell, LR; Partha, R | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Izzo, F; Nisticò, C; Sperduti, I; Terzoli, E; Tropea, F; Vaccaro, V | 1 |
| Duivenvoorden, WC; Foroodi, F; Singh, G | 1 |
| Dick, M; Harbeck, N; Hoopmann, M; Kates, R; Mallmann, P; Thomas, A; Warm, M | 1 |
| Chen, Q; Dong, JT; Fu, L; Gu, F; Li, D; Liu, B; Liu, M; Peng, G; Wang, H; Zhang, C; Zhou, J | 1 |
| Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Petrillo, A; Rinaldo, M; Siani, C | 1 |
| Matard, B; Pinquier, L; Prevezas, C; Reygagne, P | 1 |
| Gupta, GK; Jain, V; Mishra, PR; Nath, B; Pant, AB; Shah, PP; Siddiqui, MA | 1 |
| Ando, M; Baba, S; Matsuyama, Y; Rai, Y; Sagara, Y; Tamada, S | 1 |
| Hirai, Y; Kiyoi, M; Miyasaka, M; Naito, K; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Shimizu, Y; Tamaki, T; Yoshimasu, T | 1 |
| Andreeff, M; Guo, H; Huang, WC; Li, P; Lu, J; Su, XH; Symmans, F; Tan, M; Treekitkarnmongkol, W; Tseng, LM; Yang, WT; Yu, D | 1 |
| Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, ES; Lee, KS; Nam, BH; Ro, J; Shin, KH | 1 |
| Marquez, A; Perez-Ruiz, E; Ribelles, N; Roman, A; Sanchez-Muñoz, A | 1 |
| Arisan, ED; Basaga, H; Bodur, C; Kutuk, O; Telci, D; Tezil, T | 1 |
| Gohda, K; Hortobagyi, GN; Ishihara, H; Katayama, A; Kawasaki, Y; Matsushima, T; Nakayama, S; Noguchi, S; Sakai, T; Sudo, T; Takahashi, T; Torikoshi, Y; Ueno, NT; Yoshida, T | 1 |
| Achilefu, S; Odonkor, CA | 1 |
| Amir, E; Freedman, O; Seruga, B; Tannock, I | 1 |
| Baek, HM; Bahri, S; Chen, JH; Mehta, RS; Nalcioglu, O; Nie, K; Su, MY; Yu, HJ | 1 |
| Bagley, RG; Crawford, JL; Krumbholz, RD; Kurtzberg, LS; Roth, SD; Rouleau, C; Schmid, SM; Teicher, BA; Yao, M | 1 |
| Jänsch, A; Pandey-Hoffmann, U; Pflugbeil, C; Schlodder, D; Schrag, S; Stange, R; Uehleke, B | 1 |
| Fujii, K; Miyahara, S; Miyake, T; Nakamura, H; Tadokoro, K; Taniguchi, M; Tanimura, M; Yamamura, K | 1 |
| Ando, M; Baba, S; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Tamada, S | 1 |
| Carpenter, PM; Marshall, J; Mehta, RS; Schubbert, T | 1 |
| Kim, EL; Sanchez, JJ; Vaidya, KS; Welch, DR | 1 |
| Cao, X; Garofalo, A; Grande, F; Louie, S; Neamati, N; Oshima, T; Yamada, R | 1 |
| Horiguchi, J; Iino, Y; Ikeda, F; Ishikawa, Y; Kikuchi, M; Koibuchi, Y; Nagaoka, H; Nagaoka, R; Odawara, H; Oyama, T; Rokutanda, N; Sato, A; Takata, D; Takeyoshi, I; Yokoe, T | 1 |
| Hisamatsu, K; Horiguchi, J; Ito, Y; Rai, Y; Seriu, T; Tajima, T; Taki, T; Tamura, K | 1 |
| Baselga, J; Bonadonna, G; Bozhok, A; Byakhov, M; Cussac, AL; Eiermann, W; Gianni, L; Greco, M; Lluch, A; Lopez, JJ; Mansutti, M; Martinez-Agulló, A; Porta, VG; Raab, G; Sabadell, D; Semiglazov, V; Valagussa, P; Zambetti, M | 1 |
| Czeczuga-Semeniuk, E; Jarzabek, K; Lemancewicz, D; Wołczyński, S | 1 |
| Lin, YJ; Zhen, YS | 1 |
| Fauvet, R; Gondry, J; Merviel, P; Mychaluk, J; Piprot, C; Sevestre, H | 1 |
| Dakhil, SR; Davidson, N; Dueck, AC; Halyard, MY; Kaufman, P; Kutteh, L; Marks, L; Martino, S; Perez, EA; Pierce, L; Pisansky, TM; Solin, L; Suman, V | 1 |
| Chang, KJ; Chen, PS; Hsu, HC; Huang, HY; Kuo, ML; Lin, MT; Prakash, E; Wang, MY | 1 |
| Irie, T; Mori, A; Morioka, M; Saito, M; Tanaka, M | 1 |
| Albert, US; Bauerfeind, I; Harbeck, N; Hinke, A; Jänicke, F; Kahlert, S; Konecny, GE; Kreienberg, R; Kuhn, W; Lebeau, A; Lück, HJ; Möbus, V; Muck, BR; Petry, KU; Schneeweiss, A; Thomssen, C; Untch, M; von Koch, F; Wallwiener, D; Werner, C | 1 |
| Desmedt, C; Haibe-Kains, B; Hatzis, C; Hortobagyi, GN; Kuerer, H; Liedtke, C; Piccart-Gebhart, M; Pusztai, L; Sotiriou, C; Symmans, WF; Valero, V | 1 |
| Dalrymple, SL; Dannals, RF; Davidson, NE; Frost, JJ; Huang, Y; Isaacs, JT; Madar, I; Ravert, H | 1 |
| Batist, G; Bier, A; Kandouz, M; Mamane, Y; Oviedo-Landaverde, I; Zhao, J | 1 |
| Hawthorne, VS; Huang, WC; Hung, MC; Neal, CL; Tseng, LM; Yu, D | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Bai, L; Dou, K; Guo, G; Jin, C; Song, W; Wu, H | 1 |
| Kumar, S; Lavhale, MS; Mishra, SH; Sitasawad, SL | 1 |
| Chiba, N; Ishihara, K; Jinno, H; Kitagawa, Y; Shimada, T; Ueda, M; Wada, M; Watanabe, J | 1 |
| Bamdad, C; Fessler, SP; Mahanta, SK; Wotkowicz, MT | 1 |
| Chen, FY; Du, YZ; Hu, FQ; Lou, YM; Yu, HY; Yuan, H; Zhao, MD | 1 |
| Bachelot, T; Blay, JY; Favier, B; Fayette, J; Galy, G; Guastalla, JP; Labidi, SI; Mosbah, K; Ray-Coquard, I; Treilleux, I | 1 |
| Asaga, T; Chishima, T; Doi, T; Hamaguchi, Y; Ichikawa, Y; Inaba, M; Ishikawa, T; Kasahara, A; Katayama, K; Kito, A; Matsumoto, C; Momiyama, N; Morita, S; Narui, K; Ohta, I; Shimada, H; Shimizu, D; Shimizu, S; Suda, T; Tanabe, M; Yamaguchi, N; Yoshimoto, M | 1 |
| Afton, SE; Bahassi, el M; Ben-Jonathan, N; LaPensee, CR; LaPensee, EW; Schwemberger, SJ | 1 |
| Jackson, D; Mehta, RS; Schubbert, T | 1 |
| Kiniwa, M; Kurebayashi, J; Nukatsuka, M; Sonoo, H; Uchida, J | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Krasnojon, D; Makhson, AN; Manikhas, GM | 1 |
| Anan, K; Ishikawa, M; Iwakuma, N; Mitsuyama, S; Takamatsu, Y; Tamura, K; Umeda, S | 1 |
| Kennedy, AM; Nam, KH; Rapoport, NY; Scaife, CL; Shea, JE | 1 |
| Castañeda, CA; Gomez, HL | 1 |
| Chaudhury, M; Frank, DA; Nelson, EA; Richardson, A; Signoretti, S; Walker, SR; Zou, L | 1 |
| Coleman, R; Dranitsaris, G; Gradishar, W | 1 |
| Kim, SJ; Morimoto, K; Noguchi, S; Shimazu, K; Taguchi, T; Tamaki, Y; Tanei, T; Tanji, Y | 1 |
| Fox, MJ; Gentry, ER; Goldblatt, EM; Gryaznov, SM; Herbert, BS; Shen, C | 1 |
| Miele, E; Spinelli, GP; Tomao, F; Tomao, S | 1 |
| Kameda, C; Katano, M; Kubo, M; Kuroki, S; Nakamura, M; Sato, N; Tanaka, H; Tanaka, M | 1 |
| Arpaci, F; Gündüz, U; Işeri, OD; Kars, MD | 1 |
| Adler, G; Kulaksiz, H; Stephani, J; von Figura, G; Wagner, M; Wegener, M; Wolf, C | 1 |
| Behrendt, JM; Gunn, RM; Hailes, HC; Ho, KK; Lafitte, VG; Lam, EW; Myatt, SS; Numbere, MG; Rosivatz, E; Smith, ME; Stavropoulou, AV; Wong, JB; Woscholski, R | 1 |
| Chakrabarty, S; Liu, G; Patmasiriwat, P; Promkan, M | 2 |
| Bateman, NW; Conrads, TP; Flint, MS; Hood, BL; Kim, G; Stewart, NA | 1 |
| Brent, S; Dunn, G; Dyker, A; Erhorn, S; Ferrie, L; Griffin, S; Horsley, W; Humphries, C; Macfarlane, K; Palmer, S; Thomas, S; White, S | 1 |
| Bydon, A; Garces-Ambrossi, G; Gok, B; Gokaslan, ZL; McGirt, MJ; Nelson, C; Noggle, J; Sciubba, DM; Witham, TF; Wolinsky, JP | 1 |
| Fujimori, T; Fushimi, K; Kadowaki, M; Miyazaki, M; Nagashima, T; Nakatani, Y; Onai, Y; Sakakibara, M; Suzuki, H; Yokomizo, J | 1 |
| Alvarado-Miranda, A; Arrieta, O; Bargallo-Rocha, E; Gamboa-Vignolle, C; Lara-Medina, F; Morales-Barrera, R; Perez-Sanchez, V; Ramirez-Ugalde, T; Saavedra-Perez, D; Zinser-Sierra, J | 1 |
| Balzer, EM; Cho, EH; Martin, SS; Matrone, MA; Whipple, RA | 1 |
| Buzdar, A; Morrow, PK; Reyes-Gibby, CC; Shete, S | 1 |
| Fischer, T; Harbeck, N; Kates, R; Thomas, A; Warm, M | 1 |
| Baggerly, KA; Coombes, KR; Hess, K; Hortobagyi, GN; Kiesel, L; Liedtke, C; Pusztai, L; Symmans, WF; Tordai, A; Wang, J | 1 |
| Niu, R; Shi, Y; Wei, X; Yang, Y; Yu, M; Zang, F | 1 |
| Barsoum, J; Cui, X; Giuliano, A; Liu, B; Qu, Y; Sim, MS; Wang, J | 1 |
| Han, X; Li, CJ; Lv, JH; Sun, YJ; Wang, T; Zhang, XF | 1 |
| He, WS; Huang, T; Ren, JH | 1 |
| Fu, JF; Hong, ZW; Wang, B | 1 |
| Arbushites, M; Dering, J; Di Leo, A; Finn, RS; Koehler, M; Oliva, C; Press, MF; Williams, LS | 1 |
| Kim, SJ; Noguchi, S; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y | 1 |
| Kossoff, E; O'Connor, TL | 1 |
| Jiang, SG; Li, XE; Liu, JG; Wang, JT; Wu, DM; Zhang, T; Zhang, Y; Zhang, ZY; Zu, YG | 1 |
| Beuselinck, B; Dirix, L; Kains, JP; Paridaens, R; Wildiers, H; Wynendaele, W | 1 |
| Blackwell, KL; Craciunescu, OI; Dewhirst, MW; Jones, EL; Liotcheva, V; Macfall, JR; Prosnitz, LR; Rosen, EL; Samulski, TV; Vujaskovic, Z; Wong, TZ; Yu, D | 1 |
| Allan, S; Bajdik, C; Chia, S; Gelmon, KA; Hassell, P; Hayes, MM; Norris, B; O'Reilly, SE; Shenkier, TN; Speers, C; Yerushalmi, R | 1 |
| Ehrlichová, M; Gut, I; Kovár, J; Ojima, I; Smejkalová, B; Zanardi, I | 1 |
| Alì, G; Allegrini, G; Barletta, MT; Bocci, G; Bona, E; Coltelli, L; Danesi, R; Del Tacca, M; Falcone, A; Fioravanti, A; Fontanini, G; Giuntini, N; Orlandi, P | 1 |
| Ahamed, E; Lim, A; Mauri, FA; Pakter, G; Stebbing, J | 1 |
| Andre, F; Gong, Y; Hortobagyi, GN; Jeong, JH; Kim, C; Paik, S; Pusztai, L; Ross, JS; Rouzier, R; Symmans, WF; Wolmark, N | 1 |
| Hua, H; Jiang, Y; Li, M; Liu, D; Luo, T; Wang, J; Wang, R; Xu, L; Yin, Y; Zhang, Y | 1 |
| Hibi, K; Ishibashi, K; Kigawa, G; Kou, Y; Matsumiya, A; Nemoto, H; Saito, M; Sanada, Y; Shirahata, A; Watanabe, R | 1 |
| Fridrichová, P; Malírová, E; Melichar, B; Tomsová, M | 1 |
| Bhattacharya, S; Bowden, C; Comis, RL; Gray, R; Miller, K | 1 |
| Dizon, DS; Fenton, MA; Gass, JS; Graves, TA; Kennedy, TA; Legare, RD; Sikov, WM; Strenger, R; Theall, KP | 1 |
| Glinskii, AB; Glinskii, OV; Glinsky, GV; Glinsky, VV; Huxley, VH; Kiriakova, G; Mawhinney, TP; Mossine, VV; Price, JE; Turk, JR | 1 |
| Aogi, K; Kakishita, T; Kurita, A; Okita, A; Okita, R; Osumi, S; Saeki, T; Taira, N; Takashima, S | 1 |
| Billam, M; Casero, RA; Davidson, NE; Hacker, A; Pledgie-Tracy, A; Sobolewski, MD; Woster, PM; Zhang, Z | 1 |
| Kaide, A; Kodama, K; Matsuoka, J; Ootawa, Y; Ootsuka, N; Watanabe, N | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Aloe, A; Astier, L; Berzins, J; Biganzoli, L; Gorbunova, V; Jassem, J; Jelic, S; Munier, S; Nagykalnai, T; Pienkowski, T; Pluzanska, A | 1 |
| Chen, S; Chen, Y; Nie, D; Tang, Y | 1 |
| Ishii, M; Kimijima, I; Suzuki, M | 1 |
| Ankola, DD; Bhardwaj, V; Gupta, SC; Kumar, MN; Lehr, CM; Schneider, M | 1 |
| Blaskó, G; Nagy, Z; Turcsik, V | 1 |
| Hatta, M; Kamigaki, S; Masuda, N; Nakayama, T; Sakamoto, J; Taguchi, T; Yamamura, J | 1 |
| Aránega, A; Boulaiz, H; Caba, O; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Ramos, JL; Segura, A; Vélez, C | 1 |
| Gaasch, JA; Goda, S; Lockman, PR; Mittapalli, RK; Palmieri, D; Rudraraju, V; Smith, QR; Steeg, PS; Taskar, K; Thomas, FC; Thorsheim, HR | 1 |
| Ardavanis, A; Charalampia, M; Doufexis, D; Karagiannis, A; Kardara, E; Kountourakis, P; Malliou, S; Rigatos, G; Sykoutri, D | 1 |
| Bang, YJ; Han, HS; Im, SA; Jeon, YK; Kim, JH; Kim, JS; Kim, TY; Lee, KW; Oh, DY; Park, IA; Park, JH; Park, SY | 1 |
| Benedict, A; Cameron, DA; Corson, H; Jones, SE | 1 |
| Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L | 1 |
| Rivera Rosado, LA; Yoshida, T; Zhang, B; Zhang, Y | 1 |
| Arbushites, M; Di Leo, A; Finn, RS; Gagnon, R; Koehler, M; Press, MF | 1 |
| Beal, K; Damast, S; Elkin, E; Fornier, MN; Ho, AY; Ishill, N; McCormick, B; Montgomery, L | 1 |
| An, HT; Kim, J; Kim, YS; Ko, J | 1 |
| Albain, KS; Bramwell, V; Burnell, M; Chalchal, H; Chapman, JA; Gelmon, K; Levine, MN; O'Brien, P; Perez, EA; Pritchard, K; Rugo, H; Shepherd, LE; Vandenberg, T; Walley, B | 1 |
| Chen, C; Come, S; Dang, CT; Dickler, M; Godfrey, L; Hudis, CA; Lin, N; McArthur, HL; Morris, PG; Moy, B; Norton, L; Nulsen, B; Rugo, H; Steingart, R; Sugarman, S; Traina, T; Winer, E | 1 |
| Caneva-Soumetz, F; Erokhina, S; Pastorino, L; Ruggiero, C | 1 |
| Shiba, E; Takahara, S; Tokushima, Y; Yamamoto, H | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Carrico, ZM; Francis, MB; Hsiao, SC; Wu, W | 1 |
| Fitzpatrick, P; Furlong, F; Gorman, S; Harrison, M; Klinger, R; McCann, A; Mosetto, M; O'Connor, D; O'Sullivan, J; Prencipe, M; Roninson, IB; Tosetto, M | 1 |
| Batist, G; Hu, L; Kandouz, M; Loignon, M; Miao, W | 1 |
| Bristianou, M; Georgiou, C; Kamposioras, K; Karathanasi, I; Mauri, D; Polyzos, NP; Tsali, L; Valachis, A | 1 |
| Hong, SW; Jeong, H; Jeong, J; Jung, W; Kim, KH; Koo, JS; Lee, HD; Shin, E | 1 |
| Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR | 1 |
| Bonner, JA; Quiles, S; Raisch, KP; Safavy, A; Sanford, LL | 1 |
| Gupta, GK; Gupta, VK; Mishra, PR; Pant, AB; Shukla, P | 1 |
| Bao, J; Huang, L; Li, Z; Liu, K; Mei, L; Song, C; Sun, H; Sun, L; Tang, L; Tian, G; Tian, Y; Zhang, Y | 1 |
| Jiang, H; Kanwar, JR; Pan, S; Sun, X; Tao, W; Zhang, M | 1 |
| Ishiguro, K; Nishimura, M; Suda, T; Uchida, N | 1 |
| Ames, MM; Goetz, MP; Kuffel, MJ; Reinicke, KE | 1 |
| Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH | 1 |
| Cataruozolo, PE; Chuang, E; Collier, M; Gowland, PA; Huang, X; Kern, KA; Kozloff, M; Miller, K; Starr, A; Verkh, L | 1 |
| Farach-Carson, MC; Meckling, KA; Nemere, I; Richard, CL; Rohe, B | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K; Shiono, M | 1 |
| Aramaki, N; Iizuka, M; Kuranami, M; Kurita, A; Miyauchi, K; Nakakuma, T; Sengoku, N; Shiozawa, K; Ueno, S | 1 |
| Aoyagi, H; Hamada, S; Kaneko, J; Katsuta, E; Maejima, S; Makinose, T; Okubo, K; Saguchi, M; Sato, T; Sekine, T; Someno, Y; Sugihara, K | 1 |
| Amano, S; Enomoto, K; Fujisaki, S; Kitajima, A; Matsuo, S; Ogura, M; Sakurai, K; Shiono, M; Tani, M | 1 |
| Abad, M; Alba, E; Batista, N; Caballero, R; Calvo, L; Crespo, C; Cubedo, R; de Alava, E; Domínguez, S; Florián, J; García, MJ; Godes, M; Llorca, C; Martín, M; Méndez, M; Murias, A; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Santaballa, A | 1 |
| Kolivas, ED; Smitherman, TA | 1 |
| Abusief, ME; Ginsburg, ES; Missmer, SA; Partridge, AH; Weeks, JC | 1 |
| Arbuck, SG; Broglio, K; Buzdar, AU; Holmes, FA; Hortobagyi, GN; Moulder, SL; Seidman, A; Thall, P; Tolcher, AW; Valero, V | 1 |
| Baggerly, K; Coutant, C; Kim, YC; Lee, JK; Pusztai, L; Qi, Y; Rouzier, R; Symmans, WF; Theodorescu, D | 1 |
| Ayers, GD; Bauer, JA; Caprioli, RM; Chakravarthy, AB; De Matos Granja-Ingram, N; Formenti, SC; Johnson, KN; Kelley, MC; Mayer, IA; Means-Powell, JA; Meszoely, IM; Mi, D; Olivares, MG; Pietenpol, JA; Rosenbluth, JM; Sanders, ME; Schneider, RJ; Seeley, EH; Tsai, CJ | 1 |
| Hama, Y; Nakagawa, K | 1 |
| Han, L; Jia, Z; Kang, CS; Mei, M; Pu, PY; Ren, Y; Wang, GX; Yao, Z; Yuan, XB; Zhou, X | 1 |
| Aykin-Burns, N; Coleman, MC; Hadzic, T; Jacobson, GM; Leick, K; Spitz, DR; Zhu, Y | 1 |
| Chang, KJ; Cheng, AL; Hsu, C; Hu, FC; Huang, CS; Kuo, KT; Kuo, WH; Lee, WC; Liau, JY; Lin, CH; Lu, YS; Shao, YY | 1 |
| Eguchi, H; Kogure, Y; Komatsubara, K; Matsuhisa, T; Miyoshi, K | 1 |
| Amonkar, MM; Aziz, Z; Bines, J; Di Leo, A; Gomez, HL; Sherrill, B; Wu, Y; Zvirbule, Z | 1 |
| Chiu, CY; Huang, CC; Lo, CP; Shyur, LF | 1 |
| Díaz-Rubio, E; López-Tarruella, S; Manzano, A; Martin, M; Puente, J | 1 |
| Ito, S; Okuda, M | 1 |
| Baronio, R; Barton, C; Baselga, J; Bozhok, A; Byakhow, M; Ciruelos, E; Climent, MA; Eiermann, W; Feyereislova, A; Gianni, L; Lichinitser, M; Lluch, A; Manikhas, A; Mansutti, M; Ojeda, B; Semiglazov, V; Tjulandin, S; Valagussa, P; Vazquez, F; Zambetti, M | 1 |
| Buzdar, AU; Desai, AM; Fehrenbacher, L; Fourchotte, V; Geyer, CE; Jacobs, S; Mamounas, EP; Pajon, ER; Quinaux, E; Rastogi, P; Robidoux, A; Shalaby, IA; Wolmark, N; Younan, RJ | 1 |
| Li, T; Liu, YH; Qin, XQ; Wang, YH; Ye, JM; Yin, HF; Zhang, H | 1 |
| Arslan, C; Kilickap, S | 1 |
| Ding, Y; Fodstad, O; Kamarajugadda, S; Ledoux, SP; Liu, H; Liu, Z; Lu, J; Owen, LB; Riker, AI; Tan, M; Zhao, Y; Zhou, M | 1 |
| Cui, X; Giuliano, A; Kuiatse, I; Lee, AV; Pan, J; Wang, J | 1 |
| Arbushites, M; Di Leo, A; Downey, L; Guzman, R; Koehler, M; Livingston, RB; Press, MF; Santiago, A; Villalobos, I; Williams, L | 1 |
| Gonlusen, G; Paydas, S; Yapar, Z | 1 |
| Costantini, DL; Reilly, RM; Vallis, KA; Villani, DF | 1 |
| Bear, HD; Di, X; Gennings, C; Gewirtz, DA; Graham, LJ; Sheth, CM; White, KL | 1 |
| Andreopoulou, E; Burrell, RA; Desmedt, C; Eklund, AC; Esteva, FJ; Gerlinger, M; Haibe-Kains, B; Juul, N; Li, Q; Pusztai, L; Sotiriou, C; Swanton, C; Symmans, WF; Szallasi, Z; Valero, V | 1 |
| Chen, CM; Chen, XS; Lu, JS; Nie, XQ; Shao, ZM; Shen, KW; Shen, ZZ; Wu, J; Wu, JY | 1 |
| Fukui, M; Yamabe, N; Zhu, BT | 1 |
| Chang, H; Chung, HC; Jeung, HC; Jung, JJ; Kim, TS; Rha, SY | 1 |
| Cook, KR; Cristofanilli, M; Huang, EH; Krishnamurthy, S; Lucci, A; Martin, C; Mosalpuria, K; Singh, B | 1 |
| Bergougnoux, L; Bidard, FC; de Cremoux, P; Degeorges, A; Delva, R; Etienne-Grimaldi, MC; Mathiot, C; Milano, G; Pierga, JY; Pivot, X; Veyret, C | 1 |
| Vitry, AI | 1 |
| Astanehe, A; Berquin, IM; Davies, AH; Dunn, SE; Eaves, CJ; Fotovati, A; Hu, K; Johnson, P; Law, JH; Lee, L; Raouf, A; Reipas, KM; Royer, HD; Stratford, AL; To, K; Wang, J | 1 |
| Domoto, K; Fujibayashi, M; Hirano, A; Kamimura, M; Kim, N; Kimura, K; Kinoshita, J; Ogawa, K; Shimizu, T; Watanabe, O | 1 |
| Batrakova, EV; Bronich, TK; Jordan, R; Kabanov, AV; Li, S; Luxenhofer, R; Roques, C; Schulz, A | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Maehara, Y; Matsuda, H; Nagata, S; Ueda, N; Yoshida, Y | 1 |
| Biganzoli, L; Conte, P; Diéras, V; Glaspy, J; Guarneri, V; Miles, D; Robert, N; Smith, I; Taran, T; Thomssen, C | 1 |
| Betof, A; Blackwell, K; Craciunescu, O; Dewhirst, MW; Jones, E; Kim, DW; Lan, L; Liotcheva, V; McCall, L; Stauffer, P; Vujaskovic, Z | 1 |
| Appleyard, VC; Mayer, M; Murray, KE; O'Neill, MA; Rolim-Santos, HM; Santos-Magalhães, NS; Thompson, AM | 1 |
| Dumontet, C; Hage-Sleiman, R; Herveau, S; Laurier, JF; Matera, EL | 1 |
| Gündüz, U; Işeri, OD; Kars, MD | 2 |
| Jiang, ZF; Shao, ZM; Xu, BH | 1 |
| Atkins, CD | 2 |
| Chen, X; Huang, Y; Li, P; Li, X; Liu, Y; Zhang, Y; Zhou, Y | 1 |
| Chen, XM; Huang, Y; Ke, XY; Wang, Y; Zhang, Q; Zhang, X; Zhao, BJ; Zhao, BX; Zhao, X | 1 |
| Barni, S; Borgonovo, K; Petrelli, F | 1 |
| Mirza, S; Pandya, P; Ralhan, R; Sharma, G | 1 |
| du Bois, A; Harbeck, N; Hinke, A; Huober, J; Jackisch, C; Konecny, GE; Kreienberg, R; Kuhn, W; Kurbacher, C; Lueck, HJ; Moebus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Khasraw, M; Murphy, CG; Seidman, AD | 1 |
| Ding, Y; Fodstad, O; Li, G; Liu, H; Liu, Z; Lu, J; Riker, AI; Tan, M; Xi, Y; Xiong, W; Zhao, Y; Zhou, M | 1 |
| Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T | 1 |
| Feng, SS; Liu, Y; Pan, J | 1 |
| Kawaguchi, H; Koga, C; Nakamura, Y; Nishimura, S; Nishiyama, K; Ohno, S; Shigematsu, H; Shiotani, S; Taguchi, K; Tanaka, K | 1 |
| Groshen, S; Lee, AS; Lee, E; Nichols, P; Spicer, D | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, C; Hudis, C; Lin, N; Morris, P; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Costantino, JP; Jeong, JH; Kidwell, K; Kim, C; Mamounas, EP; Nguyen, D; Paik, S; Swain, SM; Wolmark, N; Yang, SX | 1 |
| Asmar, L; Blum, JL; Boehm, KA; Burris, HA; Greco, FA; Hainsworth, JD; Holmes, F; Jones, S; Lindquist, D; Loesch, D; McIntyre, K; Modiano, MR; Pippen, J; Robert, N; Sandbach, J; Sedlacek, S; Senzer, NN; Vukelja, SJ; Zhan, F | 1 |
| Diaz, R; Hallahan, DE; Harth, E; Passarella, RJ; Phillips, JG; Sathiyakumar, V; Spratt, DE; van der Ende, AE; Wu, H; Zhou, L | 1 |
| Kirson, ED; Palti, Y; Schneiderman, RS; Shmueli, E | 1 |
| Fukatsu, K; Iwaya, K; Moriya, T; Osaki, A; Ueda, S; Yamamoto, J | 1 |
| Bafaloukos, D; Bobos, M; Fountzilas, G; Gogas, H; Kalofonos, HP; Kostopoulos, I; Lianos, E; Papaxoinis, G; Pavlakis, K; Pectasides, D; Petraki, K; Skarlos, D | 1 |
| Burstein, HJ; Dhakil, S; Fabian, C; Kozloff, M; Mayer, EL; Parmar, H; Patel, T; Qamar, R; Samant, M; Sundaram, S; Volterra, F | 1 |
| Huang, X; Lee, CK; Liu, B; Wang, S | 1 |
| Bepler, G; Cognetti, F; Conti, F; Di Lauro, L; Fabi, A; Giannarelli, D; Lopez, M; Metro, G; Sergi, D; Tomao, F; Vici, P | 1 |
| Petrenko, VA; Torchilin, VP; Wang, T | 1 |
| Eller, J; Kahán, Z; Kelemen, G; Ormándi, K; Thurzó, L; Uhercsák, G | 1 |
| Boussen, H; Cristofanilli, M; DeSilvio, M; Salazar, V; Spector, N; Zaks, T | 1 |
| Carr, JR; Kiefer, MM; Park, HJ; Raychaudhuri, P; Wang, Z | 1 |
| Agostara, B; Amadori, D; Boccardo, F; Catalano, G; Faedi, M; Farris, A; Gambi, A; Guglielmini, P; Rubagotti, A; Sismondi, P | 1 |
| Fujiwara, I; Magae, J; Mizuta, N; Nakajima, H; Sakaguchi, K; Tanuma, S; Yoshimori, A | 1 |
| Fujimoto-Ouchi, K; Furugaki, K; Kurasawa, M; Mori, K; Nakano, K; Yamashita, Y; Yanagisawa, M; Yorozu, K | 1 |
| Fujikuni, N; Hashimoto, M; Iwako, H; Kuranishi, F; Kuroda, Y; Moriyuki, T; Niitsu, H | 1 |
| Chishima, T; Endo, I; Hasegawa, S; Ishikawa, T; Ota, Y; Shimizu, D; Yamada, A | 1 |
| Lazzati, V; Lohsiriwat, V; Petit, JY; Veronesi, P; Zygoń, J | 1 |
| Arteaga, CL; Bauer, JA; Lehmann, BD; Marshall, CB; Pendleton, CS; Pietenpol, JA; Shyr, Y; Ye, F | 1 |
| Li, JF; Lin, BY; Lu, AP; Ouyang, T; Qi, M; Xie, YT | 1 |
| Chen, FS; Chen, XH; Chen, XJ; Luo, RC; Zhang, BM | 1 |
| Baez, O; Castrellon, A; Ferrell, A; Glück, S; Higgins, C; Hurley, E; Hurley, J; Lobo, C; Lopes, G; Reis, I; Richman, S; Seo, P; Silva, O; Slingerland, J; Tukia, K; Welsh, C | 1 |
| Bryan, M; Pavlick, AC; Pliner, L; Pulte, ED; Saunders, T; Toomey, KC; Wieder, R | 1 |
| Roy, V; Vishnu, P | 1 |
| Georgoulias, V; Karachaliou, N; Mavroudis, D; Saloustros, E; Vamvakas, L | 1 |
| Buckland, TW; Craik, AC; Czernick, M; Damaraju, S; Ghosh, S; Goping, IS; Kyselytzia, K; Lai, R; Mackey, JR; Underhill, DA; Veldhoen, RA | 1 |
| Inaji, H; Masuda, N; Morimoto, T; Motomura, K; Nakano, Y; Nakayama, T; Noguchi, S; Nomura, T; Shimazu, K; Taguchi, T; Takatsuka, Y; Tsukamoto, F; Wakita, K; Yamamoto, H; Yoneda, K | 1 |
| Aogi, K; Fujimoto, T; Funai, J; Kamigaki, S; Okazaki, M; Saeki, T; Sagara, Y; Takashima, S; Toi, M; Yoshida, M | 1 |
| Baricordi, OR; Ferlini, A; Indelli, M; Lelli, G; Rimessi, P; Rizzo, R; Spaggiari, F | 1 |
| Chen, T; Ding, X; Guo, Y; Guo, Z; Jin, X; Liang, R; Sun, Y; Xu, Y; Zhao, L | 1 |
| Arase, K; Iizaka, M; Inoue, K; Kuriwaki, K; Sueta, A; Yamamoto, Y | 1 |
| Bousetta, N; Brain, E; Brignone, C; Cvitkovic, F; Gligorov, J; Grygar, C; Gutierrez, M; Jarcau, R; Marcu, M; Medioni, J; Mefti, F; Triebel, F | 1 |
| Araque Arroyo, P; Calleja Hernández, MA; Cancela Díez, B; Fernández Feijóo, MA; Hernández Magdalena, J; Ubago Pérez, R | 1 |
| Burris, H; Hainsworth, J; Inhorn, R; Melnik, M; Peacock, N; Raefsky, E; Shipley, D; Yardley, D | 1 |
| Cao, D; Fukuda, K; Furuta, E; Iiizumi, M; Kobayashi, A; Liu, W; Mo, YY; Murphy, LL; Okuda, H; Pai, SK; Pandey, PR; Shindo, K; Watabe, K; Watabe, M; Xia, B; Xing, F | 1 |
| Dash, R; Fisher, PB; Mandal, M; Mazumdar, A; Sarkar, D; Sarkar, S | 1 |
| Burris, HA; Daniel, B; Hainsworth, JD; Inhorn, R; Lane, CM; Naot, Y; Vazquez, ER; Yardley, DA; Zubkus, J | 1 |
| Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H | 2 |
| Chen, JY; Li, J; Zhu, X | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kardara, E; Kountourakis, P; Maliou, S; Margari, C; Sykoutri, D; Tzovaras, A | 1 |
| Chaudhury, M; Frank, DA; Nelson, EA; Walker, SR | 1 |
| Davidson, NE; Dueck, AC; Gralow, JR; Harris, LN; Hillman, DW; Ingle, JN; Jenkins, RB; Kaufman, PA; Ketterling, RP; Lingle, WL; Martino, S; Perez, EA; Reinholz, MM; Schroeder, MJ; Sledge, GW; Tenner, KS; Visscher, DW | 1 |
| Bach, A; Brufsky, AM; Clawson, A; Conlin, AK; D'Andrea, G; Danso, M; Dickler, M; Hudis, CA; Lake, D; Saleh, M; Seidman, AD; Traina, T | 1 |
| Barnadas, A | 1 |
| Borowicz, H; Glados, M; Heilmann, V; Hinke, A; Jackisch, C; Lehnert, A; Möbus, V; Müller, V; Schmidt, M; Thomssen, C | 1 |
| Hata, K; Ito, A; Kanamoto, A; Shinozaki, M; Tahara, H; Tsurita, G; Yoneyama, K | 1 |
| Gu, YJ; Mao, J; Peng, WJ; Tan, HN; Tang, F; Wang, XH; Xin, C | 2 |
| Matouskova, E; Mladkova, J; Sanda, M; Selicharova, I | 1 |
| Hudis, CA; Lake, D; Murphy, CG; Theodoulou, M; Walsh, JB | 1 |
| Abe, M; Kiniwa, M; Matsuo, K; Nakagawa, F; Noguchi, S; Nukatsuka, M; Saito, H; Shibata, J; Uchida, J | 1 |
| Fitzgerald, GK; Hile, ES; Studenski, SA | 1 |
| Balachandran, R; Balasubramani, M; Cardamone, J; Day, BW; Jordan, MA; Kamath, K; Leslie, KL; Nakao, C; Uechi, GT; Wilson, L | 1 |
| Adkins, CE; Bohn, KA; Gaasch, JA; Gril, B; Huang, S; Lockman, PR; Mittapalli, RK; Palmieri, D; Roberts, A; Rudraraju, V; Smith, QR; Steeg, PS; Taskar, KS; Thorsheim, HR | 1 |
| Barajas-Figueroa, LJ; Coutant, C; Doimi, FD; Gomez, H; Gong, Y; Hess, KR; Hortobagyi, GN; Ibrahim, NK; Lluch, A; Martin, M; Pusztai, L; Qi, Y; Souchon, E; Symmans, WF; Tabchy, A; Valero, V; Vidaurre, T | 1 |
| Fang, QH; Feng, CR; Han, XQ; Hou, JL; Li, ZH; Shen, J; Shi, YK; Wang, FS; Wang, HH; Wang, P; Wang, ZH; Yi, JH; Zhang, PF | 1 |
| Devineni, S; Ghebre, R; Ghosh, G; Jing, Y; Joshi, HP; Ramakrishnan, S; Subramanian, IV; Truskinovsky, AM | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Adams, S; Bauer, JA; Chakravarthy, AB; Donach, M; Formenti, SC; Goldberg, JD; Hochman, T; Lymberis, S; Muggia, F; Pietenpol, JA; Schneider, RJ; Singh, B; Spicer, D | 1 |
| Akiyama, F; Hatake, K; Horii, R; Ito, Y; Iwase, T; Makita, M; Matsuura, M; Miki, Y; Nagasaki, K; Noda, T; Takahashi, S; Tokudome, N; Ushijima, M; Yoshimoto, M | 1 |
| Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Mavroudis, D; Polyzos, A; Saloustros, E; Vardakis, N | 1 |
| Chen, J; Dai, L; Feng, Y; Li, Y; Lu, L; Wang, H; Zhang, P | 1 |
| Kratz, F; Moktan, S; Raucher, D; Ryppa, C | 1 |
| Amiji, M; Duan, Z; Milane, L | 1 |
| Clawson, A; Iglesias, J; Krekow, L; O'Shaughnessy, J; Robert, N; Stokoe, C | 1 |
| Casado, MÁ; Cortés, J; Frías, C; Oyagüez, I; Seguí, MÁ | 1 |
| Conrad, B; Forstbauer, H; Koehne, CH; Kremers, S; Linder, M; Loibl, S; Moebus, V; Mueller, V; Nekljudova, V; von Minckwitz, G | 1 |
| Cartledge, D; Godwin, AK; Kouadio, A; Zhang, H | 1 |
| Andre, F; Campone, M; Hurvitz, SA; Manlius, C; Massacesi, C; Mukhopadhyay, P; Naughton, M; O'Regan, R; Sahmoud, T; Soria, JC | 1 |
| Brandt, BH; Dittmar, T; Haverkampf, S; Meyer-Staeckling, S; Niggemann, B; Reith, G; Schwitalla, S; Seidel, J; Zänker, KS | 1 |
| Li, XR; Liao, N; Wang, K; Yao, M; Zhang, GC; Zu, J | 1 |
| Song, ST | 1 |
| Cruz, A; Hines-Telang, G; Kroumpouzos, G; Temu, T | 1 |
| Anthony, S; Chen, WC; Cooper, BW; Hanks, SH; Kim, E; Kim, J; Leeming, R; Lyons, JA; Overmoyer, B; Shenk, R; Silverman, P | 1 |
| Campbell, KL; McNeely, ML | 1 |
| Charnley, M; Håkanson, M; Textor, M | 1 |
| Chang, HL; Donahoe, PK; Li, X; MacLaughlin, DT; Nicolaou, F; Pieretti-Vanmarcke, R; Wei, X | 1 |
| Ben Larbi, S; Cohen, PA; Collins, C; Ghayad, SE; Grisard, E; Payen, L; Thollet, A; Vendrell, JA; Villedieu, M | 1 |
| Bravencová, Z | 1 |
| Akhtar, MS; Fatimi, S; Kousar, F; Masood, M | 1 |
| Cheng, L; Hu, S; Huang, H; Ling, B; Liu, J; Shen, G; Song, L; Wei, W; Wu, Q; Xiao, W; Zhang, A; Zhao, T | 1 |
| Patlak, M | 1 |
| Abbey, R; DeSilvio, M; Dobrovolskaya, N; Jagiello-Gruszfeld, A; Manikhas, A; Pienkowski, T; Ridderheim, M; Tjulandin, S | 1 |
| Huang, W; Lin, Q; Wei, H; Yang, C; Zhang, H | 1 |
| Guan, Z; Jiang, Z; Shen, Z; Xu, B; Zhang, X | 1 |
| Fujibayashi, M; Hirano, A; Kamimura, M; Kim, N; Kimura, K; Kinoshita, J; Ogawa, K; Ogura, K; Shimizu, T; Watanabe, O | 1 |
| Hudis, CA; Morris, PG | 1 |
| Fojo, T; Wilkerson, J | 1 |
| Awad, D; Brafman, L; Crew, KD; Fuentes, D; Hershman, DL; Kranwinkel, G; Wang, A; Weimer, LH | 1 |
| Balabanova, M; Broshtilova, V; Darlenski, R; Gergovska, M; Kazandjieva, J; Márina, S; Stransky, L | 1 |
| Cui, L; Huang, XE; Jiang, Y; Tang, JH; Xiang, J; Yan, PW | 1 |
| Arenas, DR; Arvelo, F; Kouznetsov, VV; Muñoz, A; Sojo, F | 1 |
| Fujii, S; Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Oota, Y; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Nagykálnai, T | 3 |
| Alipour, M; Heney, M; Mugabe, C; Omri, A; Suntres, Z; Th'ng, J; Vergidis, D | 1 |
| Chen, SM; Chen, YY; Huang, CH; Li, SH; Rau, KM; Tang, Y; Wu, SC | 1 |
| Di, L; Jia, J; Lu, Z; Ma, B; Ren, J; Song, G; Wang, X; Yu, J; Yuan, Y; Zhou, X; Zhu, Y | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F | 1 |
| Amiji, M; Duan, ZF; Milane, L | 1 |
| Chen, C; Chen, Y; Liu, F; Liu, G; Meng, X; Mougin, B; Shao, Z; Shen, Z; Wu, F; Wu, J; Xu, Q; Yang, B; Ye, X | 1 |
| Barlow, WE; Ellis, GK; Gralow, JR; Hortobagyi, GN; Lew, D; Livingston, RB; Perez, EA; Royce, ME; Russell, CA | 1 |
| DI, GH; Hu, XC; Li, JJ; Liu, GY; Lu, JS; Shao, ZM; Wang, Y; Wang, ZH; Wu, J; Yang, WT | 1 |
| Choi, YH; Kim, GY; Kim, WJ; Moon, DO; Moon, SK | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 2 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Kaneko, J; Katsuta, E; Maejima, S; Ohkubo, T; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Ansari, KA; Cavalli, R; Torne, SJ; Trotta, F; Vavia, PR | 1 |
| Bast, RC; Feng, Y; Huan, J; Jia, L; Jin, H; Lu, Z; Yao, M; Yu, Y; Zhao, N; Zou, CF | 1 |
| Anderson, SK; Andorfer, CA; Bedroske, PP; Chen, B; Davidson, NE; Dueck, AC; Geiger, XJ; Gralow, JR; Harris, LN; Ingle, JN; Jenkins, RB; Kanehira, K; Kaufman, PA; Ketterling, RP; Kutteh, LA; Lingle, WL; Martino, S; McCullough, AE; Perez, EA; Reinholz, MM; Sledge, GW; Sukov, WR; Wiktor, AE | 1 |
| Gao, Z; Gupta, R; Jeong, EK; Kennedy, AM; Kim, T; Liu, X; Mohan, P; Nam, KH; Parker, DL; Payne, A; Rapoport, N; Scaife, C; Shea, J; Todd, N | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Naoi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanei, T; Tominaga, N; Tsunashima, R | 1 |
| Ju, RJ; Li, RJ; Lu, WL; Wang, XX; Yao, HJ; Yu, Y; Zhang, L; Zhang, Y | 1 |
| Chen, Z; Kong, LY; Wang, JS; Wei, DD; Yang, L | 1 |
| Friedlander, ML; Kiernan, MC; Krishnan, AV; Lewis, CR; Lin, CS; Park, SB | 1 |
| Bhawal, UK; Fujimoto, K; Kato, Y; Kawamoto, T; Kijima, H; Morohashi, S; Noshiro, M; Sato, F; Wu, Y | 1 |
| Eilertsen, K; Jeansonne, DP; Kirk-Ballard, H; Koh, GY; Liu, D; Liu, Z; Wolff, L; Zhang, F | 1 |
| Awang, K; Azmi, MN; Ibrahim, H; In, LL; Nagoor, NH | 1 |
| Hao, Y; Ho, KC; Lai, D; Yang, X | 1 |
| Cordeiro, P; D'Andrea, G; Dang, C; Dickler, MN; Fornier, M; Gilewski, T; Grothusen, J; Hawks, L; Hudis, CA; Lake, D; Laragh, JH; McArthur, HL; Melisko, M; Merali, C; Moasser, M; Modi, S; Morrow, M; Moynahan, ME; Norton, L; Nulsen, B; Park, J; Patil, S; Paulson, M; Robson, M; Rugo, H; Sealey, JE; Seidman, A; Sklarin, N; Steingart, R; Sugarman, S; Theodoulou, M; Traina, T; Zhou, Q | 1 |
| Bando, H; Iwata, H; Kashiwaba, M; Mizuno, T; Murakami, S; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Yamamoto, Y | 1 |
| Hao, YL; Huang, ZQ; Liu, N; Nie, SH; Sun, MM; Tai, W; Zhang, XN | 1 |
| Bethke, K; Cianfrocca, M; Gordon, J; Gradishar, W; Hansen, N; Jeruss, JS; Jovanovic, B; Kaklamani, VG; Khan, SA; Lacouture, M; Meservey, C; Parimi, V; Rosen, S; Scholtens, D; Siziopikou, K; Uthe, R; Von Roenn, J; Wayne, J | 1 |
| Fan, ZY; He, ZJ; Hu, YH | 1 |
| Abdel-Nabi, H; Bernacki, R; Cui, H; Mousa, SA; Phillips, PG; Sajjad, M; Veith, J; Yalcin, M | 1 |
| Beckmann, MW; Conrad, U; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Konecny, GE; Kurzeder, C; Lebeau, A; Lenhard, M; Liedtke, B; Loibl, S; Lück, HJ; Müller, V; Nekljudova, V; Salat, C; Schmidt, M; Stickeler, E; Untch, M; Urbaczyk, H; von Minckwitz, G | 1 |
| Conrad, U; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Konecny, GE; Kurzeder, C; Lebeau, A; Lenhard, M; Liedtke, B; Loibl, S; Lück, HJ; Müller, V; Nekljudova, V; Salat, C; Schmidt, M; Schuster, T; Stickeler, E; Untch, M; Urbaczyk, H; von Koch, F; von Minckwitz, G | 1 |
| Shi, J; Sun, Y; Wang, S; Ying, W | 1 |
| Abbruzzi, A; Bromberg, J; Chang, J; D'Andrea, G; Dang, C; Dickler, M; Fornier, MN; Gilewski, T; Hudis, CA; Modi, S; Morris, PG; Norton, L; Seidman, AD; Sklarin, N | 1 |
| Hirsch, HA; Iliopoulos, D; Struhl, K | 1 |
| Cheema, UY; Kalapurakal, S; Khan, AU; White, P | 1 |
| Blake, DJ; Chen, P; Guo, H; Hao, X; Kong, X; Li, M; Niu, R; Zhang, N | 1 |
| Buzdar, AU | 2 |
| Adewoye, H; Adrover, E; Alba, E; Almel, S; Baños, A; Cabaribere, D; Crown, J; Eiermann, W; Hei, YJ; Hurvitz, S; Jagiełło-Gruszfeld, A; Kennedy, MJ; Lang, I; Latreille, J; Lemmerick, Y; Lindsay, MA; Mackey, JR; Martin, M; Moroose, R; Munoz, M; Pienkowski, T; Pinter, T; Priou, F; Provencher, L; Ramos, M; Roche, H; Rolski, J; Rupin, M; Snyder, R | 1 |
| Bazan, F; Chaigneau, L; Demarchi, M; Dufresne, A; N'guyen, T; Pivot, X; Stein, U; Thierry Vuillemin, A; Villanueva, C | 1 |
| Biganzoli, L; Bogdanova, N; Chen, Z; Cheng, Y; Chmielowska, E; Crivellari, D; Dalenc, F; Delva, R; Di Vincenzo, E; Espié, M; Hamm, C; Jiang, Z; Just, M; Lichinitser, M; Semiglazov, V; Shen, Z; Smith, I; Vinholes, J; Vivanco, GL | 1 |
| Jiang, C; Jin, Q; Li, X; Ling, T; Qiu, B; Yan, F; Zhang, Z; Zheng, H | 1 |
| Chung, HC; Del Giglio, A; Feng, J; Jiang, Z; Kim, SB; Malzyner, A; Pen, DL; Shen, LJ; Xu, B; Yu, S | 1 |
| Afchain, P; Bengrine-Lefevre, L; Chibaudel, B; De Gramont, A; Gervais, H; Louvet, C; Tournigand, C | 1 |
| Chihade, D; Desai, N; Flister, MJ; Ran, S; Trieu, V; Volk, LD | 1 |
| Bebek, G; Budd, GT; De, S; Downs-Kelly, E; Eng, C; Orloff, MS; Stark, GR; Tan, MH; Wesolowski, R | 1 |
| Khar, RK; Mishra, PR; Singodia, D; Talegaonkar, S | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Choe, S; Eckert, A; Liu, W; Liu, Y; McGraw, J; Murray, S; Ryan, TE; Seyhan, AA; Varadarajan, U; Woods, M | 1 |
| Bento, S; Dávila, C; Ferreira, A; Pereira, D; Rodrigues, A; Rodrigues, H; Vieira, C | 1 |
| Plummer, RS; Shea, CR | 1 |
| Akazawa, K; Iwase, S; Kawaguchi, T; Kitamura, K; Kuroda, Y; Nagumo, Y; Odagiri, H; Teramoto, S; Yamamoto, D | 1 |
| Bertotto, I; Carbonaro, LA; Martincich, L; Montemurro, F; Ponzone, R; Regge, D; Sardanelli, F | 1 |
| De Palma, M; Lewis, CE | 1 |
| Baba, Y; Iwamoto, T; Kim, SJ; Kishi, K; Nakamura, Y; Nakayama, T; Naoi, Y; Noguchi, S; Oshima, K; Shimazu, K; Tamaki, Y | 1 |
| Chen, YW; Ding, Y; Fodstad, O; Kristian, A; Liu, H; Liu, Z; Mælandsmo, GM; Nesland, JM; Tan, M; Tekle, C; Wang, B; Zhao, Y; Zhou, M | 1 |
| Acevedo, LM; Barnes, LA; Cheresh, DA; Majeti, BK; Mukthavaram, R; Murphy, EA | 1 |
| Aravind, G; Karthik, A; Kumar, AR; Naseer, M; Praful, BD; Reddy, MS; Shavi, GV; Udupa, N | 1 |
| Jansen, JA; Kamphuis, GJ; Lopez-Heredia, MA; Öner, FC; Thüne, PC; Walboomers, XF | 1 |
| Chen, W; Kreike, B; Liu, G; Meng, F; Miller, FR; Sethi, S; Wu, G; Zhang, H | 1 |
| Benayoun, L; Eldar-Boock, A; Miller, K; Polyak, D; Satchi-Fainaro, R; Segal, E; Shaked, Y | 1 |
| Albert, JM; Allen, PK; Buchholz, TA; Buzdar, AU; Guzman, R; Hoffman, KE; Hunt, KK; Oh, JL; Perkins, GH; Strom, EA; Tereffe, W; Woodward, WA | 1 |
| Aas, T; Anker, G; Chrisanthar, R; Fjösne, HE; Knappskog, S; Lillehaug, JR; Lundgren, S; Løkkevik, E; Lønning, PE; Mjaaland, I; Nysted, A; Ostenstad, B; Risberg, T; Schlichting, E; Skjønsberg, G | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Kommor, M; Molthrop, DC; Peacock, N; Spigel, DR; Vazquez, ER; Yardley, DA | 1 |
| Bryant, A; Williams, C | 1 |
| Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW | 1 |
| Chidiac, T; Cosgriff, T; Harker, G; Keaton, M; Min, M; Mirtsching, B | 1 |
| Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P | 1 |
| Ducros, C; Montana, M; Rathelot, P; Terme, T; Vanelle, P; Verhaeghe, P | 1 |
| Blijham, GH; Erdkamp, FL; Knibbeler-van Rossum, CT; Lalisang, RI; Loosveld, OJ; Nortier, JW; Rodenburg, CJ; Schouten, HC; Slee, PH; Smals, AE; Tjan-Heijnen, VC; van Bochove, A; Voest, EE; Wals, J; Wils, JA | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Cochran, MC; Eisenbrey, J; Ouma, RO; Soulen, M; Wheatley, MA | 1 |
| Hirano, M; Kataoka, H; Kiriyama, T; Kitauchi, T; Saito, K; Ueno, S | 1 |
| Güler, N; Koçer, M; Muallaoğlu, S | 1 |
| Jefferson, B; Lobert, S; Morris, K | 1 |
| Chang, FR; Chen, GY; Lee, CL; Lin, YY; Lu, MC; Wu, YC; Yang, JC | 1 |
| Escobar-Cabrera, E; Giovinazzi, S; Han, HS; Ishov, AM; Lindsay, CR; McIntosh, LP; Morozov, VM; Summers, MK | 1 |
| Bollet, MA; Campana, F; Chira, C; Derhem, N; Fourquet, A; Jacob, J; Kirova, YM; Marchand, V; Pierga, JY | 1 |
| Bekele, RT; Brindley, DN; Goping, IS; Samadi, N; Schang, LM | 1 |
| Fu, ZY; Lv, JH; Ma, CY; Wang, T; Yang, DP | 1 |
| Berry, DA; Bleiweiss, IJ; Broadwater, G; Cowan, D; Dressler, LG; Edgerton, S; Ellis, MJ; Goldstein, LJ; Hayes, DF; Henderson, IC; Hudis, CA; Ingle, JN; Lara, JF; Martino, S; Norton, L; Thor, AD; Winer, EP | 1 |
| Arends, J; Büchert, M; Fasol, U; Fiedler, U; Frost, A; Mross, K; Scharr, D; Scheuenpflug, J | 1 |
| Cirrincione, CT; Cohen, HJ; Hudis, C; Hurria, A; Lichtman, SM; Muss, HB; Seidman, AD; Winer, E | 1 |
| Cho, Y; Kulp, SK; Lee, LJ; Lee, RJ; Li, H; Lin, SH; Lin, YC; Mao, Y; Piao, L; Xu, P; Ye, W; Zhong, S | 1 |
| Abe, E; Arima, Y; Hayashi, H; Hayashi, N; Kai, K; Mikami, S; Nakamura, S; Sasaki, M; Saya, H; Sugihara, E; Yoshida, A | 1 |
| Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L | 1 |
| Goel, PN; Gude, RP | 1 |
| Burris, HA; Castillo, R; Hainsworth, JD; Lahiry, A; Locicero, R; Raefsky, E; Shastry, M; Thompson, D; Yardley, DA | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Ghiringhelli, F; Ladoire, S; Pfitzenmeyer, P; Quipourt, V; Rambach, L | 1 |
| Gupta, R; Krissansen, GW; Kuhn-Sherlock, B; Macgibbon, AK; Sun, X; Zhang, J | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimomura, A; Tamaki, Y; Yasojima, H | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Baillet, A; Baudin, B; Boursier, C; Crépin, R; Froidevaux-Klipfel, L; Poirier, F; Poüs, C | 1 |
| Davidson, NE; Geyer, CE; Jeong, JH; Kaufman, PA; Mamounas, EP; Martino, S; Perez, EA; Romond, EH; Suman, VJ; Wolmark, N | 1 |
| Casado, MA; Ginés, J; Grau, M; Martorell, C; Monroy, M; Sabater, E | 1 |
| Beck, T; Camara, O; du Bois, A; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Höss, C; Kahlert, S; Konecny, GE; Kreienberg, R; Kühn, T; Lebeau, A; Loibl, S; Mehta, KM; Müller, V; Stickeler, E; Untch, M; von Minckwitz, G | 1 |
| Bertucci, F; Birnbaum, D; Borg, JP; Finetti, P; Gonçalves, A; Kadra, G; Toiron, Y; Viens, P | 1 |
| Mehta, RS; Shieh, MP | 1 |
| Doihara, H; Ikeda, H; Miyoshi, S; Nogami, T; Okada, M; Shien, K; Shien, T; Taira, N | 1 |
| Aogi, K; Fujiwara, Y; Ito, Y; Iwata, H; Kamigaki, S; Kashiwaba, M; Masuda, N; Oda, T; Ohno, S; Takashima, S; Ueno, T | 1 |
| Filatova, LV; Gershanovich, ML; Latipova, DKh; Semiglazova, TIu | 1 |
| Gemeinhart, RA; Hollis, CP; Li, T; Sun, L; Zhang, H; Zhao, R | 1 |
| Miller, KD; O'Neill, A; Perez, EA; Seidman, AD; Sledge, GW | 1 |
| Akazawa, K; Ishihara, H; Kim, SJ; Matsushima, T; Nakayama, S; Noguchi, S; Shibayama, M; Shimazu, K; Tamaki, Y; Torikoshi, Y; Tsukamoto, F | 1 |
| Chen, YJ; Liu, Q; Liu, XJ; Wang, J | 1 |
| Chirgwin, J; Chua, SL | 1 |
| Russell, C | 1 |
| Aapro, M; Bhar, P; Gradishar, W; Tjulandin, S | 1 |
| Adler, S; Bear, HD; Choyke, PL; Hirsch, JI; Kalen, JD; Kurdziel, KA; Logan, J; McCumisky, J; Moorman-Sykes, K; Wilson, JD | 1 |
| Ando, M; Fujiwara, Y; Hashimoto, K; Hirata, T; Katsumata, N; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M | 1 |
| Aravantinos, G; Bafaloukos, D; Bobos, M; Christodoulou, C; Dimopoulos, AM; Efstratiou, I; Fountzilas, G; Kotoula, V; Kourea, HP; Koutras, A; Miliaras, D; Papadimitriou, C; Papakostas, P; Papandreou, CN; Papazisis, KT; Pectasides, D; Pentheroudakis, G; Petraki, K; Razis, E; Repana, D; Televantou, D; Timotheadou, E | 1 |
| Horiguchi, J; Kikuchi, M; Nagaoka, R; Odawara, H; Oyama, T; Rokutanda, N; Sato, A; Takata, D; Takeyoshi, I; Tokiniwa, H; Tozuka, K | 1 |
| Cella, D; Miller, K; Wagner, L; Wang, M | 1 |
| Bahri, S; Butler, JA; Carpenter, PM; Chen, JH; Feig, SA; Hsiang, DJ; Kuzucan, A; Lane, KT; Lin, M; Mehta, RS; Nalcioglu, O; Su, MY; Yu, HJ | 1 |
| Basir, Z; Chen, G; Hou, S; Lepp, A; Li, R; Lou, Z; Qi, X | 1 |
| Buchsbaum, DJ; Forero, A; Kim, H; Lee, CH; Li, Y; LoBuglio, AF; Oliver, PG; Zhai, G; Zhou, T; Zinn, KR | 1 |
| Bao, Y; Chang, CJ; Hortobagyi, GN; Hsu, JL; Hung, MC; Lang, JY; Meric-Bernstam, F; Wang, Q; Woodward, WA; Xie, X; Yamaguchi, H; Yu, D | 1 |
| Rzymowska, J; Ziaja-Sołtys, M | 1 |
| Arakawa, A; Hayashi, S; Kasumi, F; Saito, M; Seino, Y; Tokuda, E; Yamaguchi, Y | 1 |
| Bast, RC; Chang, YW; Chen, PB; Cheng, X; Hortobagyi, GN; Hou, CF; Hsiao, M; Hsu, JM; Hua, KT; Hung, MC; Ko, HW; Lee, DF; Su, JL; Wang, YN; Yamaguchi, H | 1 |
| Bordeleau, L; Kim, S; Rotstein, C; Tannock, IF | 1 |
| Albain, KS; Donaldson, GW; Liepa, AM; Melemed, AS; Moinpour, CM; O'Shaughnessy, J | 1 |
| Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D | 1 |
| Bayraktar, S; Buzdar, AU; Gonzalez-Angulo, AM; Hortobagyi, GN; Kuerer, HM; Lei, X; Melhem-Bertrandt, A; Meric-Bernstam, F; Sahin, AA; Valero, V | 1 |
| Arlinghaus, LR; Atuegwu, NC; Chakravarthy, BA; Gore, JC; Li, X; Welch, EB; Yankeelov, TE | 1 |
| Achilefu, S; Cui, S; Du, C; Gu, Y; Qian, Z; Shan, L; Wan, S | 1 |
| Campos, FC; Cecchini, AL; Cecchini, R; Colado Simão, AN; Herrera, AC; Lemos, LG; Panis, C; Pinge-Filho, P; Victorino, VJ | 1 |
| Chen, J; Sun, WL; Wang, YP; Wasylyk, B; Zheng, H | 1 |
| Aranda Aguilar, E; de la Haba-Rodríguez, JR; Gómez-España, MA; Ortiz-Morales, MJ | 1 |
| Dong, B; Li, D; Li, J; Liu, M; Ren, Y; Sun, X; Wang, Z; Yang, Y; Zhou, J | 1 |
| Abair, T; O'Shaughnessy, J | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| André, N; Carre, M; Ciccolini, J; Fanciullino, R; Giacometti, S; Kavallaris, M; Montero, MP; Pasquier, E; Pouchy, C; Serdjebi, C | 1 |
| Badwe, RA; Bakshi, A; Bharath, R; Desai, SB; Gupta, S; Parmar, V; Patil, VM; Shet, T | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Tamaki, Y; Tanei, T; Tominaga, N; Tsunashima, R | 1 |
| Wang, J; Wang, X; Zhang, H; Zhang, Q; Zhang, X; Zhang, Y | 1 |
| Brown, RJ; Gabrielson, E; Huso, DL; Jacobs, LK; Jeter, S; Khouri, NF; Kominsky, SL; Lange, JR; Mori, T; Powers, P; Rudek, MA; Stearns, V; Sukumar, S; Tarpinian, K; Tsangaris, TN; Yoshida, T; Zhang, Z | 1 |
| Chen, X; Huang, O; Lu, H; Shen, K; Wu, J | 1 |
| Croom, KF; Dhillon, S | 1 |
| Dalla Palma, M; Donach, M; Fiduccia, P; Fiore, D; Gusella, M; Lombardi, G; Nicoletto, MO; Zagonel, V; Zuin, A | 1 |
| Brennan, DJ; Coussens, LM; DeNardo, DG; Gallagher, WM; Hwang, ES; Jirström, K; Junaid, SA; Keil, SD; Madden, SF; Rexhepaj, E; Ruffell, B; Rugo, HS; Shiao, SL; Wadhwani, N; West, BL | 1 |
| Hoshiai, H; Kotani, Y; Shiota, M; Tobiume, T; Umemoto, M | 1 |
| Berretta, M; Cappellani, A; Cavallaro, A; Di Vita, M; Grosso, G; Lanzafame, S; Piccolo, G; Zanghì, A | 1 |
| Bareschino, MA; Ciardiello, F; Colantuoni, G; Gridelli, C; Maione, P; Rossi, A; Rossi, E; Schettino, C | 1 |
| Aravantinos, G; Batistatou, A; Bournakis, E; Christodoulou, C; Economopoulos, T; Fountzilas, G; Gogas, H; Kalogeras, KT; Kronenwett, R; Linardou, H; Makatsoris, T; Pavlidis, N; Pectasides, D; Psyrri, A; Timotheadou, E; Wirtz, RM | 1 |
| Arihiro, K; Emi, A; Haruta, R; Kadoya, T; Kajitani, K; Kataoka, T; Kobayashi, Y; Masumoto, N; Oda, M; Okada, M; Sasada, T; Shigematsu, H | 1 |
| Ávila, R; Castilla, C; Flores, ML; Japón, MA; Ruiz-Borrego, M; Sáez, C | 1 |
| Kanto, S; Konishi, S; Sakamoto, K; Uehara, M; Yokoyama, D; Yoshino, K | 1 |
| Berger, MJ; Dunlea, LJ; Lustberg, MB; Phillips, GS; Rettig, AE; Shapiro, CL | 1 |
| Hu, D; Li, MQ; Su, J; Xu, H | 1 |
| Ahn, JH; Ahn, JS; Ha, SW; Im, SA; Im, YH; Kang, HS; Kim, JH; Kim, SB; Kwon, Y; Lee, ES; Lee, KS; Noh, DY; Park, IA; Ro, J; Shin, KH | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Ando, M; Fujiwara, Y; Harano, K; Hashimoto, K; Hirakawa, A; Katsumata, N; Kinoshita, T; Shimizu, C; Tamura, K; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Breidenbach, M; Duda, V; Eichler, C; Gossmann, A; Harbeck, N; Hoopmann, M; Kates, RE; Ohlinger, R; Thomas, A; Warm, M | 1 |
| Liu, J; Yang, Z; Zhang, L; Zhao, X | 1 |
| Adams, B; Diaz-Montero, CM; Glück, S; Montero, AJ | 1 |
| Alba, E; García-Tapiador, A; González-Sánchez, LA; Jiménez, B; Medina, L; Navarro, V; Romero-García, G; Sánchez-Muñoz, A | 1 |
| Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C | 1 |
| Arena, FP; Epperson, AL; Mintzer, DM; Schwartzberg, LS; Walker, MS | 1 |
| Akiyama, F; Ando, M; Aogi, K; Fujiwara, Y; Ino, H; Iwata, H; Kasai, H; Kurosumi, M; Masuda, N; Nakamura, S; Takeuchi, M; Tokuda, Y; Tsuda, H; Yamamoto, N | 1 |
| Cho, CS; Cho, MH; Choi, YJ; Guo, DD; Hong, SH; Jiang, HL; Jiang, T; Kim, JE; Kim, JH; Kim, YK; Minai-Tehrani, A; Shin, JY | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Cui, F; Fang, L; Li, X; Liang, N; Piao, H; Sun, S | 1 |
| Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E | 1 |
| He, Y; Song, C; Yu, M; Zhang, L | 1 |
| Guo, X; Li, N; Liu, X; Ma, X; Yu, W; Zhang, Y; Zhou, H | 1 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 2 |
| Bhalla, K; Christos, P; Chuang, E; Cohen, B; Espinoza-Delgado, I; Fiskus, W; Goetz, M; Hershman, DL; Luu, T; Pellegrino, C; Ramaswamy, B; Shapiro, CL; Somlo, G; Sparano, JA; Stearns, V; Swaby, R | 1 |
| Amano, S; Enomoto, K; Fujisaki, S; Hara, Y; Maeda, T; Nagashima, S; Sakurai, K; Shibata, M; Ueda, Y | 1 |
| Bordeleau, L; Kim, S; Seki, J; Sridhar, S; Tannock, I | 1 |
| Barar, J; Khosroushahi, AY; Naderi-Manesh, H; Omidi, Y; Yeganeh, H | 1 |
| Armstrong, SR; Guo, B; Hembruff, SL; Kalatskaya, I; Lanner, C; Parissenti, AM; Reed, K; Sprowl, JA; Stein, L; Tam, A | 1 |
| Cao, W; He, ZG; Lian, H; Liu, YH; Sun, J; Sun, YH; Wang, SL; Wang, YJ; Yu, YP | 1 |
| Carter, WB; Cox, CE; Gross-King, M; Ismail-Khan, R; Lacevic, M; Minton, SE; Moore, AP; Munster, PN; Xu, P | 1 |
| Barg, FK; DeMichele, A; Farrar, JT; Hennessy, S; Mao, JJ; Speck, RM; Stineman, MG | 2 |
| Bessonov, AA; Dashian, GA; Kolar'kova, VV; Paltuev, RM; Pen'kov, KD; Remizov, AS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Ando, N; Asahara, F; Harada, H; Hoshimoto, S; Kawaguchi, S; Matsui, J; Ogawa, S; Sato, M; Takayama, S; Ueno, H | 1 |
| Heth, JA; Wilson, TJ | 1 |
| Aktan, G; Aura, C; Baselga, J; Bradbury, I; Chang, TW; Coccia-Portugal, M; de Azambuja, E; Di Cosimo, S; Dinh, P; Domont, J; Eidtmann, H; Fauria, K; Gelber, RD; Goldhirsch, A; Gómez, H; Horváth, Z; Kunz, G; Lerzo, G; Palacova, M; Piccart-Gebhart, M; Probachai, V; Pusztai, L; Semiglazov, V; Sohn, JH; Tseng, LM; Untch, M; Van Dooren, V | 1 |
| Conte, P; Dieci, MV; Guarneri, V | 1 |
| Dong, XL; Fu, ZY; Li, QP; Miao, C; Tang, PY; Wang, T; Xu, PF | 1 |
| Cohen, PR; Paul, LJ | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Izawa, H; Karasawa, K; Mitsuhashi, N; Ozawa, S; Saito, M; Suzuki, T | 1 |
| Bathen, TF; Bofin, A; Cao, MD; Giskeødegård, GF; Gribbestad, IS; Lundgren, S; Lønning, PE; Sitter, B | 1 |
| Ajabnoor, GM; Coley, HM; Crook, T | 1 |
| Dong, K; Lin, F; Liu, L; Long, M; Ren, J; Wang, X; Wei, J; Yin, G; Zhang, H | 1 |
| Chen, Y; Duan, C; Hao, L; Jia, L; Liu, G; Liu, Y; Wang, F; Zhang, D; Zhang, Q; Zheng, D | 1 |
| Ancoli-Israel, S; Dimsdale, JE; Fiorentino, L; Liu, L; Mills, PJ; Natarajan, L; Parker, BA; Rissling, M; Sadler, GR | 1 |
| Henderson, M; Hui, A; Skandarajah, A; Speakman, D | 1 |
| Corey, SJ; Park, BJ; Whichard, ZL | 1 |
| Asuncion, D; Doroshow, JH; Forman, S; Frankel, P; Koczywas, M; Leong, L; Luu, T; Margolin, K; Morgan, R; Paz, IB; Pezner, R; Shibata, S; Somlo, G; Twardowski, P; VanderWalde, A; Wong, J; Ye, W | 1 |
| Dunn, SE; Fotovati, A; Hu, K; Law, JH | 1 |
| Kim, SJ; Maruyama, N; Nakamura, Y; Nakayama, T; Naoi, Y; Noguchi, S; Oshima, K; Shimazu, K; Shimomura, A; Tamaki, Y | 1 |
| Gyorffy, B; Haltrich, I; Likó, I; Pénzváltó, Z; Szállási, Z; Tegze, B; Tóth, Z | 1 |
| Kim, SJ; Maruyama, N; Miyake, T; Nakayama, T; Naoi, Y; Noguchi, S; Otani, Y; Shimazu, K; Shimomura, A; Tamaki, Y; Yamamoto, N | 1 |
| Huang, XE; Li, CG; Li, Y; Lu, YY; Tang, JH; Xiang, J | 1 |
| Fu, J; Leng, H; Liang, L; Liu, YL; Xing, W; Zhang, HW | 1 |
| Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS | 1 |
| Imai, A; Mizuta, N; Nakatsukasa, K; Sakaguchi, K; Taguchi, T | 1 |
| Barron, R; Edelsberg, J; Kartashov, A; Lyman, G; Weycker, D | 1 |
| Dong, Y; Fu, X; Hill, SM; Qi, Y; Rowan, BG; Xiong, Z; Zhang, H | 1 |
| Chia, S; Lohmann, AE | 1 |
| Song, Y; Xu, B; Zhan, Q; Zhao, W | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K | 1 |
| Wong, HL; Xue, HY | 1 |
| Chang, J; Fan, W; Sui, M | 1 |
| Cao, J; Gong, Y; Jin, K; Li, G; Li, Z; Sun, X; Teng, L; Teng, X; Wang, H; Yu, X; Zhang, J; Zheng, Y | 1 |
| Koroleva, IA; Mochalova, AS | 1 |
| Jin, S; Liang, XJ; Ma, X; Wang, H; Wu, Y | 1 |
| Anker, G; Chrisanthar, R; Knappskog, S; Leirvaag, B; Lundgren, S; Løkkevik, E; Lønning, PE; Miletic, H; Mjaaland, I; Risberg, T; Østenstad, B | 1 |
| Carrera-González, Mdel P; Dueñas, B; Martínez-Ferrol, J; Martínez-Martos, JM; Mayas, MD; Ramírez-Expósito, MJ | 1 |
| Burt, HM; Chiao, M; Jackson, JK; Pirmoradi, FN; Wan, CP | 1 |
| Banman, SL; Goping, IS; Hemmerling, DR; Odsen, R; Simmen, T; Simmonds, AJ; Underhill, DA; Veldhoen, RA | 1 |
| Kuranami, M; Ohashi, Y; Ohno, S; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Clarke, R; Dakshanamurthy, S; Dobbin, ZC; Hickman, FE; Shajahan, AN | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yu, KD; Zhou, RJ | 1 |
| Boulaamane, L; Boutayeb, S; Errihani, H | 1 |
| Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W | 1 |
| Berger, AM; Farr, L; Fischer, P; Geary, CR; Hertzog, M | 1 |
| Aracil, M; Arguelaguet, E; Hernández-Losa, J; Jimeno, J; Marés, R; Pons, B; Ramón Y Cajal, S; Somoza, R; Teixidó, C | 1 |
| Li, Q; Ling, Y; Yu, L | 1 |
| Artioli, F; Bagnalasta, M; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; D'Amico, R; Frassoldati, A; Generali, DG; Giardina, G; Guarneri, V; Marini, L; Musolino, A; Orlando, L; Piacentini, F; Ravaioli, A; Sarti, S; Serra, P; Untch, M | 1 |
| Kim, RJ; Kim, SR; Lee, SY; Lee, YK; Nam, JS; Park, JR; Roh, KJ | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Dong, Z; Fauzee, NJ; Juan, P; Li, QG; Lu, X; Mandarry, MT; Wang, T; Wang, YL | 1 |
| Carey, LA; Dees, EC; Drobish, A; Hertz, DL; McLeod, HL; Motsinger-Reif, AA; Winham, SJ | 1 |
| Golan-Vered, Y; Pud, D | 1 |
| Hu, M; Sun, Y; Tao, A; Zha, X; Zhou, H; Zhou, X; Zhu, D | 1 |
| Hindenburg, HJ; Hinke, A; John, M; Mohr, B; Papke, J; Schlosser, J; Stauch, M; Wolf, H | 1 |
| Chen, CM; Liu, GY; Shao, ZM; Shen, ZZ; Wu, J; Yu, KD; Zhou, XY; Zhou, Y | 1 |
| Aranishi, T; Hausheer, FH; Katsumata, N; Kuranami, M; Kuroi, K; Makino, H; Morita, S; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takeuchi, A; Watanabe, T | 1 |
| Bando, H; Hara, H; Ito, Y; Okamoto, Y; Tanaka, Y | 1 |
| Gradishar, WJ | 6 |
| Campos, FC; Cecchini, AL; Cecchini, R; Colado-Simão, AN; Herrera, AC; Panis, C; Victorino, VJ | 1 |
| Giuliano, M; Schiff, R; Trivedi, MV | 1 |
| Chen, L; He, H; Jia, J; Liu, J; Xiao, Y; Zhang, M; Zhang, W | 1 |
| Antón, A; Barnadas, A; Carrasco, E; Castellá, E; García-Andrade, C; Lomas, M; Palacios, JL; Ramírez, C; Ramírez, JL; Ríos, MJ; Rodríguez-Pinilla, M; San Antonio, B; Sánchez-Rovira, P; Velasco, A | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C | 1 |
| Bafaloukos, D; Batistatou, A; Bobos, M; Chrisafi, S; Dafni, U; Dimopoulos, MA; Filippidis, T; Fountzilas, G; Gogas, H; Kalogeras, KT; Koletsa, T; Kotoula, V; Koutras, A; Malamou-Mitsi, V; Miliaras, S; Papadopoulos, S; Pectasides, D; Skarlos, DV; Sotiropoulou, M; Televantou, D; Trihia, H | 1 |
| Chang, J; Di, X; Fan, W; Shen, Y; Sui, M; Zhang, H | 1 |
| Dahmani, FZ; Yang, H; Yao, J; Zhang, Q; Zhang, T; Zhou, J | 1 |
| Arbushites, MC; Bernini, P; Bertini, I; Biganzoli, L; Cappadona, S; Claudino, WM; Di Leo, A; Luchinat, C; Nepi, S; Oakman, C; Tenori, L | 1 |
| Boers, P; Gupta, RK; Mainstone, P; McNamara, B; Quintyne, KI; Wallis, F | 1 |
| Aruga, T; Honda, Y; Horiguchi, K; Kitagawa, D; Kuroi, K; Nako, Y; Shigekawa, T; Yamashita, T | 1 |
| Bhar, P; Cheporov, S; Clawson, A; Gradishar, WJ; Iglesias, J; Krasnojon, D; Makhson, AN; Manikhas, GM; McGuire, JR | 1 |
| Bhinge, KN; Blaylock, B; Gupta, V; Hosain, SB; Liu, YY; Meyer, SA; Satyanarayanajois, SD; Zhang, QJ | 1 |
| Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG | 1 |
| Barutca, S; Meydan, N; Tanriverdi, O | 1 |
| Kim, SJ; Maruyama, N; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimomura, A; Tamaki, Y; Tominaga, N | 1 |
| Climent, F; de Olza, MO; Falo, C; Fernandez-Otega, A; García-Tejedor, A; Germà, JR; Gil-Gil, M; Gumà, A; López-Ojeda, A; Mesia, C; Pérez-Martin, FJ; Pernas, S; Petit, A; Pla, MJ; Urruticoechea, A | 1 |
| Ali, A; Anbalagan, M; Bu, Y; Carrier, L; Hangauer, D; Jones, RK; Marsden, CG; Rowan, BG; Sheng, M | 1 |
| Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Soushi, M; Taguchi, T | 1 |
| Charnley, M; Cukierman, E; Håkanson, M; Kobel, S; Lutolf, MP; Textor, M | 1 |
| Alaoui-Jamali, MA; Bijian, K; Garcia, AG; Nedev, H; Saragovi, HU; Su, J | 1 |
| Cheng, Y; Deng, W; Dong, M; Fu, P; Hu, W; Liu, L; Liu, X; Lv, K; Teng, L; Teng, R; Wang, L; Wu, L; Yu, J | 1 |
| Atkins, JN; Becker, HP; Berry, DA; Cirrincione, CT; Hudis, C; Kimmick, G; Martino, S; Mayer, E; Muss, H; Norton, L; O'Regan, R; Perez, EA; Schneider, CJ; Shulman, LN; Winer, EP | 1 |
| Biswas, J; Mukherjee, S; Royt, M; Sarkar, R | 1 |
| Aogi, K; Fujisawa, T; Fukuda, H; Inoue, K; Iwata, H; Kinoshita, T; Masuda, N; Nakamura, K; Shibata, T; Shien, T | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Baldwin, RM; Chhibber, A; Eclov, RJ; Friedman, PN; Hudis, CA; Jiang, C; Jorgenson, EM; Kroetz, DL; Kubo, M; McLeod, HL; Mefford, J; Nakamura, Y; Owzar, K; Ratain, MJ; Shulman, LN; Watson, D; Winer, EP; Witte, JS; Zembutsu, H | 1 |
| Davidson, NE; Jones, V; Martino, S; Perez, EA; Saphner, T; Schneider, BP; Sledge, GW; Sparano, JA; Stearns, V; Wang, M; Wolff, AC; Wood, WC; Zhao, F | 1 |
| da Costa Viera, RA; Folgueira, MA; Kerr, L; Matthes, ÂC; Michelli, RA; Uemura, G; Zucca Matthes, AG | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Petasis, NA; Schönthal, AH; Sharma, N; Thomas, S | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Kim, PH; Kim, SW; Nam, HY; Nam, K | 1 |
| Adewoye, AH; Chan, A; De Boer, RH; Kaufman, PA; Koczwara, B; Kotasek, D; Mainwaring, P; Melara, R; Sikorski, R; White, S; Ye, Y | 1 |
| Gong, C; Lei, N; Luo, F; Qian, Z; Wang, C; Wang, H; Wei, Y | 1 |
| Bhat, A; Cardonick, E; Gilmandyar, D; Somer, R | 1 |
| Lim, E; Lin, NU | 1 |
| Adams, BB; Housholder, AL | 1 |
| Asghari Jafarabadi, M; Ayromlou, H; Darabi, M; Djalali, M; Djazayeri, A; Esfahani, A; Ghoreishi, Z; Golestan, B; Hashemzade, S; Keshavarz, SA; Montazeri, V | 1 |
| Chen, CM; Chen, YZ; Liu, F; Liu, GY; Meng, X; Shao, ZM; Shen, ZZ; Wu, F; Wu, J; Xu, QH; Xue, JY; Yang, BL; Ye, X | 1 |
| Bang, YJ; Han, HS; Han, SW; Han, W; Im, SA; Jeon, YK; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Noh, DY; Oh, DY; Park, IA | 1 |
| Chen, JJ; Chen, LP; Chen, ZS; Huang, RC; Huang, RP; Shi, Z; Yang, DH; Yang, WM; Zhou, Q; Zhu, J | 1 |
| Akcakanat, A; Arteaga, CL; Chen, H; Do, KA; Gonzalez-Angulo, AM; Meric-Bernstam, F; Miller, TW; Mills, GB; Sangai, T; Tarco, E; Wu, Y | 1 |
| Arnould, T; De Backer, O; Flamant, L; Hayez, A; Michiels, C; Pierre, M; Poumay, Y; Roegiers, E; Sterpin, C | 1 |
| Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L | 1 |
| Atkinson, R; Buchholz, TA; Debeb, BG; Krishnamurthy, S; Lacerda, L; Larson, R; Reuben, JM; Solley, T; Sulman, EP; Ueno, NT; Woodward, WA; Xu, W | 1 |
| Armesilla, AL; Baggott, RR; Blanc, MC; Brown, JE; Brown, S; Cartwright, EJ; Holton, M; Mohamed, TM; Neyses, L; Oceandy, D; Roux-Soro, SC; Wang, W | 1 |
| Hao, J; Liu, GY; Wang, DH; Xu, YF; Yu, J; Yuan, BB | 1 |
| Ding, HJ; Han, X; Li, AD; Li, XJ; Shi, JF; Si, XX; Sun, YJ | 1 |
| Ando-Tanabe, N; Iwamitsu, Y; Kuranami, M; Miyaoka, H; Nakatani, Y; Okazaki, S; Watanabe, M; Yamamoto, K; Yasuda, H | 1 |
| Deng, QT; Li, XR; Liao, N; Liu, YH; Wang, K; Wu, YL; Xu, FP; Zhang, GC; Zu, J | 1 |
| Braun, M; Feller, AM; Fersching, DM; Gabka, CJ; Hamann, U; Heinemann, V; Holdenrieder, S; Nagel, D; Salat, C; Siegele, B; Steinkohl, O; Stoetzer, OJ | 1 |
| Kagara, N; Kim, SJ; Maruyama, N; Morimoto, K; Naoi, Y; Noguchi, S; Oda, N; Shimazu, K; Shimoda, M; Shimomura, A | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, A; Ewer, MS; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Gross, HM; Jeong, JH; Mamounas, EP; Polikoff, J; Rastogi, P; Rathi, V; Romond, EH; Swain, SM; Tan-Chiu, E; Wolmark, N; Yothers, G; Zapas, JL; Zheng, P | 1 |
| Hoffmann, G; Mylonas, I | 1 |
| Choi, YH; Yoo, YH | 1 |
| Chung, HC; Hong, S; Jung, M; Kim, JH; Kim, SI; Koo, JS; Lee, SH; Moon, YW; Park, BW; Park, S; Rha, SY; Sohn, J | 1 |
| Bell, R; Khasraw, M | 1 |
| Ambudkar, SV; Bhatnagar, J; Chen, JJ; Chen, WM; Chen, ZS; Lan, P; Ruan, ZX; Shu, C; Sodani, K; Wang, J; Xiao, ZJ; Ye, WC; Zhang, DM | 1 |
| Awada, A; Beijnen, JH; Diéras, V; Govaerts, AS; Huitema, AD; Kerklaan, BM; Le Tourneau, C; Marreaud, S; Mergui-Roelvink, M; Milojkovic Kerklaan, B; Piccart-Gebhart, MJ; Rosing, H; Schellens, JH | 1 |
| Kim, YC; Koo, NK | 1 |
| Bergstrom, CS; Rahman, HT; Yeh, S | 1 |
| Cognetti, F; D'Auria, G; De Vita, F; Fabi, A; Ferretti, G; Giannarelli, D; Metro, G; Nisticò, C; Papaldo, P; Russillo, M; Vidiri, A | 1 |
| Fang, X; Hao, J; Wei, Z; Yuan, S | 1 |
| Banerjee, A; Bougen, NM; Liu, DX; Liu, S; Lobie, PE; Qian, P; Ren, X; Steiner, M; Wu, ZS; Zhu, T | 1 |
| Hall, KL; Rajput, S; Ran, S; Volk-Draper, LD; Wilber, A | 1 |
| Torchilin, VP; Wu, H; Zhu, L | 1 |
| Date, M; Fujiwara-Honjo, N; Haba, R; Hashimoto, S; Houchi, H; Kontani, K; Kuroda, N; Kushida, Y; Murazawa, C; Norimura, S; Ohtani, M; Tanaka, H; Yamauchi, A; Yokomise, H | 1 |
| Kharbanda, S; Kufe, D; Raina, D; Uchida, Y | 1 |
| Wang, T; Yao, J; Zhang, L; Zhang, Q; Zhou, J | 1 |
| Jiang, L; Mason, RP; McColl, RW; Tripathy, D; Weatherall, PT | 1 |
| Mukai, H; Yamaguchi, T | 1 |
| Guo, H; Jiang, L; Liu, H; Ma, J; Xu, Y; Yang, H; Yu, G; Yuan, C; Zhang, Y | 1 |
| Chavez-Macgregor, M; Chen, H; Do, KA; Gonzalez-Angulo, AM; Hortobagyi, GN; Liu, S; Meric-Bernstam, F; Mills, GB; Sahin, A | 1 |
| Bafaloukos, D; Christodoulou, C; Fountzilas, G; Gogas, H; Kalogeras, KT; Koutras, AK; Kouvatseas, G; Kronenwett, R; Linardou, H; Pectasides, D; Samantas, E; Wirtz, RM; Zagouri, F | 1 |
| Li, Y; Shen, J; Sun, H; Wang, S; Xu, P; Yin, Q; Yu, H; Zhang, Z | 1 |
| Jinta, E; Sakurai, T; Suzuma, T; Umemura, T; Yoshimura, G | 1 |
| Chon, SY; Ivan, D; Rashid, RM; Richards, KN | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Advani, SH; Bakshi, A; Bapsy, PP; Gangadharan, VP; Goswami, C; Maru, A; Mohapatra, R; Nag, S; Parikh, P; Patil, S; Raghunadharao, D; Raina, V; Ranade, AA; Sambasivaiah, K; Sekhon, JS | 1 |
| Kim, EJ; Kim, J; Moon, M; Park, UH; Um, SJ | 1 |
| Gao, X; Huang, Y; Li, J; Li, S; Lu, J; Marquez, RT; Meng, X; Venkataramanan, R; Wang, Z; Zhao, W | 1 |
| Fujii, S; Matsubara, N; Mukai, H; Wada, N | 1 |
| Grant, AD; Marwick, TH; Negishi, T; Plana, JC; Popović, ZB; Thavendiranathan, P | 1 |
| Dong, C; Feng, EF; Gao, CL; He, JC; Luo, CX; Ren, HX; Wang, XN; Yang, RX; Zhuang, L | 1 |
| Baldwin, RM; Cox, NJ; Dolan, ME; Gamazon, ER; Hudis, CA; Jiang, C; Kroetz, DL; Kubo, M; Nakamura, Y; Njiaju, UO; Njoku, C; Owzar, K; Ratain, MJ; Shterev, I; Shulman, LN; Watson, D; Wheeler, HE; Winer, EP; Wing, C; Zembutsu, H | 1 |
| Aparicio, S; Chafe, SC; Dedhar, S; Lock, FE; Lou, Y; McDonald, PC; Ostlund, C; Serrano, I; Supuran, CT; Winum, JY | 1 |
| Chen, S; Huang, F; Wu, JJ; Xu, B; Zhuang, YG | 1 |
| Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW | 1 |
| Chang, WW; Chen, HH; Chen, L; Chen, YA; Hsu, HL; Liou, GG; Shih, HJ; Wang, LH; Wu, MH | 1 |
| Erickson, D; Mak, M; Reinhart-King, CA | 1 |
| Baek, JS; Cho, CW | 1 |
| Annuar, MA; Ho, GF; Jabir, RS; Munisamy, M; Naidu, R; Stanslas, J | 1 |
| He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Lin, H; Qu, D; Xue, J; Zhang, C; Zhang, N | 1 |
| Bosserman, L; DeSilvio, ML; Hagan, MK; Hart, L; Mahoney, JM; Nagarwala, Y; Richards, P; Salleh, MN; Waterhouse, DM; Yardley, DA | 1 |
| Catalano, PJ; Colson, YL; Gilmore, DM; Grinstaff, MW; Liu, R; Padera, RF; Xu, X; Zubris, KA | 1 |
| Cen, S; Hu, X; Li, Y; Liao, S; Liao, X; Lin, Y; Liu, Z; Wei, J; Yang, L | 1 |
| Cronin, EB; DeFusco, PA; Hart, J; Hegde, PU; Kane, M; Ricci, A; Tannenbaum, SH; Tavakoli, B; Xu, Y; Zhu, Q | 1 |
| Amano, S; Enomoto, K; Fujisaki, S; Gonda, K; Hara, Y; Maeda, T; Nagashima, S; Sakurai, K; Shibata, M; Suzuki, S; Tomita, R | 1 |
| Ishiba, T; Kasahara, M; Kawauchi, H; Kubota, I; Nagahara, M; Nakagawa, T; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Akazawa, N; Ebuchi, M; Maruyama, M; Maruyama, S; Murakata, A; Ono, S; Sakoma, T; Satoh, E; Sugano, N; Suzuki, K; Tanami, H; Uehira, D; Yonekura, K | 1 |
| Ishiba, T; Kasahara, M; Kawachi, H; Kubota, K; Nagahara, M; Nakagawa, T; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Amano, S; Enomoto, K; Hagiwara, M; Hara, Y; Matsumoto, K; Nagashima, S; Sakurai, K; Tani, M; Ueda, Y; Waga, E | 1 |
| Bauer, JA; Pietenpol, JA; Shyr, Y; Ye, F | 1 |
| Biti, G; Bonomo, P; Cecchini, S; Desideri, I; Greto, D; Livi, L; Meacci, F; Meattini, I; Nori, J; Orzalesi, L; Paiar, F; Sanchez, LJ; Scotti, V; Simontacchi, G | 1 |
| Cai, RG; Fan, Y; Ma, F; Ma, WY; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yuan, P; Zhang, BL; Zhang, P; Zheng, S | 1 |
| Hu, P; Lei, L; Li, J; Liu, R; Wang, J; Wu, J; Zeng, W | 1 |
| Dmytrenko, G; Español, AJ; Jacob, G; Sales, ME | 1 |
| Eto, H; Shirahata, S; Teruya, K; Yoshida, T; Zhang, Z | 1 |
| Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Akutsu, H; Kimura, H; Lee, SW; Masui, S; Nagashima, Y; Nishi, M; Perrem, K; Quinn, G; Ryo, A; Sakai, Y; Umezawa, A; Yamamoto, N | 1 |
| Aström, G; Blomqvist, L; Carlsson, L; Einbeigi, Z; Fujii, H; Glimelius, B; Hatschek, T; Jacobsson, H; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundqvist, M; Suzuki, C; Walz, TM | 1 |
| Agelaki, S; Apostolaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kalykaki, A; Mavroudis, D; Perraki, M; Vardakis, N; Xenidis, N; Xyrafas, A | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
| Chan, S; Horak, CE; Liu, D; Pusztai, L; Saura, C; Trifan, OC; Tseng, LM; Welcher, R; Xing, G | 1 |
| Badve, SS; Cobleigh, MA; Davidson, NE; Dickler, MN; Gralow, JR; Gray, RJ; Jiang, G; Li, L; Miller, KD; Müller, S; Perez, EA; Radovich, M; Schneider, BP; Shen, F; Shenkier, TN; Sledge, GW; Sparano, JA; Thor, A; Vance, G; Vang Nielsen, K | 1 |
| Bekah, D; El Kaffas, A; Kolios, MC; Kumaradas, JC; Rui, M | 1 |
| Gollahon, L; Lee, J | 1 |
| Brunetti, G; Ruocco, E; Ruocco, V | 1 |
| Gabrielson, M; Tina, E | 1 |
| Berges, R; Bourgarel-Rey, V; Braguer, D; Carre, M; Chacon, C; Pobel, I; Rovini, A; Savry, A | 1 |
| Anderson, SK; Eckel-Passow, JE; Jen, J; Kocher, JP; Mahoney, DW; Perez, EA; Reinholz, MM; Therneau, TM | 1 |
| Miles, DW | 1 |
| Lipp, HP | 1 |
| Choi, M; Gaber, G; Gradishar, W; Kiel, K; Mehta, M; Refaat, T; Small, W | 1 |
| Arteaga, CL; Balko, JM; Bhola, NE; Cook, RS; Dugger, TC; Kuba, MG; Sánchez, V; Sanders, M; Stanford, J | 1 |
| Al Zaman, AS | 1 |
| Esteva, FJ | 1 |
| Hortobagyi, GN | 8 |
| Valero, V | 3 |
| Biganzoli, L; Bruning, P; Calvert, AH; Coleman, R; Cufer, T; Duchateau, L; Epelbaum, R; Fargeot, P; Gamucci, T; Lohrisch, C; Piccart, MJ; Twelves, C | 1 |
| Brassard, M; Budman, DR; Cohen, G; Dhami, M; George, T; Glaspy, J; Hackett, J; Holmes, FA; Jones, SE; Liang, BC; Meza, L; O'Shaughnessy, J; Richards, D; Savin, M; Vukelja, S; Yang, BB | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A | 1 |
| Ligibel, JA; Winer, EP | 1 |
| Perez, EA; Qu, G | 1 |
| Cao, Y; Liu, H; Liu, P; Qiao, X; Tong, F; Yang, D; Zhang, J; Zhou, B | 2 |
| Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I | 1 |
| Budman, DR; Calabro, A | 1 |
| Balkenende, A; Coco-Martin, J; Michalides, R; Tiemessen, M; Verschoor, T | 1 |
| Chappuis, PO; Foulkes, WD; Ghadirian, P; Goffin, J; Perret, C; Tonin, PN; Wong, N | 1 |
| Baron, R; Binder, A; Hilpert, F; Pfisterer, J; Schattschneider, J; Wasner, G | 1 |
| Hortobagyi, GN; Kris, MG | 1 |
| Lindsay, MA; Nabholtz, JM; Reese, DM; Riva, A | 2 |
| Chan, AT; Chiu, SK; Ho, WM; Johnson, PJ; Kwan, WH; Lam, KC; Leung, TW; Mo, FK; Mok, TS; Tse, KK; Yeo, W | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Oberhuber, G; Pluschnig, U; Rudas, M; Steger, GG; Taucher, S; Wenzel, C; Zielinski, CC | 1 |
| Friedrichs, K; Hölzel, F; Jänicke, F | 1 |
| Adjei, AA; Baron, AT; Geeraerts, L; Hatfield, AK; Ingle, JN; Kugler, JW; Kuross, SA; Lafky, JM; Maihle, N; Michalak, JC; Perez, EA; Suman, VJ | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| Antman, K; Balmaceda, C; Donovan, D; Frederick, D; Haythe, J; Hesdorffer, CS; Kaufman, E; Nichols, G; Papadopoulos, K; Savage, D; Sharpe, E; Tiersten, A; Troxel, A; Vahdat, LT | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T | 1 |
| Alvarez, E; Faul, MM; Menon, K; Shih, C; Teicher, BA | 1 |
| Bach, A; Cramer, L; Dougherty, J; Duck, ET; Hudis, C; Modi, S; Norton, L; Panageas, KS; Seidman, A; Weinstock, N | 1 |
| Dank, M | 1 |
| Láng, I | 1 |
| Alessandroni, P; Catalano, G; Catalano, V; Fedeli, A; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Testa, E | 1 |
| Goker, E; Karabulut, B; Omay, SB; Sanli, UA; Saydam, G; Sezgin, C; Uslu, R | 1 |
| Ahmadi, MA; Esmaeli, B; Hutto, T; Jackson, DM; Newman, RA; Rivera, E; Valero, V | 1 |
| Asmar, L; Cox, E; Dakhil, S; Gregurich, MA; Loesch, D; O'Rourke, M; Robert, N | 1 |
| Green, MC; Hortobagyi, GN | 1 |
| Assouline, D; Brun, O; Coeffic, D; Fric, D; Page, E; Winckel, P | 1 |
| Aruga, E; Karasawa, K; Kimura, T; Kohno, M; Maebayashi, K; Mitsuhashi, N; Muramatsu, H; Nasu, S; Saitou, M; Seki, K; Suzuki, K; Ueda, M; Umeda, M | 1 |
| Aida, Y; Chishima, Y; Kitajima, A; Noro, M; Okamoto, H; Satou, Y; Takano, S | 1 |
| Street, JC; Taguchi, T | 1 |
| Bovik, AC; Ling, J; Miller, MA; Moore, RV; Weitman, SD | 1 |
| Twelves, CJ; Wright, TL | 1 |
| Ansari, R; Einhorn, LH; Fata, F; McClean, JW; Miller, KD; Porcu, P; Sledge, GW; Soule, SE; Zon, R | 1 |
| Accurso, V; Agostara, B; Failla, G; Fanelli, M; Ferraù, F; Gasparini, G; Leonardi, V; Massidda, B; Morabito, A; Palmeri, S; Tamburo De Bella, M; Vaglica, M; Valenza, R | 1 |
| Ajarim, D; Al Malik, OA; Al-Sobhi, SS; Baslaim, MM; Chaudhary, MA; Ezzat, A; Ibrahim, E; Sorbris, RA; Tulbah, A | 1 |
| Hortobagyi, G; Hung, MC; Klos, K; Lan, KH; Lee, S; Sellappan, S; Yang, W; Yu, D | 1 |
| Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 1 |
| Asola, R; Ekholm, E; Hinkka, S; Korpela, J; Mali, P; Pyrhönen, S; Salminen, E; Varjo, P; Varpula, M | 1 |
| Bleiweiss, I; Gurry, R; Lehrer, D; Paciucci, PA; Raptis, G; Weltz, C | 1 |
| Breidenbach, M; König, E; Kurbacher, C; Mallmann, P; Schwonzen, M | 1 |
| Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ | 1 |
| Baker, MN; Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Levin, J; McGuirt, PV; Patton, JW; Willcutt, NT | 1 |
| Azli, N; Bisset, D; Kaye, SB; Ramazeilles, C; Riva, A; Roché, H; Terret, C; Twelves, CJ; Vasey, PA; Vernillet, L | 1 |
| Brugarolas, A; Calvo, E; Cortes, J; Fernández-Hidalgo, O; Martínez-Monge, R; Perez-Calvo, J; Rodríguez, J; Santisteban, M | 1 |
| Crivellari, D; Gatti, A; Lombardi, D; Magri, MD; Scuderi, C; Spazzapan, S; Veronesi, A | 1 |
| Hahn, PF; Halpern, EF; Jhaveri, KS; Prasad, SR; Saini, S; Sumner, JE | 1 |
| Wolff, AC | 1 |
| Bu, CF; Chang, KJ; Chao, TY; Chen, MM; Cheng, AL; Hsu, C; Huang, CS; Lu, YS | 1 |
| Benezery, K; Lagrange, JL; Magné, N; Namer, M; Otto, J | 1 |
| Krempien, R; Piroth, MD; Wannenmacher, M; Zierhut, D | 1 |
| Anagnostopoulos, A; Bafaloukos, D; Christodoulou, C; Economopoulos, T; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Markopoulos, C; Onyenadum, A; Papadimitriou, C; Papakostas, P; Tsavdaridis, D | 1 |
| Bachmann, N; Barberi-Heyob, M; Merlin, JL | 1 |
| Boldt, S; Kolch, W; Weidle, UH | 1 |
| Piccart, M; Tan-Chiu, E | 1 |
| Blohmer, JU; Caputo, A; Costa, SD; Eidtmann, H; Gademann, G; Gerber, B; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Tulusan, AH; von Minckwitz, G | 1 |
| Cantin, J; Chang, J; Guevin, R; Lindsay, MA; Mackey, J; Nabholtz, JM; Patel, R; Reese, D; Riva, A; Tkaczuk, K; Vodvarka, P | 1 |
| Booser, DJ; Buzdar, AU; Ewer, M; Frye, D; Giordano, SH; Hortobagyi, GN; Ibrahim, NK; Murray, JL; Ordonez, NG; Rahman, ZU; Rivera, E; Rosales, MF; Theriault, RL; Valero, V | 1 |
| O'Shaughnessy, J | 4 |
| Di Leo, A | 1 |
| Eremin, O; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, I; Walker, LG | 1 |
| Davidson, NE | 1 |
| Anklesaria, P; Bartholomeusz, C; Bruckheimer, EM; Huang, L; Hung, MC; Li, S; Mebel, E; Paul, R; Ueno, NT; Xia, W; Yo, GH | 1 |
| Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H | 1 |
| Adjei, AA; Dy, GK | 1 |
| Budman, DR | 1 |
| Besse, B; Spano, JP | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Calvert, S; Greco, FA; Hainsworth, JD | 1 |
| Armstrong, DK; Davidson, NE; Emens, LA; Fetting, JH; Garrett, E; Kennedy, MJ | 1 |
| Hall, J; Schürpf, T; Simões-Wüst, AP; Stahel, RA; Zangemeister-Wittke, U | 1 |
| Aapro, M; O'Shaughnessy, J; Twelves, C | 1 |
| Miles, D; Seidman, AD; von Minckwitz, G | 1 |
| Alli, E; Bash-Babula, J; Hait, WN; Yang, JM | 1 |
| Banerjee, D; Bertino, JR; Brennan, MF; Chou, TC; Guan, Y; Li, W; Scotto, KW; Takahashi, N; Wada-Takahashi, Y | 1 |
| Bocci, G; Kerbel, RS; Nicolaou, KC | 1 |
| Harada, A; Ishikawa, T; Murakami, H; Nakamura, H; Noda, S; Okamura, Y; Sakakibara, T; Yaguchi, T | 1 |
| Mayer, LD; Shabbits, JA | 1 |
| Cardoso, F; Di Leo, A; Piccart, MJ | 1 |
| Eich, D; Eich, HT; Krieg, T; Scharffetter-Kochanek, K; Tantcheva-Poor, I | 1 |
| Abali, H; Celik, I | 1 |
| Clark, AS; Dennis, PA; Streicher, S; West, K | 1 |
| Bottomley, A; Curran, D; Kramer, J; Molenberghs, G; Sylvester, R; Van Steen, K; Van Vreckem, A | 1 |
| Mokbel, K; Singh-Ranger, G | 1 |
| Crawford, J | 1 |
| Baselga, J; Clemens, MR; Galid, A; Gascon, P; Green, MD; Guillem, V; Koelbl, H; Lalisang, RI; Liang, BC; Piccart, MJ; Renwick, J; Samonigg, H; Siena, S; Zani, V | 1 |
| Biganzoli, L; Bruning, P; Coleman, RE; Cufer, T; Delhaye, F; Duchateau, L; Hamilton, A; Miles, D; Nooij, M; Piccart, M; Rapoport, B; Sulkes, A | 1 |
| Friess, T; Osl, F; Scheuer, WV; Schneider, T; Stockinger, H | 1 |
| Blomqvist, C; Elomaa, L; Järvenpää, R; Kellokumpu-Lehtinen, P; Kokko, R; Lantto, A; Lehtinen, R | 1 |
| Lück, HJ; Roché, H | 1 |
| Borges, VF; Bunnell, CA; Burstein, HJ; Christian, RL; Ellisen, LW; Gadd, MA; Gelman, R; Harris, LN; Kaelin, CM; Kennedy, PR; Kuter, I; Lester, SC; Nunes, RA; Parker, LM; Smith, BL; Winer, EP; Younger, J | 1 |
| Bontenbal, M; Mross, K; Seynaeve, C; Smorenburg, CH; Sparreboom, A; ten Tije, AJ; van Zomeren, DM; Verweij, J | 1 |
| Altieri, DC; O'Connor, DS; Plescia, J; Pommier, Y; Wall, NR | 1 |
| Bando, H; Kuroi, K; Saji, S; Toi, M | 1 |
| Hudis, C | 2 |
| Anderson, SJ; Brown, A; Desai, AM; Kardinal, CG; Lembersky, BC; Mamounas, EP; Scholnik, AP; Smith, RE | 1 |
| Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
| Conte, PF; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B | 1 |
| Collingwood, M; Grafton, C; Simera, I; Williams, C | 1 |
| Camerlo, J; Catalin, J; Ciccolini, J; Genre, D; Giovanini, M; Gonçalves, A; Gravis, G; Maraninchi, D; Viens, P; Viret, F | 1 |
| Crawford, JG; Ellis, MJ; Farhad, A; Hayes, DF; Isaacs, C; Novielli, A; Pennanen, M; Singh, B; Slack, R; Stearns, V; Tibery, C; Tsangaris, T | 1 |
| Cheng, F; Gabrilovich, D; Kusmartsev, S; Nefedova, Y; Paolini, M; Sotomayor, E; Yu, B | 1 |
| Antila, K; Ekholm, E; Korpela, J; Salminen, E; Syvänen, K; Varjo, P; Varpula, M | 1 |
| Antman, K; Brafman, L; Fine, R; Nelsen, C; Petrylak, DP; Shriberg, L; Talbot, S; Tiersten, AD; Troxel, A; Vahdat, L | 1 |
| Chaudhry, M; Chaudhry, V; Crawford, TO; Griffin, JW; Simmons-O'Brien, E | 1 |
| Iwasa, T; Kanai, T; Koike, S; Komatsu, D; Nakamura, T; Shimizu, T | 1 |
| Fukuda, K; Hosono, M; Kimura, F; Kokufu, I; Tamaoka, K; Tanei, T; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Hofer, S; Hunziker, S; Ludwig, CU; Tornillo, L | 1 |
| Aihara, T; Hiraki, S; Horikoshi, N; Inaji, H; Itoh, K; Katsumata, N; Noguchi, S; Sasaki, Y; Sonoo, H; Tabei, T; Takatsuka, Y; Watanabe, T | 1 |
| Antón, A; Cuevas, JM; Estévez, LG; Florián, J; Fortes, J; Herrero, A; Lobo, F; López-Vega, JM; Velasco, A | 1 |
| Chinchilli, V; Engle, L; Lipton, A; Santala, SM; Witters, LM | 1 |
| Aglietta, M; Alabiso, O; Capaldi, A; Choa, G; Donadio, M; Faggiuolo, R; Minischetti, M; Montemurro, F; Salomone, A; Sperti, E; Vietti-Ramus, G | 1 |
| Bernardo, P; Ingle, JN; Martino, S; Neuberg, D; Rowinsky, EK; Sledge, GW; Wood, WC | 1 |
| Tuma, RS | 1 |
| Amorim De Albuquerque, A; Anelli, A; Brentani, RR; Gadelha, AP; Soares, F | 1 |
| Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M | 1 |
| Alba, E; Antón, A; Florián, J; Godes, MJ; Llanos, M; López-Vega, JM; Menéndez, M; Pelegri, A; Pérez-Carrión, R; Ribelles, N | 1 |
| Borsellino, N; Colombo, A; Ferrera, P; Gebbia, V; Marrazzo, A; Mauceri, G; Musso, M; Porretto, F; Testa, A; Tirrito, ML | 1 |
| Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ | 1 |
| Cardoso, F; Dochy, E; Piccart, M | 1 |
| Bettini, AC; Cohen, D; Danenberg, P; Florentine, B; Formenti, SC; Gee, C; Groshen, S; Muggia, F; Perez, E; Press, M; Skinner, KA; Spicer, D; Volm, M | 1 |
| Ishihara, A; Ishiodori, H; Koga, Y; Kudo, S; Muranaka, T; Nakamura, T; Ochiai, T; Ogata, K; Ohchi, T | 1 |
| Fukushima, M; Ono, Y; Sawada, M | 1 |
| Chang, HK; Chen, SC; Cheung, YC; Hsueh, S; Lin, YC; See, LC; Su, MY; Tsai, CS | 1 |
| Filipits, M; Jakesz, R; Pirker, R; Pohl, G; Rudas, M; Steger, GG; Stranzl, T; Taucher, S | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Da Prada, G; Fagnoni, FF; Fregoni, V; Gibelli, N; Lozza, L; Oliviero, B; Pavesi, L; Perotti, C; Ponchio, L; Robustelli della Cuna, G; Zambelli, A; Zibera, C | 1 |
| Brinkbäumer, K; Hahn, K; Kessler, M; Linke, R; Sommer, H; Tiling, R; Untch, M | 1 |
| Baick, CH; Chiou, JY; Fruehauf, JP; Mehta, RS; Nalcioglu, O; Su, MY; Wang, J; Yu, H | 1 |
| Chaikin, P; Durrleman, S | 1 |
| Haidara, K; Mamer, O; Nikolakakis, A; Sauriol, F; Zamir, LO | 1 |
| Buchholz, TA; Davis, DW; Hess, KR; McConkey, DJ; Sahin, AA; Valero, V | 1 |
| Emi, M; Inoue, H; Kim, R; Tanabe, K; Toge, T; Uchida, Y | 1 |
| Glaspy, J; Green, MD; Hackett, J; Holmes, FA; Kubista, E; Neumann, T | 1 |
| Miller, KD | 1 |
| Pater, JL; Pritchard, KI | 1 |
| Hortobagyi, GN; Valero, V | 1 |
| Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J | 1 |
| Berry, DA; Carpenter, JT; Cirrincione, CT; Cooper, MR; Demetri, GD; Duggan, DB; Fleming, G; Frei, E; Goldstein, LJ; Hayes, DF; Henderson, IC; Holland, JF; Ingle, JN; Martino, S; Muss, HB; Norton, L; Schilsky, RL; Tkaczuk, KH; Wood, WC | 1 |
| Bonneterre, J; Fumoleau, P; Luporsi, E | 1 |
| Aperis, G; Barbounis, V; Demiri, M; Drufakou, S; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Alessandrino, PE; Bertolini, A; Collovà, E; Danova, M; Ferrari, S; Porta, C; Riccardi, A; Rovati, B | 1 |
| Abrams, J; Berry, DA; Carpenter, J; Cirrincione, C; Citron, ML; Davidson, NE; Gradishar, WJ; Holland, JF; Hudis, C; Hurd, D; Ingle, JN; Leung, EH; Livingston, R; Martino, S; Muss, HB; Norton, L; Perez, EA; Sartor, CI; Schilsky, RL; Smith, BL; Winer, EP | 1 |
| Hait, WN; Wu, H; Yang, JM | 1 |
| Buchsbaum, D; Kimberly, R; Makhija, S; Ohtsuka, T; Oliver, P; Zhou, T | 1 |
| Haritoglou, C; Mueller, AJ | 1 |
| Apltauerová, M; Gasová, Z; Hrubá, A; Jelínek, J; Klener, P; Mares, P; Marinov, I; Trnĕný, M | 1 |
| Ahmed, A; Enev, VS; Hanbauer, M; Hoegenauer, EK; Kaehlig, H; Mulzer, J; Ohler, E | 1 |
| Han, SS; Koh, WS; Lee, M | 1 |
| Teitelbaum, BA; Tresley, DJ | 1 |
| Doughman, DJ; Skolnick, CA | 1 |
| Agelaki, S; Alexopoulos, A; Androulakis, N; Ardavanis, A; Bozionelou, V; Georgoulias, V; Kandylis, C; Kouroussis, Ch; Malamos, N; Mavroudis, D; Stavrinidis, E | 1 |
| Heinemann, V | 2 |
| Barbieri, V; Blotta, S; Boland, CR; Costanzo, F; Goel, A; Martelli, ML; Perricelli, A; Quaresima, B; Tagliaferri, P; Tassone, P; Venuta, S | 1 |
| Fountzilas, G; Gogas, H | 1 |
| Jiang, ZM; Li, ZH; Lin, XG; Liu, TH; Xie, DR; Yao, HR | 1 |
| Li, WL; Qin, YK; Yao, Q; Zhu, SW | 1 |
| Arizcun, A; Cruz, JJ; del Barco, E; Diz, P; Fonseca, E; García-Palomo, A; Gómez-Bernal, A; López, Y; Martín, G; Pujol, E; Rodríguez, C; Sánchez, P | 1 |
| Bachhuber, A; Knapstein, PG; Lehr, HA; Mahlke, M; Pilch, H; Schmidt, M; Steiner, E; Victor, A; Weikel, W | 1 |
| Fumoleau, P | 3 |
| Sledge, GW | 6 |
| Hatake, K; Sugimoto, Y; Takahashi, S | 1 |
| Basso, AD; Olshen, AB; Rosen, N; Scher, HI; Solit, DB | 1 |
| Burd, B; Horwitz, SB; Martello, L; Orr, GA; Verdier-Pinard, P; Wang, F | 1 |
| Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T | 1 |
| O'Shaughnessy, JA | 1 |
| Delorme, S; Fink, C; Junkermann, H; Klein, SK; Lüdemann, HP; Sinn, HP; Wasser, K; Zuna, I | 1 |
| Thürlimann, B; von Moos, R | 1 |
| Besson, D; Bougnoux, P; Bourgeois, H; Delozier, T; Gamelin, E; Lortholary, A; Lotz, V; Monnier, A; Riffaud, JCh; Tubiana-Mathieu, N | 1 |
| Ilersich, AL; Verma, S | 1 |
| Mayor, S | 1 |
| Achard, JL; Amat, S; Body, G; Bougnoux, P; Chollet, P; Curé, H; Dauplat, J; Fétissof, F; Kwiatkowski, F; Penault-Llorca, F | 1 |
| Baker, SD; Gelderblom, H; Sparreboom, A; Verweij, J; Zhao, M | 1 |
| Ballot, J; Crown, J; McDonnell, D | 1 |
| Chang, TW; Chen, GY; Chen, WC | 1 |
| Archibald, H; Hutcheon, A; Macduff, C; Mackenzie, T; Melville, L | 1 |
| Sasaki, F; Taguchi, K; Takahashi, H; Takahashi, M; Todo, S | 1 |
| Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T | 1 |
| Kuroiwa, S; Maruyama, S; Nishikawa, K; Saimoto, A | 1 |
| Chen, Q; Li, L; Li, LQ; Liu, J; Wang, YJ; Zhang, QZ; Zhao, WH; Zhou, QH | 1 |
| Bellizzi, A; Cardone, RA; Casavola, V; Paradiso, A; Reshkin, SJ; Tommasino, M | 1 |
| Almanza, C; Amenedo, M; Gamazo, JL; Gómez-Martín, C; González-Ageitos, A; González-Quintas, A; Losada, G; Ramos, M; Romero, C; Togores, P | 1 |
| Elsdon, M; Farrugia, D; Guglani, S; Owen, JR; Parmar, M | 1 |
| Ferrero, JM; Foa, C; Largillier, R; Magné, N; Namer, M | 1 |
| Horikoshi, N | 1 |
| Rowinsky, EK; Takimoto, CH | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, ML; Malmström, P; Mouridsen, H; Ottoson, S; Pluzanska, A; Sjöström, J; Tennvall, L; Valvere, V | 1 |
| Ghetti, E; Piraccini, BM; Tosti, A | 1 |
| Emoto, T; Fujii, M; Fujikawa, M; Komaki, T; Maeda, S; Naka, Y; Nezu, R; Yoshikawa, K; Yoshioka, Y | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Marchionatti, S; Pedani, F; Recalenda, V; Tagini, V | 2 |
| Baioni, M; Ballardini, M; De Giorgi, U; Ferrari, E; Marangolo, M; Minzi, MR; Rosti, G; Zaniboni, A; Zornetta, L | 1 |
| Comesse, S; Golinski, M; Grossman, RB; Huang, H; Liu, S; Lu, X; Moscow, JA; Watt, D | 1 |
| Nabholtz, JM | 3 |
| Crown, J; Pegram, M | 1 |
| Heys, SD; Hutcheon, AW; Sarkar, TK | 1 |
| Piccart, M | 3 |
| Bear, HD; Goble, S | 1 |
| Ahmadi, MA; Burnstine, MA; Esmaeli, B; Prieto, VG | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Blumenstengel, K; Höffken, K; Issa, MC; Kasper, C; Kath, R; Mügge, LO; Sayer, HG; Schilling, K; Vogt, T | 1 |
| Fujimori, M; Hama, Y; Ito, K; Kimura, M; Maeno, K; Nakagomi, H; Sano, M; Shingu, K; Tsuchiya, S | 1 |
| Mio, H | 1 |
| Kobayashi, Y; Maruyama, T; Natsume, T; Saito, T; Shimizu, T; Tanaka, H; Tohnosu, N; Watanabe, Y | 1 |
| Capri, G; Cresta, S; Gianni, L; Grasselli, G; Minotti, G; Perotti, A | 1 |
| Brenton, JD; Caldas, C | 1 |
| Allred, DC; Chamness, GC; Chang, JC; Elledge, R; Gutierrez, MC; Hilsenbeck, SG; Mohsin, S; O'Connell, P; Osborne, CK; Tsimelzon, A; Wooten, EC | 1 |
| Alasio, L; Dagrada, GP; Mezzelani, A; Pierotti, MA; Pilotti, S; Romanò, R; Ruggeri, M | 1 |
| Donoghue, E; Ghersi, D; Simes, J; Wilcken, N | 2 |
| Jongsomboonkusol, S; Junnu, S; Kaslungka, S; Kosem, N; Moongkarndi, P; Neungton, N; Theptaranon, Y | 1 |
| Albares, MP; Belinchón, I; Betlloch, I; Blanes, M; Pascual, JC; Vergara, G | 1 |
| Bernard-Marty, C; Cardoso, F; Piccart, MJ | 1 |
| Campone, M; Fumoleau, P; Merlin, JL | 1 |
| Lim, JT; Masuda, M; Suzui, M; Weinstein, IB | 1 |
| Goodger, NM; Pogrel, MA; Wang, J | 1 |
| Buzdar, AU; Hortobagyi, GN | 1 |
| Dang, C; Seidman, AD | 1 |
| Ali, S; Ball, G; Carmichael, J; Creaser, C; Ellis, I; Holding, F; Hornbuckle, J; Li, G; McArdle, S; Mian, S; Rees, R | 1 |
| Rivera, E | 1 |
| Bouffette, P; Llory, JF; Nabholtz, JM; Vannetzel, JM | 1 |
| Asim, M; Chen, X; Shankar, S; Singh, TR; Srivastava, RK | 1 |
| De Giorgi, U; Frassineti, GL; Marangolo, M; Monti, M; Rosti, G | 1 |
| Arnold, A; Ayoub, JP; Dias, R; Gelmon, K; Ghahramani, P; Leyland-Jones, B; Verma, S | 1 |
| Klos, KS; Lee, S; Nagata, Y; Yang, W; Yu, D; Zhang, L; Zhou, X | 1 |
| Jordan, MA; Kamath, K | 1 |
| Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T | 1 |
| Brosens, JJ; Coffer, PJ; Coombes, RC; Fernández de Mattos, S; Lam, EW; Medema, RH; Saunders, CA; Stahl, M; Sunters, A; Zoumpoulidou, G | 1 |
| Berta, L; Catalano, MG; Fazzari, A; Fortunati, N; Frairia, R; Raineri, M | 1 |
| Chow, C; Cowan, KH; Cusack, G; Danforth, D; Eng-Wong, J; Kohler, DR; O'Shaughnessy, J; Riseberg, D; Venzon, D; Zujewski, JA | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Missitzis, J; Vassilomanolakis, M | 1 |
| Carty, M; Gilmore, PM; Harkin, DP; Johnston, PG; Kennedy, RD; Mullan, PB; Quinn, JE | 1 |
| Doroshow, JH; Sparreboom, A; Spicer, D; Synold, TW; ten Tije, AJ; Verweij, J | 1 |
| Hamada, K; Ito, S; Kubota, K; Mikami, H; Nakagawa, A; Okada, T; Tagaya, N | 1 |
| La Mura, N; Lombardi, D; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A | 1 |
| Amadori, D; Fabbri, M; Frassineti, GL; Ibrahim, T; Monti, M; Ricotti, L; Zoli, W | 1 |
| Atalay, G; Biganzoli, L; Calvert, AH; Coleman, R; Cufer, T; Gamucci, T; Minisini, A; Paridaens, R; Piccart, MJ; Renard, F; Therasse, P | 1 |
| Almadrones, L; Cella, DF; Donnelly, J; Herzog, TJ; McGuire, WP; Moore, DH; Waggoner, SE | 1 |
| Kawaguchi, Y; Saji, S; Sugiyama, Y | 1 |
| Iwamoto, M; Kobayashi, T; Lee, SW; Nohara, T; Sumiyoshi, K; Tanigawa, N | 1 |
| Hosogi, H; Nakagami, M; Ohsumi, K; Tokuka, A; Tokunaga, Y | 1 |
| Fitzpatrick, FA; Wheeler, R | 1 |
| Bryce, C; Chia, S; Kennecke, H; Ragaz, J | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Cardoso, F; Piccart, MJ | 1 |
| Breitbach, P; Eggemann, H; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G; Schlosser, H | 1 |
| Fujii, Y; Hara, Y; Iwase, H; Sugiura, H; Toyama, T; Yamashita, H | 1 |
| Crawford, J; Dale, DC; Lyman, GH | 1 |
| Albanell, J; Baselga, J; Bianchi, G; Borquez, D; Eiermann, W; Gianni, L; Locatelli, A; Molina, R; Raab, G; Vanhauwere, B; Viganò, L; Vitali, G | 1 |
| Guo, B; Hembruff, SL; Kirwan, AF; Parissenti, AM; Villeneuve, DJ | 1 |
| Arun, B; Booser, D; Bruera, E; Cleeland, CS; Fritsche, HA; Hortobagyi, GN; Ibrahim, N; Lara, J; Martinez, MM; Mendoza, TR; Pusztai, L; Reuben, JM; Rivera, E; Royce, M; Syed, A; Valero, V; Willey, JS | 1 |
| Aglietta, M; Ballestrero, A; Capaldi, A; Danova, M; Friedman, D; Gonella, R; Montemurro, F; Patrone, F; Puglisi, M | 1 |
| Basurto, C; Bisacci, C; Cherubini, R; Colozza, M; Crinò, L; De Angelis, V; Franceschi, E; Gori, S; Mosconi, AM; Rulli, A; Sidoni, A; Tonato, M | 1 |
| Koller, E; Marietta, PM; Mingo-Sion, AM; Van Den Berg, CL; Wolf, DM | 1 |
| Comandini, D; Del Mastro, L; Mammoliti, S; Pietropaolo, M; Repetto, L | 1 |
| Bocca, C; Bozzo, F; Gabriel, L; Miglietta, A | 2 |
| Bontenbal, M; Kerkhofs, LG; Schothorst, KL; Seynaeve, C; Smorenburg, CH; Sparreboom, A; Stoter, G; ten Tije, AJ; van Reisen, LG; Verweij, J | 1 |
| Beamon, K; Doroshow, JH; Forman, S; Longmate, J; Margolin, K; Morgan, R; Openshaw, H; Shibata, S; Slatkin, NE; Somlo, G; Synold, TW | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; Fernández, Y; García-Conde, J; Guillem, V; Hornedo, J; Llombart-Cussac, A; Lluch, A; Montero, S; Ojeda, B | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Delfino, C; Flores Morales, D; Mickiewicz, E; Riva Gonzáles, L; Rodger, J; Zori Comba, A | 1 |
| Murad, AM | 1 |
| Bruzzi, P; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B | 1 |
| Ajarim, DS; Al-Malik, OA; Al-Shabanah, M; Ezzat, AA; Ibrahim, EM; Rahal, MM; Raja, MA; Sorbris, R; Tulbah, AM | 1 |
| Cao, Y; Liu, H; Liu, P; Qiao, X; Tong, F; Wang, S; Yang, D; Zhang, J; Zhou, B | 1 |
| Giannopoulos, A; Gogas, H; Kosmas, C; Kosmidis, C; Kouraklis, G; Markopoulos, C; Papadopoulos, O; Polyzos, A; Stamatiadis, D; Toufexi, H; Tsavaris, N | 1 |
| Bhan, V; Hoskin, DW; Mader, JS | 1 |
| Angeloni, SV; Castro-Galache, MD; Ferragut, JA; Garcia-Morales, P; Martin, MB; Saceda, M; Sholler, PF | 1 |
| Curran, EM; Dougherty, MK; El-Ashry, D; Ellis, MJ; Jordan, VC; Schumaker, LM; Welshons, WV | 1 |
| Buzdar, AU; Cristofanilli, M; Frye, DK; Gonzalez-Angulo, AM; Hortobagyi, GN; Kau, SW | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Comba, AZ; Delfino, C; Gonzáles, LR; Mickiewicz, E; Morales, DF; Rodger, J | 1 |
| Lombardo, D; Tomadoni, A; Wainstein, R | 1 |
| Blais, DE; Bonin, M; Guo, B; Hembruff, SL; Kirwan, AF; Parissenti, AM; Villeneuve, DJ | 1 |
| Buzdar, AU; Fiterman, DJ; Frye, D; Gal-Gombos, E; Green, M; Hortobagyi, GN; Kuerer, H; Poniecka, A; Pusztai, L; Rajan, R; Rouzier, R; Smith, TL; Symmans, WF; Whitman, G; Yang, Y | 1 |
| Chang, CC; Chang, HL; Chau, YP; Chen, ST; Kuo, ML; Lin, MT; Su, JL | 1 |
| Barutcu, I; Esen, AM; Gullu, H; Ozdemir, R; Sezgin, AT | 1 |
| Ji, CY; Li, AM; Liao, WJ; Luo, RC; Miao, JX; Zhang, JY | 1 |
| Nitta, M; Saya, H; Sudo, T; Ueno, NT | 1 |
| Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Mewani, RR; Rahman, A; Tang, W | 1 |
| Bergh, J; Linderholm, B | 1 |
| Fjaestad, K; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA | 1 |
| Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
| Chen, D; Hackl, W; Ortmann, O; Treeck, O | 1 |
| Biganzoli, L; Bottomley, A; Calvert, HA; Coens, C; Coleman, RE; Cufer, T; Efficace, F; Fargeot, P; Gamucci, T; Piccart, M; Twelves, C; Van Steen, K | 1 |
| Baggerly, KA; Drake, RR; Esteva, FJ; Gregory, BW; Hortobagyi, GN; Koomen, J; Kuerer, HM; Laronga, C; Peng, B; Pusztai, L; Semmes, OJ; Symmans, WF; Vlahou, A; Wagner, P; Wright, GL | 1 |
| Ciftci, K; Gupte, A | 1 |
| Hamanaka, K; Miyagawa, Y; Munakata, Y; Nishimura, H; Ohno, Y; Sakai, H; Seki, H | 1 |
| Broome, C; Burris, H; Greco, FA; Hainsworth, J; Houston, G; Jones, S; Thompson, D; White, M; Yardley, D | 1 |
| Adair, C; Arciero, C; Peoples, GE; Shriver, CD | 1 |
| Guh, JH; Liao, CH; Pan, SL; Teng, CM | 1 |
| Arun, B; Ayers, M; Booser, D; Clark, E; Damokosh, AI; Hess, K; Hortobagyi, GN; Ibrahim, N; Lecocke, M; Metivier, J; Pusztai, L; Ross, J; Royce, M; Sneige, N; Stec, J; Symmans, WF; Valero, V; Whitman, G | 1 |
| Bastert, G; Gückel, B; Lindner, M; Meyer, A; Stumm, S; Wallwiener, D | 1 |
| Paridaens, R; Wildiers, H | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Ahlgren, J; Batista, N; Carabantes, F; Casinello, J; Castellanos, J; Constenla, M; Gonzalez Barón, M; Murias, A; Perez-Manga, G; Regueiro, P; Ruiz, A; Söderberg, M; Villman, K | 1 |
| Davidson, NE; Park, BH | 1 |
| Bocca, C; Bozzo, F; Gabriel, L; Miglietta, A; Panno, ML | 1 |
| Buyukberber, S; Camci, C; Sevinc, A | 1 |
| Estévez, LG; Gradishar, WJ | 1 |
| Crown, J; O'Leary, M; Ooi, WS | 1 |
| Berry, DA; Duggan, D; Fleming, GF; Graham, ML; Harris, LN; Henderson, IC; Hudis, C; Keresztes, R; Kirshner, JA; Kornblith, A; Michaelson, RA; Muss, H; Norton, L; Perry, MC; Sharp, SA; Winer, EP; Woolf, S | 1 |
| Amsalhem, P; Boaziz, C; Bouillet, T; Breau, JL; Brunel, P; Brunet-Pommeyrol, A; Hennebelle, F; Kanoui, A; Morere, JF; Morin, F; Piperno-Neumann, S; Spano, JP | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, N; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y | 1 |
| Ando, M; Rai, Y; Sagara, Y; Takahama, T | 1 |
| Ghersi, D; Hamilton, A; Nowak, AK; Stockler, MR; Wilcken, NR | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Chasen, MR; Eek, R; McMichael, G; Mohammed, C; Rapoport, BL; Slabber, C; Vorobiof, DA | 1 |
| Amin, B; Chen, YM; Gradishar, WJ; Hill, T; Lower, EE; Marcom, PK; Meza, LA; Samid, D | 1 |
| Andrews, HN; Carty, M; Duprex, WP; Gilmore, PM; Gorski, JJ; Harkin, DP; Johnston, PG; Kennedy, RD; Liu, ET; McCabe, N; McWilliams, S; Mullan, PB; Quinn, JE | 1 |
| Chan, G; Dowling, ML; Harris, E; Kao, GD; Keutmann, MK; Lee, EA | 1 |
| Jassem, J; Senkus-Konefka, E | 1 |
| Eralp, Y; Lachman, LB; Maughan, MF; Polo, JM; Wang, JP; Wang, X | 1 |
| Bonneterre, J; Catimel, G; Tubiana-Hulin, M | 1 |
| Jänicke, F; Köhler, G; Löning, T; Lück, HJ; Möbus, V; Müller, V; Pantel, K; Sattler, D; Thomssen, C; von Minckwitz, G; Wilczak, W; Witzel, I | 1 |
| Fujimoto, M; Furukawa, J; Higaki, J; Hoashi, T; Ikeda, N; Inui, N; Kogire, M; Matsunami, T; Nakano, K; Nishi, T; Nomura, T; Ogino, N; Takagaki, K; Takeda, C; Tanaka, H; Uenishi, M; Yamada, S; Yamanaka, E; Yamasaki, M; Yamauchi, E; Yayoi, E | 1 |
| Horiguchi, J; Iijima, K; Iino, Y; Kanoh, T; Kikuchi, M; Koibuchi, Y; Morishita, Y; Oyama, T; Takata, D; Yoshida, M; Yoshida, T | 1 |
| Brizel, DM; Dewhirst, MW; Hardenbergh, PH; Jones, EL; Marcom, PK; Marks, LB; Prosnitz, LR; Vujaskovic, Z | 1 |
| Altundag, K; Baltali, E; Guler, N; Ozisik, Y; Tekuzman, G | 1 |
| Broglio, KR; Buzdar, AU; Esteva, FJ; Gonzalez-Angulo, AM; Hortobagyi, GN; Krishnamurthy, S; Pusztai, L; Yamamura, Y | 1 |
| Hung, MC; Liao, Y; Xia, WY; Zou, YY | 1 |
| Bengala, C; Campani, D; Collecchi, P; Conte, PF; Donati, S; Gennari, A; Guarneri, V; Maur, M; Orlandini, C | 1 |
| Dellon, AL; Livengood, MS; Maloney, CT; Swier, P; Werter, S | 1 |
| Ciamarra, P; De Palma, GD; Rega, M | 1 |
| Dandekar, S; du Bois, A; Eidtmann, H; Jänicke, F; Konecny, GE; Kuhn, W; Lück, HJ; Möbus, V; Olbricht, S; Pauletti, G; Pegram, MD; Ramos, L; Slamon, DJ; Steinfeld, D; Thomssen, C; Untch, M; von Minckwitz, G; Wang, HJ | 1 |
| Plosker, GL; Simpson, D | 1 |
| Cameron, DA | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Costantini, M; Giannessi, P; Guarneri, V; Mammoliti, S; Moyano, A; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Andre, F; Bachelot, T; Barrelier, A; Delaloge, S; Dunant, A; Kabbaj, O; Marsiglia, H; Namer, M; Rouzier, R; Slimane, K; Spano, JP; Spielmann, M | 1 |
| Blohmer, JU; Elling, D; Heilmann, V; Köhler, G; Krocker, J; Michniewicz, K; Morack, G; Possinger, K; Schaller-Kranz, T; Schmid, P | 1 |
| Hesdorffer, C; Horwich, T; Jacobson, C; Savage, D; Tiersten, A; Troxel, A; Weitzman, A; Wo, J | 1 |
| Dvorák, J; Filip, S; Melichar, B; Odrázka, K; Petera, J; Zoul, Z | 1 |
| Currie, VE; D'Andrea, GM; Dang, CT; Dickler, MN; Fornier, M; Hudis, CA; Hurria, A; Lake, D; Moynahan, ME; Norton, L; Panageas, KS; Robson, ME; Seidman, AD; Theodoulou, M | 1 |
| Dakhil, SR; Davidson, NE; Gersh, BJ; Ingle, JN; Jaffe, AS; Kaufman, PA; Martino, S; Perez, EA; Rodeheffer, RJ; Suman, VJ | 1 |
| Nortier, JW | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Kosmidis, P; Makrantonakis, P; Maniadakis, N; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pectasides, D; Razis, E; Siafaka, V; Skarlos, D; Tsavdaridis, D | 1 |
| Ab, O; Baloglu, E; Chari, RV; Goldmacher, VS; Leece, BA; Miller, ML; Roller, EE; Zhao, RY | 1 |
| Buzdar, AU; Hortobagyi, GN; Ibrahim, NK; Li, Z; Mante Menchu, RP; Theriault, R; Valero, V; Wang, M; Wathen, JK | 1 |
| Au, JL; Song, S; Wei, Y; Wientjes, MG; Yu, B | 1 |
| Broglio, K; Buzdar, AU; Cristofanilli, M; Gonzalez-Angulo, AM; Hortobagyi, GN; Kau, SW; Sneige, N; Valero, V; Yamamura, Y | 1 |
| Dekel, Y; Margalit, R; Melikhov, D; Peer, D | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F | 1 |
| Garg, K; Lemos, LB; Papasozomenos, S; Qu, Z | 1 |
| Clynes, M; Gammell, P; Glynn, SA; Heenan, M; Keenan, J; Liang, Y; O'Connor, R | 1 |
| Hudis, C; Keefe, D; Lieberman, G; Paton, V; Seidman, A; Tripathy, D | 1 |
| Carpenter, RJ; Gonzalez-Angulo, AM; Gwyn, K; Perkins, GH; Ross, MI; Theriault, RL; Walters, RS | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Aebi, S; Ballabeni, P; Brauchli, P; Mingrone, W; Pestalozzi, BC; Rauch, D; Rijken, N; Rochlitz, C; Uhlmann, C | 1 |
| Bogart, J; Fitzgerald, TJ; Henderson, IC; Laurie, F; Norton, L; Peterson, BL; Sartor, CI; Turrisi, AJ; Woolf, S | 1 |
| Buchholz, TA; Buzdar, AU; Hortobagyi, GN; Kau, SW; McNeese, MD; Perkins, GH; Schechter, NR; Strom, EA; Thames, HD; Thomas, ES; Whitman, GJ; Yu, TK | 1 |
| Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J | 1 |
| Aneja, R; Chandra, R; Joshi, HC; Liu, M; Zhou, J | 1 |
| Aiba, K; Hagino, T; Hirano, A; Kawase, K; Kobayashi, M; Kobayashi, T; Okawa, Y; Shioya, H; Sugiyama, K; Uno, S; Usui, N; Yoshida, K | 1 |
| Azumi, T; Daito, K; Hirai, K; Hirai, T; Hojo, T; Inui, H; Shiozaki, H; Ueda, K; Watatani, M; Yamato, M | 1 |
| Horwitz, KB; Jacobsen, BM; Richer, JK; Schittone, SA | 1 |
| Duan, Y; Duan, Z; Lamendola, DE; Seiden, MV; Yusuf, RZ | 1 |
| Guan, ZZ; Hawkins, M; Liu, DG; Luo, HY; Soon-Shiong, P; Teng, XY; Yao, ZW; Zhou, NN | 1 |
| Aravantinos, G; Christodoulou, C; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Papakostas, P; Razis, E; Skarlos, D; Tsavdaridis, D | 1 |
| Janku, F; Pazdrova, G; Petruzelka, L; Pribylova, O; Safanda, M; Zemanova, M; Zimovjanova, M | 1 |
| Griggs, DW; Lupu, R; Mehmi, I; Menendez, JA; Teng, PK; Vellon, L | 1 |
| Katano, M; Kubo, M; Kuroki, H; Matsumoto, K; Morisaki, T; Nakamura, K; Nakamura, M; Nakashima, H; Tasaki, A; Yamanaka, N | 1 |
| Besova, NS; Gorbunova, VA | 1 |
| Palmieri, FM; Perez, EA; Tack, DK | 1 |
| Buyse, M; Diéras, V; Fumoleau, P; Guastalla, JP; Kerbrat, P; Maillart, P; Mauriac, L; Namer, M; Pénault-Llorca, F; Pouillart, P; Pujade-Lauraine, E; Romieu, G; Tubiana-Hulin, M | 1 |
| Abumiya, K; Kamachi, H; Kamiyama, N; Kamiyama, T; Khor, LW; Kobayashi, H; Kurauchi, N; Matsushita, M; Nakagawa, T; Nakajima, H; Nakanishi, K; Taguchi, K; Takahashi, H; Takahashi, M; Todo, S; Tsukahara, M; Watanabe, K | 1 |
| Kuo, HS; Lin, YL; Peng, YC; Tsai, HD; Yang, YP | 1 |
| Argyriou, AA; Chroni, E; Ellul, J; Iconomou, G; Kalofonos, HP; Katsoulas, G; Koutras, A; Papapetropoulos, S | 1 |
| Colomer, R; Lupu, R; Menendez, JA; Vellon, L | 1 |
| Hausmaninger, H; Heilmann, V; Huebner, G; Nitsch, T; Possinger, K; Schippinger, W; Schmid, P; Schultze, W; Wischnewsky, M | 1 |
| Fornier, MN; Ghani, F; Hudis, C; Norton, L; Schwartz, MK; Seidman, AD; Thiel, R | 1 |
| Domchek, SM; Fox, K; Hwang, WT; Schwartz, J | 1 |
| Bighin, C; Catzeddu, T; Del Mastro, L; Fratino, L; Maggi, E; Manzione, L; Marenco, D; Perrone, F; Repetto, L; Rosso, R; Venturini, M; Venturino, A; Zagonel, V | 1 |
| Ardine, M; Bellino, R; Berruti, A; Bertetto, O; Bitossi, R; Bottini, A; Danese, S; Dogliotti, L; Donadio, M; Farris, A; Generali, D; Gorzegno, G; Katsaros, D; Lorusso, V; Milani, M; Rigault de la Longrais, IA; Sarobba, MG | 1 |
| Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S | 1 |
| Colomer, R | 2 |
| Poole, C | 1 |
| Han, GZ; Liu, ZJ; Shimoi, K; Zhu, BT | 1 |
| Bergstralh, DT; Chou, TC; Danishefsky, SJ; Taxman, DJ; Ting, JP | 1 |
| Flashner-Barak, M; Hinchcliffe, M; Lerner, EI; Parnas, H; Ratner, E; Tzafriri, AR | 1 |
| Bonn, D | 1 |
| Chang, YL; Guh, JH; Liao, CH; Lin, CH; Pai, HC; Pan, SL; Teng, CM | 1 |
| Argyriou, AA; Chroni, E; Iconomou, A; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| Castells, M; Feldweg, AM; Lee, CW; Matulonis, UA | 1 |
| Akbulut, H; Altinbas, M; Baltali, E; Boruban, C; Büyükcelik, A; Coşkun, S; Demirkazik, A; Erkisi, M; Icli, F; Komurcu, S; Onur, H; Sak, SD; Sencan, O; Senler, FC; Uner, A; Yalcin, B; Zengin, N | 1 |
| Beslija, S; Brodowicz, T; Cervek, J; Chernozemsky, I; Ghilezan, N; Grgic, M; Inbar, M; Kahan, Z; Khamtsov, D; Mrsic-Krmpotic, Z; Pawlega, J; Soldatenkova, V; Spanik, S; Szanto, J; Tzekova, V; Vrbanec, D; Wagnerova, M; Welnicka-Jaskiewicz, M; Wiltschke, C; Zielinski, C | 1 |
| Arun, BK; Berry, D; Booser, DJ; Buchholz, TA; Buzdar, AU; Cristofanilli, M; Ewer, MS; Francis, D; Frye, DK; Giordano, SH; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Sahin, AA; Singletary, SE; Smith, TL; Theriault, RL; Thomas, ES | 1 |
| Chao, TC; Chen, PM; Chiou, TJ; Chu, Z; Hsiao, LT; Hsieh, RK; Liu, JH; Tseng, LM; Wang, WS; Yang, MH; Yen, CC | 1 |
| Gong, C; Jia, W; Ma, X; Ouyang, N; Song, E; Su, F; Xu, H; Zhu, P | 1 |
| Conzen, SD; Fleming, GF; Heimann, R; Jaskowiak, NT; Kao, J; Masters, GA; Recant, W; Singh, R; Song, DH | 1 |
| Fuchs, SY; Li, Y; Spiegelman, VS; Tang, W; Thomas-Tikhonenko, A; Yu, D | 1 |
| Carvajal, D; Heimbrook, DC; Tovar, C; Vassilev, LT; Vu, BT; Yang, H | 1 |
| Dong, J; Hung, MC; Jian, W; Meric-Bernstam, F; Mills, GB; Mondesire, WH; Peng, J; Zhang, H | 1 |
| Ando, M; Fujiwara, Y; Katsumata, N; Kouno, T; Matsumoto, K; Shimizu, C; Takeuchi, M; Tokunaga, S; Uno, H; Yamanaka, Y; Yonemori, K | 1 |
| Kris, MG; Lobo, J; Rosen, N; Scher, HI; She, Y; Sirotnak, FM; Solit, DB | 1 |
| Hao, CF; Jiang, ZF; Liu, F; Liu, XQ; Shen, G; Song, ST; Sun, JZ; Wang, T; Yan, M; Zhang, SH | 1 |
| Abi-Raad, R; Ancukiewicz, M; Assaad, SI; Attia, K; Boucher, Y; Casty, A; Kuter, I; Molokhia, P; Powell, SN; Sullivan, T; Taghian, AG; Yeh, E | 1 |
| Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R | 1 |
| Largillier, R; Magné, J; Magné, N; Marcy, PY; Namer, M | 1 |
| Chen, SZ; Jiang, M; Zhen, YS | 1 |
| Di, X; Dumur, C; Elmore, LW; Gewirtz, DA; Holt, SE | 1 |
| Abrial, C; Amat, S; Chollet, P; Delva, R; Fleury, J; Gamelin, E; Leduc, B; Penault-Llorca, F; Sillet-Bach, I; Van Praagh, I | 1 |
| Goker, E; Goksel, G; Karabulut, B; Ozdemir, N; Sanli, UA; Sezgin, C; Uslu, R; Zekioglu, O | 1 |
| Akashi, T | 1 |
| Berman, AW; Brufsky, A; Fojo, T; Lee, JJ; Low, JA; Mannan, N; Poruchynsky, MS; Steinberg, SM; Swain, SM; Wedam, SB; Yang, SX | 1 |
| Qin, SR; Qiu, XL; Tan, QY; Yang, H; Zhang, JQ; Zhang, ZR | 1 |
| Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H | 1 |
| Ansari, TN; Khattak, BK; Mahmood, A; Rasul, S; Syed, AS | 1 |
| Cabot, MC; Giuliano, AE; Gouazé, V; Liu, YY; Prickett, CS; Yu, JY | 1 |
| El-Naggar, A; Giannakakou, P; Hamel, E; Khuri, FR; Marcus, AI; Nivens, M; O'Brate, A; Wong, J; Yao, TP; Zhou, J | 1 |
| Bokemeyer, C; Hartmann, JT; Kuczyk, M; Malenke, E; Mayer, F; Mueller, S | 1 |
| Matsue, T; Shiku, H; Takagi, A; Torisawa, YS; Yasukawa, T | 1 |
| Adamson, B; Braverman, AS; McManus, M; Pierre, S; Rao, S; Salvatti, ME | 1 |
| Hamada, Y; Ishikawa, E; Kato, M; Koga, T; Mitsuyama, S; Nishimura, R; Ogawa, T; Shibata, T; Tamura, K; Tanaka, M | 1 |
| Assaad, SI; Floyd, SR; Niemierko, A; Powell, SN; Taghian, AG | 1 |
| Cagnano, E; Cohen, AD; Cohen, Y; Geffen, DB; Halevy, S; Mamet, R; Mermershtain, W; Schoenfeld, N | 1 |
| Lamph, WW; Yen, WC | 1 |
| Bryant, J; Fehrenbacher, L; Fisher, B; Lembersky, B; Mamounas, EP; Sedlacek, SM; Soran, A; Wickerham, DL; Wolmark, N; Yothers, G | 1 |
| Greenberg, VL; Zimmer, SG | 1 |
| Assouad, S; Breau, JL; Gligorov, J; Lotz, JP; Morère, JF; Roché, H; Saintigny, P; Selle, F | 1 |
| Colomer, R; Lupu, R; Menendez, JA | 1 |
| Aglietta, M; Biglia, N; Cirillo, S; De Rosa, G; Gatti, M; Marra, V; Martincich, L; Montemurro, F; Regge, D; Sismondi, P | 1 |
| Arun, B; Ayers, M; Buchholz, TA; Gold, DL; Green, M; Hess, KR; Hortobagyi, GN; Kuerer, H; Pusztai, L; Rajan, R; Ross, JS; Rouzier, R; Stec, J; Symmans, WF; Wagner, P; Zhang, P | 1 |
| Araki, T; Kashiyama, S; Komiyama, T; Kuriyama, K; Marino, K; Ohnishi, H | 1 |
| Chiriatti, A; Latorre, A; Lorusso, V; Mangia, A; Paradiso, A; Schittulli, F; Tommasi, S; Zito, A | 1 |
| Gasparini, G; Longo, R; Morabito, A; Torino, F | 1 |
| Accurso, A; Cancello, G; Caputo, F; De Laurentiis, M; De Placido, S; Esposito, A; Giordano, A; Giuliano, M; Malorni, L; Montagna, E; Pennacchio, R; Silvestro, L; Zinno, L | 1 |
| Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S | 1 |
| Chang, HK; Chen, MF; Chen, SC; Cheung, YC; Hsueh, S; Leung, WM; Lin, YC; Tsai, CS | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Romano, G; Rubulotta, MR; Thomas, R | 1 |
| Abali, H; Altundag, K; Atahan, IL; Baltali, E; Engin, H; Erman, M; Guler, N; Karaoglu, A; Onat, D; Ozisik, Y; Sayek, I; Tekuzman, G | 1 |
| He, PQ; Li, YF; Liu, GY; Shen, ZZ; Sheng, Y; Shi, JY; Su, FX; Yang, MT; Zou, Q | 1 |
| Altundag, K; Altundag, O; Turen, S | 1 |
| Cao, YM; Liu, HJ; Liu, P; Qiao, XM; Tong, FZ; Yang, DQ; Zhou, B | 1 |
| Altundag, K; Altundag, MB; Altundag, O; Boruban, C; Turen, S | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Gulati, A; Rai, A; Rajeshkumar, NV; Shord, S | 1 |
| Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Kosmidis, P; Kourea, H; Lambropoulos, S; Linardou, H; Markopoulos, C; Mavroudis, D; Papadimitriou, C; Papadopoulos, S; Pavlidis, N; Pectasides, D; Razis, E; Skarlos, D | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Eren, F; Gökaslan, H; Kavak, Z; Pekin, T; Yörük, P | 1 |
| Balmaceda, CM; Gooch, CL; Hesdorffer, CS; Stubblefield, MD; Troxel, AB; Vahdat, LT | 1 |
| Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L | 1 |
| Adachi, S; Itamochi, H; Sudo, T; Takahashi, T; Tamamori-Adachi, M; Ueno, NT; Yamasaki, F | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; D'Aniello, R; De Rosa, V; Di Bonito, M; Frasci, G; Giordano, R; Lapenta, L; Thomas, R; Vallone, P | 1 |
| Boda, K; Hajnal-Papp, R; Kahan, Z; Thurzo, L; Uhercsak, G | 1 |
| Argyriou, AA; Assimakopoulos, K; Chroni, E; Gourzis, P; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| Daniewski, WM; Gajkowska, B; Godlewski, MM; Górka, M; Lusakowska, E; Motyl, T | 1 |
| Smorenburg, CH; ten Tije, AJ | 1 |
| Christakis, NA; Henderson, IC; Herndon, JE; Lamont, EB; Lilenbaum, R; Schilsky, RL; Weeks, JC | 2 |
| Altundag, K; Altundag, O; Ersoy, Y; Gundeslioglu, O; Silay, YS | 1 |
| Bourbouloux, E; Campone, M; Fumoleau, P; Kerbrat, P; Roché, H | 1 |
| Chen, J; Ehrlichova, M; Gut, I; Kovar, J; Kuznetsova, LV; Ojima, I; Pepe, A; Truksa, J; Vaclavikova, R | 1 |
| Jain, PN; Jalali, R; Kavishvar, N | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Booser, DJ; Buzdar, AU; Carter, C; Cristofanilli, M; Frye, D; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Rivera, E; Rosales, MF; Sahin, AA; Sikov, W; Smith, T; Strom, EA; Symmans, WF; Theriault, RL; Valero, V | 1 |
| Clark, E; Lee, H; Pusztai, L; Rouzier, R; Wagner, P; Wang, B | 1 |
| Budd, GT; Erban, J; Hutchins, L; Jones, SE; Laufman, L; Lower, E; Mennel, R; Meyers, ML; Olsen, S; Overmoyer, B; Pritchard, KI; Ravdin, PM; Richards, D; Sundaram, S; Urba, WJ | 1 |
| Fujita, S; Hirota, M; Inoue, Y; Nomura, M; Ohshima, M; Sakao, J; Souda, S | 1 |
| Anderson, K; Ayers, M; Cristofanilli, M; Fan, C; Hess, KR; Hortobagyi, GN; Ibrahim, N; Morandi, P; Perou, CM; Pusztai, L; Rabiul, I; Ross, JS; Rouzier, R; Stec, J; Symmans, WF; Wagner, P | 1 |
| Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A | 1 |
| Capri, G; Caraceni, A; Curzi, S; Luca, G; Martini, C; Scaioli, V | 1 |
| Bhar, P; Desai, N; Doval, D; Hortobagyi, GN; Ibrahim, NK; Nair, MK; Page, R; Patel, KM; Rao, SC; Samuels, B | 1 |
| Hembruff, SL; Parissenti, AM; Villeneuve, DJ | 1 |
| Yardley, DA | 1 |
| Baker, J; Carcangiu, M; Clark, K; Cronin, M; Gianni, L; Hortobagyi, GN; Mariani, G; Pusztai, L; Rodriguez, J; Ross, JS; Rouzier, R; Shak, S; Symmans, WF; Valagussa, P; Watson, D; Wu, J; Zambetti, M | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Polychronis, A; Razis, E; Siafaka, V; Skarlos, D; Timotheadou, E; Tsavdaridis, D | 1 |
| Burstein, HJ; Klein, P; Lieberman, G; Slamon, DJ; Winer, EP | 1 |
| Alwindi, AA; Elhabbash, M | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Deutsch, M; Werner, R | 1 |
| Chen, CH; Hour, TC; Jan, KY; Pu, YS; Ramanathan, B; Yu, HJ | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Giunchi, DC; Maltoni, R; Ricotti, L; Rosetti, M; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| de Azambuja, E; de Castro, G; Demonty, G; Puglisi, F | 1 |
| Bhar, P; Davidson, N; Desai, N; Gradishar, WJ; Hawkins, M; O'Shaughnessy, J; Shaw, H; Tjulandin, S | 1 |
| Saito, T; Takahashi, K; Tokunaga, Y | 1 |
| Bokma, HJ; Bontenbal, M; Braun, HJ; Creemers, GJ; de Boer, AC; Goey, SH; Janssen, JT; Kerkhofs, LG; Leys, RB; Ruit, JB; Schmitz, PI; Schothorst, KL; Seynaeve, C; van der Velden, PC; Verweij, J | 1 |
| Beamon, K; Longmate, J; Openshaw, H; Slatkin, NE; Somlo, G; Synold, T | 1 |
| Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Saraydaroglu, O; Tasdelen, I; Tolunay, S; Topal, U | 1 |
| Liu, HJ; Qiao, XM; Tong, FZ; Wang, S; Yang, DQ; Zhang, JQ | 1 |
| Disilvestro, P; Dizon, DS; Gordinier, ME; Granai, CO; Legare, RD; Miller, J; Moore, R; Pires, L; Rojan, A; Schwartz, J | 1 |
| DeNardo, G; DeNardo, S; Lamborn, K; Miers, L; Natarajan, A; Richman, C; Yuan, A | 1 |
| Ellis, P; Harper, P; Harries, M | 1 |
| Biroccio, A; D'Angelo, C; Leonetti, C; Lopez, M; Paoletti, G; Scarsella, M; Zupi, G | 1 |
| Dworkin, RH; Griggs, J; Herrmann, D; Jung, BF; Oaklander, AL | 1 |
| Goldhirsch, A; Munzone, E; Nolè, F; Sanna, G | 1 |
| Heinemann, V; Kahlert, S; Kolb, HJ; Lindhofer, H; Menzel, H; Salat, C; Stemmler, HJ | 1 |
| Senior, K | 3 |
| Abadie-Lacourtoisie, S; Capitain, O; Lortholary, A | 1 |
| Ahluwalia, MS; Daw, HA | 1 |
| Brown, AM; Bryant, J; Dakhil, SR; Davidson, NE; Fehrenbacher, L; Geyer, CE; Ingle, JN; Jenkins, RB; Kaufman, PA; Klein, PM; Kutteh, LA; Lingle, WL; Mamounas, EP; Martino, S; Paik, S; Perez, EA; Pisansky, TM; Romond, EH; Suman, VJ; Swain, SM; Tan-Chiu, E; Visscher, DW; Vogel, VG; Wolmark, N; Yothers, G | 1 |
| Bellon, JR; Bunnell, CA; Burstein, HJ; Galper, S; Garber, JE; Gelman, R; Harris, JR; Kuter, I; Lu, HM; Parker, LM; Powell, SN; Taghian, AG; Winer, EP; Wong, J | 1 |
| Aggarwal, BB; Banerjee, S; Bueso-Ramos, CE; Newman, RA; Price, JE; Shishodia, S; Takada, Y | 1 |
| Eniu, A; Palmieri, FM; Perez, EA | 1 |
| Formenti, SC | 1 |
| Brown, A; Bryant, J; Ewer, M; Fehrenbacher, L; Geyer, CE; Keefe, D; Mamounas, EP; Rastogi, P; Romond, E; Seay, TE; Shannon, RP; Swain, SM; Tan-Chiu, E; Vogel, VG; Wolmark, N; Yothers, G | 1 |
| Ajarim, DS; Ezzat, AA; Ibrahim, EM; Rahal, MM; Raja, MM | 1 |
| Gupta, S | 1 |
| Ellis, PA; Ring, AE | 1 |
| Beryt, M; Czernin, J; Gangloff, A; Hsueh, WA; Kesner, AL; Kiesewetter, DO; Pegram, MD; Phelps, ME; Pio, BS; Silverman, DH; Townsend, A | 1 |
| Fawcett, H; Giacomantonio, C; Hoskin, DW; Mader, JS; Robichaud, M | 1 |
| Moreno-Aspitia, A; Perez, EA | 2 |
| Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P | 1 |
| Cameron, DA; Carmichael, J; Howell, A; Jones, AL; Langley, RE; Parmar, M; Qian, W; Uscinska, B | 1 |
| Andre, F; Atallah, D; Berry, DA; Buzdar, AU; Delaloge, S; Garbay, JR; Gonzalez-Angulo, AM; Hess, KR; Hortobagyi, GN; Mathieu, MC; Pusztai, L; Rouzier, R; Spielmann, M; Symmans, WF; Valero, V; Wagner, P | 1 |
| Bunnell, CA; Burstein, HJ; Come, SE; Doherty, J; Gelman, R; Haldoupis, M; Harris, LN; Keshaviah, A; Moy, B; Parker, LM; Partridge, AH; Ryan, PD; Schapira, L; Schumer, ST; Winer, EP; Younger, J | 1 |
| Endo, W; Fukunaga, H; Hojo, S; Maeura, Y; Ota, H; Yamazaki, K; Yoshioka, S | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Abrams, M; Abu-Khalaf, MM; Ananthanarayanan, G; Burtness, BA; Chung, GG; DiGiovanna, MP; Ebisu, K; Farber, LR; Haffty, BG; Hsu, AD; Reiss, M; Salikooti, S; Windsor, S; Zelterman, D | 1 |
| Cecchetto, M; Dew, WA; Hembruff, SL; Parissenti, AM; Veitch, Z; Villeneuve, DJ | 1 |
| Marutaka, M; Miyake, M; Suguri, T; Yoshimura, K | 1 |
| Chen, B; Chen, JZ; Cui, F; Huang, YX; Luo, RC | 1 |
| Baselga, J; Bonadonna, G; Bozhok, A; Byakhov, M; Eiermann, W; Gianni, L; Greco, M; Guillem Porta, V; Llombart Cussac, A; Lluch, A; Lopez Lopez, JJ; Mansutti, M; Martinez-Agulló, A; Raab, G; Sabadell, D; Semiglazov, V; Valagussa, P; Zambetti, M | 1 |
| Fujimori, M; Fujita, T; Hama, Y; Ito, K; Izumi, H; Kimura, M; Kohno, K; Maeno, K; Nakagomi, H; Sano, M; Shingu, K; Tsuchiya, S | 1 |
| Emens, LA | 1 |
| Fazli, L; Gleave, M; Huntsman, D; Sinnemann, S; So, A | 1 |
| Arbach, H; Bauchet, T; Boualaga, N; Bride, N; Guinebretière, JM; Joab, I; Lefeu, F; Mathieu, MC; Mourah, S; Peyrat, JP; Podgorniak, MP; Ramirez, V; Seignerin, JM; Takada, K; Viglasky, V | 1 |
| Davis, AL; Klitus, M; Mintzer, DM | 1 |
| Flynn, PJ; Ingle, JN; Jenkins, RB; Kardinal, CG; Krook, JE; Loprinzi, CL; Mailliard, JA; Perez, EA; Rowland, KM; Salim, M; Suman, VJ; Thrower, AR; Visscher, DW | 1 |
| Blohmer, JU; Breitbach, GP; Budner, M; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Lichtenegger, W; Morack, G | 1 |
| Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S | 1 |
| Aubert, M; Brosens, JJ; Burgering, BM; Cook, SJ; Coombes, RC; Lam, EW; Madureira, PA; Pomeranz, KM; Sunters, A | 1 |
| Lai, YJ; Zhang, QY; Zhao, WH | 1 |
| Fujimura, M; Inoue, K; Isobe, K; Komagata, H; Sakai, H; Shirai, T; Tabei, T; Yoneda, S | 1 |
| Conzen, S; Fleming, G; Heimann, R; Kao, J; Recant, W | 1 |
| Bennett, GJ; Carr, D; Cianfrocca, M; Flatters, SJ; Gillis, TA; McNicol, E; Relias, V | 1 |
| Bonizzi, G; Curigliano, G; Goldhirsch, A; Munzone, E; Nolè, F; Renne, G; Rocca, A | 1 |
| Ames, FC; Babiera, GV; Buzdar, AU; Chagpar, AB; Dempsey, P; Feig, BW; Hunt, KK; Kuerer, HM; Meric-Bernstam, F; Middleton, LP; Mirza, AN; Ross, MI; Sahin, AA; Singletary, SE | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Limeres González, MA; Pavcovich Ruiz, M | 1 |
| Adamo, V; Altavilla, G; Cascinu, S; Ferraù, F; Girlando, A; Maisano, R; Numico, G; Palazzolo, C; Pergolizzi, S; Russi, E; Santacaterina, A; Settineri, N; Spadaro, P | 1 |
| Ishida, E; Konishi, N; Matsuyoshi, S; Nakamura, M; Shimada, K | 1 |
| Perez, E; Wirk, B | 1 |
| Inoue, K; Iwase, H; Kawazoe, T; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yamamoto, Y; Yoshida, Y | 1 |
| Fong, WF; Han, R; He, FT; Tzang, CH; Wang, J; Xiao, PG; Yang, MS | 1 |
| Dang, CT | 1 |
| Butler, J; Farrell, FX; Gechtman, Z; Hall, C; LaMontagne, KR; Marshall, DJ; Meshaw, A; Tullai, J | 1 |
| Arcasoy, MO; Blackwell, KL; Dewhirst, MW; Hardee, ME; Kirkpatrick, JP; Rabbani, ZN; Vujaskovic, Z | 1 |
| Mehta, D; Radhakrishnan, L; Villano, JL | 1 |
| Muss, HB; Perez, E | 1 |
| Boumendjel, A; Ehrlichová, M; Gut, I; Kovár, J; Václavíková, R | 1 |
| Hatake, K; Ito, Y; Sugimoto, Y; Takahashi, S | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Iwamoto, E; Kinosita, T; Takasugi, M; Yamaguchi, J | 1 |
| Agostara, B; Barni, S; Bria, E; Colella, E; Cuppone, F; D'Ottavio, AM; Frontini, L; Izzo, F; Nistico, C; Sperduti, I; Terzoli, E; Valenza, R | 1 |
| Niu, MY; Pratt, MA; Renart, LI | 1 |
| Beauchamp, RD; Billheimer, D; Chakravarthy, AB; Grau, AM; Johnson, DH; Jones, C; Kelley, MC; Mayer, IA; McLaren, B; Pietenpol, JA; Simpson, JF; Truica, CI | 1 |
| Duan, Z; Freeman, J; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF | 1 |
| Chang, CC; Chou, TC; Hsu, CI; Huang, RC; Klutz, A; Lee, YC; Liang, YC; Lin, CF; Mold, DE | 1 |
| Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Norton, L | 4 |
| Lanza-Jacoby, S; McGuire, KP; Neavyn, M; Ngoubilly, N | 1 |
| Coleman, RE; Evans, CA; Holen, I; Neville-Webbe, HL | 1 |
| Brechbiel, MW; Kelly, MP; Lee, FT; Scott, AM; Smyth, FE | 1 |
| Aulitzky, WE; Fritz, P; Gerteis, A; Gutzeit, S; McClellan, M; Mürdter, TE; Simon, W; Sonnenberg, M; van der Kuip, H | 1 |
| Di, X; Gewirtz, DA; Sawyer, ST; Walker, TD | 1 |
| Tominaga, T | 1 |
| Ai, B; Han, XH; He, XH; Huang, DZ; Li, B; Liu, P; Qin, Y; Shi, YK; Sun, Y; Yang, S; Zhang, CG | 1 |
| Andò, S; Aquila, S; Bonofiglio, D; Brunelli, E; Giordano, F; Mastroianni, F; Mauro, L; Miglietta, A; Morelli, C; Palma, MG; Panno, ML; Pellegrino, M | 1 |
| Blohmer, JU; Breitbach, GP; Budner, M; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G | 1 |
| Aldaz Pastor, A; Aramendia Beitia, JM; Arrobas Velilla, J; Giraldez Deiró, J; Zufía López, L | 1 |
| Arano Bermejo, JI; Cabañas Navarro, L; Capote Armas, LF; González-Palacios Martínez, F; Reguero Callejas, ME; Ruiz Tovar, J | 1 |
| Chabalier, C; Lamare, C; Larminat, F; Privat, M; Racca, C; Valette, A | 1 |
| Bria, E; Carlini, P; Ciccarese, M; Cognetti, F; Cuppone, F; Giannarelli, D; Milella, M; Natoli, G; Nistico, C; Terzoli, E | 1 |
| De Giorgi, U; Emiliani, E; Frassineti, L; Giannini, M; Giovannini, N; Kopf, B; Marangolo, M; Palazzi, S; Rosti, G; Zumaglini, F | 1 |
| Bagchi, S | 1 |
| de Korte, MA; de Vries, EG; Gietema, JA; Jager, PL; Jonkman, S; Kosterink, JG; Lub-De Hooge, MN; Perik, PJ; Sleijfer, DT; van der Graaf, WT; van Veldhuisen, DJ | 1 |
| Carlini, P; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Papaldo, P | 1 |
| Athanassiadis, A; Fountzilas, G; Pavlidis, N; Pentheroudakis, G; Razis, E | 1 |
| Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S | 1 |
| Keating, GM; Robinson, DM | 1 |
| Davidson, N; Harper, P; Harries, M; Ibrahim, N | 1 |
| Heim, S; Kaufmann, M; Kurunci-Csacsko, E; Lindenau, C; Spänkuch, B; Strebhardt, K; Yuan, J | 1 |
| Au, JL; Gan, Y; Wientjes, MG | 1 |
| Abadie-Lacourtoisie, S; Boisdron-Celle, M; Bourgeois, H; Chabrun, V; Chieze, S; Delozier, T; Ferru, A; Gamelin, E; Joly, F; Lortholary, A; Tourani, JM | 1 |
| Limwattananon, C; Limwattananon, S; Maoleekulpairoj, S; Soparatanapaisal, N | 1 |
| Clavarezza, M; Del Mastro, L; Venturini, M | 1 |
| Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P | 1 |
| Blum, JL; O'Shaughnessy, JA | 1 |
| Dang, C; Hudis, C | 2 |
| Aparicio, LM; Ayerbes, MV; Budino, BS; Campelo, RG; Curbera, GA; Facal, MS; Lopez, MR; Martinez, LC; Novoa, SA; Sancho, MI; Varela, MQ | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 2 |
| Inaba, S; Liu, J; Zhou, Y | 1 |
| Appel, S; Berry, D; Broadwater, G; Crocker, A; Dressler, L; Fleming, G; Harris, L; Hudis, C; Kirshner, J; Messino, M; Michaelson, R; Muss, H; Norton, L; Rincon, M; Sutton, L; Weaver, D; Winer, E | 1 |
| Eger, A; Mikula, M; Mikulits, W; Mogg, M; Oehler, S; Pacher, M; Schreiber, M; Schweifer, N; Seewald, MJ; Sommergruber, W; Varecka, R; Vinatzer, U | 1 |
| Fan, Z; Glazer, RI; Li, X; Liang, K; Lu, Y; Mills, GB; Zeng, X | 1 |
| Albain, K; Asmar, L; Belt, R; Cobleigh, M; Fuchs, L; Ilegbodu, D; Leyland-Jones, B; Loesch, D; McCullough, C; Raju, R; Robert, N; Sayre, R; Slamon, D; Valentine, E | 1 |
| Perez, EA; Roy, V | 1 |
| Smith, IE | 1 |
| Ben Yosef, R; Sarid, D; Shalmon, A; Sperber, F; Weinstein, Y; Yaal-Hahoshen, N | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Safra, T; Yaal-Hahoshen, N | 1 |
| Lupu, R; Mehmi, I; Menendez, JA | 1 |
| Amadori, D; Caputo, A; Cognetti, F; Crivellari, D; De Sio, L; Filippelli, G; Gasparini, G; Gion, M; Lambiase, A; Mariani, L; Morabito, A; Papaldo, P; Silingardi, V; Spada, A; Torino, F; Zancan, M | 1 |
| Fan, W; Kraft, AS; Sui, M; Xiong, X | 1 |
| Shen, KW; Shen, ZZ; Wang, LP | 1 |
| Ayala, R; Cortés-Funes, H; Gamarra, S; Gilsanz, F; Guzman, C; Hitt, R; Hornedo, J; Jimeno, A; López, JM; Quintela-Fandino, M | 1 |
| McGuire, WP | 1 |
| Battelli, N; Braconi, C; Cascinu, S; Cobelli, S; Dinota, A; Giacomini, G; Giorgi, F; Manzione, L; Massacesi, C; Morale, D; Pilone, A; Scanni, A; Sturba, F; Tummarello, D | 1 |
| Anderson, K; Booser, D; Buzdar, AU; Dempsey, PJ; Gómez, HL; Hess, KR; Hortobagyi, GN; Ibrahim, N; Mejia, JA; Pusztai, L; Ross, JS; Rouzier, R; Sneige, N; Symmans, WF; Theriault, RL; Valero, V; Vidaurre, T | 1 |
| Altundag, K; Bulut, N; Dizdar, O; Harputluoglu, H | 1 |
| Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W | 1 |
| Cai, YM; Chen, ZM; Han, XH; He, XH; Liu, P; Shi, YK; Yang, S | 1 |
| Amadori, D; Bruzzi, P; Conte, PF; De Lena, M; Gennari, A; Lorusso, V; Manzione, L; Nanni, O | 1 |
| Asmar, L; Blum, JL; Boehm, KA; Chacko, A; Dees, EC; Doane, L; Ethirajan, S; Hopkins, J; Ilegbodu, D; McMahon, R; Merten, S; Negron, A; Neubauer, M; O'Shaughnessy, JA | 1 |
| Hikino, H; Kawashima, M; Ozaki, N; Yamada, T | 1 |
| Carey, LA; Collichio, F; Dees, EC; Dressler, L; Gatti, L; Graham, ML; Ivanova, A; Kelly, H; Kimmick, G; Sawyer, L | 1 |
| Caravelli, J; D'Andrea, G; Hudis, C; Modi, S; Norton, L; Rosen, PP; Seidman, AD; Yao, TJ | 1 |
| Berry, D; Delaloge, S; Garbay, JR; Hortobagyi, GN; Hunt, KK; Kuerer, HM; Pusztai, L; Rouzier, R | 1 |
| Bafaloukos, D; Bourli, A; Christodoulou, C; Dafni, U; Fillipidis, T; Fountzilas, G; Gogas, H; Kafiri, G; Karagianni, E; Kyriakou, V; Malamou-Mitsi, V; Markaki, S; Papadopoulos, S; Papakostas, P; Papaspyrou, I; Pavlakis, K; Scopa, C; Sotiropoulou, M; Toliou, T; Tzaida, O; Vlachodimitropoulos, D | 1 |
| Ando, N; Chin, K; Mizuno, Y; Oike, E | 1 |
| Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T | 1 |
| Inoue, K; Nagamoto, N; Nakahara, O; Ohsako, T; Yoshida, Y | 1 |
| Beijnen, JH; Helgason, HH; Huitema, AD; Kruijtzer, CM; Marcus, SG; Schellens, JH; Schornagel, JH; Schot, ME; ten Bokkel Huinink, WW | 1 |
| Fernando, R; Foster, JS; Henley, D; Isbill, M; Wimalasena, J | 1 |
| Gao, S; Wang, Y; Yang, YY; Ye, WH; Yoon, HS | 1 |
| Delva, R; Douville, I; Longerey, B; Pienkowski, T; Tubiana, N; Vanhoefer, U | 1 |
| Ibrahim, NK; Pinder, MC | 1 |
| Anan, K; Fujiyoshi, K; Mitsuyama, S; Tamura, K; Taniguchi, H; Tateishi, T; Yamamoto, Y | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Iodice, G; Rubulotta, MR; Thomas, R | 1 |
| Abu-Khalaf, MM; Burtness, BA; Chung, GG; DiGiovanna, MP; Haffty, B; Juneja, V; Lee, FA; McGurk, M; Reiss, M; Sipples, R; Wackers, FJ; Zelterman, D | 1 |
| Einama, T; Mochizuki, H; Sato, K; Tsuda, H | 1 |
| Buyse, M; Decoster, G; Fabre-Guillevin, E; Jouhaud, A; Liénard, JL; Piedbois, P; Quinaux, E | 1 |
| Bosch, RJ; Herrera, E; López, N; Tejera, A | 1 |
| Clynes, M; Dowd, A; Dowling, P; Glynn, S; Henry, M; Meleady, P | 1 |
| Baeuerle, PA; Clark, D; Freimark, B; Nickel, J; Pernasetti, F; Van Epps, D | 1 |
| Belle, D; Chui, SY; Dul, CL; Koop, DR; Lycette, JL; Munar, M; Nichols, CR | 1 |
| Auerbach, JD; Baldwin, K; Chin, KR; Lackman, RD; Pandya, NK | 1 |
| Burstein, HJ; Partridge, AH; Sheib, RG; Tolaney, SM; Winer, EP | 1 |
| Abramson, N; Carlson, RW; Davidson, NE; Goldstein, LJ; O'Neill, AM; Sikic, BI; Stewart, JA; Wood, WC | 1 |
| Kajiki, M; Kobayashi, TR; Kuriyama, H; Sugahara, S | 1 |
| Darvishian, F; Wang, J | 1 |
| Berry, D; Bleiweiss, I; Broadwater, G; Cowan, D; Dressler, L; Ellis, M; Harris, LN; Hayes, DF; Lara, J; Lin, NU; Miron, A; Schnitt, SJ; Winer, EP | 1 |
| Beryt, M; Czernin, J; Gangloff, A; Hsueh, WA; Kesner, AL; Pegram, MD; Phelps, ME; Silverman, DH | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Grogan, L; Kearns, G; McCaffrey, J; McMahon, MA | 1 |
| Abrial, C; Achard, JL; Chollet, P; Cure, H; Durando, X; Ferrière, JP; Gimbergues, P; Leheurteur, M; Mouret-Reynier, MA; Van Praagh, I | 1 |
| Akiyama, F; Furukawa, K; Hatake, K; Horikoshi, N; Ito, Y; Kasumi, F; Mizunuma, N; Sakamoto, G; Sawaki, M; Tajiri, T; Takahashi, S | 1 |
| Chen, WG; Du, LL; Lei, W; Liang, J; Ma, XZ; Xu, M | 1 |
| Chen, HP; Chen, JZ; Fan, GC; Wang, QM; Wu, F | 1 |
| Feng, SQ; Jiang, ZF; Liu, F; Song, ST; Sun, JZ; Zhang, SH | 1 |
| Bria, E; Calabretta, F; Carpino, A; Cognetti, F; Cuppone, F; Ferretti, G; Nisticò, C; Sperduti, I; Terzoli, E; Toglia, G; Tomao, S; Vitelli, G | 1 |
| Braunhut, SJ; Marx, KA; McIntosh, D; Montrone, A; Zhou, T | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, HM; Yang, TS | 1 |
| Campisi, M; Cavallaro, G; Giammona, G; Maniscalco, L; Schillaci, D | 1 |
| Block, KI; Ellis, J; Gupta, G; Gyllenhaal, C; Koch, A; Lo, C; Oberbaum, M; Samuels, N; Singer, SR; Tripathy, D | 1 |
| Borghouts, C; Buerger, C; Groner, B; Kunz, C | 1 |
| Clarke, R; Decker, M; Liu, MC; Minshall, RD; Shajahan, AN; Wang, A | 1 |
| Chen, Z; Clayton, S; Shen, D; Vadgama, JV; Wu, Y | 1 |
| Bader, AA; Petru, E; Pristauz, G; Schlembach, D; Tamussino, KF | 1 |
| Atienza, M; Bromberg, J; D'Andrea, G; Fornier, MN; Hudis, C; Lake, D; Norton, L; Panageas, KS; Robson, M; Seidman, AD; Van Poznak, C | 1 |
| Broglio, KR; Buchholz, TA; Buzdar, AU; Esteva, F; Ewer, MS; Francis, D; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Sahin, AA; Singletary, SE; Symmans, WF; Theriault, RL; Valero, V | 1 |
| de Bree, E; Georgatos, SD; Georgoulias, V; Michalakis, J; Polioudaki, H; Romanos, J; Theodoropoulos, PA; Tsiftsis, DD | 1 |
| Bremer, E; Gebhardt, S; Gehrmann, M; Hasenclever, D; Hengstler, JG; Hermes, M; Koelbl, H; Lehr, HA; Mahlke, M; Mustea, A; Pilch, H; Schiffer, IB; Schmidt, M; Steiner, E; Tanner, B; Victor, A | 1 |
| Iwama, T; Karasawa, K; Kato, K; Sato, S; Sato, T; Takahashi, T; Tsunozaki, H | 1 |
| Endo, W; Fujie, Y; Fukunaga, H; Hojo, S; Maeura, Y; Okada, Y; Ota, H; Yoshioka, S | 1 |
| Amano, S; Enomoto, K; Matsuo, S; Sakurai, K | 1 |
| Ling, MT; Wang, X; Wong, YC; Zhang, X | 1 |
| Chandrasekharan, S; Clouth, B; Davidson, N; Inwang, R; Sauven, P; Smith, S | 1 |
| Ando, M; Inoue, K; Kurosumi, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T | 1 |
| Suzuki, M | 1 |
| Bailey, AR; Liew, TV; Wheeler, DW | 1 |
| Frankel, P; King, CR; Li, X; Marsh, S; McLeod, HL; Shannon, WD; Somlo, G; Synold, TW | 1 |
| Banerjee, T; DuHadaway, J; Hou, DY; Johnson, M; Mellor, AL; Muller, AJ; Munn, DH; Prendergast, GC; Sharma, MD | 1 |
| Marsh, S; McLeod, HL | 1 |
| Kim, CK; Lee, MK; Lim, SJ | 1 |
| Coley, HM; Hughes, MP; Labeed, FH; Thomas, H | 1 |
| Alli, E; Ford, JM; Hait, WN; Yang, JM | 1 |
| Ben-Yosef, R; Grinberg, Y; Kahan, P; Kovner, F; Maimon, N; Marmor, S; Ron, IG; Sarid, D; Sperber, F; Stadler, Y; Weinstein, J; Yaal-Hahoshen, N | 1 |
| Bellizzi, A; Chiriatti, A; Fedele, V; Kavallaris, M; Kendzierski, N; Lacalamita, R; Latorre, A; Lorusso, V; Mangia, A; Paradiso, A; Schittulli, F; Thomssen, C; Tommasi, S; Zito, F | 1 |
| Bai, L; Guo, G; Jin, C; Liu, J; Wu, H | 1 |
| Fang, X; Han, L; Sha, X; Wang, Y; Yu, L | 1 |
| Anderson, K; Andre, F; Buchholz, TA; Buzdar, AU; Frye, D; Gonzalez-Angulo, AM; Hess, KR; Hortobagyi, GN; Kau, SW; Kuerer, HM; Mazouni, C; Pusztai, L; Symmans, WF | 1 |
| Kamiyama, K; Morikawa, T; Nakata, J; Sakata, N; Sato, S; Seki, K; Tominaga, T; Wada, N; Wada, Y; Yamatoya, Y | 1 |
| Fuhr, U; Hempel, G; Hunz, M; Jaehde, U; Jetter, A; Kurbacher, C; Pantke, E; Tuscher, M; Untch, M; Warm, M | 1 |
| Chrisanthar, R; Knappskog, S; Lillehaug, JR; Lønning, PE; Staalesen, V | 1 |
| Chan, J; Cheng, GZ; Sun, CD; Wang, LH; Wang, Q; Zhang, W | 1 |
| Kob, A; Mestres, P; Morguet, A; Schmidt, W; Thedinga, E | 1 |
| Aebi, S; Ballabeni, P; Gick, U; Hess, V; Lanz, D; Mingrone, W; Pestalozzi, B; Rauch, D; Rochlitz, C | 1 |
| Burstein, HJ; Come, SE; Gelman, R; Haldoupis, M; Lin, NU; Parker, LM; Ryabin, N; Shulman, LN; Winer, EP | 1 |
| Kaufmann, M; Kurunci-Csacsko, E; Spänkuch, B; Strebhardt, K | 1 |
| Amare, M; Asmar, L; Blum, JL; Dees, EC; Gill, DP; Ilegbodu, D; McMahon, RT; O'Shaughnessy, JA; Vukelja, SJ | 1 |
| Xiong, H; Yu, S; Zhuang, L | 1 |
| Bai, L; Guo, G; Jin, C | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Han, W; Heo, DS; Im, SA; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Noh, DY; Oh, DY; Park, IA | 1 |
| Alexandre, J; Hu, Y; Huang, P; Lu, W; Pelicano, H | 1 |
| Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC | 1 |
| Barber, DF; Camacho, LH; Cheung, A; Curley, SA; Gupta, S; Hortobagyi, GN; Kim, EE; Kurzrock, R; Madoff, DC; Mavligit, G; Wallace, MJ | 1 |
| Andre, F; Frye, D; Gonzalez-Angulo, AM; Green, M; Hortobagyi, GN; Kau, SW; Liedtke, C; Mazouni, C; Pusztai, L; Symmans, WF | 1 |
| Aiba, K; Hayashi, K; Ichiba, T; Inoue, D; Kobayashi, T; Mouri, J; Sakuyama, T | 1 |
| Ishov, AM; Lindsay, CR; Morozov, VM; Scholz, A | 1 |
| Chung, HC; Im, SA; Kim, CS; Kim, SB; Lee, KS; Lee, MY; Park, YH; Rha, SY; Ro, J | 1 |
| Green, MD; Ng, R | 1 |
| Higgins, LS; Orlowski, RZ; Shi, YY; Small, GW | 1 |
| Amblard, F; Arbiser, JL; Karlan, BY; Koeffler, HP; Nguyen, A; O'Kelly, J; Wakimoto, N; Wolf, I | 1 |
| Garretson, BR; Joshi, MM | 1 |
| Bria, E; Calabretta, F; Cuppone, F; Galiè, E; Graziano, G; Jandolo, B; Natoli, G; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E; Tomao, S | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Berstein, LM; Bozhok, AA; Dashyan, GA; Ivanov, VG; Kletzel, A; Melnikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Ziltsova, EK | 1 |
| Davidson, NE; Fan, W; Huang, Y; Park, BH; Sui, M | 1 |
| Fujiwara, Y; Ono, M | 1 |
| Chae, JS; Cho, JH; Cho, SG; Choi, EJ; Hwang, SG; Kang, SS; Kim, BW; Kim, EK; Kim, HC; Kim, J; Kim, KJ; Kim, MJ; Lang, F; Yoon, KW; Yun, HJ | 1 |
| Friday, E; Turturro, F; Von Burton, G | 1 |
| Bralet, MP; Chebib, A; Gholam, D; Hauteville, D; Jasmin, C | 1 |
| Adachi, A; Horikawa, T | 1 |
| Choi, MK; Chung, SJ; Cui, FD; Kim, DD; Kim, JS; Shim, CK; Yang, T | 1 |
| Ewer, MS; O'Shaughnessy, JA | 1 |
| Chao, TY; Hong, RL; Hsieh, RK; Hwang, WS; Kao, WY; Lin, CH; Wang, CH | 1 |
| Augusto, C; Cinzia, M; Luca, G; Pietro, M; Sara, C; Scaioli, V; Sergio, C | 1 |
| Agostini, C; Bachelot, T; Cassier, PA; Chabaud, S; Cure, H; Guastalla, JP; Jacquin, JP; Martin, C; Orfeuvre, H; Peaud, PY; Pérol, D; Salles, B; Tigaud, JD; Trillet-Lenoir, V | 1 |
| Baron, AD; Burstein, HJ; Gelman, R; Hart, RD; Keshaviah, A; Lambert-Falls, R; Marcom, PK; Winer, EP | 1 |
| Bhatia, V; Henderson, IC | 1 |
| Imai, S; Jitsuko, A; Nishikawa, H; Otoshi, M; Takahara, S; Tsubono, M; Wada, Y | 1 |
| Cho, H; Hasegawa, S; Kobayashi, O; Osaragi, T; Sairenji, M; Tsuburaya, A; Yoshida, T; Yoshikawa, T | 1 |
| Fujino, M; Maruhashi, K; Mitsudou, Y; Nakamura, T; Shimomatsuya, T; Shiraishi, S; Yonezawa, K | 1 |
| Butt, K; Liu, H; Wang, L; Wang, Z | 1 |
| Altorjai, G; Bartsch, R; Forstner, B; Mader, RM; Pluschnig, U; Rizovski, B; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Kurebayashi, J; Masuda, N; Nakayama, T; Noguchi, S; Sakamoto, J; Shiba, E; Taguchi, T; Takatsuka, Y; Watatani, M | 1 |
| Broglio, K; Buzdar, AU; Dawood, S; Gonzalez-Angulo, AM; Hortobagyi, GN; Islam, R; Kau, SW; Peintinger, F; Symmans, WF | 1 |
| Bergström, M; Blomqvist, C; Carlsson, J; Josephsson, R; Långström, B; Monazzam, A | 1 |
| Choe, KJ; Choi, HY; Choi, SH; Han, WS; Kim, HA; Kim, HK; Moon, BI; Oh, SY; Park, HK; Sung, SH; Yom, CK; Yoon, EJ | 1 |
| Altundag, K; Dede, DS; Purnak, T | 1 |
| Bradner, J; Duan, Z; Foster, R; Greenberg, E; Mahoney, J; Mazitschek, R; Seiden, MV | 1 |
| Miyaguni, T; Murayama, S; Nishimaki, T | 1 |
| Masuda, N | 1 |
| Bergquist, H; Gee, MS; Josephson, L; Mahmood, U; Upadhyay, R; Weissleder, R | 1 |
| Aiba, K; Hatake, K; Ishikawa, E; Ito, Y; Kobayashi, T; Minowa, S; Mitsuhashi, J; Nakane, M; Shibata, H; Sugimoto, Y; Suzuki, R; Takahashi, S; Tsukahara, S; Tsuruo, T | 1 |
| Andreetta, C; Banna, G; Battelli, N; Berardi, R; Bisagni, G; Boni, C; Bottini, A; Conte, P; Cresti, N; Di Blasio, B; Ficarra, G; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Maiorana, A; Michelotti, A; Piacentini, F; Puglisi, F; Santoro, A | 1 |
| Bagley, CA; Bookland, MJ; Gokaslan, ZL; Ozmen, T; Pindrik, JA; Witham, TF | 1 |
| Dragounová, E; Dvorák, J; Hyspler, R; Kalábová, H; Melichar, B; Tichá, A | 1 |
| Berry, DA; Budman, DR; Cirrincione, C; Citron, ML; Henderson, IC; Hudis, CA; Muss, HB; Norton, L; Winer, EP | 1 |
| Furlow, B | 1 |
| Ivanova, A; Qaqish, B; Salama, I | 1 |
| Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD | 1 |
| Bria, E; Carpino, A; Cognetti, F; Cuppone, F; Fornier, M; Nisticò, C; Pace, A; Sperduti, I; Terzoli, E | 1 |
| Li, Q; Liu, J; Wang, JY; Xu, BH; Zhang, P; Zhao, LM | 1 |
| Akazawa, K; Arai, T; Kim, SJ; Maruyama, N; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Abbas, F; Gligorov, J; Khalil, A; Lotz, JP; Namer, M; Selle, F | 1 |
| Bonezzi, K; Frapolli, R; Giavazzi, R; Kuhn, E; Martinelli, M; Riccardi, E; Ryan, AJ; Taraboletti, G; Zucchetti, M | 1 |
| Horwitz, SB; Wiesen, KM; Xia, S; Yang, CP | 1 |
| Azambuja, E; Cardoso, F; Colozza, M; Durbecq, V; Larsimont, D; Piccart-Gebhart, M; Rosa, DD | 1 |
| Baick, CH; Butler, JA; Hsiang, DJ; Lane, KT; Mehta, RS; Su, MY; Yamamoto, M | 1 |
| Fukuda, T; Kawahara, M; Kikuchi, S; Kodama, H; Suzuki, H; Watanabe, T | 1 |
| Imai, S; Ito, T; Kawamoto, K; Nagahisa, Y; Niwano, M; Ogasahara, K; Okabe, M; Park, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Jiang, S; Krag, DN; Li, P; Michejda, CJ; Oligino, L; Pero, SC; Roller, PP | 1 |
| Davis, S; Hind, D; Rees, A; Simpson, E; Ward, S; Wilkinson, A | 1 |
| Hiraoka, M; Imagunbai, T; Inoue, T; Mitsumori, M; Negoro, Y; Sai, H; Sasaki, S; Sasaki, Y; Shikama, N; Takegawa, H; Teshima, T; Yamauchi, C | 1 |
| Hernández-Vargas, H; Julián-Tendero, M; Moreno-Bueno, G; Palacios, J; Sánchez-Estévez, C; von Kobbe, C | 1 |
| Gluck, S; Lobo, C; Lopes, G; Silva, O | 1 |
| Altundag, K; Dizdar, O; Harputluoglu, H | 1 |
| Fu, J; Liang, M; Su, DM; Zhang, P | 1 |
| Berveiller, P; Goffinet, F; Goldwasser, F; Mir, O; Pons, G; Ropert, S; Treluyer, JM | 1 |
| Berry, DA; Broadwater, G; Cowan, D; Dressler, LG; Edgerton, S; Ellis, MJ; Goldstein, LJ; Hayes, DF; Henderson, IC; Hudis, CA; Ingle, JN; Martino, S; Norton, L; Thor, AD; Weaver, D; Winer, EP | 1 |
| Moore, A | 1 |
| Dotsu, M; Fukada, T; Minamikawa, H; Nishida, K; Oka, S; Sakaushi, S; Senda-Murata, K; Sugimoto, K | 1 |
| Akutsu, Y; Kano, M; Matsubara, H; Matsushita, K; Miyazawa, Y; Murakami, K; Nishimori, T; Ochiai, T; Sakata, H; Usui, A; Yoneyama, Y | 1 |
| Ferguson, T; Ghersi, D; Nowak, AK; Vagg, R; Wilcken, N | 1 |
| Feng, SS; Ranganathan, B; Sun, B | 1 |
| Bai, J; Gu, P; Margolick, JB; Zhang, H; Zhang, Y; Zhou, J | 1 |
| Bershteĭn, LM; Bozhok, AA; Damenia, AO; Dashian, GA; Donskikh, RV; Ivanov, VG; Klettsel', AA; Kochetova, IA; Krivorot'ko, PV; Mel'nikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Tonuzov, EE; Voskresenskiĭ, DA; Zernov, KIu; Zhil'tsova, EK | 1 |
| Akiyama, F; Horii, R; Ito, Y; Iwase, T; Matsuura, M; Miki, Y | 1 |
| Furukawa, T; Hirai, I; Hirai, Y; Kawago, M; Kiyoi, M; Kokawa, Y; Naito, K; Nakamura, R; Okamura, Y; Ota, F; Oura, S; Shimizu, Y; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
| Akashi-Tanaka, S; Kinoshita, T; Shien, T; Terada, K; Tsukamoto, S | 1 |
| Radaideh, SM; Sledge, GW | 1 |
| Liu, H; Lupu, R; Menendez, JA; Vellon, L | 1 |
| Amadori, D; Cecconetto, L; Fabbri, F; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Tesei, A; Zoli, W | 1 |
| de Lemos, ML; Ellard, S; Hu, F; Kuik, K; Olivotto, IA; Speers, CH; Taylor, SC; Vu, T | 1 |
| Jacobs, CI; Link, JS; Nguyen, B; Waisman, JR | 1 |
| Choi, BS; Robins, HI | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Arnedos, M; Ashley, S; Smith, I; Sutherland, S | 1 |
| Balduzzi, A; Bottiglieri, L; Colleoni, M; Ghisini, R; Giovanardi, F; Goldhirsch, A; Luini, A; Orlando, L; Rocca, A; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Carpenter, PM; Chen, JH; Mehta, RS; Nalcioglu, O; Su, MY | 1 |
| García-Aranda, M; Gleave, ME; Hortas, ML; Morell, M; Redondo, M; Roldan, MJ; Serrano, A; Téllez, T | 1 |
| Altundag, K; Buzdar, AU; Esteva, FJ; Hortobagyi, GN; Lin, F; Mejia, JA; Pusztai, L; Symmans, WF; Valero, V; Wang, J; Yan, K | 1 |
| Brunet, J; Colomer, R; De Llorens, R; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| Chung, H; Kim, H; Kim, HJ; Kim, Y; Kong, G; Lee, JY; Oh, MY | 1 |
| Cella, D; Cobleigh, M; Davidson, NE; Dickler, M; Gralow, J; Miller, K; Perez, EA; Shenkier, T; Wang, M | 1 |
| Bianco, AR; Cancello, G; Criscitiello, C; D'Agostino, D; De Laurentiis, M; De Placido, S; Esposito, A; Forestieri, V; Giordano, A; Giuliano, M; Lauria, R; Limite, G; Montagna, E; Montanino, A; Pennacchio, R; Silvestro, L | 1 |
| Oktay, K; Oktem, O; Reh, A | 1 |
| Cognetti, F; Felici, A; Ferretti, G | 1 |
| Alamani, M; Arapantoni-Dadioti, P; Aravantinos, G; Briasoulis, E; Dafni, U; Fountzilas, G; Gogas, H; Kalofonos, HP; Kastritis, E; Kostopoulos, I; Kyriakou, V; Kyroudi, A; Malamou-Mitsi, V; Papaspyrou, I; Pectasides, D; Skopa, C; Tzaida, O | 1 |
| Roukos, DH | 1 |
| Mehta, R | 1 |
| Nash, I | 1 |
| Hansch, C; Verma, RP | 1 |
| Day, JM; Foster, PA; Ho, YT; Judde, JG; Lassalle, M; Leese, MP; Newman, SP; Potter, BV; Prevost, G; Purohit, A; Reed, MJ; Stengel, C | 1 |
| Berry, DA; Broadwater, G; Demetri, GD; Duggan, D; Hayes, DF; Henderson, IC; Hopkins, J; Hudis, CA; Kaufman, PA; Lin, N; Liu, MC; Lyss, A; Marcom, PK; Norton, L; Robert, NJ; Tkaczuk, K; Winer, EP; Younger, J | 1 |
| Marino, P | 1 |
| Lazo, JS; McDonald, PR; Sikorski, RP; Skoko, JJ; Tamewitz, A; Vogt, A; Wipf, P | 1 |
| Blum, JL; Clawson, A; Edelman, G; Geister, BV; Kirby, RL; O'Shaughnessy, JA; Pippen, JE; Robert, NJ; Savin, MA | 1 |
| Hudis, CA; McArthur, HL | 1 |
| McBride, D | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kohno, T; Seki, K; Shibata, T; Shien, T; Shimizu, C | 1 |
| Hashimoto, K; Igishi, T; Matsumoto, S; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K; Ueda, Y; Yamasaki, A | 1 |
| Ai, CZ; Dong, PP; Ge, GB; Liu, CX; Liu, Y; Yang, L; Zhang, YY | 1 |
| Allegrini, PR; Brueggen, J; Floersheimer, A; Maira, M; McSheehy, PM; O'Reilly, T; Wartmann, M | 1 |
| Dufresne, A; Pivot, X; Viel, E; Villanueva, C | 1 |
| Altundag, K; Bulut, N; Kilickap, S; Sari, E | 1 |
| Currie, V; D'Andrea, G; Dang, C; Dickler, M; Drullinsky, P; Fornier, M; Gilewski, T; Hudis, C; Lake, D; Mills, N; Moynahan, ME; Norton, L; Panageas, K; Robson, M; Seidman, A; Sklarin, N; Steingart, R; Sugarman, S; Troso-Sandoval, T; Wasserheit-Leiblich, C | 1 |
| Fukushima, M; Garbo, CL; Ishiguro, H; Kitano, T; Toi, M; Ueno, T; Yanagihara, K; Yasuda, H; Yoshibayashi, H | 1 |
| Berta, L; Canaparo, R; Chiarle, R; Frairia, R; Serpe, L; Zara, GP | 1 |
| Ardizzoni, A; Bisagni, G; Bortesi, B; Camisa, R; Capelletti, M; Laccabue, D; Missale, G; Musolino, A; Naldi, N; Neri, TM; Pezzuolo, D; Zerbini, A | 1 |
| Graziani, SR; Hegg, R; Maranhão, RC; Pires, LA; Rodrigues, DG; Valduga, CJ | 1 |
| Bayo, J; Bernabé, R; Jiménez, J; Lomas, M; Lopez-Ladrón, A; Moreno, A; Ruiz, M; Salvador, J; Valero, M; Vicente, D | 1 |
| Fillmore, CM; Kuperwasser, C | 1 |
| Cao, Q; Chen, K; Chen, X; He, L; Li, ZB; Neamati, N; Wu, Z | 1 |
| Berry, D; Burstein, H; Cirrincione, C; Gipson, G; Harris, L; Hudis, C; Lake, D; Marcom, PK; Muss, H; Norton, L; Seidman, AD; Shapiro, CL; Ungaro, P; Winer, E | 1 |
| Acharya, CR; Anders, CK; Anguiano, A; Barry, WT; Dressman, HK; Garman, KS; Marcom, KP; Mukherjee, S; Nevins, JR; Olson, J; Potti, A; Redman, R; Salter, KH; Walters, KS | 1 |
| Akehurst, R; Booth, A; Kaltenthaler, E; Tappenden, P | 1 |
| Marty, M; Pivot, X | 1 |
| Feng, SS; Pan, J | 1 |
| Haines, IE; Miklos, GL | 1 |
| Burris, HA | 5 |
| Gridelli, C; Rossi, A; Torri, V | 1 |
| Biakhov, MIu; Kaziulin, AN; Koroleva, IA; Kozlov, SV; Kucheriavyĭ, IuA | 1 |
| Davidson, NE; Jones, V; Martino, S; Perez, EA; Saphner, T; Sledge, GW; Sparano, JA; Wang, M; Wolff, AC; Wood, WC | 1 |
| Dash, AK; Nagvekar, AA; Trickler, WJ | 1 |
| Andre, F; Hortobagyi, GN; Liedtke, C; Pusztai, L; Sotiriou, C; Symmans, WF; Tordai, A; Wang, J; Yan, K | 1 |
| Mehta, RS; Schubbert, T | 1 |
| Ardavanis, A; Baziotis, N; Garoufali, A; Kountourakis, P; Kyriakou, F; Malliou, S; Mantzaris, I; Rigatos, G; Scorilas, A; Yiotis, I | 1 |
| Foretová, L; Fridrichová, P; Lukesová, S; Melichar, B; Mergancová, J; Ryska, A; Urminská, H | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Bongiovanni, G; Cantero, J; Eynard, A; Goleniowski, M | 1 |
| Blackwell, K; Lokshin, AE; Luong, TM; Marks, JR; Nolen, BM; Rand, A; Ta'san, S; Wang, Y | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Hidaka, T; Horiuchi, A; Ishida, N; Kawachi, K; Nakagawa, H; Sato, K; Sugishita, H; Watanabe, Y; Yamamoto, Y; Yoshida, M; Yukumi, S | 1 |
| Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S | 1 |
| Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F | 1 |
| Baselga, J; Fennelly, D; Hudis, CA; Norton, L; Raptis, G; Seidman, AD | 2 |
| Gelmon, KA | 2 |
| Jekunen, A; Lehtovirta, P; Pyrhönen, S | 1 |
| Crown, JP; Currie, V; Gilewski, TA; Hakes, TB; Heelan, R; Lebwohl, DE; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 2 |
| Cowan, KH; Fisherman, JS; Goldspiel, B; McCabe, M; Noone, M; O'Shaughnessy, JA; Ognibene, FP; Venzon, DJ | 1 |
| Divgi, CR; Goldsmith, SJ; Larson, SM; Macapinlac, HA; Schneider, JA; Scott, AM; Seidman, AD | 1 |
| Crown, JP; Gilewski, TA; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 1 |
| Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W | 1 |
| Baselga, J; Crown, JP; Currie, V; Forsythe, P; Gilewski, TA; Hakes, TB; Hudis, CA; Reichman, BS; Seidman, AD; Yao, TJ | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN | 1 |
| Cavalli, F; Goldhirsch, A; Pagani, O; Parma, G; Sessa, C | 1 |
| Gudi, R; Krishnamurthy, M; Pachter, BR | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Demirer, T; Lilleby, K; Rowley, S; Schiffman, K; Storb, R | 1 |
| Abrams, JS; Adams, J; Baltz, J; Canetta, R; Christian, M; Desmond-Hellmann, S; Friedman, MA; Montello, M; Onetto, N; Vena, DA | 1 |
| Beijnen, JH; Bierhorst, F; Heimans, JJ; Huizing, MT; Mandjes, IA; Pinedo, HM; Postma, TJ; ten Bokkel Huinink, WW; Vermorken, JB; Winograd, B | 1 |
| Hudis, CA; Norton, L; Seidman, AD | 1 |
| Donehower, RC; Kennedy, MJ; Rowinsky, EK | 1 |
| Holmes, FA | 4 |
| Beltangady, M; Grechko, J; Kortmansky, J; Lepore, J; Mont, EK; Onetto, N; Portenoy, R; Ren, L; Seidman, AD; Yao, TJ | 1 |
| Anand, A | 1 |
| Eckhardt, S | 2 |
| Mukaiyama, T; Okamoto, R; Sasaki, T | 1 |
| Eisenhauer, EA; Trudeau, M | 1 |
| Smith, GA | 1 |
| Barrett, S; Crown, J; Currie, V; Gilewski, T; Gollub, M; Hudis, C; Lepore, J; Seidman, AD; Tiersten, A; Yao, TJ | 1 |
| Cortes, JE; Pazdur, R | 1 |
| Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Laffranchi, A; Martini, C; Munzone, E; Spreafico, C; Tarenzi, E; Villani, F | 2 |
| Baughman, C; Cogleigh, M; Goldstein, LJ; McCaskill-Stevens, W; Neuberg, D; Robert, N; Rowinsky, E; Sledge, GW; Sparano, JA | 1 |
| Gelmon, KA; O'Reilly, SE | 1 |
| Greco, FA; Hainsworth, JD | 3 |
| Asbury, R; Boros, L; Chang, AY; Garrow, G | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC | 1 |
| Garin, AM; Gorbunova, VA; Orel, NF; Roshchin, EM; Tiuliandin, SA; Voĭnarevich, OA | 1 |
| Balis, FM; Berg, SL; Cowan, KH; Denicoff, AM; Noone, M; O'Shaughnessy, JA; Ognibene, FP; Tolcher, A | 1 |
| Gelmon, KA; Tolcher, AW | 1 |
| Chazard, M; Corette, L; Dieras, V; Garet, F; Marty, M; Mignot, L; Morvan, F; Onetto, N; Serin, D; Tubiana, N | 1 |
| Kaye, SB | 1 |
| Bontenbal, M; Moll, JW; van den Bent, MJ; van der Burg, ME; van Gerven, JM; Vecht, CJ; Verweij, J | 1 |
| Freilich, RJ; Seidman, AD | 1 |
| Shparik, IV | 1 |
| Heimans, JJ; Liefting, AJ; Pinedo, HM; Postma, TJ; Vermorken, JB | 1 |
| Kaddurah-Daouk, R; Martin, KJ; Teicher, BA; Vassallo, CD | 1 |
| Crown, JP; Gilewski, TA; Hakes, TB; Heelan, R; Lebwohl, DE; Norton, L; Reichman, BS; Seidman, AD; Surbone, A; Yao, TJ | 1 |
| DeLisa, AF; Gregory, RE | 1 |
| Crown, JP; Currie, V; Gilewski, TA; Hakes, TB; Heelan, R; Hudis, CA; Lebwohl, DE; Reichman, BS; Seidman, AD; Surbone, A | 1 |
| Armour, EP; Corry, PM; Lee, YJ; Martinez, AA; Stromberg, JS | 1 |
| Brouty-Boyé, D; Kolonias, D; Lampidis, TJ; Savaraj, N; Wu, CJ | 1 |
| Taguchi, T | 1 |
| Hudes, GR; Smith, CD; Tew, KD; Zhang, X; Zilfou, JT | 1 |
| Ravdin, PM; Valero, V | 1 |
| Chang, AY; Garrow, GC | 1 |
| Berry, DA; Rosner, GL | 1 |
| Cowan, KH; O'Shaughnessy, JA | 1 |
| Azli, N; Bayssas, M; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Van Glabbeke, M | 1 |
| Amadori, D; Bajorko, P; De Paola, F; Flamigni, A; Frassineti, GL; Gasperi-Campani, A; Milandri, C; Zoli, W | 1 |
| Clarke, MF; Ealovega, MW; Nuñez, G; Sumantran, VN; Wicha, MS | 1 |
| Bonadonna, G; Capri, G; Egorin, MJ; Giani, A; Gianni, L; Kearns, CM; Lacatelli, A; Viganó, L | 1 |
| Bishop, JF; Phillips, KA; Urch, M | 1 |
| Abrams, J; Cheson, BD; Phillips, PH | 1 |
| Brouty-Boye, D; Kolonias, D; Lampidis, TJ | 1 |
| Depenbrock, H; Hanauske, AR; Rastetter, J; Shirvani, D | 1 |
| Azli, N; Bayssas, M; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Roche, H; Van Glabbeke, M | 1 |
| Goldberg, HL; Vannice, SB | 1 |
| Djavanmard, MP; Gnant, MF; Jakesz, R; Steger, GG | 1 |
| Arbuck, SG | 2 |
| Donehower, RC; Rowinsky, EK | 3 |
| Chazard, M; Garet, F; Lavail, Y; Lenaz, L; Lucidi, B; Pellae-Cosset, B; Soares, JA | 1 |
| Alagaratnam, TT | 1 |
| Cook, JA; Fisher, J; Liebmann, JE; Lipschultz, C; Mitchell, JB; Teague, D | 1 |
| Balis, FM; Berg, SL; Cowan, KH; Denicoff, AM; Fisherman, JS; Hillig, M; O'Shaughnessy, JA; Poplack, DG | 1 |
| Baldini, F; Biadi, O; Conte, PF; Gherarducci, G; Giannessi, PG; Mariani, M; Mengozzi, G; Strata, G; Surbone, A | 1 |
| Cook, JA; Fisher, J; Liebmann, J; Lipschultz, C; Mitchell, JB; Teague, D | 1 |
| Martin, V | 1 |
| Abrams, JS; Arbuck, SG; Cheson, BD; Phillips, PH | 1 |
| Angioli, R; Averette, HE; Chou, TC; Koechli, OR; Perras, JP; Sevin, BU; Steren, A; Untch, M | 1 |
| Kurz, C; Mayerhofer, K; Obermair, A; Sevelda, P; Stolzlechner, J | 1 |
| Beller, U; Hornreich, G; McDaniel, C; Peretz, T; Shacter, J; Sulkes, A; Winograd, B | 1 |
| Arbuck, SG; Dorr, A; Friedman, MA | 1 |
| Arioka, H; Saijo, N | 1 |
| Calzone, K; McCauley, DL; Wicha, M | 1 |
| Alkan-Onyuksel, H; Chai, HB; Pezzuto, JM; Ramakrishnan, S | 1 |
| Angioli, R; Averette, HE; Koechli, O; Perras, JP; Sevin, BU; Untch, A; Untch, M | 1 |
| Nightingale, SL | 1 |
| Kuhn, W; Meden, H; Rath, W | 1 |
| Booser, DJ; Buzdar, AU; Fraschini, G; Frye, D; Gibbs, HR; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS | 1 |
| Capri, G; Caraceni, A; Fulfaro, F; Gianni, L; Martini, C; Munzone, E; Scaioli, V; Tarenzi, E | 1 |
| Abrams, JS; Friedman, M; Moore, TD | 1 |
| Barrett, S; Canezo, S; Seidman, AD | 1 |
| Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE | 1 |
| Burkley, M; Kodali, S; Moudgil, VK; Nag, K; Taylor, RC | 1 |
| Rowinsky, EK | 2 |
| Dittrich, C; Fazeny, B; Fiegl, M; Grisold, W; Huber, H; Zifko, U | 1 |
| Bergh, J; Fjällskog, ML; Frii, L | 2 |
| Gabel, M; Khil, MS; Kim, JH; Kim, SH; Lee, YJ; Ryu, S | 1 |
| Chevalier, B; Clavel, M; Verweij, J | 1 |
| Alakl, M; Clavel, M; Franklin, H; Piccart, M; Prove, AM; Steward, W; ten Bokkel Huinink, WW; Tursz, T; Verweij, J; Wanders, J | 1 |
| Cook, JA; Fisher, J; Liebmann, J; Mitchell, JB; Teague, D | 1 |
| Hata, Y; Loehrer, PJ; Sandler, A; Sledge, GW; Weber, G | 1 |
| Cook, JA; Fisher, J; Liebmann, JE; Teague, D | 1 |
| Aaron, AD | 1 |
| Baughman, C; Cobeligh, M; Goldstein, LJ; McCaskill-Stevens, W; Neuberg, D; Robert, N; Rowinsky, E; Sledge, GW; Sparano, JA | 1 |
| Cowan, KH; Fisherman, JS; O'Shaughnessy, JA | 1 |
| Capri, G; Gianni, L; Munzone, E; Straneo, M | 1 |
| Aiba, K; Akatsuka, Y; Besho, A; Horikoshi, N; Inamoto, Y; Inoue, K; Mukaiyama, T; Ogihara, A; Sumida, T; Uchida, T | 1 |
| Adachi, I; Hirata, K; Kitajima, M; Kunii, Y; Sano, M; Shimada, H; Suwa, T; Tabei, T; Taguchi, T; Tominaga, T | 1 |
| Gelmon, K | 1 |
| Spielmann, M | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN; Theriault, RL | 1 |
| Abe, R; Enomoto, K; Fujita, M; Hamano, K; Hasegawa, K; Mori, S; Morishita, Y; Sasaki, Y; Tabei, T; Taguchi, T | 1 |
| Sevin, BU; Untch, M | 1 |
| Cheson, BD | 2 |
| Choyke, PL; Cowan, KH; Fisherman, JS; O'Shaughnessy, JA; Pestalozzi, BC; Sotos, GA | 1 |
| Bloomer, WD; Merkel, DE; Raghavan, VT | 1 |
| Reed, E; Sarosy, G | 1 |
| Cook, J; Fisher, J; Goldspiel, B; Hahn, SM; Kaufman, D; Liebmann, JE; Mitchell, JB; Venzon, D | 1 |
| Cohen, PR; Kavanagh, JJ; Kudelka, AP; Pazdur, R; Raber, MN | 1 |
| Eisenhauer, E | 1 |
| Bellet, RE; Bierman, WA; Burris, HA; Cook, G; Eisenberg, P; Genevois, E; Kane, M; Mortimer, J; Ravdin, PM | 1 |
| Bellet, RE; Buzdar, AU; Esparza, L; Fonseca, GA; Fraschini, G; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS | 1 |
| Chou, TC; Otter, GM; Sirotnak, FM | 1 |
| Weber, G; Yeh, YA | 1 |
| Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T | 1 |
| Davidson, NG | 2 |
| Becher, R; Diergarten, K; Eberhardt, W; Harstrick, A; Klaassen, U; Pari, CP; Seeber, S; Strumberg, D; Wilke, H | 1 |
| Cheung, KL; Luk, IS; Ma, L; Shek, TW | 1 |
| Day, BW; Gunasekera, SP; Hamel, E; Kowalski, RJ; Lin, CM; Longley, RE; Rosenkranz, HS; ter Haar, E | 1 |
| Pronk, LC; Stoter, G; Verweij, J | 1 |
| Balmaceda, C; Baselga, J; Bruno, R; Crown, JP; Currie, V; Freilich, R; Gilewski, TA; Gollub, M; Hakes, TB; Hudis, CA; Lebwohl, DE; Norton, L; Raptis, G; Robles, M; Seidman, AD | 1 |
| Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J | 1 |
| Berkman, A; Mardelli, TJ; Soe, MS | 1 |
| el-Yazigi, A; Yusuf, A | 1 |
| Caraceni, A; Fulfaro, F; Martini, C; Munzone, E; Palazzini, E; Scaioli, V; Tarenzi, E | 1 |
| Piccart, MJ | 2 |
| Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB | 1 |
| Crinis, NA; Millward, MJ; Morton, CG; Webster, LK | 1 |
| van Oosterom, AT | 1 |
| Trudeau, ME | 5 |
| Ravdin, PM | 6 |
| Burris, HA; Fields, S; Peacock, N | 1 |
| Capri, G; Fulfaro, F; Gianni, L; Tarenzi, E | 1 |
| Boehm, DK; Maksymiuk, AW | 1 |
| Blagosklonny, MV; Neckers, LM; Nguyen, P; Schulte, T; Trepel, J | 1 |
| Bowling, K; Chen, TL; Donehower, RC; Kennedy, MJ; Noe, DA; Rowinsky, EK; Sartorius, S; Zahurak, ML | 1 |
| Arron, J; Bearman, SI; Cagnoni, PJ; Day, T; Dufton, C; Hami, L; Jones, RB; Martinez, C; Matthes, S; Purdy, MH; Shpall, EJ; Stemmer, SM; Taffs, S | 1 |
| Blum, JL; Greco, FA; Hainsworth, JD; Jones, SE; Mennel, RG | 1 |
| DeAngelis, LM; Freilich, RJ; Seidman, AD | 1 |
| Anand, A; Huberman, M | 1 |
| Boesgaard, M; Dombernowsky, P; Gehl, J; Jensen, BV; Jensen, TP | 1 |
| Amadori, D; Casadei Giunchi, D; Frassineti, GL; Gentile, A; Ravaioli, A; Salzano, E; Tienghi, A; Zoli, W | 1 |
| Baldini, E; Biadi, O; Conte, PF; DaPrato, M; Gentile, A; Giannessi, PG; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Diergarten, K; duBois, A; Hecker, D; Janicke, F; Konecny, G; Kuhnle, H; Lindner, C; Lisboa, BW; Luck, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Tolcher, AW | 2 |
| Holmes, FA; Hortobagyi, GN | 2 |
| Harstrick, A; Klaassen, U; Seeber, S; Wilke, H | 2 |
| DeVore, RD; Garrett, AM; Johnson, DH; Meshad, M; Paul, DM; Porter, LL | 1 |
| Hortobagyi, GN; Ibrahim, N | 1 |
| Bonadonna, G | 1 |
| Baselga, J; Crown, J; Currie, V; Fennelly, D; Gilewski, T; Hudis, C; Lebwohl, D; Moynahan, M; Norton, L; Raptis, G; Seidman, A; Sklarin, N; Surbone, A; Theodoulou, M; Uhlenhopp, M | 1 |
| Andreotti, PE; Bruckner, HW; Kolster, B; Krebs, D; Kurbacher, CM; Wagner, U | 1 |
| Delorme, F; Eisenhauer, EA; Higgins, BP; Letendre, F; Lofters, WS; Muldal, AM; Norris, BD; Trudeau, ME; Vandenberg, TA | 1 |
| Buzdar, A; Cohen, PR; Dhingra, K; Gagel, R; Holmes, F; Payne, JY | 1 |
| James, WD; Lee, N; Montemarano, AD; Sau, P; Weiss, RB; Young, PC | 1 |
| Guy, RK; Nicolaou, KC; Potier, P | 1 |
| Boesgaard, M; Dombernowsky, P; Ejlertsen, B; Gehl, J; Jensen, BW; Jensen, TP | 1 |
| Baselga, J; Currie, V; Fennelly, D; Gilewski, T; Hudis, CA; Lebwohl, D; Moynahan, ME; Raptis, G; Seidman, AD; Sklarin, N | 1 |
| Balis, FM; Barnes, CS; Berg, SL; Chang, R; Cowan, KH; Denicoff, AM; Fetsch, PA; Goldspiel, B; Gossard, MR; Noone, MH; O'Shaughnessy, JA; Ognibene, F; Solomon, D; Tolcher, AW; Venzon, DJ | 1 |
| Ayers, D; Bryce, C; Campbell, C; Coppin, C; Gelmon, KA; Healey, D; McDermott, B; Nakashima, L; O'Reilly, SE; Onetto, N; Plenderleith, IH; Ragaz, J; Tolcher, AW | 1 |
| Sharma, S | 1 |
| Perry, JR; Warner, E | 1 |
| Chillemi, S; Cusumano, V; Losi, E; Mancuso, G; Merendino, RA; Pastura, G; Rossano, F; Teti, G; Tomasello, F; Trifiletti, R | 1 |
| Aronadio, O; Costa, G; d'Aquino, S; Fulco, RA; Gangemi, RM | 1 |
| Akutsu, M; Kano, Y; Miura, Y; Suzuki, K; Tsunoda, S; Yazawa, Y | 1 |
| Bonneterre, J; Bontenbal, M; Catimel, G; Conte, P; Fumoleau, P; Gelmon, K; Klaassen, U; Nabholtz, JM; Namer, M; Spielmann, M; Winograd, B | 1 |
| Auguste, L; Baselga, J; Currie, V; Edelman, B; Fennelly, D; Francis, P; Gilewski, TA; Gollub, M; Hochhauser, D; Hudis, CA; Moynahan, ME; Norton, L; O'Donaghue, M; Salvaggio, R; Seidman, AD; Spriggs, D; Tong, W; Yao, TJ | 1 |
| DiPaola, RS; Kaufman, A; Mikhail, MM | 1 |
| Beijnen, JH; Huizing, MT; Mandjes, I; Pinedo, HM; Rosing, H; ten Bokkel Huinink, WW; Vermorken, JB | 1 |
| Chan, S; Gardner, S; Winterbottom, L | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L | 1 |
| Blum, R; Chachoua, A; Downey, A; Frazein, A; Hochster, H; Oratz, R; Sorich, J; Speyer, J; Wasserheit, C; Wernz, J; Zeleniuch-Jacquotte, A | 1 |
| Dawson, NA; Diehl, LF; Phillips, ET; Rickles, NM; Solimando, DA; Weiss, RB | 1 |
| Athanassiades, A; Bafaloukos, D; Dombros, N; Fountzilas, G; Giannakakis, T; Karakousis, K; Kosmidis, P; Skarlos, D | 1 |
| Lillis, P; McCarty, MJ; Peake, MF; Vukelja, SJ | 1 |
| Abe, K; Fujii, H; Igarashi, T; Itoh, K; Ohtsu, T; Sasaki, Y; Sekine, I; Wakita, H | 1 |
| Honig, SF; Swain, SM; Tefft, MC; Walton, L | 1 |
| Fulton, B; Spencer, CM | 1 |
| Bernacki, RJ; Ojima, I; Sharma, A; Straubinger, RM | 1 |
| Azli, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Misset, JL; Murawsky, M; Pouillart, P; Riva, A; Roche, H | 1 |
| Azli, N; Bougon, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, Y; Maugard-Louboutin, C; Misset, JL; Riva, A; Roche, H | 1 |
| Ogretmen, B; Safa, AR | 1 |
| Adachi, K; Akutsu, M; Ando, J; Ikeda, T; Inoue, Y; Kano, Y; Matsui, J; Suzuki, K; Tsunoda, S | 1 |
| Hung, MC; Li, J; Liu, B; Tan, M; Wang, SS; Yu, D | 1 |
| Bitton, R; Kohn, E; Reed, E; Sarosy, G | 1 |
| Eberhardt, W; Klaassen, U; Korn, M; Seeber, S; Strumberg, D; Wilke, H | 1 |
| Markman, M | 1 |
| Champlin, R; Deisseroth, AB; Holmes, F; Hortobagyi, G | 1 |
| Hájek, R; Slavik, M; Vorlicek, J | 1 |
| Chan, AT; Johnson, PJ; Leung, WT; Yeo, W | 1 |
| Armand, JP | 1 |
| Khayat, D | 1 |
| Azli, N; Bourgeois, H; Dieras, V; Fumoleau, P; Misset, JL; Pouillart, P | 1 |
| Archer, PG; Jones, RB; Merouani, A; Schrier, RW; Shpall, EJ | 1 |
| Booser, DJ; Buzdar, AU; Fraschini, G; Holmes, FA; Hortobagyi, GN; Madden, T; Newman, RA; Theriault, RL; Valero, V; Walters, RS; Willey, J | 1 |
| Hekmat, E | 1 |
| Awada, A; Bruning, P; Gamucci, T; Klijn, J; Kusenda, Z; Paridaens, R; Piccart-Gebhart, MJ; Roy, JA; Van Vreckem, A | 1 |
| Boesgaard, M; Dombernowsky, P; Gehl, J; Jensen, BV; Paaske, T | 2 |
| Amadori, D; Frassineti, GL; Gentile, A; Milandri, C; Ravaioli, A; Salzano, E; Tienghi, A; Zoli, W | 2 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Michelotti, A; Salvadori, B; Salzano, E; Tibaldi, C | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Giannessi, PG; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Klaassen, U; Seeber, S; Wilke, H | 2 |
| Hartmann, LC; Perez, EA | 1 |
| Boesgaard, M; Dombernowsky, P; Gehl, J; Paaske, T; Vittrup Jensen, B | 1 |
| Bamberg, M; Bokemeyer, C; Heneka, M; Kanz, L; Lampe, C; Schabet, M | 1 |
| Baldini, E; Conte, PF; Gennari, A; Michelotti, A; Salvadori, B; Tibaldi, C; Tognoni, A | 1 |
| Kennedy, MJ | 1 |
| Ingham, J; Lepore, J; Portenoy, R; Seidman, A; Yao, TJ | 1 |
| Campbell, N; Chan, YT; Chick, JB; Davidson, NG; Perren, TJ; Thompson, JM | 1 |
| Budman, DR; O'Mara, V; Weiselberg, L | 1 |
| Hoff, PM; Holmes, FA; Hortobagyi, GN; Hudis, C; Valero, V; Whealin, H | 1 |
| Verlag, GT | 1 |
| D'Amato, RJ; Flynn, E; Hamel, E; Klauber, N; Parangi, S | 1 |
| Dittrich, C; Fazeny, B; Grisold, W; Huber, H; Meryn, S; Zifko, U | 1 |
| Akerley, W | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Giannessi, PG; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Bearman, SI; Cagnoni, PJ; Jones, RB; Matthes, S; Ross, M; Shpall, EJ; Taffs, S | 1 |
| Kühnle, H | 1 |
| Christensen, C; Deppe, G; Lawrence, WD; Ruan, H; Saunders, DE; Wappler, NL | 1 |
| Cousins, JP; Harper, G | 1 |
| Coombes, RC; English, J; Lowdell, C; Rees, CN; Sinnett, D | 1 |
| Palackdharry, CS | 1 |
| Asanuma, F; Hoshiya, Y; Kitajima, M; Koh, JI; Kubota, T; Matsuzaki, SW; Watanabe, M; Yamada, Y | 1 |
| Capri, G; Gianni, L | 1 |
| Bonneterre, J; Catimel, G; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Spielmann, M; Tubiana-Hulin, M | 1 |
| Diergarten, K; du Bois, A; Hecker, D; Jänicke, F; Konecny, G; Kühnle, H; Lindner, C; Lisboa, BW; Lück, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Panagos, GE | 1 |
| Hande, KR; Johnson, DH; Paul, D | 1 |
| Keren-Rosenberg, S; Muggia, FM | 1 |
| Buzdar, AU; Champlin, R; Holmes, FA; Hortobagyi, GN; Ibrahim, N | 1 |
| Dobkin, J; Fracasso, PM; Luker, GD; Piwnica-Worms, D | 1 |
| Davison, JD; Francis, PA; Ganju, V; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC | 1 |
| Rodenhuis, S; ten Bokkel Huinink, WW; Westermann, AM | 1 |
| Klaassen, U; Seeber, S | 2 |
| Feenstra, J; Stricker, BH; Vermeer, RJ | 2 |
| DeNardo, DG; DeNardo, GL; DeNardo, SJ; Kroger, LA; Kukis, DL; Lamborn, KR; Meares, CF; Miers, LA; O'Donnell, RT | 1 |
| Baselga, J; Norton, L; Rosen, PP; Seidman, AD | 1 |
| Bhalla, K; Huang, Y; Ibrado, AM; Nawabi, A; Ray, S; Reed, JC; Tang, C | 1 |
| Preston, NJ | 1 |
| Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E | 1 |
| Caleffi, M; Ferreira Filho, AF; Kalakun, L; Koya, R; Mans, DR; Menke, CH; Pohlman, P; Schunemann, H; Schwartsmann, G; Venegas, LF; Xavier, N | 1 |
| Amadori, D; Frassineti, GL; Gentile, A; Milandri, C; Ravaioli, A; Salzano, E; Serra, P; Tienghi, A; Zoli, W | 1 |
| Du Bois, A; Hecker, D; Köhler, G; Lisboa, B; Lück, HJ; Thomssen, C; Untch, M | 1 |
| Achterrath, W; Borquez, D; Diergarten, K; Harstrick, A; Klaassen, U; Korn, M; Müller, C; Seeber, S; Wilke, H | 1 |
| Battaglia, M; Bertolini, F; Da Prada, GA; Gibelli, N; Pavesi, L; Pedrazzoli, P; Perotti, C; Preti, P; Robustelli della Cuna, G; Salvaneschi, L; Torretta, L | 1 |
| Glick, JH; Goldstein, LJ; Neuberg, D; Robert, NJ; Sledge, GW; Sparano, JA; Wood, W | 1 |
| Bonadonna, G; Capri, G; Giani, A; Gianni, L; Locatelli, A; Tarenzi, E; Viganò, L | 1 |
| Adamkiewicz, BB; Ellis, GK; Gralow, JR; Livingston, RB; Long, CA; McGuirt, C; White, R; Williams, MA | 1 |
| Browne, V; Champlin, RE; Johansen, MJ; Madden, T; Mehra, RC; Newman, RA; Rondon, G; Wood, JG | 1 |
| Bakogeorgou, E; Castanas, E; Hatzoglou, A | 1 |
| Claringbold, PG | 1 |
| Bell, DR; Bishop, JF; Friedlander, ML; Levi, JA; Michael, M; Olver, IN; Smith, JG; Toner, GC; Zalcberg, JR | 1 |
| Béhar, A; Brun, MD; Chauvin, FF; Feuilhade de Chauvin, F; Hille, D; Maurel, A; Oulid-Aissa, D; Pujade-Lauraine, E | 1 |
| Hortobágyi, G | 2 |
| Diéras, V | 3 |
| Delorme, F; Janowska, A; Mackey, J; Nabholtz, JM; Noel, D; Paterson, A; Riva, A; Smylie, M | 1 |
| Azli, N; Delecroix, V; Féty, R; Fumoleau, P; Perrocheau, G | 1 |
| Baldini, E; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Dell'Anna, R; Gennari, A; Gentile, A; Innocenti, F; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Bates, S; Fojo, T; Hose, C; Monks, A; Scala, S; Zhan, Z | 1 |
| Giannikos, L; Gogas, J; Kosmas, C; Polyzos, A; Tsavaris, N | 1 |
| Chun, MH | 1 |
| Tsukagoshi, S | 1 |
| Pestalozzi, BC | 1 |
| André, J; Song, M; Vandenbossche, L; Vandeveire, A; Vanhooteghem, O; Vindevoghel, A | 1 |
| Antoine, EC; Auclerc, G; Khayat, D; Rixe, O; Weil, M | 1 |
| Balmaceda, C; Brasher, P; DeAngelis, LM; Forsyth, PA; Peterson, K; Seidman, AD | 1 |
| Babcock, W; Birch, R; Buckner, CD; Campos, L; Drapkin, R; Grapski, R; Greco, FA; Hainsworth, J; Hazelton, B; Lautersztain, J; Schnell, F; Schwartzberg, LS; Schwerkoske, J; Weaver, CH | 1 |
| Egan, CL; Guzzo, CA; Laughinghouse, KA; Li, LJ; Tangoren, IA; Weinberg, JM | 1 |
| Di Leo, A; Piccart, MJ | 2 |
| Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G | 1 |
| Hung, MC; Ueno, NT; Yu, D | 1 |
| Awada, A; Bontenbal, M; Coleman, R; Klijn, J; Mauriac, L; Nooij, M; Paridaens, R; Piccart, MJ; Selleslags, J; Van Glabbeke, M; Van Vreckem, A | 1 |
| Cavalli, F; Cerny, T; de Jong, J; Goldhirsch, A; Martinelli, G; Pagani, O; Sessa, C; Zimatore, M | 2 |
| Bazarbashi, S; Berry, J; el-Warith, A; Ezzat, A; Rahal, M; Raja, MA; Zwaan, F | 1 |
| Bibby, MC; Nicholson, KM; Phillips, RM | 1 |
| Fukuoka, K; Saijo, N | 1 |
| Faivre, S; Goldwasser, F; Misset, JL; Soulié, P | 1 |
| Bombardelli, E; De Vincenzo, R; Distefano, M; Fattorossi, A; Ferlini, C; Gaggini, C; Mancuso, S; Ojima, I; Panici, PB; Riva, A; Scambia, G | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN; Rahman, Z; Theriault, RL | 1 |
| Garrett, M; Hande, KR; Johnson, DH; Nicholson, B; Paul, D; Shyr, Y | 1 |
| de Vries, EG; Haaxma-Reiche, H; Hofstra, LS; van der Graaf, WT; Willemse, PH | 1 |
| Von Hoff, DD | 1 |
| Antoine, E; Khayat, D | 1 |
| D'Andrea, GM; Seidman, AD | 1 |
| Antila, K; Ekholm, E; Rantanen, V; Salminen, E | 1 |
| Viens, P | 1 |
| Bonneterre, J; Launois, RJ; Reboul-Marty, JM | 1 |
| Abu-Rasmi, R; Drumea, K; Haim, N; Stein, ME | 1 |
| Panetta, JC | 1 |
| Chan, S | 1 |
| Aapro, MS; Alaki, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Melnychuk, D; Murawsky, M; Nabholtz, JM; Rapoport, B; Riva, A; Rosso, R; Thuerlimann, B; Trillet-Lenoir, V; Vandenberg, TA | 1 |
| al-Tweigeri, T; Au, D; Delorme, F; Mackey, JR; Nabholtz, JM; Noel, D; Paterson, AH; Riva, A; Sansregret, E; Smylie, M | 1 |
| Aapro, MS | 2 |
| Llombart-Cussac, A; Pivot, X; Spielmann, M | 1 |
| Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E | 1 |
| Agresti, R; Bertuzzi, A; Bonadonna, G; Capri, G; Gianni, L; Grasselli, G; Greco, M; Lombardi, F; Moliterni, A; Pilotti, S; Piotti, P; Salvadori, B; Tarenzi, E; Terenziani, M; Valagussa, P | 1 |
| Andersen, E; Boesgaard, M; Dombernowsky, P; Jensen, BV | 1 |
| Amadori, D; Frassineti, GL; Gentile, A; Gianni, L; Milandri, C; Salzano, E; Serra, P; Silvestro, L; Tienghi, A; Zoli, W | 1 |
| Barnabas, A; Benito, D; Colomer, R; Lluch, A; Martin, M; Massuti, B; Ojeda, B | 1 |
| Ames, F; Asmar, L; Buzdar, AU; Hortobagyi, GN; McNeese, M; Rahman, Z; Singletary, S; Theriault, RL | 1 |
| Diergarten, K; du Bois, A; Köhler, G; Lisboa, B; Lück, HJ; Thomssen, C; Untch, M | 2 |
| Fuechsel, G; Kettner, E; Köhler, U; Olbricht, SS; Richter, B; Ridwelski, K | 1 |
| Carmichael, J; Hutchinson, T; Jones, A | 1 |
| Dicato, M; Duhem, C; Kleiber, K; Ries, F | 1 |
| Borquez, D; Harstrick, A; Klaassen, U; Müller, C; Seeber, S; Wilke, H | 1 |
| Buzdar, AU; Holmes, FA; Hortobagyi, GN; Rahman, Z; Theriault, RL; Willey, J | 1 |
| Asbury, R; Boros, L; Chang, AY; Hui, L; Rubins, J | 1 |
| Currie, V; Gollub, M; Hudis, CA; McCaffrey, J; Moynahan, ME; Norton, L; Seidman, AD; Tepler, I; Theodoulou, M; Tong, W | 1 |
| Champlin, R; Frye, D; Hortobagyi, G; Mehra, R; Rahman, Z; Rondon, G; Valero, V | 1 |
| Gianni, L | 2 |
| Adkins, D; Ford, C; Reilly, W; Spitzer, G | 1 |
| Akerley, W; Cummings, F; Marchant, D; Safran, H; Sikov, WM; Strenger, R | 1 |
| Knobf, MT; Staugaard, C | 1 |
| Blackburn, BK; Carter, P; Lee, A; Mullins, S; Rodrigues, ML; Wirth, C | 1 |
| Conte, PF; Gennari, A | 1 |
| Baltali, E; Boyacioğlu, S; Haznedaroğlu, IC; Ustündağ, Y | 1 |
| Baldin, V; Barboule, N; Chadebech, P; Valette, A; Vidal, S | 1 |
| Bishop, JF; Macarounas-Kirchman, K | 1 |
| Bachelot, T; Biron, P; Blay, JY; Catimel, G; Chauvin, F; Droz, JP; Guastalla, JP; Merrouche, Y; Ray-Coquard, I | 1 |
| Dimitriadis, KA; Geromichalos, GD; Kortsaris, AH; Papazisis, KT | 1 |
| Huang, TS; Jee, SH; Kuo, ML; Shen, SC | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Emanuel, EJ; Patterson, WB | 1 |
| Costa, SD; von Minckwitz, G | 1 |
| Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L | 1 |
| Mayo, DJ | 1 |
| Hainsworth, JD | 1 |
| Nelson, NJ | 2 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Bergh, J; Freijs, A; Karlsson, MO; Larsson, R; Molnar, V | 1 |
| Clemons, M; Howell, A; Jayson, G; Leahy, M; Ranson, M; Valle, J | 1 |
| Baselga, J; Currie, V; Fennelly, D; Gilewski, T; Hellmann, S; Holmes, F; Hortobagyi, G; Hudis, C; Maickel, N; Moynahan, M; Norton, L; Raptis, G; Riccio, L; Seidman, A; Sklarin, N; Surbone, A; Uhlenhopp, M; Usakewicz, J; Yao, TJ | 1 |
| Aravantinos, G; Athanassiadis, A; Bafaloukos, D; Briasoulis, E; Dombros, N; Fountzilas, G; Ioannidis, I; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Skarlos, D | 1 |
| Rubens, RD | 1 |
| Azli, N; Diéras, V; Fumoleau, P; Kalla, S; Misset, JL; Pouillart, P | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Cottu, PH; Espié, M; Extra, JM; Marty, M | 1 |
| Bengala, C; Conte, PF; Favre, C; Greco, F; Macchia, P; Mazzoni, A; Menconi, MC; Pazzagli, I; Tibaldi, C; Vanacore, R | 1 |
| Balachandran, R; Day, BW; Grant, SG; ter Haar, E; Welsh, MJ | 1 |
| Benassai, G; Caponigro, F; Carola, M; Citarella, A; Facchini, G; Iaffaioli, RV; Marzano, N; Persico, G; Santangelo, M; Tortoriello, A | 1 |
| Ballaré, C; Mordoh, J; Portela, P; Schiaffi, J; Yomha, R | 1 |
| Baselga, J; Currie, V; Fennelly, D; Gilewski, T; Hudis, C; Keefe, D; Lebwohl, D; Moynahan, M; Norton, L; Raptis, G; Riccio, L; Seidman, A; Sklarin, N; Surbone, A; Yao, TJ | 1 |
| Hudis, CA | 2 |
| Muggia, F; O'Leary, J; Volm, M; Wasserheit, C | 1 |
| Casado, A; Diaz-Rubio, E; Garcia Carbonero, I; Martin, M; Perez Segura, P | 1 |
| Bengala, C; Conte, PF; Gennari, A; Pazzagli, C; Salvadori, B | 1 |
| Aravantinos, G; Athanassiades, A; Bafaloukos, D; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Nicolaides, C; Papadimitriou, V; Papakostas, P; Razi, E; Xiros, N | 1 |
| Bowling, K; Chen, TL; Donehower, RC; Duerr, M; Grochow, LB; Kennedy, MJ; Noe, D; Rowinsky, EK; Sartorius, S; Zahurak, ML | 1 |
| Fruehauf, JP; Garcia, R; Kim, H; Kyshtoobayeva, A; Mechetner, E; Parker, RJ; Stroup, R; Zonis, S | 1 |
| Achterrath, W; Eberhardt, W; Harstrick, A; Klaassen, U; Lenaz, L; Neumann, K; Philippou Pari, C; Seeber, S; Strumberg, D; Wilke, H | 1 |
| Calcutt, NA; Campana, WM; Eskeland, N; Misasi, R; Myers, RR; O'Brien, JS | 1 |
| Buckwalter, CA; Perez, EA | 1 |
| Haskill, JS; Lee, LF; Martin, BK; Ting, JP; White, CM | 1 |
| Das, B; Madhubala, R; Rao, AR | 1 |
| Cherney, B; Fan, S; O'Connor, PM; Reinhold, W; Rucker, K | 1 |
| Bhalla, K; Harris, WB | 1 |
| Mamounas, EP | 1 |
| Spencer, CM; Wiseman, LR | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 2 |
| Hortobagyi, GN; Hung, MC; Ibrahim, N; Jing, T; Liu, B; Price, JE; Singletary, SE; Sun, D; Yu, D | 1 |
| Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Heimenz, JW; Kronish, LA; Partyka, JS; Perkins, JB; Saez, RA; Sullivan, DM | 1 |
| Cho-Chung, YS; Korsmeyer, SJ; Longo, DL; Nesterova, M; Srivastava, AR; Srivastava, RK | 1 |
| Di Nunno, L; Herrington, JD; Rinehart, JJ | 1 |
| Andres, JL; Fan, S; Goldberg, ID; Lamszus, K; Rosen, EM; Turkel, GJ; Twu, NF; Wang, JA; Yuan, RQ | 1 |
| Eliel, MR; Nortier, JW; Rodenburg, CJ; Slee, PH | 1 |
| Eland, IA; Krommendijk, R; Otter, R; Stricker, BH | 1 |
| Bressolle, F; Grosse, PY; Pinguet, F | 1 |
| Diergarten, K; Eberhardt, W; Hanske, M; Harstrick, A; Klaassen, U; Korn, M; Müller, C; Seeber, S; Weyhofen, R; Wilke, H | 1 |
| Ansari, R; Bitran, JD; Fasanmade, AA; Fleming, GF; Hoffman, PC; Klepsch, A; Kugler, JW; Malone, D; Ratain, MJ; Vokes, EE | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Heras, P; Kakolyris, S; Kourousis, C; Samonis, G; Vamvakas, L; Vlachonicolis, J; Vlata, M | 1 |
| Hoefnagel, CA; ten Bokkel Huinink, WW; Valdés Olmos, RA | 1 |
| Bauknecht, T; Häring, B; Hauns, B; Maier-Lenz, H; Meerpohl, HG; Mross, K; Unger, C | 1 |
| Robertson, D | 1 |
| Albanell, J; Baselga, J; Kim, YM; Mendelsohn, J; Norton, L | 1 |
| Adachi, I; Ando, M; Fujii, H; Igarashi, T; Itoh, K; Katsumata, N; Narabayashi, M; Ohtsu, T; Omuro, Y; Sasaki, Y; Taguchi, T; Tokue, Y; Wakita, H; Watanabe, T; Ying, DF | 1 |
| Ball, E; deMagalhaes-Silverman, M; Hammert, L; Lembersky, B; Lister, J; Rybka, W | 1 |
| Antman, K; Ayello, J; Bagiella, E; Balmaceda, C; Dunleavy, J; Fung, B; Garrett, T; Heitjan, D; Hesdorffer, C; Kaufman, E; McGovern, T; Papadopoulos, K; Savage, D; Tiersten, A; Vahdat, LT | 1 |
| Binderup, L; Koeffler, HP; Koike, M; Koshizuka, K; Kubota, T; Said, J | 1 |
| Au, JL; Gan, Y; Lu, J; Wientjes, MG | 1 |
| Barbarulo, D; Budillon, A; Capasso, I; Caponigro, F; Caratení, G; Casaretti, R; Comella, G; Comella, P; D'Aiuto, G; Daponte, A; Frasci, G; Gentile, A; Gravina, A; Maiorino, L; Thomas, R | 1 |
| Barrett, JC; Baserga, R; Dunn, SE; Ehrlich, M; Hawkins, R; Reiss, K; Sharp, NJ; Solomon, G | 1 |
| Bombardelli, E; De Vincenzo, R; Distefano, M; Ferlini, C; Filippini, P; Gallo, D; Mancuso, S; Riva, A; Scambia, G | 1 |
| Bastert, G; Diel, IJ; Emig, R; Meyberg, G; Sinn, HP; Solomayer, EF; Wallwiener, D | 1 |
| McCauley, MD; Ogretmen, B; Safa, AR | 1 |
| Adelantado, S; González, P; Iñiguez, C; Larrodé, P; Mayordomo, JI; Morales, F; Trés, A; Yubero, A | 1 |
| Gooch, JL; Lee, AV; Yee, D | 1 |
| Bontenbal, M; de Wit, R; Klijn, JG; Seynaeve, C | 1 |
| Bissery, MC; Fellous, A; Martinez, C; Veitia, R | 1 |
| Arlet, P; Auvinet, M; Dahan, S; Dingremont, C; Juchet, H; Ollier, S | 1 |
| Tankanow, RM | 1 |
| Albanel, J; Albanell, J; Baselga, J; Currie, V; Gollub, M; Hudis, CA; Moynahan, ME; Norton, L; Seidman, AD; Tepler, I; Theodoulou, M; Tong, W | 1 |
| Booser, DJ; Burris, HA; Earhart, RH; Erban, JK; Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Jones, SE; Mennel, RG; Rahman, Z; Ravdin, PM; Schottstaedt, MW; Valero, V; Von Hoff, DD | 1 |
| Grinblatt, DL; Malloy, R; Williams, SF; Zimmerman, TM | 1 |
| Kosmas, C; Tsavaris, NB | 1 |
| Paridaens, R; Thomas, J; Van Oosterom, A; Van Vaerenbergh, W; Wildiers, J | 1 |
| Jackisch, C | 1 |
| Crompton, NE; Haller, U; Hornung, R; Jentsch, B; Keefe, KA; Köchli, OR; Perewusnyk, G; Walt, H | 1 |
| Archer, CD; Coombes, RC; English, J; Khan, S; Lowdell, C; Sinnett, HD | 1 |
| Fan, W; Johnson, KR; Miller, MC; Wang, L; Willingham, MC | 1 |
| Davidson, NE; Kaufmann, SH; McCloskey, DE; Prestigiacomo, LJ | 1 |
| Aravantinos, G; Athanassiades, A; Bafaloukos, D; Dimopoulos, AM; Fountzilas, G; Kalogera-Fountzila, A; Keramopoulos, A; Kosmidis, P; Nicolaides, C; Papadimitriou, C; Pavlidis, N; Skarlos, D | 1 |
| Asanuma, F; Kawamura, E; Kobayashi, H; Kubota, T; Lee, K; Suzuki, T; Yamada, T; Yamada, Y | 1 |
| Beijnen, JH; Dubbelman, RC; Hillebrand, MJ; Koopman, FJ; Panday, VR; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Tellingen, O | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Andreeff, M; Bachier, C; Berenson, R; Calvert, L; Champlin, R; Claxton, D; Dayne, A; Deisseroth, A; Ellerson, D; Fu, S; Gajewski, J; Giles, R; Hamer, J; Hanania, E; Heimfeld, S; Holmes, F; Holzmayer, T; Kavanagh, J; Kudelka, A; Mechetner, E; Mehra, R; Ostrove, J; Rahman, Z; Verschraegen, C; Zu, Z | 1 |
| Akrivakis, C; Flath, B; Lüftner, D; Mergenthaler, HG; Petrides, PE; Possinger, K; Prinz, B; Schweigert, M; Wernecke, KD | 1 |
| Hilkens, PH; Pronk, LC; Stoter, G; van den Bent, MJ; van Putten, WL; Verweij, J | 1 |
| Hung, MC; Jing, T; Liu, B; McDonnell, TJ; Tan, M; Yao, J; Yu, D | 1 |
| Abe, R; Horikoshi, N; Ito, Y; Kitajima, M; Kobayashi, T; Koyama, H; Kuraishi, Y; Nomura, Y; Ogawa, M; Okawa, T; Orita, K; Sasaki, Y; Tabei, T; Takashima, S; Tamura, K; Tominaga, T; Watanabe, T; Yamaguchi, S | 1 |
| Arnold, A; Cano, P; Dorreen, M; Dulude, H; Gallant, G; Germond, C; Glück, S; Koski, T; Lopez, P | 1 |
| Berrettini, S; De Vito, A; Pazzagli, I; Tibaldi, C | 1 |
| Coniglio, D; Elkordy, M; Fishman, R; Gilbert, C; Hussein, A; Matters, L; Peters, WP; Petros, W; Ross, M; Rubin, P; Vredenburgh, J | 1 |
| Bearzatto, A; Costa, A; Santi, S; Silvestrini, R; Villa, R; Zaffaroni, N | 1 |
| Balog, A; Bertino, JR; Chou, TC; Danishefsky, SJ; Harris, CR; Kuduk, SD; Savin, KA; Zhang, XG | 1 |
| Ayers, D; Bryce, C; Campbell, C; Dulude, H; Gelmon, KA; Nakashima, L; O'Reilly, S; Ragaz, J; Rielly, S; Shenkier, T; Tolcher, A | 1 |
| Cuvier, C; Espié, M; Gorins, A; Marty, M | 1 |
| Crown, J; Nabholtz, JM | 1 |
| Colombo, T; D'Incalci, M; Riva, A; Schüller, J; Zucchetti, M | 1 |
| Paridaens, R | 1 |
| Aapro, M | 1 |
| Crown, J | 5 |
| Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Pagani, O | 1 |
| Löffler, TM | 1 |
| Canfield, VA; Geyer, CE; Goodwin, DK; Green, SJ; Martino, S; Meyers, FJ; Moinpour, CM; O'Sullivan, J; Osborne, CK | 1 |
| Bastert, G; Goldschmidt, H; Haas, R; Hohaus, S; Huober, J; Martin, S; Meyer, A; Schneeweiss, A; Wallwiener, D; Wittmann, G | 1 |
| Brown, RE; Hutton, J | 1 |
| Espie, M | 1 |
| de Boer-Dennert, M; Pronk, LC; Stoter, G; van Beurden, V; van Putten, WL; Verweij, J | 1 |
| Hagen, K; Kong, AN; Mandlekar, S; Roninson, IB; Shtil, AA; Tan, TH; Walter, RJ; Yu, R | 1 |
| Amadori, D; Barzanti, F; Casadei Giunchi, D; Dal Susino, M; Frassineti, GL; Milandri, C; Ricotti, L; Zoli, W | 1 |
| Frackelton, AR; Ravichandran, KS; Stevenson, LE | 1 |
| Ettenberg, SA; Keane, MM; Lipkowitz, S; Nau, MM; Russell, EK | 1 |
| Baselga, J; D'Andrea, G; Fennelly, D; Gilewski, T; Hudis, C; Moynahan, ME; Norton, L; Raptis, G; Seidman, AD; Sklarin, N; Surbone, A; Templeton, MA; Theodoulou, M; Yao, TJ | 1 |
| Bömecke, M; Hess, CF; Lehmann, J; Meden, H; Pradier, O; Rave-Fränk, M; Schmidberger, H | 1 |
| Akutsu, M; Ando, J; Furuta, M; Kano, Y; Tsunoda, S; Yazawa, Y | 1 |
| Bombardelli, E; Polizzi, D; Pratesi, G; Riva, A; Supino, R; Tortoreto, M; Zunino, F | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J | 1 |
| Egorin, MJ; Fry, D; Gradishar, WJ; Liebes, L; Mendoza, S; Sparano, JA; Speyer, J; Sridhara, R | 1 |
| Miller, KD; Sledge, GW | 2 |
| Blum, JL; Brown, CS; Burger, HU; Buzdar, AU; Griffin, T; Jones, SE; Kuter, I; LoRusso, PM; Osterwalder, B; Vogel, C | 1 |
| Barrett-Lee, PJ; Bizzari, JP; Eggleton, SP; Leonard, RC; O'Brien, ME | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Hardwick, JM; Longo, DL; Mi, QS; Srivastava, RK | 1 |
| Buckner, CD; Franco, C; Hazelton, B; Moore, M; Schwartzberg, LS; Smith, R; Van Amburg, A; Weaver, CH; White, L; Zhen, B | 1 |
| Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M | 1 |
| Lønning, PE | 1 |
| Berdeaux, G; Hurteloup, P | 1 |
| Bonneterre, J; Henry, B; Launois, R; Reboul-Marty, J | 1 |
| Perez, EA | 2 |
| Birch, R; Buckner, CD; Giudice, R; Kalman, L; Schnell, F; Schwartzberg, LS; Sobong, E; Weaver, CH | 1 |
| Bressolle, F; Culine, S; Pinguet, F; Roch, I; Romieu, G | 1 |
| Janowska-Wieczorek, A; Mackey, J; Nabholtz, JM; Smylie, M; Tonkin, K | 1 |
| Cohen, D; Danenberg, PV; Formenti, SC; Skinner, K; Spicer, D; Symmans, WF; Volm, M | 1 |
| Agrawal, S; Bianco, AR; Caputo, R; Ciardiello, F; Mendelsohn, J; Pepe, S; Pomatico, G; Tortora, G | 1 |
| Culine, S | 1 |
| Da Prada, GA; della Cuna, GR; Pedrazzoli, P; Ponchio, L; Zibera, C | 1 |
| Baly, D; Beryt, M; Coombs, D; Hsu, S; Kabbinavar, F; Lewis, G; Pegram, M; Pietras, R; Slamon, D; Sliwkowski, M | 1 |
| Ellis, GK; Gralow, JR; Livingston, RB; Pierce, HI; Williams, MA | 1 |
| Aapro, M; Alakl, M; Bezwoda, WR; Deschênes, L; Douma, J; Drbal, J; Genot, JY; Hupperets, PS; Melnychuk, D; Molino, A; Murawsky, M; Nabholtz, JM; Nagykalnai, T; Nortier, JW; Pannuti, F; Rapoport, B; Richel, DJ; Rosso, R; Senn, HJ; Siedlecki, P; Skarlos, D; Tomiak, EM; Trillet-Lenoir, V; Vandenberg, TA; Wilking, N | 1 |
| Armstrong, DK; Blajeski, AL; Davidson, NE; Earnshaw, WC; Kaufmann, SH; Kottke, TJ; Martins, LM; Mesner, PW | 1 |
| Nabholtz, JM; Vogel, CL | 1 |
| Lamb, HM; Wiseman, LR | 1 |
| Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E | 1 |
| Ciolino, HP; Daschner, PJ; Plouzek, CA; Yeh, GC | 1 |
| Asmar, L; Booser, DJ; Buzdar, AU; Fraschini, G; Frye, D; Gibbs, H; Holmes, FA; Hortobagyi, GN; Theriault, RL; Valero, V; Walters, RS; Willey, J | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Francis, P; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Strickland, A; Toner, GC; Wolf, M; Zalcberg, J | 1 |
| Beijnen, JH; Koopman, FJ; Panday, VR; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Vermorken, JB | 1 |
| Azevedo, C; Braga Cruz, F; Correia, O; Pinto Ferreira, E; Polónia, J | 1 |
| Abe, R; Kimijima, I; Ohtake, T; Sagara, H; Tsuchiya, A; Watanabe, T | 1 |
| Asmar, L; Hortobagyi, GN; Pivot, X | 1 |
| Kaufman, PA | 1 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; Salter, E; Smylie, M; Tonkin, K | 1 |
| Kokawa, Y; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tamaki, T; Tanino, H; Umemura, T; Yoshimura, G | 1 |
| Bauer, J; Borner, M; Buonadonna, A; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Martinelli, G; Pagani, O; Riva, A; Sessa, C; Thürlimann, B; Zampino, G; Zimatore, M | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kouroussis, C; Malamos, N; Mavroudis, D; Panagos, G; Papadouris, S; Potamianou, A; Samonis, G; Sara, E; Xydakis, E | 1 |
| Aussel, JP; Azli, N; Beuzeboc, P; Bourgeois, H; Bozec, L; Cvitkovic, E; Dieras, V; Gruia, G; Jasmin, C; Kalla, S; Misset, JL; Pouillart, P; Riva, A | 1 |
| Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L | 1 |
| Geoffroy, FJ; Grem, JL; Kao, V; Monahan, BP; Nguyen, D | 1 |
| Blohmer, JU; Costa, SD; Dresel, V; Eidtmann, H; Gademann, G; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; von Minckwitz, G | 1 |
| Abati, A; Carter, C; Chang, YN; Chiang, Y; Chow, C; Cowan, KH; Cusack, G; Dunbar, C; Goldspiel, B; Gottesman, MM; Hines, K; Huang, H; Leitman, SF; McDonagh, K; Moscow, JA; Nienhuis, A; Noone, M; O'Shaughnessy, J; Pastan, I; Read, EJ; Schneider, E; Sorrentino, B; Steinberg, S; Wilson, W; Zujewski, JA | 1 |
| Delohery, TM; Motwani, M; Schwartz, GK | 1 |
| Blum, JL | 1 |
| Blanke, C; Cohen, A; Dickson, NR; Hande, K; Johnson, D; Nicholson, BP | 1 |
| Benner, S; Borquez, D; Harstrick, A; Klaassen, U; Lang, S; Oberhoff, C; Seeber, S | 1 |
| Dethling, J; Kühnle, H; Lück, HJ; Scholz, U | 1 |
| Chadderton, A; Gannon, BR; Glück, S; Kirwan-rhude, AF; Parissenti, AM; Villeneuve, DJ | 1 |
| Akrivakis, C; Flath, B; Lüftner, D; Mergenthaler, HG; Possinger, K; Prinz, B; Wernecke, KD | 1 |
| Chen, L; Fan, W; Willingham, MC; Zheng, S | 1 |
| Alexopoulos, A; Alexopoulos, CG; Efremidis, AP; Papacharalambous, A; Patila, E; Rigatos, G; Vassilomanolakis, M | 1 |
| Hamaguchi, Y; Hasegawa, S; Hisatomi, H; Ichikawa, Y; Ishikawa, T; Kamiyama, M; Momiyama, N; Narita, T; Shimada, H | 1 |
| Amato, S; Barbieri, M; Fasce, H; Grasso, S; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Pérez, J; Rodríguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Vallejo, C | 1 |
| Baselga, J; Crown, JP; Fennelly, D; Gilewski, T; Hudis, C; Lebwohl, D; Moynahan, M; Norton, L; Raptis, G; Riedel, E; Seidman, A; Sklarin, N; Surbone, A; Uhlenhopp, M; Yao, TJ | 1 |
| Adams, LM; Buchbinder, A; Budman, DR; Donahue, L; Lichtman, SM; O'Mara, V; Weiselberg, L | 1 |
| Barbaroux, C; de Cremoux, P; Dieras, V; Liva, S; Magdelenat, H; Martin, EC; Pouillart, P; Sastre-Garau, X; Vincent-Salomon, A | 1 |
| Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S | 1 |
| Alvarez, A; Balbiani, L; Bertoncín, AM; Breier, S; Cazap, E; Cóppola, F; Di Notto, MR; Estévez, R; Grasso, S; Jovtis, S; Lewi, D; Mickiewicz, E; Pascual, M; Pazos, C; Róndinón, M; Suárez, A; Témperley, G; Trigo, M; Triguboff, E; Uranga, G; Ventriglia, M | 1 |
| Aiba, K; Hanai, M; Horikoshi, N; Ito, Y; Osawa, H; Takahashi, S; Uno, S; Yamada, Y | 1 |
| Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Yoneda, K | 1 |
| Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J | 1 |
| Chen, X; Germond, C; Wang, Z; Yeung, TK | 1 |
| Bergh, J; Freijs, A; Karlsson, MO; Larsson, R; Molnar, V; Nygren, P | 1 |
| Fan, W; Johnson, KR; Young, KK | 1 |
| Aritake, N; Fukunaga, M; Gotoh, K; Hasegawa, S; Imamoto, H; Kan, K; Kim, Y; Maruyama, H; Oozato, H; Takatsuka, Y; Touno, T; Yamazaki, K | 1 |
| Hada, M; Hagiwara, J; Kamiya, K; Koshizuka, K; Muto, S; Nakagomi, H; Tada, Y; Takano, K | 1 |
| Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S; Yazawa, Y | 1 |
| Loesch, DM; McCaskill-Stevens, W; Miller, KD; Monaco, F; Seshadri, R; Sisk, J; Sledge, GW | 1 |
| Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B | 1 |
| Dranitsaris, G; Leung, PP; Oza, AM; Puodziunas, A; Tannock, IF | 1 |
| Fox, KC; Gendron, K; Maguire, AM; Piccone, MR | 1 |
| Bast, R; Buzdar, AU; Hortobagyi, GN; Ibrahim, NK; Murray, JL; Rahman, Z; Theriault, RL; Valero, V; Willey, J | 1 |
| Da Prada, GA; Gibelli, N; Lanza, A; Pedrazzoli, P; Perotti, C; Ponchio, L; Robustelli della Cuna, G; Salvaneschi, L; Torretta, L; Zambelli, A; Zibera, C | 1 |
| Anibali-Charpiat, MF; Calluaud, L; Fabre-Guillevin, E; Ravaud, A; Tchen, N | 1 |
| Gooch, JL; Van Den Berg, CL; Yee, D | 1 |
| Akutsu, M; Ando, J; Kano, Y; Suzuki, K; Tsunoda, S | 1 |
| Moiseenko, VM; Orlova, RV | 1 |
| Anderson, SJ; Atkins, JH; Baez, L; Bearden, JD; Brown, AM; Davila, E; DeFusco, PA; Lembersky, BC; Mamounas, EP; Shibata, HR; Smith, RE; Thirlwell, MP; Tipping, SJ | 1 |
| Ames, F; Asmar, L; Booser, DJ; Buzdar, AU; Frye, D; Hortobagyi, GN; Hunt, K; Ibrahim, N; Kau, SW; Manuel, N; McNeese, M; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Valero, V | 1 |
| Bengala, C; Bruzzi, P; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Gennari, A; Orlandini, C; Salvadori, B | 1 |
| Fan, W; Johnson, KR; Miller, MC; Willingham, MC | 1 |
| Choy, H | 1 |
| Abella, E; Baynes, R; Cassells, L; Couwlier, C; Dansey, R; Flowers, M; Hamm, C; Karanes, C; Klein, J; Peters, W; Rey, P | 1 |
| Kadota, M; Masuda, N; Miyazaki, M; Monden, M; Ohue, M; Ooka, M; Sakita, I; Sekimoto, M; Tamaki, Y; Tomita, N | 1 |
| Harada, K; Konishi, T; Maeda, Y; Mori, N; Nishida, M; Oka, M; Somura, H; Takao, T; Tamesa, T; Tangoku, A | 1 |
| Kim, SJ; Maeura, Y; Matsunaga, S; Saito, M; Ueda, N | 1 |
| Bergman, M; Ekholm, E; Huhtala, S; Salminen, E | 1 |
| Angiolini, C; Bergaglio, M; Del Mastro, L; Esposito, M; Garrone, O; Lunardi, G; Rosso, R; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M | 1 |
| Blohmer, JU; Costa, SD; Eiermann, W; Jackisch, C; Kaufmann, M; Tulusan, AH; von Minckwitz, G | 1 |
| Alakl, M; Bodrogi, I; Buzzi, F; Chan, S; Crown, J; Duarte, R; Friedrichs, K; Gil Gil, M; González Mancha, R; Korec, S; Murawsky, M; Murray, E; Noel, D; Pintér, T; Richardson, G; Riva, A; Ronzoni, M; Simmonds, P; Van Belle, S; von Minckwitz, G; Vorobiof, D; Walpole, E; Yelle, L | 1 |
| Ackland, S; Bishop, JF; Canetta, R; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Smith, J; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E | 1 |
| Apicella, A; Bianchi, U; Biglietto, M; Capasso, I; Cartenì, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Lapenta, L; Maiorino, L; Piccolo, S; Thomas, R | 1 |
| Falkson, CI; Hu, P; Rao, RM; Sparano, JA; Wolff, AC; Wood, WC | 1 |
| Hayashi, K; Kuroi, K; Nagai, S; Toi, M; Tominaga, T | 1 |
| Funahashi, H; Hayashi, H; Imai, T; Itoh, T; Kikumori, T; Mase, T; Oiwa, M; Sekiya, M; Shibata, A | 1 |
| Balmaceda, C; Hesdorffer, CS; Lee, RT; Oster, MW; Papadopoulos, KP; Vahdat, LT | 1 |
| Bilgrami, SA; Sporn, JR | 1 |
| Gnant, M; Jakesz, R; Locker, GJ; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Alavarez, JG; Duda, RB; Li, MZ; Navas, V; Toy, BR; Zhong, Y | 1 |
| Blume, KG; Chao, NJ; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Chabner, BA; Duan, Z; Feller, AJ; Penson, RT; Seiden, MV | 1 |
| Bianchi, AB; Girit, E; Hellström, I; Hellström, KE; Henderson, AJ; Lasch, S; Trail, PA; TrailSmith, MD; Willner, D | 1 |
| Arakawa, H; Kodera, T; Morishima, H; Morita, M; Nishimura, S; Ohkubo, M; Okura, A | 1 |
| Miller, M | 1 |
| Huang, P; Ke, S; Li, C; Oldham, EA; Wallace, S | 1 |
| Bishop, WR; Chen, J; Ferrari, E; Gurnani, M; Hajian, G; Lipari, P; Liu, M; Malkowski, M; Nielsen, LL; Shi, B; Yaremko, B | 1 |
| Blohmer, JU; Elling, D; Fleige, B; Grineisen, Y; Kissner, L; Lichtenegger, W; Paepke, S | 1 |
| Anderson, H; Bengtsson, NO; Bergh, J; Blomqvist, C; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Palm-Sjövall, M; Pluzanska, A; Sjöström, J; Valvere, V; Wist, E | 1 |
| Fitch, TR; Hartmann, LC; Hatfield, AK; Hillman, DW; Ingle, JN; Kardinal, CG; Krook, JE; Mailliard, JA; Nair, S; Perez, EA; Stella, PJ | 1 |
| Crown, JP | 2 |
| Antman, KH; Ayello, J; Hesdorffer, CS; Kaufman, E; Papadopoulos, KP; Reiss, RF; Troxel, A; Vahdat, LT | 1 |
| Heys, SD; Hutcheon, AW; Smith, IC | 1 |
| Burton, GV; Johnson, DM; Middlebrooks, M; Mills, KM | 1 |
| Le Cesne, A; Llombart, A; Rixe, O; Spielmann, M; Sverdlin, R; Zelek, L | 1 |
| Cortesi, E; Leone, G; Mancuso, S; Martelli, O; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Amodio, A; Belli, F; Conti, F; Di Lauro, L; Gionfra, T; Lopez, M; Vici, P | 1 |
| Lyerly, HK; Morse, MA; Vredenburgh, JJ | 1 |
| Alexandre, J; Bensmaïne, A; Bleuzen, P; Bonneterre, J; Chahine, A; Cvitkovic, E; Faivre, S; Guastalla, J; Mahjoubi, M; Marty, M; Misset, JL; Spielman, M; Sutherland, W; Viens, P | 1 |
| Gnant, M; Jakesz, R; Janschek, E; Kandioler-Eckersberger, D; Kappel, S; Ludwig, C; Mittlböck, M; Rudas, M; Schlagbauer-Wadl, H; Steger, G; Wenzel, C | 1 |
| Doi, K; Inoue, K; Ishihara, A; Kimura, Y; Kudo, S; Ochiai, T; Ohchi, T; Sakae, T; Sakamoto, T; Takahashi, M | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Olszewski, W | 1 |
| Awada, A; Biganzoli, L; Bruning, P; Coleman, R; Gamucci, T; Houston, S; Klijn, JG; Paridaens, R; Piccart, M; Schachter, J; Sylvester, R; Van Vreckem, A; Wildiers, J | 1 |
| Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Kazierad, D; Khan, AM; Khan, IA; Rodriguez-Pinero, F; Tutschka, PJ | 1 |
| Ayala, F; de Arriba, F; Gómez-Espuch, J; Lozano, ML; Moraleda, JM; Ortuño, F; Vallejo, C; Vicente, V | 1 |
| Bergerat, JP; Bonneterre, J; Bourgeois, H; Chollet, P; Fumoleau, P; Guastalla, JP; Mahjoubi, M; Marty, M; Mauriac, L; Misset, JL; Namer, M; Roché, H; Spielman, M; Trandafir, L; Viens, P | 1 |
| Boehnke-Michaud, L; Buzdar, AU; Dubrow, RA; Hortobagyi, GN; Ibrahim, NK; Lynch, PM; Sahin, AA; Valero, V | 1 |
| Acciarri, R; De Giorgi, U; Fiorentini, G; Marangolo, M; Rosti, G | 1 |
| Canetta, R; Lebwohl, DE | 1 |
| Alfonso, R; Casado, A; de Paz, L; Diaz-Rubio, E; Esteban, C; García-Conde, J; Garciía Carbonero, I; Insa, A; Lluch, A; Martín, M | 1 |
| Almagro, M; Fonseca, E; Garcia, J; Pozo, JD; Vasquez, A | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; De Paz, L; Fernández, Y; Guillem, V; Llombart, A; Lluch, A; Ojeda, B | 1 |
| Ajaikumar, BS; Cleveland, MG; Reganti, R | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM | 1 |
| Bunnell, CA; Burstein, HJ; Clarke, KD; Garber, JE; Manola, J; Matulonis, UA; Parker, LM; Scheib, R; Shulman, LN; Winer, EP; Younger, J | 1 |
| Hejaz, HA; Potter, BV; Purohit, A; Reed, MJ; Singh, A | 1 |
| Ames, FC; Buzdar, AU; Feig, BW; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Vlastos, G | 1 |
| Aiba, K | 1 |
| Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yamamiti, N; Yoshimasu, T | 1 |
| Bergh, J | 1 |
| Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA | 1 |
| Chen, L; Willingham, MC; Zheng, S | 1 |
| de Matteis, A; Landi, G; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Ang, P; Cheong, WK; Khoo, KS | 1 |
| Czerwenka, K; Elahi, F; Greinix, HT; Hoecker, P; Jakesz, R; Kalhs, P; Kubista, E; Linkesch, W; Neumeister, G; Rabitsch, W; Schulenburg, A; Seifert, M; Steger, G; Zielinski, C | 1 |
| Antoine, EC; Coeffic, D; Khayat, D | 1 |
| Anthony, SP; Davis, SA; Hamilton, JW; Ihnat, MA; Kaltreider, RC; Lariviere, JP; Nervi, AM; Pesce, CA; Warren, AJ | 1 |
| Blanco Sequeiros, G; Jekunen, AP; Kaleva-Kerola, J; Maiche, AG | 1 |
| Bartholomeus, S; Crown, J; Di Leo, A; Dolci, S; Duffy, K; Larsimont, D; Nogaret, JM; O'Higgins, N; Paesmans, M; Piccart, MJ; Riva, A; Rowan, S | 1 |
| Corso, F; Florentine, B; Formenti, SC; Lomis, TJ; Silberman, H; Skinner, KA; Spicer, D | 1 |
| Avril, N; Dose, J; Graeff, H; Jänicke, F; Kuhn, W; Nährig, J; Römer, W; Sattler, D; Schelling, M; Schwaiger, M; Werner, M | 1 |
| Ah-See, AK; Chilcott, F; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Payne, S; Sharp, PF; Smith, IC; Waikar, S; Welch, AE; Whitaker, T | 1 |
| Christakos, S; Uytingco, MS; Wang, Q; Wieder, R; Yang, W | 1 |
| Figgitt, DP; Wiseman, LR | 1 |
| Carpino, A; Cognetti, F; D'Ottavio, AM; Ferraresi, V; Giannarelli, D; Marsella, A; Milella, M; Nisticò, C; Papaldo, P; Terzoli, E; Thorel, MF; Vaccaro, A | 1 |
| Awasthy, BS; Gairola, M; Julka, PK; Rath, GK; Sharma, DN | 1 |
| Amano, G; Furuta, A; Harada, Y; Ikegaki, H; Kijima, G; Ohnuki, K; Ohuchi, N; Satomi, S; Yoshida, R | 1 |
| Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E | 1 |
| Crown, J; O'Leary, M | 1 |
| McNeil, C | 1 |
| Chen, Z; Fei, H; He, Z; Liu, S; Shen, Z; Yuan, J | 1 |
| Au, HJ; Au, R; Mackey, J; Morrish, D; Nabholtz, JM; North, S; Salter, E; Smylie, M; Tonkin, K | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P | 1 |
| Angiolini, C; Bertelli, G; Del Mastro, L; Esposito, M; Lunardi, G; Numico, G; Pastrone, I; Rosso, R; Straneo, M; Tolino, G; Vannozzi, MO; Venturini, M; Viale, M | 1 |
| Antila, KJ; Ekholm, EM; Huikuri, HV; Jalonen, J; Rantanen, VT; Salmi, TA; Salminen, EK | 1 |
| Adamson, B; Anderson, DN; Braverman, AS; Hussain, S; McManus, M; Salvatti, ME | 1 |
| Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Du, W; Hamm, C; Karanes, C; Klein, JL; Peters, WP; Rey, PM | 1 |
| Brodowicz, T; Herscovici, V; Koestler, WJ; Steger, GG; Tomek, S; Vaclavik, I; Wiltschke, C; Zielinski, CC | 1 |
| Blais, DE; Chadderton, A; Gannon, BR; Gluck, S; Kirwan-Rhude, AF; Parissenti, AM; Villeneuve, DJ | 1 |
| Rajdev, L; Sparano, JA | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Baek, HS; Yoo, WH | 1 |
| Hauns, B; Holländer, N; Maier-Lenz, H; Mross, K; Schumacher, M | 1 |
| Falkson, CI; O'Neill, A; Schaefer, PL; Sparano, JA; Wood, WC | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kouroussis, C; Samonis, G; Souglakos, J; Voloudaki, A | 1 |
| Blijham, GH; Erdkamp, FL; Hillen, HF; Lalisang, RI; Nortier, JW; Schouten, HC; Voest, EE; Wals, J; Wils, JA | 1 |
| Bella, MA; Beretta, MD; Cocconi, G; Ferrozzi, F; Mambrini, A; Quarta, M; Vasini, G | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| Barnadas, A; Casado, A; Colomer, R; Cortés-Funes, H; Lloveras, B; Lluch, A; Massutí, B; Montero, S; Ojeda, B | 1 |
| Hung, MC; Yu, D | 1 |
| Djoerban, Z; Gondhowiardjo, S; Poetiray, ED; Reksodipoetro, AH; Tjarta, A | 1 |
| Darwis, I; Muthalib, A; Prayogo, N | 1 |
| Beijnen, JH; Bo, M; Lustig, V; Mackay, M; Pronk, L; Schellens, JH; Ten Bokkel Huinink, WW; van Tinteren, H; Verweij, J | 1 |
| Breidenbach, M; Heindel, W; Kolhagen, H; Kurbacher, CM; Mallmann, P; Rein, D; Schmidt, T | 1 |
| Bastien, L; Bour-Dill, C; Gramain, MP; Marchal, S; Merlin, JL | 1 |
| Bergh, J; Blomqvist, C; Hakamies-Blomqvist, L; Luoma, M; Malmström, P; Mjaaland, I; Mouridsen, H; Ostenstad, B; Ottosson-Lönn, S; Pluzanska, A; Sjödin, M; Sjöström, J | 1 |
| Budman, D; Kreis, W; Petrylak, D; Savarese, D | 1 |
| Bates, SE; Bishop, P; Mendelsohn, J; Silverman, JA; Wosikowski, K | 1 |
| Chen, ST; Huang, CM; Wu, YT | 1 |
| Dabas, B; Khattab, J; Terebelo, HR | 1 |
| Coleman, RE; Eggleton, SP; Howell, A; Maling, SJ; Miles, DW | 1 |
| Bates, SE; Bishop, PC; Blagosklonny, MV; Fojo, T; Robey, R | 1 |
| Atad, J; Borovik, R; Palti, S; Rosenberg, T; Sneiderman, B; Steiner, M | 1 |
| Cockerham, MB; Lerchie, SB; Weinberger, BB | 1 |
| Bdolah-Abram, T; Burtness, BA; D'Andrea, E; Gollerkeri, A; Lee, FA; Psyrri, A; Rose, M | 1 |
| Jiang, Z; Liu, X; Song, S | 1 |
| Guan, Z; Lin, T; Wu, H | 1 |
| Chen, L; Fan, W; Zheng, S | 1 |
| Aravantinos, G; Bafaloukos, D; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Nicolaides, C; Pavlidis, N; Samelis, G | 1 |
| Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y | 1 |
| Amaya, H; Aotake, T; Chiba, Y; Fujii, H; Horiuchi, T; Shimomatsuya, T; Uchinami, M; Yokomachi, J | 1 |
| Bontenbal, M; Bruning, PF; Curran, D; de Haes, JC; Groenvold, M; Klijn, JG; Kramer, JA; Paridaens, R; Piccart, M; van Pottelsberghe, C | 1 |
| Bruning, P; Curran, D; de Haes, JC; Klijn, J; Kramer, JA; Paridaens, R; Piccart, M; Van Hoorebeeck, I | 1 |
| Altbach, MI; Galons, JP; Gillies, RJ; Paine-Murrieta, GD; Taylor, CW | 1 |
| Hatae, M; Nakamura, T; Ohnishi, Y | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Ito, K; Kubota, K; Minami, H; Saeki, T; Sasaki, Y; Takashima, S | 1 |
| Kubota, K | 1 |
| Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G | 1 |
| Aloe, A; Calabrese, P; Catino, A; De Lena, M; Latorre, A; Lorusso, V; Mazzei, A | 1 |
| Gilewski, T; Hudis, C; Norton, L; Seidman, A | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Boguslawski, KV; Heikkilä, P; Malmström, P; Mjaaland, I; Ostenstadt, B; Räisänen-Sokolowski, A; Saksela, E; Sjöström, J; Valvere, V; Wist, E | 1 |
| Bhat-Nakshatri, P; Boswell, SH; Gelfanov, V; Goulet, RJ; Nakshatri, H; Newton, TR; Nozaki, S; Patel, NM; Rice, S; Shortle, NH; Sledge, GW | 1 |
| Endo, T; Fujimoto, K; Haseyama, Y; Koike, T; Koizumi, K; Nishio, M; Sawada, K; Takashima, H; Yamamoto, S | 1 |
| Austin Seymour, MM; Bellon, JR; Ellis, GK; Gralow, JR; Lindsley, KL; Livingston, RB | 1 |
| Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L | 1 |
| Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S | 1 |
| Levin, ER; Pedram, A; Razandi, M | 1 |
| Castiglione-Gertsch, M; Coates, AS; Francis, P; Gelber, RD; Goldhirsch, A | 1 |
| Antonopoulos, M; Kosmas, C; Malamos, NA; Tsavaris, N | 1 |
| Brechbiel, MW; Clarke, K; Lee, FT; Old, LJ; Scott, AM; Smyth, FE | 1 |
| Chen, YZ; Fan, W; Fu, L; Johnson, KR; Zeng, S | 1 |
| Ames, FC; Bedi, D; Buzdar, AU; Feig, BW; Fornage, BD; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Tolley, SM; Vlastos, G; Winchester, DJ | 1 |
| Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
| Carmichael, J; Howells, A; Jones, A; Lind, M; Poole, C; Stuart, N; White, J | 1 |
| Camidge, DR; Kunkler, IH | 1 |
| Andrews, DF; Gilmore, GL; Lister, J; Shadduck, RK; Zeigler, ZR | 1 |
| Fukuda, H; Fukuda, K; Kim, YH; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Andersen, RJ; Anderson, HJ; Bigg, CM; Cinel, B; Jiang, X; Kelly, MT; Lim, L; Roberge, M; Xu, L | 1 |
| Capasso, I; Carteni, G; Comella, G; Comella, P; D'Aiuto, G; D'Aniello, R; De Lucia, L; Di Bonito, M; Frasci, G; Frezza, P; Lapenta, L; Maiorino, L; Rivellini, F; Thomas, R | 1 |
| Demicheli, R; Garbagnati, F; Mariani, G; Potepan, P; Verderio, P; Zambetti, M | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wall, D; Wolf, M | 1 |
| Takatsuka, Y | 1 |
| Kaise, H; Koyanagi, Y; Kusama, M | 1 |
| Tashiro, H | 1 |
| Fujii, H | 1 |
| Ito, Y | 1 |
| Adachi, I | 1 |
| Naito, Y; Oura, S; Tanino, H | 1 |
| Ames, FC; Breslin, TM; Buzdar, AU; Cohen, L; Delpassand, ES; Feig, BW; Fleming, JB; Hortobagyi, GN; House, R; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Sahin, A; Singletary, SE | 1 |
| Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Awada, A; Piccart, MJ | 1 |
| Baselga, J | 2 |
| Kuhnt, T; Tanner, J | 1 |
| Adeyanju, MO; Conzen, SD; Fleming, GF; Karrison, T; Olopade, OI; Poelman, SM; Recant, WM; Robertson, MA | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Kashimura, M; Minami, H; Ohashi, Y; Ohtsu, T; Onozawa, Y; Sasaki, Y; Wakita, H; Watanabe, Y | 1 |
| Farndon, JR; Fowler, CA; Holly, JM; Newcomb, PV; Perks, CM; Savage, PB | 1 |
| Kimura, M; Koida, T; Yanagita, Y | 1 |
| Asanuma, F; Kawamura, E; Suzuki, T; Yamada, T; Yamada, Y | 1 |
| Ajarim, DS; Al-Malik, OA; Bazarbashi, SM; Ezzat, AA; Ibrahim, EM; Kandil, A; Rahal, MM; Raja, MA; Stuart, RK; Tulbah, AM | 1 |
| Khan, KS; Kleijnen, J; Lister-Sharp, D; McDonagh, MS | 1 |
| Chang, HK; Chen, JS; Liaw, CC; Lin, YC; Wang, CH | 1 |
| Hortobagyi, G; Michaud, LB; Valero, V | 1 |
| Azama, T; Furukawa, J; Hashimoto, T; Katsumoto, Y; Nakaguchi, K; Okajima, S; Shingai, T; Sue, F; Takekuni, K; Yoshihara, W; Yukawa, M | 1 |
| Doi, K; Ishihara, A; Kudo, S; Ochiai, T; Ohchi, T; Sakae, T; Sakamoto, T; Takahashi, M | 1 |
| Canzler, U; Kühnle, H; Lück, HJ; Robner, D; Scholz, U | 1 |
| Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M | 1 |
| Albanese, C; Amanatullah, DF; Hulit, J; Lisanti, MP; Pestell, RG; Reutens, A; Rosen, E; Sparano, JA; Wang, C; Zafonte, BT | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Tsavaris, N; Ziras, N | 1 |
| Adams, LM; Budman, DR; Calabro, A; Kreis, W; Liu, XM; Stiel, L; Wang, LG | 1 |
| Gilks, CB; Irving, JA; McFarland, DF; Stuart, DS | 1 |
| Depisch, D; Haider, K; Kornek, G; Kwasny, W; Lang, F; Penz, M; Scheithauer, W; Ulrich-Pur, H; Valencak, J | 1 |
| Takatsuka, Y; Tominaga, T | 1 |
| Bunnell, C | 1 |
| Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I | 1 |
| Kurbacher, CM; Mallmann, P; Schwonzen, M | 1 |
| Beijnen, JH; Jewell, RC; Koopman, FJ; Malingré, MM; Paul, EM; Rosing, H; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Brugarolas, A; Fernández-Hidalgo, O; Martín-Algarra, S; Pérez-Calvo, J; Salgado, E; Subirá, ML | 1 |
| Angeles, C; Barnadas, A; Casado, A; Colomer, R; Lluch, A; Maroto, P; Massuti, B; Ojeda, B | 1 |
| Booser, D; Buzdar, AU; Dhingra, K; Fraschini, G; Frye, D; Holmes, FA; Hortobagyi, GN; Rivera, E; Theriault, RL; Valero, V; Walters, R | 1 |
| Amodio, A; Belli, F; Botti, C; Conti, F; Di Lauro, L; Ferraironi, A; Foggi, P; Gionfra, T; Lopez, M; Morelli, MF; Vici, P | 1 |
| Demaria, S; Formenti, SC; Kim, AY; Klein, P; McMullen, H; Muggia, F; Oratz, R; Perkins, AB; Shapiro, RL; Symmans, WF; Volm, MD; Yee, HT | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Penz, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Randal, J | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Fleming, DR; Goldsmith, GH; Goldsmith, J; Herzig, RH; Stevens, DA | 1 |
| Buban, GM; Doucette, WR; Link, BK | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Matsuo, K; Miyakawa, K; Nakamura, T; Shimizu, C; Tsuda, H | 1 |
| Ashizawa, T; Katayanagi, S; Katsumata, K; Koyanagi, Y; Kusama, M; Murohashi, T; Sumi, T; Yamamoto, K | 1 |
| Heilmann, M; Langer-Nitsche, C; Lück, HJ | 1 |
| Al-Tweigeri, T; Azli, N; Mackey, JR; Nabholtz, JM; Noël, DR; North, S; Paterson, A; Riva, A; Smylie, M; Tonkin, K | 1 |
| Adachi, I; Ando, M; Katsumata, N; Nagata, K; Narabayashi, M; Watanabe, T | 1 |
| Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT | 1 |
| Blach, M; Brodowicz, T; Budinsky, AC; Hojas, S; Ilsinger, P; Kubista, E; Locker, GJ; Maca, S; Pluschnig, U; Schmidinger, M; Seewann, L; Steger, GG; Wenzel, C; Zabernigg, A; Zielinski, CC | 1 |
| Atkins, KA; Berry, GJ; Leung, AN; Montoya, JG; Ruoss, SJ; Stockdale, FE; Wong, P | 1 |
| Minami, H; Ogawa, M; Sasaki, Y; Watanabe, T | 1 |
| Butash, KA; Casero, RA; Davidson, NE; Deveraux, WL; Dunn, VR; Hahm, HA; Woster, PM | 1 |
| Esteva, FJ; Fornier, M; Seidman, AD | 1 |
| Antman, K; Drazen, J; Lagakos, S | 1 |
| Chen, Y; Dan, Q; Delgado, C; Jadus, MR; Jeffes, EW; Sanchez, R; Sippel, B; Tran, TV; Trinh, H; Wepsic, HT; Williams, CC | 1 |
| Bastert, G; Egerer, G; Goerner, R; Grischke, EM; Haas, R; Hensel, M; Ho, AD; Hohaus, S; Khbeis, T; Schneeweiss, A; Solomayer, E | 1 |
| Colomer, R; Cortés-Funes, H; del Mar Barbacid, M; Escrich, E; Menéndez, JA; Montero, S; Sevilla, E; Solanas, M | 1 |
| Buzdar, AU; Dhingra, K; Hortobagyi, GN; Ibrahim, NK; Valero, V; Willey, J | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Katsumata, N; Matsuo, K; Miyakawa, K; Nanasawa, T; Tsuda, H; Watanabe, T | 1 |
| Doihara, H; Hino, M; Ishibe, Y; Nagahiro, I; Ogasawara, Y; Sano, Y; Shimizu, N; Teramoto, A; Yoshitomi, S | 1 |
| Boccardo, F; Foglia, G; Marenghi, C; Miglietta, L; Nizzo, R; Ragni, N | 1 |
| Bajamonde, A; Baselga, J; Eiermann, W; Fleming, T; Fuchs, H; Leyland-Jones, B; Norton, L; Paton, V; Pegram, M; Shak, S; Slamon, DJ; Wolter, J | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N | 1 |
| Georgoulias, VA | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini'Neto, AO | 1 |
| Ansari, R; Gize, G; Miller, KD; Monaco, F; Nattam, S; Pennington, K; Sisk, J; Sledge, GW | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Hara, A; Harada, T; Hashimoto, K; Izumi, N; Matsubara, C; Miyazaki, H; Satake, K; Tsunematsu, I | 1 |
| Kamata, S; Kiyosawa, Y; Kudo, T; Nakagawa, T; Ogawa, J; Onuki, M; Seto, T | 1 |
| Arthur, T; Avigan, D; Ayash, L; Demetri, G; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; Levine, J; Reich, E; Richardson, P; Warren, D; Wheele, C | 1 |
| Baron, R; Hilpert, F; Pfisterer, J; Wasner, G | 1 |
| Bafaloukos, D; Briassoulis, E; Dimopoulos, AM; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Keramopoulos, A; Kosmidis, P; Papadimitriou, C; Pavlidis, N; Razis, E; Samantas, E | 1 |
| Pegram, M; Slamon, D | 1 |
| Nabholtz, JM; Slamon, D | 1 |
| Bertuzzi, A; Capri, G; Cresta, S; Giani, A; Gianni, L; Grasselli, G; Locatelli, A; Materazzo, C; Perotti, A; Spreafico, C; Tarenzi, E; Valagussa, P; Viganò, L | 1 |
| Abela, K; Aravantinos, G; Bafaloukos, D; Briassoulis, E; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, E; Kalofonos, HP; Kosmidis, P; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pavlidis, N; Razis, E; Skarlos, D | 1 |
| Coleman, RE; Croucher, PI; Jagdev, SP; Rostami-H, A; Shipman, CM | 1 |
| Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T | 1 |
| Mileshkin, L; Prince, HM; Rischin, D; Zimet, A | 1 |
| Bacus, SS; Gudkov, AV; Keyomarsi, K; Komarov, AP; Lowe, M; Lyass, L; Seger, R; Yarden, Y; Yung, Y | 1 |
| Chiernsilp, A; Jootar, S; Ratanatharathorn, V; Ungkanont, A | 1 |
| Milla, L; Milla-Santos, A; Rallo, L; Solano, V | 1 |
| Kokawa, Y; Matsuyama, K; Naito, Y; Nakamura, T; Oura, S; Sakurai, T; Tanino, H; Yoshimasu, T | 1 |
| Bauer, J; Borner, M; Crivellari, D; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Veronesi, A | 1 |
| Bressi, JC; Douglass, JG; Seligson, AL; Sovak, M; Terry, RC | 1 |
| Beijnen, JH; Koopman, FJ; Mandjes, IA; Meerum Terwogt, JM; Rocchetti, M; Rosing, H; Schellens, JH; Schot, M; ten Bokkel Huinink, WW; Zurlo, MG | 1 |
| Beijnen, JH; Duchin, K; Koopman, FJ; Lieverst, J; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; van Tellingen, O | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Ardizzoia, A; Conti, A; Fumagalli, E; Gardani, G; Lissoni, P; Maestroni, GJ; Tancini, G; Vaghi, M | 1 |
| Wojtaszek, C | 1 |
| Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, AM; Ekonomopoulos, T; Fountzilas, G; Kalofonos, H; Nicolaides, C; Papadimitriou, C; Pavlidis, N; Skarlos, D; Stathopoulos, G | 1 |
| Miller, ID; Smith, IC | 1 |
| Pintér, T; Szántó, J | 1 |
| Inbar, MJ; Merimsky, O | 1 |
| Pagani, O; Sessa, C | 1 |
| Baselga, J; Tabernero, JM | 1 |
| Dettke, M; Greinix, HT; Höcker, P; Kalhs, P; Kührer, I; Worel, N | 1 |
| al Raheb, K; Bemer, M; Muhizi, J; Platini, C; Steinbach, G; Tomassini, E | 1 |
| Borzilleri, R; Fairchild, CR; Kim, SH; Kramer, RA; Lee, FY; Long, BH; Reventos-Suarez, C; Rose, WC; Vite, GD | 1 |
| Arroyo, C; Bach, A; Cristofanilli, M; Currie, V; D'Andrea, G; Dickler, M; Esteva, FJ; Fornier, MN; Gilewski, T; Hortobagyi, GN; Hudis, CA; Kaptain, S; Moasser, M; Moynahan, ME; Norton, L; Panageas, KS; Rivera, E; Seidman, AD; Sklarin, N; Tan, L; Theodoulou, M; Valero, V | 1 |
| Chen, ZJ; Hopper, E; Murphy, M; Shen, H; Tew, KD; Zilfou, JT | 1 |
| Fleming, GF; Grinblatt, DL; Laport, GG; Waggoner, S; Williams, SF; Zimmerman, TM | 1 |
| Prescott, LM | 1 |
| Conte, P; Donati, S; Gennari, A; Landucci, E; Salvadori, B | 1 |
| Aydiner, A; Karadeniz, A; Sakar, B; Tas, F; Tenekeci, N; Topuz, E | 1 |
| Ikeda, H; Koshiba, R | 1 |
| Burtness, BA; Gollerkeri, A; Harrold, L; Jain, D; Rose, M | 1 |
| Berruti, A; Bertetto, O; Bottini, A; Bumma, C; Castiglione, F; Danese, S; DeFabiani, E; Dogliotti, L; Donadio, M; Gorzegno, G; Lorusso, V; Manzin, E; Moro, G; Sarobba, MG | 1 |
| Cabot, MC; Charles, AG; Giuliano, AE; Han, TY; Hansen, N; Liu, YY | 1 |
| Bruno, R; Montay, G; Rhodes, GR; Veyrat-Follet, C; Vivier, N | 1 |
| Baldini, E; Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Damjanov, N; Huang, C; Rahman, A; Treat, J; Zrada, S | 1 |
| Egawa, C; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y | 1 |
| Alvarnas, J; Chow, W; Doroshow, JH; Forman, SJ; Kogut, N; Leong, LA; Longmate, J; Margolin, KA; Morgan, RJ; Raschko, JW; Reardon, D; Schriber, J; Shibata, SI; Somlo, G; Synold, T; Tetef, ML; Yen, Y | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Hopkins, U; Malik, U; Rajdev, L; Sarta, C; Sparano, JA; Wolff, AC | 1 |
| Bojko, P; Borquez, D; Kasimir-Bauer, S; Mayer, S; Neumann, R; Seeber, S | 1 |
| Dvorák, J; Jandík, P; Kopecký, O; Melichar, B; Tousková, M | 1 |
| Hung, MC; Makino, K; Yu, D | 1 |
| Bando, H; Hayashi, K; Kuroi, K; Nagai, S; Tanaka, C; Toi, M | 1 |
| Haga, S; Hirano, A; Imamura, H; Kajiwara, T; Kimura, K; Kinoshita, J; Nagumo, H; Okabe, T; Shimizu, T; Utada, Y; Watanabe, O | 2 |
| Fountzilas, G; Razis, ED | 1 |
| Blum, JL; Diab, S; Elledge, R; Griffin, T; Jones, SE; Khoury, P; Kraynak, M; Kromelis, P; Moczygemba, J; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, D | 1 |
| Carlson, LE; Glück, S; Koski, T | 1 |
| Hamazoe, R; Komuro, I; Murata, Y; Shimoyama, M; Sumi, KI | 1 |
| Ambrosini, G; Antoine, EC; Azli, N; Benhammouda, A; Borg-Olivier, O; Chollet, P; Khayat, D; Mazen, MF; Monfardini, S; Ramazeilles, C; Riva, A; Sorio, R | 1 |
| Bernardo, G; Brugnatelli, S; Danova, M; Fava, S; Giardina, G; Giordano, M; Grasso, D; Montanari, G; Pedrotti, C; Poli, MA; Pugliese, P; Riccardi, A; Rinaldi, E; Tinelli, C; Trotti, G | 1 |
| Brugarolas, A; García-Rayo, S; Inogés, S; Martín-Algarra, S; Martínez-Aguillo, M; Ordóñez, JM; Pérez-Calvo, J; Ramón y Cajal, T; Santisteban, M; Subirá, ML | 1 |
| Atencio, IA; Avanzini, JB; Beltran, JC; Hajian, G; Johnson, D; McAllister, DL; Neuteboom, S; Nielsen, LL; Nodelman, M; Philopena, J; Ramachandra, M; Sugarman, BJ; Sutjipto, S; Vaillancourt, MT; Wills, KN | 1 |
| Delozier, T; Fumoleau, P; Guastalla, JP; Kerbrat, P; Roché, H; Viens, P | 1 |
| Pawlicki, M; Rolski, J; Rysz, B; Utych, G; Wiczyńska, B; Zemełka, T | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Donaldson, KL; Mixan, BJ; Siegall, CB; Trail, PA; Wahl, AF | 1 |
| Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Eiermann, W; Gademann, G; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Merkle, E; Raab, G; Tulusan, AH; von Minckwitz, G | 1 |
| Baker, M; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Grimaldi, M; Hainsworth, JD; Kalman, LA; Sullivan, T; Yardley, DA | 1 |
| Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J | 1 |
| Basso, A; Münster, PN; Norton, L; Rosen, N; Solit, D | 1 |
| Beckman, BS; Burow, ME; Clayton, JL; Jaffe, BM; Rolfe, KW; Weldon, CB | 1 |
| Bunnell, CA; Burstein, HJ; Winer, EP | 1 |
| Swain, SM; Tan, AR | 1 |
| Bernacki, RJ; Cabral, F; Greco, WR; Kanter, P; Kee, K; Ojima, I; Pera, P; Sharma, A; Veith, J; Vredenburg, MR | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R | 1 |
| Smith, I | 1 |
| Azli, N; Bissery, MC; Borg-Olivier, O; Campone, M; Delecroix, V; Deporte-Fety, R; Fumoleau, P; Louboutin, JP; Perrocheau, G; Riva, A; Vernillet, L | 1 |
| Luker, KE; Pica, CM; Piwnica-Worms, D; Schreiber, RD | 1 |
| Hada, M; Koshizuka, K; Mouri, N; Muto, S; Nakagomi, H; Serizawa, M; Tada, Y; Takano, K | 1 |
| Aoudjit, F; Vuori, K | 1 |
| Azinovic, I; Brugarolas, A; Fernández-Hidalgo, O; García-Rayo, S; Martín-Algarra, S; Martínez-Aguillo, M; Martínez-Monge, R; Pérez-Calvo, J; Rebollo, J; Subirá, L | 1 |
| Berry, D; Cooper, BW; Goldberg, S; Gray, R; Jennis, A; Lazarus, HM; Pecora, AL; Preti, R; Stadtmauer, EA; Van Vliet, A; Winter, J | 1 |
| Holmes, FA; Rowinsky, EK | 1 |
| Dieras, V; Perez, E; Valero, V | 1 |
| Mamounas, EP; Sledge, GW | 1 |
| Pagani, O; Trudeau, M | 1 |
| Vogel, SN; Zaks, TZ; Zaks-Zilberman, M | 1 |
| Beryt, M; Felber, M; Hepp, H; Kahlert, S; Konecny, G; Langer, E; Lude, S; Pegram, M; Slamon, D; Untch, M | 1 |
| Goldwasser, F; Misset, JL | 1 |
| Fujii, H; Igarashi, T; Imoto, S; Ishizawa, K; Itoh, K; Minami, H; Saeki, T; Sasaki, Y; Shigeoka, Y | 1 |
| Kameda, K; Kubo, A; Mochizuki, Y; Momiyama, N; Natori, S; Takekawa, Y | 1 |
| Andres, R; Bueso, P; Escudero, P; Filipovich, E; Isla, MD; Martí, JL; Mayordomo, JI; Murillo, L; Saenz, A; Tres, A | 1 |
| Amadori, D; Arbuck, SG; Brown, M; Dombernowsky, P; Gianni, L; Martin, M; Messina, M; Ravdin, P; Sledge, G; Tuck, D; Weil, C; Winograd, B | 1 |
| Bergaglio, M; Cognetti, F; Del Mastro, L; Donati, S; Frevola, L; Lionetto, R; Lunardi, G; Michelotti, A; Papaldo, P; Rosso, R; Sguotti, C; Venturini, M | 1 |
| Giesel, BU; Kutz, GG; Thiel, HJ | 1 |
| Avigan, D; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; Levine, J; McCauley, M; McDermott, D; Richardson, P; Warren, D; Wheeler, C | 1 |
| Andrews, H; Gervin, C; Gilmore, PM; Haber, DA; Harkin, DP; Johnston, PG; Liu, E; Maheswaran, S; McCabe, N; McKenna, S; McWilliams, S; Mullan, PB; Quinn, JE; Song, YH; White, P | 1 |
| Demaria, S; Formenti, SC; Muggia, F; Oratz, R; Shapiro, RL; Symmans, WF; Volm, MD; Yee, HT | 1 |
| Berman, E; Cohen, JS; Mardor, Y; Ringel, I; Sterin, M | 1 |
| Blajeski, AL; Kaufmann, SH; Kottke, TJ | 1 |
| Bignon, YJ; Ferrara, M; Lafarge, S; Sylvain, V | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Blajeski, AL; Boerner, SA; Chilcote, TJ; Earnshaw, WC; Henriquez, NV; Kaufmann, SH; Kottke, TJ; Lord, J; Meng, XW; Mesner, PW; Ruchaud, S; Salmon, M; Samejima, K; Svingen, PA | 1 |
| Brenneman, DC; Chan, D; Fridkin, M; Gelber, E; Gozes, I; Levy, A; Leyton, J; Moody, TW | 1 |
| Omuro, Y; Sasaki, T | 1 |
| Suzuki, Y; Tokuda, Y | 1 |
| Ishikawa, T; Itasaka, H; Kume, K; Matsusaka, T; Ohshiro, T; Ohta, M; Sonoda, K; Tashiro, H; Yamamura, S | 1 |
| Akaike, H; Ashizawa, I; Chiba, S; Imamura, K; Mitui, T; Miyauchi, Y; Muto, S; Nakagomi, H; Nakazawa, M; Okuda, J; Takahashi, M | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Schwetz, BA | 1 |
| Leyland-Jones, B | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P | 1 |
| Leyland-Jones, B; Smith, I | 1 |
| Chen, PM; Chiou, TJ; Fan, FS; Liu, JH; Tai, CJ; Wang, WS; Yen, CC | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Yu, D | 1 |
| Ishitobi, M; Kikkawa, N; Shin, E | 1 |
| Honda, S; Kawaguchi, Y; Kimura, A; Kunieda, K; Matsui, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H | 1 |
| Kawano, R; Kuroki, S; Matsuo, K; Nagata, S; Ogawa, T; Onzuka, T; Shinohara, M; Sumitomo, K; Suzuki, H; Yamanaka, N; Yoshida, J | 1 |
| Ezumi, K; Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masuda, N; Masutani, S; Miya, A; Satomi, T; Shimizu, J; Tatsuta, M | 1 |
| Oka, M; Saito, K; Takano, N; Tangoku, A | 1 |
| Irwin, DH; Kirshner, JJ; Patel, R; Perez, EA; Vogel, CL | 2 |
| Blohmer, JU; Caputo, A; Costa, SD; du Bois, A; Eidtmann, H; Gademann, G; Gerber, B; Graf, E; Hilfrich, J; Jackisch, C; Kaufmann, M; Lampe, D; Merkle, E; Raab, G; Schütte, M; Sinn, HP; Tulusan, AH; von Minckwitz, G | 1 |
| Bastert, G; Beldermann, F; Geberth, M; Goerner, R; Lenz, F; Schneeweiss, A; Solomayer, E | 1 |
| Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, S | 1 |
| Araújo, F; Fernandes, A; Figueira, A; Lobato, R; Morais, J; Moreira, A; Oliveira, J; Passos-Coelho, JL; Ribeiro, J; Silva, S; Sousa, C; Vale, D | 1 |
| Hiraga, K; Honda, O; Matsuo, K | 1 |
| Biswas, RS; Cha, HJ; Hardwick, JM; Srivastava, RK | 1 |
| Airoldi, M; Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Recalenda, V; Tagini, V | 1 |
| Adams, LM; Budman, DR; Kreis, W; Liu, XM; Wang, LG | 1 |
| Aiba, K; Hashimoto, D; Horikoshi, N; Irie, T; Ito, Y; Mizunuma, N; Nakane, M; Saotome, T; Sugiyama, K; Takahashi, S; Tanigawara, Y; Yoshida, N | 1 |
| Matsuo, Y; Shibasaki, F; Shibata, M; Shitashige, M; Toi, M; Yano, T | 1 |
| Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K | 1 |
| Ishihama, H | 1 |
| Fukuda, K; Kim, Y; Kitano, H; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Assaad, SI; Kuter, I; Niemierko, A; Powell, SN; Roche, M; Schoenthaler, R; Taghian, AG; Younger, J | 1 |
| Brown, RE; Burrell, A; Hutton, J | 1 |
| Ahmadi, MA; Esmaeli, B | 1 |
| Beckman, BS; Burow, ME; McLachlan, JA; Tang, Y; Weldon, CB | 1 |
| Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O | 1 |
| Booser, D; Buzdar, AU; Cristofanilli, M; Hortobagyi, GN; Hunt, K; Ibrahim, N; McNeese, M; Murray, JL; Rivera, E; Singletary, ES; Smith, T; Sneige, N; Stelling, C; Strom, E; Ueno, N; Valero, V; Wasaff, B | 1 |
| Currie, V; D'Andrea, G; Fornier, MN; Gilewski, T; Hudis, C; Moasser, M; Moynahan, ME; Norton, L; Panageas, KS; Salvaggio, R; Seidman, AD; Sklarin, N; Theodoulou, M | 1 |
| Bischoff, J; Forstpointner, R; Geuenich, S; Gutschow, K; Heinemann, V; Hiddemann, W; Kentenich, CH; Malekmohammadi, M; Sommer, H; Stemmler, HJ | 1 |
| Buyse, M; Duchateau, L; Lohrisch, C; Piccart, MJ | 1 |
| Ando, A; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y | 1 |
| Guan, X; Li, L; Zou, Y | 1 |
| Abella, E; Baynes, RD; Cassells, L; Dansey, RD; Hamm, C; Karanes, C; Klein, JL; Peters, WP | 1 |
| Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G | 1 |
| Rosenblum, MD; Shivers, RR | 1 |
| Ebihara, Y; Kato, M; Kitagawa, Y; Masuyama, M; Nakase, Y; Watanabe, S; Yasuoka, R | 1 |
| Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J | 1 |
| Bohlen, P; Green, SK; Hicklin, D; Huang, P; Kerbel, RS; Klement, G; Man, S; Mayer, B | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Bernacki, RJ; Geng, X; Lin, S; Ojima, I; Pera, P | 1 |
| Katagiri, T; Kitahara, S; Nonaka, K; Ogata, H; Shiba, T | 1 |
| Bando, H; Hayashi, K; Kuroi, K; Saji, S; Tanaka, C; Toi, M | 1 |
| Glaspy, J; Hill, LR; Holmes, FA; Jones, SE; Liang, BC; Meza, L; Moore, M; Neumann, TA; O'Shaughnessy, JA; Savin, M; Shogan, J; Vukelja, S; Wiznitzer, I | 1 |
| Fleming, D; Hahl, M; Morkas, M | 1 |
| Adamou, A; Bafaloukos, D; Christodoulou, CH; Fountzilas, G; Gogas, H; Kalofonos, CH; Kalogera-Fountzila, A; Kosmidis, P; Papakostas, P; Razis, E; Skarlos, D; Stathopoulos, G; Timotheadou, E; Tsavdaridis, D | 1 |
| Arkad'eva, TV; Artamonova, EV; Davidenko, IS; Manziuk, LV; Poddubnaia, IV | 1 |
| Caruso, A; De Carolis, S; De Santis, M; Ferrazani, S; Lucchese, A | 1 |
| Agata, N; Bamberg, M; Dickerson, WM; Fram, R; Kalluri, R; Kamphaus, GD; Kharbanda, S; Kufe, D; Milhollen, M; Reimer, CL; Rook, SL; Tammam, JG | 1 |
| Ames, FC; Buchholz, TA; Buzdar, AU; Hortobagyi, GN; Hunt, KK; Kuerer, HM; Pusztai, L; Ross, MI; Singletary, SE; Valero, V | 1 |
| Frye, D; Hortobagyi, GN; Ibrahim, NK; Murray, JL; Rahman, Z; Valero, V | 1 |
| Mortimer, JE; Picus, J; Read, WL | 1 |
| Ali, SM; Boge, TC; Georg, GI; Himes, RH; Liu, Y; Marquez, RT; Victory, S; Zygmunt, J | 1 |
| Cohen, Y; Hertzanu, Y; Mermershtain, W; Schulman, H | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Fukuda, K; Kimura, F; Kokufu, I; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Hirano, M; Kikkawa, H; Kikuchi, T; Murakami, N; Nozawa, H; Okuda, T; Oya, J; Uno, Y | 1 |
| Ashby, M; Hudis, C; Keefe, D; Murphy, M; Paton, V; Pierri, MK; Seidman, A; Shak, S; Stewart, SJ | 1 |
| Dijkstra, B; Hill, AD; Kelly, L; Leonard, DS; McDermott, E; O'Higgins, NJ | 1 |
| Bettini, A; Cohen, D; Danenberg, K; Danenberg, P; Formenti, SC; Groshen, S; Naritoku, W; Press, M; Salonga, D; Skinner, K; Spicer, D; Tsao-Wei, D | 1 |
| Bengtsson, NO; Bergh, J; Blomqvist, C; Collan, J; Franssila, K; Malmström, P; Mjaaland, I; Saksela, E; Sjöström, J; Skiöld-Petterson, D; Valvere, V; von Boguslawski, K; Wist, E; Østenstad, B | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Burke, PA; DeNardo, GL; DeNardo, SJ; Kukis, DL; Miers, LA | 1 |
| Ahmadi, MA; Arbuckle, R; Booser, D; Delpassand, E; Esmaeli, B; Esteva, F; Hortobagyi, G; Ibrahim, N; Valero, V | 1 |
| Bighin, C; Del, ML; Esposito, M; Lunardi, G; Schettini, G; Tolino, G; Vannozzi, MO; Venturini, M | 1 |
| Aihara, T; Kim, Y; Takatsuka, Y | 1 |
| Sun, Y | 1 |
| Demetri, GD; Ette, E; Garg, V; Harding, MW; Overmoyer, B; Pollak, M; Russell, C; Seidman, AD; Tkaczuk, K; Toppmeyer, D; Verma, S | 1 |
| Ah-See, AK; Eggleton, SP; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, IC; Walker, LG | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Beauchamp, D; Chakravarthy, A; Frexes-Steed, M; Johnson, D; Kelley, M; Nicholson, B; Pietenpol, J; Shyr, Y; Simpson, J | 1 |
| Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Bruning, P; Drijkoningen, M; Guastalla, JP; Hamilton, A; Hanby, A; Houston, S; Larsimont, D; Paridaens, R; Piccart, M; Sylvester, R; Treilleux, I; van de Vijver, M; Van Vreckem, A | 1 |
| Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
| Partridge, A; Winer, E | 1 |
| Bourlon-Cuellar, R; Candelaria, M; Noel-Ettiene, LM; Sánchez-Sánchez, JM; Zubieta, JL | 1 |
| Agelaki, S; Georgoulias, V; Giannakakis, T; Kalbakis, K; Kosmas, C; Kouroussis, Ch; Malamos, N; Mavroudis, D; Papadouris, S; Souglakos, J | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Rudas, M; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Arun, B; Booser, D; Cristofanilli, M; Esmaeli, B; Esteva, FJ; Fritsche, HA; Guerra, LT; Hortobagyi, GN; Murray, JL; Pusztai, L; Smith, TL; Sneige, N; Valero, V | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Labonia, V; Landi, G; Mastro, AA; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Inaji, H; Kobayashi, H; Motomura, K; Noguchi, S; Taguchi, T; Takamura, Y | 1 |
| Ames, FC; Buchholz, T; Buzdar, AU; Hunt, KK; Kuerer, HM; Newman, LA; Ross, MI; Singletary, SE | 1 |
| Choudhary, K; Deng, HB; Houser, SR; Parekh, HK; Simpkins, H | 1 |
| Choi, CW; Goo, BH; Kim, BS; Kim, JS; Kim, YH; Seo, JH; Shin, SW; Whang, YM | 1 |
| Campone, M; Fumoleau, P | 1 |
| Amamoo, MA; Collichio, FA; Fogleman, J; Graham, M; Griggs, J | 1 |
| Hamaguchi, Y; Ichikawa, Y; Ishikawa, T; Kawano, N; Maegawa, J; Nakatani, Y; Ogino, I; Ohnishi, H; Shimada, H; Shimura, M | 1 |
| Alvarez, I; Andres, R; Escudero, P; Filipovich, E; Isla, D; Marti, JL; Mayordomo, JI; Polo, E; Saenz, A; Tres, A | 1 |
| Nabholtz, JM; Riva, A | 1 |
| Conte, PF; Gennari, A; Landucci, E; Orlandini, C | 1 |
| Fukuda, K; Kimura, F; Kokufu, I; Tanei, T; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
| Ohta, M; Saitou, Y; Suzuki, Y; Tajima, T; Tokuda, Y | 1 |
| Arroyo, CD; Hudis, C; Norton, L; Panageas, KS; Seidman, AD; Tan, L; Van Poznak, C | 1 |
| Areman, EM; Cairo, MS; Ebadi, M; Gehan, E; Herscowitz, HB; Lippman, ME; Meehan, KR; Slack, R | 1 |
| Friedrich, MJ | 1 |
| Antila, K; Ekholm, E; Jalonen, J; Rantanen, V; Salminen, E; Syvänen, K | 1 |
| Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S | 1 |
| Thomssen, C | 1 |
| Atadja, P; Buxton, F; Cohen, D; Towbin, H; Yan-Neale, Y | 1 |
| Symmans, FW | 1 |
| Baldini, E; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Fogli, S; Gennari, A; Innocenti, F; Salvadori, B | 1 |
| Bashford, J; Blakey, D; Briggs, P; Francis, P; Haylock, D; Januszewicz, EH; Parker, N; Prince, HM; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Simmons, P; Toner, GC; Wall, D; Wolf, M | 1 |
| Blakey, D; Briggs, P; Haylock, D; Januszewicz, EH; Prince, HM; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Simmons, P; Toner, GC; Wall, D; Westerman, D; Wolf, M | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
| Ames, F; Berry, D; Booser, DJ; Buzdar, AU; Frye, DK; Holmes, FA; Hortobagyi, GN; Hoy, E; Hunt, K; Ibrahim, NK; Kau, SW; Manuel, N; McNeese, MD; Rahman, Z; Rivera, E; Singletary, SE; Smith, TL; Strom, E; Theriault, RL; Thomas, E; Valero, V; Walters, R | 1 |
| Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V | 1 |
| Avigan, D; Elias, AD; Frei, E; Ibrahim, J; Joyce, R; McCauley, M; Reich, E; Richardson, P; Wheeler, C | 1 |
| Bovik, AC; Ling, J | 1 |
| Ajarim, DS; El Weshi, AN; Ezzat, AA; Ibrahim, EM; Rahal, MM; Sorbris, R; Tulbah, AM | 1 |
| Krup, M; Ofir, R; Rabinski, T; Seidman, R; Weinstein, Y; Wolfson, M; Yavelsky, V | 1 |
| Markman, M; Mekhail, TM | 1 |
| Algarra, I; Gaforio, JJ; Jaén, A; Lozano, A; Sánchez-Rovira, P; Serrano, MJ | 1 |
| Emoto, T; Fujii, M; Fujikawa, M; Hamada, E; Komaki, T; Naka, Y; Yoshikawa, K; Yoshioka, Y | 1 |
| Fujioka, A; Fukushima, M; Kitazato, K; Nakagawa, F; Nukatsuka, M; Ohshimo, H | 1 |
| Ahmadi, MA; Arbuckle, R; Booser, D; Delpassand, E; Esmaeli, B; Esteva, FJ; Guerra, L; Hortobagyi, GN; Rivera, E; Valero, V | 1 |
| Arlinghaus, R; Fang, D; Hung, MC; Jing, T; Lan, KH; Lee, S; Li, P; Liu, J; Nagata, Y; Neal, CL; Tan, M; Yu, D | 1 |
| Brichese, L; Valette, A | 1 |
| Banerjee, A | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Gorschlüter, M; Kleinschmidt, R; Mey, U; Sauerbruch, T; Schlegel, U; Schmidt-Wolf, IG; Schöttker, B; Ziske, CG | 1 |
| Zielinski, CC | 1 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
| Boulamatsis, D; Kanelopoulos, P; Kosmas, C; Tsavaris, N; Vadiaka, M | 1 |
| Gon, G; Iwamoto, M; Iwamoto, S; Kobayashi, T; Nohara, T; Tanigawa, N | 1 |
| Blajeski, AL; Kaufmann, SH; Kottke, TJ; Phan, VA | 1 |
| Korn, EL; Simon, R | 1 |
| Gunby, P | 1 |
| Costanza, ME | 1 |
| Arbuck, SG; Canetta, RM; Onetto, N; Rowinsky, EK | 1 |
| Hawkins, MJ | 1 |
| Maugard-Louboutin, C | 1 |
| Buzdar, AU; Forman, AD; Frye, DK; Holmes, FA; Hortobagyi, GN; Newton, LK; Raber, MN; Theriault, RL; Walters, RS | 1 |
| Abbaszadeh, H; Hafezi, K; Hemmati, AA; Makvandi, M; Valizadeh, A | 1 |
| Cong, B; Dong, M; Gu, YC; Huo, CH; Kiyota, H; Ni, ZY; Sauriol, F; Shi, QW; Wang, YF; Wu, YB; Zhang, ML | 1 |
| de Vos, FY; van Laarhoven, HM | 1 |
| Birch, NP; Cooney, J; Jensen, D; Li, Y; Paxton, JW; Scheepens, A; Tan, KW | 1 |
496 review(s) available for paclitaxel and Breast Neoplasms
| Article | Year |
|---|---|
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles | 2021 |
Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Compounding; Drug Synergism; Female; Humans; Medical Oncology; Nanomedicine; Nanoparticles; Paclitaxel | 2021 |
A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer.
Topics: Albumins; Asian People; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel | 2021 |
Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Nanoparticles; Paclitaxel; Randomized Controlled Trials as Topic; Solvents; Taxoids | 2022 |
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2022 |
Weekly Paclitaxel Administered During a Twin Pregnancy for Recurrent Breast Cancer: Case Report and Review of the Literature.
Topics: Breast Neoplasms; Female; Humans; Infant, Newborn; Paclitaxel; Pregnancy, Twin; Premature Birth | 2022 |
"The emerging role of capivasertib in breast cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2022 |
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Topics: Breast Neoplasms; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Female; Genetic Markers; Humans; Liver-Specific Organic Anion Transporter 1; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Polymorphism, Single Nucleotide; Taxoids | 2022 |
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
Topics: Adult; Albumin-Bound Paclitaxel; Breast Neoplasms; Female; Humans; Nanoparticles; Neutropenia; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2022 |
Association of Apatinib and Breast Cancer: A systematic review and meta-analysis.
Topics: Breast Neoplasms; Female; Humans; Liposomes; Paclitaxel; Pyridines; Treatment Outcome | 2022 |
Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Death; Female; Heart Failure; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2022 |
Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Polyphenols; Resveratrol; Stilbenes; Tumor Microenvironment; Water | 2022 |
EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions.
Topics: Antineoplastic Agents; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cell Movement; Cisplatin; Drug Resistance; Epithelial-Mesenchymal Transition; Female; Humans; MicroRNAs; Paclitaxel; RNA, Long Noncoding; Tamoxifen; Vimentin | 2022 |
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Topics: Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Female; Humans; Myalgia; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Platinum; Prognosis; Triple Negative Breast Neoplasms | 2023 |
Three-dimensional cell cultures as preclinical models to assess the biological activity of phytochemicals in breast cancer.
Topics: Antineoplastic Agents; Biological Products; Breast Neoplasms; Cell Culture Techniques, Three Dimensional; Cell Line, Tumor; Female; Humans; Paclitaxel; Phytochemicals; Spheroids, Cellular | 2023 |
Successful Prevention of Tumour Lysis Syndrome in HER2-positive Breast Cancer: Case Report and Literature Review.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Paclitaxel; Trastuzumab; Tumor Lysis Syndrome | 2023 |
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2023 |
Long Noncoding RNAs in Taxane Resistance of Breast Cancer.
Topics: Breast Neoplasms; Female; Humans; Paclitaxel; RNA, Long Noncoding; Taxoids | 2023 |
Taxanes for adjuvant treatment of early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Network Meta-Analysis; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate | 2019 |
Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Paclitaxel | 2019 |
Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Computer Simulation; Disease Management; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Molecular Docking Simulation; Nanoparticles; Nanotechnology; Paclitaxel; Peptides; Receptors, Estrogen | 2021 |
Is the interstitial lung disease induced by trastuzumab? Case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Epstein-Barr Virus Infections; Female; Ganciclovir; Humans; Lung Diseases, Interstitial; Paclitaxel; Trastuzumab | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab | 2020 |
Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2020 |
Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Nanomedicine; Ovarian Neoplasms; Paclitaxel | 2021 |
Role of TDM-based dose adjustments for taxane anticancer drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2021 |
Resistance to Intervention: Paclitaxel in Breast Cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel | 2021 |
Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Solvents; Taxoids | 2021 |
Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.
Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Breast Neoplasms; Cancer Vaccines; Cell Line, Tumor; Cell Proliferation; Cytokines; Drug Resistance, Neoplasm; Female; Lymphocytes, Tumor-Infiltrating; Mice, Transgenic; Oncogene Proteins; Paclitaxel; Phenotype; Signal Transduction; Th1 Cells; Tumor Burden; Tumor Microenvironment | 2021 |
A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
Topics: Albumins; Breast Neoplasms; Female; Humans; Neoplasm Metastasis; Paclitaxel; Risk Factors; Treatment Outcome | 2021 |
Neuro-immune interactions in paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Neuroimmunomodulation; Paclitaxel; Peripheral Nervous System Diseases | 2021 |
Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Hospitalization; Humans; Insurance Claim Review; Middle Aged; Paclitaxel; Patient Care; Retrospective Studies; Taxoids; Young Adult | 2017 |
Onychomadesis associated with chemotherapy: case report and mini literature review.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Female; Follow-Up Studies; Humans; Nail Diseases; Paclitaxel | 2017 |
A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Humans; Mice; Nanomedicine; Paclitaxel; Polyglutamic Acid; Research Design | 2018 |
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.
Topics: Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cross Reactions; Docetaxel; Drug Hypersensitivity; Female; Humans; Paclitaxel; Taxoids | 2017 |
Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatal Outcome; Female; Humans; Intestinal Perforation; Intestine, Small; Middle Aged; Paclitaxel; Shock, Septic | 2018 |
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Nervous System; Neutropenia; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2019 |
When a metastatic breast cancer is mimicking a pancreatic cancer: case report and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Diagnosis, Differential; Female; Humans; Jaundice; Liver Neoplasms; Lymph Nodes; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retroperitoneal Space; Tomography, X-Ray Computed; Trastuzumab; Ultrasonography; Weight Loss | 2020 |
Adjuvant systemic therapies in breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Mastectomy; Paclitaxel; Practice Guidelines as Topic; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Genes, BRCA1; Humans; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[Impact of taxanes in the adjuvant setting of node-negative breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Methotrexate; Paclitaxel; Tamoxifen; Taxoids | 2013 |
New issues for copper-64: from precursor to innovative PET tracers in clinical oncology.
Topics: Breast Neoplasms; Cell Line, Tumor; Cisplatin; Copper Radioisotopes; Drug Resistance, Neoplasm; Female; Homeostasis; Humans; Male; Neurodegenerative Diseases; Paclitaxel; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals | 2013 |
Everolimus: a new hope for patients with breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Immunosuppressive Agents; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab | 2014 |
Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Topics: Albumins; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Nanoparticles; Nanotechnology; Neoplasm Metastasis; Paclitaxel; Research; Taxoids; Treatment Outcome | 2014 |
Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Asia, Western; Breast Neoplasms; China; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2014 |
Emerging nanotherapeutic strategies in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Drug Delivery Systems; Female; Humans; Liposomes; Micelles; Nanoparticles; Paclitaxel; Polymers; RNA Interference | 2014 |
Liposomal chemotherapeutics.
Topics: Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Multiple Myeloma; Paclitaxel; Pancreatic Neoplasms; Thyroid Neoplasms | 2013 |
CNS metastases in breast cancer: old challenge, new frontiers.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Central Nervous System Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Trastuzumab | 2013 |
[A case of carcinomatous cardiac tamponade caused by breast cancer treated with instillation of paclitaxel and minocycline].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Tamponade; Combined Modality Therapy; Female; Humans; Middle Aged; Minocycline; Paclitaxel; Pericardial Effusion | 2014 |
nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Early Detection of Cancer; Female; Humans; Infusions, Intravenous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2014 |
nab-Paclitaxel for the treatment of aggressive metastatic breast cancer.
Topics: Albumins; Animals; Breast Neoplasms; Female; Humans; Paclitaxel; Prognosis | 2014 |
Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Trastuzumab; Treatment Outcome | 2015 |
The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Neutropenia; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2015 |
Assessing the role of platinum agents in aggressive breast cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Female; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel | 2015 |
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2015 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Secondary breast angiosarcoma and paclitaxel-dependent prolonged disease control: report of two cases and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Hemangiosarcoma; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2015 |
[A case of secondary sclerosing cholangitis caused by chemotherapy with nab-paclitaxel].
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Female; Humans; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pneumonia; Prognosis | 2017 |
[Nab-paclitaxel].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; France; Humans; Neoadjuvant Therapy; Neoplasm Proteins; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Prognosis | 2015 |
Taxane-containing regimens for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Disease Progression; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Tamoxifen; Taxoids | 2015 |
nab-Paclitaxel dose and schedule in breast cancer.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2015 |
Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Vinblastine; Vinorelbine | 2015 |
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
Topics: Albumins; Animals; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Nanoparticles; Paclitaxel; Taxoids | 2016 |
[A Case of a Suspected Photosensitive Reaction Induced by Weekly Paclitaxel as Neoadjuvant Chemotherapy for Breast Cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Photosensitivity Disorders | 2015 |
Adenocarcinoma With Breast/Adnexal and Upper Gastrointestinal Differentiation Arising in an Ovarian Mature Cystic Teratoma: A Case Report and Review of the Literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Female; Gastrointestinal Neoplasms; Humans; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Skin Neoplasms; Teratoma; Treatment Outcome | 2016 |
Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Incidence; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Platinum Compounds; Salpingectomy | 2015 |
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.
Topics: Albumins; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Expert Testimony; Female; Humans; Neoplasm Metastasis; Paclitaxel; Practice Guidelines as Topic; Precision Medicine | 2016 |
[A Case of Disseminated Bone Marrow Carcinomatosis Arising from Breast Cancer for Which Paclitaxel and Bevacizumab Treatment Was Effective].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow Neoplasms; Breast Neoplasms; Female; Humans; Paclitaxel; Treatment Outcome | 2016 |
Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Decision-Making; Disease-Free Survival; Female; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2016 |
Statistical controversies in clinical research: statistical significance-too much of a good thing ….
Topics: Breast Neoplasms; Clinical Medicine; Double-Blind Method; Everolimus; Female; Humans; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2016 |
Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbachol; Cholinergic Agonists; Female; Humans; Paclitaxel; Receptors, Muscarinic | 2016 |
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mutation; Neoplasm Staging; Oncogene Protein v-akt; Paclitaxel; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2016 |
Neoadjuvant nab-paclitaxel in the treatment of breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2016 |
Management of patients treated with pertuzumab in the Australian clinical practice setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Bridged-Ring Compounds; Disease Management; Disease Progression; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2016 |
Systematic review of ixabepilone for treating metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Administration Schedule; Epothilones; Female; Furans; Humans; Ketones; Paclitaxel; Survival Analysis; Treatment Outcome | 2017 |
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Breast Neoplasms; Clinical Trials, Phase I as Topic; Humans; Paclitaxel; Programmed Cell Death 1 Receptor; Triple Negative Breast Neoplasms | 2016 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Fatigue; Female; Humans; Leukopenia; Nanoparticles; Nausea; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Treatment Outcome | 2017 |
MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer.
Topics: Animals; Antineoplastic Agents; Biological Products; Breast Neoplasms; Curcumin; Female; Humans; MicroRNAs; Paclitaxel | 2016 |
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2008 |
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Time Factors; Trastuzumab | 2008 |
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Paclitaxel and docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Guidelines as Topic; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2009 |
Novel anti-tubulin cytotoxic agents for breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Delivery Systems; Epothilones; Female; Furans; Humans; Ketones; Nanoparticles; Paclitaxel; Taxoids; Tubulin Modulators; Vinca Alkaloids | 2009 |
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Delayed-Action Preparations; Drug Compounding; Humans; Paclitaxel; Serum Albumin | 2009 |
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.
Topics: Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2010 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Carriers; Drug Delivery Systems; Female; Humans; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
Controversies in the management of adjuvant breast cancer with taxanes: review of the current literature.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids | 2011 |
[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2011 |
Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2011 |
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous; Mastectomy; Middle Aged; Paclitaxel; Paraneoplastic Syndromes; Ribonucleoproteins; Salvage Therapy; Tamoxifen; Taxoids; Trastuzumab | 2011 |
Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Standard of Care; Taxoids | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Role of gemcitabine in treatment of metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Paclitaxel; Trastuzumab; Treatment Outcome | 2011 |
Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Paclitaxel; Treatment Outcome | 2011 |
Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 2011 |
Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Estrogens; Fatal Outcome; Female; Gallbladder Neoplasms; Humans; Lymph Node Excision; Mastectomy, Segmental; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Postmenopause; Progesterone; Radiotherapy, Adjuvant | 2011 |
The role of antiangiogenetic agents in the treatment of breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Paclitaxel; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2011 |
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
Topics: Albumins; Animals; Breast Neoplasms; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2011 |
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Paclitaxel; Taxoids | 2012 |
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Female; Humans; Infusions, Intravenous; Nanoparticles; Paclitaxel; Treatment Outcome | 2012 |
Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail.
Topics: Aged; Breast Neoplasms; Female; Granuloma, Pyogenic; Humans; Nail Diseases; Paclitaxel | 2012 |
Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cardiotoxins; Disease-Free Survival; Female; Humans; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.
Topics: Antineoplastic Agents; Birth Weight; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Docetaxel; Female; Gestational Age; Humans; Ovarian Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Retrospective Studies; Taxoids | 2012 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Topics: Breast Neoplasms; Docetaxel; Female; Humans; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2012 |
Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
[nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Female; Humans; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel | 2013 |
The current status of docetaxel for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 2002 |
Integration of docetaxel into adjuvant breast cancer treatment regimens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2002 |
Primary chemotherapy with docetaxel for the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2002 |
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
Expanding horizons: an update on the use of docetaxel in non-small cell lung, ovarian, and breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Docetaxel in the treatment of breast cancer: an update on recent studies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Hematologic Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Adjuvant chemotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Paclitaxel; Patient Selection; Postmenopause; Premenopause; Receptors, Estrogen; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Systemic therapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Diphosphonates; Enzyme Inhibitors; ErbB Receptors; Estrogen Receptor Modulators; Female; Humans; Neoplasm Metastasis; Paclitaxel; Patient Care Planning | 2002 |
[Radiation recall dermatitis after docetaxel and external beam radiotherapy. Report of two cases and review of the literature].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiodermatitis; Radiotherapy; Taxoids | 2002 |
Moving forward: Herceptin in the adjuvant setting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Paclitaxel; Time Factors; Trastuzumab | 2002 |
Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
The European experience with docetaxel in the treatment of early-stage breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Europe; Female; Genes, p53; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2002 |
HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Paclitaxel; Platinum Compounds; Receptor, ErbB-2; Taxoids; Trastuzumab; Up-Regulation | 2002 |
Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Risk Factors; Taxoids; Trastuzumab; United States | 2002 |
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Design; Drug Synergism; Enzyme Induction; Epirubicin; Female; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Thymidine Phosphorylase; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Economics, Pharmaceutical; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Research Design; Taxoids; Trastuzumab | 2002 |
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Patient Selection; Treatment Outcome | 2002 |
Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Forecasting; Humans; Paclitaxel; Treatment Outcome | 2002 |
Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Paclitaxel; Taxoids | 2003 |
Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; United States | 2002 |
Short versus long duration infusions of paclitaxel for any adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2003 |
[Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Postmenopause; Premenopause; Survival Analysis; Treatment Outcome | 2002 |
Adjuvant systemic therapy of early stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Enzyme Inhibitors; Female; Humans; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
[News in the medical treatment of breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Trastuzumab | 2003 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials as Topic; Docetaxel; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2003 |
[Gene therapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Genes, erbB-2; Genes, MDR; Genes, p53; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; Interleukins; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Retroviridae; Taxoids | 2003 |
The evolving role of capecitabine in breast cancer.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Prodrugs; Taxoids; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2003 |
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Eruptions; Exudates and Transudates; Female; Fluorouracil; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2003 |
[Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Heart; Heart Diseases; Humans; Paclitaxel | 2003 |
[Reduction of adverse reactions of anticancer agents with altered dose and schedule].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel | 2003 |
Docetaxel-anthracycline combinations in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
The role of taxanes in the adjuvant treatment of early stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2003 |
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2003 |
Cardiotoxic effects of anthracycline-taxane combinations.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Heart Diseases; Humans; Paclitaxel; Risk; Taxoids | 2003 |
Taxane containing regimens for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Disease Progression; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Tamoxifen; Taxoids | 2003 |
ABI 007.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Breast Neoplasms; Clinical Trials, Phase II as Topic; Humans; Injections, Intra-Arterial; Paclitaxel; Taxoids | 2003 |
Use and abuse of taxanes in the management of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bias; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Substance-Related Disorders; Taxoids | 2003 |
[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Drug Screening Assays, Antitumor; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab | 2003 |
Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Incidence; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Probability; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Time Factors; Treatment Outcome | 2003 |
Liposomal anthracyclines in metastatic breast cancer: clinical update.
Topics: Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Doxorubicin; Heart Diseases; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel | 2003 |
Liposomal anthracyclines for breast cancer: overview.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Doxorubicin; Heart Failure; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel | 2003 |
Advances in the use of taxanes in the adjuvant therapy of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Ifosfamide in advanced/disseminated breast cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Neoplasm Staging; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Liver Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2003 |
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
Topics: Animals; Breast Neoplasms; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids | 2003 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
The best use of chemotherapy in the adjuvant setting.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2003 |
[Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Retreatment; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Inflammation; Middle Aged; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
Trastuzumab in the treatment of advanced breast cancer. Our single-center experience and spotlights of the latest national consensus meeting.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2004 |
ABI 007.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Humans; Paclitaxel; Taxoids | 2004 |
Taxanes in elderly breast cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Bevacizumab in the treatment of breast cancer: rationale and current data.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel; Vascular Endothelial Growth Factor A | 2004 |
Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Paclitaxel | 2004 |
Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Outcome; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2004 |
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Paclitaxel | 2004 |
Gemcitabine and paclitaxel in metastatic breast cancer: a review.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2004 |
[Centrosome as an organizing center of intracellular information: insights viewed from the spindle pole of budding yeast].
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calcium-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Centrosome; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, cdc; Humans; Mitosis; Paclitaxel; Phosphorylases; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Spindle Apparatus; Tubulin; Tubulin Modulators | 2005 |
Taxane containing regimens for metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Disease Progression; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Tamoxifen; Taxoids | 2005 |
[Dose density and dose intensity in the treatment of breast cancer].
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 2004 |
Therapy of breast cancer with molecular targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab | 2005 |
The role of taxanes in the treatment of breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Taxanes in adjuvant breast cancer setting: which standard in Europe?
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Europe; Female; Humans; Paclitaxel; Taxoids | 2005 |
Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo.
Topics: Alternative Splicing; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Immunohistochemistry; In Vitro Techniques; Inhibitory Concentration 50; Microtubule-Associated Proteins; Microtubules; Models, Biological; Oligonucleotide Array Sequence Analysis; Paclitaxel; RNA, Messenger; RNA, Small Interfering; tau Proteins; Tubulin | 2005 |
Gemcitabine plus paclitaxel in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2005 |
Angiosarcoma of the breast with delay in diagnosis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Biopsy; Breast Neoplasms; Carcinoma; Diagnosis, Differential; Early Diagnosis; False Negative Reactions; Fatal Outcome; Female; Hemangiosarcoma; Humans; Lymph Node Excision; Mastectomy, Segmental; Middle Aged; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Paclitaxel; Pigmentation Disorders; Radiodermatitis; Radiotherapy, Adjuvant; Telangiectasis | 2004 |
Neuropathic pain associated with non-surgical treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Female; Humans; Neuralgia; Paclitaxel; Peripheral Nerves; Peripheral Nervous System Diseases; Radiation Injuries; Radiotherapy; Rats | 2005 |
Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2005 |
Taxanes in the treatment of early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2005 |
What is the best schedule for administration of gemcitabine-taxane?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Remission Induction; Taxoids; Trastuzumab | 2005 |
Towards a therapeutic breast cancer vaccine: the next steps.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Humans; Immune Tolerance; Immunotherapy; Paclitaxel; Randomized Controlled Trials as Topic; T-Lymphocytes; Trastuzumab | 2005 |
Role of Gemcitabine in Breast Cancer Management: An Update.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2 | 2006 |
Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Gene therapy for breast cancer. --Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Combined Modality Therapy; DNA, Complementary; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Retroviridae; Transduction, Genetic; Transplantation, Autologous | 2006 |
Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Humans; Paclitaxel | 2005 |
Use of dose-dense chemotherapy in the management of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Movement; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2006 |
[Clinical trials of vnorelbine in breast cancer--its scientific usefulness and development history until regulatory approval].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Approval; Female; Fluorouracil; Humans; Japan; Lung Neoplasms; Male; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2006 |
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2006 |
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Paclitaxel | 2006 |
Albumin-bound paclitaxel: a next-generation taxane.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Drug Administration Schedule; Drug Delivery Systems; Endothelial Cells; Female; Glycerol; Humans; Infusions, Intra-Arterial; Nanotechnology; Neoplasm Metastasis; Osteonectin; Paclitaxel; Randomized Controlled Trials as Topic; Solvents; Survival Rate; Therapeutic Equivalency | 2006 |
Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2006 |
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
New therapies in the treatment of breast cancer.
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Fulvestrant; Humans; MAP Kinase Signaling System; Paclitaxel; Sirolimus; Vinblastine | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2006 |
[Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2006 |
Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Paclitaxel | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
[Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer].
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Contraindications; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Pharmacogenetics and oncology treatment for breast cancer.
Topics: Aromatase Inhibitors; Biological Transport; Breast Neoplasms; Cytochrome P-450 CYP2D6; Docetaxel; Female; Gene Amplification; Genes, bcl-1; Glucuronosyltransferase; Humans; Paclitaxel; Pharmacogenetics; Tamoxifen; Taxoids | 2007 |
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Receptors, Estrogen; Survival Analysis; Taxoids; Tumor Burden | 2007 |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
Managing cardiotoxicity in anthracycline-treated breast cancers.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Heart; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel; Razoxane; Trastuzumab | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2007 |
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Paclitaxel | 2007 |
[Role of G-CSF for breast cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel | 2007 |
[Breast conserving surgery after preoperative chemotherapy].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Evidence-Based Medicine; Female; Humans; Mastectomy, Segmental; Paclitaxel; Preoperative Care; Prognosis; Sentinel Lymph Node Biopsy; Taxoids; Trastuzumab | 2007 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Docetaxel; Female; Fluorouracil; Humans; Informed Consent; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Patient Care Team; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Silicates; Taxoids; Titanium; Trastuzumab | 2007 |
[Updates on gemcitabine on metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Trastuzumab; Vinblastine; Vinorelbine | 2007 |
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Mastectomy; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Models, Biological; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2007 |
Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Lapatinib; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2008 |
Taxanes for adjuvant treatment of early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2007 |
Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2008 |
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Staging; Paclitaxel; Prognosis | 2007 |
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Topics: Animals; Bone Marrow; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Tubulin Modulators | 2008 |
Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Making; Docetaxel; Early Diagnosis; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Uncertainty | 2008 |
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
Preclinical investigations with epothilones in breast cancer models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Epothilones; Female; Fluorouracil; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Tubulin Modulators | 2008 |
Treatment of metastatic breast cancer: looking towards the future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Lapatinib; Medical Oncology; Neoplasm Metastasis; Paclitaxel; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
The taxane limbo: how low can we go?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Meta-Analysis as Topic; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Retrospective Studies; Taxoids | 2008 |
Management of breast cancer: status and future trends.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Hormones; Humans; Mastectomy; Neoplasm Metastasis; Paclitaxel | 1995 |
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Growth Substances; Humans; Lymphatic Metastasis; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic | 1995 |
[Paclitaxel, a new anticancer drug].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel | 1994 |
Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis | 1995 |
[Use of taxol in the management of malignant tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Testicular Neoplasms | 1995 |
[Autologous hematopoietic stem cell transplantation for the treatment of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel | 1995 |
Current status of vinorelbine for breast cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Fluorouracil; Humans; Infusions, Intravenous; Mitomycins; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome; Vinblastine; Vinorelbine | 1995 |
Docetaxel.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Female; Humans; Paclitaxel | 1995 |
[Current issues in the chemotherapy of malignant tumors. Taxol (paclitaxel), Taxoter].
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Humans; Neoplasms; Neoplasms, Experimental; Paclitaxel | 1994 |
[Taxenes: a new hope of clinical oncology in the 90-ies].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins | 1993 |
[Recent advance in chemotherapy for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Docetaxel; Female; Humans; Irinotecan; Mitoxantrone; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids | 1994 |
Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
Current status of paclitaxel in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Humans; Paclitaxel | 1995 |
Current status of Taxotere (docetaxel) as a new treatment in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Tolerance; Humans; Paclitaxel; Taxoids | 1995 |
Single-agent use of Taxol (paclitaxel) in breast cancer.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance; Female; Humans; Neoplasm Staging; Paclitaxel; Salvage Therapy | 1994 |
Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiotherapy, Adjuvant; Treatment Outcome | 1994 |
Taxol (paclitaxel): mechanisms of action.
Topics: Animals; Binding Sites; Breast Neoplasms; Cell Cycle; Female; Humans; Microtubules; Ovarian Neoplasms; Paclitaxel; Radiotherapy, Adjuvant | 1994 |
Taxol (paclitaxel): future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Forecasting; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1994 |
Paclitaxel (taxol)
Topics: Arrhythmias, Cardiac; Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
[Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes].
Topics: Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Otorhinolaryngologic Neoplasms; Ovarian Neoplasms; Paclitaxel; Spindle Apparatus | 1994 |
Overview of paclitaxel (TAXOL).
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Microtubules; Ovarian Neoplasms; Paclitaxel | 1993 |
[Favorable remission rates of metastatic breast cancer with taxol therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1993 |
Taxol: initial Israeli experience with a novel anticancer agent.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Israel; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Time Factors | 1994 |
Paclitaxel (Taxol) in breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Resistance; Female; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents | 1994 |
[Microtubules and antineoplastic drugs].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Lactones; Lung Neoplasms; Macrolides; Microtubule-Associated Proteins; Microtubules; Ovarian Neoplasms; Paclitaxel; Tubulin; Vinca Alkaloids | 1994 |
[Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
Topics: Breast Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Survival Rate | 1994 |
New chemotherapeutic agents for breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1994 |
Update on the antitumor activity of paclitaxel in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1994 |
Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Dogs; Drug Screening Assays, Antitumor; Female; Humans; Mice; Ovarian Neoplasms; Paclitaxel; Rats; Taxoids; Tumor Cells, Cultured | 1994 |
Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Humans; National Institutes of Health (U.S.); Neoplasm Metastasis; Paclitaxel; United States | 1994 |
The taxoids: paclitaxel and docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Hypersensitivity; Drug Interactions; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1994 |
Taxol dose intensification and its clinical implications.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1993 |
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1993 |
An overview of experience with TAXOL (paclitaxel) in the U.S.A.
Topics: Breast Neoplasms; Head and Neck Neoplasms; Heart; Humans; Lung Neoplasms; Neoplasms; Nervous System; Paclitaxel; United States | 1993 |
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lethal Dose 50; Lung Neoplasms; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Case report: paclitaxel-induced myocardial ischemia.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Myocardial Ischemia; Neoplasm Metastasis; Paclitaxel | 1996 |
Taxoid compounds in breast cancer: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1995 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa | 1995 |
Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 1995 |
Taxoids: effective agents in anthracycline-resistant breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere) in combination: a step forward.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Clinical Trials as Topic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
The role of taxanes in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Taxoids | 1996 |
Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Humans; Paclitaxel; Randomized Controlled Trials as Topic; United States | 1996 |
Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; United States | 1996 |
Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
Single-agent paclitaxel for the treatment of breast cancer: an overview.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic | 1996 |
Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1995 |
Transient encephalopathy after paclitaxel (Taxol) infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Brain Diseases; Breast Neoplasms; Cognition Disorders; Electroencephalography; Fatal Outcome; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Paclitaxel | 1996 |
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Docetaxel: a new defence in the management of breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Female; Humans; Liver Neoplasms; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 1995 |
Paclitaxel dose intensity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel | 1996 |
Docetaxel (Taxotere) for advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Melanoma; Microtubules; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Paclitaxel | 1996 |
Docetaxel: a review of its pharmacology and clinical activity.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Eruptions; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Microtubules; Neutropenia; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Taxoids; Tubulin | 1996 |
Treatment of advanced breast cancer: current status.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1996 |
Treatment of patients with liver metastases.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Liver Neoplasms; Paclitaxel; Taxoids | 1996 |
The clinical rationale for developing docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; Humans; Paclitaxel; Taxoids | 1996 |
Taxoids in combination chemotherapy for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Paclitaxel and carboplatin for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Breast Neoplasms; Carboplatin; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Tolerance; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Quality of Life; Thrombopoietin | 1996 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Topics: Aminopterin; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Synergism; Drugs, Investigational; Female; Fluorouracil; Genetic Therapy; Humans; Leucovorin; Neoplasm Metastasis; Oncogenes; Paclitaxel; Radiotherapy, Adjuvant | 1996 |
Paclitaxel-induced radiation recall dermatitis.
Topics: Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiodermatitis | 1996 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Fluorouracil; Humans; Ifosfamide; Neoplasm Metastasis; Paclitaxel | 1996 |
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Breast Cancer I.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
[Progress and perspectives in palliative therapy of breast carcinoma].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Goserelin; Humans; Paclitaxel; Palliative Care; Tamoxifen; Taxoids | 1996 |
Paclitaxel and doxorubicin in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Humans; Neoplasm Metastasis; Paclitaxel | 1996 |
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Vinblastine; Vinorelbine | 1996 |
Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel | 1997 |
The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Paclitaxel | 1997 |
[Paclitaxel in therapy of breast carcinoma. Value and perspectives].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Paclitaxel; Survival Rate | 1996 |
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 4: Breast Cancer II. Marrakech, Morocco, January 18-20, 1996 and St Croix, US Virgin Islands, March 13-16, 1996.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Paclitaxel | 1997 |
The taxanes: dosing and scheduling considerations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1997 |
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Paclitaxel; Quality of Life | 1997 |
Paclitaxel-based combination chemotherapy for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Paclitaxel | 1997 |
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptor, ErbB-2 | 1997 |
The international experience with docetaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1997 |
Paclitaxel (Taxol)--a guide to administration.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Oncology Nursing; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic | 1996 |
Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Forecasting; Humans; Paclitaxel | 1997 |
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life | 1997 |
Docetaxel in breast cancer and a rationale for combination therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Mice; Paclitaxel; Taxoids | 1997 |
Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel a
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Paclitaxel | 1996 |
[Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin | 1997 |
Docetaxel. A review of its role in breast cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Paclitaxel; Remission Induction; Safety; Taxoids | 1997 |
Generalized pustular dermatosis following paclitaxel therapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Diagnosis, Differential; Drug Eruptions; Female; Humans; Neoplasms; Paclitaxel; Skin Diseases, Vesiculobullous | 1997 |
Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Future perspectives of docetaxel (Taxotere) in front-line therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Taxoids | 1997 |
Paclitaxel and docetaxel in breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1997 |
[Antimitotic agents].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Small Cell; Drosophila Proteins; Estramustine; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lung Neoplasms; Mice; Microtubules; Ovarian Neoplasms; Paclitaxel; Vinca Alkaloids | 1997 |
Conceptual basis for advances in the systemic drug therapy of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Paclitaxel; Patient Selection | 1997 |
The taxoids: same roots, different drugs.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance; Female; Humans; Paclitaxel; Taxoids | 1997 |
[A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 1997 |
Anthracyclines-paclitaxel combinations in the treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Epirubicin; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
The pharmacoeconomics of cancer therapies.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Quality of Life | 1997 |
Efficacy and safety of docetaxel in clinical trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Male; Paclitaxel; Taxoids | 1997 |
[Docetaxel (taxotere) for therapy of breast carcinoma. Highest effectiveness with moderate side effects].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Synergism; Female; Humans; Liver Neoplasms; Paclitaxel; Survival Rate; Taxoids | 1997 |
Fibrin sheath formation and chemotherapy extravasation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheterization, Central Venous; Catheters, Indwelling; Constriction, Pathologic; Cyclophosphamide; Equipment Failure; Extravasation of Diagnostic and Therapeutic Materials; Female; Fibrin; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Plasminogen Activators; Urokinase-Type Plasminogen Activator | 1998 |
The taxoids. Comparative clinical pharmacology and therapeutic potential.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
Review of recent trials of chemotherapy for advanced breast cancer: the taxanes.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
The role of docetaxel in improving treatment outcomes in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination with doxorubicin or vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Prospects with docetaxel in the treatment of patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Taxanes in adjuvant and neoadjuvant therapies for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1998 |
Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Phenotype; Taxoids | 1998 |
Primary chemotherapy regimens and schedules.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids | 1998 |
Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Humans; Lymph Node Excision; Mastectomy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1998 |
Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms | 1998 |
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Mitoxantrone; Neoplasm Staging; Paclitaxel; Taxoids; Thiotepa | 1998 |
[The effect of docetaxel on malignant tumors].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1998 |
[Chemotherapy in metastasized breast carcinoma].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Palliative Care; Quality of Life; Survival Rate; Taxoids | 1998 |
Docetaxel: a taxoid for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1998 |
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1998 |
[Current developments in use of docetaxel (taxotere) in gynecologic oncology].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 1998 |
The emerging role of paclitaxel in breast cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Mice; Mice, Nude; Paclitaxel; Randomized Controlled Trials as Topic; Transplantation, Heterologous | 1995 |
[Taxanes in the treatment of breast and ovarian cancers: current indications and results].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
An expanding role for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1998 |
Evolution in the treatment of advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Research Design; Taxoids | 1998 |
Taxanes in the treatment of breast cancer: a prodigy comes of age.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Palliative Care; Survival Analysis; Taxoids; Tubulin; Vinca Alkaloids | 1999 |
The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Humans; Neoplasm Metastasis; Paclitaxel | 1999 |
Metastatic breast cancer: the role of chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy | 1999 |
Kinetic concepts in the systemic drug therapy of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 1999 |
Paclitaxel plus nonanthracycline combinations in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Humans; Neoplasm Metastasis; Paclitaxel | 1999 |
A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recently initiated studies: neoadjuvant treatments in the next century.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1999 |
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. St. Thomas, U.S.Virgin Islands, March 25-29, 1998. Proceedings and abstracts.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1999 |
[Taxotere as second-line for metastatic breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Monotherapy of metastatic breast cancer: a review of newer agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Paclitaxel; Palliative Care; Taxoids; Vinblastine; Vinorelbine | 1999 |
Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Economics, Pharmaceutical; Female; Humans; Paclitaxel; Taxoids | 1998 |
The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
Single-agent paclitaxel in the treatment of breast cancer: phase I and II development.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Paclitaxel | 1999 |
Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 1999 |
Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Mitomycin; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine | 1999 |
Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Pyrazoles; Pyrazolones; Randomized Controlled Trials as Topic | 1999 |
Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Single-agent docetaxel (Taxotere) in randomized phase III trials.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Failure | 1999 |
Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Recent progress in the clinical development of docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Xeloda in the treatment of metastatic breast cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
Taxanes in combined-modality therapy for solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids | 1999 |
Expanding options in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Current and potential chemotherapeutic agents used for induction chemotherapy in the treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorouracil; Humans; Paclitaxel; Tamoxifen | 2000 |
New developments in chemotherapy of advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doxorubicin; Humans; Paclitaxel; Phenyl Ethers; Randomized Controlled Trials as Topic; Trastuzumab | 1999 |
[New combination chemotherapies for breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Taxol in the management of cancers of the breast and the ovary.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Ovarian Neoplasms; Paclitaxel; Prognosis | 2000 |
Docetaxel: an update of its use in advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Economics, Pharmaceutical; Female; Humans; Metabolic Clearance Rate; Paclitaxel; Taxoids; Tissue Distribution; Tumor Cells, Cultured | 2000 |
The taxanes: an update.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel (Taxotere) in the treatment of cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Taxoids | 2000 |
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Prognosis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Radiation-Sensitizing Agents | 2000 |
Role of erbB2 in breast cancer chemosensitivity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Female; Gene Expression; Genes, erbB-2; Humans; Paclitaxel; Trastuzumab; Tretinoin | 2000 |
Preliminary report concomitant irradiation and paclitaxel as radiosensitizer to increase the operability of unresectable locally advanced breast cancer.
Topics: Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2000 |
[Evidenced-based medicine and future direction of Taxol].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Evidence-Based Medicine; Female; Forecasting; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Signal Transduction | 2000 |
[Evidence for Taxotere treatment with solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Evidence-Based Medicine; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Stomach Neoplasms; Taxoids | 2000 |
[Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Evidence-Based Medicine; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Humans; Immunotherapy; Paclitaxel; Trastuzumab | 2000 |
Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Choroid Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Meningeal Neoplasms; Methotrexate; Mitoxantrone; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Neoadjuvant chemotherapy for locally advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Premedication; Tamoxifen; Taxoids | 2000 |
[Neoadjuvant chemotherapy for breast-conservative surgery].
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Female; Humans; Paclitaxel; Premedication; Taxoids; Treatment Outcome | 2000 |
[Standard chemotherapy for metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Practice Guidelines as Topic; Prognosis; Taxoids | 2000 |
[Docetaxel hydrate for treatment of advanced breast cancers].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2000 |
[Paclitaxel for treatment of advanced breast cancers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Hypersensitivity; Female; Humans; Paclitaxel; Trastuzumab | 2000 |
[Overview of vinorelbine for metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Humans; Mitoxantrone; Paclitaxel; Vinblastine; Vinorelbine | 2000 |
[Chemosensitivity test of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Taxoids; Tumor Cells, Cultured | 2000 |
State-of-the-art chemotherapy for advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2000 |
Current and planned clinical trials with trastuzumab (Herceptin).
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Humans; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Trastuzumab | 2000 |
A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis; Taxoids | 2000 |
Risks and benefits of taxanes in breast and ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Paclitaxel; Premedication; Taxoids | 2000 |
Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Databases, Factual; Enzyme Inhibitors; Flavonoids; Humans; Microtubule-Associated Proteins; Neovascularization, Pathologic; Oncogenes; Paclitaxel; Piperidines; Receptors, Estrogen; Tamoxifen; Transforming Growth Factor beta; Trastuzumab; Tumor Suppressor Proteins | 2000 |
Current perspectives for treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Trastuzumab | 2000 |
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Trastuzumab | 2000 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Heart; Heart Failure; Humans; Incidence; Paclitaxel | 2001 |
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Docetaxel; Drug Synergism; Genes, erbB-2; Heart Failure; Humans; Paclitaxel; Prognosis; Proto-Oncogene Mas; Taxoids; Trastuzumab | 2001 |
New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Genes, erbB-2; Humans; Paclitaxel; Trastuzumab | 2001 |
Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; ErbB Receptors; Genes, erbB-2; Heart; Heart Failure; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2001 |
The platinum agents: a role in breast cancer treatment?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Trastuzumab | 2001 |
Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Methylprednisolone; Middle Aged; Paclitaxel; Taxoids; Thiotepa | 2001 |
Issues involved in research into the neoadjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Research; Taxoids | 2001 |
Docetaxel: overview of an active drug for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Docetaxel and epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2001 |
Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Weekly docetaxel in breast cancer: applying clinical data to patient therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chronotherapy; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2001 |
Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Oligonucleotides, Antisense; Paclitaxel; Taxoids | 2001 |
Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Humans; Paclitaxel; Taxoids | 2001 |
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Neoplasms; Nonlinear Dynamics; Paclitaxel; Prospective Studies; Research Design; Taxoids | 2001 |
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Topics: Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Italy; Meta-Analysis as Topic; Paclitaxel; Taxoids | 2001 |
New combinations with epirubicin in advanced breast cancer.
Topics: Adult; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Rate; Time Factors | 2001 |
Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel.
Topics: Breast Neoplasms; Clinical Trials, Phase I as Topic; Cytotoxins; Drug Delivery Systems; Drug Resistance, Multiple; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2001 |
Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Meta-Analysis as Topic; Middle Aged; Paclitaxel; Survival Rate | 2001 |
Paclitaxel: epirubicin in metastatic breast cancer--a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Epirubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
New cytotoxic agents and schedules for advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Adjuvant chemotherapy for breast cancer: an update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Doxorubicin; Female; Humans; Paclitaxel; Trastuzumab | 2001 |
Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Paclitaxel; Practice Guidelines as Topic; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Trastuzumab | 2001 |
Pharmacokinetic profiles of doxorubicin in combination with taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Drug Interactions; Humans; Paclitaxel; Taxoids | 2001 |
Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2001 |
Combined anthracycline-taxane regimens in the adjuvant setting.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Humans; Paclitaxel | 2001 |
Epirubicin in combination with the taxanes.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Epirubicin; Heart Diseases; Humans; Paclitaxel; Taxoids | 2001 |
[Clinical use of oxaliplatin in solid tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Prostatic Neoplasms; Vinblastine; Vinorelbine | 2001 |
[Recall dermatitis caused by re-exposure to docetaxel following irradiation of the brain. Case report and review of the literature].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Drug Eruptions; Female; Humans; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Taxoids | 2001 |
[Paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Paclitaxel | 2001 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids | 2001 |
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Safety; Single-Blind Method; Survival Analysis; Trastuzumab; Treatment Outcome | 2001 |
Dose scheduling--Herceptin.
Topics: Abdominal Muscles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Feasibility Studies; Female; Fluorouracil; Half-Life; Haplorhini; Humans; Infusions, Intravenous; Injections, Subcutaneous; Methotrexate; Neoplasm Metastasis; Paclitaxel; Safety; Trastuzumab; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Interaction between Herceptin and taxanes.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Role of Herceptin in primary breast cancer: views from North America and Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Interactions; Europe; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; North America; Paclitaxel; Palliative Care; Pilot Projects; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Safety; Survival Analysis; Tamoxifen; Taxoids; Trastuzumab; Treatment Outcome | 2001 |
Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Drug Resistance, Neoplasm; Gene Expression; Genes, erbB-2; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Cost effectiveness of treatment options in advanced breast cancer in the UK.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Docetaxel; Female; Humans; Paclitaxel; Quality-Adjusted Life Years; Salvage Therapy; Taxoids; United Kingdom; Vinblastine; Vinorelbine | 2001 |
Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Interleukin-2; Multicenter Studies as Topic; Paclitaxel; Prognosis; Receptor, ErbB-2; Trastuzumab | 2002 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
Paclitaxel in the adjuvant setting: results so far are inconclusive.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2001 |
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Platinum compounds in the treatment of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Mastectomy; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Preoperative Care; Severity of Illness Index; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Utilization; Female; Humans; Medical Oncology; Paclitaxel; Patient Selection; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
[Weekly administration of paclitaxel in the treatment of metastatic breast cancer: from rational to practice].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Humans; Paclitaxel; Trastuzumab | 2002 |
The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Decision Making; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Prognosis; Research Design; Taxoids | 2001 |
Role of epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
[Trastuzumab (Herceptin)].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Heart; Humans; Mice; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2002 |
Trials of new combinations of Herceptin in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Breast cancer response to paclitaxel in vivo.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Cycle; Disease-Free Survival; Female; Humans; Paclitaxel | 2001 |
Paclitaxel in cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel | 2002 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Taxol: the first of the taxanes, an important new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Evaluation; Drug Evaluation, Preclinical; Drugs, Investigational; Female; Forecasting; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Ovarian Neoplasms; Paclitaxel | 1992 |
[Cancer of the breast].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tamoxifen | 1992 |
1163 trial(s) available for paclitaxel and Breast Neoplasms
| Article | Year |
|---|---|
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel | 2021 |
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Analysis of Variance; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; China; Confidence Intervals; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Premenopause; Progression-Free Survival; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Viscera | 2021 |
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Hormones; Humans; Neoplasm Recurrence, Local; Paclitaxel; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Receptor, ErbB-2 | 2022 |
Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carboplatin; Female; Germ Cells; Humans; Paclitaxel | 2022 |
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Male; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Testicular Neoplasms; Trastuzumab | 2022 |
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Impact of Cold Therapy on Paclitaxel-Induced Peripheral Neuropathy and Quality of Life in Patients With Breast Cancer.
Topics: Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2022 |
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Female; Humans; Mutation; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Toluidines | 2022 |
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Paclitaxel; Protein Kinase Inhibitors; Trastuzumab; Treatment Outcome | 2022 |
Comparison of three standard neoadjuvant chemotherapy regimens based on pathological tumor response in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Trastuzumab; Young Adult | 2022 |
Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Topics: Acrylamides; Albumins; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Diarrhea; Female; Humans; Incidence; Neoplasm Staging; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Treatment Outcome | 2022 |
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Topics: Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Transforming Growth Factor beta; Triple Negative Breast Neoplasms | 2022 |
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carboplatin; Female; Humans; Paclitaxel | 2022 |
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Male; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 tr
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Trastuzumab | 2022 |
Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.
Topics: Breast Neoplasms; Female; Humans; Paclitaxel; Progression-Free Survival; Skin Neoplasms; Treatment Outcome | 2022 |
Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia - a randomized controlled trial.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Hypothermia, Induced; Paclitaxel; Prospective Studies; Scalp; Taxoids | 2022 |
EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE.
Topics: Acetylcholinesterase; Aminoquinolines; Breast Neoplasms; Cholinesterase Inhibitors; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Thioctic Acid | 2022 |
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Denosumab; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2022 |
Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Doxorubicin; Female; Humans; Neurotensin; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Thioctic Acid; Tumor Necrosis Factor-alpha | 2022 |
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Breast Neoplasms; Female; Humans; Ligands; Nivolumab; Paclitaxel; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
[Neoadjuvant Epirubicin-Cyclophosphamide Therapy followed by Nab-Paclitaxel in Patients with Operable Breast Cancer-A Single-Center Phase Ⅱ Trial].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2022 |
Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial.
Topics: Albumins; Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2022 |
A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2022 |
Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Polymers | 2022 |
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Female; Humans; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab | 2022 |
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; RNA; Trastuzumab | 2023 |
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Immunoglobulin G; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Transcriptome; Trastuzumab; Treatment Outcome | 2023 |
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2023 |
Efficacy of Duloxetine on electrodiagnostic findings of Paclitaxel-induced peripheral neuropathy, does it have a prophylactic effect? A randomized clinical trial.
Topics: Breast Neoplasms; Duloxetine Hydrochloride; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES.
Topics: Acetylcholinesterase; Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Sural Nerve; Thioctic Acid | 2022 |
Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial.
Topics: Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2023 |
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Topics: Breast; Breast Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2023 |
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum; Prospective Studies; Quality of Life; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2023 |
Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 2023 |
Mild Cryotherapy for Prevention of Paclitaxel-Induced Nail Toxicity in Breast Cancer Patients: A Phase II Single-Arm Clinical Trial.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cryotherapy; Female; Humans; Ice; Middle Aged; Nail Diseases; Onycholysis; Paclitaxel; Young Adult | 2023 |
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hair; Humans; Hypothermia, Induced; Neoplasms; Paclitaxel; Registries; Scalp | 2023 |
Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Breast Neoplasms; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms | 2023 |
Persistent weekly paclitaxel-induced peripheral neuropathy in early breast cancer patients enrolled in a randomized trial of cryotherapy.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cross-Sectional Studies; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quality of Life; Receptor, ErbB-2; Trastuzumab | 2023 |
Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
Effect of cilostazol on preventing paclitaxel-induced neuropathy in patients with breast cancer: A randomized controlled trial.
Topics: Breast Neoplasms; Cilostazol; Female; Humans; Nerve Growth Factor; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2023 |
Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort.
Topics: Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Paclitaxel; Receptor, ErbB-2 | 2023 |
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Fulvestrant; Humans; Mutation; Paclitaxel | 2023 |
A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Gloves, Surgical; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bioaccumulation; Blood Glucose; Brain; Brassica napus; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Catalysis; Child; China; Chlorides; Chlorine; Chromium; Chronic Disease; Cohort Studies; Copper; Corrosion; COVID-19; Creatinine; Dermatitis; Diabetes Mellitus; Diazepam; Disease-Free Survival; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Dyspnea; Electron Spin Resonance Spectroscopy; Environmental Monitoring; Escherichia coli; Escherichia coli Infections; Esophageal Neoplasms; Esophagogastric Junction; Estradiol; Exercise Test; Exercise Tolerance; Female; Ferric Compounds; Fishes; Food Chain; gamma-Aminobutyric Acid; Genomics; Halogenation; HEK293 Cells; Hemolysis; Heterocyclic Compounds; Hospitalization; Humans; Hydrogen Peroxide; Hyperglycemia; Introns; Iron; Kidney; Kinetics; Laboratories; Limit of Detection; Lipopolysaccharides; Liver Neoplasms; Magnesium; Male; Mammals; Materials Testing; Mercury; Metal-Organic Frameworks; Methylmercury Compounds; Mice; Microscopy, Electron, Scanning; Mifepristone; Minerals; Molecular Weight; Mutation; Nanoparticles; Neuroprotection; NF-kappa B; Nitrates; Nitrogen; NLR Family, Pyrin Domain-Containing 3 Protein; Orthopedics; Ovarian Neoplasms; Ovariectomy; Oxidation-Reduction; Oxidative Stress; Oxygen; Oxygen Consumption; Paclitaxel; Phenols; Progesterone; Prospective Studies; Proteins; Protons; Pulmonary Disease, Chronic Obstructive; Ramucirumab; Rats; Receptor, ErbB-2; Respiratory Function Tests; Retrospective Studies; Saliva; SARS-CoV-2; Seeds; Sesbania; Shock, Septic; Silicon Dioxide; Sleep; Soil; Specimen Handling; Spectroscopy, Mossbauer; Spin Labels; Staphylococcus aureus; Stomach Neoplasms; Streptococcus mutans; Thiamine; Toll-Like Receptor 2; Toll-Like Receptor 4; Trastuzumab; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Ubiquitin-Protein Ligases; Water; Water Pollutants, Chemical; Water Purification; Xeroderma Pigmentosum; Zebrafish | 2023 |
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinica
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Vinorelbine | 2023 |
A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2.
Topics: Acute Pain; Breast Neoplasms; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects | 2023 |
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Mice; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Risk Factors; Vitamin D; Vitamin D Deficiency | 2023 |
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Treatment Outcome; Tumor Burden | 2019 |
Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; RNA, Long Noncoding | 2019 |
Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cryotherapy; Female; Foot; Hand; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Prospective Studies | 2019 |
Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Exercise Therapy; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Quality of Life; Survival Rate | 2019 |
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab; United States; Young Adult | 2019 |
[Effects of cryotherapy on chemotherapy-induced peripheral neuropathy: self-controlled clinical trial].
Topics: Antineoplastic Agents; Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2019 |
Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cancer-Associated Fibroblasts; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Stromal Cells; Transcriptome | 2019 |
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Breast Neoplasms; Cyclophosphamide; Dietary Supplements; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Proportional Hazards Models; Vitamins | 2020 |
Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Compression Bandages; Cryotherapy; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome | 2020 |
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Heart Diseases; Humans; Middle Aged; Paclitaxel; Trastuzumab | 2020 |
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Heterocyclic Compounds, 3-Ring; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Steroid; Trastuzumab | 2020 |
Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients.
Topics: Aged; Breast Neoplasms; Cryotherapy; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Surveys and Questionnaires | 2020 |
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Polyethylene Glycols; Progression-Free Survival; Receptor, ErbB-2; Time Factors; Triple Negative Breast Neoplasms | 2020 |
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Incidence; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Premenopause; Prognosis; Prospective Studies; Receptors, Estrogen; Retrospective Studies; Taxoids; Young Adult | 2020 |
Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lipid Peroxidation; Malondialdehyde; Middle Aged; Nerve Growth Factor; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life | 2020 |
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2020 |
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Therapeutic Equivalency; Tomography, X-Ray Computed; Trastuzumab; Young Adult | 2020 |
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carboplatin; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Treatment Outcome | 2020 |
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Paclitaxel; Survival Analysis; Trastuzumab; Treatment Outcome | 2020 |
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Membrane Proteins; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinorelbine | 2021 |
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Transcriptome; Trastuzumab; Young Adult | 2020 |
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Case-Control Studies; Cost-Benefit Analysis; Cross-Linking Reagents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Trastuzumab; Tubulin Modulators; United States | 2020 |
Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2021 |
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Janus Kinase Inhibitors; Middle Aged; Neoplasm Metastasis; Nitriles; Paclitaxel; Pyrazoles; Pyrimidines; Receptor, ErbB-2 | 2021 |
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Furans; Humans; Ketones; Paclitaxel; Quality of Life; Treatment Outcome | 2021 |
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Furans; Homologous Recombination; Humans; Japan; Ketones; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Paclitaxel; Pregnancy; Treatment Outcome | 2021 |
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Feasibility Studies; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Propranolol; Receptor, ErbB-2; Treatment Outcome | 2021 |
Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Progression-Free Survival; Receptor, ErbB-2; Treatment Outcome | 2021 |
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Height; Body Mass Index; Body Weight; Breast Neoplasms; Epothilones; Exercise; Female; Humans; Middle Aged; Obesity; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Treatment Outcome; Young Adult | 2021 |
Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
Topics: Adult; Aged; Breast Neoplasms; Compression Bandages; Double-Blind Method; Female; Gloves, Surgical; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Young Adult | 2021 |
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Trastuzumab | 2021 |
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Universities | 2021 |
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Topics: Ado-Trastuzumab Emtansine; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Maytansine; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Young Adult | 2021 |
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Phthalazines; Piperazines; Prognosis; Receptor, ErbB-2; Survival Rate; Young Adult | 2021 |
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Paclitaxel; Receptor, ErbB-2 | 2021 |
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Piperazines; Pyrimidines; Triple Negative Breast Neoplasms | 2021 |
Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2021 |
Does bevacizumab carry a hope for metastatic triple-negative breast cancer in the era of immunotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Progression-Free Survival; Prospective Studies; Remission Induction; Triple Negative Breast Neoplasms | 2022 |
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Furans; Gemcitabine; Humans; Ketones; Nuclear Proteins; Paclitaxel; Pharmacogenomic Testing; Polymorphism, Genetic; Prospective Studies; Repressor Proteins | 2021 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retreatment; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Critically short telomeres and toxicity of chemotherapy in early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; In Situ Hybridization, Fluorescence; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Telomere; Telomere Shortening | 2017 |
A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Incidence; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2017 |
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Early Diagnosis; Epirubicin; Female; Filgrastim; Germany; Humans; Ibandronic Acid; Middle Aged; Paclitaxel; Polyethylene Glycols; Young Adult | 2017 |
The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Phosphorylation; Prognosis; Retinoblastoma Protein; Tumor Suppressor Protein p53; Young Adult | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Epothilones; Female; Humans; Models, Biological; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases | 2017 |
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2017 |
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Germany; Humans; Mastectomy; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Taxoids; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2017 |
Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
Topics: Adult; Aged; Albumins; Australia; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Sensitivity and Specificity; Trastuzumab | 2018 |
Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Middle Aged; Neoplasm Proteins; Paclitaxel; Preoperative Period; Vorinostat | 2018 |
Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Animals; Breast Neoplasms; Carboplatin; Docetaxel; Female; Humans; Hypothermia, Induced; Induction Chemotherapy; Middle Aged; Paclitaxel; Quality of Life; Scalp; Taxoids; Trastuzumab | 2018 |
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Early Termination of Clinical Trials; Europe; Female; Humans; Ki-67 Antigen; Lymphocytes, Tumor-Infiltrating; Middle Aged; Morpholines; Mutation; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly pacl
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab; Young Adult | 2017 |
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
Topics: Adult; Aged; Breast Neoplasms; Canada; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Mammalian orthoreovirus 3; Middle Aged; Neoplasm Metastasis; Oncolytic Virotherapy; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2018 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Single-Blind Method; Temozolomide; Young Adult | 2018 |
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Risk Factors; Survival Rate | 2018 |
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitax
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Survivors; Cardiovascular System; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Time Factors; Treatment Outcome; Young Adult | 2017 |
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Genetic Testing; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2018 |
Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Paclitaxel; Treatment Outcome | 2018 |
Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Imidazoles; Mastectomy, Segmental; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Receptor, ErbB-2; Zoledronic Acid | 2017 |
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maintenance Chemotherapy; Middle Aged; Paclitaxel; Progression-Free Survival; Treatment Outcome | 2018 |
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Incidence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Topics: Aged; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Abnormalities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin T | 2018 |
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Europe; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Singapore; Treatment Outcome; Western Australia | 2018 |
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Hypokalemia; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Receptor, ErbB-3 | 2018 |
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Topics: Acetylcarnitine; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Docetaxel; Double-Blind Method; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Placebos; Taxoids; Treatment Outcome | 2018 |
Immune gene expression and response to chemotherapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Breast Neoplasms; Capecitabine; Epirubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2018 |
Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre,
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2018 |
Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Fluorouracil; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2018 |
Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Non-Randomized Controlled Trials as Topic; Paclitaxel | 2018 |
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dasatinib; Female; Humans; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Treatment Outcome | 2018 |
Cold therapy to prevent paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Breast Neoplasms; Cryotherapy; Female; Humans; Hypothermia, Induced; Middle Aged; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases; Surveys and Questionnaires; Treatment Outcome | 2018 |
Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Exercise; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Sensorimotor Cortex; Survivors; Young Adult | 2018 |
A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Topics: Acupuncture Therapy; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Contusions; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Treatment Outcome | 2018 |
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.
Topics: Animals; Breast Neoplasms; Capecitabine; CD11c Antigen; Cell Line, Tumor; Cell Membrane; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Ketones; Leukocytes, Mononuclear; Macrophages; Mice; Mice, SCID; Myeloid Cells; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Pilot Projects; Transcription, Genetic; Transforming Growth Factor beta | 2018 |
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Heart Failure; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel; Young Adult | 2018 |
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Receptors, Estrogen; Retrospective Studies; Treatment Outcome | 2018 |
Phase I trial of selenium plus chemotherapy in gynecologic cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Chemotherapy-Induced Febrile Neutropenia; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression; Glutathione Peroxidase; Humans; Infections; Lung Diseases; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; RNA-Binding Proteins; Selenious Acid; Selenium; Selenoprotein P | 2018 |
The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Drug Substitution; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Middle Aged; Paclitaxel; Premedication; Prospective Studies; Quality of Life | 2019 |
Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2018 |
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Longitudinal Studies; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Netherlands; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2 | 2018 |
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Letrozole; Middle Aged; Nausea; Paclitaxel; Sulfonamides; Trastuzumab | 2018 |
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Puerto Rico; Receptor, ErbB-2; Risk Factors; Time Factors; Trastuzumab; United States | 2019 |
Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Contrast Media; Disease Progression; Female; Humans; Japan; Magnetic Resonance Imaging; Meglumine; Middle Aged; Organometallic Compounds; Paclitaxel; Predictive Value of Tests; Prospective Studies; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2018 |
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azepines; Breast Neoplasms; Disease Progression; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Pyrimidines; Time Factors; United States | 2019 |
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Heart Diseases; Humans; Injections, Subcutaneous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Stroke Volume; Trastuzumab | 2018 |
A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Geriatric Assessment; Humans; Male; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2019 |
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2019 |
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2019 |
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dasatinib; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2019 |
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Chemotherapy, Adjuvant; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polyethylene Glycols; Receptor, ErbB-2; Trastuzumab | 2019 |
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor Burden; Tumor Microenvironment | 2019 |
Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Double-Blind Method; Female; Gabapentin; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Placebos | 2019 |
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab; Young Adult | 2019 |
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Estrogen; Survival Rate | 2019 |
Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Non-Randomized Controlled Trials as Topic; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Poisson Distribution; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Recurrence; Risk; Trastuzumab; Treatment Outcome | 2019 |
Concurrent Paclitaxel and Radiotherapy for Node Positive Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies | 2019 |
AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lymphocyte Activation Gene 3 Protein; Multicenter Studies as Topic; Paclitaxel; Placebos; Progression-Free Survival; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins | 2019 |
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2019 |
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Topics: Adult; Aged; Area Under Curve; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Diffusion Magnetic Resonance Imaging; Drug Administration Schedule; Echo-Planar Imaging; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies; Trastuzumab; Treatment Outcome; Tumor Burden | 2019 |
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Topics: Administration, Intravenous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Biosimilar Pharmaceuticals; Breast Neoplasms; Double-Blind Method; Female; Humans; Models, Biological; Nonlinear Dynamics; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2019 |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Receptor, ErbB-2; Republic of Korea; Surveys and Questionnaires | 2019 |
Effects of omega-3 fatty acids supplementation on neoadjuvant chemotherapy-induced toxicity in patients with locally advanced breast cancer: a randomized, controlled, double-blinded clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Body Composition; Body Weight; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dietary Supplements; Double-Blind Method; Doxorubicin; Fatty Acids, Omega-3; Female; Glycated Hemoglobin; Humans; Insulin; Lipids; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quality of Life; Trastuzumab; Xerostomia | 2019 |
Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: An assessor-blinded randomized controlled trial.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Follow-Up Studies; Humans; Massage; Middle Aged; Neuralgia; Paclitaxel; Prospective Studies; Quality of Life; Treatment Outcome | 2019 |
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Lapatinib; Mastectomy; Neoadjuvant Therapy; Paclitaxel; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Trastuzumab | 2019 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2013 |
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Up-Regulation | 2013 |
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Castor Oil; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Markov Chains; Models, Economic; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Spain; Time Factors; Treatment Outcome | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Everolimus; Exanthema; Female; Humans; Mastectomy, Segmental; Middle Aged; Mucositis; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2013 |
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Prognosis; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Decision Making; Female; Humans; Lapatinib; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Republic of Korea; Treatment Outcome; Watchful Waiting | 2013 |
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2013 |
Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab; Treatment Outcome | 2013 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Epothilones; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2013 |
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; PTEN Phosphohydrolase; Receptor, ErbB-2; Trastuzumab; Young Adult | 2013 |
Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis | 2013 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Constipation; Dexamethasone; Doxorubicin; Female; Headache; Humans; Isoquinolines; Middle Aged; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2013 |
Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; DNA Topoisomerases, Type II; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Nodes; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Risk Assessment; Survival Analysis; Treatment Outcome | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multivariate Analysis; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Taxoids | 2013 |
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Survival Rate | 2013 |
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epothilones; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Tubulin | 2013 |
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Transfusion; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Proportional Hazards Models; Quality of Life; Recombinant Proteins; Risk Assessment; Treatment Outcome | 2013 |
Increased expression of mitotic arrest deficient-like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Proteins; Chromosomal Instability; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Nuclear Proteins; Paclitaxel; Prognosis; Tissue Array Analysis | 2013 |
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Treatment Outcome | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Fibroblast Growth Factor 2; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Time Factors; Trastuzumab; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult | 2013 |
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Failure; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2013 |
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Lapatinib; Logistic Models; Mastectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Protein Kinase Inhibitors; Puerto Rico; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome; United States | 2013 |
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Sirolimus; Taxoids; Trastuzumab; Treatment Failure | 2013 |
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Treatment Outcome | 2014 |
Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Salvage Therapy; Survival Rate | 2013 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Puerto Rico; Receptor, ErbB-2; Stroke Volume; Time Factors; Trastuzumab; Treatment Outcome; United States | 2013 |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Female; Humans; Incidence; Lapatinib; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2013 |
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT5 Transcription Factor; Trastuzumab | 2013 |
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2014 |
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Membrane Transport Proteins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
[Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study].
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cytokine-Induced Killer Cells; Fatigue; Female; Humans; Immunotherapy, Adoptive; Middle Aged; Nausea; Paclitaxel; Prospective Studies; Quality of Life; Surveys and Questionnaires; Vomiting | 2013 |
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
Topics: Antineoplastic Agents, Phytogenic; Axons; Breast Neoplasms; Female; Humans; Multifactorial Inheritance; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Sensory Receptor Cells | 2014 |
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Middle Aged; Nanocapsules; Paclitaxel; Treatment Outcome | 2014 |
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Epothilones; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; DNA-Binding Proteins; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Tumor Suppressor Proteins | 2014 |
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2014 |
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Connecticut; Female; Fluorescent Antibody Technique; Humans; Neoadjuvant Therapy; Paclitaxel; Phosphorylation; Proteomics; Receptor, ErbB-2; Rhode Island; Time Factors; Trastuzumab; Treatment Outcome | 2014 |
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Gene Expression; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Ki-67 Antigen; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Vorinostat | 2014 |
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2014 |
HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2014 |
Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; gamma-Glutamyltransferase; Humans; Indoles; Lymphopenia; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Treatment Outcome | 2014 |
High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Recurrence; Remission Induction; Survival Analysis; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Receptor, Angiotensin, Type 1; Receptor, ErbB-2; Survival Rate; Translational Research, Biomedical | 2015 |
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2014 |
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Febrile Neutropenia; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Paclitaxel; Proportional Hazards Models; Young Adult | 2015 |
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Preoperative Period; Receptor, ErbB-2; Safety; Time Factors; Treatment Outcome; Young Adult | 2015 |
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Breast Neoplasms; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel | 2015 |
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytokines; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Receptor, ErbB-2; Receptors, IgG; Trastuzumab; Treatment Outcome; Young Adult | 2014 |
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Basic Helix-Loop-Helix Transcription Factors; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Genetic Association Studies; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-8; Neoplasm Staging; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Sulfonamides; Trastuzumab | 2015 |
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 2015 |
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Indazoles; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Sulfonamides | 2015 |
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2015 |
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Paclitaxel; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2015 |
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Drug Eruptions; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2015 |
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Treatment Outcome; Young Adult | 2015 |
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Fusion Proteins | 2015 |
Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Doxorubicin; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Pneumonia; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2015 |
Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Tegafur | 2015 |
Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Paclitaxel; Trastuzumab; Young Adult | 2015 |
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2015 |
MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; F-Box Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; MicroRNAs; Middle Aged; Paclitaxel; Protein-Arginine N-Methyltransferases; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm, Residual; Paclitaxel; Prognosis; Reproducibility of Results; Survival Rate; Tumor Burden | 2015 |
Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Female; Hemoglobins; Humans; Japan; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Survival Rate | 2015 |
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cardiotoxicity; Comorbidity; Cyclophosphamide; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Risk Factors; Treatment Outcome | 2015 |
Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2015 |
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2015 |
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Drug Administration Schedule; Epothilones; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2015 |
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Longitudinal Studies; Middle Aged; Neoplasm Staging; Obesity; Paclitaxel; Taxoids | 2015 |
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Epirubicin; Fatigue; Female; Humans; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptors, IgG; Remission Induction; Trastuzumab; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Everolimus; Female; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Sirolimus; Survival Analysis; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Routes; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Paclitaxel; Treatment Outcome | 2015 |
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2015 |
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Topics: Adaptive Immunity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD8-Positive T-Lymphocytes; Female; Humans; Immunity, Innate; Immunophenotyping; Killer Cells, Natural; Middle Aged; Neoadjuvant Therapy; NF-kappa B; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab; Treatment Outcome | 2015 |
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2015 |
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Salvage Therapy; Treatment Failure | 2015 |
Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy.
Topics: Adolescent; Adult; Breast Neoplasms; Cell Line, Tumor; Female; HEK293 Cells; Humans; Middle Aged; Neurotoxins; Paclitaxel; Peripheral Nervous System Diseases; Sphingolipids | 2015 |
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Skin Neoplasms; Treatment Outcome | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2016 |
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2015 |
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Stromal Cells; Time Factors; Trastuzumab; Treatment Outcome | 2016 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Combinations; Edema; Fatigue; Female; Follow-Up Studies; Health Status; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tegafur | 2016 |
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Trastuzumab | 2015 |
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2016 |
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Eruptions; Female; Humans; Lapatinib; Middle Aged; Paclitaxel; Quinazolines; Trastuzumab | 2016 |
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.
Topics: Albumins; Antineoplastic Agents, Immunological; B-Lymphocytes; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Immunity, Innate; Lymphocyte Activation; Macrophages; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor; Receptor, ErbB-2; T-Lymphocytes, Helper-Inducer; Trastuzumab; Treatment Outcome | 2016 |
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Topics: Adult; Aged; Albumins; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2016 |
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Esophageal Neoplasms; Female; Heterocyclic Compounds, 3-Ring; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2016 |
A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Injections; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Maximum Tolerated Dose; Maytansine; Middle Aged; Paclitaxel; Trastuzumab | 2016 |
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cardiotoxicity; Female; Humans; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin I; Ventricular Function, Left | 2016 |
Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatigue; Female; Humans; Induction Chemotherapy; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Treatment Outcome | 2017 |
Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pain; Pain Measurement; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2016 |
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosomal Instability; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Paclitaxel; Prognosis; Taxoids | 2016 |
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Quinolines; Receptor, ErbB-2; Trastuzumab | 2016 |
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Fibroblast Growth Factor 2; Furans; Hemodynamics; Hemoglobins; Humans; Ketones; Neoplasm Proteins; Oxygen; Oxyhemoglobins; Paclitaxel; Spectroscopy, Near-Infrared; Transforming Growth Factor beta1; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2016 |
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunization; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine | 2016 |
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2016 |
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2016 |
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2016 |
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Adaptive Randomization of Neratinib in Early Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2016 |
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Taxoids; Tissue Array Analysis; Transcriptome; Trastuzumab; Treatment Outcome; Young Adult | 2016 |
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Recurrence; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2016 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cisplatin; Cyclophosphamide; Diarrhea; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab | 2016 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Receptor, ErbB-2; Survival Rate | 2016 |
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-c
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sulfonamides | 2016 |
ANG1005 for breast cancer brain metastases: correlation between
Topics: Adult; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Peptides; Positron-Emission Tomography; Treatment Outcome | 2016 |
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Diarrhea; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proanthocyanidins; Prognosis; Quality of Life; Taxoids; Trastuzumab; Young Adult | 2017 |
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III tr
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Quality of Life; Receptor, ErbB-2; Retreatment; Treatment Outcome | 2016 |
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
Topics: Antineoplastic Agents, Phytogenic; Black or African American; Breast Neoplasms; Chemotherapy, Adjuvant; Exome Sequencing; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Paclitaxel; Peripheral Nervous System Diseases; Phenotype; Polymorphism, Single Nucleotide; Protein Tyrosine Phosphatases, Non-Receptor; Risk Factors | 2016 |
Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytochrome P-450 CYP2C8; Female; Gene Frequency; Genotype; Humans; Microfilament Proteins; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide | 2016 |
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Clinical Protocols; Dacarbazine; Drug Monitoring; Female; Humans; Models, Statistical; Paclitaxel; Research Design; Sample Size; Temozolomide | 2017 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor Burden | 2017 |
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Proportional Hazards Models; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2017 |
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Topics: Aged; Albumins; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2017 |
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Echocardiography; Female; Heart; Heart Failure; Humans; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Prospective Studies; Stroke Volume | 2017 |
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Disease Progression; Docetaxel; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Analysis; Taxoids; Therapeutic Equipoise; Time Factors; Trastuzumab | 2017 |
Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mice; Middle Aged; Models, Biological; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies | 2016 |
Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Young Adult | 2017 |
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Aged; Aged, 80 and over; Albumins; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Humans; Imiquimod; Lymphocytes, Tumor-Infiltrating; Middle Aged; Monocytes; Paclitaxel; Programmed Cell Death 1 Receptor; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2017 |
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Tamoxifen; Tumor Burden | 2017 |
First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment | 2017 |
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Health Resources; Humans; Kaplan-Meier Estimate; Netherlands; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Taxoids | 2017 |
Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Female; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neoplasms; Neurofeedback; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Platinum Compounds; Survivors; Taxoids; Time Factors; Treatment Outcome; Waiting Lists | 2017 |
Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Young Adult | 2017 |
Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Cross-Over Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2009 |
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Fluorouracil; Greece; Humans; Mastectomy; Methotrexate; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Risk Assessment; Treatment Outcome | 2008 |
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cross-Over Studies; Fallopian Tube Neoplasms; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Solvents | 2008 |
Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polyethylene Glycols | 2008 |
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome | 2008 |
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance | 2008 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel | 2008 |
Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Paclitaxel; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2009 |
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Lymphopenia associated with adjuvant anthracycline/ taxane regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4 Lymphocyte Count; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Incidence; Lymphopenia; Middle Aged; Opportunistic Infections; Paclitaxel | 2008 |
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Floxuridine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis | 2008 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Skin Diseases | 2008 |
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Scalp; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Treatment Outcome | 2008 |
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Genotype; Haplotypes; Humans; Hypertension; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects | 2008 |
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Receptor, ErbB-2; Research Design; Taxoids; Trastuzumab | 2008 |
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Placebos; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2008 |
[A phase I study of combination therapy with capecitabine and paclitaxel for patients with inoperable breast cancer or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2008 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2009 |
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Genes, erbB-2; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab; Up-Regulation | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Epistaxis during treatment with paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Epistaxis; Female; Humans; Incidence; Middle Aged; Paclitaxel; Platelet Count; Prospective Studies; Severity of Illness Index | 2009 |
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume; Survival Rate; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2009 |
Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Epoetin Alfa; Erythropoietin; Female; Hematinics; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Recombinant Proteins | 2009 |
[Comparison of the pharmacokinetics and safety of a paclitaxel injection NK and Taxol injection in breast cancer patients].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 2009 |
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2009 |
Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2009 |
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel | 2009 |
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Odds Ratio; Paclitaxel; Radiotherapy, Adjuvant; Risk Assessment; Time Factors; Trastuzumab; Treatment Outcome; United States; Young Adult | 2009 |
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Treatment Outcome | 2009 |
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2009 |
nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Delivery Systems; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Taxoids | 2010 |
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2009 |
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Frail Elderly; Humans; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2010 |
DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Contrast Media; Doxorubicin; Female; Gadolinium DTPA; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Prognosis | 2009 |
A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Platinum; Treatment Outcome | 2009 |
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Survival Analysis | 2009 |
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Female; Fever; Humans; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Trastuzumab; Treatment Outcome | 2009 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Europe; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Prevalence; Survival Analysis; Survival Rate; Treatment Outcome | 2009 |
The effect of LMWH (Nadroparin) on tumor progression.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Nadroparin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Retrospective Studies; Survival Analysis; Time Factors | 2009 |
Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2010 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids | 2010 |
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2010 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2010 |
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2010 |
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2010 |
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Health Status; Humans; Lapatinib; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quinazolines; Receptor, ErbB-2 | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Time Factors; Trastuzumab | 2010 |
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
Topics: Adult; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel | 2010 |
Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2010 |
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Recurrence; Survival Analysis; Treatment Outcome | 2010 |
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Tegafur | 2010 |
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Filgrastim; Follow-Up Studies; Gene Amplification; Granulocyte Colony-Stimulating Factor; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Recombinant Proteins; Survival Rate; Trastuzumab; Treatment Outcome | 2010 |
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Serine; Tissue Array Analysis; Treatment Outcome | 2010 |
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; tau Proteins | 2010 |
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ribonucleoside Diphosphate Reductase; Survival; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2011 |
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Inflammation; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines | 2010 |
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multivariate Analysis; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; ROC Curve; Treatment Outcome | 2010 |
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Florida; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Breast Neoplasms; Disease Progression; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome; Tretinoin | 2011 |
Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer [KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Japan; Middle Aged; Neoplasm Staging; Paclitaxel; Postmenopause; Premenopause; Survival Analysis | 2010 |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Phenotype; Receptor, ErbB-2 | 2011 |
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.
Topics: Aged; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Drug Administration Schedule; Female; Humans; Immunity; Immunotherapy; Lymphocyte Activation; Lymphocyte Activation Gene 3 Protein; Middle Aged; Monocytes; Neoplasm Metastasis; Paclitaxel; Remission Induction; Treatment Outcome | 2010 |
A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Pilot Projects; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome; United States | 2010 |
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2010 |
Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dyspnea; Emotions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Quality of Life; Regression Analysis; Sleep Initiation and Maintenance Disorders; Social Behavior; Surveys and Questionnaires; Sweden; Time Factors; Treatment Outcome; Young Adult | 2010 |
Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2010 |
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2010 |
Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Risk Factors; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome | 2010 |
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen | 2011 |
Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Time Factors; Treatment Outcome; United States | 2011 |
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Time Factors; Young Adult | 2011 |
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Sirolimus; Trastuzumab; Treatment Outcome | 2010 |
[Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2010 |
A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carbon Monoxide; Chemoradiotherapy; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphatic Irradiation; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Pulmonary Diffusing Capacity; Radiodermatitis | 2012 |
A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lapatinib; Latvia; Middle Aged; Paclitaxel; Poland; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Romania; Russia; Up-Regulation | 2010 |
A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2010 |
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Paclitaxel; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Young Adult | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Health Status; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2012 |
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Ventricular Function, Left | 2011 |
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Health Status; Humans; Kaplan-Meier Estimate; Methotrexate; Paclitaxel; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2011 |
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Darbepoetin alfa; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Patient Compliance; Preoperative Care; Treatment Outcome; Young Adult | 2011 |
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary brea
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Darbepoetin alfa; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Young Adult | 2011 |
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Dasatinib; Edema; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pleural Effusion, Malignant; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Oligonucleotides; Paclitaxel; Receptor, ErbB-2 | 2011 |
Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 2011 |
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Hypertension; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2012 |
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2011 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Young Adult | 2011 |
Variation of breast vascular maps on dynamic contrast-enhanced MRI after primary chemotherapy of locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cohort Studies; Contrast Media; Doxorubicin; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Predictive Value of Tests; Treatment Outcome | 2011 |
Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Topics: Antineoplastic Agents; Base Sequence; Breast Neoplasms; Cohort Studies; DNA Primers; Epirubicin; Female; Genes, p53; Genotype; Humans; Mutation; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; Survival Analysis | 2011 |
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Administration Schedule; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab | 2011 |
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Young Adult | 2011 |
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Tumor Suppressor Protein p53 | 2011 |
Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiotensin II; Area Under Curve; Breast Neoplasms; Colorectal Neoplasms; Contrast Media; Endothelin-1; Female; Humans; Interleukins; Liposomes; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Ultrasonography; Vascular Endothelial Growth Factor A | 2012 |
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Hypertension; Japan; Middle Aged; Paclitaxel; Receptor, ErbB-2 | 2011 |
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Paclitaxel; Pilot Projects | 2012 |
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; CDC2 Protein Kinase; Cyclin-Dependent Kinase 2; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Steroid; Risk Factors; Treatment Outcome | 2012 |
Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Pelvic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Breast Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Japan; Male; Metabolic Clearance Rate; Middle Aged; Nanoparticles; Nausea; Neoplasm Metastasis; Neoplasms; Paclitaxel; Treatment Outcome | 2012 |
Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life | 2011 |
Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Data Collection; Deoxycytidine; Female; Gemcitabine; Health Status Indicators; Humans; Internationality; Middle Aged; Paclitaxel; Pain Measurement; Psychometrics; Quality of Life; Stress, Psychological; Treatment Outcome | 2012 |
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2012 |
Integration of diffusion-weighted MRI data and a simple mathematical model to predict breast tumor cellularity during neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Chemotherapy, Adjuvant; Cisplatin; Computer Simulation; Diffusion Magnetic Resonance Imaging; Drug Therapy, Computer-Assisted; Everolimus; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Middle Aged; Models, Biological; Paclitaxel; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Sirolimus; Systems Integration; Treatment Outcome | 2011 |
Immunological effects of taxol and adryamicin in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cytokines; Doxorubicin; Female; Humans; Immunomodulation; Middle Aged; Nitric Oxide; Oxidative Stress; Paclitaxel | 2012 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Single agent weekly paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies | 2012 |
Preclinical and clinical evaluation of intraductally administered agents in early breast cancer.
Topics: Adult; Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Doxorubicin; Drug Administration Routes; Female; Fluorouracil; Humans; Mammary Glands, Animal; Mammary Neoplasms, Animal; Methylnitrosourea; Paclitaxel; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Young Adult | 2011 |
Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drainage; Female; Humans; Instillation, Drug; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pleural Cavity; Pleural Effusion, Malignant; Tissue Distribution | 2012 |
[Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Young Adult | 2011 |
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome | 2012 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Young Adult | 2012 |
Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Greece; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
Topics: Acetylation; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Processing, Post-Translational; Treatment Outcome; Tubulin; Vorinostat | 2012 |
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fertility; Fluorouracil; Follicle Stimulating Hormone; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Inhibins; Menstruation; Neoadjuvant Therapy; Neoplasm Staging; Ovary; Paclitaxel; Tamoxifen; Time Factors; Treatment Outcome; Triptorelin Pamoate | 2012 |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lapatinib; Liver; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Epirubicin; Female; Humans; Magnetic Resonance Spectroscopy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Prognosis; Survival Analysis | 2012 |
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Inflammatory Breast Neoplasms; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Treatment Outcome | 2012 |
Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; China; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 2011 |
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Thailand; Treatment Outcome | 2012 |
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Cell Cycle Proteins; Checkpoint Kinase 2; Cohort Studies; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mitomycin; Mutation; Paclitaxel; Predictive Value of Tests; Promoter Regions, Genetic; Prospective Studies; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Neoadjuvant chemotherapy modifies serum angiotensinase activities in women with breast cancer.
Topics: Aminopeptidases; Angiotensin II; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Endopeptidases; Female; Glutamyl Aminopeptidase; Humans; Middle Aged; Naphthalenes; Neoadjuvant Therapy; Paclitaxel; Reference Values; Renin-Angiotensin System | 2012 |
Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Edema; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Taxoids | 2012 |
Circadian rhythms, symptoms, physical functioning, and body mass index in breast cancer survivors.
Topics: Activities of Daily Living; Adult; Affective Symptoms; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Body Mass Index; Breast Neoplasms; Circadian Rhythm; Cyclophosphamide; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Humans; Middle Aged; Paclitaxel; Quality of Life; Sleep; Survivors; Taxoids | 2012 |
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Trastuzumab; Treatment Outcome | 2012 |
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Middle Aged; Neurotoxicity Syndromes; Paclitaxel; Paresthesia; Peripheral Nervous System Diseases; Quality of Life; Surveys and Questionnaires; Taxoids | 2012 |
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide; Receptors, Estrogen; Survivin | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2012 |
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Hypertension; Middle Aged; Neutropenia; Paclitaxel; Proteinuria; Taxoids; Thromboembolism; Young Adult | 2012 |
Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2012 |
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fibroblast Growth Factor 2; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Suramin; Taxoids; Treatment Outcome | 2012 |
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Risk Factors | 2012 |
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Triazoles; Young Adult | 2012 |
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Incidence; Microfilament Proteins; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Receptor, EphA5; Sensory Receptor Cells | 2012 |
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Nervous System Diseases; Paclitaxel; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2012 |
Feasibility of oncoplastic techniques in the surgical management of locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Feasibility Studies; Female; Humans; Mammaplasty; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies; Treatment Outcome | 2012 |
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oligonucleotides; Paclitaxel; Proto-Oncogene Proteins c-kit; Receptors, Platelet-Derived Growth Factor; Taxoids; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Middle Aged; Neural Conduction; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 2012 |
PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; DNA Repair; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Peroxisome Proliferator-Activated Receptors; Polymerase Chain Reaction; Signal Transduction; Treatment Outcome | 2012 |
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib | 2013 |
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal gr
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; ErbB Receptors; Female; Follow-Up Studies; Heart Failure; Heart Function Tests; Humans; Lymphatic Metastasis; Middle Aged; Models, Statistical; Paclitaxel; Risk Factors; Trastuzumab | 2012 |
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Piperidines; Pyridines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Contrast Media; Cyclophosphamide; Doxorubicin; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Oxygen; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2013 |
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Vascular Endothelial Growth Factors; Young Adult | 2012 |
A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polymers; Prognosis; Salvage Therapy; Survival Rate; Young Adult | 2013 |
Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Creatine Kinase, MB Form; Electrocardiography; Epirubicin; Female; Half-Life; Humans; L-Lactate Dehydrogenase; Middle Aged; Myocardium; Paclitaxel | 2012 |
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyglutamic Acid; Proportional Hazards Models; Treatment Outcome | 2014 |
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Nausea; Paclitaxel; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2013 |
[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Large-Core Needle; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Young Adult | 2012 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2 | 2013 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2013 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epothilones; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microfilament Proteins; Microtubule-Associated Proteins; Neoadjuvant Therapy; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Prognosis; Tubulin | 2013 |
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tissue Array Analysis; Vascular Endothelial Growth Factor A | 2013 |
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Europe; Female; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2002 |
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Taxoids; Treatment Outcome | 2002 |
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Treatment Outcome | 2002 |
Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Humans; Lymphopenia; Menopause; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Palliative Care; Prospective Studies; Safety; Taxoids; Treatment Outcome | 2002 |
A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Case-Control Studies; Cyclophosphamide; Disease Progression; Docetaxel; Doxorubicin; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Taxoids | 2002 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Humans; Melphalan; Middle Aged; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Remission Induction; Survival Analysis; Survival Rate; Thiotepa | 2002 |
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Logistic Models; Middle Aged; Neoplasm Metastasis; New York City; Paclitaxel; Prospective Studies; Quality of Life | 2002 |
Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2002 |
Docetaxel secretion in tears: association with lacrimal drainage obstruction.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Female; Gas Chromatography-Mass Spectrometry; Humans; Infusions, Intravenous; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Taxoids; Tears | 2002 |
Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Doxorubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tamoxifen; Treatment Outcome | 2002 |
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Estramustine; Female; Humans; Microtubules; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival; Taxoids; Treatment Outcome; Venous Thrombosis | 2002 |
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms | 2002 |
Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Paclitaxel; Treatment Outcome; Uracil | 2002 |
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2002 |
Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Paclitaxel; Taxoids; Tomography, Spiral Computed; Treatment Outcome | 2002 |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Synergism; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Greece; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postmenopause; Premenopause; Probability; Risk Assessment; Survival Rate; Treatment Outcome | 2002 |
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 2002 |
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-3; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Fusion Proteins; Recombinant Proteins; Taxoids; Treatment Outcome | 2002 |
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Time Factors; Treatment Outcome | 2002 |
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Scotland; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Vincristine | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infections; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Survival Rate | 2002 |
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Diarrhea; Doxorubicin; Drug Administration Schedule; Erythema; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Sleep Wake Disorders; Time Factors | 2002 |
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Heart; Humans; Middle Aged; Paclitaxel; Risk Factors; Safety; Survival Rate; Treatment Outcome | 2003 |
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Receptor, ErbB-2; Trastuzumab | 2003 |
[Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cause of Death; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Pilot Projects; Risk Assessment; Salvage Therapy; Soft Tissue Neoplasms; Survival Analysis; Taxoids | 2002 |
Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors | 2003 |
Docetaxel with epirubicin--investigations on cardiac safety.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular System; Confidence Intervals; Docetaxel; Epirubicin; Female; Follow-Up Studies; Heart Function Tests; Humans; Middle Aged; Paclitaxel; Taxoids | 2003 |
A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Estramustine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Remission Induction; Survival Analysis; Taxoids | 2003 |
Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Spain; Taxoids; Treatment Outcome | 2003 |
Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Gene Expression; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids; Trastuzumab | 2003 |
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Quality of Life; Survival Rate | 2003 |
Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Prospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2003 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prospective Studies; Spain; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2003 |
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Feasibility Studies; Female; Humans; Mastectomy, Modified Radical; Middle Aged; Neoplasm Staging; Paclitaxel; Postoperative Care; Postoperative Complications; Preoperative Care; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome | 2003 |
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left | 2003 |
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Proportional Hazards Models; Treatment Outcome | 2003 |
Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2003 |
Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
[Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
[Clinical research of taxotere in treatment of metastatic breast cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Germany; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection | 2003 |
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids | 2003 |
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
Topics: Antineoplastic Agents, Phytogenic; Blood Cell Count; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Distribution of paclitaxel in plasma and cerebrospinal fluid.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Female; Half-Life; Humans; Infusions, Intravenous; Middle Aged; Models, Biological; Paclitaxel | 2003 |
The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Hypothermia, Induced; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
[Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-small-cell lung cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies | 2003 |
Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pulmonary Fibrosis; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prognosis; Quality of Life; Statistics as Topic; Survival Analysis; Taxoids | 2003 |
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Recombinant Proteins | 2003 |
Neoadjuvant docetaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids | 2003 |
Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Thiotepa; Treatment Outcome | 2003 |
ABI 007.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Breast Neoplasms; Clinical Trials, Phase II as Topic; Humans; Injections, Intra-Arterial; Paclitaxel; Taxoids | 2003 |
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Canada; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Female; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab; Treatment Outcome | 2003 |
Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neutropenia; Paclitaxel; Ranitidine; Soft Tissue Neoplasms; Vomiting, Anticipatory | 2003 |
A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Pilot Projects; Treatment Outcome | 2003 |
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cyclosporins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Immunosuppressive Agents; Injections, Intravenous; Middle Aged; Paclitaxel; Time Factors | 2003 |
Doxorubicin, paclitaxel and gemcitabine: a Phase I study of a new sequential treatment in stage III B - IV breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2003 |
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Protective Agents; Treatment Outcome | 2003 |
Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential follow
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Biweekly paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2003 |
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Doxorubicin; Echocardiography; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Receptor, ErbB-2; Trastuzumab | 2003 |
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Blood; Breast Neoplasms; Cyclophosphamide; Cytokines; Data Interpretation, Statistical; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Interleukin-1; Interleukin-10; Interleukin-12; Interleukin-6; Interleukin-8; Middle Aged; Nausea; Paclitaxel; Pain; Patient Selection; Quality of Life; Tumor Necrosis Factor-alpha | 2004 |
Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Heart; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study.
Topics: Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Paclitaxel | 2004 |
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Paclitaxel; Survival Analysis | 2004 |
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome | 2004 |
Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Selection; Survival Rate; Treatment Outcome; World Health Organization | 2003 |
Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection; Salvage Therapy; Survival Analysis; Trastuzumab; Treatment Outcome; World Health Organization | 2003 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab; Treatment Outcome | 2003 |
Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2004 |
[Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Epirubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neurotoxicity Syndromes; Paclitaxel | 2004 |
Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Salvage Therapy; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Treatment Outcome | 2004 |
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quality of Life; Survival Analysis | 2004 |
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2004 |
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2004 |
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Multivariate Analysis; Paclitaxel; Quality of Life; Survival Rate; Treatment Failure; United States | 2004 |
Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Heart Failure; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Risk Factors; Ventricular Dysfunction, Left | 2004 |
First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Soft Tissue Neoplasms; South Africa; Survival Analysis; Treatment Outcome | 2004 |
Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left | 2004 |
Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2004 |
[Efficacy and safety of weekly taxol (TXL) for advanced recurrent breast cancer evaluated in a multi-center cooperative clinical trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2004 |
Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer.
Topics: Adult; Breast Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fever; Humans; Hypoxia; Mastectomy; Middle Aged; Oxygen; Paclitaxel; Prospective Studies; Temperature; Time Factors | 2004 |
Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome | 2004 |
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Quality of Life | 2004 |
Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Stomatitis; Treatment Outcome | 2004 |
Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Female; Heart Failure; Humans; Melphalan; Middle Aged; Paclitaxel; Thiotepa | 2004 |
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymph Nodes; Middle Aged; Paclitaxel; Pilot Projects; Risk Factors; Survival Rate; Taxoids | 2004 |
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left | 2004 |
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Chemotherapy, Adjuvant; Female; Hematologic Diseases; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Survival Analysis; Treatment Outcome; Ventricular Function, Left | 2004 |
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Heart; Heart Diseases; Heart Failure; Humans; Immunohistochemistry; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Nails; Paclitaxel; Skin; Switzerland; Treatment Outcome | 2004 |
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Elective Surgical Procedures; Female; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy; Retrospective Studies | 2005 |
Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Pneumonia; Prospective Studies; Radiation Dosage; Radiotherapy, Adjuvant | 2004 |
Clinical experience of weekly paclitaxel-based treatment as preoperative chemotherapy for patients with primary breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Treatment Outcome | 2004 |
[A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Diplopia; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nanotechnology; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel | 2004 |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neutropenia; Paclitaxel; Trastuzumab; Treatment Outcome | 2004 |
4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Patient Selection; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2004 |
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2004 |
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
Topics: Administration, Oral; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Testicular Neoplasms; Uterine Cervical Neoplasms; Vitamin E | 2005 |
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel; Survival Analysis | 2005 |
Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Turkey | 2005 |
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase I
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2005 |
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2005 |
Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 2005 |
Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mammaplasty; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiodermatitis; Wound Healing | 2005 |
Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Drug Administration Schedule; Extracellular Fluid; Female; Humans; Menopause; Middle Aged; Oxygen Consumption; Paclitaxel | 2005 |
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Epothilones; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Middle Aged; Nervous System; Paclitaxel; Taxoids; Treatment Outcome | 2005 |
Toxicity profile and objective response of paclitaxel in metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pakistan; Survival Rate; Treatment Outcome | 2005 |
Weekly paclitaxel in the treatment of advanced or metastatic breast cancer previously treated or not treated with docetaxel: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Survival Rate | 2005 |
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymph Nodes; Middle Aged; Paclitaxel; Receptors, Estrogen; Survival Rate; Tamoxifen | 2005 |
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Ondansetron; Paclitaxel; Patient Satisfaction; Prochlorperazine; Serotonin Antagonists; Treatment Outcome; United States; Vomiting | 2005 |
Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Epirubicin; Feasibility Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome | 2005 |
A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Preoperative Care; Survival Rate | 2005 |
A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Safety; Survival Rate; Treatment Outcome | 2005 |
[Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 2005 |
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Gefitinib; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Treatment Outcome | 2005 |
Preoperative second-line chemotherapy induces objective responses in primary breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.
Topics: Action Potentials; Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Electrophysiology; Glutamine; Granulocyte Colony-Stimulating Factor; Humans; Melphalan; Neural Conduction; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Stem Cell Transplantation; Thiotepa | 2005 |
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids | 2005 |
Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel | 2005 |
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome | 2005 |
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chi-Square Distribution; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Logistic Models; Middle Aged; Paclitaxel; Proportional Hazards Models; Quality of Life; Taxoids; Treatment Outcome | 2005 |
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Electrophysiological evaluation of visual pathways in paclitaxel-treated patients.
Topics: Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Electrophysiology; Evoked Potentials, Visual; Female; Flicker Fusion; Humans; Middle Aged; Optic Nerve; Paclitaxel; Retina; Scotoma; Visual Pathways | 2006 |
Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2005 |
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Paclitaxel; Prevalence; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Sampling Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2005 |
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Castor Oil; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Nanostructures; Paclitaxel; Survival Rate; Treatment Outcome | 2005 |
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis | 2005 |
Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2005 |
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Diseases; Humans; Mastectomy; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Recurrence; Survival Analysis; Trastuzumab | 2005 |
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Paclitaxel; Prospective Studies; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2006 |
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Heart; Heart Failure; Humans; Incidence; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2005 |
Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis | 2005 |
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Statistics, Nonparametric; Survival Analysis; United Kingdom | 2005 |
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Topics: Adult; Aged; Algorithms; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boston; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Darbepoetin alfa; Doxorubicin; Erythrocyte Transfusion; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2005 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Time Factors | 2005 |
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multivariate Analysis; Paclitaxel; Preoperative Care; Treatment Outcome | 2005 |
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2005 |
[Effect on late-stage mammary cancer treated by endocrinotherapy or chemotherapy combined with pingxiao capsule].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Middle Aged; Paclitaxel; Phytotherapy; Sepharose; Tamoxifen | 2005 |
Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.
Topics: Adult; Aged; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Breath Tests; Carcinoma, Non-Small-Cell Lung; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Outpatients; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Paclitaxel; Phenotype; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2006 |
Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2006 |
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arthralgia; Blood Cell Count; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2006 |
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Paclitaxel; Prognosis | 2006 |
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Pneumonitis; Radiodermatitis; Razoxane; Recombinant Proteins | 2006 |
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Doxorubicin; Drug Interactions; Female; Heart; History, Medieval; Humans; Infusions, Intravenous; Liposomes; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Time Factors; Treatment Outcome | 2006 |
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2006 |
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2007 |
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis | 2006 |
[Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins | 2006 |
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Patient Selection; Proportional Hazards Models; Survival Analysis; Treatment Failure | 2006 |
Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Treatment Outcome | 2006 |
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; North Carolina; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Ventricular Dysfunction, Left | 2006 |
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Drug Synergism; ErbB Receptors; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2006 |
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gene Expression; Humans; Methotrexate; Middle Aged; Molecular Diagnostic Techniques; Paclitaxel; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Tumor Suppressor Protein p53 | 2006 |
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclosporine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Vinblastine; Vinorelbine | 2007 |
[Adjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study in a variety of practice settings in Kyushu].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neutropenia; Paclitaxel; Vomiting, Anticipatory | 2006 |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Diarrhea; Drug Administration Schedule; Epirubicin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2006 |
Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Medical Oncology; Outcome Assessment, Health Care; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Research Design | 2006 |
A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2006 |
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Black or African American; Breast Neoplasms; Female; Genes, erbB-2; Genes, p53; Humans; Neoplasm Metastasis; Paclitaxel; Predictive Value of Tests; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; White People | 2006 |
[Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Fatigue; Female; Humans; Injections, Subcutaneous; Interleukin-11; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Platelet Count; Recombinant Proteins; Stomach Neoplasms; Thrombocytopenia; Treatment Outcome | 2006 |
Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Echocardiography; Epirubicin; Female; Genes, erbB-2; Humans; Middle Aged; Monitoring, Physiologic; Myoglobin; Paclitaxel; Stroke Volume; Troponin T | 2007 |
A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Pilot Projects; Recombinant Proteins; Time Factors | 2007 |
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2007 |
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Biological Transport; Breast Neoplasms; Cyclophosphamide; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Disease-Free Survival; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Gene Frequency; Homozygote; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Treatment Outcome | 2007 |
Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Ventricular Function, Left | 2006 |
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Receptors, Estrogen; Survival Analysis; Taxoids; Tumor Burden | 2007 |
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Topics: Adipose Tissue; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Double-Blind Method; Epirubicin; Female; Humans; Microdialysis; Paclitaxel | 2007 |
Albumin-bound paclitaxel improves response rate vs docetaxel in metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2007 |
Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2006 |
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyglutamic Acid; Taxoids | 2007 |
Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2007 |
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Drug Administration Schedule; Drug Carriers; Drug Compounding; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Korea; Micelles; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Polymers; Time Factors; Treatment Outcome | 2008 |
Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Time Factors; Treatment Outcome | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Triazoles | 2007 |
A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Fever; Foot Dermatoses; Hand Dermatoses; Humans; Liposomes; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Paresthesia; Polyethylene Glycols; Salvage Therapy; Treatment Outcome | 2008 |
Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings.
Topics: Action Potentials; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Electric Stimulation; Electrophysiology; Female; Humans; Middle Aged; Neural Conduction; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Reaction Time; Severity of Illness Index | 2008 |
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2008 |
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[A phase II study of weekly paclitaxel for advanced or recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ranitidine; Survival Rate | 2007 |
Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel.
Topics: Aged; Breast Neoplasms; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Middle Aged; Paclitaxel; Thymidine Phosphorylase | 2007 |
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel | 2008 |
The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; bcl-X Protein; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Taxoids; Tumor Suppressor Protein p53 | 2008 |
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Ki-67 Antigen; Neoplasm Staging; Paclitaxel; Patient Compliance; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Lymphatic Metastasis; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Paclitaxel | 2007 |
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins | 2007 |
Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Female; Genetic Markers; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Paclitaxel; Taxoids | 2008 |
HER2 and response to paclitaxel in node-positive breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2007 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2007 |
Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Leucovorin; Maximum Tolerated Dose; Middle Aged; Models, Theoretical; Neoplasm Metastasis; Paclitaxel; Tegafur; Uracil | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Preoperative Care; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction | 2008 |
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Quality of Life; Receptor, ErbB-2; Survival Analysis | 2007 |
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Genes, erbB-1; Humans; Immunohistochemistry; Methotrexate; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis | 2007 |
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pilot Projects; Recombinant Proteins | 2008 |
Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Topics: Abdominal Neoplasms; Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Feasibility Studies; Female; Gene Amplification; Heart; Heart Failure; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2008 |
Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cholesterol; Drug Carriers; Drug Resistance, Neoplasm; Emulsions; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Receptors, Lipoprotein | 2009 |
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Female; Gastrointestinal Diseases; Genes, erbB-2; Half-Life; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Trastuzumab | 2008 |
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leu
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2008 |
[Pancreatoxicity during neoadjuvant and adjuvant chemotherapy of HER-negative breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Doxorubicin; Female; Humans; Lipase; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreas; Pancreatitis; Receptor, ErbB-3; Retrospective Studies; Ultrasonography | 2007 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Receptors, Steroid; Taxoids | 2008 |
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome | 2008 |
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Doxorubicin; Humans; Hyperthermia, Induced; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Treatment Outcome | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2008 |
Biweekly paclitaxel in the treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Premedication; Treatment Outcome | 1995 |
Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.
Topics: Adult; Aged; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins | 1993 |
Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Neoplasm Metastasis; Paclitaxel | 1993 |
Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Radionuclide Imaging; Recombinant Proteins; Technetium Tc 99m Medronate; Time Factors | 1994 |
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Remission Induction; Salvage Therapy | 1994 |
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 1995 |
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chi-Square Distribution; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; National Institutes of Health (U.S.); Neoplasm Metastasis; Neutropenia; Paclitaxel; Referral and Consultation; Remission Induction; United States | 1995 |
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cohort Studies; Disease Progression; Drug Resistance; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Middle Aged; Netherlands; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Safety; Thrombocytopenia | 1995 |
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Care Facilities; Chemotherapy, Adjuvant; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphatic Metastasis; Neoplasm Metastasis; New York City; Paclitaxel; Quality of Life; Remission Induction; Survival Rate | 1995 |
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction | 1995 |
Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Care Facilities; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Texas | 1995 |
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bayes Theorem; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Salvage Therapy | 1995 |
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Doxorubicin; Drug Administration Schedule; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction | 1995 |
Biweekly paclitaxel and cisplatin: a phase I/II study in the first-line treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Remission Induction | 1995 |
One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Topics: Blood Cell Count; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Premedication; Remission Induction | 1995 |
Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Remission Induction | 1995 |
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Adenoid Cystic; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Sarcoma | 1995 |
Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Metabolic Clearance Rate; Paclitaxel; Verapamil | 1995 |
Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction | 1995 |
Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cross-Over Studies; Disease Progression; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Remission Induction | 1995 |
Pruritus caused by 3-hour infusion of high-dose paclitaxel and improvement with tricyclic antidepressants.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Breast Neoplasms; Humans; Infusions, Intravenous; Nortriptyline; Paclitaxel; Pruritus | 1995 |
Paclitaxel-induced neuropathy.
Topics: Adult; Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand Strength; Humans; Incidence; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Perception; Prospective Studies; Vibration | 1995 |
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1995 |
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Treatment Outcome | 1993 |
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Bone Marrow Diseases; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Treatment Outcome | 1993 |
Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Vinblastine; Vinorelbine | 1995 |
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
Topics: Aged; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Time Factors | 1995 |
Radiation-recall dermatitis in a patient treated with paclitaxel.
Topics: Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Recurrence | 1995 |
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Confidence Intervals; Docetaxel; Drug Tolerance; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Quality Control; Taxoids; Time Factors | 1995 |
Taxol: initial Israeli experience with a novel anticancer agent.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Israel; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Time Factors | 1994 |
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1993 |
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Topics: Adult; Aged; Agranulocytosis; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Resistance; Female; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Mitoxantrone; Mouth Mucosa; Paclitaxel; Stomatitis | 1994 |
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Premedication; Prospective Studies; Remission Induction | 1994 |
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Europe; Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Prospective Studies | 1994 |
Biweekly paclitaxel (Taxol) and cisplatin in breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1994 |
Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.
Topics: Adult; Alopecia; Antibiotics, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1994 |
[Phase I study of paclitaxel].
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1994 |
[An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Paclitaxel; Remission Induction; Taxoids | 1994 |
Taxol (paclitaxel) in patients with metastatic breast carcinoma who have failed prior chemotherapy: interim results of a multinational study.
Topics: Breast Neoplasms; Canada; Carcinoma; Drug Administration Schedule; Female; France; Germany; Humans; Infusions, Intravenous; Italy; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 1994 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Asthenia; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Topics: Adult; Aged; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Taxoids | 1995 |
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests | 1996 |
Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1995 |
Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis | 1995 |
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Edema; Female; Humans; Injections, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Taxoids | 1996 |
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Equipment Failure; Erythrocyte Transfusion; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Home Infusion Therapy; Humans; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1996 |
Plasma alcohol concentrations in patients following paclitaxel infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Solvents | 1996 |
Docetaxel (Taxotere): an overview of first-line monotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
Docetaxel (Taxotere) in combination: a step forward.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Clinical Trials as Topic; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1995 |
Paclitaxel premedication regimens.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Drug Hypersensitivity; Female; Glucocorticoids; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Ovarian Neoplasms; Paclitaxel; Premedication; Ranitidine | 1996 |
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia | 1996 |
High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis | 1996 |
Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mitoxantrone; Paclitaxel; Survival Analysis | 1996 |
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel.
Topics: Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Female; Humans; Neoplasm Metastasis; Paclitaxel | 1995 |
A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel | 1996 |
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Paclitaxel; Remission Induction | 1996 |
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Breast Neoplasms; Cross-Over Studies; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Treatment Outcome; Verapamil | 1996 |
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Treatment Outcome | 1996 |
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1996 |
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Taxoids | 1996 |
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Remission Induction | 1995 |
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel | 1996 |
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate | 1996 |
New sequential dosing regimen shows promise in node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Paclitaxel; Receptors, Granulocyte Colony-Stimulating Factor; Treatment Outcome | 1996 |
A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1995 |
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 1996 |
A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1996 |
Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Remission Induction | 1996 |
Treatment of patients resistant to anthracycline therapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1996 |
First-line treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Europe; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; North America; Paclitaxel; Taxoids | 1996 |
Taxoids in combination chemotherapy for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Cisplatin; Creatinine; Cyclophosphamide; Dose-Response Relationship, Drug; Electrolytes; Female; Hematopoiesis; Humans; Kidney Function Tests; Neoplasm Metastasis; Neutropenia; Paclitaxel; Renal Insufficiency; Risk Factors; Transplantation, Autologous | 1996 |
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Liver; Middle Aged; Paclitaxel | 1996 |
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Over Studies; Disease Progression; Doxorubicin; Europe; Female; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Remission Induction | 1996 |
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Muscular Diseases; Neutropenia; Paclitaxel; Pain; Peripheral Nervous System Diseases; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Tolerance; Epirubicin; Feasibility Studies; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mucous Membrane; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Time Factors; Vinblastine; Vinorelbine | 1996 |
Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Rate | 1996 |
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Heart; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1996 |
Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 1996 |
The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Remission Induction | 1996 |
A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Rate | 1996 |
Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Nervous System Diseases; Paclitaxel; Patient Selection; Vinblastine; Vinorelbine | 1997 |
Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Kidney; Middle Aged; Nervous System Diseases; Paclitaxel; Reflex; Salvage Therapy; Vinblastine; Vinorelbine | 1996 |
Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1996 |
A pilot study to evaluate paclitaxel (Taxol) as primary medical treatment for patients with inoperable stage III and IV breast carcinoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Treatment Outcome | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunoblastic Lymphadenopathy; Lung Neoplasms; Male; Mesothelioma; Paclitaxel; Prostatic Neoplasms; Recombinant Proteins | 1997 |
Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Neutropenia; Paclitaxel; Recombinant Proteins | 1997 |
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Cyclophosphamide; Epirubicin; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel | 1997 |
Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estramustine; Fatigue; Female; Humans; Middle Aged; Nausea; Ovarian Neoplasms; Paclitaxel; Treatment Outcome; Vomiting | 1997 |
Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclosporins; Cystadenocarcinoma; Drug Resistance, Multiple; Female; Humans; Kidney; Liver; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Radionuclide Imaging; Technetium Tc 99m Sestamibi | 1997 |
Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Forecasting; Humans; Paclitaxel | 1997 |
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life | 1997 |
A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Paclitaxel; Survival | 1997 |
Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Paclitaxel; Treatment Outcome | 1997 |
Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Pleural Neoplasms; Treatment Outcome; Ventricular Function, Left | 1997 |
Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis | 1997 |
Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.
Topics: Ambulatory Care; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ovarian Neoplasms; Paclitaxel | 1997 |
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 1997 |
The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Female; Flavonoids; Humans; Infusions, Intravenous; Lymphatic System; Middle Aged; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Taxoids; Water-Electrolyte Balance | 1997 |
Docetaxel in combination with doxorubicin: a phase I dose-finding study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Survival Rate; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 1997 |
Docetaxel combined with vinorelbine: phase I results and new study designs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Neutropenia; Paclitaxel; Research Design; Taxoids; Vinblastine; Vinorelbine | 1997 |
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Least-Squares Analysis; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 1997 |
A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Dexamethasone; Feasibility Studies; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Premedication; Promethazine; Ranitidine; Safety | 1997 |
Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel a
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Paclitaxel | 1996 |
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Risk Factors; Sensory Thresholds | 1997 |
Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Specimen Collection; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins | 1997 |
Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Salvage Therapy | 1997 |
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Body Fluids; Breast Neoplasms; Cetirizine; Docetaxel; Drug Administration Schedule; Drug Eruptions; Edema; Europe; Female; Histamine H1 Antagonists; Humans; Methylprednisolone; Middle Aged; Paclitaxel; Pleural Effusion; Severity of Illness Index; Skin; Taxoids; Treatment Outcome; Water-Electrolyte Imbalance | 1997 |
Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Thrombocytopenia | 1997 |
A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Paclitaxel; Prospective Studies; Remission Induction; Survival Analysis | 1997 |
Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Heart; Humans; Neoplasm Metastasis; Paclitaxel | 1997 |
Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 1997 |
Paclitaxel changes sympathetic control of blood pressure.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Autonomic Nervous System; Blood Pressure; Breast Neoplasms; Female; Heart Rate; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Posture; Respiration; Valsalva Maneuver | 1997 |
Metastatic breast cancer: treatment with fluorouracil-based combinations.
Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Nausea; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 1997 |
Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Doxorubicin; Drug Administration Schedule; Estrogen Antagonists; Female; Fever; Humans; Infusions, Intravenous; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Tamoxifen; Taxoids | 1997 |
Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bacterial Infections; Breast Neoplasms; Cause of Death; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fever; Heart Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia | 1997 |
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Mitomycins; Neoplasm Metastasis; Paclitaxel; Quality of Life; Remission Induction; Safety; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine | 1997 |
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids | 1997 |
Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fever; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1997 |
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Prednisone; Survival Analysis | 1997 |
Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects | 1997 |
Doxorubicin plus paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Paclitaxel plus doxorubicin in breast cancer: an Italian experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel | 1997 |
Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume; Ventricular Function, Left | 1997 |
Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies | 1997 |
Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Humans; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quality of Life | 1997 |
Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Paclitaxel | 1997 |
Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1997 |
Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Mitoxantrone; Neoplasm Metastasis; Paclitaxel | 1997 |
Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Heart; Heart Function Tests; Humans; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Stroke Volume | 1997 |
Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel | 1997 |
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Heart; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Respiratory Function Tests | 1997 |
A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1997 |
Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1997 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Leucovorin; Methotrexate; Middle Aged; Mitoxantrone; Paclitaxel | 1997 |
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 1997 |
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Treatment Outcome | 1997 |
[Taxotere: the first drug better than acrdiamycin, the most frequently used drug in the treatment of metastasized breast cancer. Phase III study shows a better response than standard treatment].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1997 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Middle Aged; Paclitaxel | 1998 |
Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Vinblastine; Vinorelbine | 1998 |
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
Topics: Adult; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Heart; Heart Failure; Humans; Middle Aged; Paclitaxel; Risk Factors; Stroke Volume | 1998 |
Dose-dense paclitaxel-containing adjuvant therapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Prospective Studies | 1998 |
One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1998 |
Fluorouracil-based combinations in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Forecasting; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
Paclitaxel plus epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Therapy, Combination; Epirubicin; Female; Humans; Paclitaxel | 1998 |
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1998 |
Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Paclitaxel; Salvage Therapy; Treatment Outcome | 1998 |
Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Middle Aged; Paclitaxel; Time Factors | 1998 |
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Regression Analysis; Topotecan; Treatment Outcome | 1998 |
Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Salvage Therapy; Survival Analysis; Taxoids; Vinblastine | 1998 |
Clinical phase I study with one-hour paclitaxel infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1998 |
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Humans; Melphalan; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Thiotepa; Treatment Outcome | 1998 |
Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids; Thrombocytopenia; Treatment Failure; Tumor Cells, Cultured | 1998 |
Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel.
Topics: Adult; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germinoma; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 1998 |
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1998 |
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Taxoids | 1998 |
A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Breast Neoplasms; Carcinoma; Cohort Studies; Cyclophosphamide; Diarrhea; Esophagitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Lung Diseases; Middle Aged; Neoplasm Staging; Paclitaxel; Pulmonary Alveoli; Remission Induction; Stomatitis; Survival Rate; Thiotepa; Transplantation, Autologous | 1998 |
Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Pilot Projects | 1998 |
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Paclitaxel; Treatment Outcome | 1998 |
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Topics: Adult; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Glycerol; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel | 1998 |
Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Transplantation, Autologous | 1998 |
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Female; Glucocorticoids; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group.
Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel | 1998 |
A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Paclitaxel; Survival Analysis; Treatment Outcome | 1998 |
The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 1998 |
A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Mitomycin; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Vinblastine | 1998 |
Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel | 1998 |
Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 1998 |
Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 1998 |
Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1998 |
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Neuromuscular Diseases; Paclitaxel; Pain Measurement; Palliative Care; Survival Analysis; Treatment Failure | 1998 |
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Thiotepa | 1998 |
[Breast cancer: new therapeutic strategies].
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Taxoids; Treatment Outcome | 1998 |
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Humans; Hydroxyethylrutoside; Middle Aged; Paclitaxel; Pericardial Effusion; Pleural Effusion; Taxoids; Water-Electrolyte Imbalance | 1999 |
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 1999 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Count; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Ventricular Function, Left | 1999 |
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Half-Life; Humans; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Remission Induction; Ventricular Function, Left | 1999 |
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Survival Analysis | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Neoplasm Metastasis; Paclitaxel; Prospective Studies | 1999 |
Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support.
Topics: Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Survival Analysis | 1999 |
Concurrent paclitaxel and radiation therapy for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1999 |
Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Vinblastine; Vinorelbine | 1999 |
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Health Status; Humans; Middle Aged; Mitomycins; Neutropenia; Paclitaxel; Patient Compliance; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taxoids; Thrombocytopenia; Vinblastine | 1999 |
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Leukapheresis; Mitoxantrone; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Thiotepa | 1999 |
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Heart Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Paclitaxel; Severity of Illness Index; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Severity of Illness Index; Survival Rate; Thiotepa; Treatment Outcome | 1999 |
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1999 |
[Docetaxel therapy against anthracycline resistant breast cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids | 1999 |
Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Middle Aged; Paclitaxel; Taxoids; Ventricular Function, Left | 1999 |
Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors | 1999 |
Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Combined Modality Therapy; DNA, Complementary; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Pilot Projects; Polymerase Chain Reaction; Retroviridae; T-Lymphocyte Subsets; Transduction, Genetic; Transplantation, Autologous | 1999 |
Paclitaxel, UFT, and calcium folinate in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 1999 |
Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Female; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Premedication; Tegafur; Treatment Outcome; Uracil | 1999 |
UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leucovorin; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 1999 |
A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 1999 |
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects | 1999 |
A phase I study of sequential vinorelbine followed by paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA, Neoplasm; Docetaxel; Doxorubicin; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; Neoadjuvant Therapy; Paclitaxel; Polymerase Chain Reaction; Receptor, ErbB-2; Reproducibility of Results; Taxoids | 1999 |
Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Argentina; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Treatment Outcome | 1999 |
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 1999 |
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Paclitaxel; Radiation-Protective Agents; Treatment Outcome; Vomiting | 1999 |
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Resistance; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Efficacy of epirubicin/paclitaxel combination in mobilizing large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clone Cells; Combined Modality Therapy; Epirubicin; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Middle Aged; Paclitaxel; Prospective Studies; Time Factors; Transplantation, Autologous | 1999 |
Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1999 |
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies | 1999 |
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Echocardiography; Epirubicin; Female; Heart Failure; Humans; Life Tables; Middle Aged; Paclitaxel; Risk Factors; Ventricular Function, Left | 1999 |
Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Breast Neoplasms; Cyclophosphamide; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Middle Aged; Paclitaxel; Prognosis; Recombinant Proteins | 1999 |
Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Statistics, Nonparametric; Taxoids | 1999 |
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 1999 |
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Quality of Life | 1999 |
Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Paclitaxel; Recombinant Proteins | 1999 |
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 1999 |
[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids | 1999 |
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Recurrence; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1999 |
Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunohistochemistry; Mastectomy; Mesna; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Protective Agents; Recombinant Proteins; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Topics: Adult; Aged; Algorithms; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Patient Compliance; Taxoids; Treatment Failure | 1999 |
A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Thiotepa; Transplantation, Autologous | 1999 |
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids | 1999 |
First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Chemical and Drug Induced Liver Injury; Docetaxel; Drug Resistance, Neoplasm; Female; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Stomatitis; Taxoids; Treatment Outcome | 2000 |
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Codon; Cyclophosphamide; Epirubicin; Exons; Female; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Introns; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Tumor Suppressor Protein p53 | 2000 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chi-Square Distribution; Cross-Over Studies; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Logistic Models; Middle Aged; Paclitaxel; Proportional Hazards Models; Remission Induction; Survival Rate | 2000 |
Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematocrit; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Platelet Count; Recombinant Proteins; Thrombocytopenia; Time Factors | 2000 |
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Enterocolitis, Pseudomembranous; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Safety; Time Factors; Vinblastine; Vinorelbine | 2000 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 2000 |
Docetaxel administered on a weekly basis for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2000 |
[Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Screening Assays, Antitumor; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2000 |
Intestinal side-effects of docetaxel/vinorelbine combination.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastroenteritis; Humans; Neutropenia; Paclitaxel; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2000 |
Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Prognosis; Risk Factors; Treatment Outcome | 2000 |
High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Treatment Outcome | 2000 |
A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Female; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Taxoids | 2000 |
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Floxuridine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 2000 |
Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Synergism; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Radiotherapy; Risk; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Austria; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Ventricular Function, Left | 2000 |
Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Economics, Pharmaceutical; Female; Fever; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix; Female; Humans; Immunohistochemistry; Menopause; Mucin-1; Multivariate Analysis; Paclitaxel; Prospective Studies; Protein Structure, Tertiary; Receptor, ErbB-2; Time Factors; Treatment Outcome | 2000 |
Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Indonesia; Liver Neoplasms; Middle Aged; Paclitaxel; Remission Induction; Stroke Volume; Taxoids; Ventricular Function, Left | 2000 |
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Middle Aged; Netherlands; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2000 |
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Paclitaxel; Quality of Life; Taxoids | 2000 |
Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
[Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Disease-Free Survival; Doxorubicin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Outpatients; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 1998 |
[A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids | 2000 |
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bias; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Doxorubicin; Female; Humans; Paclitaxel; Patient Compliance; Prospective Studies; Quality of Life; Treatment Outcome | 2000 |
Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
High efficacy of paclitaxel and doxorubicin as first-line therapy in advanced breast cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Australia; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Europe; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Failure; United States | 2000 |
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Physical Examination; Premedication; Prospective Studies; Ranitidine; Remission Induction; Sensitivity and Specificity; Ultrasonography | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
A multicentre phase II pilot study of epirubicin and Taxol (paclitaxel) in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Heart Function Tests; Humans; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 2000 |
Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2000 |
Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
[Paclitaxel versus doxorubicin in first-line therapy of metastatic breast carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2000 |
Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Cross-Over Studies; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Time Factors | 2000 |
[Weekly administration of paclitaxel for advanced or metastatic breast cancer--short-course premedications for outpatients].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2000 |
High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Saudi Arabia; Survival Analysis; Treatment Outcome | 2000 |
[Intra-arterial infusion chemotherapy with docetaxel for locally advanced breast cancer and inflammatory breast cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Paclitaxel; Tegafur; Uracil | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; Disease Progression; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Stomatitis; Survival Analysis; Taxoids; Thiotepa; Thrombocytopenia; Transplantation Conditioning | 2000 |
Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2000 |
Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Taxoids | 2000 |
Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Liposomes; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2000 |
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
Topics: Acridines; Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Tetrahydroisoquinolines | 2001 |
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Stroke Volume | 2000 |
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2000 |
Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neutrophils; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Middle Aged; Paclitaxel; Taxoids | 2000 |
Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Remission Induction; Survival Analysis; Taxoids | 2001 |
Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Regression Analysis; Thiotepa; Time Factors | 2001 |
Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Female; Fever; Humans; Infusions, Intravenous; Kinetics; Leukocyte Count; Leukopenia; Middle Aged; Models, Biological; Paclitaxel | 2001 |
Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Vinblastine; Vinorelbine | 2001 |
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2001 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2001 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia | 2001 |
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Melphalan; Middle Aged; Paclitaxel; Remission Induction; Survival Rate | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Greece; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis | 2001 |
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Epirubicin; Female; Humans; Myocardium; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
High dose chemotherapy and peripheral blood stem cell transplantation for high risk primary breast cancer: a single center experience in Thailand.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Thailand | 2000 |
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Survival Analysis; Taxoids | 2001 |
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Incidence; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Taxoids | 2001 |
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Topics: Adult; Aged; Anemia; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Methacrylates; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Polymers; Prodrugs; Remission Induction; Skin Neoplasms; Solubility; Taxoids | 2001 |
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Stomach Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 2001 |
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Female; Humans; Hyperprolactinemia; Injections, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Prolactin; Remission Induction; Taxoids | 2001 |
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Paclitaxel; Prognosis; Treatment Outcome | 2001 |
[Effectiveness of doxorubicin-docetaxel or doxorubicin-cyclophosphamide combination in advanced breast cancer with distant metastasis].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Taxoids; Treatment Outcome | 2001 |
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Gene Amplification; Genes, erbB-2; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Trastuzumab; Treatment Outcome | 2001 |
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukocyte Count; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Stem Cells; Taxoids | 2001 |
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2001 |
Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Meta-Analysis as Topic; Middle Aged; Paclitaxel; Survival Rate | 2001 |
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome | 2001 |
Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy | 2001 |
Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Tolerance; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2001 |
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 2001 |
Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Survival Analysis; Taxoids | 2001 |
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Survival Analysis | 2001 |
Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunomagnetic Separation; Middle Aged; Models, Biological; Ovarian Neoplasms; Paclitaxel; Stem Cells; Time Factors; Transplantation, Autologous; Treatment Outcome | 2001 |
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids | 2001 |
[Evaluation of efficacy and toxicity of docetaxel (Taxotere) in patients with advanced mammary gland cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2001 |
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Floxuridine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Patient Compliance; Preoperative Care; Prospective Studies; Tamoxifen; Taxoids | 2001 |
Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2001 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mitoxantrone; Nausea; Neutropenia; Paclitaxel; Sepsis; Survival Rate; Taxoids | 2001 |
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[Effect of weekly docetaxel in patients with recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pilot Projects; Taxoids | 2001 |
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infections; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2001 |
Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Transplantation, Autologous; Treatment Outcome | 2001 |
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Taxoids | 2001 |
A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Survival Rate; Treatment Failure; Treatment Outcome | 2001 |
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; CD3 Complex; CD8 Antigens; Chemotherapy, Adjuvant; Female; Humans; Immunohistochemistry; Lymphocytes, Tumor-Infiltrating; Membrane Proteins; Middle Aged; Paclitaxel; Poly(A)-Binding Proteins; Proteins; RNA-Binding Proteins; T-Cell Intracellular Antigen-1; Treatment Outcome | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Quality of Life; Treatment Outcome | 2001 |
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Female; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Taxoids; Treatment Outcome | 2001 |
Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Heart; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Paclitaxel; Stroke Volume | 2001 |
A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Failure | 2001 |
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis | 2001 |
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Hospitalization; Humans; Lymphatic Metastasis; Mammography; Mastectomy, Modified Radical; Middle Aged; Paclitaxel | 2001 |
Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Middle Aged; Neutrophils; Paclitaxel; Pilot Projects; Survival Rate; Taxoids; Vomiting | 2002 |
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Docetaxel; Double-Blind Method; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome | 2001 |
Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Weekly paclitaxel therapy for metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2002 |
[Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Ranitidine; Vomiting, Anticipatory | 2002 |
Cardiac dysfunction in the trastuzumab clinical trials experience.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophosphamide; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Risk Factors; Trastuzumab | 2002 |
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Taxoids | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Recurrence, Local; Paclitaxel; Piperidines; Pyridines; Safety; Time Factors; Tissue Distribution; Treatment Outcome | 2002 |
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Linear Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Taxoids; Treatment Outcome; Vincristine | 2002 |
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2000 |
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Female; Forecasting; Humans; Immunoenzyme Techniques; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Tumor Suppressor Protein p53 | 2000 |
Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Monitoring; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Paclitaxel; Proportional Hazards Models; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Viscera | 2000 |
Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Prospective Studies; Survival Rate; Taxoids | 2002 |
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Up-Regulation | 2002 |
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Patient Selection; Prospective Studies | 2002 |
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2002 |
Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion Pumps; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis | 2002 |
Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
Topics: Adult; Antigens, CD34; Breast Neoplasms; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukocyte Count; Middle Aged; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prognosis; Recombinant Proteins | 2002 |
Docetaxel does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Circadian Rhythm; Docetaxel; Electrocardiography; Female; Heart Rate; Humans; Middle Aged; Paclitaxel; Taxoids | 2002 |
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2002 |
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Glycerol; Humans; In Vitro Techniques; Infusions, Intravenous; Middle Aged; Paclitaxel | 2002 |
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Paclitaxel; Thiotepa; Transplantation, Autologous | 2002 |
CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Thiotepa; Transplantation, Autologous | 2002 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fever; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome | 2002 |
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Uracil | 2002 |
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estrogens; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Life Tables; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Progesterone; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Thiotepa; Time Factors; Treatment Outcome | 2002 |
Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Intubation; Lacrimal Apparatus; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Trastuzumab | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Weekly paclitaxel in women age 65 and above with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leucovorin; Middle Aged; Paclitaxel; Treatment Outcome | 2002 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
Topics: Adult; Antibody Formation; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytokines; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Growth Substances; Humans; Immunity, Cellular; Killer Cells, Lymphokine-Activated; Middle Aged; Paclitaxel; Taxoids | 2002 |
[Cancer of the breast].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tamoxifen | 1992 |
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female; Heart Diseases; Humans; Methotrexate; Middle Aged; Muscular Diseases; Paclitaxel; Pain; Peripheral Nervous System Diseases; Remission Induction; Soft Tissue Neoplasms; Thrombocytopenia | 1991 |
2808 other study(ies) available for paclitaxel and Breast Neoplasms
| Article | Year |
|---|---|
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1996 |
Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Esters; Female; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 1997 |
Remangilones A-C, new cytotoxic triterpenes from Physena madagascariensis.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Screening Assays, Antitumor; Epithelial Cells; Gas Chromatography-Mass Spectrometry; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Plant Leaves; Plants, Medicinal; Spectrophotometry, Ultraviolet; Triterpenes; Tumor Cells, Cultured | 1999 |
New taxane analogues from the needles of Taxus canadensis.
Topics: Adenocarcinoma; Alkaloids; Breast Neoplasms; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Molecular Structure; Spectrometry, Mass, Fast Atom Bombardment; Trees; Tumor Cells, Cultured | 2001 |
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Kinetics of P-glycoprotein-mediated efflux of paclitaxel.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Female; Genes, MDR; Humans; Models, Biological; Paclitaxel; Reproducibility of Results; Transfection; Tumor Cells, Cultured | 2001 |
Modulation of human mammary cell sensitivity to paclitaxel by new quinoline sulfonamides.
Topics: Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Models, Molecular; Paclitaxel; Quinolines; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured | 2001 |
Design, synthesis, and bioactivities of steroid-linked taxol analogues as potential targeted drugs for prostate and breast cancer.
Topics: Breast Neoplasms; Drug Screening Assays, Antitumor; Estradiol; Female; Humans; Male; Molecular Structure; Paclitaxel; Prostate; Stereoisomerism; Succinates; Tumor Cells, Cultured | 2004 |
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
Topics: Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Mice; Mice, Nude; Nitrogen Mustard Compounds; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured; Vinblastine; Xenograft Model Antitumor Assays | 2004 |
Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Disulfides; Dose-Response Relationship, Drug; Female; Histone Deacetylase Inhibitors; Humans; Micronesia; Porifera; PPAR gamma; Tyrosine | 2006 |
Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines.
Topics: Antineoplastic Agents; Benzoxepins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Hydrogen; Microwaves; Molecular Structure; Purines; Stereoisomerism; Structure-Activity Relationship | 2008 |
Pyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation.
Topics: Adenosine Triphosphatases; Breast Neoplasms; Cell Proliferation; Female; HSP70 Heat-Shock Proteins; Humans; Molecular Chaperones; Peptoids; Pyrimidinones | 2008 |
Synthesis, biological evaluation and radiochemical labeling of a dansylhydrazone derivative as a potential imaging agent for apoptosis.
Topics: Apoptosis; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Cytoplasm; Dansyl Compounds; Female; Fluorine Radioisotopes; Humans; Hydrazines; Isotope Labeling; Molecular Structure; Molecular Weight; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Stereoisomerism | 2008 |
Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts.
Topics: Animals; Body Weight; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Female; Humans; Macrolides; Mice; Xenograft Model Antitumor Assays | 2008 |
In vitro and in vivo anticancer activity of 2-deacetoxytaxinine J and synthesis of novel taxoids and their in vitro anticancer activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line; Cell Line, Tumor; Epithelial Cells; Female; Humans; Inhibitory Concentration 50; Kidney; Plant Bark; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Taxoids; Taxus | 2009 |
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Topics: Animals; Antineoplastic Agents, Alkylating; Aza Compounds; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Cross-Linking Reagents; DNA; Female; Humans; Indenes; Mice; Mice, Nude; Neoplasms; Remission Induction; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2009 |
Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Furans; Humans; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Mice, SCID; Pyrones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Microwaves; Neoplasms; Ovarian Neoplasms | 2010 |
Conjugate (MTC-220) of muramyl dipeptide analogue and paclitaxel prevents both tumor growth and metastasis in mice.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Division; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytokines; Dipeptides; Female; Humans; Inflammation Mediators; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel | 2011 |
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Topics: Adenine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Dansyl Compounds; Female; Fluorescent Dyes; Humans; Protein Kinase Inhibitors | 2011 |
Total synthesis and bioactivity of the marine alkaloid pityriacitrin and some of its derivatives.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indole Alkaloids; Malassezia; Male; Prostatic Neoplasms | 2011 |
Asperjinone, a nor-neolignan, and terrein, a suppressor of ABCG2-expressing breast cancer cells, from thermophilic Aspergillus terreus.
Topics: Antineoplastic Agents; Aspergillus; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Caspase 7; Cyclopentanes; Drug Screening Assays, Antitumor; Female; Humans; Lignans; Molecular Structure; Neoplasm Proteins; Nuclear Magnetic Resonance, Biomolecular; Proto-Oncogene Proteins c-akt; Taiwan | 2012 |
Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Female; Humans; Inula; Molecular Structure; Plant Components, Aerial; Plant Extracts; Terpenes | 2013 |
4,5-Di-substituted benzyl-imidazol-2-substituted amines as the structure template for the design and synthesis of reversal agents against P-gp-mediated multidrug resistance breast cancer cells.
Topics: Amines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imidazoles; Mice | 2014 |
Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Chemistry Techniques, Synthetic; Dioxolanes; Drug Design; Female; Genes, Tumor Suppressor; Glutathione; Humans; Microtubules; Mutation; Reactive Oxygen Species; Stilbenes; Tumor Suppressor Protein p53 | 2016 |
Cytotoxic Evaluation against Breast Cancer Cells of Isoliquiritigenin Analogues from Spatholobus suberectus and Their Synthetic Derivatives.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Chalcones; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Fabaceae; Female; Humans; Molecular Structure | 2016 |
Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Proliferation; DNA Damage; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Molecular Structure; Receptor, ErbB-2; Receptors, Progesterone; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Dioxolanes; Female; Humans; MCF-7 Cells; Microtubules; Models, Molecular; Piperidones; Reactive Oxygen Species; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2017 |
A Bis-benzopyrroloisoquinoline Alkaloid Incorporating a Cyclobutane Core and a Chlorophenanthroindolizidine Alkaloid with Cytotoxic Activity from Ficus fistulosa var. tengerensis.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Crystallography, X-Ray; Cyclobutanes; Ficus; Heterocyclic Compounds, 4 or More Rings; Humans; Indolizines; Inhibitory Concentration 50; Isoquinolines; Malaysia; Molecular Conformation; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Phenanthrolines; Plant Leaves; Stereoisomerism | 2017 |
Pyranocarbazole derivatives as potent anti-cancer agents triggering tubulin polymerization stabilization induced activation of caspase-dependent apoptosis and downregulation of Akt/mTOR in breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carbazoles; Caspases; Cell Line, Tumor; Down-Regulation; Humans; Inhibitory Concentration 50; PC-3 Cells; Polymerization; Proto-Oncogene Proteins c-akt; Pyrans; Rats; TOR Serine-Threonine Kinases; Tubulin | 2019 |
Synthesis, structure-activity relationship and in vitro pharmacodynamics of A-ring modified caged xanthones in a preclinical model of inflammatory breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Inflammatory Breast Neoplasms; Molecular Structure; Structure-Activity Relationship; Xanthones | 2019 |
Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Design; Female; Humans; Molecular Docking Simulation; Quinazolinones; Thiophenes; Topoisomerase I Inhibitors; Tubulin; Tubulin Modulators | 2019 |
Anti-cancer potential of novel glycosylated 1,4-substituted triazolylchalcone derivatives.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Chalcone; Click Chemistry; Cycloaddition Reaction; Drug Screening Assays, Antitumor; Female; Glycosylation; Humans; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colchicine; Crystallography, X-Ray; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Models, Molecular; Pyridines; Structure-Activity Relationship; Tubulin Modulators | 2020 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Fulvestrant; Humans; MCF-7 Cells; Mice; Models, Molecular; Piperazines; Protein Domains; Pyridines; Pyridones; Receptors, Estrogen; Tissue Distribution; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.
Topics: Animals; Animals, Genetically Modified; Breast Neoplasms; Catalysis; Cell Line, Tumor; Enzyme Inhibitors; Female; Focal Adhesion Protein-Tyrosine Kinases; Glycoproteins; Humans; Integrins; Isoenzymes; Molecular Docking Simulation; Neoplasm Metastasis; NF-kappa B; Paxillin; Phosphorylation; Sialyltransferases; Signal Transduction; Talin; Zebrafish | 2021 |
Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbon Monoxide; Cell Line, Tumor; Cell Survival; Chloramphenicol; Coordination Complexes; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Screening Assays, Antitumor; Humans; Light; Manganese; Paclitaxel | 2021 |
Design, synthesis and broad spectrum antibreast cancer activity of diarylindoles via induction of apoptosis in aggressive breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Molecular Structure; Polymerization; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2021 |
New synthetic phenylquinazoline derivatives induce apoptosis by targeting the pro-survival members of the BCL-2 family.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Proto-Oncogene Proteins c-bcl-2 | 2022 |
Formulation effects on paclitaxel transfer and uptake in the human placenta.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compounding; Female; Humans; Micelles; Nanoparticles; Paclitaxel; Placenta; Polyethylene Glycols; Pregnancy | 2021 |
Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance.
Topics: Animals; Breast Neoplasms; Cell Transformation, Neoplastic; F-Box Proteins; Female; Humans; Mice; NF-kappa B; Paclitaxel; Transcription Factor RelA; Ubiquitin-Protein Ligases; Ubiquitination | 2022 |
Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Cytoskeleton; Female; Humans; Microtubules; Mitosis; Ovarian Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured; Ultrasonic Waves | 2021 |
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
Topics: Breast Neoplasms; Female; Humans; Paclitaxel; Premedication; Prospective Studies | 2021 |
The relevance of macrocytosis induction during neoadjuvant dose-dense chemotherapy in breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Erythrocytes; Erythrocytes, Abnormal; Female; Hematologic Tests; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies | 2022 |
Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Benzoquinones; Breast Neoplasms; Drug Compounding; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nanoparticles; Paclitaxel; Poloxamer; Polylactic Acid-Polyglycolic Acid Copolymer | 2021 |
Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel.
Topics: Breast Neoplasms; Chromosomal Instability; Female; Humans; Paclitaxel | 2021 |
Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Non-Randomized Controlled Trials as Topic; Observational Studies as Topic; Paclitaxel; Prognosis; Random Allocation; Retrospective Studies; Survival Rate | 2021 |
An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2021 |
Poly(2-oxazoline)-magnetite NanoFerrogels: Magnetic field responsive theranostic platform for cancer drug delivery and imaging.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Ferrosoferric Oxide; Humans; Magnetic Fields; Micelles; Oxazoles; Paclitaxel; Precision Medicine | 2022 |
Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Cell Survival; Dactinomycin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Irinotecan; MCF-7 Cells; Paclitaxel; Proteome; Proteomics; Vinorelbine | 2021 |
Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Transformation, Neoplastic; Doxorubicin; Female; Humans; Mesenchymal Stem Cells; Mice; Mice, SCID; Neoplasm Invasiveness; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Injectable hydrogel loaded with paclitaxel and epirubicin to prevent postoperative recurrence and metastasis of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Epirubicin; Female; Humans; Hydrogels; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel | 2021 |
Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study.
Topics: Aged; Biomarkers; Breast Neoplasms; Cognitive Dysfunction; Female; Humans; Intermediate Filaments; Middle Aged; Multiple Sclerosis; Paclitaxel; Prospective Studies | 2022 |
A four-in-one pure nanomedicine for synergistic multi-target therapy against breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Mice; Mice, Inbred BALB C; Molecular Structure; Nanomedicine; Paclitaxel; Stilbenes; Sulfonamides | 2021 |
Development and optimization of paclitaxel loaded Eudragit/PLGA nanoparticles by simplex lattice mixture design: Exploration of improved hemocompatibility and in vivo kinetics.
Topics: Animals; Antineoplastic Agents; Blood Coagulation; Breast Neoplasms; Drug Carriers; Drug Compounding; Drug Liberation; Half-Life; Hemolysis; Humans; Injections, Intravenous; Male; MCF-7 Cells; Nanoparticles; Nanotechnology; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Polymethacrylic Acids; Rats, Wistar; Tissue Distribution | 2021 |
Symptom status, body perception, and risk of anxiety and depression in breast cancer patients receiving paclitaxel: a prospective longitudinal study.
Topics: Anxiety; Breast Neoplasms; Depression; Female; Humans; Longitudinal Studies; Paclitaxel; Perception; Prospective Studies | 2022 |
T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy.
Topics: Adoptive Transfer; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; CD8-Positive T-Lymphocytes; Extracellular Matrix; Extracellular Matrix Proteins; Female; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, SCID; Paclitaxel; Protein-Lysine 6-Oxidase | 2022 |
Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Carbonic anhydrase 12 gene silencing reverses the sensitivity of paclitaxel in drug-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Carbonic Anhydrases; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; MCF-7 Cells; Neoplasm Proteins; Paclitaxel | 2021 |
Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Follow-Up Studies; Furans; Humans; Ketones; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2021 |
Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer.
Topics: Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Female; Humans; MicroRNAs; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2021 |
Experimental and computational assessment of the synergistic pharmacodynamic drug-drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Trastuzumab | 2022 |
[Paclitaxel plus Bevacizumab Therapy plus Surgical Resection Results in Local Control of Stage ⅢC Breast Cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Mastectomy; Paclitaxel; Quality of Life; Triple Negative Breast Neoplasms | 2021 |
DEHP mediates drug resistance by directly targeting AhR in human breast cancer.
Topics: Adult; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Breast Neoplasms; Cell Line, Tumor; Diethylhexyl Phthalate; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Knockout; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Aryl Hydrocarbon; Survival Rate; Tamoxifen; Xenograft Model Antitumor Assays; Zebrafish | 2022 |
Paclitaxel-based supramolecular hydrogel loaded with mifepristone for the inhibition of breast cancer metastasis.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Carriers; Drug Liberation; Female; Humans; Hydrogels; Mice; Mifepristone; Nanostructures; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2022 |
Anisocoria as a side effect of paclitaxel treatment.
Topics: Anisocoria; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel | 2021 |
Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF3 κB-p53-caspase-3 pathways modulation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cinnamates; Depsides; Inflammation; Mice; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Rosmarinic Acid; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2021 |
Novel polysaccharide building hybrid nanoparticles: remodelling TAMs to target ERα-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Female; Humans; Nanoparticles; Paclitaxel; Polysaccharides; Tumor Microenvironment; Tumor-Associated Macrophages | 2022 |
"Attractive/adhesion force" dual-regulatory nanogels capable of CXCR4 antagonism and autophagy inhibition for the treatment of metastatic breast cancer.
Topics: Animals; Autophagy; Breast Neoplasms; Cell Adhesion; Female; Humans; Mice; Nanogels; Paclitaxel; Receptors, CXCR4 | 2022 |
Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cancer Survivors; Drug Therapy; Duloxetine Hydrochloride; Female; Genital Neoplasms, Female; Humans; Japan; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Factors | 2021 |
A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Neoadjuvant Therapy; Paclitaxel | 2022 |
ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of nonapoptotic phosphatidylserine.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Myeloid-Derived Suppressor Cells; Neoplasm Metastasis; Neoplasms, Second Primary; Paclitaxel; Phosphatidylserines; Skin Neoplasms; Tumor Microenvironment | 2022 |
Manganese-based multifunctional nanoplatform for dual-modal imaging and synergistic therapy of breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Glucose; Glucose Oxidase; Humans; Ions; Manganese; Nanoparticles; Paclitaxel; Phospholipids; Reactive Oxygen Species | 2022 |
Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Humans; Microtubules; Paclitaxel; Tubulin | 2022 |
Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Immunotherapy; Muscles; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Role of aurora kinase B in regulating resistance to paclitaxel in breast cancer cells.
Topics: Animals; Aurora Kinase B; Breast Neoplasms; Female; Humans; Paclitaxel; Phosphorylation; RNA, Small Interfering | 2022 |
Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; BRCA1 Protein; Breast Neoplasms; Carboplatin; DNA Breaks, Double-Stranded; DNA Repair; Embryonic Development; Fanconi Anemia Complementation Group Proteins; Female; Fertilization in Vitro; Genes, Tumor Suppressor; Germ-Line Mutation; Heterozygote; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Animal; Ovarian Follicle; Ovarian Reserve; Paclitaxel; RNA Helicases | 2022 |
Knockdown of long non‑coding RNA DDX11‑AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA‑497 expression.
Topics: Antigens, CD; Breast Neoplasms; Cadherins; Cell Line; Cell Movement; Cell Proliferation; DEAD-box RNA Helicases; DNA Helicases; Drug Resistance, Neoplasm; Humans; MicroRNAs; Paclitaxel; RNA, Long Noncoding; Up-Regulation | 2022 |
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Breast Neoplasms; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Injections, Intravenous; Lapatinib; Mice; Micelles; Paclitaxel; Peptides; Tumor Cells, Cultured | 2022 |
Effect of turmeric supplementation on the pharmacokinetics of paclitaxel in breast cancer patients: A study with population pharmacokinetics approach.
Topics: Breast Neoplasms; Curcuma; Dietary Supplements; Female; Humans; Longitudinal Studies; Paclitaxel; Prospective Studies | 2022 |
Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Histone-Lysine N-Methyltransferase; Humans; MCF-7 Cells; Paclitaxel; Wnt Signaling Pathway | 2022 |
Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Drug Combinations; Drug Repositioning; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Paclitaxel | 2022 |
Engineering Lipusu with lysophosphatidylcholine for improved tumor cellular uptake and anticancer efficacy.
Topics: Animals; Breast Neoplasms; Female; Humans; Liposomes; Lysophosphatidylcholines; Mice; Paclitaxel; Tissue Distribution | 2022 |
Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Clodronic Acid; Female; Humans; Mice; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor-Associated Macrophages | 2022 |
Nanosized paclitaxel-loaded niosomes: formulation, in vitro cytotoxicity, and apoptosis gene expression in breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cholesterol; Female; Gene Expression; Humans; Liposomes; MCF-7 Cells; Paclitaxel; Particle Size | 2022 |
Zerumbone-induced reactive oxygen species-mediated oxidative stress re-sensitizes breast cancer cells to paclitaxel.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Oxidative Stress; Paclitaxel; Reactive Oxygen Species | 2023 |
Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Liposomes; Paclitaxel; RNA, Small Interfering | 2022 |
Ambra1 regulates apoptosis and chemosensitivity in breast cancer cells through the Akt-FoxO1-Bim pathway.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Breast Neoplasms; Female; Forkhead Box Protein O1; Humans; Paclitaxel; Proto-Oncogene Proteins c-akt | 2022 |
Low temperature mitigating the paclitaxel-induced damages in mouse cell and hair follicle model.
Topics: Alopecia; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Hair Follicle; Humans; Hypothermia, Induced; Mice; Paclitaxel; Scalp; Temperature | 2022 |
Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Life Style; Liver Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Receptor, ErbB-2; Trastuzumab | 2022 |
Curcumin and Paclitaxel Co-loaded Heparin and Poloxamer P403 Hybrid Nanocarrier for Improved Synergistic Efficacy in Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Curcumin; Drug Carriers; Female; Heparin; Humans; Nanogels; Nanoparticles; Paclitaxel; Poloxamer; Spectroscopy, Fourier Transform Infrared | 2022 |
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients.
Topics: Adult; Biomarkers; Breast Neoplasms; Female; Humans; Intermediate Filaments; Middle Aged; Neurofilament Proteins; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lipopolysaccharides; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Treatment Outcome | 2022 |
Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Furans; Histone Deacetylase Inhibitors; Humans; Paclitaxel; Quinolines; Sirtuin 2 | 2022 |
A neutrophil-mediated carrier regulates tumor stemness by inhibiting autophagy to prevent postoperative triple-negative breast cancer recurrence and metastasis.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydroxychloroquine; Inflammation; Liposomes; Neoplasm, Residual; Neutrophils; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
Paclitaxel-nanocrystals-loaded network thermosensitive hydrogel for localised postsurgical recurrent of breast cancer after surgical resection.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydrogels; Mice; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Poloxamer | 2022 |
Increased LZTS1 expression is associated with a good response to paclitaxel-based chemotherapy in breast cancer.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Female; Humans; Immunohistochemistry; MCF-7 Cells; Paclitaxel; Tumor Suppressor Proteins | 2022 |
Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice.
Topics: Albumins; Animals; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Humans; Mice; Nanoparticles; Paclitaxel; Tumor Microenvironment | 2022 |
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines | 2022 |
Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; Brain Neoplasms; Breast Neoplasms; Calcium-Binding Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoribonucleases; Female; Glioblastoma; Humans; Membrane Glycoproteins; Mice; Paclitaxel; Prospective Studies; Protein Serine-Threonine Kinases; Receptors, Cytoplasmic and Nuclear; Receptors, Peptide; Xenograft Model Antitumor Assays | 2022 |
Anticancer Efficacy of 6-Gingerol with Paclitaxel against Wild Type of Human Breast Adenocarcinoma.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 7; Catechols; Cell Line, Tumor; Fatty Alcohols; Female; Humans; Paclitaxel | 2022 |
pH-Responsive Nanoparticles for Multidimensional Combined Chemo-Immunotherapy of Cancer.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Cell Line, Tumor; Ecosystem; Female; Humans; Hydrogen-Ion Concentration; Immunotherapy; Nanoparticles; Paclitaxel; Tumor Microenvironment | 2022 |
Biosynthesis of folic acid appended PHBV modified copper oxide nanorods for pH sensitive drug release in targeted breast cancer therapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Copper; Drug Carriers; Drug Liberation; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Nanoparticles; Nanotubes; Oxides; Paclitaxel; Polyesters | 2022 |
Trastuzumab, pyrotinib and paclitaxel for HER2-positive breast cancer after multi-line targeted therapies.
Topics: Acrylamides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2023 |
A precision medicine approach to metabolic therapy for breast cancer in mice.
Topics: Animals; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Mice; Paclitaxel; Precision Medicine; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catechin; Chlorogenic Acid; Cyclophosphamide; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Ligands; Molecular Docking Simulation; Paclitaxel; Quercetin; Tamoxifen; Trastuzumab | 2022 |
Honokiol nanosuspensions loaded thermosensitive hydrogels as the local delivery system in combination with systemic paclitaxel for synergistic therapy of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydrogels; Lignans; Mice; Nanoparticles; Paclitaxel | 2022 |
Laser-responsive multi-functional nanoparticles for efficient combinational chemo-photodynamic therapy against breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Chlorophyllides; Female; Humans; Lasers; Nanoparticles; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Porphyrins | 2022 |
Vitamin D enhances the sensitivity of breast cancer cells to the combination therapy of photodynamic therapy and paclitaxel.
Topics: Aminolevulinic Acid; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Female; Humans; Paclitaxel; Photochemotherapy; Proto-Oncogene Proteins c-bcl-2; Vitamin D | 2022 |
The Ethyl Acetate Fraction of Marine Sponge Stylissa carteri Induces Breast Cancer Cell Death via Upregulation of Mcl-1S: an In vitro Study.
Topics: Acetates; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Death; Cell Line, Tumor; Female; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Porifera; Up-Regulation | 2022 |
MAP7 promotes proliferation and migration of breast cancer cells and reduces the sensitivity of breast cancer cells to paclitaxel.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel | 2023 |
Taxane-induced neuropathy: How serious is this problem for patients with early breast cancer?
Topics: Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Retrospective Studies; Taxoids | 2023 |
Anti-cancer potential of cannabis terpenes in a Taxol-resistant model of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cannabinoid Receptor Agonists; Cannabinoids; Cannabis; Female; Flavonoids; Humans; Paclitaxel; Terpenes | 2022 |
GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Mutation; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors | 2022 |
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life | 2022 |
Complete regression of xenografted breast tumors by dextran-based dual drug conjugates containing paclitaxel and docosahexaenoic acid.
Topics: Albumin-Bound Paclitaxel; Animals; Breast Neoplasms; Cell Line, Tumor; Dextrans; Docosahexaenoic Acids; Drug Carriers; Drug Delivery Systems; Female; Heterografts; Humans; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Pharmaceutical Preparations; Water | 2022 |
Optimum inhibition of MCF-7 breast cancer cells by efficient targeting of the macropinocytosis using optimized paclitaxel-loaded nanoparticles.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Tumor Microenvironment | 2022 |
Antineoplastic Enzyme as Drug Carrier with Activatable Catalytic Activity for Efficient Combined Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glucose Oxidase; Humans; Hydrogen Peroxide; Nanoparticles; Neoplasms; Paclitaxel; Sorafenib; Tumor Microenvironment | 2022 |
Biodegradable gellan gum hydrogels loaded with paclitaxel for HER2+ breast cancer local therapy.
Topics: Breast Neoplasms; Cysteine; Female; Humans; Hydrogels; Paclitaxel; Polysaccharides, Bacterial | 2022 |
Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Female; Histone Deacetylase Inhibitors; Humans; Paclitaxel; Sirtuins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Micro ribonucleic acid-448 regulates zinc finger e-box binding homeobox 1 to inhibit the growth of breast cancer cells and increase their sensitivity to chemotherapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Homeobox; Humans; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Zinc Finger E-box-Binding Homeobox 1; Zinc Fingers | 2022 |
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Glucose deprivation reduces proliferation and motility, and enhances the anti-proliferative effects of paclitaxel and doxorubicin in breast cell lines in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Glucose; Humans; Lactates; Paclitaxel | 2022 |
Circ_0,007,331 Promotes the PTX Resistance and Progression of Breast Cancer via miR-200b-3p/ANLN.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Contractile Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; RNA, Circular | 2022 |
Neural correlates in functional brain mapping among breast cancer survivors receiving different chemotherapy regimens: a qEEG/HEG-based investigation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Mapping; Breast Neoplasms; Cancer Survivors; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neurotoxicity Syndromes; Paclitaxel | 2022 |
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Child; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Macular Edema; Middle Aged; Optic Nerve Diseases; Paclitaxel; Retrospective Studies; Tamoxifen; Taxoids | 2022 |
Effect of cryotherapy on paclitaxel-induced peripheral neuropathy of the hand in female breast cancer patients: A prospective self-controlled study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2023 |
The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Obesity; Overweight; Paclitaxel; Retrospective Studies | 2022 |
ABCC6P1 pseudogene induces ABCC6 upregulation and multidrug resistance in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Multidrug Resistance-Associated Proteins; Paclitaxel; Pseudogenes; Up-Regulation | 2022 |
GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to paclitaxel by forming a vicious cycle with IGF1/IGF1R signaling pathway.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Humans; Insulin-Like Growth Factor I; Mice; Mice, Nude; Paclitaxel; Phenotype; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction | 2022 |
Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Paclitaxel; Quality of Life; Taxoids | 2023 |
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Liver Neoplasms; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2023 |
PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR.
Topics: Breast Neoplasms; Female; Humans; Neoplastic Stem Cells; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphodiesterase 4 Inhibitors; Proto-Oncogene Proteins c-akt; Rolipram; TOR Serine-Threonine Kinases | 2022 |
Engineered Magnetic Polymer Nanoparticles Can Ameliorate Breast Cancer Treatment Inducing Pyroptosis-Starvation along with Chemotherapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Emulsions; Female; Glucose Oxidase; Humans; Magnetic Phenomena; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyroptosis; Solvents | 2022 |
Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel-induced peripheral neurotoxicity.
Topics: Biomarkers; Breast Neoplasms; Female; Humans; Intermediate Filaments; Neurofilament Proteins; Paclitaxel; Peripheral Nervous System Diseases | 2023 |
Hyaluronidase responsive second near-infrared fluorescent nanocomplex for combined HER2 blockade and chemotherapy of HER2+ breast cancer.
Topics: Animals; Breast Neoplasms; Coloring Agents; Female; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2022 |
Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1).
Topics: Apoptosis; Breast Neoplasms; Caspases; Drug Combinations; Female; Humans; Paclitaxel | 2022 |
Cerium oxide nanoparticles exert antitumor effects and enhance paclitaxel toxicity and activity against breast cancer cells.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Female; Humans; Nanoparticles; Paclitaxel | 2023 |
Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway.
Topics: Breast Neoplasms; Estrogen Receptor alpha; Female; Glucose Transporter Type 1; Glycolysis; Humans; Paclitaxel; Receptors, Estrogen | 2023 |
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Topics: Adult; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies; Scalp; Taxoids | 2022 |
Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.
Topics: Adenosine Diphosphate; Antimalarials; Antineoplastic Agents; Artesunate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benztropine; Breast Neoplasms; Cell Line, Tumor; Chloroquine; Colonic Neoplasms; Containment of Biohazards; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Fluoxetine; Fluphenazine; Humans; Ki-67 Antigen; MCF-7 Cells; Michigan; NF-kappa B; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Ribose; Sertraline; Thioridazine | 2022 |
Blockade of Platelet CysLT1R Receptor with Zafirlukast Counteracts Platelet Protumoral Action and Prevents Breast Cancer Metastasis to Bone and Lung.
Topics: Animals; Anti-Asthmatic Agents; Breast Neoplasms; Female; Glutathione; Humans; Lung; Mice; Mice, Nude; Paclitaxel; Transferases | 2022 |
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Taxoids | 2022 |
Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Paclitaxel; Treatment Outcome | 2023 |
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Inflammatory Breast Neoplasms; Paclitaxel; Signal Transduction; STAT3 Transcription Factor; Stem Cells | 2023 |
[Possibility of Prolonging Treatment by Preventing Paclitaxel-Induced Peripheral Neuropathy Using Compression Therapy].
Topics: Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.
Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Genomics; Humans; Paclitaxel; Precision Medicine | 2022 |
Exploration of hemocompatibility and intratumoral accumulation of paclitaxel after loco-regional administration of thermoresponsive hydrogel composed of poloxamer and xanthan gum: An application to dose-dense chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Humans; Hydrogels; Paclitaxel; Poloxamer | 2023 |
Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Morphine; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Triple Negative Breast Neoplasms | 2022 |
Biointerfacial giant capsules with high paclitaxel loading and magnetic targeting for breast tumor therapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Magnetic Phenomena; Nanoparticles; Paclitaxel | 2023 |
Bioinspired Nanocomplexes Comprising Phenolic Acid Derivative and Human Serum Albumin for Cancer Therapy.
Topics: Albumins; Animals; Breast Neoplasms; Female; Humans; Mice; Nanoparticles; Paclitaxel; Serum Albumin, Human | 2022 |
Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.
Topics: Breast Neoplasms; Female; Humans; Paclitaxel; Phosphorylation; Protein Kinases | 2023 |
miR-142-3p improves paclitaxel sensitivity in resistant breast cancer by inhibiting autophagy through the GNB2-AKT-mTOR Pathway.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
Identification of KCNK1 as a potential prognostic biomarker and therapeutic target of breast cancer.
Topics: Biomarkers; Breast Neoplasms; Female; Humans; Paclitaxel; Potassium Channels; Prognosis | 2023 |
IFT20 Confers Paclitaxel Resistance by Triggering β-arrestin-1 to Modulate ASK1 Signaling in Breast Cancer.
Topics: Apoptosis; beta-Arrestin 1; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MAP Kinase Kinase Kinase 5; Neoplasm Recurrence, Local; Paclitaxel | 2023 |
Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.
Topics: Breast Neoplasms; Chlorides; East Asian People; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2023 |
Palmitic acid-modified human serum albumin paclitaxel nanoparticles targeting tumor and macrophages against breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Liver Neoplasms; Macrophages; Nanoparticles; Paclitaxel; Palmitic Acid; Serum Albumin, Human; Tumor Microenvironment | 2023 |
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
Topics: Adult; Biomarkers; Breast Neoplasms; Female; Humans; Lapatinib; Ovarian Reserve; Paclitaxel | 2023 |
Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel; Prognosis; Smoking; Vascular Endothelial Growth Factor A | 2023 |
Nitric Oxide-Loaded Bioinspired Lipoprotein Normalizes Tumor Vessels To Improve Intratumor Delivery and Chemotherapy of Albumin-Bound Paclitaxel Nanoparticles.
Topics: Albumin-Bound Paclitaxel; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Lipoproteins; Nanoparticles; Nitric Oxide; Paclitaxel | 2023 |
Paclitaxel-loaded liposome-incorporated chitosan (core)/poly(ε-caprolactone)/chitosan (shell) nanofibers for the treatment of breast cancer.
Topics: Breast Neoplasms; Chitosan; Female; Humans; Liposomes; Nanofibers; Paclitaxel; Polyesters | 2023 |
Exosomal lncRNA NEAT1 induces paclitaxel resistance in breast cancer cells and promotes cell migration by targeting miR-133b.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Paclitaxel; RNA, Long Noncoding; Tumor Microenvironment | 2023 |
Nanogels co-loading paclitaxel and curcumin prepared
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Curcumin; Female; Humans; Mice; Nanogels; Paclitaxel | 2023 |
[A Case of Drug-Induced Interstitial Pneumonia after Dose-Dense AC Therapy].
Topics: Aged; Breast Neoplasms; Doxorubicin; Female; Humans; Lung Diseases, Interstitial; Paclitaxel | 2022 |
[A Case of Locally Advanced Breast Cancer That Responded to Paclitaxel plus Bevacizumab and Underwent Radical Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Paclitaxel | 2022 |
Resveratrol Analogs and Prodrugs Differently Affect the Survival of Breast Cancer Cells Impairing Estrogen/Estrogen Receptor α/Neuroglobin Pathway.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Globins; Gold; Humans; Metal Nanoparticles; Nerve Tissue Proteins; Neuroglobin; Paclitaxel; Prodrugs; Resveratrol | 2023 |
Diffusion-mediated carving of interior topologies of all-natural protein nanoparticles to tailor sustained drug release for effective breast cancer therapy.
Topics: Breast Neoplasms; Caseins; Cell Line, Tumor; Drug Liberation; Eugenol; Female; Humans; Nanoparticles; Paclitaxel | 2023 |
Evaluation of the parameters affecting the loading of anticancer drug Paclitaxel on coated gold nanoparticles for breast cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Gold; Humans; Metal Nanoparticles; Nanoparticles; Paclitaxel; Polyethylene Glycols | 2023 |
Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2023 |
Promoting GSDME expression through DNA demethylation to increase chemosensitivity of breast cancer MCF-7 / Taxol cells.
Topics: Breast Neoplasms; Decitabine; DNA Demethylation; Female; Humans; MCF-7 Cells; Paclitaxel | 2023 |
Pearls & Oy-sters: Case of Atypical Peripheral Nerve Findings Following Paclitaxel for Breast Cancer.
Topics: Breast Neoplasms; Carpal Tunnel Syndrome; Female; Humans; Median Nerve; Neural Conduction; Paclitaxel | 2023 |
Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lipopolysaccharides; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2023 |
MiR-26a-5p Heightens Breast Cancer Cell Sensitivity to Paclitaxel via Targeting Flap Endonuclease 1.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flap Endonucleases; Humans; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-bcl-2 | 2023 |
TIPE2 sensitizes breast cancer cells to paclitaxel by suppressing drug-induced autophagy and cancer stem cell properties.
Topics: Autophagy; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Neoplastic Stem Cells; Paclitaxel | 2023 |
[Rare tumors: Angiosarcoma].
Topics: Breast Neoplasms; Female; Hemangiosarcoma; Humans; Paclitaxel; Prognosis; Sarcoma | 2023 |
Synthesis and Biological Evaluation of Paclitaxel-aminoguanidine Conjugates for Suppressing Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Esterases; Female; Humans; Paclitaxel; Water | 2023 |
Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Tumor Microenvironment | 2023 |
A five arm natural history study of nasal vestibulitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Prospective Studies | 2023 |
Transforming a Toxic Non-Ionizable Drug into an Efficacious Liposome via Ionizable Prodrug and Remote Loading Strategies against Malignant Breast Tumors.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Liposomes; Paclitaxel; Prodrugs | 2023 |
[Chemotherapy-Resistant Breast Cancer and Carcinomatous Pleuritis Successfully Treated with Abemaciclib plus Letrozole Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Letrozole; Paclitaxel; Pleurisy | 2023 |
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
A core-satellite micellar system against primary tumors and their lymphatic metastasis through modulation of fatty acid metabolism blockade and tumor-associated macrophages.
Topics: Breast Neoplasms; Fatty Acids; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Matrix Metalloproteinase 2; Micelles; Paclitaxel; Tumor Microenvironment; Tumor-Associated Macrophages | 2023 |
Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Glycoproteins; Humans; Membrane Transport Proteins; Mice; Paclitaxel; Prolactin | 2023 |
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
Hybrid peptides as platform for synchronized combination therapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell-Penetrating Peptides; Collagen; Doxorubicin; Drug Delivery Systems; Female; Fluorouracil; Humans; Nanoparticles; Paclitaxel; Peptides; Tissue Distribution | 2023 |
Radical Resection of Locally Advanced Chest Wall cSCC With Muscle Flap Reconstruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Humans; Muscles; Paclitaxel; Skin Neoplasms; Thoracic Wall | 2023 |
3D-printing-assisted synthesis of paclitaxel-loaded niosomes functionalized by cross-linked gelatin/alginate composite: Large-scale synthesis and in-vitro anti-cancer evaluation.
Topics: Alginates; Breast Neoplasms; Cell Line, Tumor; Female; Gelatin; Humans; Liposomes; MCF-7 Cells; Paclitaxel; Printing, Three-Dimensional | 2023 |
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Topics: Breast Neoplasms; Docetaxel; Electronic Health Records; Female; Humans; Paclitaxel; Retrospective Studies; Taxoids; Trastuzumab | 2023 |
Ginsenoside Rb1 stabilized and paclitaxel / protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Ginsenosides; Humans; Nanoparticles; Paclitaxel; Retinoblastoma Binding Proteins; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2023 |
Circ_0069094 regulates malignant phenotype and paclitaxel resistance in breast cancer cells via targeting the miR-136-5p/YWHAZ axis.
Topics: 14-3-3 Proteins; Apoptosis; Breast; Breast Neoplasms; Cell Count; Cell Proliferation; Female; Humans; MicroRNAs; Paclitaxel | 2023 |
S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Female; Humans; Mice; Paclitaxel; Proto-Oncogene Proteins c-mdm2; S100 Calcium Binding Protein A6; Tumor Suppressor Protein p53; Ubiquitination | 2023 |
Paraneoplastic or treatment-associated dermatomyositis: a diagnostic challenge.
Topics: Adult; Antibodies, Monoclonal; Autoantibodies; Breast Neoplasms; Dermatomyositis; Female; Humans; Paclitaxel | 2023 |
A retrospect study based on real-world data to observe metabolic function in cancer patients using albumin-bound paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Creatine Kinase; Creatine Kinase, MB Form; Female; Humans; Paclitaxel; Retrospective Studies | 2023 |
Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Glycoproteins; Humans; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Subcellular Organelle-Targeted Nanostructured Lipid Carriers for the Treatment of Metastatic Breast Cancer.
Topics: Breast Neoplasms; Cell Nucleus; Female; Humans; Lipids; Melanoma, Cutaneous Malignant; Nanostructures; Paclitaxel | 2023 |
Calcium Orthophosphate in Liposomes for Co-Delivery of Doxorubicin Hydrochloride/Paclitaxel in Breast Cancer.
Topics: Breast Neoplasms; Calcium; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Liposomes; Nanoparticles; Paclitaxel; Phosphates | 2023 |
Functionalized europium-doped hollow mesoporous silica nanospheres as a cell imaging and drug delivery agents.
Topics: Apoptosis; Biocompatible Materials; Breast Neoplasms; Cell Line, Tumor; Europium; Humans; Hyaluronic Acid; Nanoparticles; Paclitaxel; Silicon Dioxide | 2023 |
Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Female; Gene Expression; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2023 |
Human papillomavirus maybe is a critical player in the regulation of chemoresistance related factors (P53, Rb, TWIST, Bcl-2, Bcl-XL, c-IAP2, cytochrome C, and caspase 3) in breast cancer.
Topics: Breast Neoplasms; Caspase 3; Cytochromes c; Drug Resistance, Neoplasm; Female; Human Papillomavirus Viruses; Humans; Oncogene Proteins, Viral; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2023 |
Role of Xihuang capsule combined with albumin-bound paclitaxel on the treatment of stage III breast cancer and T cell subsets, survival rate and adverse reactions.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Survival Rate; T-Lymphocyte Subsets | 2023 |
Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Celecoxib; Cell Line, Tumor; Female; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms | 2023 |
CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Retrospective Studies | 2023 |
Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab.
Topics: Breast Neoplasms; Carcinoma; Female; Humans; Paclitaxel; Trastuzumab | 2023 |
Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Mastectomy; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2023 |
MiR-138-5p improves the chemosensitivity of MDA-MB-231 breast cancer cell line to paclitaxel.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; Phosphatidylinositol 3-Kinases | 2023 |
New SDS-Based Polyelectrolyte Multicore Nanocarriers for Paclitaxel Delivery-Synthesis, Characterization, and Activity against Breast Cancer Cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Electrolytes; Humans; Mitochondria; Nanoparticles; Paclitaxel; Sodium Dodecyl Sulfate | 2023 |
Tumor-derived exosomes RNA expression profiling identifies the prognosis, immune characteristics, and treatment in HR+/HER2-breast cancer.
Topics: Breast Neoplasms; Docetaxel; Exosomes; Female; Humans; Paclitaxel; Prognosis | 2023 |
Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer.
Topics: Apoptosis; Breast Neoplasms; Copper; Female; Ferroptosis; Humans; Machine Learning; Paclitaxel; Prognosis; Tumor Microenvironment | 2023 |
Label-free drug response evaluation of human derived tumor spheroids using three-dimensional dynamic optical coherence tomography.
Topics: Algorithms; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Humans; Irinotecan; Paclitaxel; Tomography, Optical Coherence | 2023 |
Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Taxoids | 2023 |
The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.
Topics: Adrenergic Agonists; Albuterol; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Paclitaxel; Propranolol; Triple Negative Breast Neoplasms | 2023 |
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Denosumab; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor Activator of Nuclear Factor-kappa B; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2023 |
Active Targeted Janus Theranostic Nanoplatforms Enable Chemo-Photothermal Therapy to Inhibit the Growth of Breast Cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; Nanoparticles; Paclitaxel; Phototherapy; Photothermal Therapy; Precision Medicine; Theranostic Nanomedicine | 2023 |
Phloridzin Docosahexaenoate Inhibits Spheroid Formation by Breast Cancer Stem Cells and Exhibits Cytotoxic Effects against Paclitaxel-Resistant Triple Negative Breast Cancer Cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docosahexaenoic Acids; Female; Humans; Neoplastic Stem Cells; Paclitaxel; Phlorhizin; Triple Negative Breast Neoplasms | 2023 |
A dual drug-loaded peptide system with morphological transformation prolongs drug retention and inhibits breast cancer growth.
Topics: Breast Neoplasms; Drug Carriers; Female; Humans; Nanoparticles; Paclitaxel; Peptides; Tumor Microenvironment | 2023 |
Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1α/PI3K/AKT Signaling Pathways in Breast Cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2023 |
PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Topics: Animals; Breast Neoplasms; Female; Humans; Mice; Oncogenes; Paclitaxel; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases | 2023 |
MDR1-EXPRESSING CD4
Topics: Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Th17 Cells | 2023 |
Blockade of CCR5 suppresses paclitaxel-induced peripheral neuropathic pain caused by increased deoxycholic acid.
Topics: Breast Neoplasms; Deoxycholic Acid; Female; Humans; Maraviroc; Neuralgia; Paclitaxel; Receptors, CCR5 | 2023 |
Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Biosimilar Pharmaceuticals; Breast Neoplasms; Cardiotoxicity; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab | 2023 |
Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cancer Survivors; Female; Humans; Inflammation; Paclitaxel; Peripheral Nervous System Diseases; Transcriptome | 2019 |
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Multicenter Studies as Topic; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Risk Factors; Treatment Outcome; Young Adult | 2019 |
Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Over Studies; Female; Humans; Micelles; Middle Aged; Paclitaxel; Random Allocation; Romania; Therapeutic Equivalency | 2019 |
Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Circular Dichroism; Female; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats; Trastuzumab; Xenograft Model Antitumor Assays | 2019 |
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Female; Humans; Middle Aged; Models, Biological; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Chromatin Immunoprecipitation; Epithelial-Mesenchymal Transition; Epothilones; Female; Furans; Gene Expression; Genes, jun; Humans; Ketones; Microtubules; Paclitaxel; Smad2 Protein; Smad3 Protein; Smad4 Protein; Snail Family Transcription Factors; Transforming Growth Factor beta; Tubulin Modulators; Vinorelbine | 2019 |
Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dendrimers; Docetaxel; Drug Interactions; Drug Liberation; Fluorescent Dyes; Humans; Paclitaxel; Receptor, ErbB-2; Surface Properties; Trastuzumab; Treatment Outcome | 2019 |
The use of a predictive statistical model to make a virtual control arm for a clinical trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Models, Statistical; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis | 2019 |
In utero exposure to breast cancer treatment: a population-based perinatal outcome study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Carboplatin; Case-Control Studies; Cesarean Section; Cohort Studies; Congenital Abnormalities; Continuous Positive Airway Pressure; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gestational Age; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Small for Gestational Age; Labor, Induced; New Zealand; Paclitaxel; Perinatal Death; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth; Prospective Studies; Respiratory Distress Syndrome, Newborn; Stillbirth; Tamoxifen; Trastuzumab | 2019 |
Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calibration; Cell Death; Cell Line, Tumor; Computer Simulation; Female; Humans; Models, Biological; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2019 |
Management of neuropathic pain: A graph theory-based presentation of literature review.
Topics: Breast Neoplasms; Gabapentin; Humans; Neuralgia; Paclitaxel | 2020 |
Transferrin receptor-targeted redox/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Disulfides; Drug Resistance, Multiple; Female; Glutathione; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Mice; Micelles; Nanoparticles; Oxidation-Reduction; Paclitaxel; Podophyllotoxin; Polyethylene Glycols; Prodrugs; Receptors, Transferrin | 2019 |
Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Mouth Neoplasms; Oligonucleotides, Antisense; Paclitaxel; Serine-Arginine Splicing Factors | 2019 |
Reply to A.K. Goel et al.
Topics: Breast Neoplasms; Follow-Up Studies; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2019 |
APT Trial: Would It Really Help in De-Escalation of Therapy?
Topics: Breast Neoplasms; Dimaprit; Follow-Up Studies; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2019 |
PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden.
Topics: Animals; Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Curcumin; Dogs; Drug Compounding; Drug Liberation; Drug Therapy, Combination; Female; Humans; Lipid Bilayers; Lysosomes; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Nanocapsules; Paclitaxel; Polyethylene Glycols; Porosity; Rats, Sprague-Dawley; Silicon Dioxide; Surface Properties; Tumor Burden | 2019 |
Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Paclitaxel; Rats; Stilbenes; Tissue Distribution | 2019 |
[Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients].
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2019 |
Stimuli-responsive nanodrug self-assembled from amphiphilic drug-inhibitor conjugate for overcoming multidrug resistance in cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Magnetic Resonance Spectroscopy; MCF-7 Cells; Mice; Microscopy, Confocal; Nanoparticles; Oxidation-Reduction; Paclitaxel | 2019 |
Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2019 |
Definitive alopecia post-docetaxel.
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2020 |
Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy.
Topics: Animals; Breast Neoplasms; Doxorubicin; Drug Delivery Systems; Female; Humans; Hydrogels; Male; MCF-7 Cells; Mice; Mice, Nude; Paclitaxel; Xenograft Model Antitumor Assays | 2019 |
Catalase-Functionalized Iron Oxide Nanoparticles Reverse Hypoxia-Induced Chemotherapeutic Resistance.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Breast Neoplasms; Catalase; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Ferric Compounds; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Metal Nanoparticles; Mice; Oxidative Stress; Paclitaxel; Spectroscopy, Fourier Transform Infrared; Treatment Outcome | 2019 |
Melanoleuconychia: A rare reversible entity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Mastectomy; Nail Diseases; Nails; Paclitaxel; Pigmentation Disorders | 2020 |
Cancer cell membrane-coated mesoporous silica loaded with superparamagnetic ferroferric oxide and Paclitaxel for the combination of Chemo/Magnetocaloric therapy on MDA-MB-231 cells.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport, Active; Biomimetic Materials; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Combined Modality Therapy; Drug Delivery Systems; Female; Humans; Hyperthermia, Induced; Magnetite Nanoparticles; Paclitaxel; Silicon Dioxide | 2019 |
Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Liberation; Liposomes; Mice; Paclitaxel | 2019 |
Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug resistance by curcumin and vitamin D3 increases sensitivity to paclitaxel in breast cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cholecalciferol; Curcumin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Paclitaxel; Receptors, Calcitriol; Retinal Dehydrogenase | 2020 |
XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Line; Cell Survival; Chemokine CXCL1; Drug Resistance, Neoplasm; Drug Synergism; Drugs, Chinese Herbal; Epirubicin; Female; Gene Expression Regulation; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Oviposition; Paclitaxel; Zebrafish | 2019 |
Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Biomarkers, Tumor; Breast; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Liquid Biopsy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; RNA, Long Noncoding | 2020 |
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.
Topics: Adult; Agammaglobulinemia; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Docetaxel; Female; Gram-Positive Bacterial Infections; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2020 |
Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; Up-Regulation | 2019 |
Injectable gel self-assembled by paclitaxel itself for in situ inhibition of tumor growth.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Delayed-Action Preparations; Female; Gels; Hydrogen Bonding; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel | 2019 |
A novel strategy to block mitotic progression for targeted therapy.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred BALB C; Mitosis; Models, Biological; Models, Molecular; Molecular Targeted Therapy; Neoplasm Proteins; Paclitaxel; Prognosis; Proteasome Endopeptidase Complex; Proteolysis; Ubiquitin; Xenograft Model Antitumor Assays | 2019 |
Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Epirubicin; Estrone; Female; Humans; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Paclitaxel; Particle Size; Polyethylene Glycols; Receptors, Estrogen; Tissue Distribution | 2020 |
Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Doxorubicin; Energy Metabolism; Female; Humans; Lymph Node Excision; Mastectomy; Mastectomy, Segmental; Metabolomics; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Sentinel Lymph Node Biopsy; Trastuzumab; Young Adult | 2020 |
Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
Topics: Aneuploidy; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cytokinesis; DNA, Neoplasm; Drug Resistance, Neoplasm; Gene Expression Profiling; Heterografts; Humans; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Paclitaxel; Randomized Controlled Trials as Topic; RNA Interference; Spindle Apparatus; Taxoids; Time-Lapse Imaging; Tumor Suppressor Proteins | 2019 |
Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Compounding; Drug Delivery Systems; Extracellular Vesicles; Female; Humans; Liposomes; Lung Neoplasms; Macrophages; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Trastuzumab | 2019 |
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2020 |
Cascade signal amplification sensing strategy for highly specific and sensitive detection of homologous microRNAs in different molecular subtypes of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbocyanines; Cell Line, Tumor; DNA Probes; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Humans; Inverted Repeat Sequences; MicroRNAs; Microscopy, Confocal; Microscopy, Fluorescence; Nucleic Acid Hybridization; Paclitaxel; Proof of Concept Study | 2020 |
Building momentum for subsets of patients with advanced triple-negative breast cancer.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Double-Blind Method; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
Topics: Albumins; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Computer Simulation; Drug Administration Schedule; Drug Tapering; Epothilones; Female; Humans; Models, Biological; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Precision Medicine | 2020 |
CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Chemistry, Pharmaceutical; Doxorubicin; Drug Delivery Systems; Female; Humans; MCF-7 Cells; Paclitaxel; Polymers | 2020 |
Posttranscriptional regulation of AKT by circular RNA angiomotin- like 1 mediates chemoresistance against paclitaxel in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Proto-Oncogene Proteins c-akt; RNA Processing, Post-Transcriptional; RNA, Circular | 2019 |
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Female; Genetic Variation; Humans; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Eph Family | 2020 |
Effect of cryotherapy on dose of adjuvant paclitaxel in early-stage breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cryotherapy; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Reported Outcome Measures | 2020 |
Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured | 2020 |
Paclitaxel induces lymphatic endothelial cells autophagy to promote metastasis.
Topics: Autophagy; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Lymphatic Metastasis; Lysosomes; Paclitaxel; Proto-Oncogene Proteins c-akt; Sentinel Lymph Node | 2019 |
Herceptin-decorated paclitaxel-loaded poly(lactide-
Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Breast Neoplasms; Drug Delivery Systems; Female; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Trastuzumab; Ultrasonic Waves | 2020 |
Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Female; Humans; Paclitaxel; Photochemotherapy; Prodrugs; Rats; Rats, Inbred F344 | 2020 |
Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Qualitative Research | 2020 |
Combinational treatment of gap junction enhancers and paclitaxel attenuates mammary tumor growth.
Topics: Aminoquinolines; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Therapy, Combination; Female; Gap Junctions; Humans; Mice; Mice, Nude; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Enhanced therapeutic effect of paclitaxel with a natural polysaccharide carrier for local injection in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Female; Humans; Hydrogels; MCF-7 Cells; Paclitaxel; Polysaccharides | 2020 |
STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment.
Topics: Animals; Antimitotic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line; Female; Gene Knockout Techniques; Humans; Interferon Type I; Membrane Proteins; Mice; Nucleotidyltransferases; Paclitaxel; Paracrine Communication; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2020 |
Thymoquinone Enhances Paclitaxel Anti-Breast Cancer Activity via Inhibiting Tumor-Associated Stem Cells Despite Apparent Mathematical Antagonism.
Topics: Benzoquinones; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; Neoplastic Stem Cells; Nuclear Proteins; Paclitaxel; Snail Family Transcription Factors; Twist-Related Protein 1 | 2020 |
Artichoke Polyphenols Sensitize Human Breast Cancer Cells to Chemotherapeutic Drugs via a ROS-Mediated Downregulation of Flap Endonuclease 1.
Topics: Breast Neoplasms; Cynara scolymus; Down-Regulation; Female; Flap Endonucleases; Gene Expression Regulation, Enzymologic; Humans; MAP Kinase Signaling System; MCF-7 Cells; Paclitaxel; Polyphenols; Reactive Oxygen Species | 2020 |
Hydrous icaritin nanorods with excellent stability improves the
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Stability; Female; Flavonoids; Humans; Injections, Intravenous; MCF-7 Cells; Mice; Mice, Nude; Nanotubes; Paclitaxel; Particle Size | 2020 |
Chemopreventive efficacy of stampidine in a murine breast cancer model.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Breast Neoplasms; Dideoxynucleotides; Disease Models, Animal; Disease-Free Survival; Female; Mice; Mice, Inbred BALB C; Paclitaxel; Stavudine; Survival Rate; Thymidine Monophosphate; Time Factors | 2020 |
Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Mice; Middle Aged; Paclitaxel; RNA, Messenger; Taxoids; Xenograft Model Antitumor Assays | 2020 |
Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Ovarian Neoplasms; Paclitaxel; Sulfonamides; Toll-Like Receptor 4; Tumor Microenvironment | 2019 |
Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.
Topics: Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Breast Neoplasms; Butylamines; Cell Line, Tumor; Contrast Media; Drug Carriers; Drug Delivery Systems; Female; Heterocyclic Compounds, 1-Ring; Humans; Mice, Inbred BALB C; Molecular Imaging; Nanostructures; Paclitaxel; Particle Size; Receptors, CXCR4; Tissue Distribution; Ultrasonography; Xenograft Model Antitumor Assays | 2019 |
Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Emulsions; Female; Heterografts; Humans; Immunity, Innate; Mice; Nanoparticles; Oxaliplatin; Paclitaxel; Phospholipids; Soybean Oil; Xenograft Model Antitumor Assays | 2020 |
Estrogen-related receptors are targetable ROS sensors.
Topics: Animals; Antineoplastic Agents; Biosensing Techniques; Breast Neoplasms; Drug Resistance, Neoplasm; ERRalpha Estrogen-Related Receptor; Female; Gene Expression Regulation, Neoplastic; Glutamine; Glutathione; Humans; Mice; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Receptors, Estrogen; Rotenone; Signal Transduction; Tamoxifen | 2020 |
Targeting claudin-4 enhances chemosensitivity in breast cancer.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cell Proliferation; Claudin-1; Claudin-4; Drug Synergism; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Paclitaxel; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Low DEDD expression in breast cancer cells indicates higher sensitivity to the Bcl-2-specific inhibitor ABT-199.
Topics: Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Death Domain Receptor Signaling Adaptor Proteins; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Sulfonamides; Transcription, Genetic | 2020 |
Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine.
Topics: Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Precision Medicine; Tamoxifen; Transcriptome | 2020 |
Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Doxorubicin; Ethiopia; Female; Humans; Middle Aged; Nausea; Neutropenia; Paclitaxel; Prospective Studies | 2020 |
Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Deoxycytidine; Dose-Response Relationship, Drug; Drug Compounding; Drug Synergism; Female; Gemcitabine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Treatment Outcome | 2020 |
Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Folic Acid; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties | 2020 |
Synergistic Chemotherapy for Breast Cancer and Breast Cancer Brain Metastases via Paclitaxel-Loaded Oleanolic Acid Nanoparticles.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Humans; Mice; Mice, Nude; Nanoparticles; Oleanolic Acid; Paclitaxel | 2020 |
[Case Report of Long-Term Clinical Efficacy of Paclitaxel plus Bevacizumab Combination Therapy for Stage Ⅳ AdvancedBreast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2019 |
[A Case of Breast Cancer Liver Metastases with Jaundice Responding to Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Jaundice; Liver Neoplasms; Middle Aged; Paclitaxel | 2019 |
Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; Half-Life; Humans; Liposomes; MCF-7 Cells; Mice, Inbred BALB C; Mice, Inbred ICR; Paclitaxel; Toxicity Tests, Acute; Xenograft Model Antitumor Assays | 2020 |
Cytotoxicity of Novel Redox Sensitive PEG
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Disulfides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Micelles; Ovarian Neoplasms; Oxidation-Reduction; Paclitaxel; Polyethylene Glycols | 2020 |
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Prospective Studies; Retrospective Studies; Severity of Illness Index; Vitamin D Deficiency | 2020 |
Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Markov Chains; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Rate | 2020 |
Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Electronic Health Records; Female; Health Literacy; Humans; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Pilot Projects; Socioeconomic Factors; Trust | 2020 |
Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colchicine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Ketones; Mice, Inbred BALB C; Mice, Nude; Microtubules; Paclitaxel; Proto-Oncogene Proteins c-fos; RNA, Messenger; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Progression-Free Survival; Prospective Studies; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2020 |
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Hippo Signaling Pathway; Humans; MAP Kinase Kinase Kinases; Membrane Proteins; Metformin; Mice, Inbred BALB C; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Serine-Threonine Kinases; Protein Transport; Signal Transduction; Tamoxifen; Transcription Factors; Tumor Suppressor Proteins; YAP-Signaling Proteins | 2020 |
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Middle Aged; NAV1.7 Voltage-Gated Sodium Channel; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate | 2020 |
GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Endoplasmic Reticulum Chaperone BiP; Female; Follow-Up Studies; Heat-Shock Proteins; Humans; Leukocytes, Mononuclear; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Survival Rate | 2020 |
Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotin; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Female; Glucose; Humans; Ligands; Liposomes; Mammary Neoplasms, Experimental; Mice; Molecular Structure; Paclitaxel; Structure-Activity Relationship | 2020 |
Cardiac Masses in a Patient With Pancreatic Adenocarcinoma and a History of Breast Carcinoma.
Topics: Adenocarcinoma; Albumins; Anticoagulants; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombosis; Warfarin | 2020 |
Cancer cell membrane-coated biomimetic platform for targeted therapy of breast cancer in an orthotopic mouse model.
Topics: Animals; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Delivery Systems; Female; Humans; Mice; Nanoparticles; Paclitaxel | 2020 |
Efficacy and Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone Marrow Infiltration.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Survival Analysis | 2020 |
[Axillary Arterial Bleeding with Administration of Bevacizumab plus Paclitaxel in a Patient with Recurrent Breast Cancer-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Bevacizumab; Breast Neoplasms; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
A High-Throughput Image Cytometry Method for the Formation, Morphometric, and Viability Analysis of Drug-Treated Mammospheres.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Female; High-Throughput Screening Assays; Humans; Image Cytometry; MCF-7 Cells; Neoplastic Stem Cells; Oxyquinoline; Paclitaxel; Pyrans; Spheroids, Cellular | 2020 |
Degradable porous drug-loaded polymer scaffolds for localized cancer drug delivery and breast cell/tissue growth.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Kinetics; Mice; Mice, Nude; Paclitaxel; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Porosity; Prodigiosin; Thermodynamics; Tissue Scaffolds | 2020 |
Cell subtype-dependent formation of breast tumor spheroids and their variable responses to chemotherapeutics within microfluidics-generated 3D microgels with tunable mechanics.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Immobilized; Cisplatin; Extracellular Matrix; Female; Humans; Microfluidics; Microgels; Paclitaxel; Polymers; Spheroids, Cellular | 2020 |
miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines.
Topics: Animals; Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Transplantation; Paclitaxel; SOXB1 Transcription Factors | 2020 |
ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
Topics: Aged; Albumins; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2020 |
Localized delivery of active targeting micelles from nanofibers patch for effective breast cancer therapy.
Topics: Animals; Breast Neoplasms; Cell Survival; Cholic Acid; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Epidermis; Fibroblasts; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Mice; Micelles; Microscopy, Electrochemical, Scanning; Nanofibers; Paclitaxel; Polymers; Psyllium; Subcutaneous Absorption; Swine | 2020 |
Delayed docetaxel extravasation in case of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2020 |
Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; E2F3 Transcription Factor; Female; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nuclear Proteins; Paclitaxel; Prognosis; RNA, Circular; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2020 |
Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling.
Topics: Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Quercetin; Signal Transduction; Toll-Like Receptor 4 | 2020 |
Fomes fomentarius and Tricholoma anatolicum (Agaricomycetes) Extracts Exhibit Significant Multiple Drug-Resistant Modulation Activity in Drug-Resistant Breast Cancer Cells.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Breast Neoplasms; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Resistance, Multiple; Female; Humans; Inhibitory Concentration 50; MCF-7 Cells; Paclitaxel; Phenols; Tricholoma; Vincristine | 2020 |
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Testicular Neoplasms; Young Adult | 2021 |
Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2021 |
GC-MS based comparative metabolomic analysis of MCF-7 and MDA-MB-231 cancer cells treated with Tamoxifen and/or Paclitaxel.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Gas Chromatography-Mass Spectrometry; Humans; MCF-7 Cells; Paclitaxel; Tamoxifen | 2020 |
Monosialoganglioside GM1 reduces toxicity of Ptx and increase anti-metastasic effect in a murine mammary cancer model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Gangliosides; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols | 2020 |
Lichenoid inflammation of DSAP lesions following treatment with durvalumab, olaparib and paclitaxel: A potential diagnostic pitfall mimicking lichenoid drug eruptions associated with PDL-1 inhibitors.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diagnosis, Differential; Drug Eruptions; Female; Humans; Inflammation; Lichenoid Eruptions; Paclitaxel; Phthalazines; Piperazines; Porokeratosis; Skin | 2020 |
Highlights from the 2019 San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Oxazoles; Paclitaxel; Prognosis; Pyridines; Quinazolines; Texas; Trastuzumab | 2020 |
[Thermosensitive gel of polysaccharide from Ganoderma applanatum combined with paclitaxel for mice with 4T1 breast cancer].
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Ganoderma; Mice; Neoplasms; Paclitaxel; Poloxamer; Polysaccharides | 2020 |
Immobilization of Paclitaxel on Hydroxyapatite for Breast Cancer Investigations.
Topics: Breast Neoplasms; Cell Survival; Chitosan; Durapatite; Female; Humans; Nanoparticles; Paclitaxel | 2020 |
LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Topics: Adult; Animals; Biomarkers, Tumor; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Middle Aged; Paclitaxel; Prognosis; RNA Interference; RNA, Long Noncoding; Transcription Factors; Trefoil Factor-3; Xenograft Model Antitumor Assays | 2020 |
Evaluation of miR-34a Effect on CCND1 mRNA Level and Sensitization of Breast Cancer Cell Lines to Paclitaxel.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; DNA; Female; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; HEK293 Cells; Humans; Inhibitory Concentration 50; MicroRNAs; Paclitaxel; Plasmids; RNA, Messenger | 2020 |
Dual-encapsulated biodegradable 3D scaffold from liposome and waterborne polyurethane for local drug control release in breast cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug and Narcotic Control; Drug Delivery Systems; Drug Liberation; Female; Humans; Liposomes; Paclitaxel; Polyurethanes | 2020 |
[A Case of Male Recurrent Breast Cancer Successfully Treated with Bevacizumab plus Paclitaxel Therapy for Carcinomatous Pericarditis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Male; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Pericarditis | 2020 |
Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer-derived extracellular vesicles.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Elastic Modulus; Extracellular Vesicles; Female; Humans; Lung; Mice; Neoplasm Transplantation; Paclitaxel; Tumor Microenvironment | 2020 |
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2021 |
A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; Taxoids; Tubulin | 2020 |
Unsuccessful Desensitization to Paclitaxel in a Patient With High Basophil Sensitivity.
Topics: Antineoplastic Agents; Basophil Degranulation Test; Basophils; Breast Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Paclitaxel; Treatment Failure | 2021 |
Plasma polymerized nanoparticles effectively deliver dual siRNA and drug therapy in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Mice; Nanoparticles; Paclitaxel; Plasma; Polymerization; RNA, Small Interfering; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2020 |
An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition.
Topics: Breast Neoplasms; Cell Line, Tumor; Exosomes; Humans; Nanoparticles; Paclitaxel; Prodrugs | 2020 |
ATIP3 deficiency facilitates intracellular accumulation of paclitaxel to reduce cancer cell migration and lymph node metastasis in breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Gene Silencing; HeLa Cells; Humans; Lymphatic Metastasis; Microtubules; Paclitaxel; Tumor Suppressor Proteins | 2020 |
Paclitaxel and quercetin co-loaded functional mesoporous silica nanoparticles overcoming multidrug resistance in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nanoparticles; Paclitaxel; Quercetin; Silicon Dioxide | 2020 |
miR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; PTEN Phosphohydrolase; RNA, Neoplasm; Ubiquitin-Specific Proteases | 2020 |
Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2020 |
MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1.
Topics: Animals; Apoptosis; Breast Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Minichromosome Maintenance Complex Component 7; Models, Biological; Paclitaxel; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Retinoblastoma Protein | 2020 |
[Combination Therapy of Bevacizumab plus Paclitaxel Was Effective for a Metastatic Choroidal Tumor Secondary to Breast Cancer in a Patient with Ocular Symptoms].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Choroid Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
Nanomedicine-Cum-Carrier by Co-Assembly of Natural Small Products for Synergistic Enhanced Antitumor with Tissues Protective Actions.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Glycyrrhetinic Acid; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Molecular Conformation; Nanomedicine; Nanoparticles; Oleanolic Acid; Paclitaxel; Particle Size; Stereoisomerism; Surface Properties | 2020 |
A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab; United States; United States Food and Drug Administration | 2020 |
Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Particle Size; Pharmaceutical Preparations; Wound Healing; Xanthones; Xenograft Model Antitumor Assays | 2020 |
Paclitaxel- and/or cyclophosphamide-induced severe ischaemic retinopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; Paclitaxel; Retinal Diseases | 2020 |
Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Curcumin; Drug Delivery Systems; Female; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel | 2020 |
Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Paclitaxel; Pharmacogenetics; Racial Groups; Smoking | 2021 |
RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Nucleus; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Endoribonucleases; Female; Gene Knockdown Techniques; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mice; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Xenograft Model Antitumor Assays | 2020 |
Advancing immunotherapy for early-stage triple-negative breast cancer.
Topics: Albumins; Anthracyclines; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Double-Blind Method; Humans; Immunotherapy; Neoadjuvant Therapy; Paclitaxel | 2020 |
Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.
Topics: Animals; Breast Neoplasms; Deoxycytidine; Drug Combinations; Drug Delivery Systems; Female; Gemcitabine; Kidney; Liver; Lung; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Spleen; Tissue Distribution | 2020 |
Paclitaxel and betulonic acid synergistically enhance antitumor efficacy by forming co-assembled nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Oleanolic Acid; Paclitaxel; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Internal Oligoguanidinium Transporter: Mercury-Free Scalable Synthesis, Improvement of Cellular Localization, Endosomal Escape, Mitochondrial Localization, and Conjugation with Antisense Morpholino for NANOG Inhibition to Induce Chemosensitization of Taxo
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Mitochondria; Morpholinos; Nanog Homeobox Protein; Paclitaxel | 2020 |
Identification of genes and miRNAs in paclitaxel treatment for breast cancer.
Topics: Activating Transcription Factor 3; Breast Neoplasms; Chemokine CXCL2; Cyclooxygenase 2; Humans; MicroRNAs; Paclitaxel; Protein Interaction Maps; RNA, Messenger; Tubulin Modulators | 2021 |
Paclitaxel-nanoparticles-loaded double network hydrogel for local treatment of breast cancer after surgical resection.
Topics: Breast Neoplasms; Cell Line, Tumor; Humans; Hydrogels; Nanoparticles; Paclitaxel; Polyethylene Glycols | 2020 |
Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carboplatin; Caspase 3; Female; Gallic Acid; Humans; MCF-7 Cells; Paclitaxel; RNA, Messenger; Tumor Suppressor Protein p53 | 2021 |
Neoadjuvant therapy improves pCR rate.
Topics: Albumins; Anthracyclines; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Double-Blind Method; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Anti-Tumor Effects of Exosomes Derived from Drug-Incubated Permanently Growing Human MSC.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Exosomes; Extracellular Vesicles; Female; Heterografts; Humans; Lung Neoplasms; Mesenchymal Stem Cells; Mice; Ovarian Neoplasms; Paclitaxel; Tetraspanin 28; Tetraspanin 29; Tetraspanin 30; Tetraspanins | 2020 |
Limbal stem cell deficiency secondary to systemic paclitaxel (Taxol) for breast cancer: a case report.
Topics: Aged; Breast Neoplasms; Corneal Diseases; Epithelium, Corneal; Female; Humans; Limbus Corneae; Paclitaxel; Stem Cells | 2020 |
Breast Cancer-Derived Microparticles Reduce Cancer Cell Adhesion, an Effect Augmented by Chemotherapy.
Topics: Actin Cytoskeleton; Adult; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Extracellular Vesicles; Female; Humans; Hyaluronan Receptors; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2020 |
Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Breast Neoplasms; Cisplatin; Computational Biology; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide | 2020 |
Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.
Topics: Animals; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Mice, Inbred NOD; Mice, SCID; Microtubules; NF-kappa B; Paclitaxel; Prognosis; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; Taxoids | 2020 |
Turmeric supplementation improves the quality of life and hematological parameters in breast cancer patients on paclitaxel chemotherapy: A case series.
Topics: Breast Neoplasms; Curcuma; Dietary Supplements; Humans; Paclitaxel; Prospective Studies; Quality of Life | 2020 |
Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Transformed; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Proteins; RNA, Long Noncoding; Xenograft Model Antitumor Assays | 2020 |
Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2 | 2021 |
A targeted and redox/pH-responsive chitosan oligosaccharide derivatives based nanohybrids for overcoming multidrug resistance of breast cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Chitosan; Drug Carriers; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Folic Acid; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Nanoparticles; Oxidation-Reduction; Paclitaxel; Polyethyleneimine; RNA, Small Interfering | 2021 |
pH-Activatable cell penetrating peptide dimers for potent delivery of anticancer drug to triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell-Penetrating Peptides; Female; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; Paclitaxel; Pharmaceutical Preparations; Triple Negative Breast Neoplasms | 2021 |
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Topics: Administration, Inhalation; Administration, Intravenous; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Paclitaxel; Phosphorylation; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment; Tumor-Associated Macrophages | 2020 |
Folate Modified Long Circulating Nano-Emulsion as a Promising Approach for Improving the Efficiency of Chemotherapy Drugs in Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compounding; Emulsions; Female; Folic Acid; Folic Acid Transporters; Injections, Intravenous; Mice; Mice, Inbred BALB C; Nanoparticles; Nanotechnology; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Rats, Sprague-Dawley; Tumor Burden | 2020 |
Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter.
Topics: A549 Cells; Acidosis, Lactic; Animals; Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus, Type 2; Doxorubicin; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; MCF-7 Cells; Metformin; Mice, Inbred NOD; Mice, SCID; Neoplasms; Paclitaxel | 2021 |
Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Therapy, Combination; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
A "dual-guide" bioinspired drug delivery strategy of a macrophage-based carrier against postoperative triple-negative breast cancer recurrence.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Liposomes; Macrophages; Nanoparticles; Paclitaxel; Triple Negative Breast Neoplasms | 2021 |
Novel multi-targeted nanoparticles for targeted co-delivery of nucleic acid and chemotherapeutic agents to breast cancer tissues.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Folic Acid; Humans; Nanoparticles; Nucleic Acids; Paclitaxel; Pharmaceutical Preparations; Polyethylene Glycols | 2021 |
[Patient with Recurrent Breast Cancer Who Developed Radiation Esophagitis with Severe Esophageal Stenosis after Combined Bevacizumab and Paclitaxel Therapy-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Esophageal Stenosis; Esophagitis; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patients; Positron Emission Tomography Computed Tomography; Radiation | 2020 |
Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A | 2020 |
Limitations of an ex vivo breast cancer model for studying the mechanism of action of the anticancer drug paclitaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Death; Female; Humans; MCF-7 Cells; Mitosis; Paclitaxel; Pyrans; Time Factors; Tissue Culture Techniques; Vincristine | 2021 |
New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells.
Topics: Antimalarials; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Synergism; Humans; MCF-7 Cells; Paclitaxel | 2020 |
A case of a patient receiving combination therapy with paclitaxel plus bevacizumab and adoptive activated αβ T-cell immunotherapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Immunotherapy, Adoptive; Paclitaxel; T-Lymphocytes | 2020 |
Anacardic 6-pentadecyl salicylic acid induces apoptosis in breast cancer tumor cells, immunostimulation in the host and decreases blood toxic effects of taxol in an animal model.
Topics: Anacardic Acids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Immunity, Cellular; Immunization; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Paclitaxel | 2021 |
CCDC170 affects breast cancer apoptosis through IRE1 pathway.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carrier Proteins; Disease-Free Survival; Endoplasmic Reticulum Stress; Endoribonucleases; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Transcriptome; X-Box Binding Protein 1 | 2020 |
Surface functionalisation of poly-APO-b-polyol ester cross-linked copolymers as core-shell nanoparticles for targeted breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemical Phenomena; Drug Carriers; Drug Delivery Systems; Esters; Female; Humans; MCF-7 Cells; Molecular Targeted Therapy; Molecular Weight; Nanoparticles; Nanostructures; Paclitaxel; Palm Oil; Particle Size; Polymerization; Polymers | 2020 |
Genome-wide DNA methylation analysis of breast cancer MCF-7 / Taxol cells with MeDIP-Seq.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Ontology; Gene Regulatory Networks; Humans; Immunoprecipitation; MCF-7 Cells; Paclitaxel; rac1 GTP-Binding Protein; Sequence Analysis, DNA | 2020 |
Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Taxoids | 2020 |
Lipid and Biosurfactant Based Core-Shell-Type Nanocapsules Having High Drug Loading of Paclitaxel for Improved Breast Cancer Therapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Humans; Lipids; Nanocapsules; Paclitaxel | 2020 |
Chondroitin sulfate-based nanoparticles for enhanced chemo-photodynamic therapy overcoming multidrug resistance and lung metastasis of breast cancer.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Proliferation; Chlorophyllides; Chondroitin Sulfates; Combined Modality Therapy; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Infrared Rays; Lasers; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Paclitaxel; Photosensitizing Agents; Porphyrins; Quercetin; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
Breast cancer patient-derived scaffolds as a tool to monitor chemotherapy responses in human tumor microenvironments.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplastic Stem Cells; Paclitaxel; Phenotype; Printing, Three-Dimensional; Tissue Scaffolds; Transcriptome; Tumor Microenvironment | 2021 |
Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Unknown Primary; Paclitaxel; Salpingo-oophorectomy | 2021 |
Clinical and economic burden of intravenous paclitaxel or nab-paclitaxel for metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost of Illness; Female; Humans; Medicare; Paclitaxel; United States | 2021 |
Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medicare; Paclitaxel; Peripheral Nervous System Diseases; United States | 2021 |
Cost of home vs clinic administration of paclitaxel in metastatic breast cancer.
Topics: Breast Neoplasms; Cost Savings; Female; Humans; Paclitaxel | 2021 |
Cell growth analysis and nucleotide excision repair modulation in breast cancer cells submitted to a protocol using doxorubicin and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; DNA Repair; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia | 2021 |
Continuing Advancements in Breast Cancer Care.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Humans; Medical Oncology; Paclitaxel; Thiazoles | 2021 |
CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cell Cycle; Cell Proliferation; Doxorubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Paclitaxel; RNA, Messenger | 2021 |
[A Case of Chemotherapy with Low-Dose Paclitaxel and Bevacizumab for Elderly Recurrent Breast Cancer Patient].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel | 2020 |
Response to trastuzumab and investigation of expression profiles of matrix metalloproteinase-related proteins in primary breast cancer stem cells.
Topics: Breast Neoplasms; Carboplatin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinases; Neoplastic Stem Cells; Paclitaxel; Primary Cell Culture; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2021 |
Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Doxorubicin; Female; Heart Diseases; Humans; Inflammation Mediators; Middle Aged; Paclitaxel; Trastuzumab | 2021 |
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lipids; Mice; Nanocapsules; Paclitaxel; Tissue Distribution | 2021 |
Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Infertility; Neoplasms; Paclitaxel; Pregnancy; Pregnant Women; Taxoids | 2021 |
Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.
Topics: Breast Neoplasms; Female; Humans; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2021 |
MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
tLyP-1 Peptide Functionalized Human H Chain Ferritin for Targeted Delivery of Paclitaxel.
Topics: Animals; Antineoplastic Agents; Apoferritins; Apoptosis; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Endocytosis; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Peptides, Cyclic; Spheroids, Cellular; Wound Healing | 2021 |
Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Colorectal Neoplasms; Female; Hemoglobins; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Obesity; Overweight; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors; Severity of Illness Index; Sex Factors; Young Adult | 2021 |
Nuclear Her2 contributes to paclitaxel resistance in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Female; Humans; Karyopherins; Paclitaxel; Receptor, ErbB-2; Survivin | 2021 |
[A Case of HER2-Positive Metastatic Breast Cancer Achieved a Complete Response to Paclitaxel and Trastuzumab in Combination with Pertuzumab in Fifth Therapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Mastectomy; Paclitaxel; Positron Emission Tomography Computed Tomography; Receptor, ErbB-2; Trastuzumab | 2021 |
Fabrication and evaluation of aptamer-conjugated paclitaxel-loaded magnetic nanoparticles for targeted therapy on breast cancer cells.
Topics: Animals; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Liberation; Endocytosis; Female; Fluorescence; Humans; Inhibitory Concentration 50; Magnetite Nanoparticles; Mice; Molecular Targeted Therapy; Paclitaxel; Particle Size; Reproducibility of Results; Spectroscopy, Fourier Transform Infrared; Static Electricity; Thermogravimetry; X-Ray Diffraction | 2021 |
Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
Topics: Animals; Blood Proteins; Breast Neoplasms; Cell Dedifferentiation; Cell Line, Tumor; Cilostazol; Demyelinating Diseases; Female; Galectins; Ganglia, Spinal; Humans; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Wistar; Schwann Cells; Sciatic Nerve | 2021 |
Folic Acid and Poly(ethylene glycol) Decorated Paclitaxel Nanocrystals Exhibit Enhanced Stability and Breast Cancer-Targeting Capability.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats | 2021 |
Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Blood Cell Count; Blood Platelets; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunity; Lymphocytes; Middle Aged; Monocytes; Neutrophils; Paclitaxel; Receptor, ErbB-2 | 2021 |
MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carrier Proteins; Cell Movement; Cell Proliferation; Databases, Genetic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MCF-7 Cells; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Paclitaxel | 2021 |
Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells.
Topics: Antibodies; Antineoplastic Agents; Apoptosis; Biocompatible Materials; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Fluorescent Dyes; G2 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Inhibitory Concentration 50; Lysine; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Nanomedicine; Nanoparticles; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2021 |
Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.
Topics: Acrylic Resins; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Breast Neoplasms; Cell Proliferation; Cetrimonium; Drug Carriers; Drug Liberation; Female; G2 Phase Cell Cycle Checkpoints; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Mice, Inbred ICR; Nanoparticles; Oligopeptides; Paclitaxel; Porosity; Silicon Dioxide; Xenograft Model Antitumor Assays | 2021 |
Damaging Tumor Vessels with an Ultrasound-Triggered NO Release Nanosystem to Enhance Drug Accumulation and T Cells Infiltration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nitric Oxide; Nitroso Compounds; Paclitaxel; Serum Albumin, Human; Tissue Distribution; Tumor Cells, Cultured; Tumor Microenvironment; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2021 |
Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization.
Topics: Adult; Breast Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypersensitivity, Immediate; Male; Paclitaxel; Retrospective Studies | 2022 |
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Minnesota; Neoplasms; Paclitaxel | 2021 |
Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study.
Topics: Age Factors; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cancer Survivors; Estrogens; Female; Humans; Mice; Mice, Inbred Strains; Middle Aged; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Postmenopause; Rats; Retrospective Studies; Risk Factors; Thrombomodulin | 2021 |
Theranostic potential of biodegradable polymeric nanoparticles with paclitaxel and curcumin against breast carcinoma.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Curcumin; Humans; Mice; Nanoparticles; Paclitaxel; Polyethylene Glycols; Precision Medicine | 2021 |
Polyethyleneimine- -Tocopherol Hydrogen Succinate/Hyaluronic Acid-Quercetin (PEI-TOS/HA-QU) Core-Shell Micelles Delivering Paclitaxel for Combinatorial Treatment of MDR Breast Cancer.
Topics: alpha-Tocopherol; Animals; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Humans; Hyaluronic Acid; Hydrogen; Mice; Micelles; Paclitaxel; Polyethyleneimine; Quercetin; Succinates | 2021 |
The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Vena Cava, Superior | 2021 |
Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycolysis; HEK293 Cells; Humans; Immunoprecipitation; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phosphofructokinase-2; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins | 2021 |
An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-6; RNA, Small Interfering | 2021 |
A paclitaxel-induced variant of hand-foot syndrome affecting dorsal surfaces.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Skin | 2021 |
Lipid nanocapsules co-encapsulating paclitaxel and salinomycin for eradicating breast cancer and cancer stem cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lipids; Nanocapsules; Neoplastic Stem Cells; Paclitaxel; Pyrans | 2021 |
Pterostilbene nanoparticles with small particle size show excellent anti-breast cancer activity
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Drug Compounding; Female; HeLa Cells; Humans; Lecithins; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Solubility; Stilbenes; Treatment Outcome; Tumor Burden; Vitamin E; Xenograft Model Antitumor Assays | 2021 |
Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
Topics: Angiopoietin-2; Animals; Biglycan; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Fibrosis; Humans; Mice; Mice, Knockout; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prognosis; Signal Transduction; Stromal Cells; Treatment Outcome; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2021 |
The palladacycle, BTC2, exhibits anti-breast cancer and breast cancer stem cell activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chick Embryo; Female; Humans; MCF-7 Cells; Neoplastic Stem Cells; Paclitaxel; Palladium; Xenograft Model Antitumor Assays | 2021 |
Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Mice; Mice, Inbred BALB C; Microfilament Proteins; Nanoparticles; Oligopeptides; Paclitaxel; Protein-Tyrosine Kinases; RNA, Small Interfering | 2021 |
The Potential Predictors in Chemotherapy Sensitivity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Humans; Paclitaxel | 2021 |
Heat/pH-boosted release of 5-fluorouracil and albumin-bound paclitaxel from Cu-doped layered double hydroxide nanomedicine for synergistical chemo-photo-therapy of breast cancer.
Topics: Albumin-Bound Paclitaxel; Breast Neoplasms; Cell Line, Tumor; Drug Liberation; Female; Fluorouracil; Hot Temperature; Humans; Hydrogen-Ion Concentration; Hydroxides; Nanomedicine; Nanoparticles; Paclitaxel; Tissue Distribution | 2021 |
Circumventing paclitaxel resistance in breast cancer cells using a nanoemulsion system and determining its efficacy via an impedance biosensor.
Topics: Apoptosis; Biosensing Techniques; Breast Neoplasms; Cell Line, Tumor; Electric Impedance; Humans; Paclitaxel | 2021 |
Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Caspase 2; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Paclitaxel; RNA, Antisense; RNA, Long Noncoding; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1; Up-Regulation | 2021 |
Network pharmacology-based evaluation of natural compounds with paclitaxel for the treatment of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chick Embryo; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Molecular Docking Simulation; Paclitaxel; Protein Structure, Secondary; Protein Structure, Tertiary; Treatment Outcome | 2021 |
Integrating transcriptomics, proteomics, glycomics and glycoproteomics to characterize paclitaxel resistance in breast cancer cells.
Topics: Breast Neoplasms; Female; Glycomics; Humans; Paclitaxel; Polysaccharides; Proteomics; Transcriptome | 2021 |
TPGS and chondroitin sulfate dual-modified lipid-albumin nanosystem for targeted delivery of chemotherapeutic agent against multidrug-resistant cancer.
Topics: Albumins; Animals; Breast Neoplasms; Cell Proliferation; Cell Survival; Chondroitin Sulfates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hyaluronan Receptors; Lipids; MCF-7 Cells; Mice; Nanoparticles; Paclitaxel; Vitamin E; Xenograft Model Antitumor Assays | 2021 |
[Role of Palliative Care in the Introduction of Chemotherapy in Patients with Poor Performance Status].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Trastuzumab | 2021 |
Mechanism underlying resveratrol's attenuation of paclitaxel cytotoxicity in human breast cancer cells: Role of the SIRT1-FOXO1-HER3 signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O1; Humans; Paclitaxel; Protective Agents; Receptor, ErbB-3; Resveratrol; Signal Transduction; Sirtuin 1 | 2021 |
Self-promoted Albumin-Based Nanoparticles for Combination Therapy against Metastatic Breast Cancer via a Hyperthermia-Induced "Platelet Bridge".
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blood Platelets; Breast Neoplasms; Cell Movement; Cell Proliferation; Combined Modality Therapy; Drug Delivery Systems; Female; Humans; Hyperthermia, Induced; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Serum Albumin, Human; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Granulocytes; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Morpholines; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome; Triazines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Preventive effects of self-administered cryotherapy on paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer: a propensity score analysis.
Topics: Breast Neoplasms; Cryotherapy; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Propensity Score; Retrospective Studies | 2021 |
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Feasibility Studies; Female; Humans; Magnetic Resonance Spectroscopy; Metabolomics; Middle Aged; Paclitaxel; Prospective Studies; Treatment Outcome | 2021 |
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER
Topics: Animals; Breast; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Drug Resistance, Neoplasm; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Neoplastic Stem Cells; Nuclear Receptor Coactivator 3; Paclitaxel; Phosphofructokinase-2; Phosphorylation; Receptors, Estrogen; Tamoxifen; Transcription Factors; Up-Regulation | 2021 |
Lapatinib enhances paclitaxel toxicity in MCF-7, T47D, and MDA-MB-321 breast cancer cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Female; Humans; Lapatinib; Paclitaxel; Protein Kinase Inhibitors | 2021 |
Nitric Oxide Synthase Potentiates the Resistance of Cancer Cell Lines to Anticancer Chemotherapeutics.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Doxorubicin; Female; Humans; Nitric Oxide Synthase; Paclitaxel; Proto-Oncogene Proteins c-bcl-2 | 2022 |
Successful Treatment of a Locally Recurrent and Metastatic Malignant Phyllodes Tumor with Accelerated Radiotherapy and Nab-Paclitaxel, Cisplatin, and Liposomal Doxorubicin Chemotherapy.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Phyllodes Tumor; Polyethylene Glycols; Positron Emission Tomography Computed Tomography; Remission Induction | 2021 |
EphA8 inhibits cell apoptosis via AKT signaling and is associated with poor prognosis in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice; Middle Aged; Neoplasm Transplantation; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptor, EphA8; Signal Transduction; Tumor Burden; Up-Regulation | 2021 |
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Pharmacological; Breast Neoplasms; Egypt; Female; Genotype; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prognosis | 2021 |
Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Paclitaxel; Tumor Cells, Cultured | 2021 |
LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; RNA, Long Noncoding; Tumor-Associated Macrophages; Xenograft Model Antitumor Assays | 2021 |
lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Hepatocyte Nuclear Factor 3-alpha; Humans; MicroRNAs; Middle Aged; Paclitaxel; RNA, Long Noncoding; Up-Regulation; Young Adult | 2021 |
[A Case of Pseudopancreatic Cyst Development during Bevacizumab plus Paclitaxel Therapy for Pancreatic Metastasis of Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cysts; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2021 |
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Retrospective Studies | 2022 |
Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; RNA, Small Interfering; Vascular Endothelial Growth Factor A | 2021 |
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cells.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cytoskeleton; Female; Humans; Insulin Receptor Substrate Proteins; Microscopy, Fluorescence; Microtubules; Paclitaxel; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Tubulin; Tyrosine | 2017 |
Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Attitude to Health; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Paclitaxel; Patient Preference; Physicians; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Surveys and Questionnaires; Survival Rate; Tumor Burden | 2017 |
Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Coculture Techniques; Cytokines; Drug Carriers; Drug Interactions; Emulsions; Female; Humans; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Signal Transduction; Vitamin E | 2017 |
Magnetic nanobubbles with potential for targeted drug delivery and trimodal imaging in breast cancer: an in vitro study.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Dextrans; Drug Delivery Systems; Female; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Microbubbles; Multimodal Imaging; Paclitaxel; Photoacoustic Techniques; Trastuzumab; Ultrasonography | 2017 |
Isolation of Taxol-Producing Endophytic Fungi from Iranian Yew Through Novel Molecular Approach and Their Effects on Human Breast Cancer Cell Line.
Topics: Alkaloids; bcl-2-Associated X Protein; Breast Neoplasms; Cell Line, Tumor; Cladosporium; Endophytes; Female; Humans; Iran; MCF-7 Cells; Paclitaxel; Plant Leaves; Plant Stems; Proto-Oncogene Proteins c-bcl-2; Taxoids; Taxus | 2017 |
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Female; Heart; Heart Failure; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Ventricular Dysfunction, Left | 2017 |
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Calpain; Carcinoembryonic Antigen; Cell Plasticity; Cell Proliferation; Drug Resistance, Neoplasm; E1A-Associated p300 Protein; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Lentivirus; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transforming Growth Factor beta2 | 2017 |
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents.
Topics: Animals; Antimitotic Agents; Apoptosis; Benzothiazoles; Breast Neoplasms; Cell Survival; DNA Damage; Endothelial Cells; Female; Histones; Humans; Macrophages; Major Histocompatibility Complex; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Mitosis; Paclitaxel; Picolinic Acids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2017 |
Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Care; Preoperative Care; Treatment Outcome | 2017 |
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Calibration; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Theoretical; Neoplasm Metastasis; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
[A Case Report of Disappearance of Gastric Metastasis of Breast Cancer Treated with Combination Therapy Consisting of Paclitaxel and Cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Humans; Middle Aged; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2017 |
Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines.
Topics: Acetylation; Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Heterozygote; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mutation; Neoplasm Proteins; p300-CBP Transcription Factors; Paclitaxel; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Recombinant Proteins; Tubulin Modulators | 2017 |
Subharmonic-Aided Pressure Estimation for Monitoring Interstitial Fluid Pressure in Tumors: Calibration and Treatment with Paclitaxel in Breast Cancer Xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calibration; Cell Line, Tumor; Drug Monitoring; Extracellular Fluid; Female; Humans; Image Interpretation, Computer-Assisted; Manometry; Paclitaxel; Pressure; Rats; Rats, Nude; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Ultrasonography | 2017 |
Investigation of the pH Dependent Cytotoxicity of Paclitaxel Conjugated Gold Nanoparticles.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Gold; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Paclitaxel; Particle Size; Surface Properties | 2017 |
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Topics: Adult; Aged; Aging; Antineoplastic Agents, Phytogenic; Asian People; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cytochrome P-450 CYP2C8; Female; Genotype; Humans; Incidence; Middle Aged; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Sensory Receptor Cells; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2017 |
Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Carriers; Drug Liberation; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Nanostructures; Paclitaxel; Particle Size; Surface Properties; Tocopherols | 2017 |
Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo.
Topics: Aged; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Middle Aged; NIMA-Related Kinases; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Synergistic effects of coralyne and paclitaxel on cell migration and proliferation of breast cancer cells lines.
Topics: Berberine Alkaloids; Breast Neoplasms; Cell Adhesion; Cell Death; Cell Movement; Cell Proliferation; Drug Interactions; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; Neoplasm Proteins; Paclitaxel; RNA, Messenger | 2017 |
Histone Deacetylase Inhibitors Enhance Cytotoxicity Towards Breast Tumors While Preserving the Wound-Healing Function of Adipose-Derived Stem Cells.
Topics: Adipose Tissue; Apoptosis; Breast Neoplasms; Cell Movement; Cell Survival; Gene Expression; Histone Deacetylase Inhibitors; Humans; Mammaplasty; Paclitaxel; Real-Time Polymerase Chain Reaction; Stem Cells; Tumor Cells, Cultured; Wound Healing | 2017 |
Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Liberation; Drug Resistance, Multiple; Female; Humans; Hydrogen-Ion Concentration; Lipoproteins, LDL; MCF-7 Cells; Mice, Nude; Micelles; Oxidation-Reduction; Paclitaxel; Polymers; RNA Interference; RNA, Small Interfering; Tissue Distribution | 2017 |
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Immunoprecipitation; Mice; Paclitaxel; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Estrogen; Remission Induction; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Reply to Garcia J. et al.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dolphins; Granulocyte Colony-Stimulating Factor; Humans; Paclitaxel | 2017 |
HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; Receptor, ErbB-2; RNA, Neoplasm | 2018 |
Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy.
Topics: Antineoplastic Agents; Autophagy; Breast Neoplasms; Cell Proliferation; Cell Survival; Dichloroacetic Acid; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; E-Selectin; Humans; Hyaluronic Acid; Mice; Micelles; Neoplasm Metastasis; Paclitaxel; Peptides; Polyethylene Glycols | 2017 |
Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cyclodextrins; Drug Delivery Systems; Female; Folic Acid; Folic Acid Transporters; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel | 2018 |
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2017 |
Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity.
Topics: Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Gene Knockdown Techniques; HEK293 Cells; Humans; MCF-7 Cells; Microtubule-Associated Proteins; Microtubules; Paclitaxel; Tubulin | 2017 |
Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Liposomes; Mice; Neoplasm Metastasis; Oligopeptides; Oxidation-Reduction; Paclitaxel; RNA, Small Interfering | 2017 |
HPI/AMF inhibition halts the development of the aggressive phenotype of breast cancer stem cells.
Topics: Breast Neoplasms; Cell Hypoxia; Cell Movement; Cell Proliferation; Doxorubicin; Epithelial-Mesenchymal Transition; Female; Gluconates; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Neoplasm Metastasis; Neoplastic Stem Cells; Paclitaxel; RNA, Small Interfering; Sugar Phosphates; Sulfonamides | 2017 |
Sensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposome.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Energy Metabolism; Female; Humans; Liposomes; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Paclitaxel; Photosensitizing Agents; Porphyrins | 2017 |
Hepatitis B Reactivation in a Patient Receiving Chemotherapy for Breast Cancer: A Case Report.
Topics: Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Hepatitis B; Hepatitis B virus; Humans; Immunosuppressive Agents; Liver Failure; Middle Aged; Paclitaxel; Tenofovir; Virus Activation | 2017 |
Chemosensitizing indomethacin-conjugated dextran-based micelles for effective delivery of paclitaxel in resistant breast cancer therapy.
Topics: Animals; Breast Neoplasms; Dextrans; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Indomethacin; MCF-7 Cells; Mice; Micelles; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Breast Neoplasms; Cell Count; Chemotherapy, Adjuvant; Cyclophosphamide; Cytokines; Doxorubicin; Female; Granulocytes; Humans; Middle Aged; Monocytes; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Treatment Outcome; White People | 2017 |
Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Female; Humans; Lipid Metabolism; Paclitaxel | 2017 |
An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autocrine Communication; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Interleukin-8; Mice; Mice, Nude; Neoplastic Stem Cells; NF-kappa B; Paclitaxel; Receptors, Interleukin-8A; Receptors, Interleukin-8B; Signal Transduction; Sulfonamides; Transplantation, Heterologous | 2017 |
Matrix Stiffness Differentially Regulates Cellular Uptake Behavior of Nanoparticles in Two Breast Cancer Cell Lines.
Topics: Breast Neoplasms; Humans; MCF-7 Cells; Nanoparticles; Paclitaxel; Poloxamer; Polyethylene Glycols; Vitamin E | 2017 |
Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Lactic Acid; Nanoparticles; Paclitaxel; Polyglycolic Acid | 2017 |
Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Topics: Administrative Claims, Healthcare; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Comparative Effectiveness Research; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Medicare; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Propensity Score; Retrospective Studies; SEER Program; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States | 2017 |
N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.
Topics: Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Chemokines; Cyclin D1; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; Peptides; Receptors, CXCR4 | 2017 |
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; T-Lymphocytes, Cytotoxic; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Female; Gene Expression; Gene Silencing; Humans; Lipid Peroxidation; Membrane Potential, Mitochondrial; Paclitaxel; Reactive Oxygen Species; Retinal Dehydrogenase; RNA, Small Interfering; Transfection | 2017 |
Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tunicamycin; Xenograft Model Antitumor Assays | 2017 |
Stress-inducible gene
Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mice; Neoplasm Metastasis; Paclitaxel; Stress, Physiological | 2017 |
[Third- and Fourth-Line Chemotherapies including Paclitaxel and Bevacizumab for Metastatic Breast Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2017 |
[Three Poor Performance Status(PS)Cases of Metastatic Breast Cancer Controlled with Adjustment of Dosing Interval and Dosage of Bevacizumab and Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pleural Effusion; Treatment Outcome | 2017 |
Long-term peripheral neuropathy symptoms in breast cancer survivors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cancer Survivors; Cross-Sectional Studies; Docetaxel; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Prevalence; Retrospective Studies; Taxoids | 2017 |
Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Models, Biological; Neoplastic Stem Cells; Nuclear Proteins; Paclitaxel; SOXB1 Transcription Factors; Spheroids, Cellular; Transcriptome; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Twist-Related Protein 1 | 2017 |
Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Lignans; MCF-7 Cells; Neoplasm Metastasis; Paclitaxel | 2017 |
Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Nasal Septal Perforation; Neoplasm Metastasis; Paclitaxel | 2017 |
Silencing Aurora A leads to re-sensitization of breast cancer cells to Taxol through downregulation of SRC-mediated ERK and mTOR pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aurora Kinase A; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Heterografts; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Paclitaxel; src-Family Kinases; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Liberation; Drug Synergism; Female; Humans; Lactams, Macrocyclic; Mice, Nude; Micelles; Paclitaxel; Particle Size; Peptides; Polyethylene Glycols; Receptor, ErbB-2; Surface Properties; Thermodynamics; Trastuzumab | 2017 |
Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplastic Stem Cells; Paclitaxel; Spheroids, Cellular; Treatment Outcome; Tumor Microenvironment; Up-Regulation | 2017 |
The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Peripheral Nervous System Diseases; Treatment Failure | 2017 |
pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Curcumin; Drug Carriers; Drug Liberation; Drug Synergism; Female; Humans; Hydrogen-Ion Concentration; Imidazoles; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; Particle Size; Polyethylene Glycols; Polyvinyls; Surface Properties | 2017 |
Paclitaxel-related scleredema-like skin changes in a patient with breast cancer.
Topics: Adult; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Immunohistochemistry; Mastectomy; Paclitaxel; Risk Assessment; Scleroderma, Diffuse; Withholding Treatment | 2018 |
Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Topics: 14-3-3 Proteins; Animals; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; MicroRNAs; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplastic Cells, Circulating; Paclitaxel; Prognosis | 2018 |
Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Ibuprofen; Nanoparticles; Paclitaxel; Tumor Cells, Cultured | 2017 |
Huaier extract enhances the treatment efficacy of paclitaxel in breast cancer cells via the NF-κB/IκBα pathway.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Complex Mixtures; Drug Synergism; Drugs, Chinese Herbal; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Proto-Oncogene Proteins c-met; Signal Transduction; Trametes; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2017 |
Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro.
Topics: Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Cell Line; Female; Humans; Lignans; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; Polyethylene Glycols; Spheroids, Cellular; Triglycerides; Tumor Cells, Cultured | 2017 |
Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Insurance Claim Review; Lymph Node Excision; Mastectomy; Middle Aged; Office Visits; Paclitaxel | 2018 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
Methods to Evaluate Cell Growth, Viability, and Response to Treatment in a Tissue Engineered Breast Cancer Model.
Topics: Animals; Bioreactors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Equipment Design; Extracellular Matrix; Female; Green Fluorescent Proteins; Humans; Keratin-18; L-Lactate Dehydrogenase; Luminescent Measurements; Mice; Microscopy, Confocal; Paclitaxel; Tissue Engineering; Xenograft Model Antitumor Assays | 2017 |
Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Technetium; Tissue Distribution | 2018 |
[A Case of Locally Advanced Breast Cancer Successfully Treated with Local Control That Achieved a Pathological Complete Response after Bevacizumab and Paclitaxel Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Breast Neoplasms; Female; Humans; Paclitaxel; Treatment Outcome | 2017 |
A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dasatinib; Drug Liberation; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; Micelles; Oxidation-Reduction; Paclitaxel; Polyethylene Glycols | 2017 |
Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.
Topics: Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Muscle, Skeletal; Paclitaxel; Survival Analysis; Treatment Outcome; Wasting Syndrome | 2018 |
Symptom clusters using the Brief Pain Inventory in patients with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cancer Pain; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pain Measurement; Prospective Studies; Quality of Life; Taxoids | 2017 |
Evaluation Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus in Combination With Anticancer Drugs in Human Cancer Orthotopic Mouse Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Fucus; Humans; MCF-7 Cells; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Polysaccharides; Tamoxifen; Undaria | 2018 |
Baker's Yeast Sensitizes Metastatic Breast Cancer Cells to Paclitaxel In Vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; DNA Damage; Humans; MCF-7 Cells; Paclitaxel; Saccharomyces cerevisiae | 2018 |
IGF-1-mediated PKM2/β-catenin/miR-152 regulatory circuit in breast cancer.
Topics: Base Sequence; beta Catenin; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Membrane Proteins; MicroRNAs; Paclitaxel; Protein Binding; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2017 |
MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer.
Topics: Animals; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Insulin Receptor Substrate Proteins; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction | 2017 |
Novel sulforaphane-enabled self-microemulsifying delivery systems (SFN-SMEDDS) of taxanes: Formulation development and in vitro cytotoxicity against breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Drug Delivery Systems; Emulsions; Excipients; Female; Humans; Isothiocyanates; MCF-7 Cells; Paclitaxel; Solubility; Sulfoxides; Taxoids | 2018 |
Novel multi‑kinase inhibitor, T03 inhibits Taxol‑resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Mice; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; raf Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aptamers, Nucleotide; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Extracellular Vesicles; Female; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nucleolin; Paclitaxel; Phosphoproteins; RNA-Binding Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
[Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells].
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel; RNA, Long Noncoding | 2017 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
PATEO syndrome: periarticular thenar erythema with onycholysis.
Topics: Breast Neoplasms; Erythema; Female; Hand-Foot Syndrome; Humans; Joint Diseases; Middle Aged; Onycholysis; Paclitaxel; Syndrome | 2018 |
Effect of XlogP and Hansen Solubility Parameters on Small Molecule Modified Paclitaxel Anticancer Drug Conjugates Self-Assembled into Nanoparticles.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Nanoparticles; Paclitaxel; Small Molecule Libraries; Solubility | 2018 |
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
Topics: Benzimidazoles; Breast Neoplasms; Carboplatin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Temozolomide | 2018 |
Neoadjuvant Systemic Therapy for Breast Cancer: Searching for More Effectively Curative Therapies.
Topics: Albumin-Bound Paclitaxel; Albumins; Anthracyclines; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2 | 2018 |
Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-κB Signaling.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Cell Survival; Female; Human Umbilical Vein Endothelial Cells; Humans; Leupeptins; MCF-7 Cells; Mice, Inbred C57BL; Neoplasm Invasiveness; NF-kappa B; Paclitaxel; Phenotype; Proteasome Inhibitors; Signal Transduction | 2018 |
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Mass Index; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2 | 2018 |
Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Enzyme Inhibitors; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Liposomes; MCF-7 Cells; Mice, Inbred BALB C; Paclitaxel; Prodrugs; Tumor Microenvironment | 2018 |
Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Insulin-Like Growth Factor I; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Paclitaxel; Receptor, IGF Type 1; Treatment Outcome | 2018 |
Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau.
Topics: Abietanes; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Paclitaxel | 2018 |
Targeting Therapy of Neuropilin-1 Receptors Overexpressed Breast Cancer by Paclitaxel-Loaded CK3-Conjugated Polymeric Micelles.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Immunohistochemistry; Mice, Inbred BALB C; Mice, Nude; Micelles; Neuropilin-1; Paclitaxel; Peptides; Polyethylene Glycols | 2016 |
Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel; Phosphorylation; Receptors, Cell Surface; Receptors, Estrogen; RNA Interference | 2018 |
Evaluation of cell penetrating peptide coated Mn:ZnS nanoparticles for paclitaxel delivery to cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Drug Carriers; Female; HeLa Cells; Humans; Manganese; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polymers; Sulfides; Zinc Compounds | 2018 |
[Clinical Efficacy of Paclitaxel plus Bevacizumab Combination Therapy for Bone Marrow Carcinomatosis Arising from Breast Cancer - A Case Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Bevacizumab; Bone Marrow Neoplasms; Breast Neoplasms; Female; Humans; Paclitaxel | 2017 |
Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Topics: Animals; Biomimetic Materials; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Neoplasm Transplantation; Paclitaxel; Protein Stability; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Survivin; Up-Regulation | 2018 |
Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; DNA; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphatic Metastasis; Matrix Metalloproteinase 2; MCF-7 Cells; Middle Aged; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; Tropomyosin | 2018 |
miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; GRB2 Adaptor Protein; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; MicroRNAs; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl | 2018 |
Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Dexamethasone; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Middle Aged; Paclitaxel; Premedication; Retrospective Studies; Taxoids | 2018 |
Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cytochromes c; Dequalinium; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Micelles; Mitochondria; Nanostructures; Paclitaxel; Polyethylene Glycols; Polyvinyls; Xenograft Model Antitumor Assays | 2018 |
Co-administration of tLyp-1 with polymeric paclitaxel conjugates: Enhanced intratumoral accumulation and anti-tumor efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Feasibility Studies; Female; Mice; Mice, Inbred BALB C; Paclitaxel; Peptides, Cyclic; Proteins; Tandem Mass Spectrometry; Tumor Burden; Tumor Microenvironment | 2017 |
The microbial flora of taxane therapy-associated nail disease in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Bacteria; Breast Neoplasms; Dermatomycoses; Docetaxel; Female; Fungi; Humans; Paclitaxel; Paronychia; Skin Diseases, Bacterial; Taxoids | 2018 |
Modulation by hydroxytyrosol of oxidative stress and antitumor activities of paclitaxel in breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Female; Oxidative Stress; Paclitaxel; Phenylethyl Alcohol; Rats; Rats, Sprague-Dawley; Treatment Outcome; Tumor Burden | 2019 |
Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Delivery Systems; Humans; Mice; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Peptides; Receptor, EphA2 | 2018 |
Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomimetic Materials; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Delayed-Action Preparations; Drug Delivery Systems; Female; Humans; Macrophages; Mice; Nanoparticles; Paclitaxel; Tumor Microenvironment | 2018 |
Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
Topics: Acetates; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Interleukin-6; Interleukin-8; Melanoma; Paclitaxel; Signal Transduction; Toll-Like Receptor 4; Tumor Microenvironment; Tyramine | 2018 |
Machine Learning Methods to Extract Documentation of Breast Cancer Symptoms From Electronic Health Records.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Electronic Health Records; Fatigue; Female; Humans; Machine Learning; Male; Middle Aged; Nausea; Paclitaxel; Pain | 2018 |
A Promising Microtubule Inhibitor Deoxypodophyllotoxin Exhibits Better Efficacy to Multidrug-Resistant Breast Cancer than Paclitaxel via Avoiding Efflux Transport.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Female; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Neoplasm Proteins; Paclitaxel; Podophyllotoxin | 2018 |
Doxorubicin and paclitaxel carried by methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) is superior than traditional drug-delivery methods.
Topics: Animals; Breast Neoplasms; Doxorubicin; Drug Delivery Systems; Female; Humans; Kidney; Mammary Neoplasms, Animal; Metabolomics; Mice; Nanoparticles; Paclitaxel; Polyesters; Polyethylene Glycols | 2018 |
Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chlorophyllides; Drug Compounding; Drug Delivery Systems; Female; Heparin, Low-Molecular-Weight; Humans; Infrared Rays; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Transplantation; Optical Imaging; Paclitaxel; Photochemotherapy; Porphyrins; Random Allocation; Reactive Oxygen Species; Theranostic Nanomedicine; Tumor Burden; Whole Body Imaging | 2018 |
Surface modification of paclitaxel-loaded liposomes using d-α-tocopheryl polyethylene glycol 1000 succinate: Enhanced cellular uptake and cytotoxicity in multidrug resistant breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Survival; Drug Liberation; Drug Resistance, Neoplasm; Female; Humans; Liposomes; MCF-7 Cells; Microscopy, Confocal; Paclitaxel; Particle Size; Polysorbates; Solubility; Vitamin E | 2018 |
A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Therapy; Flow Cytometry; Folic Acid; Heterografts; Humans; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Models, Biological; Molecular Targeted Therapy; Neoplasm Transplantation; Paclitaxel; Prodrugs; Protein Binding; Treatment Outcome; Tumor Protein, Translationally-Controlled 1 | 2018 |
Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Middle Aged; Paclitaxel; Receptors, Natural Killer Cell | 2018 |
Synthesis and evaluation of a paclitaxel-binding polymeric micelle for efficient breast cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Stability; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanostructures; Paclitaxel; Particle Size; Polyethylene Glycols; Tissue Distribution; Xenograft Model Antitumor Assays | 2018 |
Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Transcriptome | 2018 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Models, Biological; Neoadjuvant Therapy; Paclitaxel; Receptors, Estrogen; Young Adult | 2018 |
Application of a simple desolvation method to increase the formation yield, physical stability and hydrophobic drug encapsulation capacity of chitosan-based nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Buffers; Cell Survival; Chitosan; Culture Media; Drug Carriers; Drug Compounding; Drug Stability; Female; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Molecular Dynamics Simulation; Nanoparticles; Nanotechnology; Paclitaxel; Technology, Pharmaceutical | 2018 |
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Breast Neoplasms; Female; Furans; Humans; Ketones; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2018 |
Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Breast Neoplasms; Female; Humans; Hypertension; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proteinuria; Treatment Outcome | 2018 |
Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Paclitaxel; Protein Binding; Structure-Activity Relationship | 2018 |
Theranostic size-reducible and no donor conjugated gold nanocluster fabricated hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Delivery Systems; Female; Gold; Hyaluronan Receptors; Hyaluronic Acid; Indocyanine Green; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nitric Oxide; Nitric Oxide Donors; Paclitaxel; Particle Size; Serum Albumin, Bovine; Theranostic Nanomedicine; Tumor Microenvironment | 2018 |
Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; Neoplastic Stem Cells; Paclitaxel; Protein Transport; Quercetin; Vincristine; Y-Box-Binding Protein 1 | 2018 |
Dental pulp stem cells used to deliver the anticancer drug paclitaxel.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Differentiation; Dental Pulp; Drug Delivery Systems; Humans; MCF-7 Cells; Paclitaxel; Stem Cells | 2018 |
Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors | 2018 |
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Survival Analysis | 2018 |
Lx2-32c inhibits the formation of mammosphere from MDA-MB-231 cells and induces apoptosis involving in down-regulating FoxM1.
Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Down-Regulation; Female; Forkhead Box Protein M1; Humans; Hyaluronan Receptors; Inhibitory Concentration 50; Neoplastic Stem Cells; Paclitaxel; Spheroids, Cellular; Thiostrepton; Tumor Cells, Cultured | 2018 |
Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Genes, erbB-2; Humans; Inhibitor of Apoptosis Proteins; Mesenchymal Stem Cells; Neuregulin-1; Paclitaxel; Paracrine Communication; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; Survivin | 2018 |
Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cations; Cyclophosphamide; Doxorubicin; Electrocardiography; Female; Follow-Up Studies; Heart Conduction System; Heart Diseases; Humans; Middle Aged; Natriuretic Peptide, Brain; Paclitaxel; Prospective Studies; Troponin I | 2018 |
Synergistic tumor microenvironment targeting and blood-brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Cell Proliferation; Cell-Penetrating Peptides; Drug Delivery Systems; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Ligands; Liposomes; Mice; Mice, Inbred BALB C; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78.
Topics: Animals; Apoptosis; Betulinic Acid; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Heat-Shock Proteins; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Paclitaxel; Pentacyclic Triterpenes; Triterpenes; Xenograft Model Antitumor Assays | 2018 |
l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Mice; Mice, Nude; Myelin Basic Protein; Nanoparticles; Paclitaxel; Peptide Fragments; Prodrugs | 2018 |
Codelivery of Paclitaxel and Everolimus at the Optimal Synergistic Ratio: A Promising Solution for the Treatment of Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Everolimus; Female; Flow Cytometry; Humans; MCF-7 Cells; Nanoparticles; Paclitaxel; Polymers | 2018 |
Co-delivery of Metformin and Paclitaxel Via Folate-Modified pH-Sensitive Micelles for Enhanced Anti-tumor Efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Metformin; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
[Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Synergism; Humans; Paclitaxel; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2016 |
A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis | 2019 |
Ultrasound-Triggered Drug Delivery for Breast Tumor Therapy Through iRGD-Targeted Paclitaxel-Loaded Liposome-Microbubble Complexes.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Humans; Liposomes; Microbubbles; Paclitaxel; Ultrasonography | 2018 |
The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Dual-Specificity Phosphatases; Humans; Paclitaxel; Prognosis; Up-Regulation | 2018 |
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Female; Humans; Markov Chains; Models, Biological; Neoplasm Metastasis; Paclitaxel | 2018 |
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cryotherapy; Female; Follow-Up Studies; Humans; Incidence; Japan; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Prospective Studies; Severity of Illness Index | 2018 |
Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Biomarkers; Breast Neoplasms; Female; Histidine; Humans; Magnetic Resonance Spectroscopy; Metabolomics; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Phenylalanine; Threonine | 2018 |
Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Male; Mice; Nanoparticles; Paclitaxel; Polymers; Rats; Rats, Sprague-Dawley; Tissue Distribution; Tumor Cells, Cultured | 2019 |
Apparent diffusion coefficient measurement in luminal breast cancer: will tumour shrinkage patterns affect its efficacy of evaluating the pathological response?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cisplatin; Diffusion Magnetic Resonance Imaging; Female; Humans; Middle Aged; Observer Variation; Paclitaxel; Retrospective Studies; Treatment Outcome; Tumor Burden | 2018 |
Inhibition of Survivin by Adenovirus Vector Enhanced Paclitaxel-induced Apoptosis in Breast Cancer Cells.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Fungal; Female; Gene Knockdown Techniques; Genetic Therapy; Genetic Vectors; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Paclitaxel; Survivin | 2018 |
Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Luciferases; Mice; MicroRNAs; Oligoribonucleotides; Paclitaxel; RNA, Long Noncoding; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Hexokinase; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Xenograft Model Antitumor Assays | 2018 |
A drug-delivering-drug strategy for combined treatment of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caseins; Cell Proliferation; Drug Combinations; Drug Delivery Systems; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinases; Mice; Nanoparticles; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Cell Movement; Cell Proliferation; Chemokines; Chemotherapy, Adjuvant; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MCF-7 Cells; MicroRNAs; Myeloid Differentiation Factor 88; Paclitaxel; Peptides; Receptors, CXCR4; Signal Transduction; Viral Proteins | 2018 |
In vivo tailor-made protein corona of a prodrug-based nanoassembly fabricated by redox dual-sensitive paclitaxel prodrug for the superselective treatment of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Disulfides; Drug Liberation; Endocytosis; Female; Humans; Maleimides; Mice; Mice, Inbred BALB C; Nanostructures; NIH 3T3 Cells; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Prodrugs; Protein Corona; Rats, Sprague-Dawley; Reactive Oxygen Species; Serum Albumin, Bovine | 2018 |
Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MicroRNAs; Paclitaxel; Receptor, ErbB-2 | 2018 |
Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Retrospective Studies | 2018 |
[A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Disease Progression; Epirubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic | 2018 |
Theranostic micelles combined with multiple strategies to effectively overcome multidrug resistance.
Topics: Albumins; Blood-Brain Barrier; Breast Neoplasms; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Ferric Compounds; Humans; Indoles; MCF-7 Cells; Metal Nanoparticles; Micelles; Organometallic Compounds; Paclitaxel; Silicon Dioxide; Theranostic Nanomedicine | 2018 |
Investigation of the relationship among fatigue, self-efficacy and quality of life during chemotherapy in patients with breast, lung or gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Quality of Life; Self Care; Self Efficacy; Surveys and Questionnaires; Turkey | 2019 |
[A Case of Recurrent Breast Cancer with Complete Response to Eribulin Monotherapy after Bevacizumab plus Paclitaxel Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Furans; Humans; Ketones; Paclitaxel; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2018 |
[A Case of Locally Advanced and Metastatic Breast Cancer Treated with Preoperative Bevacizumab Combination Chemotherapy That Attained Local Control].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Neoplasm Staging; Paclitaxel | 2018 |
[A Case of Microangiopathic Hemolytic Anemia with Bone Marrow Carcinomatosis from Breast Cancer].
Topics: Anemia, Hemolytic; Antineoplastic Agents, Phytogenic; Biopsy; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Middle Aged; Paclitaxel | 2018 |
Curcumin and paclitaxel induce cell death in breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Caspase 3; Caspase 7; Cell Proliferation; Curcumin; Drug Synergism; Female; Humans; NF-kappa B; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Tumor Cells, Cultured | 2018 |
SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MCF-7 Cells; Mice; Mice, Nude; Middle Aged; Neoplasms, Experimental; Nuclear Proteins; Paclitaxel; RNA Interference; RNA, Small Interfering; Twist-Related Protein 1 | 2018 |
RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeleton; Drug Synergism; Female; Gene Knockdown Techniques; HEK293 Cells; Humans; MCF-7 Cells; Mice; Nogo Proteins; Paclitaxel; Proteomics; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Therapy; Female; HEK293 Cells; Humans; Induction Chemotherapy; Intracellular Signaling Peptides and Proteins; Macrophages; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Prognosis; Protein Serine-Threonine Kinases; Quality of Life; Stromal Cells; Tumor Microenvironment | 2018 |
Biomimetic nano-surfactant stabilizes sub-50 nanometer phospholipid particles enabling high paclitaxel payload and deep tumor penetration.
Topics: Animals; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Micelles; Paclitaxel; Peptides; Phospholipids; Surface-Active Agents; Xenograft Model Antitumor Assays | 2018 |
Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2018 |
A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis.
Topics: Allografts; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Female; Humans; Mammary Neoplasms, Animal; Mice; Paclitaxel; Treatment Outcome | 2018 |
Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Drug Delivery Systems; Female; Gene Transfer Techniques; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Micelles; Neovascularization, Pathologic; Paclitaxel; Polyesters; Polyethylene Glycols; RNA, Small Interfering; RNAi Therapeutics; Vascular Endothelial Growth Factor A | 2018 |
Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer.
Topics: Autophagy; Autophagy-Related Protein 5; Autophagy-Related Proteins; Breast Neoplasms; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Female; HMGB1 Protein; Humans; Luminescent Proteins; MCF-7 Cells; Mediator Complex; Microtubule-Associated Proteins; Paclitaxel; Proteolysis; Red Fluorescent Protein; RNA-Binding Proteins; Sequestosome-1 Protein; Signal Transduction; Transfection; Ubiquitin-Conjugating Enzymes | 2019 |
TRIM59 overexpression correlates with poor prognosis and contributes to breast cancer progression through AKT signaling pathway.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Metalloproteins; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Survival Analysis; Tripartite Motif Proteins; Triple Negative Breast Neoplasms; Tumor Burden; Up-Regulation | 2018 |
Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Chalcones; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; MCF-7 Cells; Paclitaxel | 2018 |
Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth.
Topics: Adipose Tissue; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Female; Humans; MCF-7 Cells; Mice, Nude; Paclitaxel; Stem Cells; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Coculture Techniques; Culture Media, Conditioned; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estrogen Receptor alpha; Extracellular Matrix; Female; Humans; Integrin alpha5; MCF-7 Cells; Paclitaxel; Placenta; Pregnancy; Signal Transduction | 2019 |
Magnetic nanoparticle hyperthermia potentiates paclitaxel activity in sensitive and resistant breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Hyperthermia, Induced; Magnetite Nanoparticles; Paclitaxel; Tumor Cells, Cultured | 2018 |
Anticancer activity of paclitaxel-loaded keratin nanoparticles in two-dimensional and perfused three-dimensional breast cancer models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Survival; Drug Liberation; Female; Gene Expression Regulation, Neoplastic; Humans; Keratins; MCF-7 Cells; Models, Biological; Nanoparticles; Paclitaxel | 2018 |
Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation.
Topics: Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pentacyclic Triterpenes; Triterpenes | 2018 |
Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Membrane Proteins; Mice, Nude; Nanoparticles; Paclitaxel; Retrospective Studies; RNA Interference; RNA-Binding Proteins; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dextrans; Drug Delivery Systems; Drug Liberation; Drug Synergism; Fluorocarbons; Humans; Hyperthermia, Induced; Light; Magnetite Nanoparticles; Mice, Nude; Multimodal Imaging; Nanoparticles; Paclitaxel; Phase Transition; Photoacoustic Techniques; Phototherapy; Polyesters; Polyethylene Glycols; Receptor, ErbB-2; Spectroscopy, Near-Infrared; Ultrasonics | 2018 |
Cytotoxicity Enhancement of Paclitaxel by Loading on Stearate-g-dextran Micelles on Breast Cancer Cell Line MCF-7
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Dextrans; Drug Liberation; Female; Humans; Micelles; Paclitaxel; Polymers; Stearates; Tumor Cells, Cultured | 2018 |
Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cadherins; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Inhibitor of Differentiation Protein 1; MCF-7 Cells; Melatonin; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Deglycase DJ-1; Signal Transduction; Transcription Factors | 2019 |
Downregulation of miR‑200c‑3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.
Topics: 3' Untranslated Regions; Breast Neoplasms; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; SOXB1 Transcription Factors | 2018 |
Synthesis and Characterization of PDMS-PMOXA-Based Polymersomes Sensitive to MMP-9 for Application in Breast Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Carriers; Drug Liberation; Embryo, Nonmammalian; Female; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Nanoparticles; Oxazoles; Paclitaxel; Polymers; Treatment Outcome; Xenograft Model Antitumor Assays; Zebrafish | 2018 |
Monitoring Early Breast Cancer Response to Neoadjuvant Therapy Using H-Scan Ultrasound Imaging: Preliminary Preclinical Results.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Female; Mice; Mice, Nude; Neoadjuvant Therapy; Paclitaxel; Phantoms, Imaging; Treatment Outcome; Ultrasonography | 2019 |
Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Body Mass Index; Body Surface Area; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk Factors | 2018 |
Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Movement; Cell Proliferation; Chromatography, Liquid; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Nanoparticles; Paclitaxel; Particle Size; Surface Properties; Tandem Mass Spectrometry; Tannins; Tumor Cells, Cultured | 2019 |
Self-assembly of biotinylated poly(ethylene glycol)-poly(curcumin) for paclitaxel delivery.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotinylation; Breast Neoplasms; Chemistry, Pharmaceutical; Curcumin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Excipients; Glutathione; Humans; Inhibitory Concentration 50; MCF-7 Cells; Nanoparticles; Paclitaxel; Polyethylene Glycols; Solubility | 2018 |
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furans; Humans; Ketones; Lymphocyte Count; Middle Aged; Paclitaxel; Predictive Value of Tests; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab | 2018 |
HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MCF-7 Cells; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Receptors, Notch; Signal Transduction; Tumor Microenvironment; Up-Regulation; Wnt Proteins | 2018 |
On-Demand Versatile Prodrug Nanomicelle for Tumor-Specific Bioimaging and Photothermal-Chemo Synergistic Cancer Therapy.
Topics: Animals; Breast Neoplasms; Female; Humans; Hyperthermia, Induced; Indocyanine Green; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanostructures; NIH 3T3 Cells; Optical Imaging; Paclitaxel; Phototherapy; Prodrugs; Xenograft Model Antitumor Assays | 2018 |
COL‑3 enhances the anti‑proliferative and pro‑apoptotic effects of paclitaxel in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; MCF-7 Cells; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Tetracyclines | 2019 |
VE-Albumin Core-Shell Nanoparticles for Paclitaxel Delivery to Treat MDR Breast Cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Nanoparticles; Paclitaxel; Protein Structure, Secondary; Rhodamines; Vitamin E; Xenograft Model Antitumor Assays | 2018 |
Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms | 2018 |
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2019 |
MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS.
Topics: Biological Phenomena; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; GTP Phosphohydrolases; HEK293 Cells; Humans; MCF-7 Cells; Membrane Proteins; MicroRNAs; Paclitaxel; Proto-Oncogene Mas | 2018 |
Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cohort Studies; Docetaxel; Female; Humans; Incidence; Medicare; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; SEER Program; United States | 2019 |
Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Middle Aged; Paclitaxel; Ramucirumab; Stomach Neoplasms; Treatment Outcome | 2018 |
Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Gemcitabine; Lipids; Mice; Nanoparticles; Oligopeptides; Paclitaxel; Tissue Distribution | 2018 |
Reversing multi-drug tumor resistance to Paclitaxel by well-defined pH-sensitive amphiphilic polypeptide block copolymers via induction of lysosomal membrane permeabilization.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Membrane Permeability; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Lysosomes; Paclitaxel; Peptide Fragments; Polymers; Tumor Cells, Cultured; Uterine Neoplasms | 2019 |
Circulating renin-angiotensin system-regulating specific aminopeptidase activities in pre- and post- menopausal women with breast cancer treated or not with neoadyuvant chemotherapy. A two years follow up study.
Topics: Aminopeptidases; Angiotensin II; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; CD13 Antigens; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Glutamyl Aminopeptidase; Humans; Immunotherapy; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Premenopause; Radiotherapy, Adjuvant; Renin-Angiotensin System; Tamoxifen | 2019 |
Development of a Subcellular Semimechanism-Based Pharmacokinetic/Pharmacodynamic Model to Characterize Paclitaxel Effects Delivered by Polymeric Micelles.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Micelles; Paclitaxel; Polyesters; Polyethylene Glycols; Polymers; Tubulin | 2019 |
Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Drug Carriers; Drug Liberation; Female; Humans; Mice, Nude; Micelles; Ovarian Neoplasms; Oxazoles; Paclitaxel | 2019 |
Development of drug-loaded protein nanoparticles displaying enzymatically-conjugated DNA aptamers for cancer cell targeting.
Topics: Antineoplastic Agents; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Elastin; Female; Humans; MCF-7 Cells; Nanoparticles; Neoplasms; Paclitaxel | 2019 |
Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17β-estradiol/estrogen receptor α/neuroglobin pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Drug Synergism; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neuroglobin; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduction | 2019 |
Hydrogen-Bonded Tannic Acid-Based Anticancer Nanoparticle for Enhancement of Oral Chemotherapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Caco-2 Cells; Drug Carriers; Female; Humans; Hydrogen Bonding; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Rats; Rats, Sprague-Dawley; Tannins; Xenograft Model Antitumor Assays | 2018 |
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.
Topics: Albumins; Breast Neoplasms; Consensus; Female; Humans; Paclitaxel; Practice Guidelines as Topic; Receptor, ErbB-2; Survival Rate; Treatment Outcome | 2019 |
Paclitaxel-betulinic acid hybrid nanosuspensions for enhanced anti-breast cancer activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Breast Neoplasms; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Pentacyclic Triterpenes; Structure-Activity Relationship; Tissue Distribution; Triterpenes | 2019 |
Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Retrospective Studies; Spain | 2019 |
Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbamates; Cell Line, Tumor; Drug Repositioning; Humans; KCNQ Potassium Channels; Male; Neuralgia; Neurons; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Phenylenediamines; Random Allocation; Rats, Sprague-Dawley | 2019 |
Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis.
Topics: Acute Pain; Adult; Aged; Albumins; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Female; Humans; Logistic Models; Middle Aged; Paclitaxel; Predictive Value of Tests; Quality of Life; Retrospective Studies; Risk Factors; Syndrome | 2019 |
Cocktail Strategy Based on Spatio-Temporally Controlled Nano Device Improves Therapy of Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Matrix Metalloproteinase 9; MCF-7 Cells; Mice; Micelles; Nanoparticles; Neoplastic Stem Cells; Paclitaxel; T-Lymphocytes; Thioridazine; Transplantation, Heterologous | 2019 |
A four-gene signature predicts the efficacy of paclitaxel-based neoadjuvant therapy in human epidermal growth factor receptor 2-negative breast cancer.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Female; Humans; Logistic Models; Mitosis; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Treatment Outcome | 2019 |
Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Death; Cell Line, Tumor; Chlorpromazine; Dogs; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endocytosis; Female; Humans; Inhibitory Concentration 50; Lipids; Madin Darby Canine Kidney Cells; Nanoparticles; Paclitaxel; Particle Size; Verapamil | 2018 |
Mechanism of action of the trastuzumab biosimilar CT-P6.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Biosimilar Pharmaceuticals; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Humans; Paclitaxel; Phagocytosis; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Vascular Endothelial Growth Factor A | 2019 |
Exploring an interesting dual functionality of anacardic acid for efficient paclitaxel delivery in breast cancer therapy.
Topics: Anacardic Acids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gelatin; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Nanoparticles; Paclitaxel; Particle Size; Rats, Sprague-Dawley; Surface Properties | 2019 |
BDNF Val66Met is Associated with Pre-existing but not with Paclitaxel-induced Peripheral Neuropathy in an Israeli Cohort of Breast Cancer Patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain-Derived Neurotrophic Factor; Breast Neoplasms; Breast Neoplasms, Male; Cohort Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Israel; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Polymerase Chain Reaction; Polymorphism, Single Nucleotide | 2018 |
Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cardiotoxicity; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Female; Humans; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Paclitaxel; Random Allocation; Tumor Burden | 2019 |
Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2019 |
Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier.
Topics: Acrylates; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Female; Folate Receptors, GPI-Anchored; Folic Acid; Graphite; Nanoparticles; Paclitaxel; Rats; Rats, Sprague-Dawley | 2019 |
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Metaplasia; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Fatal, paraparetic acute motor axonal neuropathy, early complicating chemotherapy with nab-paclitaxel.
Topics: Aged; Albumins; Breast Neoplasms; Fatal Outcome; Female; Guillain-Barre Syndrome; Humans; Paclitaxel | 2019 |
Bromodomain‑containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2‑antagonist/killer protein.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast; Breast Neoplasms; Breast Neoplasms, Male; Cell Proliferation; Chromosomal Proteins, Non-Histone; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Male; MCF-7 Cells; Middle Aged; Paclitaxel; Promoter Regions, Genetic; Survival Rate | 2019 |
Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antrodia; beta Catenin; Breast Neoplasms; Carcinogenesis; Cell Proliferation; Cell Transformation, Neoplastic; Down-Regulation; Drug Synergism; Female; Fibroblasts; Humans; Lactones; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Sesquiterpenes; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Stereocomplex micelle loaded with paclitaxel for enhanced therapy of breast cancer in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dextrans; Disease Models, Animal; Drug Carriers; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Particle Size; Polyesters; Surface Properties; Tissue Distribution | 2019 |
Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Topics: Biopsy; BRCA1 Protein; Breast Neoplasms; DNA Methylation; Female; Gene Expression Profiling; Homologous Recombination; Humans; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Promoter Regions, Genetic; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Cellular effects of paclitaxel-loaded iron oxide nanoparticles on breast cancer using different 2D and 3D cell culture models.
Topics: Breast Neoplasms; Cell Culture Techniques; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Liberation; Female; Ferric Compounds; Humans; Kinetics; Magnetite Nanoparticles; Models, Biological; Paclitaxel | 2019 |
B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Female; Humans; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |
PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA.
Topics: Animals; Breast; Breast Neoplasms; Cell Proliferation; Disease Progression; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Paclitaxel; Prognosis; Pseudogenes; RNA, Messenger; RNA, Small Interfering; Selenoprotein W; Up-Regulation | 2019 |
Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Paclitaxel; Phenylpropionates; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Adult; Aged; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Mastectomy; Mice; Middle Aged; Obesity; Paclitaxel; Primary Cell Culture; RNA, Small Interfering; Vault Ribonucleoprotein Particles | 2019 |
Bag-1 silencing enhanced chemotherapeutic drug-induced apoptosis in MCF-7 breast cancer cells affecting PI3K/Akt/mTOR and MAPK signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspases; Cell Cycle; Cell Survival; Cisplatin; Cyclin-Dependent Kinases; DNA-Binding Proteins; Down-Regulation; Enzyme Activation; Female; Gene Silencing; Humans; MAP Kinase Signaling System; MCF-7 Cells; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Up-Regulation | 2019 |
Mitochondrial transplantation regulates antitumour activity, chemoresistance and mitochondrial dynamics in breast cancer.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Energy Metabolism; Female; Humans; MCF-7 Cells; Mitochondria; Mitochondrial Dynamics; Oxidative Stress; Paclitaxel | 2019 |
A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endocytosis; Female; Humans; Lysosomes; Mice, Nude; Mice, SCID; Mucin-4; Paclitaxel; Protein Multimerization; Receptor, ErbB-2; Recombinant Proteins; Trastuzumab; Treatment Outcome | 2019 |
[Bevacizumab plus Paclitaxel Therapy Was Effective for Metastatic Breast Cancer with Dysphagia Due to Mediastinal Lymph Node Metastasis-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deglutition Disorders; Female; Humans; Lymph Nodes; Paclitaxel; Quality of Life | 2018 |
Determination of the target proteins in chemotherapy resistant breast cancer stem cell-like cells by protein array.
Topics: Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel; Protein Array Analysis | 2019 |
Beclin1 inhibition enhances paclitaxel‑mediated cytotoxicity in breast cancer in vitro and in vivo.
Topics: Apoptosis; Beclin-1; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Gene Knockdown Techniques; Humans; Paclitaxel; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2019 |
Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Breast Neoplasms; Case-Control Studies; Constitutive Androstane Receptor; Docetaxel; Female; Glucuronosyltransferase; Humans; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Peripheral Nervous System Diseases; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prognosis; Receptors, Cytoplasmic and Nuclear | 2019 |
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cost-Benefit Analysis; Female; France; Humans; Male; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Population Surveillance; Receptor, ErbB-2; Treatment Outcome | 2019 |
Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Delivery Systems; Drug Synergism; Female; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Lipids; MCF-7 Cells; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Xenograft Model Antitumor Assays | 2019 |
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
Topics: Animals; B7-H1 Antigen; Breast Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Chemokines; Drug Therapy; Female; Glutathione; Humans; Immunosuppressive Agents; Macrophages; Mice; Paclitaxel; Phenotype; Reactive Oxygen Species; RNA, Messenger; Triple Negative Breast Neoplasms; Tumor Microenvironment; Up-Regulation | 2019 |
Ambra1 inhibits paclitaxel-induced apoptosis in breast cancer cells by modulating the Bim/mitochondrial pathway.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Humans; Mitochondria; Paclitaxel | 2019 |
Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Furans; Golgi Apparatus; High-Throughput Screening Assays; Humans; Ketones; MCF-7 Cells; Microtubules; Paclitaxel; Tubulin Modulators; Vinblastine; Vincristine; Vindesine; Vinorelbine | 2019 |
α-Tocopherol Succinate-Anchored PEGylated Poly(amidoamine) Dendrimer for the Delivery of Paclitaxel: Assessment of in Vitro and in Vivo Therapeutic Efficacy.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Breast Neoplasms; Cell Proliferation; Dendrimers; Drug Carriers; Drug Delivery Systems; Female; Humans; In Vitro Techniques; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanoparticles; Nylons; Paclitaxel; Polyamines; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Topics: Albumins; Biomarkers; Breast Neoplasms; Caveolin 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel | 2019 |
Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cyclophosphamide; Doxorubicin; Echocardiography, Doppler; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Trastuzumab; Ventricular Dysfunction, Left | 2019 |
Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imidazoles; MAP Kinase Signaling System; Membrane Glycoproteins; Microfilament Proteins; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Pyridines | 2019 |
Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Marrow Cells; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Datasets as Topic; Disease Models, Animal; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Female; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Kaplan-Meier Estimate; MCF-7 Cells; Mice; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2019 |
Leukocyte-mimicking Pluronic-lipid nanovesicle hybrids inhibit the growth and metastasis of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Carriers; Female; Humans; Leukocytes; Lipid Bilayers; Lung Neoplasms; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred BALB C; Nanostructures; Neutrophils; Paclitaxel; Poloxalene | 2019 |
Antiproliferative activity of ionic liquid-graviola fruit extract against human breast cancer (MCF-7) cell lines using flow cytometry techniques.
Topics: Annona; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Fruit; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Ionic Liquids; MCF-7 Cells; Medicine, Traditional; Paclitaxel; Plant Extracts; Resting Phase, Cell Cycle | 2019 |
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer.
Topics: 3' Untranslated Regions; Adult; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; MicroRNAs; Middle Aged; Myeloid Differentiation Factor 88; Neoplasm Transplantation; Paclitaxel | 2019 |
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cohort Studies; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Grading; Oncogene Proteins, Fusion; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Recurrence; Transcription, Genetic | 2019 |
Penfluridol overcomes paclitaxel resistance in metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasm Staging; Paclitaxel; Penfluridol; Receptor, ErbB-2; Signal Transduction | 2019 |
Magnetophoretic Delivery of a Tumor-Priming Agent for Chemotherapy of Metastatic Murine Breast Cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Delivery Systems; Drug Liberation; Female; Ferric Compounds; Injections, Intravenous; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Paclitaxel; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Treatment Outcome; Tumor Burden; Tumor Microenvironment | 2019 |
Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells.
Topics: ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Terpenes | 2019 |
Reflections on My Life with Taxol.
Topics: Antineoplastic Agents, Phytogenic; Autobiographies as Topic; Binding Sites; Breast Neoplasms; Female; HeLa Cells; Humans; M Phase Cell Cycle Checkpoints; Microtubules; Paclitaxel | 2019 |
Targeted chemo-sonodynamic therapy treatment of breast tumours using ultrasound responsive microbubbles loaded with paclitaxel, doxorubicin and Rose Bengal.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Delivery Systems; Female; Humans; Mastectomy, Segmental; MCF-7 Cells; Mice; Mice, SCID; Microbubbles; Neoadjuvant Therapy; Paclitaxel; Rose Bengal; Ultrasonic Therapy; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2019 |
Synthesis and Antiproliferative Activities of Conjugates of Paclitaxel and Camptothecin with a Cyclic Cell-Penetrating Peptide.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Esterification; Female; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Paclitaxel; Peptides, Cyclic; Solid-Phase Synthesis Techniques | 2019 |
Unveiling novel targets of paclitaxel resistance by single molecule long-read RNA sequencing in breast cancer.
Topics: Alternative Splicing; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; RNA Isoforms; Sequence Analysis, RNA; Transcriptome | 2019 |
Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Autophagosomes; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterogeneous-Nuclear Ribonucleoprotein Group F-H; Humans; Inositol 1,4,5-Trisphosphate Receptors; Mice; Mice, Nude; Middle Aged; Paclitaxel; Protein Binding; RNA, Double-Stranded; RNA, Long Noncoding; RNA, Small Interfering; Signal Transduction; Survival Analysis; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
Sternal resection and reconstruction for metastasis due to breast cancer: the Marlex sandwich technique and implantation of a pedicled latissimus dorsi musculocutaneous flap.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Bone Substitutes; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Middle Aged; Myocutaneous Flap; Neoadjuvant Therapy; Paclitaxel; Plastic Surgery Procedures; Polypropylenes; Prosthesis Implantation; Ribs; Sternum; Superficial Back Muscles; Surgical Mesh; Tomography, X-Ray Computed | 2019 |
YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
Topics: 14-3-3 Proteins; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; MCF-7 Cells; Middle Aged; Neoplasm Grading; Nuclear Proteins; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Small Interfering; Snail Family Transcription Factors; Survival Analysis; Tumor Burden; Twist-Related Protein 1 | 2019 |
Inhibition of 3β-Hydroxysteroid Dehydrogenase Type 1 Suppresses Interleukin-6 in Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dihydrotestosterone; Drug Synergism; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interleukin-6; Multienzyme Complexes; Oligonucleotide Array Sequence Analysis; Paclitaxel; Progesterone Reductase; Recombinant Proteins; RNA, Small Interfering; Steroid Isomerases | 2019 |
Simultaneous controlled release of 5-FU, DOX and PTX from chitosan/PLA/5-FU/g-C3N4-DOX/g-C3N4-PTX triaxial nanofibers for breast cancer treatment in vitro.
Topics: Breast Neoplasms; Cell Adhesion; Cell Survival; Chitosan; Delayed-Action Preparations; Doxorubicin; Drug Liberation; Female; Fluorouracil; Graphite; Humans; Kinetics; MCF-7 Cells; Nanofibers; Nitriles; Paclitaxel; Polyesters; X-Ray Diffraction | 2019 |
Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Connective Tissue Growth Factor; Drug Resistance, Neoplasm; Female; HEK293 Cells; HeLa Cells; Humans; NIMA-Interacting Peptidylprolyl Isomerase; Paclitaxel; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Stability; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; YAP-Signaling Proteins | 2019 |
Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.
Topics: Azepines; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Paclitaxel and Alisertib in Recurrent Ovarian Cancer.
Topics: Azepines; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Bioactive Compounds in the Ethanol Extract of Marine Sponge\
Stylissa carteri Demonstrates Potential Anti-Cancer Activity in\
Breast Cancer Cells
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Doxorubicin; Drug Synergism; Ethanol; Female; Humans; Paclitaxel; Porifera; Tumor Cells, Cultured | 2019 |
Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Drug Synergism; Female; Humans; Hypoglycemic Agents; Mammary Neoplasms, Experimental; Metformin; Mice, Nude; Organic Cation Transport Proteins; Paclitaxel; Tumor Burden | 2019 |
Exosomes from M1-Polarized Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Exosomes; Immunologic Factors; Macrophage Activation; Macrophages; Mice; Paclitaxel; Treatment Outcome | 2019 |
LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 6; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Middle Aged; Paclitaxel; RNA, Long Noncoding | 2019 |
Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; Drug Liberation; Endocytosis; Female; Humans; Linoleic Acid; Mice; Mice, Inbred BALB C; NAD(P)H Dehydrogenase (Quinone); Nanoparticles; NIH 3T3 Cells; Optical Imaging; Oxidation-Reduction; Paclitaxel; Prodrugs; Rats, Sprague-Dawley; Reactive Oxygen Species; Tissue Distribution | 2019 |
Co-Delivery of Paclitaxel and PLK1-Targeted siRNA Using Aptamer-Functionalized Cationic Liposome for Synergistic Anti-Breast Cancer Effects
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Humans; Liposomes; Paclitaxel; RNA, Small Interfering | 2019 |
Retrospective comparison of two consecutive cohorts of adjuvant chemotherapy regimens of cyclophosphamide with either docetaxel or paclitaxel in older patients with early breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Paclitaxel; Retrospective Studies | 2019 |
Epigenetic inhibition of the tumor suppressor ARHI by light at night-induced circadian melatonin disruption mediates STAT3-driven paclitaxel resistance in breast cancer.
Topics: Animals; Breast Neoplasms; Circadian Rhythm; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Melatonin; Paclitaxel; Rats, Nude; rho GTP-Binding Proteins; STAT3 Transcription Factor; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Radiation-associated angiosarcoma with histological features reminiscent of Kaposi's sarcoma successfully treated by radiotherapy with paclitaxel.
Topics: Aged, 80 and over; Breast; Breast Neoplasms; Chemoradiotherapy; Diagnosis, Differential; Dose Fractionation, Radiation; Female; Hemangiosarcoma; Humans; Mastectomy, Segmental; Neoplasms, Radiation-Induced; Paclitaxel; Radiotherapy, Adjuvant; Sarcoma, Kaposi; Skin; Treatment Outcome | 2019 |
Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Oncologists; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Self Report; Young Adult | 2019 |
Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Developing Countries; Docetaxel; Female; Humans; Middle Aged; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; South Africa; United Kingdom | 2019 |
EZH2 Confers Sensitivity of Breast Cancer Cells to Taxol by Attenuating p21 Expression Epigenetically.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Female; Humans; MCF-7 Cells; Paclitaxel | 2019 |
Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytochromes c1; Disease-Free Survival; Estrogen Receptor alpha; Female; Glycolysis; Humans; Ki-67 Antigen; Lactic Acid; MCF-7 Cells; Middle Aged; Paclitaxel; Phenotype; Prognosis; RNA, Small Interfering; Time Factors | 2019 |
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Lymph Nodes; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2019 |
Therapeutic strategies to induce ERα in luminal breast cancer to enhance tamoxifen efficacy.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Everolimus; Female; Humans; Hydroxamic Acids; Indazoles; MCF-7 Cells; Paclitaxel; Sulfonamides; Tamoxifen; Tumor Cells, Cultured | 2019 |
MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Mice; MicroRNAs; Paclitaxel; RNA-Binding Proteins | 2019 |
Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Glutamic Acid; Humans; Ligands; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Oligopeptides; Paclitaxel; Tumor Cells, Cultured | 2019 |
Synergistic effect of paclitaxel and verapamil to overcome multi-drug resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; MCF-7 Cells; Paclitaxel; Vasodilator Agents; Verapamil | 2019 |
EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo.
Topics: Activating Transcription Factor 4; Amino Acid Transport System y+; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Female; Gene Expression Regulation, Neoplastic; Glycine Hydroxymethyltransferase; Heme Oxygenase-1; Heterografts; Humans; Paclitaxel; Protein Serine-Threonine Kinases; Signal Transduction | 2019 |
Water dynamics in MCF-7 breast cancer cells: a neutron scattering descriptive study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calorimetry, Differential Scanning; Diffusion; Humans; Hydrodynamics; Intracellular Space; MCF-7 Cells; Neutron Diffraction; Neutrons; Paclitaxel; Water | 2019 |
Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; RNA, Long Noncoding | 2019 |
Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Liberation; Ethylene Glycols; Female; Human Umbilical Vein Endothelial Cells; Humans; Hyaluronic Acid; Methacrylates; Mice; Nanoparticles; Paclitaxel; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2019 |
Ultrasound-mediated destruction of vascular endothelial growth factor (VEGF) targeted and paclitaxel loaded microbubbles for inhibition of human breast cancer cell MCF-7 proliferation.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Proliferation; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Microbubbles; Paclitaxel; Ultrasonic Waves; Vascular Endothelial Growth Factor A | 2019 |
Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Chemoradiotherapy, Adjuvant; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, SCID; Paclitaxel; Transplantation, Heterologous; Trastuzumab; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Differentially Expressed Mitochondrial Proteins in Human MCF7 Breast Cancer Cells Resistant to Paclitaxel.
Topics: Breast Neoplasms; Carbamoyl-Phosphate Synthase (Ammonia); Cell Fractionation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MCF-7 Cells; Mitochondria; Mitochondrial Proteins; Paclitaxel; Proteome; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2019 |
Paclitaxel-Loaded Folate-Coated pH-Sensitive Liposomes Enhance Cellular Uptake and Antitumor Activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Compounding; Female; Folic Acid; G1 Phase Cell Cycle Checkpoints; Humans; Hydrogen-Ion Concentration; Liposomes; Mice; Paclitaxel; Proof of Concept Study; Radionuclide Imaging; Solubility; Xenograft Model Antitumor Assays | 2019 |
Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2019 |
Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling.
Topics: Animals; Antiprotozoal Agents; Apoptosis; Atovaquone; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Mice, Inbred BALB C; Paclitaxel; Proteasome Endopeptidase Complex; Receptor, ErbB-2; Signal Transduction | 2019 |
Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis.
Topics: Animals; B7-H1 Antigen; Biomimetic Materials; Breast Neoplasms; Cations; Cell Death; Cell Line, Tumor; Endocytosis; Female; Gold; Humans; Hyaluronoglucosaminidase; Immunotherapy; Lung Neoplasms; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Paclitaxel; Particle Size; Peptides; RAW 264.7 Cells; Reactive Oxygen Species; Tissue Distribution | 2019 |
Metachronous cellular angiolipomas of the breast.
Topics: Aged; Angiolipoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Humans; Immunohistochemistry; Mastectomy, Modified Radical; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Ultrasonography, Mammary | 2019 |
Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy.
Topics: Adult; Aged; Albumins; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cohort Studies; Compression Bandages; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gloves, Surgical; Humans; Japan; Mastectomy, Segmental; Middle Aged; Paclitaxel; Patient Safety; Peripheral Nervous System Diseases; Primary Prevention; Prognosis; Prospective Studies; Statistics, Nonparametric; Treatment Outcome | 2019 |
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?
Topics: Albumins; Breast Neoplasms; Disease-Free Survival; Humans; Neoadjuvant Therapy; Paclitaxel; Standard of Care | 2019 |
High-Performance Worm-like Mn-Zn Ferrite Theranostic Nanoagents and the Application on Tumor Theranostics.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Ferric Compounds; Human Umbilical Vein Endothelial Cells; Humans; In Situ Nick-End Labeling; Magnetic Resonance Spectroscopy; Manganese; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Polyethylene Glycols; RAW 264.7 Cells; Spectroscopy, Near-Infrared; Theranostic Nanomedicine; Zinc | 2019 |
Redox dual-responsive paclitaxel-doxorubicin heterodimeric prodrug self-delivery nanoaggregates for more effective breast cancer synergistic combination chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; MCF-7 Cells; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Prodrugs; Xenograft Model Antitumor Assays | 2019 |
Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinases; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Paclitaxel; RNA, Long Noncoding | 2019 |
G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel.
Topics: Acetylation; Apoptosis; Biocatalysis; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; G-Protein-Coupled Receptor Kinase 3; G-Protein-Coupled Receptor Kinase 5; G-Protein-Coupled Receptor Kinases; HeLa Cells; Histone Deacetylase 6; Histones; Humans; MAP Kinase Signaling System; Paclitaxel; Phosphorylation; Phosphoserine; Protein Binding; Tubulin | 2019 |
Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Filgrastim; Humans; Middle Aged; Paclitaxel; Polyethylene Glycols | 2019 |
Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Keratin-18; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peptide Fragments; Predictive Value of Tests; Prognosis; Prospective Studies; Treatment Outcome | 2020 |
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclophosphamide; Dendritic Cells; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Lymphocytes, Tumor-Infiltrating; Middle Aged; Mitoxantrone; Monocytes; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Thiotepa; Vinblastine | 2019 |
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Black or African American; Breast Neoplasms; Cohort Studies; Cytochrome P-450 CYP2C8; Female; Genetic Variation; Humans; Middle Aged; Paclitaxel; Paraneoplastic Polyneuropathy; Risk Factors; Treatment Outcome; White People; Young Adult | 2013 |
Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calcium release in a dosage dependent manner.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Calcium; Cell Line, Tumor; Endoplasmic Reticulum; Female; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2 | 2013 |
Bilateral cystoid macular edema in a patient with taxane-based chemotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Macular Edema; Paclitaxel; Tomography, Optical Coherence; Visual Acuity | 2013 |
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Mitochondria; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor | 2012 |
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Clinical Trials, Phase III as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Farnesol; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols; Random Allocation; Rats; Salicylates | 2013 |
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases.
Topics: Alendronate; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Fluorescein-5-isothiocyanate; Human Umbilical Vein Endothelial Cells; Humans; Mice; Micelles; Neovascularization, Physiologic; Paclitaxel; Polyethylene Glycols; Tibia; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; ROC Curve; Trastuzumab | 2013 |
Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Breast Neoplasms; Dimethylallyltranstransferase; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Geranyltranstransferase; Humans; MCF-7 Cells; Paclitaxel | 2013 |
Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
Topics: Aged; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; gamma-Aminobutyric Acid; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Pregabalin; Retrospective Studies | 2013 |
Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Phenotype; Prohibitins | 2013 |
ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; NF-kappa B; Paclitaxel; Receptor, Notch1; RNA, Small Interfering; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Count; Cell Proliferation; Chromans; DNA Fragmentation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inhibitory Concentration 50; MCF-7 Cells; NF-kappa B p50 Subunit; Paclitaxel; Palm Oil; Plant Oils; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteolysis; Reagent Kits, Diagnostic; Signal Transduction; Tocotrienols; Vitamin E | 2013 |
SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
Topics: Acetylation; Animals; Biomarkers, Tumor; Breast Neoplasms; Cell Death; Cell Nucleus; Cell Survival; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Epirubicin; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Immunohistochemistry; Kaplan-Meier Estimate; MCF-7 Cells; Mice; Paclitaxel; Proportional Hazards Models; Sirtuins | 2013 |
An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle Checkpoints; Cell Survival; Chlorocebus aethiops; Combined Modality Therapy; Female; Genetic Vectors; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Simplexvirus; Tumor Burden; Vero Cells; Virus Replication; Xenograft Model Antitumor Assays | 2013 |
A pH-sensitive binary drug delivery system based on poly(caprolactone)-heparin conjugates.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Doxorubicin; Female; HeLa Cells; Heparin; Humans; Hydrogen-Ion Concentration; Paclitaxel; Polyesters; Uterine Cervical Neoplasms | 2014 |
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Monitoring; Female; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Precision Medicine; Taxoids | 2013 |
IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Female; Humans; Insulin Receptor Substrate Proteins; MCF-7 Cells; Neoplasm Grading; Neoplasm Invasiveness; Paclitaxel; Phosphorylation; Signal Transduction; STAT6 Transcription Factor; Transfection | 2013 |
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2013 |
Investigating contactless high frequency ultrasound microbeam stimulation for determination of invasion potential of breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Survival; Female; Humans; Intracellular Space; Neoplasm Invasiveness; Optical Imaging; Paclitaxel; Sound | 2013 |
New advances in taxane therapy: the next generation.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Polyglutamic Acid; Taxoids | 2004 |
Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Membrane Proteins; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering | 2013 |
Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Topics: Apoptosis; Breast Neoplasms; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; RNA Interference; src-Family Kinases; Tamoxifen | 2013 |
In vitro activity of Paclitaxel-loaded polymeric expansile nanoparticles in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; In Vitro Techniques; Nanoparticles; Paclitaxel; Polymers; Tumor Cells, Cultured | 2013 |
Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Secondary Prevention; Taxoids | 2014 |
Targeted therapies: HER2-positive breast cancer-sifting through many good options.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2013 |
Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemot
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosome Aberrations; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Survival Rate; Trastuzumab | 2013 |
Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; bcl-X Protein; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Female; Humans; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; TOR Serine-Threonine Kinases | 2013 |
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Middle Aged; Paclitaxel; Skin Diseases; Survival Rate; Taxoids | 2013 |
Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment?
Topics: Aryl Hydrocarbon Hydroxylases; Black or African American; Breast Neoplasms; Cytochrome P-450 CYP2C8; Female; Humans; Paclitaxel; Paraneoplastic Polyneuropathy; White People | 2013 |
CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; CARD Signaling Adaptor Proteins; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Gene Expression; Humans; Mammary Glands, Human; Middle Aged; NF-kappa B; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2013 |
TLR4 is a novel determinant of the response to paclitaxel in breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Autocrine Communication; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Cytokine; Toll-Like Receptor 4; Transcriptional Activation | 2013 |
Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Review Literature as Topic | 2013 |
Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Mitochondrial Proteins; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Weekly paclitaxel--an effective treatment for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome | 2013 |
MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.
Topics: Adult; Animals; Apoptosis; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Female; Humans; MicroRNAs; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel | 2013 |
Predicting drug responsiveness in human cancers using genetically engineered mice.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinazolines; Tumor Microenvironment | 2013 |
Functionalized nanospheres for targeted delivery of paclitaxel.
Topics: Antibodies, Immobilized; Antineoplastic Agents, Phytogenic; Biotinylation; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Nanospheres; Paclitaxel; Polyethylene Glycols; Streptavidin | 2013 |
Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients.
Topics: Anthracyclines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Body Mass Index; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Middle Aged; Obesity; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Survival; Tamoxifen; Taxoids; Treatment Outcome | 2013 |
A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukotriene Antagonists; Mice; Mice, Nude; Paclitaxel; Receptors, Leukotriene B4; RNA, Small Interfering; Tetrazoles; Xenograft Model Antitumor Assays | 2013 |
Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Energy Metabolism; Female; Humans; Hydrogen-Ion Concentration; Paclitaxel | 2013 |
Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA; Drug Delivery Systems; Female; Humans; Light; Models, Molecular; Nanoparticles; Organometallic Compounds; Paclitaxel; Silicon Dioxide | 2013 |
Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2013 |
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
Topics: Antimitotic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biomarkers; Biphenyl Compounds; Breast Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Heterocyclic Compounds, 2-Ring; Humans; MCF-7 Cells; Neoplasm Metastasis; Nitrophenols; Nocodazole; Paclitaxel; Piperazines; Prognosis; Pteridines; Sulfonamides | 2013 |
[A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Remission Induction | 2013 |
[A patient with primary breast cancer who responded remarkably well to neoadjuvant chemotherapy with FEC100 followed by Abraxane].
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel | 2013 |
[Usefulness of bevacizumab with paclitaxel for advanced breast cancer - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Needle; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Tomography, X-Ray Computed | 2013 |
[Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients].
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Tomography, X-Ray Computed | 2013 |
Coordinated regulation of β-tubulin isotypes and epithelial-to-mesenchymal transition protein ZEB1 in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Homeodomain Proteins; Humans; MicroRNAs; Paclitaxel; RNA, Messenger; Transcription Factors; Tubulin; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2013 |
CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.
Topics: AC133 Antigen; Animals; Antibodies, Immobilized; Antigens, CD; Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Recurrence, Local; Paclitaxel; Peptides | 2013 |
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Treatment Outcome | 2013 |
CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Furans; HSP90 Heat-Shock Proteins; Humans; Indazoles; Mice; Mice, SCID; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2013 |
Exploring a natural MDR reversal agent: potential of medicinal food supplement Nerium oleander leaf distillate.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biphenyl Compounds; Breast Neoplasms; Dietary Supplements; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Nerium; Paclitaxel; Picrates; Plant Extracts; Plant Leaves; Polymerase Chain Reaction; Vincristine | 2013 |
Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Nanoparticles; Paclitaxel; Polymers; Trastuzumab | 2013 |
Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Retrospective Studies; Taxoids | 2013 |
pH-responsive and charge shielded cationic micelle of poly(L-histidine)-block-short branched PEI for acidic cancer treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Female; Histidine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Polyethyleneimine | 2013 |
Regulation of tubulin expression by micro-RNAs: implications for drug resistance.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MCF-7 Cells; MicroRNAs; Microtubules; Paclitaxel; Protein Isoforms; Signal Transduction; Spindle Apparatus; Tubulin | 2013 |
Janus nanogels of PEGylated Taxol and PLGA-PEG-PLGA copolymer for cancer therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Therapy, Combination; Female; Half-Life; Mice; Mice, Inbred BALB C; Nanogels; Paclitaxel; Polyethylene Glycols; Polyethyleneimine; Polyglactin 910 | 2013 |
Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells--an in vitro and in silico study.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Amino Acid Sequence; Antineoplastic Agents; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Ellipticines; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Sequence Data; Neoplastic Stem Cells; Paclitaxel; Protein Binding; Protein Conformation; Retinal Dehydrogenase; Spheroids, Cellular; Tumor Cells, Cultured | 2014 |
[Efficacy and tolerability of controlled-release oxycodone against nab-paclitaxel-induced musculoskeletal pain in breast cancer patients].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Humans; Middle Aged; Musculoskeletal Pain; Oxycodone; Paclitaxel | 2013 |
Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Nude; Nanoconjugates; Paclitaxel | 2013 |
Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disulfiram; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Neoplastic Stem Cells; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Treatment Outcome | 2013 |
Paclitaxel loaded fibrinogen coated CdTe/ZnTe core shell nanoparticles for targeted imaging and drug delivery to breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cadmium Compounds; Cell Line, Tumor; Diffusion; Female; Fibrinogen; Humans; Mice; Nanocapsules; Paclitaxel; Tellurium; Zinc | 2013 |
A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients.
Topics: Adult; Aged; Alleles; Alopecia; Antineoplastic Agents; Breast Neoplasms; Calcium Channels; Case-Control Studies; Female; Genetic Association Studies; Genome-Wide Association Study; Humans; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Quality of Life; Risk; Severity of Illness Index; Tubulin Modulators | 2013 |
Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Nanoparticles; Paclitaxel | 2013 |
An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Female; Humans; Interleukins; Oncolytic Virotherapy; Paclitaxel; Prohibitins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Virus Replication | 2013 |
Spiro-bicyclo[2.2.2]octane derivatives as paclitaxel mimetics. Synthesis and toxicity evaluation in breast cancer cell lines.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Conformation; Molecular Mimicry; Octanes; Paclitaxel; Spiro Compounds; Structure-Activity Relationship | 2013 |
Carbon nanotube lipid drug approach for targeted delivery of a chemotherapy drug in a human breast cancer xenograft animal model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Delivery Systems; Fatty Alcohols; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanotubes, Carbon; Paclitaxel; Xenograft Model Antitumor Assays | 2013 |
[Synergistic effect of beta-elemene injection combined paclitaxel injection on human breast cancer MB-468 cells: an in vitro study].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Female; Humans; Paclitaxel; Sesquiterpenes | 2013 |
Taxane-induced pneumonitis: our clinical experience.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diagnosis, Differential; Dyspnea; Female; Humans; Paclitaxel; Pneumonia; Pneumonia, Bacterial; Tomography, X-Ray Computed | 2014 |
Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomimetic Materials; Breast Neoplasms; Cholesterol Esters; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Female; Humans; Lipoproteins, HDL; Male; MCF-7 Cells; Mice; Mice, Inbred ICR; Paclitaxel; Particle Size; Phosphatidylcholine-Sterol O-Acyltransferase; Tissue Distribution | 2013 |
Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Sentinel Lymph Node Biopsy; Survival Rate; Tumor Burden; Ultrasonography; Vinblastine; Vinorelbine; Young Adult | 2013 |
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paclitaxel; Polyethylene Glycols; Time Factors; Treatment Outcome; Tumor Burden | 2013 |
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Capecitabine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Interleukin-10; Mexico; Middle Aged; Paclitaxel; Polymorphism, Genetic; Spain; Tamoxifen | 2013 |
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Brain; Breast Neoplasms; Cannabidiol; Cell Line, Tumor; Cell Survival; Conditioning, Operant; Drug Synergism; Female; Humans; Memory; Mice; Mice, Inbred C57BL; Neuralgia; Neurons; Neuroprotective Agents; Paclitaxel; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists | 2014 |
Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2013 |
Reply to F. Ades.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2013 |
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Drug Costs; Female; France; Hospital Costs; Hospitals, Private; Hospitals, University; Humans; Kaplan-Meier Estimate; Middle Aged; National Health Programs; Neoplasm Metastasis; Paclitaxel; Public Sector; Retrospective Studies; Taxoids; Time Factors; Transportation; Trastuzumab; Treatment Outcome | 2014 |
Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Polyethyleneimine; RNA Interference; RNA, Small Interfering; STAT3 Transcription Factor | 2014 |
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Gene Knockdown Techniques; Humans; Inhibitor of Apoptosis Proteins; Mice; Paclitaxel; Receptor, ErbB-2; Receptor, ErbB-3; Survivin; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Down-regulation of tripartite-motif containing 22 expression in breast cancer is associated with a lack of p53-mediated induction.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Camptothecin; DNA Damage; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; MCF-7 Cells; Minor Histocompatibility Antigens; Paclitaxel; Promoter Regions, Genetic; Repressor Proteins; Topoisomerase I Inhibitors; Tripartite Motif Proteins; Tubulin Modulators; Tumor Suppressor Protein p53 | 2013 |
Six1 mediates resistance to paclitaxel in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Homeodomain Proteins; Humans; MCF-7 Cells; Paclitaxel; RNA, Small Interfering | 2013 |
Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Proteins; Paclitaxel; Recombinant Proteins; Xenograft Model Antitumor Assays | 2013 |
Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Proliferation; Cyclin B1; Female; Gene Expression; Gene Knockdown Techniques; Humans; Mammary Glands, Human; MAP Kinase Kinase Kinase 1; MCF-7 Cells; Paclitaxel; RNA Interference; RNA, Small Interfering | 2014 |
Design and evaluation of a PEGylated lipopeptide equipped with drug-interactive motifs as an improved drug carrier.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Screening Assays, Antitumor; Female; Humans; Lipopeptides; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Pharmacokinetics; Polyethylene Glycols | 2014 |
Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Tumor Cells, Cultured | 2013 |
Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Breast Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterogeneous-Nuclear Ribonucleoproteins; Histone Chaperones; Humans; MCF-7 Cells; Microfilament Proteins; Muscle Proteins; Nucleoside-Diphosphate Kinase; Paclitaxel; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transcription Factors | 2014 |
STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Adenocarcinoma; Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Drug Dosage Calculations; Estrenes; Female; Humans; Hyperalgesia; Lung Neoplasms; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Paclitaxel; Peripheral Nervous System Diseases; Rats; Survival Analysis; Transplantation, Heterologous | 2013 |
Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Female; Flow Cytometry; Gene Knockdown Techniques; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Osteopontin; Paclitaxel | 2014 |
Differential network analysis applied to preoperative breast cancer chemotherapy response.
Topics: Biomarkers, Pharmacological; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Neoadjuvant Therapy; Paclitaxel; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Software; Trans-Activators | 2013 |
Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Genes, MHC Class II; Humans; Middle Aged; Models, Biological; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Prognosis; Retrospective Studies; Transcriptome; Treatment Outcome | 2014 |
Cytokinetic study of MCF-7 cells treated with commercial and recombinant bromelain.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Bromelains; Cell Proliferation; Female; Flow Cytometry; Humans; Paclitaxel; Recombinant Proteins; Tumor Cells, Cultured | 2014 |
[A case of solitary adrenal metastasis from breast cancer successfully resected by laparoscopy].
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Laparoscopy; Middle Aged; Paclitaxel; Recurrence; Trastuzumab | 2013 |
[A case of facial nerve palsy induced by nab-paclitaxel].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Facial Paralysis; Female; Humans; Imidazoles; Middle Aged; Paclitaxel; Zoledronic Acid | 2013 |
[A case of recurrent breast cancer with carcinomatous pleurisy responding to bevacizumab and paclitaxel therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pleurisy; Recurrence | 2013 |
[Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2013 |
[A patient with thyroid cancer evaluated according to Response Evaluation Criteria in Solid Tumors during treatment for breast cancer recurrence in hepatic and cervical lymph nodes].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Carcinoma, Papillary; Diagnosis, Differential; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Neck; Paclitaxel; Recurrence; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Modified arabinoxylan from rice bran, MGN-3/biobran, sensitizes metastatic breast cancer cells to paclitaxel in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; In Vitro Techniques; Oryza; Paclitaxel; Tumor Cells, Cultured; Xylans | 2014 |
[Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence | 2014 |
Albumin acts like transforming growth factor β1 in microbubble-based drug delivery.
Topics: Albumins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Capsules; Cell Line, Tumor; High-Energy Shock Waves; Humans; Paclitaxel; Sonication; Transforming Growth Factor beta1; Treatment Outcome | 2014 |
Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Microtubules; Paclitaxel; Protein Isoforms; Taxoids; Time Factors; Tubulin; Tubulin Modulators | 2014 |
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Immunohistochemistry; MCF-7 Cells; Mice; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; RNA, Small Interfering; Tumor Suppressor Proteins | 2014 |
Inhibition of Notch1 increases paclitaxel sensitivity to human breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dipeptides; Humans; Immunohistochemistry; Paclitaxel; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2013 |
Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mice; Mice, Nude; Mitosis; Paclitaxel; Random Allocation; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2014 |
Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
Topics: Albumins; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic Resonance Angiography; Mice; Mice, SCID; Neovascularization, Pathologic; Paclitaxel; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Genetic Predisposition to Disease; Genotype; Humans; Middle Aged; Paclitaxel; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Receptors, Serotonin, 5-HT3; Young Adult | 2014 |
Neoadjuvant chemotherapy and pathologic response: a retrospective cohort.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Breast tumor subgroups reveal diverse clinical prognostic power.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2014 |
Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.
Topics: Animals; Antibodies; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin G; Indium Radioisotopes; MCF-7 Cells; Mice; Multimodal Imaging; Optical Imaging; Paclitaxel; Receptors, Urokinase Plasminogen Activator; Tamoxifen; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flow Cytometry; Humans; Immunoblotting; Luteolin; Mice; Mice, Nude; Paclitaxel; STAT3 Transcription Factor | 2014 |
Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Estrogens; Female; Humans; MCF-7 Cells; Paclitaxel | 2014 |
Paclitaxel induces apoptosis in breast cancer cells through different calcium--regulating mechanisms depending on external calcium conditions.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Calcium; Cell Line, Tumor; Egtazic Acid; Endoplasmic Reticulum; Female; Humans; Paclitaxel | 2014 |
Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel | 2014 |
[2-Deoxy-D-glucose combined with Taxol inhibits VEGF expression and induces apoptosis in orthotopically transplanted breast cancer in C3H mice].
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Deoxyglucose; Drug Synergism; Female; Mice; Mice, Inbred C3H; Paclitaxel; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Survival Rate | 2014 |
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Female; Genome-Wide Association Study; Humans; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Taxoids | 2014 |
Polymeric nanotheranostics for real-time non-invasive optical imaging of breast cancer progression and drug release.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diagnostic Imaging; Drug Carriers; Female; Fluorescent Dyes; Methacrylates; Mice; Mice, Inbred BALB C; Molecular Structure; Nanostructures; Paclitaxel | 2014 |
[Cancer, pain and treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Neoplasms; Paclitaxel; Pain; Pain Management; Paraneoplastic Polyneuropathy; Peripheral Nervous System Diseases | 2014 |
Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel; S-Phase Kinase-Associated Proteins; United States | 2014 |
Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Data Collection; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Patient Preference | 2014 |
Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles.
Topics: Adult; Aged; Breast Neoplasms; Cell Cycle Checkpoints; Cell Death; Chromosome Segregation; Dose-Response Relationship, Drug; Female; Humans; Interphase; Middle Aged; Mitosis; Paclitaxel; Spindle Apparatus; Tumor Burden; Tumor Cells, Cultured | 2014 |
Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Down-Regulation; Drug Delivery Systems; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Paclitaxel; Receptors, Somatostatin; RNA Interference; RNA, Small Interfering; Somatostatin; Vascular Endothelial Growth Factor A | 2014 |
Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2.
Topics: Acetophenones; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Microfilament Proteins; Multidrug Resistance-Associated Proteins; Muscle Proteins; Neoplasm Proteins; Paclitaxel; Promoter Regions, Genetic; Up-Regulation | 2014 |
Successful readministration of trastuzumab after severe immune reactions in two breast cancer patients.
Topics: Adult; Anaphylaxis; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchodilator Agents; Chlorpheniramine; Female; Histamine H1 Antagonists; Humans; Ipratropium; Methylprednisolone; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2014 |
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP2C8; Drug Resistance, Neoplasm; Female; Genetic Heterogeneity; Genetic Predisposition to Disease; Genotype; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Young Adult | 2014 |
Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer.
Topics: Adult; Affect; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cohort Studies; Computers, Handheld; Cyclophosphamide; Data Collection; Depression; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Sleep; Taxoids | 2014 |
Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Interactions; Drug Therapy, Combination; Female; Heterografts; Humans; Mice; Mice, Nude; Naphthoquinones; Paclitaxel | 2014 |
Lack of metformin effects on different molecular subtypes of breast cancer under normoglycemic conditions: an in vitro study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; MCF-7 Cells; Metformin; Paclitaxel | 2014 |
Development of polymeric nanopaclitaxel and comparison with free paclitaxel for effects on cell proliferation of MCF-7 and B16F0 carcinoma cells.
Topics: Acrylamides; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Delayed-Action Preparations; Drug Carriers; Humans; MCF-7 Cells; Melanoma, Experimental; Nanoparticles; Paclitaxel; Particle Size; Polymers | 2014 |
[The effect of LAMP2A shRNA on the resistance of breast cancer cells to paclitaxel].
Topics: Antineoplastic Agents; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Silencing; Genetic Vectors; Humans; Lentivirus; Lysosomal-Associated Membrane Protein 2; Paclitaxel; RNA, Small Interfering; Viral Load | 2014 |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Multicenter Studies as Topic; Outcome Assessment, Health Care; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Reproducibility of Results; Retrospective Studies | 2014 |
[Pneumothorax after treatment with bevacizumab-containing chemotherapy for breast cancer - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pneumothorax; Radionuclide Imaging; Tomography, X-Ray Computed | 2014 |
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Etoposide; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Receptors, Estrogen; RNA, Messenger; Tumor Suppressor Protein p53 | 2014 |
End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Microtubule-Associated Proteins; Microtubules; Paclitaxel; RNA Interference; RNA, Small Interfering | 2014 |
[Exudative onycholysis and acute bacterial paronychia related to BIBF-1120 and paclitaxel: response to topical therapy].
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Susceptibility; Female; Fusidic Acid; Hand; Humans; Indoles; Methylprednisolone; Middle Aged; Onycholysis; Paclitaxel; Paronychia; Staphylococcal Skin Infections | 2014 |
ERα directly activated the MDR1 transcription to increase paclitaxel-resistance of ERα-positive breast cancer cells in vitro and in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice; Paclitaxel; Transcription, Genetic | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Enriched variations in TEKT4 and breast cancer resistance to paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Microtubule Proteins; Microtubules; Middle Aged; Paclitaxel; Prognosis | 2014 |
(111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Indium Radioisotopes; Neoplasm Metastasis; Paclitaxel; Radionuclide Imaging; Receptor, ErbB-2; Trastuzumab | 2014 |
Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Surgical Wound Dehiscence; Thoracic Wall | 2015 |
Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Diet; Feeding Behavior; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Stearic Acids; Weight Gain | 2014 |
Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cathepsin B; Cell Line, Tumor; Cell Survival; Dendrimers; Female; Humans; Mice; Oligopeptides; Paclitaxel; Prodrugs; Up-Regulation | 2014 |
Predicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cohort Studies; Computational Biology; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Methotrexate; MicroRNAs; Models, Genetic; Models, Statistical; Models, Theoretical; Paclitaxel; ROC Curve; Treatment Outcome | 2014 |
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Docetaxel; Drug Administration Schedule; Female; Health Care Costs; Humans; Markov Chains; Monte Carlo Method; Neoplasm Staging; New Zealand; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids | 2014 |
Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult | 2014 |
Release modeling and comparison of nanoarchaeosomal, nanoliposomal and pegylated nanoliposomal carriers for paclitaxel.
Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Drug Carriers; Female; Humans; Inhibitory Concentration 50; Lipids; Liposomes; MCF-7 Cells; Nanostructures; Nanotechnology; Neural Networks, Computer; Paclitaxel; Polyethylene Glycols; Technology, Pharmaceutical; Time Factors | 2014 |
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Logistic Models; Medicare; Middle Aged; Neoplasm Staging; Paclitaxel; Registries; Risk Assessment; Risk Factors; SEER Program; Selection Bias; Taxoids; Texas; United States | 2014 |
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Topics: Alternative Splicing; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; High-Throughput Screening Assays; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Naphthoquinones; Paclitaxel; Receptor, ErbB-2; Survivin; Tumor Suppressor Protein p53 | 2014 |
Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MCF-7 Cells; Methotrexate; Multidrug Resistance-Associated Protein 2; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Taxoids; Tubulin | 2014 |
Differentially expressed proteins in human breast cancer cells sensitive and resistant to paclitaxel.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Female; HSP27 Heat-Shock Proteins; Humans; Keratin-18; Paclitaxel; Proteomics; Serpins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Fluorescent Antibody Technique; Humans; Immunohistochemistry; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Mifepristone; Nanoparticles; Paclitaxel; Protein Isoforms; Receptors, Progesterone; Xenograft Model Antitumor Assays | 2014 |
[A case of breast cancer treated with chemotherapy after resection of giant ovarian metastasis].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Palliative Care | 2014 |
Locally advanced breast cancer with bleeding - two cases effectively treated with bevacizumab plus weekly paclitaxel.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatal Outcome; Female; Hemorrhage; Humans; Middle Aged; Paclitaxel; Postmenopause | 2014 |
Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
Topics: Base Sequence; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Prostaglandin; Sequence Analysis, DNA; Tumor Suppressor Protein p53 | 2014 |
Twenty-twenty hindsight: an adjuvant breast cancer trial through the retrospectoscope.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel | 2014 |
Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mice, SCID; Multidrug Resistance-Associated Proteins; Neoplasm Transplantation; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Tissue Array Analysis; Tumor Burden | 2014 |
In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Female; Humans; Immunohistochemistry; Isoquinolines; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mice, Nude; Paclitaxel; Sulfonic Acids; Xenograft Model Antitumor Assays | 2014 |
Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Female; Humans; MCF-7 Cells; Mice, Nude; Nanoparticles; Ovarian Neoplasms; Ovary; Paclitaxel; Polyesters | 2014 |
Expression of human endogenous retrovirus env genes in the blood of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Endogenous Retroviruses; Female; Gene Expression; Gene Products, env; Humans; Middle Aged; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2014 |
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Suramin; Xenograft Model Antitumor Assays | 2014 |
PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel.
Topics: Animals; Breast Neoplasms; Disease Models, Animal; Drug Carriers; Farnesol; Female; HCT116 Cells; Hemolysis; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols; Salicylates | 2014 |
Vanished lung metastases.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Tomography, X-Ray Computed | 2015 |
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mifepristone; Oligonucleotide Array Sequence Analysis; Paclitaxel; Receptors, Glucocorticoid | 2014 |
Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polyethylene Glycols; Receptor, ErbB-2; Remission Induction; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
MDM2 molecular imaging for the prediction of chemotherapeutic sensitivity in human breast cancer xenograft.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Female; Heterografts; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Radiopharmaceuticals; Sodium Pertechnetate Tc 99m | 2014 |
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoplasm Metastasis; Odds Ratio; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer.
Topics: Adult; Aged; Albumins; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 2014 |
p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
Topics: Apoptosis; Autoantigens; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flow Cytometry; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Paclitaxel; RNA, Small Interfering; Tumor Stem Cell Assay | 2014 |
Oxygen-carbon nanotubes as a chemotherapy sensitizer for paclitaxel in breast cancer treatment.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Nanotubes, Carbon; Oxygen; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells.
Topics: Acetates; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; MAP Kinase Signaling System; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; ROC Curve; Treatment Outcome | 2014 |
Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?
Topics: Antineoplastic Agents, Phytogenic; Antioxidant Response Elements; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Neoplastic Stem Cells; NF-E2-Related Factor 2; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Up-Regulation | 2015 |
Thymoquinone restores radiation-induced TGF-β expression and abrogates EMT in chemoradiotherapy of breast cancer cells.
Topics: Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Transdifferentiation; Epithelial-Mesenchymal Transition; Female; Humans; Paclitaxel; Radiation; Radiotherapy; Transforming Growth Factor beta | 2015 |
Fungal taxol extracted from Cladosporium oxysporum induces apoptosis in T47D human breast cancer cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cladosporium; Cytochromes c; DNA Fragmentation; Down-Regulation; Female; Fungal Proteins; Humans; Mitochondria; NF-kappa B; Paclitaxel; Up-Regulation | 2014 |
Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Epithelial-Mesenchymal Transition; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ketones; Paclitaxel | 2014 |
Tumor lysis syndrome in metastatic breast cancer after a single dose of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Paclitaxel; Tomography, X-Ray Computed; Tumor Lysis Syndrome | 2015 |
Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Killer Cells, Natural; Lymphocyte Count; Monocytes; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2014 |
In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Mice; Micelles; Paclitaxel; Polyethylene Glycols | 2016 |
[Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Humans; Liposomes; MCF-7 Cells; Oligopeptides; Paclitaxel; Particle Size; Peptide Fragments; Spheroids, Cellular | 2014 |
Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
Topics: Animals; Breast Neoplasms; Cell Survival; Drug Carriers; Female; Humans; MCF-7 Cells; Mice; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polymers | 2014 |
Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutical; Drug Stability; Female; G2 Phase Cell Cycle Checkpoints; Half-Life; Humans; Injections, Intravenous; Lipids; Liposomes; Male; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Nanomedicine; Nanoparticles; Paclitaxel; Particle Size; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tissue Distribution | 2015 |
Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Brazil; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2016 |
Inspiration comes naturally.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Breast Neoplasms; Female; Humans; Paclitaxel | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Surface Extensions; Cytoskeleton; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Metastasis; Neoplastic Stem Cells; Paclitaxel; Protein Serine-Threonine Kinases; Rho Guanine Nucleotide Exchange Factors; rhoA GTP-Binding Protein; RNA Interference; Signal Transduction; Time Factors; Transfection; Tubulin; Tubulin Modulators | 2014 |
Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Neoplasm Metastasis; Paclitaxel; Toll-Like Receptor 4 | 2014 |
Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Cytochrome P-450 CYP2C8; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Paclitaxel; Resveratrol; Stilbenes; Survivin; Tumor Stem Cell Assay | 2014 |
Trametenolic acid B reverses multidrug resistance in breast cancer cells through regulating the expression level of P-glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Paclitaxel; Trametes; Triterpenes | 2014 |
+TIP EB1 downregulates paclitaxel‑induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Microtubule-Associated Proteins; Microtubules; Paclitaxel; RNA, Small Interfering | 2015 |
Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Breast Neoplasms; China; Delivery of Health Care; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Time and Motion Studies | 2016 |
Paclitaxel-induced hyposensitivity to nociceptive chemical stimulation in mice can be prevented by treatment with minocycline.
Topics: Animals; Breast Neoplasms; Female; Formaldehyde; Humans; Hyperalgesia; Mice; Minocycline; Nociception; Paclitaxel; Peripheral Nervous System Diseases | 2014 |
[Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence | 2014 |
Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; RNA, Neoplasm; Sequence Analysis, RNA; Transcription, Genetic | 2014 |
Synergistic dual-targeting hydrogel improves targeting and anticancer effect of Taxol in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Coloring Agents; Drug Carriers; Estrone; Female; Humans; Hydrogels; Indocyanine Green; MCF-7 Cells; Mice, Nude; Oligopeptides; Paclitaxel | 2014 |
Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.
Topics: Adult; Aged; Albumins; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteonectin; Paclitaxel; Prognosis; Prospective Studies; Survival Rate | 2014 |
Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel.
Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Biomarkers, Tumor; Breast Neoplasms; Caspase 8; Caspase 9; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Sensitivity and Specificity | 2014 |
Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Epistaxis; Female; Humans; Neoplasm Grading; Neoplasm Metastasis; Paclitaxel; Severity of Illness Index | 2014 |
Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Base Sequence; Breast Neoplasms; Cytochrome P-450 CYP3A; Enzyme Stability; Exome; Female; HEK293 Cells; Humans; Middle Aged; Molecular Sequence Data; Paclitaxel; Peripheral Nervous System Diseases; Sequence Analysis, DNA | 2015 |
Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance; Female; Gene Expression; Homeodomain Proteins; Humans; Nanog Homeobox Protein; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Phenotype; Spheroids, Cellular; Tumor Cells, Cultured | 2015 |
Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Topics: Animals; Antibodies; Antigens, CD; Antineoplastic Agents, Phytogenic; Breast Neoplasms; CD4 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Humans; Immunoglobulin Fab Fragments; Immunotherapy; Interferon-gamma; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Recurrence, Local; Oligodeoxyribonucleotides; Orexin Receptors; Paclitaxel; Spleen; Transplantation, Homologous; Tumor Necrosis Factor-alpha | 2014 |
A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Combinations; Drug Compounding; Endocytosis; Female; Humans; Lactic Acid; Lapatinib; Micelles; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Quinazolines; Receptor, ErbB-2; Solubility; Surface Properties | 2015 |
Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; RNA, Messenger; tau Proteins | 2014 |
Hormone therapy with tamoxifen reduces plasma levels of NT-B-type natriuretic peptide but does not change ventricular ejection fraction after chemotherapy in women with breast cancer.
Topics: Adult; Analysis of Variance; Antineoplastic Agents, Hormonal; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Echocardiography; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Natriuretic Peptide, Brain; Paclitaxel; Peptide Fragments; Statistics as Topic; Stroke Volume; Tamoxifen | 2015 |
Use of systemic therapy in the treatment of choroidal metastases from breast cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Choroid Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2014 |
Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy | 2015 |
Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Compounding; Emulsions; Female; Hemolysis; Humans; Macrophages; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Rats; Rats, Wistar; Th1 Cells; Th2 Cells; Vitamin E | 2014 |
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Germany; Hormones; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Survival Rate; Trastuzumab; Vinblastine; Vinorelbine; Young Adult | 2014 |
Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
Topics: Adjuvants, Pharmaceutic; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
SNPs and taxane toxicity in breast cancer patients.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cytochrome P-450 CYP3A; DNA-Binding Proteins; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endonucleases; Female; Genetic Association Studies; Humans; Middle Aged; Mucositis; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2014 |
An imagable and photothermal "Abraxane-like" nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors.
Topics: Albumin-Bound Paclitaxel; Albumins; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Therapy, Combination; Female; Humans; Indocyanine Green; Models, Molecular; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Phototherapy; Protein Conformation; Subcutaneous Tissue | 2015 |
Bu-zhong-yi-qi pill alleviate the chemotherapy-related fatigue in 4 T1 murine breast cancer model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Drugs, Chinese Herbal; Fatigue; Female; Humans; Magnoliopsida; Malondialdehyde; Mice; Paclitaxel; Phytotherapy; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2014 |
Should adjuvant weekly paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel | 2015 |
Reply to V. Amoroso et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel | 2015 |
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models | 2015 |
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Famotidine; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Prospective Studies; Retrospective Studies | 2015 |
Production of CNT-taxol-embedded PCL microspheres using an ammonium-based room temperature ionic liquid: as a sustained drug delivery system.
Topics: Ammonium Compounds; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; Humans; Ionic Liquids; MCF-7 Cells; Paclitaxel; Polyesters; Temperature | 2015 |
Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Breast Neoplasms; Drug Delivery Systems; Female; Folic Acid; Hep G2 Cells; Humans; Lipoproteins; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Serum Albumin, Bovine; Sialoglycoproteins | 2015 |
The use of α-conotoxin ImI to actualize the targeted delivery of paclitaxel micelles to α7 nAChR-overexpressing breast cancer.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Apoptosis; Breast Neoplasms; Calcium; Cell Line, Tumor; Computer Systems; Conotoxins; Drug Delivery Systems; Female; Humans; Injections, Intravenous; Mice, Nude; Micelles; Nanomedicine; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Toxicity Tests; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; DNA Primers; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Luciferases; MCF-7 Cells; Mice; Mice, Inbred BALB C; Microarray Analysis; MicroRNAs; Paclitaxel; Real-Time Polymerase Chain Reaction; Thrombospondin 1 | 2015 |
Differentially expressed proteins in human MCF-7 breast cancer cells sensitive and resistant to paclitaxel.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; ATPases Associated with Diverse Cellular Activities; Breast Neoplasms; Cathepsin D; Drug Resistance, Neoplasm; Female; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; LIM Domain Proteins; MCF-7 Cells; Molecular Chaperones; Paclitaxel; Proteasome Endopeptidase Complex; Proteome; Transcription Factors | 2015 |
C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Ceramides; Cisplatin; Docetaxel; Drug Synergism; ErbB Receptors; Female; HEK293 Cells; Humans; Hydroxamic Acids; MAP Kinase Kinase 4; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Paclitaxel; Proteolysis; Taxoids; TOR Serine-Threonine Kinases; Vorinostat | 2015 |
Dual HER2 inhibition and paclitaxel in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2015 |
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2015 |
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cisplatin; Female; Gene Dosage; Genetic Predisposition to Disease; Genotype; Humans; Middle Aged; Mortality; Neoplasm Grading; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Young Adult | 2015 |
[Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
Adjuvant treatment for HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2015 |
PRP4K is a HER2-regulated modifier of taxane sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Kaplan-Meier Estimate; MCF-7 Cells; Ovarian Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Receptor, ErbB-2; Ribonucleoprotein, U4-U6 Small Nuclear; Signal Transduction | 2015 |
Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Emergency Service, Hospital; Female; Hospitalization; Humans; Middle Aged; Ontario; Paclitaxel; Retrospective Studies; Taxoids | 2015 |
MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; RNA Interference; Semaphorins; Signal Transduction; Transfection | 2015 |
Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytoplasm; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Lipids; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oleic Acid; Paclitaxel; Phosphatidylethanolamines; Serum Albumin, Bovine | 2015 |
Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Glutaminase; Glutamine; Humans; Paclitaxel; RNA Interference; RNA, Small Interfering; Up-Regulation | 2015 |
Taxol produced from endophytic fungi induces apoptosis in human breast, cervical and ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; HeLa Cells; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Ovarian Neoplasms; Paclitaxel; Plant Bark; Taxus; Trees; Uterine Cervical Neoplasms; Xylariales | 2015 |
Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA Fragmentation; Drug Resistance, Neoplasm; Epithelial Cells; Female; G1 Phase; Humans; Neoplasm Proteins; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Suppressor Protein p53 | 2015 |
Linear-dendritic copolymer composed of polyethylene glycol and all-trans-retinoic acid as drug delivery platform for paclitaxel against breast cancer.
Topics: Animals; Breast Neoplasms; Dendrimers; Drug Delivery Systems; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Polyethylene Glycols; Rats; Tretinoin | 2015 |
An injectable, thermosensitive and multicompartment hydrogel for simultaneous encapsulation and independent release of a drug cocktail as an effective combination therapy platform.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Doxorubicin; Female; Humans; Hydrocarbons, Fluorinated; Hydrogel, Polyethylene Glycol Dimethacrylate; Injections; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Polyethylene Glycols | 2015 |
Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Female; Humans; Hydrogen-Ion Concentration; Mice; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Polyesters; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2015 |
Photoacoustic-based nanomedicine for cancer diagnosis and therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Melanins; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Photoacoustic Techniques; Serum Albumin; Theranostic Nanomedicine | 2015 |
Taxol-induced unfolded protein response activation in breast cancer cells exposed to hypoxia: ATF4 activation regulates autophagy and inhibits apoptosis.
Topics: Activating Transcription Factor 4; Apoptosis; Autophagy; Breast Neoplasms; Cell Hypoxia; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Transcriptional Activation; Tumor Cells, Cultured; Unfolded Protein Response | 2015 |
High tolerated paclitaxel nano-formulation delivered by poly (lactic-co-glycolic acid)-g-dextran micelles to efficient cancer therapy.
Topics: Animals; Breast Neoplasms; Dextrans; Drug Resistance, Neoplasm; Female; Lactic Acid; MCF-7 Cells; Mice; Micelles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Prognosis; PTEN Phosphohydrolase; Receptor, ErbB-2; tau Proteins; Trastuzumab | 2015 |
[Two cases of dural metastasis of breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemoradiotherapy; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Zoledronic Acid | 2014 |
[Clinical experience of nab-Paclitaxel treatment in 31 patients with breast cancer].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel | 2014 |
[A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Remission Induction | 2014 |
[A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow Neoplasms; Breast Neoplasms; Disseminated Intravascular Coagulation; Female; Humans; Paclitaxel | 2014 |
[Long-term control of stage IV breast and gastric cancer with combination therapy of S-1 and paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2014 |
New tools for the quantitative assessment of prodrug delivery and neurotoxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Delivery Systems; Heterografts; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 9; Mice; Motor Activity; Nociception; Paclitaxel; Prodrugs | 2015 |
Combined effects of anticancer drugs and new synthetic α-methylene-δ-lactones on MCF-7 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Fluorouracil; Humans; Lactones; MCF-7 Cells; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2015 |
Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2015 |
The GLU that holds cancer together: targeting GLUtamine transporters in breast cancer.
Topics: Amino Acid Transport System A; Amino Acid Transport System ASC; Animals; Antineoplastic Agents; Breast Neoplasms; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Female; Humans; Minor Histocompatibility Antigens; Paclitaxel; Ubiquitin-Protein Ligases | 2015 |
Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.
Topics: Amino Acid Transport System A; Amino Acid Transport System ASC; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Citric Acid Cycle; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Female; Humans; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Minor Histocompatibility Antigens; Paclitaxel; Proteolysis; Signal Transduction; TOR Serine-Threonine Kinases; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Topics: Acetophenones; Apoptosis; Breast Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; MCF-7 Cells; Oncogene Protein v-akt; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Transcription Factors | 2015 |
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Topics: Adult; Antineoplastic Agents, Immunological; Breast Neoplasms; Female; Humans; Meningeal Carcinomatosis; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2016 |
Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer.
Topics: Breast Neoplasms; Carcinoma; Cell Line, Tumor; Databases, Nucleic Acid; Female; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Neoplasm Staging; Paclitaxel; Phosphorylation; Radiation Tolerance; Receptors, Estrogen; Survivin | 2015 |
Hybrid paclitaxel and gold nanorod-loaded human serum albumin nanoparticles for simultaneous chemotherapeutic and photothermal therapy on 4T1 breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Gold; Humans; Mice; Nanocapsules; Nanotubes; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Serum Albumin; Treatment Outcome | 2015 |
Evaluation of chemotherapeutics in a three-dimensional breast cancer model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Epirubicin; Female; Humans; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway.
Topics: Breast Neoplasms; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Neoplasm Staging; Neoplastic Stem Cells; Paclitaxel; Receptor, Notch1; Signal Transduction | 2015 |
Synthesis and evaluation of single-wall carbon nanotube-paclitaxel-folic acid conjugate as an anti-cancer targeting agent.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Folic Acid; Humans; MCF-7 Cells; Nanotubes, Carbon; Paclitaxel | 2016 |
Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Delivery Systems; Female; Lactones; Mice; Nanoparticles; Paclitaxel; Polyethylene Glycols | 2015 |
Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Cyclophosphamide; Decision Support Techniques; Epirubicin; Estrogen Receptor alpha; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Tumor Burden; Young Adult | 2015 |
[A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel | 2015 |
[A case of stage IV breast cancer with improved cancer pain using bevacizumab and paclitaxel].
Topics: Aged; Analgesics, Opioid; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Neoplasm Staging; Oxycodone; Paclitaxel; Pain | 2015 |
Participation of non-neuronal muscarinic receptors in the effect of carbachol with paclitaxel on human breast adenocarcinoma cells. Roles of nitric oxide synthase and arginase.
Topics: Adenocarcinoma; Arginase; Breast Neoplasms; Carbachol; Cell Line, Tumor; Drug Therapy, Combination; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Nitric Oxide Synthase Type III; Paclitaxel; Receptors, Muscarinic | 2015 |
AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.
Topics: Animals; Breast Neoplasms; Carcinogenesis; Cell Movement; Cyclin-Dependent Kinase 5; Dose-Response Relationship, Drug; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Targeted Therapy; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Collagen Type I; Drug Delivery Systems; Endocytosis; Evans Blue; Female; Humans; Hydrogen-Ion Concentration; Liposomes; Losartan; Mice, Inbred BALB C; Paclitaxel; Particle Size; Static Electricity; Tissue Distribution; Treatment Outcome | 2015 |
Preparation of sodium cholate-based micelles through non-covalent ıbonding interaction and application as oral delivery systems for paclitaxel.
Topics: Acrylates; Animals; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Female; Humans; MCF-7 Cells; Micelles; Paclitaxel; Rats; Sodium Cholate | 2016 |
Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Phosphoglycerate Kinase; Prognosis | 2015 |
Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Case-Control Studies; Diabetes Complications; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors | 2015 |
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Doxorubicin; Female; Follow-Up Studies; Humans; Mesoderm; Metaplasia; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; PTEN Phosphohydrolase; Sirolimus; Survival Rate; Young Adult | 2015 |
Multiple myeloma or metastatic carcinoma breast: diagnostic dilemma in a case presenting with lytic bony lesion.
Topics: Antineoplastic Agents; Bone Marrow Examination; Bortezomib; Breast Neoplasms; Carcinoma, Ductal, Breast; Dexamethasone; Doxorubicin; Fatal Outcome; Female; Humans; Mastectomy; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Radiotherapy; Scapula | 2015 |
Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Caseins; Catechin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lactic Acid; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.
Topics: Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Transformation, Neoplastic; Dimerization; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Paclitaxel; Receptor, ErbB-2; Signal Transduction; Up-Regulation | 2015 |
miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Binding Sites; Breast Neoplasms; Caspases; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice; MicroRNAs; Paclitaxel; RNA, Messenger; Survivin; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chlorocebus aethiops; Drug Carriers; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Mice; Nanoparticles; Paclitaxel; Xenograft Model Antitumor Assays | 2015 |
Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; France; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Survivors; Taxoids; Trastuzumab | 2015 |
A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Topics: Aminobenzoates; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; MCF-7 Cells; Naphthalenes; Paclitaxel; Telomerase | 2015 |
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Humans; Middle Aged; Nanoparticles; Paclitaxel; Patient Compliance; Prospective Studies; Quality of Life; Receptor, ErbB-2; Taxoids | 2015 |
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.
Topics: Albumins; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Female; Human Umbilical Vein Endothelial Cells; Humans; Osteonectin; Paclitaxel; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2015 |
Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Liposomes; Nanostructures; Paclitaxel | 2015 |
Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cellular Senescence; Down-Regulation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kinesins; Mice; Mitosis; Paclitaxel; Promoter Regions, Genetic; Spindle Apparatus; Tumor Cells, Cultured | 2016 |
[Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer].
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Young Adult | 2015 |
[Long-term survival of a breast cancer patient with carcinomatous pleuritis and carcinomatous cardiac tamponade successfully treated by multimodality therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cardiac Tamponade; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Paclitaxel; Pleurisy; Triazoles | 2015 |
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Maytansine; MCF-7 Cells; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2015 |
[A case of Paclitaxel-induced peripheral neuropathy successfully treated with duloxetine].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Duloxetine Hydrochloride; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Thiophenes; Trastuzumab | 2015 |
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Trastuzumab; Tumor Burden | 2015 |
miR-520h is crucial for DAPK2 regulation and breast cancer progression.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Death-Associated Protein Kinases; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; RNA, Messenger | 2016 |
The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Doxorubicin; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lapatinib; Paclitaxel; Polychlorinated Dibenzodioxins; Quinazolines; Receptors, Aryl Hydrocarbon; RNA, Messenger; RNA, Small Interfering; Transcription Factor RelB; Ultraviolet Rays | 2015 |
Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aurora Kinase A; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Diffusion; Drug Combinations; Genetic Therapy; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Inbred BALB C; Micelles; Nanocapsules; Nanoconjugates; Oxidation-Reduction; Paclitaxel; RNA, Small Interfering; Treatment Outcome | 2015 |
Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Myristoylated Alanine-Rich C Kinase Substrate; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Phosphorylation; RNA Interference; RNA, Small Interfering; Tubulin Modulators | 2015 |
Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Interactions; Female; Hepatocytes; Humans; Immunohistochemistry; Lapatinib; Mice; Paclitaxel; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Diffusion; Humans; Lung Neoplasms; Mice; Mice, Nude; Nanocapsules; Paclitaxel; Particle Size; Polyethylene Glycols; Treatment Outcome | 2015 |
Anti-tumor activity of folate targeted biodegradable polymer-paclitaxel conjugate micelles on EMT-6 breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; Folic Acid; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols | 2015 |
APC selectively mediates response to chemotherapeutic agents in breast cancer.
Topics: Adenomatous Polyposis Coli Protein; Animals; Anthracenes; Apoptosis; Breast Neoplasms; Carcinogenesis; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Kinase 4; Mice; Mice, Transgenic; Paclitaxel; Pyrimidines; src-Family Kinases | 2015 |
Inflammation of actinic keratoses during paclitaxel chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Inflammation; Keratinocytes; Keratosis, Actinic; Paclitaxel | 2015 |
Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Humans; Inhibitory Concentration 50; Lactones; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Topics: Animals; Annexin A1; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2015 |
Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Phosphorylation; Predictive Value of Tests; Proportional Hazards Models; Stathmin; Treatment Outcome | 2015 |
Optimizing Adjuvant Taxanes in Early Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Taxoids | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Topics: Alleles; Amodiaquine; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Isoenzymes; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Risk Factors; Rosiglitazone; Substrate Specificity; Thiazolidinediones | 2015 |
Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Drug Carriers; Female; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Paclitaxel; Transplantation, Heterologous; Zinc Oxide | 2015 |
A microengineered pathophysiological model of early-stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Culture Techniques; Cell Survival; Cells, Cultured; Extracellular Matrix; Female; Genes, Reporter; Humans; Mammary Glands, Human; Microfluidic Analytical Techniques; Models, Biological; Paclitaxel; Tumor Microenvironment | 2015 |
MYC Is a Major Determinant of Mitotic Cell Fate.
Topics: Animals; Antimitotic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Early Growth Response Protein 1; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mitochondrial Membrane Transport Proteins; Mitosis; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc | 2015 |
Salvianolic acid A reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Caffeic Acids; Cell Movement; Cell Shape; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gene Knockdown Techniques; Humans; Lactates; MCF-7 Cells; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Paclitaxel | 2015 |
Concentration-dependent differential effects of an epothilone analog on cell cycle and p53 signaling.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinase Inhibitor p21; Epothilones; Female; Humans; MCF-7 Cells; Paclitaxel; Signal Transduction; Tumor Suppressor Protein p53 | 2015 |
Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; Lactones; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
[A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Paclitaxel and Bevacizumab after Radical Mastectomy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Mastectomy, Radical; Middle Aged; Paclitaxel; Pleurisy; Recurrence | 2015 |
The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CD24 Antigen; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Hyaluronan Receptors; Kaplan-Meier Estimate; Kruppel-Like Transcription Factors; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrans; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Spheroids, Cellular; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2015 |
Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Oxides; Paclitaxel; Phosphoprotein Phosphatases; Protein Phosphatase 2C; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Electron Transport Complex IV; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Microscopy, Confocal; Mitochondria; Mitochondrial Proton-Translocating ATPases; Paclitaxel; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen | 2015 |
Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; ErbB Receptors; Female; Fluorescent Dyes; Genes, Reporter; Humans; Hyaluronan Receptors; Micelles; Microscopy, Fluorescence; Nanomedicine; Neoplastic Stem Cells; Paclitaxel; Polyethylene Glycols; Polyglactin 910; Retinal Dehydrogenase | 2015 |
VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding, Competitive; Bortezomib; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Centrosome; Cyclin E; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Paclitaxel; Proteasome Inhibitors; Protein Binding; Quinolines; Sulfonamides; Tumor Stem Cell Assay; Ubiquitinated Proteins; Xenograft Model Antitumor Assays | 2015 |
Characterization of Dynamic Behaviour of MCF7 and MCF10A Cells in Ultrasonic Field Using Modal and Harmonic Analyses.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Astrocytes; Brain Neoplasms; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Computer Simulation; Elasticity; Female; Glioblastoma; Humans; MCF-7 Cells; Models, Biological; Paclitaxel; Ultrasonic Therapy; Ultrasonic Waves | 2015 |
Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Drug Administration Schedule; Drug Synergism; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2015 |
Association between Met-BDNF allele and vulnerability to paclitaxel-induced peripheral neuropathy.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Brain-Derived Neurotrophic Factor; Breast Neoplasms; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2015 |
A7RC peptide modified paclitaxel liposomes dually target breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Collagen; Drug Combinations; Drug Delivery Systems; Female; Humans; Laminin; Ligands; Liposomes; Oligopeptides; Paclitaxel; Proteoglycans; Xenograft Model Antitumor Assays | 2015 |
D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Lung Neoplasms; MCF-7 Cells; Mice; Micelles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Sarcoma; Succinates; Vitamin E | 2015 |
[A Case of Gastrointestinal Metastases of Breast Cancer Effectively Treated with Gemcitabine and Paclitaxel Combination Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Intestinal Obstruction; Middle Aged; Paclitaxel; Stomach Neoplasms | 2015 |
Histopathological improvement of scleroderma induced by paclitaxel in a patient with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Prednisolone; PUVA Therapy; Scleroderma, Localized | 2015 |
Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Albumins; Animals; Antineoplastic Agents; Apoptosis; Area Under Curve; beta-Cyclodextrins; Breast Neoplasms; Cell Proliferation; Cell Survival; Creatinine; Drug Carriers; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Injections, Intravenous; Kidney; Lipids; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Rats | 2015 |
BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cellular Senescence; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; In Situ Nick-End Labeling; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Pteridines; Signal Transduction; Tamoxifen; Up-Regulation; Vascular Endothelial Growth Factor A | 2015 |
Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Machine Learning; Paclitaxel; Support Vector Machine | 2016 |
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Middle Aged; Myocardial Infarction; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stroke Volume; Trastuzumab; Ventricular Function, Left; Young Adult | 2016 |
Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Breast Neoplasms; Cell Survival; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Paclitaxel; Peptide Elongation Factor 1; Signal Transduction | 2015 |
High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Male; MCF-7 Cells; Middle Aged; Paclitaxel; Prognosis; Survival Analysis; Up-Regulation; Young Adult | 2015 |
Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Brain Chemistry; Breast Neoplasms; Cattle; Drug Resistance, Neoplasm; Epothilones; Female; Humans; MCF-7 Cells; Microtubules; Molecular Structure; Paclitaxel; Protein Binding; Protein Isoforms; RNA Interference; RNA, Small Interfering; Structure-Activity Relationship; Transfection; Tubulin; Tubulin Modulators | 2015 |
High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
Topics: Aldehyde Dehydrogenase; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Breast Neoplasms; CD24 Antigen; Cell Adhesion Molecules; Comet Assay; DNA Damage; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Female; Flow Cytometry; Humans; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Spheroids, Cellular; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Cycle; Cell Proliferation; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Female; Flow Cytometry; Gastrointestinal Diseases; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Rats, Sprague-Dawley; Serum Albumin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Paclitaxel; Tryptophan; Tumor Cells, Cultured | 2015 |
Experimental design of a liposomal lipid system: A potential strategy for paclitaxel-based breast cancer treatment.
Topics: Breast Neoplasms; Humans; Lipids; Liposomes; Paclitaxel | 2015 |
Septin cooperation with tubulin polyglutamylation contributes to cancer cell adaptation to taxanes.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Microtubules; Paclitaxel; Polyglutamic Acid; Septins; Tubulin | 2015 |
Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Movement; Cell Proliferation; Combined Modality Therapy; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Kruppel-Like Factor 4; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transforming Growth Factor beta; Tumor Cells, Cultured; Wound Healing; Xenograft Model Antitumor Assays | 2015 |
[Effect of down-regulation of Oct4 gene on biological characteristics of MDA-MB-231 breast cancer stem cells].
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Culture Media, Serum-Free; Down-Regulation; Female; Gene Knockdown Techniques; Humans; Mice; Neoplasm Invasiveness; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Transfection; Tumor Burden | 2015 |
[Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Liposomes; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2015 |
Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells.
Topics: Animals; Breast Neoplasms; Drug Delivery Systems; Female; Ferric Compounds; Humans; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Peptides; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Survival; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Compounding; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Hydrogels; Injections, Intralesional; Injections, Intravenous; Lapatinib; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanotechnology; Paclitaxel; Poloxamer; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Solubility; Technology, Pharmaceutical; Temperature; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
[Examination of the Response Rate of Paclitaxel and Bevacizumab Therapy for Metastatic Advanced Breast Cancer According to the Lymphopenia Grade].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Humans; Lymphopenia; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2015 |
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Interleukin-1 Receptor-Associated Kinases; Mice; Mice, SCID; Neoplasm Metastasis; Paclitaxel; Phosphorylation | 2015 |
Anti-Proliferative Effects of Hesa-A on Human Cancer Cells with Different Metastatic Potential.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Plant Preparations; Prostatic Neoplasms | 2015 |
Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Up-Regulation | 2015 |
Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Receptors, Interleukin-8A; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Stroke Volume; Time Factors; Trastuzumab; Ventricular Function, Left | 2015 |
Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Density Conservation Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Drug Resistance, Neoplasm; Female; Humans; Mitosis; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride | 2015 |
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Trastuzumab; Treatment Outcome; United States; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult | 2016 |
Soybean agglutinin-conjugated silver nanoparticles nanocarriers in the treatment of breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Survival; Drug Carriers; Dynamic Light Scattering; Humans; Hydrodynamics; Hydrogen-Ion Concentration; Metal Nanoparticles; Microscopy, Electron, Transmission; Paclitaxel; Plant Lectins; Polyethylene Glycols; Silver Compounds; Soybean Proteins; Spectrum Analysis, Raman | 2016 |
Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
[Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells].
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; bcl-2-Associated X Protein; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Up-Regulation | 2015 |
Mitochondrial mass and DNA repair in breast cancer stem cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 3; Humans; Mitochondria; Neoplastic Stem Cells; Paclitaxel; Wnt1 Protein | 2015 |
Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Mice; Middle Aged; Myeloid Differentiation Factor 88; Neoplasm Grading; Neoplasm Staging; NF-kappa B; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
S-1 versus taxanes for HER2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Liver Neoplasms; Oxonic Acid; Paclitaxel; Taxoids; Tegafur | 2016 |
Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Drug Screening Assays, Antitumor; Drug Stability; Humans; Lactic Acid; MCF-7 Cells; Nanoparticles; Paclitaxel; Polyethyleneimine; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Static Electricity; Trastuzumab | 2016 |
Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug.
Topics: Animals; Breast Neoplasms; Drug Carriers; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peptides; Xenograft Model Antitumor Assays | 2015 |
Sperm-associated antigen 9 overexpression correlates with poor prognosis and insensitive to Taxol treatment in breast cancer.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis | 2016 |
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2015 |
Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor.
Topics: Breast Neoplasms; Cell Line, Tumor; Ceramides; Doxorubicin; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Hyperglycemia; Paclitaxel | 2016 |
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Centromere; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2016 |
Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colchicine; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Toxicity Tests; Tubulin | 2016 |
The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Insurance Claim Review; Insurance, Health; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Time-to-Treatment; United States | 2015 |
MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Sectional Studies; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Iran; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life | 2015 |
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Collagen Type I; Drug Delivery Systems; Hydrogen-Ion Concentration; Liposomes; Losartan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Paclitaxel; Protein-Lysine 6-Oxidase | 2016 |
The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell line.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Liberation; Female; Humans; Immunoblotting; MCF-7 Cells; Micelles; Microscopy, Electron, Transmission; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Polyvinyls; Solubility; Vitamin E | 2016 |
Effect of lipoic acid combined with paclitaxel on breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Humans; MCF-7 Cells; NF-kappa B; Paclitaxel; Thioctic Acid | 2015 |
Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Ligands; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Phenotype; Receptors, Interleukin-8B; Time Factors | 2016 |
Knockdown of microRNA-29a Changes the Expression of Heat Shock Proteins in Breast Carcinoma MCF-7 Cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; RNA Interference | 2016 |
Role of the Intravoxel Incoherent Motion Diffusion Weighted Imaging in the Pre-treatment Prediction and Early Response Monitoring to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests | 2016 |
Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model.
Topics: Animals; Antibodies; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Female; Humans; Hyaluronan Receptors; Hydrazones; Mice, Inbred BALB C; Mice, Nude; Mucin-1; Nanotubes, Carbon; Neoplastic Stem Cells; Paclitaxel; Pyrans; Tumor Burden | 2016 |
Combination between Taxol-Encapsulated Liposomes and Eruca sativa Seed Extract Suppresses Mammary Tumors in Female Rats Induced by 7,12 Dimethylbenz(α)anthracene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Brassicaceae; Breast Neoplasms; Cell Proliferation; Cyclooxygenase 2; Female; Glutathione Transferase; Inflammation; Lipid Peroxidation; Liposomes; Mammary Neoplasms, Experimental; NF-kappa B; Paclitaxel; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Rats; Seeds; Superoxide Dismutase | 2016 |
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bone Marrow Cells; Breast Neoplasms; CD11b Antigen; Endothelial Cells; Female; Humans; Interleukin-10; Middle Aged; Monocytes; Paclitaxel; Pilot Projects; Proto-Oncogene Proteins c-kit; Stem Cells | 2016 |
Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Diagnostic Imaging; Drug Delivery Systems; Drug Liberation; Endosomes; Female; Glycerol; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrogen-Ion Concentration; MCF-7 Cells; Mice, Nude; Micelles; Paclitaxel; Prodrugs; Proton Magnetic Resonance Spectroscopy; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Standard of Care | 2016 |
L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Canavanine; Cell Survival; Cisplatin; Doxorubicin; Drug Synergism; Female; Fluorouracil; Humans; MCF-7 Cells; Paclitaxel; Vinblastine | 2017 |
Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Female; Folic Acid; Folic Acid Transporters; Glycerol; Ligands; Mice, Inbred BALB C; Micelles; Nanomedicine; Nanoparticles; Paclitaxel; Polyurethanes; Receptors, TNF-Related Apoptosis-Inducing Ligand; Solubility; Technology, Pharmaceutical; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden | 2016 |
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Humans; Magnetic Resonance Imaging; Mice; Paclitaxel; Survival Analysis; Treatment Outcome | 2016 |
Downregulation of importin-9 protects MCF-7 cells against apoptosis induced by the combination of garlic-derived alliin and paclitaxel.
Topics: Actins; Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cofilin 1; Cysteine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Garlic; Humans; Karyopherins; MCF-7 Cells; Paclitaxel | 2016 |
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Cyclophosphamide; Doxorubicin; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib | 2016 |
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.
Topics: Breast Neoplasms; Chromosome Segregation; Female; HCT116 Cells; HeLa Cells; Humans; M Phase Cell Cycle Checkpoints; Mad2 Proteins; MicroRNAs; Mitosis; Neoplasms; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Transfection | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Chemoradiotherapy; Craniotomy; Cyclophosphamide; Decanoic Acids; Disease-Free Survival; Doxorubicin; Female; Humans; Leuprolide; Nitriles; Paclitaxel; Polyesters; Radiosurgery; Receptors, Estrogen; Triazoles; Young Adult | 2016 |
Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Drug Resistance, Multiple; Female; Liposomes; Mice, Inbred BALB C; Paclitaxel; Resveratrol; Stilbenes; Treatment Outcome; Tubulin Modulators | 2016 |
Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Follow-Up Studies; Humans; Liposomes; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2016 |
Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Humans; Hyaluronic Acid; Liposomes; Mice, Inbred BALB C; Paclitaxel; Tumor Burden | 2016 |
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Germany; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2016 |
Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Drug Carriers; Female; Gonadotropin-Releasing Hormone; Humans; Lactic Acid; MCF-7 Cells; Mice, Nude; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2016 |
ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Promoter Regions, Genetic; Survival Rate; Tumor Cells, Cultured | 2016 |
Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Macular Edema; Optic Nerve Diseases; Paclitaxel | 2016 |
Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate | 2016 |
MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lymphatic Metastasis; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured | 2016 |
Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Therapy, Combination; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; NIH 3T3 Cells; Paclitaxel; Pyrimidines; Receptors, Endothelin; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Monitoring Apoptosis of Breast Cancer Xenograft After Paclitaxel Treatment With 99mTc-Labeled Duramycin SPECT/CT.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bacteriocins; Breast Neoplasms; Cell Line, Tumor; Feasibility Studies; Female; Humans; Mice; Organotechnetium Compounds; Paclitaxel; Phosphatidylethanolamines; Radiopharmaceuticals; Random Allocation; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Neoplasms, Second Primary; Paclitaxel; Prognosis; Quinazolines | 2016 |
An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Elastin; Electrophoresis, Polyacrylamide Gel; Female; Humans; Immune Tolerance; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Peptides; Pyrans; Tissue Distribution | 2016 |
[Breast Cancer with Multiple Liver Metastases Successfully Treated with Capecitabine Monotherapy after Failure of Combination Therapy Comprising Bevacizumab and Paclitaxel].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Female; Humans; Liver Neoplasms; Paclitaxel; Salvage Therapy | 2016 |
A New Carbon Nanotube-Based Breast Cancer Drug Delivery System: Preparation and In Vitro Analysis Using Paclitaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Drug Compounding; Drug Stability; Humans; Intracellular Space; MCF-7 Cells; Nanotubes, Carbon; Paclitaxel | 2015 |
Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clone Cells; Doxorubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Recurrence; Ribonucleoproteins, Small Nuclear; RNA, Messenger; Single-Cell Analysis; Spliceosomes; Transcriptome | 2016 |
New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydroxybutyrates; Injections, Intraperitoneal; Mammary Neoplasms, Experimental; Mice; Molecular Structure; Paclitaxel; Particle Size; Polyesters; Prohibitins; Structure-Activity Relationship; Surface Properties; Tumor Cells, Cultured | 2017 |
Low-Frequency Ultrasound Enhances Paclitaxel Efficacy in EMT6 Subcutaneous Tumors in Balb/c Mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Synergism; Electrochemotherapy; Female; Mice; Mice, Inbred BALB C; Paclitaxel; Radiation Dosage; Treatment Outcome; Ultrasonic Therapy | 2016 |
The role of Iron on breast cancer stem-like cells.
Topics: Breast Neoplasms; Cell Count; Cell Line, Tumor; Cell Survival; Deferoxamine; Epithelial Cells; Female; Humans; Iron; Iron Chelating Agents; Neoplastic Stem Cells; Paclitaxel; Receptor, ErbB-2 | 2016 |
Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Breast Neoplasms; Dogs; Female; Madin Darby Canine Kidney Cells; Paclitaxel; Panax; Plant Extracts; Rats | 2017 |
Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Breast Neoplasms; CCAAT-Enhancer-Binding Proteins; DEAD-box RNA Helicases; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Mitogen-Activated Protein Kinase 14; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Ribonuclease III; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Least-Squares Analysis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pharmacogenetics; Receptor, ErbB-2; ROC Curve; Spermidine; Tandem Mass Spectrometry; Trastuzumab; Treatment Outcome; Tryptophan; Young Adult | 2016 |
PFKFB3 potentially contributes to paclitaxel resistance in breast cancer cells through TLR4 activation by stimulating lactate production.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Silencing; Glycolysis; Humans; Inhibitory Concentration 50; Lactic Acid; Paclitaxel; Phosphofructokinase-2; Signal Transduction; Toll-Like Receptor 4 | 2016 |
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Recurrence; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Vitamin E-Oligo(methyl diglycol l-glutamate) as a Biocompatible and Functional Surfactant for Facile Preparation of Active Tumor-Targeting PLGA Nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Delivery Systems; Female; Glutamic Acid; Glycols; Humans; Lactic Acid; Mice; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface-Active Agents; Tumor Cells, Cultured; Vitamin E; Xenograft Model Antitumor Assays | 2016 |
[A Case of Drug-Induced Lung Injury Associated with Paclitaxel plus Bevacizumab Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Lung Injury; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pulse Therapy, Drug; Respiration Disorders; Steroids | 2016 |
Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Epithelial-Mesenchymal Transition; Estrogens; Female; Gene Expression; Gene Expression Profiling; Humans; Inflammation Mediators; Liver; Liver Neoplasms; Mice; Neoplasm Invasiveness; NF-kappa B; Paclitaxel | 2016 |
Neuroglobin overexpression induced by the 17β-Estradiol-Estrogen receptor-α Pathway reduces the sensitivity of MCF-7 Breast cancer cell to paclitaxel.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Globins; Humans; MCF-7 Cells; Nerve Tissue Proteins; Neuroglobin; Paclitaxel; Signal Transduction | 2016 |
A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Carriers; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Ovarian Neoplasms; Oxazoles; Paclitaxel | 2016 |
Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Postural Balance; Taxoids | 2016 |
Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lipoproteins, HDL; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Tumor Burden | 2016 |
Synergistic Chemo-Photothermal Therapy of Breast Cancer by Mesenchymal Stem Cell-Encapsulated Yolk-Shell GNR@HPMO-PTX Nanospheres.
Topics: Animals; Breast Neoplasms; Drug Delivery Systems; Female; Gold; Humans; Hyperthermia, Induced; MCF-7 Cells; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoshells; Nanospheres; Nanotubes; Organosilicon Compounds; Paclitaxel; Phototherapy; Random Allocation; Xenograft Model Antitumor Assays | 2016 |
miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Cytoprotection; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; Treatment Outcome; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
Multifunctional near-infrared light-triggered biodegradable micelles for chemo- and photo-thermal combination therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzyl Alcohols; Breast Neoplasms; Chitosan; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Compounding; Drug Stability; Female; Fluorescent Dyes; Humans; Indoles; Infrared Rays; Integrin alphaVbeta3; MCF-7 Cells; Mice, Nude; Micelles; Paclitaxel; Peptides, Cyclic; Photochemotherapy; Photolysis; Propionates; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Combinations; Drug Delivery Systems; Drug Synergism; Female; Glycerol; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; Polyethylene Glycols; Polyglutamic Acid; Polymers | 2017 |
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Exome; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genomic Instability; High-Throughput Screening Assays; Humans; Imidazoles; MCF-7 Cells; Naphthoquinones; Paclitaxel; Sequence Analysis, DNA; Small Molecule Libraries; Tamoxifen | 2016 |
[Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Lipids; MCF-7 Cells; Nanoparticles; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Small Interfering | 2016 |
Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Female; Humans; Kaplan-Meier Estimate; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference | 2016 |
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2016 |
Molecular-level effects of eribulin and paclitaxel on breast cancer based on differential co-expression network analysis.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Female; Furans; Gene Regulatory Networks; Humans; Ketones; Paclitaxel; Protein Interaction Maps; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcriptome | 2016 |
[Liver Atrophy and Failure Associated with Paclitaxel and Bevacizumab Combination Therapy for Metastatic Breast Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Bevacizumab; Breast Neoplasms; Female; Humans; Liver; Liver Failure; Liver Neoplasms; Middle Aged; Paclitaxel | 2016 |
Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Trastuzumab | 2017 |
Effect of anti-cancer drugs on microglia in patient-derived breast cancer xenografted mouse models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Mice; Mice, Nude; Microglia; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Impairment of the executive function in breast cancer patients receiving chemotherapy treatment: a functional MRI study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Breast Neoplasms; Case-Control Studies; Cognitive Dysfunction; Cyclophosphamide; Doxorubicin; Executive Function; Female; Frontal Lobe; Functional Neuroimaging; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Middle Aged; Neural Pathways; Neuropsychological Tests; Paclitaxel; Trail Making Test | 2017 |
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2016 |
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Italy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Surveys and Questionnaires | 2016 |
Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphocyte Count; Middle Aged; Paclitaxel; Platelet Count | 2016 |
Dramatic Response to Carboplatin, Paclitaxel, and Radiation in a Patient With Malignant Myoepithelioma of the Breast.
Topics: Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carboplatin; Dose Fractionation, Radiation; Fatigue; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Myoepithelioma; Paclitaxel; Radiotherapy, Adjuvant; Rare Diseases; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss | 2016 |
Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoradiotherapy; Female; Flow Cytometry; Humans; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Middle Aged; Paclitaxel; T-Lymphocytes; Trastuzumab | 2016 |
[A Case of a Corneal Disorder after Breast Cancer Treatment with Nab-paclitaxel].
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Corneal Diseases; Female; Humans; Middle Aged; Paclitaxel; Trastuzumab; Visual Acuity | 2016 |
The Urtica dioica extract enhances sensitivity of paclitaxel drug to MDA-MB-468 breast cancer cells.
Topics: Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinases; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Nuclear Proteins; Paclitaxel; Plant Extracts; Protein-Tyrosine Kinases; RNA, Messenger; Snail Family Transcription Factors; Urtica dioica; Wound Healing | 2016 |
Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disease Models, Animal; Female; Humans; Interferon-beta; Mice; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Tumor Burden; Virus Replication; Xenograft Model Antitumor Assays | 2016 |
Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Cell Survival; Culture Media, Serum-Free; Digitoxin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Energy Metabolism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MCF-7 Cells; Models, Biological; Neoplasm Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Time Factors | 2017 |
Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients.
Topics: Breast Neoplasms; Case-Control Studies; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Paclitaxel; Polymorphism, Genetic; RNA, Messenger | 2016 |
Chemotherapy enhances tumor vascularization via Notch signaling-mediated formation of tumor-derived endothelium in breast cancer.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Bridged-Ring Compounds; Doxorubicin; Endothelium, Vascular; Female; Humans; MCF-7 Cells; Mice, Nude; Microvessels; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptors, Notch; RNA Interference; Signal Transduction; Specific Pathogen-Free Organisms; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Drug Carriers; Drug Synergism; Extracellular Fluid; Humans; Injections, Intravenous; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Nanoparticles; Paclitaxel; Rats; Rats, Sprague-Dawley; Stilbenes; Tandem Mass Spectrometry; Time Factors; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
Bioresponsive and fluorescent hyaluronic acid-iodixanol nanogels for targeted X-ray computed tomography imaging and chemotherapy of breast tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line; Drug Carriers; Drug Liberation; Female; Fluorescent Dyes; Humans; Hyaluronic Acid; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Tomography, X-Ray Computed; Triiodobenzoic Acids; Tumor Burden | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Incidence; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pulmonary Embolism; Retrospective Studies; Risk Factors; Sentinel Lymph Node Biopsy; Stroke; Taxoids; Thromboembolism; Venous Thrombosis | 2016 |
Same Data; Different Interpretations.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cetuximab; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Drug Approval; Everolimus; Evidence-Based Medicine; Female; Humans; Lung Neoplasms; Medical Oncology; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Reproducibility of Results; Time Factors; Treatment Outcome | 2016 |
A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
Topics: Adult; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Gene Expression; Humans; Ki-67 Antigen; Logistic Models; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Nomograms; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; ROC Curve; Sentinel Lymph Node Biopsy; Trastuzumab; Tumor Burden | 2016 |
Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cardiomyopathies; Case-Control Studies; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Heart Failure; Humans; Immunoglobulin E; Immunoglobulin G; Middle Aged; Paclitaxel; Proteomics; Stroke Volume; Trastuzumab; Ventricular Dysfunction, Left; Young Adult | 2016 |
Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Cytoprotection; Disease-Free Survival; Female; GTP-Binding Proteins; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-pim-1; Triple Negative Breast Neoplasms; Tubulin | 2016 |
Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; DNA; Drug Carriers; Drug Delivery Systems; Female; Gene Transfer Techniques; Humans; Hydrogen-Ion Concentration; Ligands; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Chemistry, Pharmaceutical; Cholesterol; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Emulsions; Female; Flavanones; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oxidative Stress; Paclitaxel; Phospholipids; Xenograft Model Antitumor Assays | 2016 |
Exceedingly Higher co-loading of Curcumin and Paclitaxel onto Polymer-functionalized Reduced Graphene Oxide for Highly Potent Synergistic Anticancer Treatment.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Graphite; Humans; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Membrane Potential, Mitochondrial; Nanoparticles; Oxides; Paclitaxel; Polymers; Reactive Oxygen Species | 2016 |
Electrochemical approach for monitoring the effect of anti tubulin drugs on breast cancer cells based on silicon nanograss electrodes.
Topics: Breast Neoplasms; Electrodes; Female; Humans; MCF-7 Cells; Mebendazole; Nanotechnology; Paclitaxel; Silicon; Tubulin | 2016 |
Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; History, 20th Century; Humans; Mice; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2016 |
Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases.
Topics: Breast Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Imatinib Mesylate; Paclitaxel; Primary Cell Culture; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2016 |
Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel | 2016 |
Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells.
Topics: Adsorption; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Humans; Nanoparticles; Paclitaxel; Particle Size; Receptor, ErbB-2; Trastuzumab | 2016 |
Chemotherapy dosing in achondroplastic dwarfism: a case report and review of literature.
Topics: Achondroplasia; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel | 2016 |
Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle Proteins; Charcot-Marie-Tooth Disease; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Nerve Tissue; Paclitaxel; Peripheral Nervous System Diseases | 2016 |
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Practice Patterns, Physicians'; Retrospective Studies; Young Adult | 2016 |
Juglone loaded poloxamer 188/phospholipid mixed micelles evaluated in vitro and in vivo in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Humans; Micelles; Naphthoquinones; Paclitaxel; Phospholipids; Poloxamer | 2016 |
Hematopoietic PBX-Interaction Protein Promotes Breast Cancer Sensitivity to Paclitaxel Through a Microtubule-Dependent Mechanism.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Intracellular Signaling Peptides and Proteins; Microtubules; Paclitaxel; Tubulin | 2016 |
Effect of curcumin and paclitaxel on breast carcinogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Carcinogenesis; Caspase 3; Caspase 8; Cell Line, Tumor; Curcumin; Cyclin D1; Female; Humans; MCF-7 Cells; NF-KappaB Inhibitor alpha; Paclitaxel; Proto-Oncogene Proteins p21(ras); rhoA GTP-Binding Protein; STAT3 Transcription Factor; Tumor Suppressor Protein p53 | 2016 |
Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Breast; Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Epithelial Cell Adhesion Molecule; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Rats, Sprague-Dawley | 2017 |
CD44 Receptor Targeting and Endosomal pH-Sensitive Dual Functional Hyaluronic Acid Micelles for Intracellular Paclitaxel Delivery.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Liberation; Endocytosis; Endosomes; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrogen-Ion Concentration; Micelles; Paclitaxel; Tumor Cells, Cultured | 2016 |
Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Breast Neoplasms; Case-Control Studies; Cyclophosphamide; Diastole; Doxorubicin; Echocardiography; Female; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Systole; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Humans; Imidazoles; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Isoindoles; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoconjugates; Paclitaxel; Polyethylene Glycols; Prodrugs; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Sequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier.
Topics: Adsorption; Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Survival; Chitosan; Disulfides; Drug Compounding; Drug Liberation; Female; Gene Transfer Techniques; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Nanoconjugates; Nanomedicine; Oxazines; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Static Electricity; Stearic Acids; Surface Properties; Time Factors; Transfection | 2016 |
Anti-HER2 CD4
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Enzyme-Linked Immunospot Assay; Female; Humans; Immunity, Cellular; Magnetic Resonance Imaging; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Peptide Fragments; Predictive Value of Tests; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Th1 Cells; Trastuzumab; Young Adult | 2017 |
Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.
Topics: Animals; Apoptosis; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Nuclear Receptor Coactivator 3; Paclitaxel; RNA, Messenger; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Neutralization of TNFα in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
Topics: Animals; Antibodies, Neutralizing; Antibody Affinity; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cadherins; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Female; Humans; Lung Neoplasms; Male; MCF-7 Cells; Mice, Inbred BALB C; Paclitaxel; Rats, Sprague-Dawley; Signal Transduction; Single-Domain Antibodies; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2017 |
Dual pH-sensitive micelles with charge-switch for controlling cellular uptake and drug release to treat metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Compounding; Emulsions; Female; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Nanocapsules; Paclitaxel; Static Electricity; Treatment Outcome | 2017 |
Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Delivery Systems; Female; Humans; Liposomes; Mice; Mice, Nude; Oligopeptides; Paclitaxel; Vitamin E | 2017 |
Immune Complex-Mediated Proliferative Glomerulonephritis Induced by Paclitaxel Treatment.
Topics: Adult; Antigen-Antibody Complex; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Glomerulonephritis; Humans; Immune Complex Diseases; Paclitaxel | 2016 |
LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Membrane Proteins; Mitochondrial Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Long Noncoding; Signal Transduction; Transcription, Genetic; Transfection | 2016 |
PET/CT with
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Trastuzumab; Young Adult | 2017 |
In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development.
Topics: Algorithms; Area Under Curve; Biomarkers; Breast Neoplasms; Computer Simulation; Female; Gene Expression Profiling; Humans; Models, Biological; Paclitaxel; Reproducibility of Results; ROC Curve; Transcriptome | 2016 |
SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity.
Topics: Angelica; Astragalus Plant; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Paclitaxel; Plant Extracts; Trichosanthes | 2017 |
Inhibition of breast cancer metastasis by paclitaxel-loaded pH responsive poly(β-amino ester) copolymer micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Coumarins; Drug Carriers; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polymers | 2017 |
An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer.
Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Carbamates; Computational Biology; Drug Repositioning; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Molecular Docking Simulation; Mutation; Paclitaxel; Polypharmacology; Proline; Tubulin; Valine | 2017 |
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Maintenance Chemotherapy; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2017 |
DENSpm overcame Bcl-2 mediated resistance against Paclitaxel treatment in MCF-7 breast cancer cells via activating polyamine catabolic machinery.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Paclitaxel; Polyamines; Proto-Oncogene Proteins c-bcl-2; Spermine | 2016 |
Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Collagen; Drug Delivery Systems; Female; Hydrogen-Ion Concentration; Liposomes; Losartan; Mice; Mice, Inbred BALB C; Paclitaxel; Peptides | 2018 |
Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Female; Gene Amplification; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome | 2017 |
Evaluation of function and recovery of adipose-derived stem cells after exposure to paclitaxel.
Topics: Abdominal Fat; Adipose Tissue; Adult; Adult Stem Cells; Animals; Apoptosis; Breast Neoplasms; Cell Differentiation; Cell Movement; Cell Survival; Cells, Cultured; Female; Humans; Male; Osteogenesis; Paclitaxel; Rats; Rats, Sprague-Dawley; Recovery of Function; Wound Healing | 2017 |
Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzylisoquinolines; Breast Neoplasms; Caco-2 Cells; Cell Cycle; Drug Resistance, Neoplasm; Female; Glycerol; Humans; Male; MCF-7 Cells; Mice; Mice, Nude; Micelles; Neoplasm Transplantation; Paclitaxel; Particle Size; Rats; Rats, Sprague-Dawley; Solubility | 2017 |
[A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Biweekly Paclitaxel and Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel; Pleurisy; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Chickens; Drug Resistance, Neoplasm; Female; Humans; Mice; Microtubules; Paclitaxel; Protein Binding; Protein Isoforms; Salmon; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Tubulin; Xenopus laevis | 2017 |
Reply to Barroso-Sousa R et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Neoplasms; Paclitaxel; Retrospective Studies | 2017 |
Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer.
Topics: Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Carriers; Female; Humans; MCF-7 Cells; Molecular Targeted Therapy; Mucin-1; Nanoparticles; Paclitaxel; Serum Albumin | 2016 |
Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; HeLa Cells; Humans; Hyaluronic Acid; Lipids; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Phosphatidylethanolamines; Poloxamer; Tissue Distribution; Uterine Cervical Neoplasms | 2017 |
Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; MAP Kinase Signaling System; Paclitaxel; Silybin; Silymarin; STAT3 Transcription Factor | 2017 |
Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; DNA, Neoplasm; Fatal Outcome; Female; Frameshift Mutation; Genes, p53; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant | 2017 |
Stress granule-associated protein G3BP2 regulates breast tumor initiation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carcinogenesis; Carrier Proteins; Cell Line, Tumor; Cytoplasmic Granules; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred NOD; Mice, SCID; Nanog Homeobox Protein; Neoplasm Proteins; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; RNA Interference; RNA-Binding Proteins; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Small Molecule Libraries | 2017 |
Internal Mammary Misfortune.
Topics: Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Dose Fractionation, Radiation; Female; Humans; Lymphatic Irradiation; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Radiosurgery; Radiotherapy, Adjuvant; Sternum | 2017 |
[Evaluation of Bevacizumab in Combination with Weekly Paclitaxel for Locally Advanced Breast Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Treatment Outcome | 2016 |
[A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywith Immediate Reconstruction Using a Tissue Expander after Nab-Paclitaxel Combined with Chemotherapy].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Mammaplasty; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nipples; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2016 |
[A Case of Axillary Arterial Bleeding after Axillary Metastatic Lymph Node Necrosis during Treatment with Paclitaxel and Bevacizumabfor Breast Cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Fatal Outcome; Female; Hemorrhage; Humans; Lymph Nodes; Lymphatic Metastasis; Necrosis; Paclitaxel | 2016 |
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Phenotype; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Rate; Time Factors; Trastuzumab; Tumor Burden | 2017 |
Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers.
Topics: Animals; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Serum Albumin, Human | 2017 |
Exogenous vitamin C boosts the antitumor efficacy of paclitaxel containing reduction-sensitive shell-sheddable micelles in vivo.
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Breast Neoplasms; Carbocyanines; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Drug Synergism; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasm Transplantation; Oxidation-Reduction; Paclitaxel; Polyesters; Polyethylene Glycols; Succinimides; Surface Properties | 2017 |
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2017 |
STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; Tamoxifen; Tumor Suppressor Protein p53 | 2017 |
Physicochemical characterization of chitosan-hyaluronan-coated solid lipid nanoparticles for the targeted delivery of paclitaxel: a proof-of-concept study in breast cancer cells.
Topics: Breast Neoplasms; Cell Survival; Chitosan; Drug Delivery Systems; Drug Stability; Female; Humans; Hyaluronic Acid; Lipids; MCF-7 Cells; Nanoparticles; Paclitaxel | 2017 |
Enhanced apoptotic and anticancer potential of paclitaxel loaded biodegradable nanoparticles based on chitosan.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Delivery Systems; Female; Humans; Nanoparticles; Paclitaxel; Particle Size; Polyethylene Glycols | 2017 |
PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Centromere; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Editing; Gene Knockout Techniques; Genomic Instability; Genotype; Humans; Mice; Mutation; Paclitaxel; Phenotype; Tumor Suppressor Protein p53 | 2017 |
Se/Ru-Decorated Porous Metal-Organic Framework Nanoparticles for The Delivery of Pooled siRNAs to Reversing Multidrug Resistance in Taxol-Resistant Breast Cancer Cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Metal-Organic Frameworks; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Phosphatidylinositol 3-Kinases; RNA, Small Interfering; Ruthenium; Selenium | 2017 |
A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Excipients; Female; Glucose Transport Proteins, Facilitative; Humans; Micelles; Nanomedicine; Paclitaxel; Polyethylene Glycols; Polyvinyls | 2017 |
SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspase 9; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Spheroids, Cellular; Taxoids; Tumor Cells, Cultured | 2017 |
Harnessing the BMP signaling pathway to control the formation of cancer stem cells by effects on epithelial-to-mesenchymal transition.
Topics: Activin Receptors; Activin Receptors, Type I; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Morphogenetic Protein 7; Bone Morphogenetic Protein Receptors; Bone Morphogenetic Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Neoplastic Stem Cells; Paclitaxel; Peptides; Signal Transduction | 2017 |
Investigational drug combined with chemotherapy improves response in patients with BRCA-mutant breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carboplatin; Drugs, Investigational; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mutation; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors | 2017 |
Immodin and its immune system supportive role in paclitaxel therapy of 4T1 mouse breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Immune System; Leukocytes; Lymphocytes; Lymphokines; Mice; Mice, Inbred BALB C; Monocytes; Paclitaxel | 2017 |
Enhanced stability of microtubules contributes in the development of colchicine resistance in MCF-7 cells.
Topics: Acetylation; Breast Neoplasms; Colchicine; Drug Resistance, Neoplasm; Glutamic Acid; Humans; MCF-7 Cells; Microtubules; Mutation; Paclitaxel; Tubulin | 2017 |
Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Dynamic Light Scattering; Female; Humans; Lactic Acid; Mice, Nude; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Thyroxine; Xenograft Model Antitumor Assays | 2017 |
Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disease Models, Animal; Iodine Radioisotopes; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Serum Albumin; Serum Albumin, Human; Treatment Outcome | 2017 |
Personalized chemotherapy selection for breast cancer using gene expression profiles.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Therapy; Female; Humans; Male; Models, Biological; Paclitaxel; Precision Medicine; Taxoids; Transcriptome | 2017 |
Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Liposomes; Mice; Paclitaxel; Receptor, ErbB-2; Sirolimus; Trastuzumab | 2017 |
Biodegradable polymeric micelles coencapsulating paclitaxel and honokiol: a strategy for breast cancer therapy in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biocompatible Materials; Biphenyl Compounds; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Liberation; Endocytosis; Female; HEK293 Cells; Humans; Immunohistochemistry; Lignans; Mice, Inbred BALB C; Micelles; Paclitaxel; Particle Size; Polymers | 2017 |
Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Calcium-Binding Proteins; Cell Movement; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Middle Aged; Neoplasm Invasiveness; Neuronal Calcium-Sensor Proteins; Neuropeptides; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2017 |
Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast; Breast Neoplasms; Down-Regulation; Female; Humans; Imidazoles; Membrane Proteins; Mice; Mice, SCID; Neoplastic Stem Cells; Nerve Tissue Proteins; Paclitaxel; Piperazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2017 |
Ferritin Decorated PLGA/Paclitaxel Loaded Nanoparticles Endowed with an Enhanced Toxicity Toward MCF-7 Breast Tumor Cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Contrast Media; Drug Carriers; Drug Delivery Systems; Ferritins; Humans; Magnetic Resonance Imaging; MCF-7 Cells; Nanoparticles; Paclitaxel; Polyglycolic Acid; Scavenger Receptors, Class A | 2017 |
Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Neoplastic Stem Cells; NF-kappa B; Oxyquinoline; Paclitaxel; Xenograft Model Antitumor Assays | 2009 |
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Black or African American; Breast Neoplasms; Female; Humans; Logistic Models; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Failure; White People | 2008 |
Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.
Topics: Albumins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Humans; Luciferases; Mice; Models, Biological; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2008 |
[Adjuvant chemotherapy for breast cancer and targeted therapies].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Taxoids; Trastuzumab | 2008 |
FDG positron emission tomography imaging of drug-induced pneumonitis.
Topics: Aged; Anxiety Disorders; Brain Neoplasms; Breast Neoplasms; Dibenzothiazepines; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pneumonia; Positron-Emission Tomography; Quetiapine Fumarate; Sensitivity and Specificity; Tomography, X-Ray Computed; Whole Body Imaging | 2008 |
Paclitaxel-induced sickle cell crisis.
Topics: Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Black or African American; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pain | 2008 |
Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Chromosome Mapping; Cluster Analysis; Drug Resistance, Neoplasm; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Genomics; Humans; Microarray Analysis; Multidrug Resistance-Associated Proteins; Paclitaxel; RNA Interference; Taxoids | 2008 |
Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Polymorphism, Genetic | 2008 |
High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2008 |
Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Axilla; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; False Negative Reactions; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Sentinel Lymph Node Biopsy; Taxoids | 2008 |
Yes-associated protein (YAP) functions as a tumor suppressor in breast.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anoikis; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cytoprotection; Drug Resistance; Epithelium; Gene Deletion; Gene Silencing; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Paclitaxel; Phosphoproteins; Proto-Oncogene Mas; Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2008 |
[New treatment approaches in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2008 |
[A case of locally advanced breast cancer successfully treated by pre-operative systemic therapy using paclitaxel and trastuzumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immunotherapy; Mammography; Middle Aged; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Trastuzumab | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Paclitaxel; Proportional Hazards Models; Taxoids | 2008 |
Ethnicity and breast cancer research.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Ethnicity; Female; Genotype; Humans; Paclitaxel; Polymorphism, Genetic; Trastuzumab | 2008 |
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Taxoids | 2008 |
[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Doxorubicin; Fluorodeoxyglucose F18; Fluorouracil; Humans; Paclitaxel; Thymidine; Thymidine Kinase | 2008 |
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2008 |
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.
Topics: Agar; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; DNA, Complementary; Doxorubicin; Humans; Immunohistochemistry; Paclitaxel; Prolactin; Receptors, Prolactin; Reverse Transcriptase Polymerase Chain Reaction; Rhodamines; RNA, Messenger | 2008 |
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Topics: Androgen Receptor Antagonists; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Female; Gene Targeting; Humans; Male; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Sirolimus; Transforming Growth Factor alpha | 2009 |
Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Basigin; Breast Neoplasms; Cell Line, Tumor; Collagenases; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Proteasome Endopeptidase Complex; Protein Binding; RNA, Messenger; RNA, Small Interfering; Ubiquitin Thiolesterase; Ubiquitination | 2008 |
NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Basic Helix-Loop-Helix Transcription Factors; bcl-X Protein; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; E1A-Associated p300 Protein; Epithelial Cells; Female; Humans; Immunoprecipitation; Luciferases; Neoplasm Proteins; Paclitaxel; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-abl; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53 | 2008 |
Trastuzumab in inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Inflammation; Paclitaxel; Polyethylene Glycols; Trastuzumab | 2008 |
Redefining the target again: chemotherapeutics as vascular disrupting agents?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemokine CXCL12; Drug Interactions; Drug Therapy, Combination; Endothelial Cells; Female; Humans; Mice; Neoplasms; Neoplasms, Experimental; Paclitaxel; Stem Cells; Vascular Endothelial Growth Factor A | 2008 |
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Therapy, Combination; Endothelial Cells; Female; Gemcitabine; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Stem Cells; Tumor Burden; Vascular Endothelial Growth Factor A | 2008 |
Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2008 |
Trastuzumab-induced hepatotoxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Drug Monitoring; Female; Humans; Liver Function Tests; Middle Aged; Paclitaxel; Trastuzumab | 2008 |
Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cisplatin; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Paclitaxel; RNA, Messenger | 2008 |
A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biological Assay; Blood Coagulation; Breast Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fibrin; Fluorouracil; Humans; Methotrexate; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Thrombin; Vincristine | 2008 |
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Mastectomy; Neoplasms, Second Primary; Paclitaxel; Receptor, ErbB-2; Remission Induction; Skin Neoplasms; Survival Rate; Trastuzumab | 2008 |
[Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Time Factors | 2008 |
[Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Humans; Japan; Lymphatic Metastasis; Middle Aged; Paclitaxel; Time Factors | 2008 |
[A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Trastuzumab; Treatment Failure | 2008 |
[A case of recurrent breast cancer with bone marrow metastasis treated with weekly paclitaxel therapy].
Topics: Adult; Biomarkers, Tumor; Biopsy; Bone Marrow Neoplasms; Breast Neoplasms; Female; Humans; Paclitaxel; Radiography; Recurrence; Time Factors; Treatment Failure | 2008 |
[A case of advanced accessory breast cancer effectively treated with trastuzumab and paclitaxel].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Trastuzumab | 2008 |
Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Fatal Outcome; Female; Hemoptysis; Humans; Neoplasm Metastasis; Paclitaxel | 2008 |
hTERT gene expression levels and telomerase activity in drug resistant MCF-7 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids; Telomerase; Tumor Cells, Cultured; Vincristine | 2008 |
Targeting of albumin-embedded paclitaxel nanoparticles to tumors.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Immunohistochemistry; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Peptides | 2009 |
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Breast Neoplasms; Drug Resistance, Neoplasm; Genes, bcl-2; Humans; Mitochondria; Models, Biological; Nitrophenols; Paclitaxel; Piperazines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2008 |
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Breast Neoplasms; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Frequency; Genotype; Haplotypes; Homozygote; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Regression Analysis; Survival Analysis; Treatment Outcome | 2009 |
Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Skin Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2008 |
Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CHO Cells; Cricetinae; Cricetulus; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Immunoglobulin Fragments; Interleukin-2; Macaca fascicularis; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Recombinant Fusion Proteins; Stromal Cells; Tenascin; Tissue Distribution; Tumor Cells, Cultured | 2008 |
Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Tissue Distribution; Toremifene; Treatment Outcome | 2009 |
Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Affinity Labels; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dimerization; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Molecular Structure; Paclitaxel; Prazosin; Quinine; Rhodamine 123; Verapamil | 2009 |
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Remission Induction; Retrospective Studies; Tamoxifen; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Cystoid macular edema secondary to albumin-bound paclitaxel therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Macular Edema; Middle Aged; Paclitaxel; Retina; Tomography, Optical Coherence; Trastuzumab | 2008 |
Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2009 |
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Phosphorylation; Polymerase Chain Reaction; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retrospective Studies; Trastuzumab | 2009 |
In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Hypoxia-Inducible Factor 1; Luminescent Measurements; Luminescent Proteins; Mice; Mice, Inbred BALB C; Paclitaxel; Promoter Regions, Genetic | 2008 |
Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Micelles; Nanoparticles; Paclitaxel; Receptors, Vasoactive Intestinal Polypeptide, Type I | 2009 |
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Topics: Adult; Albumins; Antineoplastic Agents; Attitude of Health Personnel; Breast Neoplasms; Canada; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Calcium sensing receptor down-regulates malignant cell behavior and promotes chemosensitivity in human breast cancer cells.
Topics: Breast Neoplasms; Cell Adhesion; Cell Death; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Extracellular Space; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Invasiveness; Paclitaxel; Receptors, Calcium-Sensing; Survivin | 2009 |
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Paclitaxel; Retrospective Studies; Soft Tissue Neoplasms; tau Proteins; Treatment Outcome; Young Adult | 2009 |
Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Female; Humans; Interleukin-1beta; Interleukin-6; Paclitaxel; Thromboplastin | 2009 |
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.
Topics: Adult; Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fibroblasts; Humans; Lung; Lung Neoplasms; Middle Aged; Mutation; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Genetic; Proto-Oncogene Proteins c-mdm2; Stromal Cells; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ceramides; Humans; Lysophosphatidylcholines; Lysophospholipids; Melanoma; Membrane Potential, Mitochondrial; Multienzyme Complexes; Paclitaxel; Phosphodiesterase I; Phosphoric Diester Hydrolases; Pyrophosphatases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Paclitaxel | 2008 |
Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Incidence; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Surveys and Questionnaires | 2009 |
Replacing alkyl sulfonamide with aromatic sulfonamide in sulfonamide-type RXR agonists favors switch towards antagonist activity.
Topics: Breast Neoplasms; Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Design; Gene Expression Regulation; Humans; Inhibitory Concentration 50; Ligands; Lung Neoplasms; Models, Chemical; Molecular Conformation; Paclitaxel; Retinoid X Receptors; Structure-Activity Relationship; Sulfonamides | 2009 |
The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Caveolae; Caveolin 1; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Paclitaxel; PrPC Proteins | 2009 |
Bim is reversibly phosphorylated but plays a limited role in paclitaxel cytotoxicity of breast cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Line, Tumor; Cytotoxins; Gene Knockdown Techniques; Humans; Membrane Proteins; Mitosis; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins; RNA Interference | 2009 |
[A case of advanced breast cancer successfully treated with paclitaxel and toremifene therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Toremifene; Ultrasonography | 2008 |
[Recurrence of skin and lymph nodes from asynchronous breast cancer successfully treated with paclitaxel and toremifene therapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Toremifene; Ultrasonography | 2008 |
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Female; Humans; Mitoxantrone; Neoplasm Staging; Oxonic Acid; Paclitaxel; Tegafur; Time Factors; Tomography, X-Ray Computed; Topotecan | 2008 |
[A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immunotherapy; Liver Neoplasms; Mastectomy; Middle Aged; Paclitaxel; Time Factors; Tomography, X-Ray Computed; Trastuzumab | 2008 |
[Indoleamine 2,3-dioxygenase expression in breast cancer patients during chemotherapy].
Topics: Antineoplastic Agents; Breast Neoplasms; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Paclitaxel | 2008 |
Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Mitosis; NAV1.5 Voltage-Gated Sodium Channel; Neoplasm Invasiveness; Paclitaxel; Signal Transduction; Sodium Channels; Tubulin Modulators | 2009 |
Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Fluorescent Antibody Technique; Humans; Interleukins; Lung Neoplasms; Paclitaxel | 2008 |
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin B1; Down-Regulation; Female; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasm Proteins; Paclitaxel; RNA, Small Interfering; Transfection; Tumor Stem Cell Assay; Uterine Cervical Neoplasms | 2008 |
Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Female; Genes, Reporter; Humans; Inhibitor of Apoptosis Proteins; Luciferases; Microtubule-Associated Proteins; Paclitaxel; Plasmids; Prodigiosin; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Tumor Stem Cell Assay | 2009 |
Light scattering measurements of subcellular structure provide noninvasive early detection of chemotherapy-induced apoptosis.
Topics: Algorithms; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Doxorubicin; Flow Cytometry; G2 Phase; Humans; Interferometry; Light; Mitochondria; Organelles; Paclitaxel; Scattering, Radiation | 2009 |
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Survival Rate; Switzerland | 2009 |
Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Paclitaxel; Receptors, Estrogen | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Hospitalization; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2009 |
Vernonia amygdalina: anticancer activity, authentication, and adulteration detection.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA; Drug Contamination; Endonucleases; Female; Humans; Paclitaxel; Plant Extracts; Receptors, Estrogen; Vernonia | 2008 |
[Clinical features of paclitaxel-induced peripheral neuropathy and role of Gosya-jinki-gan].
Topics: Breast Neoplasms; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Plant Extracts; Surveys and Questionnaires; Vitamins | 2009 |
Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Scleroderma, Limited | 2009 |
[Influence of SNCG transfection on the effectiveness of anti-tumor drugs in PC-3 cell lines].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; gamma-Synuclein; Humans; Male; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Transfection | 2008 |
Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Erythema Multiforme; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Photosensitivity Disorders; Sunlight | 2009 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A | 2009 |
Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery.
Topics: Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Fullerenes; Humans; Hydrophobic and Hydrophilic Interactions; Nanostructures; Paclitaxel | 2008 |
Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Doxycycline; Drug Interactions; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Paclitaxel | 2009 |
Parkin regulates paclitaxel sensitivity in breast cancer via a microtubule-dependent mechanism.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Humans; Immunohistochemistry; Microscopy, Fluorescence; Microtubules; Paclitaxel; Protein Binding; Statistics, Nonparametric; Transfection; Ubiquitin-Protein Ligases | 2009 |
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Preoperative Care; Treatment Outcome | 2009 |
Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2009 |
Galactose-grafted chylomicron-mimicking emulsion: evaluation of specificity against HepG-2 and MCF-7 cell lines.
Topics: Antineoplastic Agents, Phytogenic; Asialoglycoprotein Receptor; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Chylomicrons; Drug Delivery Systems; Emulsions; Female; Galactosamine; Galactose; Humans; Liver Neoplasms; Paclitaxel; Palmitic Acid; Particle Size | 2009 |
[Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Time Factors; Treatment Outcome | 2009 |
Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mitosis; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survivin | 2009 |
Response to paclitaxel in a radiotherapy-induced breast angiosarcoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hemangiosarcoma; Humans; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Paclitaxel; Treatment Outcome | 2009 |
Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; Benzopyrans; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Time Factors; Transfection | 2010 |
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Chromatin; Cyclin-Dependent Kinase 2; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Caspase 7; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Lung Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Time Factors | 2009 |
Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Paclitaxel; Quinazolines | 2009 |
Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Choline; Contrast Media; Cyclophosphamide; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; ROC Curve; Statistics, Nonparametric; Trastuzumab; Treatment Outcome | 2009 |
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow Cells; Breast Neoplasms; Disease Progression; Female; Humans; Lymphoma; Male; Mice; Mice, Inbred BALB C; Multiple Myeloma; Oligopeptides; Paclitaxel; Prostatic Neoplasms; Tubulin; Tumor Stem Cell Assay; Vincristine; Xenograft Model Antitumor Assays | 2009 |
[Favourable course of persisting malignant ascites].
Topics: Ascites; Breast Neoplasms; Carboplatin; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Liver Neoplasms; Middle Aged; Mistletoe; Paclitaxel; Phytotherapy; Plant Extracts; Treatment Outcome | 2009 |
[Clinicopathological evaluation of preoperative chemotherapy with doxorubicin plus cyclophosphamide followed by paclitaxel for locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen | 2009 |
[Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2009 |
Rational and successful use of carboplatin and albumin-bound paclitaxel in a patient with recurrent metaplastic carcinoma who presented with multi-organ tumor emboli.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Humans; Metaplasia; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2009 |
Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Paclitaxel; Protein Isoforms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Recombinant Fusion Proteins; Repressor Proteins; Tumor Stem Cell Assay; Vincristine | 2009 |
Combination effects of SC144 and cytotoxic anticancer agents.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytotoxins; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Pyrazines; Quinoxalines; Xenograft Model Antitumor Assays | 2009 |
The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; beta Carotene; Breast Neoplasms; Carotenoids; Cell Line, Tumor; Cell Proliferation; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Ligands; Lycopene; Paclitaxel; RNA, Messenger; Tamoxifen; Vitamin A; Vitamins | 2009 |
Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
Topics: Animals; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Inhibitory Concentration 50; Lysine; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-raf; ras Proteins; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2009 |
[Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Ileal Neoplasms; Intestinal Perforation; Jejunal Neoplasms; Middle Aged; Paclitaxel | 2009 |
Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1.
Topics: Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Connective Tissue Growth Factor; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; Integrin alphaVbeta3; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Protein Structure, Tertiary; Recombinant Proteins; Signal Transduction; Up-Regulation | 2009 |
[Therapy-related acute myeloid leukemia with 11q23 abnormality due to paclitaxel coexisting with bone marrow metastasis of breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Breast Neoplasms; Chromosome Aberrations; Chromosomes, Human, Pair 11; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Second Primary; Paclitaxel | 2009 |
Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Receptors, Estrogen; ROC Curve; Treatment Outcome | 2009 |
Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cytochromes c; Docetaxel; Genes, bcl-2; Humans; Membrane Potential, Mitochondrial; Organophosphorus Compounds; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Taxoids; Tubulin Modulators | 2009 |
Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Connexin 43; Doxorubicin; Female; Humans; Paclitaxel; Polyribosomes; Pseudogenes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transfection | 2009 |
ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Luciferases; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins pp60(c-src); Receptor, ErbB-2; STAT3 Transcription Factor; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Albumin-bound paclitaxel: new drug. Breast cancer metastases: no progress.
Topics: Albumins; Breast Neoplasms; Drug Approval; Europe; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2009 |
Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Hypoxia; Cell Survival; Drug Carriers; Female; HeLa Cells; Humans; Lactic Acid; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Uterine Cervical Neoplasms | 2009 |
A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent.
Topics: Ailanthus; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Screening Assays, Antitumor; Female; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Paclitaxel; Plants, Medicinal; Prostatic Neoplasms; Transplantation, Heterologous; Triterpenes; Tumor Suppressor Proteins | 2009 |
Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Delivery Systems; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Infusions, Subcutaneous; Methacrylates; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Phosphorylcholine; Tissue Distribution; Tumor Cells, Cultured | 2009 |
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Dimerization; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunoglobulin Fab Fragments; Mucin-1; Neoplasm Proteins; Paclitaxel; Protein Processing, Post-Translational; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Trastuzumab; Wnt Proteins | 2009 |
Coadministration of glycolipid-like micelles loading cytotoxic drug with different action site for efficient cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Glycolipids; Humans; Micelles; Paclitaxel | 2009 |
Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Europe; Female; Humans; Paclitaxel; Vascular Endothelial Growth Factor A | 2008 |
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2009 |
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Humans; Japan; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2009 |
Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Nucleus; Cisplatin; Cytoplasm; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione Transferase; Histones; Humans; Paclitaxel; Prolactin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Vinblastine | 2009 |
Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Paclitaxel; Receptors, Steroid | 2009 |
Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Estradiol; Estrogen Antagonists; Estrogens; Female; Fluorouracil; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, EphA2; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Thymidylate Synthase | 2010 |
Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles.
Topics: Animals; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Drug Delivery Systems; Emulsions; Female; Humans; Mice; Microbubbles; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Phase Transition; Ultrasonics | 2009 |
Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2009 |
Reciprocal effects of STAT5 and STAT3 in breast cancer.
Topics: Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Proto-Oncogene Proteins c-bcl-6; STAT3 Transcription Factor; STAT5 Transcription Factor; Transcriptional Activation; Vinblastine; Vinorelbine | 2009 |
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antibiotics, Antineoplastic; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD24 Antigen; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Hyaluronan Receptors; Isoenzymes; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplastic Stem Cells; Paclitaxel; Retinal Dehydrogenase | 2009 |
The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel.
Topics: Actins; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Female; Fluorescent Antibody Technique; Focal Adhesions; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Oligonucleotides; Oligopeptides; Paclitaxel; Telomerase; Xenograft Model Antitumor Assays | 2009 |
The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Carcinoma, Pancreatic Ductal; CD24 Antigen; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Flow Cytometry; Hedgehog Proteins; Humans; Hyaluronan Receptors; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Trans-Activators; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2009 |
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Clusterin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Male; Neoplasm Proteins; Oligonucleotides, Antisense; Paclitaxel; Phosphorothioate Oligonucleotides; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Sirolimus; Substrate Specificity | 2010 |
Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel; Taxoids; Vincristine | 2010 |
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Female; Humans; Middle Aged; Paclitaxel | 2009 |
The novel molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl)-phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells.
Topics: Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Enzyme Inhibitors; Female; Fibroblasts; Humans; MAP Kinase Kinase 4; Mice; Paclitaxel; Phenylacetates; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Vinyl Chloride | 2009 |
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; BRCA1 Protein; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Invasiveness; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin | 2009 |
Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway.
Topics: 2-Aminopurine; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Epinephrine; Female; Genomics; Humans; Hydrocortisone; Norepinephrine; Paclitaxel; Proteomics; Signal Transduction | 2009 |
The use of paclitaxel in the management of early stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Female; Humans; Paclitaxel; Technology Assessment, Biomedical | 2009 |
Adjuvant treatment with locally delivered OncoGel delays the onset of paresis after surgical resection of experimental spinal column metastasis.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Drug Delivery Systems; Female; Hindlimb; Neoplasm Transplantation; Neurologic Examination; Paclitaxel; Radiotherapy, Adjuvant; Rats; Rats, Inbred F344; Spinal Neoplasms; Statistics, Nonparametric; Time Factors | 2009 |
Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Clavicle; Cyclophosphamide; Doxorubicin; Female; Humans; Keratins; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Antimitotic chemotherapeutics promote adhesive responses in detached and circulating tumor cells.
Topics: Antimitotic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Depsipeptides; Female; Fluorescent Antibody Technique; Humans; Immunoblotting; Microscopy, Confocal; Microtubules; Neoplastic Cells, Circulating; Paclitaxel | 2010 |
Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.
Topics: Analgesics; Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Comorbidity; Female; Follow-Up Studies; Humans; Logistic Models; Multivariate Analysis; Neuralgia; Odds Ratio; Paclitaxel; Patient Acceptance of Health Care; Peripheral Nervous System Diseases; Risk Factors | 2009 |
Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Female; Genes, erbB-2; Humans; Ki-67 Antigen; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone | 2009 |
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Profiling; Humans; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Predictive Value of Tests; Treatment Outcome | 2010 |
Mitochondrial DNA depletion promotes impaired oxidative status and adaptive resistance to apoptosis in T47D breast cancer cells.
Topics: Adenosine Triphosphate; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Catalase; DNA, Mitochondrial; Doxorubicin; Enzyme Inhibitors; fas Receptor; Female; Glutathione Peroxidase; Humans; L-Lactate Dehydrogenase; Lactic Acid; Mitochondria; Oxidative Stress; Oxygen Consumption; Paclitaxel; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Staurosporine; Superoxide Dismutase; Tumor Cells, Cultured; Vincristine | 2009 |
Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Separation; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Humans; Hydrazines; JNK Mitogen-Activated Protein Kinases; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction | 2010 |
Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cyclin B1; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Microscopy, Fluorescence; Mitosis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinase-1; Transfection | 2010 |
[Growth of breast cancer cells is inhibited in vitro by cyclin E-siRNA].
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin E; Doxorubicin; Female; Fluorouracil; Genetic Vectors; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Plasmids; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection; Tumor Burden | 2009 |
[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Survival Rate | 2009 |
Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen | 2009 |
Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Glycerol; Humans; Paclitaxel; Pharmaceutical Vehicles; Seizures; Time Factors | 2009 |
Voltammetric behavior of the MCF-7 cell cytoplasm and the effect of taxol on voltammetric response.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbon; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Cytoplasm; Electrochemistry; Electrodes; Female; Formazans; Guanine; Humans; Models, Biological; Oxidation-Reduction; Paclitaxel; Tetrazolium Salts; Time Factors; Ultrasonics; Xanthine | 2009 |
Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 2; Caspase 3; Caspase 8; Caspase 9; Cell Division; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; G1 Phase; G2 Phase; Humans; Microscopy, Fluorescence; Microtubules; Paclitaxel; Taxoids | 2009 |
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; DNA; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genotype; Humans; Hypertension; Liver Neoplasms; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Polymorphism, Genetic; Vascular Endothelial Growth Factor A | 2009 |
Trastuzumab: unusual responses and toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lung; Middle Aged; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2009 |
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Estrogen Receptor alpha; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; tau Proteins | 2009 |
Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 7; Catechin; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Female; Heat-Shock Proteins; Humans; Microtubules; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Unfolded Protein Response; Vinblastine | 2009 |
[A case of advanced breast cancer with anaphylaxis-like reaction after intravenous administration of dexamethasone].
Topics: Aged; Anaphylaxis; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Female; Humans; Injections, Intravenous; Paclitaxel; Premedication | 2009 |
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Genes, BRCA1; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Platinum Compounds | 2009 |
Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Drug Combinations; Galactosides; Galectin 3; Humans; In Vitro Techniques; Leucine; Lung Neoplasms; Membrane Potential, Mitochondrial; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2009 |
Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Toremifene | 2009 |
The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Oxidoreductases Acting on CH-NH Group Donors; Paclitaxel; Polyamine Oxidase; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Spermine; Xenograft Model Antitumor Assays | 2010 |
Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Treatment Outcome; Triazoles; Tumor Burden | 2010 |
Regulation of drug resistance by human pregnane X receptor in breast cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 CYP3A; Diphosphonates; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Paclitaxel; Pregnane X Receptor; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2009 |
[Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2009 |
PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat.
Topics: Administration, Oral; Animals; Breast Neoplasms; Caco-2 Cells; Cations; Cells, Cultured; Disease Models, Animal; Drug Carriers; Drug Stability; Female; Humans; Nanocapsules; Paclitaxel; Particle Size; Polyglactin 910; Rats; Rats, Sprague-Dawley; Surface-Active Agents | 2009 |
Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bacterial Toxins; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Escherichia coli Proteins; Female; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Membrane Proteins; Paclitaxel; Spheroids, Cellular; Taxoids; Transfection | 2010 |
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Mice; Mice, Nude; Paclitaxel; Peptides; Rats | 2009 |
Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival | 2009 |
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Administration Schedule; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2009 |
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Taxoids; United Kingdom | 2009 |
Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; STAT5 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Transfection | 2009 |
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Retrospective Studies | 2010 |
Effects of protein kinase Cdelta and phospholipase C-gamma1 on monocyte chemoattractant protein-1 expression in taxol-induced breast cancer cell death.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Chemokine CCL2; Chemokines; Dose-Response Relationship, Drug; Female; Humans; Paclitaxel; Phospholipase C gamma; Protein Kinase C-delta; RNA, Messenger; Up-Regulation | 2009 |
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cardiac Electrophysiology; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Middle Aged; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Stroke Volume; Trastuzumab; Treatment Outcome; Ventricular Function, Left | 2009 |
Paclitaxel-containing nano-engineered polymeric capsules towards cancer therapy.
Topics: Breast Neoplasms; Capsules; Cell Line, Tumor; Cell Survival; Crystallization; Drug Carriers; Humans; Macromolecular Substances; Materials Testing; Molecular Conformation; Nanostructures; Nanotechnology; Paclitaxel; Particle Size; Polymers; Surface Properties | 2009 |
[Safety evaluation of paclitaxel injection NK in adjuvant therapy for breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 2009 |
Genome-free viral capsids as multivalent carriers for taxol delivery.
Topics: Antineoplastic Agents; Breast Neoplasms; Capsid; Capsid Proteins; Cell Line, Tumor; Cell Survival; Cross-Linking Reagents; Cysteine; Drug Carriers; Female; Genome, Viral; Humans; Paclitaxel | 2009 |
Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.
Topics: Blotting, Western; Breast Neoplasms; Calcium-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cellular Senescence; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mad2 Proteins; Paclitaxel; Repressor Proteins; RNA, Small Interfering; Spindle Apparatus; Transfection | 2009 |
Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cullin Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Paclitaxel | 2010 |
Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2009 |
Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Stability; ErbB Receptors; Female; Humans; Immunoconjugates; Paclitaxel; Polyethylene Glycols | 2010 |
Investigations on cellular interaction of polyelectrolyte based nano-walled reservoir using MCF-7 cell lines: a novel chemotherapeutic approach.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Breast Neoplasms; Capsules; Cell Line, Tumor; Dextrans; Drug Carriers; Electrolytes; Female; Flow Cytometry; Humans; Nanostructures; Paclitaxel; Static Electricity | 2009 |
A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Resistance, Multiple; Humans; Materials Testing; Paclitaxel; Poloxamer; Polyesters | 2010 |
Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Female; Lymphangiogenesis; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Thrombospondin 1; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
[A case of aggressive primary squamous cell carcinoma of the breast refractory to preoperative neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; Cyclophosphamide; Epirubicin; Fatal Outcome; Female; Fluorouracil; Humans; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Vinblastine; Vinorelbine | 2009 |
Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colony-Forming Units Assay; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; DNA; Drug Synergism; Enzyme Induction; Female; Flavonoids; Humans; Irinotecan; Paclitaxel | 2010 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Involvement of 1,25D3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Isoflavones; Paclitaxel; Receptors, Calcitriol; RNA, Catalytic; Tretinoin; Vitamin D | 2010 |
[The combined effect of paclitaxel and toremifene therapy for metastatic breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Synergism; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Toremifene | 2009 |
[A case of bilateral breast cancer and metastatic gastric cancer with peritonitis carcinomatosa successfully treated with a combination therapy of S-1 and paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritonitis; Stomach Neoplasms; Tegafur | 2009 |
[A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Drug Combinations; Epirubicin; Female; Fluorouracil; Humans; Oxonic Acid; Paclitaxel; Pentoxifylline; Quality of Life; Tegafur; Treatment Outcome | 2009 |
[A case of advanced breast cancer with skin ulceration successfully treated with paclitaxel and toremifene therapy].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hemorrhage; Humans; Organic Chemicals; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Skin Ulcer | 2009 |
Resolution of menstrually related migraine following aggressive treatment for breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogens; Female; Humans; Menstrual Cycle; Menstruation Disturbances; Migraine Disorders; Paclitaxel; Radiotherapy; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer.
Topics: Adult; Amenorrhea; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Premenopause; Trastuzumab | 2010 |
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Sensitivity and Specificity | 2010 |
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
Topics: Biomarkers, Pharmacological; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Metabolome; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Proteomics; Taxoids; Tumor Cells, Cultured | 2010 |
Early distant relapse in early stage triple-negative breast cancer: usefulness of FDG-PET for diagnosis of distant metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dendrimers; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Transfection | 2010 |
Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.
Topics: Breast Neoplasms; Buthionine Sulfoximine; Cell Survival; Deoxyglucose; Drug Synergism; Female; Fibroblasts; Glucose; Humans; Hydrogen Peroxide; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Tumor Cells, Cultured | 2010 |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; tau Proteins; Treatment Outcome | 2010 |
[Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma].
Topics: Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Female; Glaucoma, Angle-Closure; Humans; Middle Aged; Paclitaxel; Premedication; Terfenadine | 2010 |
Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Breast Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2; Dose-Response Relationship, Drug; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lactones; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; NF-kappa B; Paclitaxel; Reactive Oxygen Species; Sesquiterpenes; Time Factors; Tumor Burden; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Hypothyroidism; Indoles; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pyrroles; Remission Induction; Sunitinib; Trastuzumab | 2010 |
[A case of cystic maculopathy during paclitaxel therapy].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Macular Degeneration; Middle Aged; Paclitaxel | 2010 |
[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids | 2009 |
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Paclitaxel; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2010 |
Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol.
Topics: Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Knockdown Techniques; Glycolysis; Humans; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Paclitaxel | 2010 |
Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Dedifferentiation; Cell Lineage; Cell Movement; Cell Survival; Cell Transformation, Neoplastic; Enzyme Activation; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Mesoderm; Mice; Neoplasm Invasiveness; Paclitaxel; Proto-Oncogene Proteins c-fos; Transcription Factor AP-1; Up-Regulation | 2010 |
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Female; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Quinazolines; Treatment Outcome | 2010 |
Stewart-Treves syndrome: questionable response to weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymphangiosarcoma; Paclitaxel; Skin Neoplasms; Tomography, X-Ray Computed | 2010 |
Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
Topics: Amino Acid Sequence; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Electrons; Flow Cytometry; Humans; Indium Radioisotopes; Methotrexate; Nuclear Localization Signals; Paclitaxel; Radiation-Sensitizing Agents; Receptor, ErbB-2; Trastuzumab | 2010 |
Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Mice; Mice, Inbred BALB C; Paclitaxel; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Time Factors; Tumor Suppressor Protein p53 | 2010 |
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Ceramides; Drug Screening Assays, Antitumor; Female; Humans; Logistic Models; Metagenomics; Middle Aged; Mitosis; Models, Genetic; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Retrospective Studies; RNA Interference | 2010 |
Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Reactive Oxygen Species; Resveratrol; Stilbenes; Transplantation, Heterologous | 2010 |
Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vorinostat | 2011 |
Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Inflammation; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Peptides; Receptors, CXCR4; Xenograft Model Antitumor Assays | 2010 |
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Endothelium, Vascular; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Reporting of studies on new medicines in major medical journals: a case study in breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Paclitaxel; Periodicals as Topic; Quinazolines; United States; United States Food and Drug Administration | 2010 |
Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Integrin alpha6; Mice; Mice, Transgenic; Nuclear Proteins; Paclitaxel; Y-Box-Binding Protein 1 | 2010 |
Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Trastuzumab; Treatment Outcome | 2010 |
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Survival; Complement Activation; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Inbred C57BL; Micelles; Neoplasms; Oxazoles; Paclitaxel; Polymers; Solubility | 2010 |
Severe interstitial pneumonitis associated with the administration of taxanes.
Topics: Adrenal Cortex Hormones; Aged; Breast Neoplasms; Docetaxel; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed | 2010 |
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diphosphonates; Docetaxel; Double-Blind Method; Drug Synergism; Female; Genes, erbB-2; Humans; Incidence; Jaw Diseases; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Oral Hygiene; Osteonecrosis; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2010 |
Does usnic acid affect microtubules in human cancer cells?
Topics: Antimitotic Agents; Antineoplastic Agents; Benzofurans; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lung Neoplasms; Microtubules; Paclitaxel; Vincristine | 2010 |
Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, SCID; Microbial Sensitivity Tests; Microtubules; Molecular Chaperones; Paclitaxel; Transfection; Tubulin; Tubulin Modulators; Vinblastine; Vinorelbine | 2010 |
Drug resistant breast cancer cells overexpress ETS1 gene.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Matrix Metalloproteinase 1; Oncogenes; Paclitaxel; Proto-Oncogene Protein c-ets-1; Taxoids; Vincristine | 2010 |
[Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2010 |
Optimal chemotherapy for high-risk early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2010 |
Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Micelles; Paclitaxel; Particle Size; Poloxamer; Polyesters; Polyethylene Glycols; Rats; Rats, Sprague-Dawley | 2010 |
Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Line, Tumor; Dimerization; Female; Humans; Membrane Proteins; Mitochondria; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering | 2010 |
Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Diffusion; Drug Compounding; Drug Stability; Female; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Treatment Outcome | 2010 |
Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Female; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2010 |
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Liposomes; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Paresthesia; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2010 |
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Female; Humans; Inhibitory Concentration 50; Kinetics; Lactic Acid; Light; Microscopy, Electron, Scanning; Nanoparticles; Paclitaxel; Particle Size; Phosphatidylglycerols; Photoelectron Spectroscopy; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polyvinyl Alcohol; Scattering, Radiation; Solubility; Surface Properties; Surface-Active Agents; Technology, Pharmaceutical | 2010 |
A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Female; Humans; Inflammatory Breast Neoplasms; Lymphatic Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Endoplasmic Reticulum Chaperone BiP; Female; Heat-Shock Proteins; Humans; Lymphatic Metastasis; Menopause; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids; Treatment Outcome | 2011 |
Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bacteriophages; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Coculture Techniques; Delayed-Action Preparations; Drug Delivery Systems; Endoplasmic Reticulum Chaperone BiP; Endothelial Cells; Glioma; Heat-Shock Proteins; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Oligopeptides; Paclitaxel; Recombinant Proteins; Xenograft Model Antitumor Assays | 2010 |
TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electric Stimulation; Emetine; Female; Humans; Inhibitory Concentration 50; Mitoxantrone; Neoplasm Proteins; Paclitaxel; Time Factors; Up-Regulation | 2010 |
[A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Quality of Life; Tomography, X-Ray Computed | 2010 |
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Microtubule-Associated Proteins; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; Survivin; TOR Serine-Threonine Kinases; Up-Regulation | 2010 |
Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Micelles; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Polymers | 2010 |
Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Mammography; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Recurrence; Risk; Treatment Outcome | 2010 |
FoxM1 mediates resistance to herceptin and paclitaxel.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Peptide Fragments; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Trastuzumab; Tubulin; Tumor Cells, Cultured | 2010 |
Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomimetic Materials; Breast Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Synergism; Female; Humans; Oligopeptides; Paclitaxel; Phosphorylation; Receptor, ErbB-2; Signal Transduction; Up-Regulation | 2010 |
Bevacizumab improves the delivery and efficacy of paclitaxel.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cell Membrane Permeability; Drug Synergism; Female; Humans; Male; Mice; Paclitaxel; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
[A case of breast cancer with multiple hepatic metastasis successfully treated with S-1/PTX and S-1 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Tegafur; Tomography, X-Ray Computed | 2010 |
[Long-term survival of a breast cancer patient with liver metastasis treated with trastuzumab and Paclitaxel].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Receptor, ErbB-2; Time Factors; Tomography, X-Ray Computed; Trastuzumab | 2010 |
Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Mastectomy; Middle Aged; Necrosis; Neoadjuvant Therapy; Paclitaxel; Postoperative Complications; Skin; Skin Diseases; Surgical Flaps; Wound Healing | 2010 |
RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Neoplasms, Basal Cell; Paclitaxel; RNA Interference; RNA, Small Interfering | 2010 |
[Value of carcinoembryonec antigen in biochemotherapy response monitoring in patients with Her-2-positive advanced breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Female; Humans; Middle Aged; Monitoring, Physiologic; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2010 |
nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Topics: Albumins; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cytotoxins; Docetaxel; Drug Therapy, Combination; Female; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Treatment Outcome | 2010 |
Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Metastasis; Paclitaxel; Proteinuria; Treatment Outcome | 2010 |
The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Breast Neoplasms; Cell Proliferation; Female; Humans; Paclitaxel | 2010 |
Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Chi-Square Distribution; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Docetaxel; Drug Hypersensitivity; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Italy; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome | 2010 |
Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bleomycin; Blotting, Western; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vincristine | 2010 |
[A case of mammary Paget's disease with early systemic recurrence after operation].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Paget's Disease, Mammary; Recurrence; Time Factors; Tomography, X-Ray Computed; Trastuzumab | 2010 |
Cacalol, a natural sesquiterpene, induces apoptosis in breast cancer cells by modulating Akt-SREBP-FAS signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Caspase 3; Cell Line, Tumor; Cyclophosphamide; Death-Associated Protein Kinases; Drug Synergism; Enzyme Activation; Fatty Acid Synthases; Female; Genes, Reporter; Humans; Luciferases, Renilla; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Sesquiterpenes; Signal Transduction; Sterol Regulatory Element Binding Proteins; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeleton; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Paclitaxel; Piperidines; Quinazolines | 2011 |
Discovering breast cancer drug candidates from biomedical literature.
Topics: Antineoplastic Agents; Breast Neoplasms; Data Mining; Doxorubicin; Drug Discovery; Etoposide; Female; Humans; Internet; MEDLINE; Paclitaxel; Publications | 2010 |
Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling.
Topics: Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Gene Expression Regulation; Genes, Reporter; Humans; Paclitaxel; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Tubulin; Tubulin Modulators; Tyrosine; Vinblastine; Vinorelbine | 2010 |
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Laboratories; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pathology, Clinical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2010 |
Neoadjuvant treatment in young women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Taxoids; Treatment Outcome | 2010 |
[Weekly injection of paclitaxel plus weekly oral administration of cyclophosphamide were very effective for a case of advanced accessory breast cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Cyclophosphamide; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Tomography, X-Ray Computed | 2010 |
[Value of diffusion weighted imaging (DWI) in evaluating early response to neoadjuvant chemotherapy in locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Diffusion Magnetic Resonance Imaging; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Prospective Studies; Young Adult | 2010 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Chromatography, Affinity; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Female; Fluorouracil; Glutathione S-Transferase pi; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neurophysiology; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Phenotype; Survival Rate; Treatment Outcome | 2010 |
Cystoid macular edema secondary to nab-paclitaxel therapy.
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Macular Edema; Middle Aged; Paclitaxel | 2010 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Combinations; Estrogen Receptor alpha; Estrogens; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oxonic Acid; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tegafur; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Uracil | 2011 |
Persistent mobility disability after neurotoxic chemotherapy.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disability Evaluation; Female; Gait Disorders, Neurologic; Humans; Mastectomy; Mobility Limitation; Paclitaxel; Peripheral Nervous System Diseases; Postural Balance | 2010 |
Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Microtubules; Mitosis; Mitotic Index; Neoplasm Proteins; Paclitaxel; Stathmin; Up-Regulation | 2011 |
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Female; Humans; Mice; Mice, Nude; Paclitaxel; Permeability; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Transplantation, Heterologous; Vorinostat | 2010 |
AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cells, Cultured; Endostatins; Endothelium, Vascular; Female; Genetic Therapy; Humans; Lung Neoplasms; Mice; Mutant Proteins; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Polyploidy; Recombinant Proteins | 2011 |
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Humans; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Paclitaxel; Phosphorylation; TRPP Cation Channels | 2011 |
A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Elastin; Female; G2 Phase Cell Cycle Checkpoints; Humans; Hydrogen-Ion Concentration; Hyperthermia, Induced; Microtubules; Paclitaxel; Prodrugs; Recombinant Proteins; Temperature; Time Factors; Tubulin Modulators | 2012 |
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Resistance, Multiple; ErbB Receptors; Female; Humans; Indazoles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Polymers | 2011 |
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Salvage Therapy; Spain; Taxoids | 2010 |
Role of gamma-synuclein in microtubule regulation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cytoskeleton; Female; Fluorescent Antibody Technique; gamma-Synuclein; Humans; Microtubule-Associated Proteins; Microtubules; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured | 2011 |
Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells.
Topics: Breast Neoplasms; Cell Fusion; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial Cells; Etoposide; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Humans; Hybrid Cells; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
[Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Contrast Media; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel | 2010 |
[Practice and consideration on neoadjuvant therapy for early breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Burden | 2010 |
Paclitaxel-induced neutrophilic adverse reaction and acral erythema.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Eruptions; Erythema; Female; Hand Dermatoses; Humans; Leg Dermatoses; Neutrophils; Paclitaxel | 2011 |
Invited commentary.
Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disability Evaluation; Female; Gait Disorders, Neurologic; Humans; Mastectomy; Mobility Limitation; Paclitaxel; Peripheral Nervous System Diseases; Postural Balance; Research Design | 2010 |
Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomedical Engineering; Breast Neoplasms; Cell Adhesion; Cell Death; Cell Line, Tumor; Cell Proliferation; Coated Materials, Biocompatible; Collagen Type I; Dimethylpolysiloxanes; Drug Screening Assays, Antitumor; Female; Fibronectins; Humans; Models, Biological; Paclitaxel; Systems Biology; Tumor Microenvironment | 2011 |
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.
Topics: Animals; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Female; Fibrosarcoma; Head and Neck Neoplasms; Humans; Neoplasm Invasiveness; Neoplasms; Ovarian Neoplasms; Paclitaxel; Receptors, Peptide; Receptors, Transforming Growth Factor beta | 2011 |
ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aurora Kinase A; Aurora Kinases; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Paclitaxel; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Trans-Activators | 2010 |
[A case of a patient with a triple negative breast cancer and complete response of lung, mediastinal and skeletal metastases after treatment with paclitaxel and bevacizumab].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction | 2010 |
Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2010 |
In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
Nanotechnology takes a new look at old drugs.
Topics: Albumins; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Carriers; Female; Humans; Lung Neoplasms; Nanoparticles; Nanotechnology; Paclitaxel; Tumor Necrosis Factor-alpha | 2010 |
[Effect of combined use of PDTC and paclitaxel on proliferation and invasion of human breast cancer cell line MCF-7].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Neoplasm Invasiveness; NF-kappa B; Paclitaxel; Pyrrolidines; Thiocarbamates | 2010 |
Optimizing dose-dense regimens for early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Erythropoietin; Female; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Analysis | 2010 |
Bevacizumab and breast cancer: the E2100 outlier.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel | 2010 |
Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hypesthesia; Middle Aged; Nervous System Diseases; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Taxoids | 2011 |
Recall dermatitis after systemic treatment with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Skin | 2010 |
Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Therapy, Computer-Assisted; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2010 |
Cytotoxic effects of new trans-2,4-diaryl-r-3-methyl-1,2,3,4-tetrahydroquinolines and their interaction with antitumoral drugs gemcitabine and paclitaxel on cellular lines of human breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Quinolines | 2011 |
[A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Shock | 2010 |
Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Chemistry, Pharmaceutical; Dimyristoylphosphatidylcholine; Drug Delivery Systems; Female; Humans; Liposomes; Paclitaxel; Particle Size; Phosphatidylglycerols; Solubility | 2010 |
Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells.
Topics: Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cell Proliferation; DNA Modification Methylases; DNA Primers; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Hedgehog Proteins; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Paclitaxel; Peptides; Phenylacetates; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Thiotepa | 2011 |
Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Female; Indazoles; Mice; Mice, Nude; Nanoparticles; Nanotechnology; Paclitaxel | 2011 |
Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; GATA3 Transcription Factor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Peptides; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Trefoil Factor-1; Trefoil Factor-3; Tumor Suppressor Proteins | 2011 |
[Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Topics: Adult; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Treatment Failure | 2010 |
Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin Immunoprecipitation; Electrophoretic Mobility Shift Assay; Flow Cytometry; Gossypol; Humans; Intercellular Adhesion Molecule-1; NF-kappa B; Okadaic Acid; Paclitaxel; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha; U937 Cells | 2011 |
[The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Receptors, Estrogen; Toremifene | 2010 |
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Letrozole; Middle Aged; Nitriles; Paclitaxel; Triazoles; Tryptophan | 2010 |
[A long-term survival case of local recurrence of breast cancer treated with combined modality therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Lymph Node Excision; Mastectomy; Neoplasm Recurrence, Local; Paclitaxel; Tamoxifen; Taxoids; Tegafur; Trastuzumab; Uracil | 2010 |
Paclitaxel loaded nanosponges: in-vitro characterization and cytotoxicity study on MCF-7 cell line culture.
Topics: Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Excipients; Female; Humans; Kinetics; Magnetic Resonance Spectroscopy; Nanostructures; Osmolar Concentration; Paclitaxel; Particle Size; Solubility; Spectroscopy, Fourier Transform Infrared | 2011 |
Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Hydroxamic Acids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; rho GTP-Binding Proteins; RNA Interference; Transplantation, Heterologous | 2011 |
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Gene Dosage; Genes, erbB-2; Genes, myc; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tissue Array Analysis; Trastuzumab; Treatment Outcome | 2011 |
Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Emulsions; Female; Fluorocarbons; Humans; Mice; Nanomedicine; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Ultrasonic Therapy; Ultrasonography | 2011 |
BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Inhibitor of Apoptosis Proteins; Mutation; Paclitaxel; Receptors, Calcium-Sensing; RNA Interference; RNA, Small Interfering; Survivin | 2011 |
Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Sensitivity and Specificity | 2011 |
The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Membrane Permeability; Cell Proliferation; Diagnostic Imaging; Drug Resistance, Neoplasm; Female; Gastrointestinal Tract; Humans; Intracellular Space; Mice; Micelles; Nanoparticles; Paclitaxel; Spheroids, Cellular; Subcellular Fractions; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Reversal of multidrug resistance in human breast cancer cells by Curcuma wenyujin and Chrysanthemum indicum.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Division; Cell Survival; Chrysanthemum; Curcuma; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; G2 Phase; Humans; Lung Neoplasms; Medicine, Chinese Traditional; Paclitaxel; Phytotherapy; Plant Extracts | 2011 |
A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reproducibility of Results; Vincristine | 2011 |
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy.
Topics: Adult; Axons; Breast Neoplasms; Disease Progression; Female; Humans; Membrane Potentials; Middle Aged; Paclitaxel; Polyneuropathies; Prospective Studies; Sensory Receptor Cells; Time Factors | 2011 |
Basic helix-loop-helix transcription factors DEC1 and DEC2 regulate the paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Paclitaxel; Protein Transport; RNA, Small Interfering | 2011 |
Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Diterpenes, Kaurane; Drug Stability; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucosides; HL-60 Cells; Humans; Paclitaxel; Pancreatic Neoplasms; Solvents | 2011 |
1'S-1'-acetoxyeugenol acetate: a novel phenylpropanoid from Alpinia conchigera enhances the apoptotic effects of paclitaxel in MCF-7 cells through NF-κB inactivation.
Topics: Alpinia; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line; Cell Line, Tumor; Drug Synergism; Drugs, Chinese Herbal; Epithelial Cells; Eugenol; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Microarray Analysis; NF-kappa B; Paclitaxel; Poly(ADP-ribose) Polymerases; Rhizome; Signal Transduction | 2011 |
Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Connective Tissue Growth Factor; Cysteine-Rich Protein 61; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Paclitaxel; Trans-Activators; Transcription Factors; Transcription, Genetic; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Transfection | 2011 |
[Study on the anti-tumor effect of paclitaxel mixed micelle by using in vivo optical imaging technique].
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Luminescent Measurements; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Micelles; Neoplasm Transplantation; Paclitaxel; Particle Size; Tumor Burden | 2010 |
Median effective effect-site concentration of intravenous anesthetics for loss of consciousness in neoadjuvant chemotherapy patients.
Topics: Adult; Anesthetics, Intravenous; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Etomidate; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Propofol; Unconsciousness | 2011 |
Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibiotics, Antineoplastic; Anticoagulants; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chick Embryo; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Female; Heparin, Low-Molecular-Weight; Humans; Iodine Radioisotopes; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Tissue Distribution; Xenograft Model Antitumor Assays | 2011 |
ER-/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Paclitaxel; Receptors, Estrogen; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2012 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Metformin; Mice; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Dose dense and concurrent trastuzumab for early breast cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Paclitaxel; Trastuzumab | 2011 |
4-Methyl-3-nitro-benzoic acid, a migration inhibitor, prevents breast cancer metastasis in SCID mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Separation; Female; Flow Cytometry; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Nitrobenzoates; Paclitaxel; Xenograft Model Antitumor Assays | 2011 |
Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Oligonucleotides; Paclitaxel; Vascular Endothelial Growth Factor A | 2011 |
Therapeutic ultrasonic microbubbles carrying paclitaxel and LyP-1 peptide: preparation, characterization and application to ultrasound-assisted chemotherapy in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Humans; In Vitro Techniques; Microbubbles; Paclitaxel; Peptides, Cyclic; Ultrasonics; Ultrasonography, Mammary | 2011 |
[Nasal septum perforation and bevacizumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Nasal Septum; Nose Diseases; Paclitaxel | 2011 |
Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
Topics: Albumins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Synergism; Female; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Neoplasm Transplantation; Paclitaxel; Transplantation, Heterotopic; Xenograft Model Antitumor Assays | 2011 |
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Cell Line, Tumor; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; HEK293 Cells; Humans; Kinesins; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Binding; Taxoids; Vincristine | 2012 |
Novel polymer coupled lipid nanoparticle of paclitaxel with synergistic enhanced efficacy against cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chitosan; Humans; Lipids; Nanocapsules; Paclitaxel; Treatment Outcome | 2011 |
A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Female; Genes, Neoplasm; Genome-Wide Association Study; Humans; Lentivirus; Oligonucleotide Array Sequence Analysis; Paclitaxel; Quinolines; Receptor, ErbB-2; Recombinant Proteins; RNA Interference; Signal Transduction | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Dermatopathologic effects of taxane therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy; Breast Neoplasms; Bridged-Ring Compounds; Cell Cycle; Docetaxel; Female; Humans; Leiomyosarcoma; Male; Mitosis; Paclitaxel; Skin; Skin Diseases; Taxoids | 2011 |
Cancer: Macrophages limit chemotherapy.
Topics: Animals; Breast Neoplasms; Cell Count; Drug Resistance, Neoplasm; Humans; Macrophages; Mice; Models, Biological; Neoplasm Metastasis; Neutrophils; Paclitaxel; Prognosis; T-Lymphocytes, Cytotoxic; Tumor Microenvironment | 2011 |
Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cluster Analysis; Cyclophosphamide; Epirubicin; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Mutation; Paclitaxel; Tumor Suppressor Protein p53 | 2011 |
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; Apoptosis; B7 Antigens; Breast Neoplasms; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; Janus Kinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Receptors, Immunologic; RNA, Small Interfering; STAT3 Transcription Factor; Survivin | 2011 |
Targeted nanogels: a versatile platform for drug delivery to tumors.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; Freeze Drying; Humans; Integrin alphaVbeta3; Lipids; Mice; Mice, Nude; Nanogels; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Polyethyleneimine; Polymers; Taxoids | 2011 |
Novel paclitaxel nanoparticles: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Nanoparticles; Paclitaxel; Particle Size; Rats; Rats, Wistar | 2010 |
An injectable calcium phosphate cement for the local delivery of paclitaxel to bone.
Topics: Biological Availability; Bone Cements; Bone Neoplasms; Breast Neoplasms; Calcium Phosphates; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Delivery Systems; Durapatite; Female; Humans; Microscopy, Electron, Scanning; Osteosarcoma; Paclitaxel; Photoelectron Spectroscopy; Porosity; Serum Albumin | 2011 |
p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Doxorubicin; Humans; Mice; Mitogen-Activated Protein Kinase 12; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phenanthrenes; Phosphatidylinositol 3-Kinase; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2011 |
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukocyte Count; Mice; Mice, Inbred BALB C; Paclitaxel | 2011 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Contrast Media; Doxorubicin; Drug Compounding; Drug Delivery Systems; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Microbubbles; Nanoparticles; Paclitaxel; Polymers; Tumor Cells, Cultured; Ultrasonics | 2011 |
A case of chemotherapy-responsive paraneoplastic rubral tremor.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ataxia; Autoantibodies; Brain Stem Neoplasms; Breast Neoplasms; Carboplatin; Electromyography; Enzyme-Linked Immunosorbent Assay; Female; Glasgow Coma Scale; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Nerve Tissue Proteins; Ovarian Neoplasms; Paclitaxel; Paraneoplastic Syndromes, Nervous System; Tomography, X-Ray Computed | 2011 |
Acute transient encephalopathy after weekly paclitaxel infusion.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Diseases; Breast Neoplasms; Fatal Outcome; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Paclitaxel | 2012 |
Regulation of β-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Dactinomycin; Female; Gene Expression Regulation, Neoplastic; Humans; Microarray Analysis; MicroRNAs; Paclitaxel; Protein Isoforms; Tubulin; Tubulin Modulators | 2011 |
Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Diterpenes; Drug Synergism; Epoxy Compounds; Female; Humans; Lactones; Mice; Mice, Nude; Oxidative Stress; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Structure-Activity Relationship; Transcriptional Activation; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Regulation of mitosis and taxane response by Daxx and Rassf1.
Topics: Adaptor Proteins, Signal Transducing; Anaphase; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Co-Repressor Proteins; Cyclin B1; Drug Resistance, Neoplasm; Female; Humans; Mice; Mitosis; Molecular Chaperones; Nuclear Proteins; Paclitaxel; Tumor Suppressor Proteins | 2012 |
Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Chemoradiotherapy; Cranial Irradiation; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies | 2011 |
Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; G2 Phase; Humans; Lysophospholipids; Mitosis; Multienzyme Complexes; Paclitaxel; Phosphodiesterase I; Phosphoric Diester Hydrolases; Pyrophosphatases; Signal Transduction | 2011 |
Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromones; Epirubicin; Female; Humans; Morpholines; NF-kappa B; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrrolidines; Signal Transduction; Thiocarbamates; Tissue Inhibitor of Metalloproteinase-1 | 2011 |
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies | 2012 |
Liposomes containing (-)-gossypol-enriched cottonseed oil suppress Bcl-2 and Bcl-xL expression in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-X Protein; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cottonseed Oil; Female; Gene Expression Regulation, Neoplastic; Gossypol; Humans; Liposomes; Mice; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2011 |
Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer.
Topics: Adult; Aged; Apoptosis; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Female; Homeodomain Proteins; Humans; Hyaluronan Receptors; Middle Aged; Nanog Homeobox Protein; Neoplasm Proteins; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Phosphorylation; Receptors, Estrogen; Retinoblastoma Protein; Smad3 Protein; SOXB1 Transcription Factors | 2012 |
Unravelling the antimetastatic potential of pentoxifylline, a methylxanthine derivative in human MDA-MB-231 breast cancer cells.
Topics: Acridine Orange; Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Clone Cells; Dose-Response Relationship, Drug; Ethidium; Extracellular Matrix; Female; Gelatinases; Humans; Neoplasm Metastasis; Paclitaxel; Pentoxifylline; Xanthines | 2011 |
Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome | 2011 |
Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cachexia; Colonic Neoplasms; Dietary Fats; Dietary Supplements; Female; gamma-Glutamyltransferase; Mice; Mice, Inbred BALB C; Milk; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Soybean Oil; Time Factors | 2011 |
Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Female; Fluorouracil; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Oligonucleotide Array Sequence Analysis; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Predictive Value of Tests; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Ultrasonography, Mammary | 2011 |
Modulation of septin and molecular motor recruitment in the microtubule environment of the Taxol-resistant human breast cancer cell line MDA-MB-231.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Microtubules; Paclitaxel; Proteome; Proteomics; Septins; Tubulin; Tubulin Modulators; Up-Regulation | 2011 |
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computer Simulation; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Inhibitory Concentration 50; Middle Aged; Models, Biological; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Phenotype; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Tubulin Modulators | 2012 |
Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy.
Topics: Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome | 2011 |
Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorouracil; Fulvestrant; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Paclitaxel; Random Allocation; Tamoxifen; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Fluorescent Dyes; Humans; Mice; Mice, Nude; Molecular Imaging; Nanoparticles; Paclitaxel; Particle Size; Random Allocation; Solubility; Tissue Distribution; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2011 |
[Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Pyrazoles; Sulfonamides | 2011 |
The role of albumin-bound paclitaxel in metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Paclitaxel | 2011 |
Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Data Interpretation, Statistical; Female; Humans; Male; Organ Specificity; Paclitaxel; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Tissue Distribution | 2011 |
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum | 2012 |
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies | 2011 |
Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2011 |
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Contrast Media; Cyclophosphamide; Doxorubicin; Female; Gadolinium DTPA; Humans; Image Interpretation, Computer-Assisted; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Trastuzumab; Treatment Outcome | 2011 |
Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Breast Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinase 12; Paclitaxel; Signal Transduction | 2011 |
Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; DEAD-box RNA Helicases; Doxorubicin; Female; Humans; Inhibitor of Apoptosis Proteins; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasms, Basal Cell; Paclitaxel; Protein Binding; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2012 |
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Claudin-4; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred BALB C; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2011 |
The determination of changes in the expression of genes for selected specific transcriptional factors in in vitro ductal breast cancer cells under the influence of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Pharmacological; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma, Ductal, Breast; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel; Primary Cell Culture; Prognosis; Taxoids; Transcription Factors; Tumor Cells, Cultured | 2011 |
Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
Topics: Acetylation; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase 6; Histone Deacetylases; Humans; Neoadjuvant Therapy; Paclitaxel; Transcription, Genetic; Treatment Outcome; Tubulin | 2012 |
FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization.
Topics: Adenocarcinoma; Adenovirus E1A Proteins; Adenoviruses, Human; Animals; Antibodies, Monoclonal; beta-Transducin Repeat-Containing Proteins; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Genetic Therapy; Genetic Vectors; Humans; I-kappa B Kinase; MAP Kinase Kinase Kinases; Mice; Mice, SCID; Neoplasm Proteins; Paclitaxel; Protein Phosphatase 2; Protein Stability; RNA, Small Interfering; Signal Transduction; Ubiquitin; Xenograft Model Antitumor Assays | 2011 |
A fatal case of Pneumocystis jirovecii pneumonia in a breast cancer patient receiving weekly paclitaxel and trastuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fatal Outcome; Female; Humans; Middle Aged; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Trastuzumab | 2012 |
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2012 |
A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Drug Carriers; Female; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Receptors, Virus | 2012 |
c-Jun N-terminal kinase mediates microtubule-depolymerizing agent-induced microtubule depolymerization and G2/M arrest in MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Flavonoids; G2 Phase; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinase Kinases; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Pyrazoles; Stilbenes | 2012 |
[ABCB1 polymorphisms in patients with Charcot-Marie-Tooth disease. A possible relationship with neurotoxicity due to cytostatic treatment].
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Charcot-Marie-Tooth Disease; Colonic Neoplasms; Cytostatic Agents; Disease Susceptibility; Female; Genotype; Humans; Multidrug Resistance-Associated Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide | 2012 |
Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Microtubule-Associated Proteins; Microtubules; Neoadjuvant Therapy; Neoplasm Proteins; Paclitaxel | 2012 |
The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Texas; Trastuzumab; Treatment Outcome | 2011 |
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endothelium, Vascular; Female; Fluorouracil; Humans; Mice; Mice, Nude; Paclitaxel; Propranolol | 2011 |
70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Gene Expression Profiling; Humans; Ki-67 Antigen; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2012 |
The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lactones; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Confocal; Neoplastic Stem Cells; Octreotide; Paclitaxel; Polyethylene Glycols; Polymers; Pyrans | 2012 |
Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Carboplatin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Humans; Middle Aged; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tubulin; Tumor Suppressor Protein p53 | 2012 |
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
Topics: Aged; Animals; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cohort Studies; Disease-Free Survival; Epithelial Cells; Female; Follow-Up Studies; Humans; Leukocytes; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Macrophages; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Survival Rate; Tumor Microenvironment | 2011 |
Incidental detection of breast apocrine carcinoma via endometrial cytology.
Topics: Apocrine Glands; Breast Neoplasms; Carcinoma; Endometrium; Female; Humans; Laparotomy; Lymph Node Excision; Mastectomy, Modified Radical; Middle Aged; Paclitaxel; Uterine Neoplasms | 2011 |
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; RNA, Messenger; Transcription, Genetic; Tumor Burden; Ubiquitin-Conjugating Enzymes; Young Adult | 2012 |
A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Trastuzumab; Treatment Outcome | 2011 |
Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Isothiocyanates; M Phase Cell Cycle Checkpoints; Paclitaxel; Protein Binding | 2012 |
[A case of pagetoid carcinoma of the breast in nearly complete response by primary systemic therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Paget's Disease, Mammary; Trastuzumab | 2011 |
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Drug Hypersensitivity; Feasibility Studies; Female; Focus Groups; Glucocorticoids; Histamine Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Premedication; United States; Withholding Treatment | 2012 |
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Young Adult | 2013 |
3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Imaging, Three-Dimensional; Middle Aged; Neoplasm Staging; Paclitaxel; Preoperative Care; Prognosis; Remission Induction; Ultrasonography, Mammary | 2011 |
Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colloids; Delayed-Action Preparations; Drug Stability; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Hydrophobic and Hydrophilic Interactions; Nanotechnology; Paclitaxel; Particle Size; Peptides | 2011 |
Cross-sensitivity between taxanes in patients with breast cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Premedication; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Pneumocystis jiroveci Pneumonia in an Atypical Host.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Linoleic Acids, Conjugated; Materials Testing; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poloxamer; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction | 2012 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
α-Tocopherol succinate-modified chitosan as a micellar delivery system for paclitaxel: preparation, characterization and in vitro/in vivo evaluations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Female; Hemolysis; Humans; Hydrophobic and Hydrophilic Interactions; Magnetic Resonance Spectroscopy; Male; Mice; Micelles; Microscopy, Electron, Transmission; Paclitaxel; Particle Size; Rabbits; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; Tocopherols; Uterine Cervical Neoplasms | 2012 |
Paclitaxel-loaded polymeric nanoparticles based on PCL-PEG-PCL: preparation, in vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Female; Injections, Intravenous; Kinetics; Lasers; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Nanotechnology; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Scattering, Radiation; Solubility; Spectrophotometry, Ultraviolet; Technology, Pharmaceutical; Tumor Burden | 2011 |
Synthesis and characterization of amphiphilic chitosan derivatives as a nano-carrier for paclitaxel delivery.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Deoxycholic Acid; Drug Carriers; Drug Compounding; Epoxy Compounds; Female; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kinetics; Microscopy, Confocal; Nanoparticles; Nanotechnology; Paclitaxel; Particle Size; Propanols; Quaternary Ammonium Compounds; Solubility; Surface-Active Agents; Technology, Pharmaceutical | 2011 |
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Centers for Medicare and Medicaid Services, U.S.; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Models, Economic; Paclitaxel; Patient Selection; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome; United States | 2012 |
[Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hormone Replacement Therapy; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Letrozole; Middle Aged; Nitriles; Paclitaxel; Time Factors; Triazoles | 2011 |
Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Glycols; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Micelles; Nanostructures; Paclitaxel; Particle Size; Polyurethanes; Real-Time Polymerase Chain Reaction; Solubility; Spectroscopy, Fourier Transform Infrared; STAT1 Transcription Factor; Water | 2012 |
Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cycloheximide; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; MCF-7 Cells; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Protein Synthesis Inhibitors; Proteolysis; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Taxoids; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2012 |
Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Diffusion; Female; Humans; Micelles; Nanocapsules; Paclitaxel; Polyethylene Glycols; Vitamin E | 2011 |
Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Pennsylvania; Peripheral Nervous System Diseases; Self Care; Taxoids; Young Adult | 2012 |
[The role of nanotechnology in creating novel antitumor agents].
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Design; Female; Humans; Liposomes; Nanoparticles; Nanostructures; Nanotechnology; Neoplasms; Paclitaxel; Tamoxifen; Taxoids | 2011 |
[A case of bone marrow carcinomatosis from breast cancer treated with weekly Paclitaxel].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Paclitaxel | 2012 |
Regression of a meningioma during paclitaxel and bevacizumab therapy for breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain; Breast Neoplasms; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2012 |
Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cyclin B1; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Paclitaxel; Tubulin; Tubulin Modulators | 2012 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoradiotherapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Breast Neoplasms; Caspase 7; Caspase 9; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Membrane Proteins; Paclitaxel; Proto-Oncogene Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; Aurora Kinases; Base Sequence; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Combined Modality Therapy; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Order; Genetic Vectors; Humans; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; Stathmin; Xenograft Model Antitumor Assays | 2012 |
Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan-folic acid micelles.
Topics: Absorbable Implants; Breast Neoplasms; Cell Membrane; Cell Nucleus; Chitosan; Drug Carriers; Female; Folic Acid; Humans; Micelles; Microscopy, Fluorescence; Paclitaxel; Rhodamines; Solubility; Tumor Cells, Cultured | 2012 |
The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy.
Topics: Actigraphy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Fatigue; Female; Fluorouracil; Humans; Longitudinal Studies; Middle Aged; Paclitaxel; Prospective Studies; Sleep; Sleep Wake Disorders; Taxoids | 2012 |
Angiosarcoma of the breast: a difficult surgical challenge.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles | 2012 |
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Doxorubicin; Female; Fluorouracil; Gene Expression; Gene Knockdown Techniques; Gene Library; Humans; Hyaluronan Receptors; Molecular Targeted Therapy; Neoplastic Stem Cells; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; RNA Interference; RNA, Small Interfering | 2012 |
14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Topics: 14-3-3 Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Methylation; Drug Resistance, Neoplasm; Epirubicin; Exonucleases; Exoribonucleases; Female; Fluorouracil; Humans; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Promoter Regions, Genetic; Retrospective Studies; Sequence Analysis, DNA; Treatment Outcome; Tumor Suppressor Protein p53 | 2012 |
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Evolution, Chemical; Female; Humans; Paclitaxel | 2012 |
GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA Methylation; Drug Resistance, Microbial; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Neoadjuvant Therapy; Paclitaxel; Promoter Regions, Genetic; Receptors, Estrogen | 2012 |
[Invasive ductal carcinoma and chronic lymphocytic leukemia: a unique case of collision tumor in breast].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel | 2011 |
[A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Paclitaxel; Tomography, X-Ray Computed | 2012 |
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Costs and Cost Analysis; Cyclophosphamide; Databases, Factual; Docetaxel; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Organoselenium Compounds; Paclitaxel; Xenograft Model Antitumor Assays | 2012 |
Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Microtubule-Associated Proteins; Microtubules; Middle Aged; Nuclear Proteins; Paclitaxel; Polo-Like Kinase 1; Proliferating Cell Nuclear Antigen; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Up-Regulation; Young Adult | 2012 |
Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apolipoproteins E; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Clusterin; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Lipids; Low Density Lipoprotein Receptor-Related Protein-2; Nanoparticles; Paclitaxel; Polyethyleneimine; RNA, Small Interfering | 2012 |
Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Paclitaxel; Prohibitins; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2012 |
Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
Topics: Adult; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulation; Estrogen Receptor alpha; Estrogens; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; JNK Mitogen-Activated Protein Kinases; M Phase Cell Cycle Checkpoints; MicroRNAs; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Paclitaxel; Signal Transduction; Transfection | 2012 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Drug Carriers; Female; Humans; Hydrogen-Ion Concentration; Methacrylates; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Phosphatidylethanolamines; Xenograft Model Antitumor Assays | 2012 |
Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line; Dogs; Drug Carriers; Electrochemotherapy; Female; High-Energy Shock Waves; Mice; Micelles; Paclitaxel; Polymers | 2012 |
The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Class III Phosphatidylinositol 3-Kinases; Female; Humans; Paclitaxel | 2013 |
Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).
Topics: Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Breast Neoplasms; Caveolin 1; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; MAP Kinase Kinase 4; Mitochondria; Mutation, Missense; Paclitaxel; Phosphorylation; Protein Structure, Tertiary | 2012 |
Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vinblastine; Vinorelbine | 2012 |
Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Meta-Analysis as Topic; Middle Aged; Morocco; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Taxoids; Treatment Outcome; Young Adult | 2012 |
ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Paclitaxel; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
GDF3 inhibits the growth of breast cancer cells and promotes the apoptosis induced by Taxol.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Down-Regulation; Female; Gene Knockdown Techniques; Growth Differentiation Factor 3; Humans; Paclitaxel; Recombinant Fusion Proteins; Tumor Stem Cell Assay | 2012 |
Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Ion Channels; MCF-7 Cells; Membrane Glycoproteins; Microfilament Proteins; Neoplasm Proteins; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleosides; RNA Interference | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Novel hydrophilic taxane analogues inhibit growth of cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Proliferation; Docetaxel; Female; Flow Cytometry; Humans; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2012 |
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2C8; Female; Gene Frequency; Genetic Association Studies; Haplotypes; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide; Tumor Burden | 2012 |
Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cluster Analysis; Depression; Fatigue; Female; Humans; Middle Aged; Neuralgia; Paclitaxel; Pain Measurement; Severity of Illness Index; Sleep Wake Disorders | 2013 |
High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Paclitaxel; Prognosis; Proportional Hazards Models; Tissue Inhibitor of Metalloproteinase-1 | 2012 |
Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Agents; Axilla; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chromosomes, Human, Pair 17; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Logistic Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Taxoids; Young Adult | 2012 |
Cystoid macular edema induced by nab-paclitaxel.
Topics: Albumins; Breast Neoplasms; Female; Humans; Macular Edema; Middle Aged; Paclitaxel; Prognosis; Quality of Life | 2015 |
Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients.
Topics: Adult; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Carcinoma, Ductal, Breast; Cytokines; Doxorubicin; Female; Humans; Inflammation; Lipid Peroxidation; Malondialdehyde; Middle Aged; Neoplasm Invasiveness; Nitric Oxide; Oxidative Stress; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Treatment Outcome | 2012 |
Die and let live: harnessing BikDD to combat breast cancer stem cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; CD24 Antigen; Female; Humans; Hyaluronan Receptors; Lapatinib; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Female; Humans; Lipoproteins, HDL; Paclitaxel; Particle Size; Phosphatidylcholine-Sterol O-Acyltransferase; Recombinant Proteins | 2012 |
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; ErbB Receptors; Female; Fluorouracil; Humans; Immunohistochemistry; Keratin-5; Methotrexate; Middle Aged; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Young Adult | 2012 |
G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Death; Cell Division; Cell Line, Tumor; Chemoradiotherapy; DNA Fragmentation; Female; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Humans; Microtubules; Paclitaxel; Prohibitins; Radiation, Ionizing; Staurosporine; Tumor Cells, Cultured; Vincristine | 2012 |
Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation.
Topics: Administration, Oral; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Drug Carriers; Drug Delivery Systems; Humans; Intestinal Absorption; Intestine, Small; MCF-7 Cells; Micelles; Paclitaxel; Particle Size; Poloxamer; Polymers; Random Allocation; Rats; Rats, Sprague-Dawley | 2012 |
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Metabolome; Metabolomics; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Profound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient.
Topics: Adult; Antineoplastic Agents, Phytogenic; Brain; Breast Neoplasms; Female; Humans; Magnetic Resonance Imaging; Neuroimaging; Paclitaxel; Peripheral Nervous System Diseases | 2011 |
[A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].
Topics: Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Sentinel Lymph Node Biopsy | 2012 |
The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Cell Count; Bone Marrow Cells; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Glucosyltransferases; Humans; Mice; Neoplastic Stem Cells; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured | 2012 |
Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Electrocardiography; Epirubicin; Female; Heart; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Radiotherapy; Receptor, ErbB-2; Retrospective Studies; Time; Trastuzumab | 2012 |
Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Breast Neoplasms; Cyclophosphamide; Epirubicin; ErbB Receptors; Female; Fluorouracil; GATA3 Transcription Factor; Hepatocyte Nuclear Factor 3-alpha; Humans; Ki-67 Antigen; Middle Aged; Mucin-1; Neoadjuvant Therapy; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Sequence Analysis, DNA; Treatment Outcome | 2012 |
Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Drug Synergism; Estrogen Receptor alpha; Female; Focal Adhesion Kinase 1; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Invasiveness; Neoplasm Micrometastasis; Neovascularization, Pathologic; Paclitaxel; Peptidomimetics; Pyridines; Pyrimidines; Receptor, ErbB-2; Receptors, Progesterone; src-Family Kinases; Thiazoles; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Administration of nab-paclitaxel for 9 metastatic breast cancer patients].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2012 |
Controlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responses.
Topics: Apoptosis; Breast Neoplasms; Cadherins; Cell Adhesion; Cell Count; Cell Cycle; Cell Death; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Integrin beta1; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Tumor Microenvironment | 2012 |
Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2013 |
Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoadjuvant Therapy; Organ Specificity; Paclitaxel; Protein Binding; Retinoblastoma Protein; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Transfection | 2012 |
Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NF-kappaB and HDAC in breast cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Curcumin; Cyclophosphamide; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Mammary Neoplasms, Experimental; Mice; NF-kappa B; Paclitaxel; Protein Kinase C; Telomerase | 2011 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent.
Topics: Antimalarials; Autophagy; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mefloquine; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitination | 2012 |
Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies.
Topics: Adaptation, Psychological; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dysgeusia; Feeding and Eating Disorders; Female; Flavoring Agents; Humans; Interviews as Topic; Middle Aged; Paclitaxel; Qualitative Research; Spices; Taste; Taxoids; Young Adult | 2013 |
TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Female; Gene Amplification; Gene Dosage; Gene Expression; Humans; Neoadjuvant Therapy; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
Paclitaxel-conjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arginine; Breast Neoplasms; Cell Line, Tumor; DNA; Female; Glutathione; Humans; Interleukin-12; Mice; Micelles; Paclitaxel; Particle Size; Polyamines; Polyethylene Glycols; Transfection | 2012 |
Therapeutic application of injectable thermosensitive hydrogel in preventing local breast cancer recurrence and improving incision wound healing in a mouse model.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Female; Hydrogel, Polyethylene Glycol Dimethacrylate; Mice; Mice, Inbred BALB C; Paclitaxel; Polyesters; Polyethylene Glycols; Secondary Prevention; Temperature; Transplantation, Homologous; Wound Healing | 2012 |
Chemotherapy-induced acral erythema sparing the palms.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel | 2012 |
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Receptor, ErbB-2; Receptors, IgG; Survival Rate; Taxoids; Trastuzumab | 2012 |
Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production.
Topics: Antibodies, Neutralizing; Antineoplastic Agents; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Chemokine CCL2; Cytokines; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Interleukin-8; MCF-7 Cells; Molecular Sequence Data; Paclitaxel; Receptors, Interleukin-6; Receptors, Interleukin-8; RNA, Small Interfering | 2012 |
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
Topics: Animals; Apoptosis; Biomarkers, Pharmacological; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Mice; Oncogene Protein v-akt; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Transplantation, Heterologous | 2012 |
TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Keratinocytes; Liver Neoplasms; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome | 2012 |
Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Dedifferentiation; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured; Valproic Acid; Wnt Signaling Pathway | 2012 |
Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Calcineurin; Cell Line, Tumor; Fas Ligand Protein; Genes, p53; Humans; NFATC Transcription Factors; Paclitaxel; Plasma Membrane Calcium-Transporting ATPases; Protein Binding; Signal Transduction | 2012 |
[Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Nocodazole; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyploidy; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Vincristine | 2012 |
ERα positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Induction; Estrogen Receptor alpha; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Paclitaxel; Promoter Regions, Genetic; Transcription, Genetic | 2012 |
Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Cognition; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neuropsychological Tests; Paclitaxel; Prognosis; Stress, Psychological; Taxoids | 2014 |
Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; tau Proteins; Treatment Outcome | 2013 |
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; HMGB1 Protein; Humans; Mucin-1; Neoadjuvant Therapy; Paclitaxel; Prognosis; Receptor for Advanced Glycation End Products; Taxoids; Trastuzumab | 2013 |
Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Forkhead Transcription Factors; Humans; Interleukin-17; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; T-Lymphocytes, Regulatory | 2012 |
Therapy of radiation-induced angiosarcoma of the breast in an elderly patient.
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Hemangiosarcoma; Humans; Hyperthermia, Induced; Neoplasms, Radiation-Induced; Paclitaxel | 2013 |
Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Female; Humans; MCF-7 Cells; Nuclear Proteins; Paclitaxel; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Up-Regulation | 2012 |
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Disease-Free Survival; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Tubulin | 2012 |
BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Calcium Channel Blockers; Camptothecin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Irinotecan; KB Cells; Liver Neoplasms; Male; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Paclitaxel; Piperidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triterpenes; Verapamil | 2012 |
A case of paclitaxel-induced maculopathy treated with methazolamide.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diuretics; Female; Humans; Macular Edema; Methazolamide; Middle Aged; Paclitaxel; Visual Acuity | 2012 |
Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Female; Humans; Intravitreal Injections; Macular Edema; Paclitaxel; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2013 |
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Maintenance Chemotherapy; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2012 |
Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Doxorubicin; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Membrane Potential, Mitochondrial; Micelles; Paclitaxel; Poloxalene; Polyethylenes; Polymers; Polypropylenes; Rhodamine 123; Rhodamines | 2013 |
Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Isoenzymes; Mice; Mice, SCID; Neoplastic Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Radiation, Ionizing; Receptors, Estrogen; Retinal Dehydrogenase; Twist-Related Protein 1; Xenograft Model Antitumor Assays | 2012 |
Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Movement; Disease Models, Animal; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2012 |
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cytosol; Diffusion; Hydrogen-Ion Concentration; Mice; Micelles; Nanocapsules; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Proteins | 2013 |
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Protein Structure, Tertiary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cytotoxins; Doxorubicin; Drug Synergism; Female; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Sequence Data; Mucin-1; Paclitaxel; Peptides; Protein Interaction Domains and Motifs | 2013 |
Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Hepatocellular; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Glycyrrhetinic Acid; Hep G2 Cells; Humans; Hyaluronic Acid; Injections, Intravenous; Liver Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Tissue Distribution; Xenograft Model Antitumor Assays | 2013 |
Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Monitoring; Epirubicin; Female; Humans; Japan; Ki-67 Antigen; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab | 2012 |
Silencing prion protein in MDA-MB-435 breast cancer cells leads to pleiotropic cellular responses to cytotoxic stimuli.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Genes, p53; Humans; Paclitaxel; Plasmids; Prions; Retroviridae; RNA, Small Interfering; Signal Transduction; Staurosporine; Trypan Blue | 2012 |
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Protein Array Analysis; Proteomics; Taxoids | 2013 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Drug Combinations; Female; Genetic Therapy; Imines; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Paclitaxel; Poloxalene; Polyethylene Glycols; Polyethylenes; RNA, Small Interfering; Transfection; Treatment Outcome; Vitamin E | 2013 |
[Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Lung Neoplasms; Paclitaxel; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed; Trastuzumab | 2012 |
Paclitaxel-induced acral erythema.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hand-Foot Syndrome; Humans; Paclitaxel | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Negative regulation of ERα by a novel protein CAC1 through association with histone demethylase LSD1.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Co-Repressor Proteins; Cullin Proteins; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Histone Demethylases; Histones; Humans; Mutant Proteins; Neoplasm Proteins; Paclitaxel; Promoter Regions, Genetic; Protamine Kinase; Recombinant Proteins; RNA Interference; Trefoil Factor-1; Tumor Suppressor Proteins | 2013 |
PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Female; Male; Mice; Mice, Inbred BALB C; Micelles; Nanocapsules; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Treatment Outcome | 2013 |
Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome | 2013 |
Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
Topics: Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Contrast Media; Cyclophosphamide; Diastole; Docetaxel; Doxorubicin; Echocardiography; Echocardiography, Three-Dimensional; Female; Heart Ventricles; Humans; Middle Aged; Paclitaxel; Prospective Studies; Reproducibility of Results; Stroke Volume; Systole; Taxoids; Trastuzumab; Ventricular Function, Left | 2013 |
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; DNA-Binding Proteins; Female; Genome-Wide Association Study; Humans; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Regulatory Factor X Transcription Factors; Transcription Factors | 2013 |
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplastic Stem Cells; Paclitaxel; Phenylurea Compounds; Spheroids, Cellular; Stem Cell Niche; Sulfonamides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model.
Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Electrochemistry; Female; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Nude; Mitoxantrone; Nanoparticles; Paclitaxel; Particle Size | 2012 |
Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity.
Topics: Animals; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Female; Gene Knockdown Techniques; Humans; Immunohistochemistry; Integrin beta4; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Oncogene Proteins; Paclitaxel; Poly(ADP-ribose) Polymerases; ras Proteins; RNA, Messenger; Shc Signaling Adaptor Proteins; Transfection; Xenograft Model Antitumor Assays | 2012 |
Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial Cells; Female; Humans; Microfluidic Analytical Techniques; Microfluidics; Microtubules; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Paclitaxel | 2013 |
2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta-Cyclodextrins; Biological Transport; Breast Neoplasms; Calcium Channel Blockers; Cell Survival; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Excipients; Female; Humans; MCF-7 Cells; Nanoparticles; Neoplasm Proteins; Paclitaxel; Stearic Acids; Surface-Active Agents; Ultrasonics; Verapamil | 2013 |
In vitro evaluation on novel modified chitosan for targeted antitumor drug delivery.
Topics: Antineoplastic Agents; Breast Neoplasms; Chitosan; Drug Carriers; Female; Folic Acid; Humans; MCF-7 Cells; Micelles; Paclitaxel; Polymers | 2013 |
Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lymph Nodes; Mice; Microscopy, Confocal; Nanoparticles; Neoplasm Metastasis; Paclitaxel | 2013 |
Short-term hyperthermia promotes the sensitivity of MCF-7 human breast cancer cells to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; MCF-7 Cells; Paclitaxel | 2013 |
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neovascularization, Pathologic; Paclitaxel; ROC Curve; Spectroscopy, Near-Infrared; Trastuzumab; Treatment Outcome; Ultrasonography, Interventional | 2013 |
[Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Trastuzumab | 2012 |
[A case of cardiac tamponade due to breast cancer treated with weekly paclitaxel].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cardiac Tamponade; Drainage; Female; Humans; Paclitaxel | 2012 |
[A case report of liver metastasis of breast cancer successfully treated by hepatic arterial infusion of docetaxel and systemic administration of nab-paclitaxel].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2012 |
[A long-surviving case of HER2-positive breast cancer with brain metastasis treated by multidisciplinary therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle Aged; Paclitaxel; Radiosurgery; Receptor, ErbB-2; Time Factors; Trastuzumab | 2012 |
[Complete response of advanced breast cancer with lymph node metastases to nab-paclitaxel therapy-report of a case].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel | 2012 |
Analysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectives.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; High-Throughput Screening Assays; Humans; Models, Statistical; Paclitaxel; RNA Interference; RNA, Small Interfering; TOR Serine-Threonine Kinases | 2012 |
The oncolytic herpes simplex virus vector G47∆ effectively targets breast cancer stem cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Oncolytic Viruses; Paclitaxel; Simplexvirus; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
Muscarinic activation enhances the anti-proliferative effect of paclitaxel in murine breast tumor cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbachol; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Mice; Muscarinic Agonists; Paclitaxel | 2013 |
Fucoidan extract enhances the anti-cancer activity of chemotherapeutic agents in MDA-MB-231 and MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Synergism; Female; Glutathione; Humans; MAP Kinase Signaling System; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Oxidative Stress; Paclitaxel; Phaeophyceae; Phosphorylation; Plant Extracts; Polysaccharides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tamoxifen | 2013 |
Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors.
Topics: Animals; Breast Neoplasms; CD24 Antigen; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cellular Reprogramming; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Dactinomycin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Induced Pluripotent Stem Cells; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mammary Glands, Human; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthoquinones; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Proto-Oncogene Proteins c-myc; Pyrans; SOXB1 Transcription Factors; Spheroids, Cellular | 2014 |
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Keratin-19; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2013 |
Investigating longitudinal changes in the mechanical properties of MCF-7 cells exposed to paclitaxol using particle tracking microrheology.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Death; Cytoplasm; Elasticity; Elasticity Imaging Techniques; Humans; MCF-7 Cells; Mitosis; Models, Statistical; Paclitaxel; Pressure; Rheology; Shear Strength; Stress, Mechanical; Time Factors; Viscosity | 2013 |
Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; NIMA-Related Kinases; Oligonucleotides, Antisense; Paclitaxel; Protein Serine-Threonine Kinases; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA Interference; RNA, Small Interfering; Spindle Apparatus | 2013 |
Recall phenomena: another facet of the immunocompromised district.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel; Radiodermatitis | 2013 |
The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neoplasms; Cell Cycle Checkpoints; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mitochondria; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor Suppressor Proteins | 2013 |
Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Forkhead Transcription Factors; Humans; Lung Neoplasms; MCF-7 Cells; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Mitochondria; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Up-Regulation; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2013 |
Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; DNA, Complementary; Doxorubicin; Female; Gene Expression Profiling; Genome, Human; Humans; Models, Statistical; Oligonucleotide Array Sequence Analysis; Paclitaxel; Paraffin Embedding; Quality Control; Randomized Controlled Trials as Topic; Receptor, ErbB-2; RNA; Trastuzumab | 2013 |
Bevacizumab in breast cancer: fundamental questions remain.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Paclitaxel | 2013 |
Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Markov Chains; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2 | 2014 |
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Interleukin-8; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Protein Serine-Threonine Kinases; Pyrazoles; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Estrogen; Receptors, Progesterone; Receptors, Transforming Growth Factor beta; RNA, Small Interfering; Signal Transduction; Smad4 Protein; Spheroids, Cellular; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2013 |
Breast cancer in patients with sickle cell disease can be treated safely with weekly paclitaxel.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Neoplasm Metastasis; Paclitaxel | 2013 |
Docetaxel improves survival and reduces risk of relapse in node-positive early-stage breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Postoperative Care; Secondary Prevention; Survival Rate; Taxoids | 2002 |
[Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Taxoids | 2002 |
[One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Docetaxel; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Medroxyprogesterone Acetate; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2002 |
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disulfiram; Docetaxel; Drug Interactions; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epirubicin; Female; Humans; Paclitaxel; Razoxane; Taxoids; Tretinoin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Overexpression of cyclin D1 enhances taxol induced mitotic death in MCF7 cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Mitosis; Paclitaxel; Tumor Cells, Cultured | 2002 |
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genes, BRCA1; Genes, BRCA2; Humans; Neoadjuvant Therapy; Paclitaxel; Preoperative Care; Treatment Outcome | 2002 |
Docetaxel-induced nail changes--a neurogenic mechanism: a case report.
Topics: Afferent Pathways; Arm; Brachial Plexus; Breast Neoplasms; Docetaxel; Efferent Pathways; Female; Humans; Middle Aged; Motor Neurons; Nail Diseases; Neoplasm Invasiveness; Neural Conduction; Neurologic Examination; Neurons, Afferent; Paclitaxel; Paralysis; Parasympathetic Nervous System; Sensory Thresholds; Skin; Sympathetic Nervous System; Taxoids; Vibration | 2002 |
Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Squamous Cell; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carboplatin; Cell Survival; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta; Regional Blood Flow; Transplantation, Heterologous | 2002 |
[Weekly Taxol (Paclitaxel) administration in the second-line treatment of breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Paclitaxel | 2002 |
[Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Europe; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
[Possibilities and results with Herceptin-Taxol combination in the treatment of breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Humans; Multicenter Studies as Topic; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; United States; Up-Regulation | 2002 |
Which dosing scheme is suitable for the taxanes? An in vitro model.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Survival; Docetaxel; Female; Humans; Indicators and Reagents; Paclitaxel; Taxoids; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Cardiac dysfunction in clinical trials of trastuzumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Trastuzumab | 2002 |
[A case of recurrent breast cancer with chronic renal failure treated on an outpatient basis].
Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Middle Aged; Paclitaxel; Radiotherapy Dosage; Renal Dialysis; Taxoids; Thoracic Neoplasms | 2002 |
[Patient with bone metastasis of breast cancer who were improved by weekly DXR/TXT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Paclitaxel; Taxoids | 2002 |
Meeting highlights 38th annual meeting of the American Society of Clinical Oncology. Advances in adjuvant chemotherapy for management of breast cancer: the emerging role of docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Medical Oncology; Middle Aged; Paclitaxel; Taxoids | 2002 |
Direct Raman imaging techniques for study of the subcellular distribution of a drug.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Models, Theoretical; Paclitaxel; Pharmacokinetics; Spectrum Analysis, Raman; Subcellular Fractions | 2002 |
Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy.
Topics: Antibiotics, Antineoplastic; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Modified Radical; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies | 2002 |
Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Down-Regulation; Drug Synergism; Enzyme Activation; Female; Humans; Mice; Mice, Inbred ICR; Mice, SCID; Paclitaxel; Phosphorylation; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Nail Diseases; Paclitaxel; Pigmentation; Quality of Life; Severity of Illness Index | 2002 |
Radiation recall dermatitis from docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Recurrence; Taxoids | 2002 |
In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gene Expression Regulation; Genes, erbB-2; Humans; Immunohistochemistry; Paclitaxel; Probability; Sensitivity and Specificity; Statistics, Nonparametric; Taxoids; Trastuzumab; Tumor Cells, Cultured | 2002 |
The role of MAPK pathways in the action of chemotherapeutic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Ceramides; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Flavonoids; HeLa Cells; Humans; Imidazoles; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Paclitaxel; Pyridines; Skin Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene.
Topics: Adenovirus E1A Proteins; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Combined Modality Therapy; DNA; Genetic Therapy; Head and Neck Neoplasms; Humans; Liposomes; Paclitaxel; Xenograft Model Antitumor Assays | 2002 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotides; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2002 |
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Cycle; Humans; Microtubule Proteins; Microtubules; Mutation; Paclitaxel; Phosphoproteins; Stathmin; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2002 |
Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Camptothecin; Cisplatin; Dioxoles; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Isoquinolines; Mice; Mice, Nude; Mitosis; Paclitaxel; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bridged-Ring Compounds; Cell Division; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Endothelium, Vascular; Epothilones; Humans; Paclitaxel; Tumor Cells, Cultured | 2002 |
[A case of metastatic breast cancer responding to weekly paclitaxel and high-dose toremifene administrated alternately].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Paclitaxel; Remission Induction; Toremifene | 2002 |
P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Survival; Ceramides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Glucosyltransferases; Humans; Microscopy, Fluorescence; Morpholines; Paclitaxel; Palmitic Acid; Protein Transport; Tubulin; Tumor Cells, Cultured; Vincristine | 2002 |
Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Eruptions; Erythema; Female; Foot; Hand; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Skin Diseases; Sweat Gland Diseases; Syndrome; Taxoids | 2002 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Central Nervous System Neoplasms; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2002 |
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Chromones; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Etoposide; Flow Cytometry; Humans; Immunoblotting; Morpholines; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tamoxifen; Time Factors; Transfection; Trastuzumab; Tumor Cells, Cultured | 2002 |
Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Humans; Paclitaxel; Principal Component Analysis; Prognosis; Quality of Life; Regression Analysis; Surveys and Questionnaires | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
Pegfilgrastim: the promise of pegylation fulfilled.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2003 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, SCID; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperazines; Polymerase Chain Reaction; Pyrimidines; Sensitivity and Specificity; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Middle Aged; Paclitaxel; Survival Rate | 2002 |
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Case-Control Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols | 2003 |
[Chemotherapy protocol with taxol increase survival by 31 percent].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2002 |
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Doxorubicin; Female; Flavonoids; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Phosphorylation; Phosphothreonine; Piperidines; RNA, Messenger; Survivin; Tumor Cells, Cultured; Ultraviolet Rays | 2003 |
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin | 2002 |
[Breast carcinoma. Preoperative chemotherapy can preserve the breast].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Paclitaxel | 2002 |
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Apoptosis; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Division; Clinical Trials as Topic; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Random Allocation; Time Factors; Treatment Outcome | 2003 |
Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; CD28 Antigens; CD4 Antigens; CD8 Antigens; Cell Division; Dendritic Cells; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Epitopes; Female; Flow Cytometry; Immunotherapy; In Situ Nick-End Labeling; Interleukin-2; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Paclitaxel; T-Lymphocytes; Time Factors | 2003 |
Toxic neuropathy in patients with pre-existing neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Lupus Erythematosus, Discoid; Lymphoma; Male; Middle Aged; Neural Conduction; Oropharyngeal Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Thalidomide; Vincristine | 2003 |
[Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel | 2003 |
[Two cases of effective weekly paclitaxel administration and concurrent radiation for metastatic breast cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents | 2003 |
Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Fatal Outcome; Female; Hepatitis, Viral, Human; Herpes Simplex; Humans; Liver Failure; Middle Aged; Paclitaxel; Taxoids | 2003 |
Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression; Genes, erbB-2; Humans; Paclitaxel; Taxoids; Transfection; Tumor Cells, Cultured | 2003 |
Dosing study seen as victory for clinical trials, mathematical models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Models, Theoretical; Neutropenia; Paclitaxel; Recombinant Proteins; Regression Analysis; Research Design; Survival Analysis; Treatment Outcome | 2003 |
[Effective transarterial neoadjuvant chemotherapy with paclitaxel (TXL) in a case of locally advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Subclavian Artery; Thoracic Arteries | 2003 |
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids | 2003 |
Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Prospective Studies; Remission Induction; Treatment Outcome | 2003 |
Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cyclin D3; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cyclophosphamide; Docetaxel; Enzyme Inhibitors; Epirubicin; Female; Fluorouracil; Gene Expression; Genes, p53; Genes, Tumor Suppressor; Humans; Ki-67 Antigen; Methotrexate; Middle Aged; Paclitaxel; Preoperative Care; Receptors, Steroid; Taxoids; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2003 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation.
Topics: Antigens, CD; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Filgrastim; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Immunologic Memory; Lymphocyte Depletion; Paclitaxel; Recombinant Proteins; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation, Autologous | 2003 |
Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography.
Topics: Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Epirubicin; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Mammography; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Radionuclide Imaging; Technetium Tc 99m Sestamibi; Treatment Outcome | 2003 |
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Docetaxel; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Paclitaxel; Radiography; Rats; Rats, Inbred F344; Taxoids; Time Factors; Treatment Outcome | 2002 |
The use of putative placebo in active control trials: two applications in a regulatory setting.
Topics: Angina, Unstable; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase III as Topic; Confidence Intervals; Data Interpretation, Statistical; Docetaxel; Doxorubicin; Enoxaparin; Female; Fibrinolytic Agents; Humans; Myocardial Infarction; Odds Ratio; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Therapeutic Equivalency | 2003 |
Semi-synthesis of an O-glycosylated docetaxel analogue.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Chemistry; Breast Neoplasms; Cattle; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glycosylation; Humans; In Vitro Techniques; Indicators and Reagents; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured | 2003 |
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Topics: Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; DNA Fragmentation; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Neoplasm Transplantation; Paclitaxel; Taxoids; Time Factors; Tumor Cells, Cultured | 2003 |
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Mitomycin; Oligonucleotides; Oligonucleotides, Antisense; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Signal Transduction; Taxoids; Time Factors | 2003 |
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Multicenter Studies as Topic; Narcotics; Neoplasm Metastasis; Paclitaxel; Pain; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Taxoids | 2003 |
E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Female; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Metastasis; Paclitaxel; Patient Selection; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Optimal chemotherapy for women with breast cancer: the plot thickens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Cyclophosphamide; Data Interpretation, Statistical; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Receptors, Estrogen; Research Design; Taxoids; Treatment Outcome | 2003 |
Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; France; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Two strategies may enhance breast cancer treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Genetic Testing; Humans; Immunotherapy; Mice; Paclitaxel; Taxoids | 2003 |
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Lineage; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Epirubicin; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Paclitaxel; Th2 Cells | 2003 |
Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Paclitaxel; RNA, Small Interfering; Transfection; Tumor Cells, Cultured; Vinblastine | 2003 |
Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway.
Topics: Acetylcysteine; Adenocarcinoma; Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Carrier Proteins; Caspases; Cisplatin; Cytochrome c Group; DNA Fragmentation; Doxorubicin; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Intracellular Membranes; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; MAP Kinase Signaling System; Membrane Potentials; Mitochondria; Mitochondrial Proteins; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Tumor Cells, Cultured | 2003 |
[Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Doxorubicin; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Paclitaxel; Pamidronate; Tamoxifen; Taxoids; Time Factors; Ultrasonography; Visual Acuity | 2003 |
[Intensive therapy with paclitaxel (Taxol) and cyclophosphamide followed by administration of G-CSF as a mobilization regimen in patients with breast carcinoma and indications for autologous hematopoietic cell transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Transplantation, Autologous | 2002 |
Total synthesis of the microtubule stabilizing antitumor agent laulimalide and some nonnatural analogues: the power of Sharpless' asymmetric epoxidation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chemistry, Organic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epothilones; Female; Humans; Indicators and Reagents; Macrolides; Molecular Structure; Paclitaxel; Porifera; Spindle Apparatus; Stereoisomerism; Taxoids; Tumor Cells, Cultured | 2003 |
Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells.
Topics: Apoptosis; Breast Neoplasms; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Humans; Immunoblotting; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Precipitin Tests; Proto-Oncogene Proteins c-raf; Time Factors; Tumor Cells, Cultured | 2003 |
Cystic maculopathy with normal capillary permeability secondary to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Docetaxel; Fatal Outcome; Female; Fluorescein Angiography; Humans; Macular Edema; Middle Aged; Paclitaxel; Retinal Vessels; Taxoids; Visual Acuity | 2003 |
Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Conjunctivitis; Docetaxel; Female; Humans; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Taxoids | 2003 |
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; BRCA1 Protein; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cisplatin; Female; Humans; Paclitaxel | 2003 |
p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Tubulin; Tumor Suppressor Protein p53 | 2003 |
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
Topics: Animals; Benzoquinones; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Drug Synergism; Enzyme Activation; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Rifabutin; Xenograft Model Antitumor Assays | 2003 |
Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Burkitt Lymphoma; DNA Mutational Analysis; DNA Primers; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Sequence Data; Mutation; Ovarian Neoplasms; Paclitaxel; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; Tubulin; Tumor Cells, Cultured | 2003 |
Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Contrast Media; Cyclophosphamide; Epirubicin; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction | 2003 |
Weekly paclitaxel (Taxol) with or without trastuzumab (Herceptin) in advanced breast cancer: a community-based observation study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Trastuzumab | 2003 |
NICE recommends new treatment for breast and bowel cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Paclitaxel; Practice Guidelines as Topic; Taxoids; Tegafur; Uracil | 2003 |
Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2003 |
[Weekly paclitaxel administration in the adjuvant therapy of primary breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Paclitaxel | 2003 |
[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Floxuridine; Humans; Leukopenia; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects | 2003 |
[Combined effects of toremifene and paclitaxel on human breast cancer cell lines].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Synergism; Humans; Paclitaxel; Selective Estrogen Receptor Modulators; Toremifene; Tumor Cells, Cultured | 2003 |
Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Female; Humans; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Signal Transduction; Sodium-Hydrogen Exchangers | 2003 |
Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Breast Neoplasms; Docetaxel; Female; Humans; Liver Failure; Paclitaxel; Taxoids | 2003 |
Dose-intense paclitaxel: deja vu all over again?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 2003 |
Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hemorrhage; Humans; Nail Diseases; Nails; Paclitaxel; Risk Assessment | 2003 |
[Clinical study of weekly paclitaxel administration for metastatic breast cancer based on time to progression (TTP) and survival].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate | 2003 |
Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis.
Topics: Apoptosis; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Membrane Transport Proteins; Methotrexate; Oligonucleotide Array Sequence Analysis; Paclitaxel; Thiamine | 2003 |
Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dacryocystorhinostomy; Docetaxel; Female; Humans; Intubation; Lacrimal Apparatus; Lacrimal Duct Obstruction; Middle Aged; Nasal Mucosa; Paclitaxel; Silicone Elastomers; Taxoids | 2003 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Drug Resistance; Female; Humans; Middle Aged; Mutation; Paclitaxel; Tubulin | 2003 |
[A case of postoperative recurrent breast cancer with multiple lung metastases that completely responded to combination therapy of docetaxel (TXT) and medroxyprogesterone acetate (MPA)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Medroxyprogesterone Acetate; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Taxoids | 2003 |
[Effective combination chemotherapy using weekly trastuzumab and paclitaxel in the treatment of a recurrent breast cancer patient with liver metastases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cranial Irradiation; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Remission Induction; Trastuzumab | 2003 |
Predictive cancer genomics--what do we need?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Neoadjuvant Therapy; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Sequence Analysis, DNA; Taxoids | 2003 |
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast; Breast Neoplasms; Docetaxel; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Neoadjuvant Therapy; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome | 2003 |
HER-2/neu assessment in primary chemotherapy treated breast carcinoma: no evidence of gene profile changing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Paclitaxel | 2003 |
Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cytotoxicity Tests, Immunologic; DNA Fragmentation; Drug Synergism; Female; Humans; Ovarian Neoplasms; Paclitaxel | 2003 |
Subungal abcesses secondary to paclitaxel.
Topics: Abscess; Acute Disease; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel; Paronychia | 2003 |
Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Catechin; Cell Division; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Genes, Reporter; Head and Neck Neoplasms; Humans; Immunoblotting; Luciferases; Paclitaxel; Phosphorylation; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Receptor, ErbB-2; Signal Transduction; Time Factors | 2003 |
Osteonecrosis of the jaws associated with cancer chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Paclitaxel; Taxoids | 2003 |
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymph Nodes; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2003 |
A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in v
Topics: Algorithms; Antineoplastic Agents; Artificial Intelligence; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Neural Networks, Computer; Paclitaxel; Predictive Value of Tests; Protein Array Analysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2003 |
Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; Camptothecin; Caspases; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine; Vincristine; Xenograft Model Antitumor Assays | 2003 |
Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Drug Administration Schedule; Female; Glycerol; Humans; Infusions, Intravenous; Nail Diseases; Paclitaxel; Pharmaceutical Vehicles; Solvents; Surface-Active Agents | 2003 |
Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Probability; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Reference Values; Trastuzumab; Tumor Cells, Cultured | 2003 |
Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
Topics: Anaphase; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Epothilones; Humans; Microtubules; Mitosis; Paclitaxel | 2003 |
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Binding Sites; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Line; Cell Line, Tumor; DNA-Binding Proteins; Forkhead Box Protein O1; Forkhead Transcription Factors; G2 Phase; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Membrane Proteins; Mitosis; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Up-Regulation | 2003 |
High energy shock waves (HESW) enhance paclitaxel cytotoxicity in MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; High-Energy Shock Waves; Humans; Paclitaxel; Treatment Outcome | 2003 |
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cisplatin; DNA Damage; Etoposide; G2 Phase; Humans; Microtubules; Mitosis; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
[Two cases of recurrent breast cancer successfully treated with paclitaxel weekly therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids | 2003 |
[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cryosurgery; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Injections, Intralesional; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Taxoids | 2003 |
[Examination of therapy using trastuzumab in patients with metastatic breast carcinoma].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Remission Induction; Trastuzumab | 2003 |
A case of chest wall recurrence of breast cancer treated with paclitaxel weekly, 5'-deoxy-5-fluorouridine, arterial embolization and chest wall resection.
Topics: Angiography; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Embolization, Therapeutic; Female; Floxuridine; Humans; Middle Aged; Paclitaxel; Plastic Surgery Procedures; Thoracic Wall; Tomography, X-Ray Computed | 2003 |
Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel; Prognosis; Receptors, Estrogen | 2003 |
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Child; Colony-Stimulating Factors; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Incidence; Logistic Models; Methotrexate; Middle Aged; Paclitaxel; Practice Patterns, Physicians'; Predictive Value of Tests; Retrospective Studies; Statistics, Nonparametric; United States | 2003 |
Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Cytoplasm; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunoblotting; Inhibitory Concentration 50; Microscopy, Fluorescence; Naphthalenes; Paclitaxel; Poly(ADP-ribose) Polymerases; Vacuoles | 2003 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells.
Topics: Anthracenes; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; DNA Replication; Doxorubicin; G2 Phase; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Mitosis; Oligonucleotides, Antisense; Paclitaxel; Tumor Suppressor Protein p53; Ultraviolet Rays | 2004 |
A sesquiterpene lactone, costunolide, interacts with microtubule protein and inhibits the growth of MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Microtubule Proteins; Paclitaxel; Sesquiterpenes; Time Factors | 2004 |
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Topics: Adult; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Narcotics; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Radiation-Protective Agents; Time Factors | 2004 |
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Rate; Treatment Outcome | 2004 |
In vitro exposure to paclitaxel modulates integrin expression by human T lymphocytes and inhibits T cell adhesion to breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cell Adhesion; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Integrins; Jurkat Cells; Paclitaxel; T-Lymphocytes | 2004 |
Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol.
Topics: Breast Neoplasms; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Gene Expression; Half-Life; Humans; Paclitaxel; Promoter Regions, Genetic; Protein Biosynthesis; Receptors, Estrogen; RNA, Messenger; Stimulation, Chemical; Time Factors; Transcription, Genetic | 2004 |
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Culture Media, Serum-Free; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Receptors, Steroid; Tumor Cells, Cultured | 2004 |
Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Caspase 9; Caspases; Cell Line, Tumor; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Paclitaxel | 2004 |
Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation.
Topics: Active Transport, Cell Nucleus; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cysteine-Rich Protein 61; DNA; Doxorubicin; Flow Cytometry; Genes, Dominant; Genes, Reporter; Humans; Immediate-Early Proteins; Integrin alphaVbeta3; Integrins; Intercellular Signaling Peptides and Proteins; Microscopy, Fluorescence; Models, Biological; Naphthoquinones; NF-kappa B; Oligonucleotides, Antisense; Paclitaxel; Promoter Regions, Genetic; Proteins; Receptors, Vitronectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Transfection; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Effect of paclitaxel administration on P wave duration and dispersion.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Electrocardiography; Female; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel | 2004 |
[Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2004 |
Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calcium-Binding Proteins; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Mad2 Proteins; Paclitaxel; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Repressor Proteins; RNA, Small Interfering; Spindle Apparatus; Transfection | 2004 |
Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Liposomes; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
Weekly taxanes--a leap forward or a minute progress?
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Norway; Paclitaxel; Premedication; Prognosis; Prospective Studies; Risk Assessment; Sampling Studies; Survival Analysis; Treatment Outcome | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Topics: Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endometrial Neoplasms; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Paclitaxel; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Postoperative Care; Preoperative Care; Proteomics; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres.
Topics: Antineoplastic Agents; Breast Neoplasms; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Combinations; Female; Fluorouracil; Humans; Lactic Acid; Microspheres; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Tumor Cells, Cultured | 2004 |
[Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptors, Estrogen | 2004 |
Case 3: infiltrating ductal breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy | 2004 |
Genistein inversely affects tubulin-binding agent-induced apoptosis in human breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cell Survival; Cyclin B; Cyclin B1; Drug Antagonism; Female; G2 Phase; Genistein; Humans; Mitosis; Paclitaxel; Phosphorylation; Protective Agents; Proto-Oncogene Proteins c-bcl-2; Tubulin; Tumor Cells, Cultured; Vincristine | 2004 |
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Feasibility Studies; Fluorouracil; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Treatment Outcome | 2004 |
Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; CD40 Ligand; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; fas Receptor; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Membrane Glycoproteins; Paclitaxel; Transfection | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
Estrogen receptor status, cell cycling and paclitaxel: looking for a "hormone"-ious explanation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Estrogen Receptor alpha; Female; Humans; Neoplasms, Hormone-Dependent; Paclitaxel | 2004 |
Insulin can modulate MCF-7 cell response to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Female; Flavonoids; Humans; Hypoglycemic Agents; Insulin; MAP Kinase Signaling System; Microtubules; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-raf; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2004 |
Cardiotoxic drugs in breast cancer.
Topics: Black or African American; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; Heart Diseases; Humans; Paclitaxel; Risk Factors | 2004 |
[Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Nausea; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Vomiting, Anticipatory | 2004 |
[Effective weekly paclitaxel therapy for massive metastatic breast cancer].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Radical; Paclitaxel; Pamidronate; Quality of Life | 2004 |
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Enzyme Activation; Humans; MAP Kinase Kinase Kinase 3; MAP Kinase Kinase Kinases; Paclitaxel; Plasmids; Protein Structure, Tertiary | 2004 |
Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Death; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Interphase; Microtubules; Mitosis; Nocodazole; Organ Specificity; Ovarian Neoplasms; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; Tumor Cells, Cultured | 2004 |
Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitors; Biotransformation; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Gene Expression Profiling; Genes, p53; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Paclitaxel; Pharmacogenetics; Tamoxifen; Trastuzumab | 2004 |
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Carcinoma; Cell Line; Combined Modality Therapy; Disease Models, Animal; Doxorubicin; Drug Administration Schedule; Epitopes; Female; Humans; Interferon-gamma; Lymphocyte Activation; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Paclitaxel; Receptor, ErbB-2; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Vaccines, DNA | 2004 |
[Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2004 |
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Gene Amplification; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Topics: Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Combined Modality Therapy; Female; Gene Transfer Techniques; Genetic Therapy; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Survival Rate; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2004 |
Chemotherapy-induced neuropathy: treatment by decompression of peripheral nerves.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carpal Tunnel Syndrome; Cisplatin; Decompression, Surgical; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand; Humans; Leg; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Nerve Compression Syndromes; Neuralgia; Ovarian Neoplasms; Paclitaxel; Pain Measurement; Paresthesia; Peripheral Nervous System Diseases; Treatment Outcome; Vincristine; Wrist | 2004 |
An unusual cause of hematemesis.
Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hematemesis; Humans; Paclitaxel; Proton Pump Inhibitors; Stomach Neoplasms; Treatment Outcome | 2004 |
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Up-Regulation | 2004 |
Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Paclitaxel | 2004 |
Paclitaxel in early breast cancer: a viewpoint by David A. Cameron.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel; Taxoids | 2004 |
Breast cancer with synchronous metastases: trends in survival during a 14-year period.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy--a pilot experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Carcinoma, Ductal; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperthermia, Induced; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Palliative Care; Treatment Outcome | 2004 |
[Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2004 |
Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.
Topics: Antineoplastic Agents; Biochemistry; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Disulfides; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Lung Neoplasms; Paclitaxel; Polyethylene Glycols; Solubility; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2004 |
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colitis; Colonoscopy; Docetaxel; Female; Humans; Paclitaxel; Radiography; Taxoids | 2004 |
Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Suramin; Time Factors; Treatment Outcome | 2004 |
p53 expression as a prognostic marker in inflammatory breast cancer.
Topics: Adult; Age Factors; Aged; Breast Neoplasms; Cell Nucleus; Disease-Free Survival; Female; Genes, p53; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2004 |
Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2004 |
Advances in taxane therapy for metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Chemistry, Pharmaceutical; Docetaxel; Drug Hypersensitivity; Heart Diseases; Humans; Nausea; Paclitaxel; Taxoids; Treatment Outcome; Vomiting; Water-Electrolyte Imbalance | 2004 |
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluoxetine; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mitomycin; Neoplasms, Experimental; Paclitaxel; Tissue Distribution; Vinblastine; Xenograft Model Antitumor Assays | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Proliferation; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Histiocytes; Humans; Intermediate Filaments; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Mastectomy, Modified Radical; Middle Aged; Paclitaxel; Sentinel Lymph Node Biopsy; Tubulin | 2004 |
Microtubule-interfering activity of parthenolide.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Colchicine; Cytoskeleton; Dose-Response Relationship, Drug; Female; Humans; Microscopy, Electron; Microscopy, Fluorescence; Microtubules; Paclitaxel; Plant Extracts; Sesquiterpenes; Tanacetum parthenium; Tubulin | 2004 |
A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Adhesion; Cell Movement; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Invasiveness; Paclitaxel; Phenotype; Selection, Genetic | 2004 |
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease Models, Animal; Drug Combinations; Female; Mice; Mice, SCID; Neoplasm Metastasis; Oxonic Acid; Paclitaxel; Pyridines; Tegafur; Transplantation, Heterologous | 2004 |
Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzofurans; Breast Neoplasms; Drug Synergism; Female; Humans; Isoquinolines; Male; Microtubules; Mitosis; Paclitaxel; Tumor Cells, Cultured | 2004 |
Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- and docetaxel-resistant inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion, Malignant; Taxoids; Trastuzumab; Treatment Outcome | 2004 |
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Topics: Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Ligands; Microscopy, Confocal; Neoplasm Metastasis; Neoplasms; Paclitaxel; Progesterone; Promoter Regions, Genetic; Protein Isoforms; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Transcription, Genetic | 2005 |
Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Genes, MDR; Humans; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Topics: Angiogenesis Inducing Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Cysteine-Rich Protein 61; Female; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Integrins; Intercellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Receptors, Vitronectin; Tumor Suppressor Protein p53 | 2005 |
Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cytotoxicity, Immunologic; Female; Humans; Killer Cells, Natural; Membrane Glycoproteins; NF-kappa B; Paclitaxel; Perforin; Pore Forming Cytotoxic Proteins; Proline; Thiocarbamates; Transcription, Genetic | 2005 |
[Role of taxanes in treatment of breast cancer].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Data Interpretation, Statistical; Disease Progression; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Taxoids; Time Factors; Trastuzumab | 2004 |
[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Collagen; Culture Media; Drug Screening Assays, Antitumor; Epirubicin; Fluorouracil; Gels; Humans; Liver Neoplasms; Paclitaxel; Tissue Embedding | 2004 |
The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Aziridines; Blotting, Western; Breast Neoplasms; Female; Genes, p53; Humans; Naphthoquinones; Paclitaxel; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cytoplasm; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Fatty Acid Synthases; Gene Silencing; Histones; Humans; Immunoblotting; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Biological; Nucleosomes; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Protein Structure, Tertiary; RNA Interference; RNA, Small Interfering; Serine | 2005 |
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Tissue Distribution; Trastuzumab | 2005 |
Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Erythropoietin; Female; Humans; Incidence; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Skin Diseases; Taxoids | 2005 |
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors | 2005 |
[A new therapy standard in metastatic breast cancer--gemzar/paclitaxel. Longer survival by optimized combination therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate | 2004 |
Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Doxorubicin; Drug Synergism; Estradiol; Female; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2005 |
A comparison of signaling activities induced by Taxol and desoxyepothilone B.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Death; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Lung Neoplasms; Paclitaxel; Signal Transduction; Tumor Cells, Cultured | 2004 |
Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Injections, Intralesional; Leydig Cell Tumor; Mathematics; Metabolic Clearance Rate; Mice; Microspheres; Models, Chemical; Models, Theoretical; Paclitaxel; Polymers; Transplantation, Heterologous | 2005 |
Does paclitaxel improve local control in breast cancer?
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Paclitaxel; Treatment Outcome | 2005 |
Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Evodia; Female; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Phosphorylation; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Quinazolines; Quinolines | 2005 |
Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?
Topics: Adult; Aged; Breast Neoplasms; Cisplatin; Drug Therapy, Combination; Female; Forecasting; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxins; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2005 |
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2005 |
Psychological stress induces chemoresistance in breast cancer by upregulating mdr1.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epinephrine; Female; Humans; Mice; Mice, SCID; Paclitaxel; Stress, Psychological; Treatment Outcome; Up-Regulation | 2005 |
Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; beta-Transducin Repeat-Containing Proteins; Breast Neoplasms; Colony-Forming Units Assay; Doxorubicin; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Mutation; Paclitaxel; RNA, Small Interfering; Tamoxifen; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2005 |
Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Female; G1 Phase; G2 Phase; Humans; Imidazoles; Mitosis; Mutation; Nuclear Proteins; Paclitaxel; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Topics: Aminophenols; Antibiotics, Antineoplastic; Antimanic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cyclin D1; Cysteine Proteinase Inhibitors; Down-Regulation; Drug Resistance, Neoplasm; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Half-Life; Humans; Indoles; Leupeptins; Lithium Chloride; Maleimides; Mitochondria; NF-kappa B; Paclitaxel; Proteasome Inhibitors; Sirolimus | 2005 |
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2005 |
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Gefitinib; Mice; Mice, Nude; Paclitaxel; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
[Relation of dose intensity and efficacy, toxicity in paclitaxel as a single agent for advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction | 2005 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Floxuridine; Humans; Hysterotomy; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Nitriles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Triazoles | 2005 |
Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; France; Heart; Humans; Middle Aged; Paclitaxel | 2005 |
HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Camptothecin; Carcinoma; Colonic Neoplasms; Coloring Agents; Drug Interactions; Drug Resistance, Neoplasm; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gene Expression Profiling; Humans; Lung Neoplasms; Paclitaxel; Potassium Channels, Voltage-Gated; Tetrazolium Salts; Thiazoles; Transfection; Vincristine | 2005 |
Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Topics: Antibiotics, Antineoplastic; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Clone Cells; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Drug Resistance, Neoplasm; Gamma Rays; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immediate-Early Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Telomerase; Teniposide; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Electromagnetic Fields; Female; Infusions, Parenteral; Kidney; Liposomes; Liver; Lung; Magnetics; Mice; Mice, Inbred BALB C; Myocardium; Paclitaxel; Rabbits; Spleen; Tumor Burden | 2005 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Invasiveness; Nitriles; Paclitaxel; Skin Neoplasms; Sternum; Triazoles | 2005 |
Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gangliosides; Glucosyltransferases; Humans; Morpholines; Oligonucleotides, Antisense; Paclitaxel; Sphingolipids; Transfection; Vinblastine | 2005 |
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Topics: Acetylation; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; Farnesyltranstransferase; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Mice; Microtubules; Mitosis; NIH 3T3 Cells; Paclitaxel; Piperidines; Pyridines; Tubulin | 2005 |
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Embryonal; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Flavonoids; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Paclitaxel; Piperidines; Uterine Cervical Neoplasms | 2005 |
A multicellular spheroid-based drug sensitivity test by scanning electrochemical microscopy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Cisplatin; Collagen; Drug Screening Assays, Antitumor; Electrochemistry; Female; Fluorouracil; Humans; Microcomputers; Microscopy, Scanning Probe; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured | 2005 |
Albumin-bound paclitaxel (Abraxane) for advanced breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Injections, Intravenous; Paclitaxel; Powders | 2005 |
Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Topics: Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies | 2005 |
Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Incidence; Lung; Middle Aged; Paclitaxel; Radiation Pneumonitis; Radiotherapy Dosage; Statistics as Topic | 2005 |
Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Photosensitivity Disorders; Porphyrins; Trastuzumab | 2005 |
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Umbilical Veins | 2005 |
Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Paclitaxel; Phosphoproteins; Phosphorylation; Protein Binding; Protein Biosynthesis | 2005 |
Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Down-Regulation; Fatty Acids, Omega-3; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 2005 |
Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Paclitaxel; Statistics, Nonparametric; Ultrasonography, Mammary | 2005 |
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Topics: Biomarkers; Breast Neoplasms; Cyclophosphamide; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Microtubules; Paclitaxel; RNA, Messenger; tau Proteins | 2005 |
[The effect of weekly docetaxel and concurrent radiation for advanced breast cancer--case report].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Remission Induction | 2005 |
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Membrane; Cytoplasm; Drug Resistance, Neoplasm; Endothelium; Epirubicin; Epithelium; Female; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Receptor, ErbB-2; Treatment Outcome; Tubulin; Vascular Endothelial Growth Factor Receptor-1 | 2005 |
Does paclitaxel decrease the interstitial fluid pressure and improve oxygenation in breast cancer in a schedule-dependent fashion?
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Respiration; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Fluid; Humans; Osmotic Pressure; Oxidation-Reduction; Oxygen; Oxygen Consumption; Paclitaxel | 2005 |
[Feasibility of breast conservation surgery after neoadjuvant chemotherapy for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2005 |
Weekly paclitaxel may improve locoregional recurrence by decreasing interstitial fluid pressure in operable node-positive breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Extracellular Fluid; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pressure | 2006 |
ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Interactions; Endothelins; Female; Methylnitrosourea; Paclitaxel; Peptide Fragments; Rats; Rats, Sprague-Dawley | 2005 |
Bilateral metastatic breast cancer as the first manifestation of ovarian cancer: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cystadenocarcinoma; Female; Gynecologic Surgical Procedures; Humans; Ovarian Neoplasms; Paclitaxel | 2005 |
Cyclin A-associated kinase activity is needed for paclitaxel sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; CDC2 Protein Kinase; Cyclin A; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Threonine; Transfection; Tumor Cells, Cultured | 2005 |
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Female; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2006 |
Autophagy is the dominant type of programmed cell death in breast cancer MCF-7 cells exposed to AGS 115 and EFDAC, new sesquiterpene analogs of paclitaxel.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Paclitaxel; Sesquiterpenes; Tubulin | 2005 |
Reply to "Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)" by L. Del Mastro et al. (Ann Oncol 2005; 16: 253-258).
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Heart Diseases; Humans; Paclitaxel | 2005 |
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Cohort Studies; Cyclophosphamide; Doxorubicin; Female; Humans; Insurance Claim Review; Lung Neoplasms; Male; Medicare; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; United States | 2005 |
Neoadjuvant chemotherapy with weekly paclitaxel in breast cancer patients may increase release of cancer cells into circulation by decreasing interstitial fluid pressure.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Extracellular Fluid; Female; Humans; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2005 |
Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; RNA, Messenger; Taxoids; Time Factors; Verapamil | 2005 |
Refractory headache in a patient with breast cancer and carcinomatous meningitis unresponsive to analgesics: case report.
Topics: Adult; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Female; Headache Disorders, Secondary; Humans; Meningeal Neoplasms; Meningitis; Paclitaxel | 2005 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
"Will weekly work"? Seems to be so....
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Humans; Paclitaxel; Treatment Outcome | 2005 |
Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Inflammation; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Remission Induction; Reoperation; Trastuzumab; Treatment Outcome | 2005 |
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast; Breast Neoplasms; Cluster Analysis; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Oligonucleotide Array Sequence Analysis; Paclitaxel; Predictive Value of Tests; Preoperative Care; Receptor, ErbB-2 | 2005 |
The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Benzothiazoles; Breast Neoplasms; Cell Line, Tumor; Diamines; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Female; Gene Amplification; Gene Expression; Humans; Microarray Analysis; Organic Chemicals; Paclitaxel; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger | 2005 |
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy, Needle; Breast; Breast Neoplasms; Doxorubicin; Female; Gene Expression Profiling; Humans; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Predictive Value of Tests; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Paclitaxel in relapsed high risk anthracycline treated breast cancer patients.
Topics: Adult; Anthracyclines; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Premenopause; Remission Induction; Retrospective Studies; Risk Assessment; Survival Analysis | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Resistance to paclitaxel is proportional to cellular total antioxidant capacity.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Breast Neoplasms; Cell Division; Cell Growth Processes; Cell Nucleus; Drug Resistance, Neoplasm; G2 Phase; Humans; Nitric Oxide; Paclitaxel; Reactive Oxygen Species | 2005 |
Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Doxorubicin; fas Receptor; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Paclitaxel | 2005 |
[A case of locally advanced breast cancer successfully treated with FEC (100) followed by weekly paclitaxel].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Mastectomy, Modified Radical; Paclitaxel | 2005 |
The effect of height on paclitaxel nerve damage.
Topics: Action Potentials; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Height; Breast Neoplasms; Female; Humans; Middle Aged; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Peroneal Nerve; Sural Nerve | 2005 |
[The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Neoadjuvant Therapy; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone | 2005 |
Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Hypersensitivity; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Retrospective Studies; Taxoids | 2006 |
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunoglobulin G; Indium Radioisotopes; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Time Factors | 2005 |
Nanoparticle albumin-bound paclitaxel for metastatic breast cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Nanostructures; Paclitaxel | 2005 |
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells.
Topics: Animals; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Paclitaxel; Taxoids; Xenograft Model Antitumor Assays | 2005 |
Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Choroid Neoplasms; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Lasting remission following multimodal treatment in a patient with metastatic breast cancer.
Topics: Adult; Antibodies; Antigens, Neoplasm; Breast Neoplasms; CD3 Complex; Cell Adhesion Molecules; Combined Modality Therapy; Epirubicin; Epithelial Cell Adhesion Molecule; Female; Humans; Leukapheresis; Liver Neoplasms; Paclitaxel; Remission Induction; Thiotepa; Treatment Outcome | 2005 |
New developments in adjuvant therapy for breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Heart Failure; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2005 |
Taxanes and breast cancer: shifting priorities.
Topics: Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 2005 |
[Cytolytic hepatitis and esomeprazole during chemotherapy].
Topics: Adult; Anti-Ulcer Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemical and Drug Induced Liver Injury; Esomeprazole; Esophagitis; Female; Humans; Paclitaxel; Trastuzumab | 2005 |
Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Humans; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2005 |
Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Curcumin; Cyclooxygenase 2; Drug Synergism; Female; Gene Expression; Humans; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 9; Mice; Mice, Nude; NF-kappa B; Paclitaxel; Promoter Regions, Genetic; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
In regard to Kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials (Int J Radiat Oncol Biol Phys 2005;61:1045-1053).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Patient Selection | 2005 |
Adjuvant chemotherapy in 780 patients with early breast cancer: 10-year data from Saudi Arabia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Saudi Arabia; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2005 |
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Fluorine Radioisotopes; Humans; Image Interpretation, Computer-Assisted; Metabolic Clearance Rate; Mice; Mice, Nude; Organ Specificity; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution | 2005 |
Contribution of reactive oxygen species and caspase-3 to apoptosis and attenuated ICAM-1 expression by paclitaxel-treated MDA-MB-435 breast carcinoma cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Enzyme Activation; Fibronectins; Humans; Intercellular Adhesion Molecule-1; Intracellular Membranes; Membrane Potentials; Mitochondria; Oligopeptides; Paclitaxel; Reactive Oxygen Species; Time Factors | 2005 |
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2005 |
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Treatment Outcome | 2006 |
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making, Computer-Assisted; Disease-Free Survival; Female; France; Humans; Internet; Logistic Models; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Nomograms; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Reproducibility of Results; Texas | 2005 |
[Two patients of recurrent breast cancer with carcinomatous pleurisy well controlled pleural effusion].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drainage; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Pleural Effusion, Malignant; Pleurisy | 2005 |
cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel; Tumor Cells, Cultured | 2006 |
[A paclitaxel-resistant case of recurrent breast cancer responded to combination therapy of capecitabine and trastuzumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lung; Lymphatic Metastasis; Lymphatic System; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab | 2005 |
[Therapeutic effect of TAX combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2005 |
Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Nucleus; Drug Resistance, Neoplasm; Female; Gene Expression Regulation; Humans; Immunohistochemistry; Paclitaxel; Promoter Regions, Genetic; Tumor Cells, Cultured; Up-Regulation; Y-Box-Binding Protein 1 | 2005 |
Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Clusterin; Female; Humans; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Polymerase Chain Reaction; RNA, Small Interfering; Thionucleotides; Transplantation, Heterologous | 2005 |
Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biopsy; Breast; Breast Neoplasms; Cell Line, Tumor; DNA, Viral; Drug Resistance, Neoplasm; Epstein-Barr Virus Nuclear Antigens; Female; Gene Expression; Genes, MDR; Herpesvirus 4, Human; Humans; Middle Aged; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Viral; Viral Proteins | 2006 |
Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Amenorrhea; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Menstruation; Middle Aged; Paclitaxel; Retrospective Studies; Tamoxifen; Taxoids | 2005 |
Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies | 2006 |
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2006 |
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Enzyme Activation; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction | 2006 |
In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Data Interpretation, Statistical; Disease-Free Survival; Female; Humans; Paclitaxel; Remission Induction | 2006 |
Peripheral neuropathy in a woman with breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 2006 |
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Physical Examination; Predictive Value of Tests; Retrospective Studies; Statistics, Nonparametric; Ultrasonography, Mammary | 2006 |
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clavicle; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis | 2006 |
FADD phosphorylation is critical for cell cycle regulation in breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Fas-Associated Death Domain Protein; Female; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Receptors, Estrogen; Signal Transduction; Tamoxifen; Tumor Cells, Cultured | 2006 |
[Two cases of stage IV breast cancer with severe hypercalcemia].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Goserelin; Humans; Hypercalcemia; Imidazoles; Leuprolide; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Quality of Life; Tamoxifen; Zoledronic Acid | 2006 |
Differential gene expression profiles in paclitaxel-induced cell cycle arrest and apoptosis in human breast cancer MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; DNA Repair; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Paclitaxel | 2005 |
Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cell Hypoxia; Cell Movement; Cell Proliferation; Erythropoietin; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptors, Erythropoietin; Recombinant Proteins; Xenograft Model Antitumor Assays | 2006 |
Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.
Topics: Adenocarcinoma; Animals; Apoptosis; Breast Neoplasms; Drug Resistance, Neoplasm; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Female; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Receptors, Erythropoietin; Recombinant Proteins; Tumor Cells, Cultured | 2006 |
Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Bilirubin; Breast Neoplasms; Female; Humans; Liver; Liver Neoplasms; Middle Aged; Mucositis; Nausea; Neutropenia; Paclitaxel | 2006 |
Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport?
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Flavonoids; Humans; Paclitaxel; Protein Structure, Tertiary; Structure-Activity Relationship | 2006 |
A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2006 |
Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Inducing Factor; Breast Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cyclin B; Cyclin B1; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Ploidies; Survivin; Tretinoin | 2006 |
Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Gamma Rays; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage | 2006 |
Impact of a scientific presentation on community treatment patterns for primary breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Congresses as Topic; Drug Approval; Drug Prescriptions; Evidence-Based Medicine; Female; Humans; Logistic Models; Lymphatic Metastasis; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; SEER Program; Taxoids; Time Factors; United States; United States Food and Drug Administration | 2006 |
Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Masoprocol; Mice; Mice, Nude; Monosaccharides; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Drug Synergism; ErbB Receptors; Female; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Phosphorylation; Receptor, ErbB-2 | 2006 |
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Imidazoles; Mevalonic Acid; Mutation; Paclitaxel; Signal Transduction; Time Factors; Zoledronic Acid | 2006 |
Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Lewis Blood Group Antigens; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Radioimmunotherapy; Radiopharmaceuticals; Tissue Distribution; Transplantation, Heterologous; Yttrium Radioisotopes | 2006 |
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.
Topics: Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Microscopy, Confocal; Microscopy, Fluorescence; Paclitaxel; Tumor Cells, Cultured | 2006 |
Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Screening Assays, Antitumor; Erythropoietin; Humans; Leukemia, Erythroblastic, Acute; Paclitaxel; Signal Transduction; Structure-Activity Relationship; Tamoxifen; Tumor Cells, Cultured | 2006 |
Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Female; G2 Phase; Humans; Paclitaxel; Proliferating Cell Nuclear Antigen; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Time Factors | 2006 |
Determination of docetaxel and Paclitaxel in human plasma by high-performance liquid chromatography: validation and application to clinical pharmacokinetic studies.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Drug Stability; Female; Half-Life; Humans; Paclitaxel; Quality Control; Reproducibility of Results; Spectrophotometry, Ultraviolet; Taxoids; Temperature | 2006 |
Malignant mixed Mullerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Fatal Outcome; Female; Femoral Neoplasms; Humans; Hysterectomy; Ifosfamide; Ilium; Middle Aged; Mixed Tumor, Mullerian; Neoplasms, Second Primary; Ovariectomy; Paclitaxel; Palliative Care; Pelvic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Sarcoma, Ewing; Spinal Neoplasms; Uterine Neoplasms | 2006 |
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
Topics: Antineoplastic Agents, Phytogenic; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Chromosomal Instability; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Spindle Apparatus; Up-Regulation | 2006 |
Combination treatment improves breast-cancer survival.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel; Survival Rate | 2006 |
Scientific meetings might affect prescribing.
Topics: Aged; Breast Neoplasms; Congresses as Topic; Delivery of Health Care; Drug Prescriptions; Education, Medical, Continuing; Female; Humans; Lymphatic Metastasis; Paclitaxel; Practice Patterns, Physicians' | 2006 |
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease Progression; Female; Heart Diseases; Heart Neoplasms; Humans; Indium Radioisotopes; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Metastasis; Paclitaxel; Pentetic Acid; Peptide Fragments; Predictive Value of Tests; Receptor, ErbB-2; Tomography, Emission-Computed, Single-Photon; Trastuzumab; Troponin I | 2006 |
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2006 |
Albumin-bound Paclitaxel: in metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glycerol; Humans; Nanostructures; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2006 |
Albumin-bound Paclitaxel in metastatic breast cancer: viewpoints.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Glycerol; Humans; Nanostructures; Neoplasm Metastasis; Neutropenia; Paclitaxel; Treatment Outcome | 2006 |
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carboplatin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Nude; Oligonucleotides, Antisense; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptor, ErbB-2; Transfection; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Humans; Male; Ovarian Neoplasms; Paclitaxel; Prognosis; Tissue Culture Techniques; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2006 |
Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph Nodes; Markov Chains; Paclitaxel; Survival Analysis | 2006 |
Taxane-containing chemotherapy in the treatment of early breast cancer patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2006 |
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2006 |
Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diagnosis, Differential; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Paraneoplastic Cerebellar Degeneration; Positron-Emission Tomography; Postmenopause; Receptor, ErbB-2; Risk Assessment; Trastuzumab | 2006 |
Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Topics: Antibiotics, Antineoplastic; Antimitotic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Female; gamma-Synuclein; Gene Silencing; Humans; Inhibitory Concentration 50; Neoplasm Proteins; Oncostatin M; Paclitaxel; RNA, Antisense; Time Factors; Transfection; Tumor Stem Cell Assay; Urea | 2006 |
Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells.
Topics: Animals; Blotting, Western; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Genome, Human; Humans; Immunoenzyme Techniques; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Thymidine; Transcription, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured | 2007 |
Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Mammary Glands, Animal; Mice; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured | 2006 |
Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoplasm Staging; Paclitaxel; Physical Examination; Retrospective Studies | 2006 |
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Neuregulin-1; Paclitaxel; Phosphorylation; Receptor, ErbB-2; Signal Transduction; Transcriptional Activation; Trastuzumab; Up-Regulation; Vincristine | 2006 |
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; I-kappa B Kinase; Mitosis; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2006 |
Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.
Topics: Adult; Aged; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Calcium-Binding Proteins; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Epithelial Cell Adhesion Molecule; Female; Fluorouracil; Follow-Up Studies; Humans; Keratins; Membrane Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; Presenilin-2; Prognosis; Receptor, ErbB-2; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Risk Factors; RNA Precursors; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thiotepa; Treatment Outcome | 2006 |
Is it time for some new approaches for treating advanced ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure | 2006 |
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microarray Analysis; Middle Aged; Neoplasm Staging; Oligonucleotides; Paclitaxel; Predictive Value of Tests; Reproducibility of Results; ROC Curve; Sensitivity and Specificity | 2006 |
Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Caveolin 1; Female; Humans; Paclitaxel; Patient Selection; Prognosis; Treatment Outcome | 2006 |
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
Motor dominant neuropathy induced by adjuvant therapy with adriamycin and cyclophosphamide followed by dose-dense paclitaxel in a breast cancer patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Motor Neuron Disease; Paclitaxel; Peripheral Nervous System Diseases | 2006 |
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Nomograms; Paclitaxel; Probability; Prognosis; Software; Treatment Outcome | 2006 |
[A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2006 |
[Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2006 |
[Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2006 |
Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Fragmentation; Estradiol; Flow Cytometry; Fulvestrant; Humans; Hydroxyurea; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Microtubule-Associated Proteins; Microtubules; Neoplasm Proteins; Paclitaxel; Purines; RNA, Small Interfering; Roscovitine; Spindle Apparatus; Survivin; Thymidine; Transfection | 2007 |
Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer.
Topics: Absorbable Implants; Antineoplastic Agents; Breast Neoplasms; Cations; Cell Line, Tumor; Coated Materials, Biocompatible; Crystallization; Drug Combinations; Drug Delivery Systems; Humans; Interleukin-12; Nanostructures; Paclitaxel; Pharmaceutical Vehicles; Plasmids; Polymers; Transfection | 2006 |
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Heart; Heart Diseases; Humans; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiac Tamponade; Drainage; Fatal Outcome; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Treatment Outcome | 2006 |
[Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
Topics: Adult; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Astringents; Breast Neoplasms; Capecitabine; Deoxycytidine; Exudates and Transudates; Female; Fluorouracil; Hallux; Humans; Keratosis; Mupirocin; Nail Diseases; Ointments; Paclitaxel; Time Factors; Treatment Outcome; Zinc Sulfate | 2006 |
Proteomic analysis of isolated membrane fractions from superinvasive cancer cells.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Breast Neoplasms; Cell Growth Processes; Chick Embryo; Collagen Type IV; Dose-Response Relationship, Immunologic; Drug Synergism; Epitopes; Extracellular Matrix; Female; Humans; Immunoglobulin G; Immunoglobulin M; Male; Melanoma; Mice; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1 | 2006 |
Effect of pregnancy on the pharmacokinetics of paclitaxel: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Ductal; Female; Half-Life; Humans; Live Birth; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Twins | 2006 |
Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chondrosarcoma; Combined Modality Therapy; Decompression, Surgical; Diagnosis, Differential; Exostoses, Multiple Hereditary; Female; Humans; Laminectomy; Liver Neoplasms; Lung Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Spinal Cord Compression; Spinal Fusion; Spinal Neoplasms; Thoracic Vertebrae; Tomography, X-Ray Computed; Trastuzumab | 2006 |
Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Pneumonia, Pneumocystis; Polyethylene Glycols; Prednisone; Recombinant Proteins; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992).
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbohydrate Sequence; Carcinoma; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dextrans; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Molecular Weight; Neoplasm Transplantation; Paclitaxel; Tissue Distribution | 2007 |
Extramedullary hematopoiesis in breast after neoadjuvant chemotherapy for breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Hematopoiesis, Extramedullary; Humans; Mastectomy; Paclitaxel | 2006 |
Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Feasibility Studies; Fluorine Radioisotopes; Mice; Mice, Nude; Paclitaxel; Prognosis; Radionuclide Imaging; Treatment Outcome | 2006 |
Association between paclitaxel and necrotic pancreatitis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Fatal Outcome; Female; Humans; Paclitaxel; Pancreatitis, Acute Necrotizing | 2006 |
Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2006 |
[Proteomic analysis of paclitaxel-induced apoptosis in MCF-7 human breast carcinoma cells].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Female; Galectin 1; Humans; Keratin-8; Paclitaxel; Phosphopyruvate Hydratase; Proteomics; Ribosomal Proteins | 2006 |
[HER-2 and ER expression in prediction of chemo-sensitivity of taxane for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Immunohistochemistry; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Remission Induction; Retrospective Studies; Taxoids | 2006 |
A comparative study of the cytoskeleton binding drugs nocodazole and taxol with a mammalian cell quartz crystal microbalance biosensor: different dynamic responses and energy dissipation effects.
Topics: Animals; Aorta; Biosensing Techniques; Breast Neoplasms; Cattle; Cell Culture Techniques; Cell Line; Cell Line, Tumor; Cytoskeleton; Endothelium, Vascular; Female; Humans; Kinetics; Microscopy, Fluorescence; Nocodazole; Paclitaxel; Quartz; Tubulin | 2007 |
Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Female; Humans; Hydrogen-Ion Concentration; Hydrolysis; Molecular Structure; Oxytocin; Paclitaxel; Peptides; Polyethylene Glycols; Prodrugs; Receptors, Oxytocin; Solubility; Time Factors | 2007 |
Integrative tumor board: metastatic breast cancer.
Topics: Acupuncture Therapy; Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Complementary Therapies; Drugs, Chinese Herbal; Female; Gallbladder Neoplasms; Homeopathy; Humans; Middle Aged; Paclitaxel | 2006 |
Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Topics: Amino Acid Motifs; Antineoplastic Agents; Aptamers, Peptide; Breast Neoplasms; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Intercellular Signaling Peptides and Proteins; Paclitaxel; Peptide Library; Protein Conformation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2006 |
Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Caveolin 1; Cell Line, Tumor; Cell Membrane Permeability; Cell Transformation, Neoplastic; Humans; Microtubules; Mitochondria; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Tubulin Modulators; Tyrosine | 2007 |
Taxol induced apoptosis regulates amino acid transport in breast cancer cells.
Topics: Alanine; Amino Acid Transport Systems; Amino Acids; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Ethylmaleimide; Female; Gene Expression Regulation; Humans; In Situ Nick-End Labeling; Maleimides; Paclitaxel; Sodium; Starvation | 2007 |
Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Infant, Newborn; Male; Oligohydramnios; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Trastuzumab | 2007 |
Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Female; Fever; Humans; Liver Neoplasms; Necrosis; Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2007 |
Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Breast Neoplasms; DNA Probes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Paclitaxel; Receptors, Progesterone; RNA, Messenger | 2007 |
[Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Catheter Ablation; Docetaxel; Fatal Outcome; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Taxoids; Trastuzumab | 2006 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Pleurisy; Pleurodesis; Radiosurgery; Triazoles | 2006 |
[A case of advanced breast cancer with meningeal carcinomas and orbital metastasis successfully treated with multi-disciplinary therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Meningeal Neoplasms; Middle Aged; Orbital Neoplasms; Paclitaxel; Quality of Life; Tegafur; Trastuzumab | 2006 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Doxorubicin; Etoposide; Female; HeLa Cells; Humans; Inhibitor of Differentiation Protein 1; Liver Neoplasms; Male; Mechlorethamine; Methotrexate; Mitomycin; Nasopharyngeal Neoplasms; Paclitaxel; Prostatic Neoplasms; Vincristine | 2007 |
The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2007 |
[Preoperative therapy with trastuzumab and paclitaxel in a stage IV advanced breast cancer with complete pathologic response].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lymph Node Excision; Mastectomy; Middle Aged; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2007 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Heart Block; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2007 |
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Drug Synergism; Female; HeLa Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Paclitaxel; Stereoisomerism; Tryptophan | 2007 |
Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Humans; Lipids; Microscopy, Electron, Scanning; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Particle Size | 2007 |
Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Topics: Anthracyclines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Survival; Cisplatin; Colchicine; Cytoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoresis; Etoposide; Female; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Membrane Potentials; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Phenotype | 2007 |
Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Silencing; Humans; Microtubules; Nuclear Proteins; Paclitaxel; Phosphorylation; Protein-Tyrosine Kinases; Stathmin; Vinblastine | 2007 |
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Base Sequence; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cytoskeleton; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Molecular Sequence Data; Mutation; Paclitaxel; Protein Isoforms; Retrospective Studies; Tubulin | 2007 |
The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Delayed-Action Preparations; Drug Carriers; Humans; Lactic Acid; Nanoparticles; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers | 2007 |
Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Membrane; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Inhibitory Concentration 50; Micelles; Paclitaxel; Poloxamer; Receptors, Cell Surface; Solubility; Time Factors | 2007 |
[A case successfully treated by desensitization for paclitaxel-associated hypersensitivity reactions].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Remission Induction | 2007 |
P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Female; Humans; Mutation; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic | 2007 |
Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Nuclear Proteins; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Transcriptional Activation; Tumor Cells, Cultured; Twist-Related Protein 1 | 2007 |
A new method to assess drug sensitivity on breast tumor acute slices preparation.
Topics: Breast Neoplasms; Diffusion Chambers, Culture; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Microtomy; Paclitaxel; Potassium Cyanide; Sodium Fluoride; Time Factors; Tissue Preservation | 2006 |
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptor, ErbB-2; RNA, Small Interfering; Transfection; Trastuzumab; Tumor Cells, Cultured | 2007 |
Changes of survivin mRNA and protein expression during paclitaxel treatment in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; Indicators and Reagents; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; RNA, Messenger; Survivin; Tetrazolium Salts; Time Factors | 2007 |
Radiosensitization by the combination of SR-2508 and paclitaxel in hypoxic human tumor cells in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etanidazole; HeLa Cells; Humans; Paclitaxel; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents | 2007 |
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Ki-67 Antigen; Lymph Node Excision; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-bcl-2; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Tumor Suppressor Protein p53 | 2007 |
Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Enzyme Activation; HL-60 Cells; Humans; Hydrogen Peroxide; Microtubules; NADPH Oxidases; Paclitaxel; Reactive Oxygen Species; Subcellular Fractions; Superoxides | 2007 |
Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Survival Rate | 2007 |
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Patient Selection; Poly-ADP-Ribose Binding Proteins; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; RNA, Messenger; tau Proteins; Time Factors; Treatment Outcome | 2008 |
[A case report of delay in switching from inpatient treatment to home-based care due to changes in pain and other symptoms following chemotherapy].
Topics: Adult; Analgesics; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Community Health Nursing; Drug Administration Schedule; Female; Home Care Services, Hospital-Based; Humans; Mastectomy, Modified Radical; Paclitaxel; Pain, Intractable; Quality of Life; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
Daxx shortens mitotic arrest caused by paclitaxel.
Topics: Adaptor Proteins, Signal Transducing; Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Drug Resistance, Neoplasm; Female; Humans; Mice; Micronucleus Tests; Mitosis; Molecular Chaperones; Nuclear Proteins; Paclitaxel; RNA Interference; Tumor Stem Cell Assay | 2007 |
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Enzyme Activation; Humans; Immediate-Early Proteins; Indoles; MAP Kinase Kinase 4; Mechlorethamine; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphoprotein Phosphatases; Protein Phosphatase 1; Protein Tyrosine Phosphatases | 2007 |
Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Doxorubicin; Drug Synergism; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Lignans; Mice; Mice, Nude; Paclitaxel; Tamoxifen; Vorinostat | 2007 |
Paclitaxel maculopathy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorescein Angiography; Humans; Macular Edema; Middle Aged; Paclitaxel; Tomography, Optical Coherence; Trastuzumab | 2007 |
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor alpha; Fulvestrant; Humans; Microtubules; Mitosis; Paclitaxel; Prohibitins; Transfection | 2007 |
[Surgery for advanced breast cancer from the viewpoint of medical oncologist].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2007 |
Negative regulation of SEK1 signaling by serum- and glucocorticoid-inducible protein kinase 1.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line; Dexamethasone; Down-Regulation; Enzyme Activation; Humans; Hydrogen Peroxide; Immediate-Early Proteins; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Paclitaxel; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; RNA Interference; Signal Transduction | 2007 |
Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cells, Cultured; Female; Flow Cytometry; Gene Expression; Humans; Hyperglycemia; Inhibitory Concentration 50; Paclitaxel; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thioredoxins | 2007 |
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negativ
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cetuximab; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2007 |
Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.
Topics: Antibodies, Antinuclear; Antineoplastic Agents, Phytogenic; Arm; Breast Neoplasms; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Paclitaxel; Sjogren's Syndrome; Skin | 2007 |
Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Cell Line, Tumor; Female; Half-Life; Humans; Immunoconjugates; Liposomes; Male; Metabolic Clearance Rate; Paclitaxel; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Trastuzumab | 2007 |
[A case of breast metastasis of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Signet Ring Cell; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Uracil | 2007 |
[A case of severe hand-foot syndrome caused by capecitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Paclitaxel; Paresthesia; Postoperative Period; Syndrome | 2007 |
The effect of seal oil on paclitaxel induced cytotoxicity and apoptosis in breast carcinoma MCF-7 and MDA-MB-231 cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Fatty Acids, Omega-3; Female; Humans; In Situ Nick-End Labeling; Lipid Peroxidation; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Seals, Earless; Thiobarbituric Acid Reactive Substances | 2007 |
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Texas; Trastuzumab; Treatment Outcome | 2007 |
Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Proliferation; Docetaxel; Doxorubicin; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ki-67 Antigen; Models, Biological; Paclitaxel; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Spheroids, Cellular; Tamoxifen; Taxoids; Tissue Distribution; Tumor Burden; Tumor Cells, Cultured | 2007 |
Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Caveolin 1; Female; Humans; Paclitaxel | 2007 |
8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Janus Kinase 2; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; STAT3 Transcription Factor; Tropanes | 2007 |
Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment.
Topics: Animals; Annexins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Early Diagnosis; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasms; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Spectrometry, Fluorescence; Spectroscopy, Near-Infrared; Trastuzumab; Up-Regulation | 2007 |
Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Combined Modality Therapy; Female; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Paclitaxel; Pilot Projects; Retroviridae; Transduction, Genetic | 2007 |
Local delivery of oncogel delays paresis in rat metastatic spinal tumor model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Injections, Intralesional; Neoplasm Transplantation; Paclitaxel; Paresis; Polymers; Rats; Rats, Inbred F344; Spinal Neoplasms; Survival Analysis | 2007 |
Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Membrane Permeability; Cisplatin; Female; Gastrointestinal Tract; Humans; Intestinal Absorption; Lactulose; Mannitol; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Sucrose; Trastuzumab; Xylose | 2007 |
Toxic effects differ in combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids | 2007 |
Efficient generation of constrained block allocation sequences.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bias; Biometry; Breast Neoplasms; Carboplatin; Cetuximab; Female; Humans; Lung Neoplasms; Models, Statistical; Paclitaxel; Patient Selection; Random Allocation; Randomized Controlled Trials as Topic | 2008 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neutropenia; Paclitaxel; Postoperative Period; Retrospective Studies; Taxoids | 2007 |
Paclitaxel plus carboplatin for women with advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Postmenopause; Premenopause; Soft Tissue Neoplasms; Survival Rate; Vomiting | 2007 |
Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Mitosis; Necrosis; Neovascularization, Pathologic; Organophosphorus Compounds; Paclitaxel; Survival Rate; Treatment Outcome; Xenograft Model Antitumor Assays | 2007 |
Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
Topics: Adenocarcinoma; Alkanes; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carbamates; Cell Line, Tumor; Cell Survival; Dimerization; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Fluorescent Antibody Technique, Indirect; Glutamic Acid; Glycine; Humans; Lactones; Models, Molecular; Mutation, Missense; Paclitaxel; Protein Structure, Quaternary; Pyrones; Taxoids; Transfection; Tubulin; Tubulin Modulators | 2007 |
Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Contrast Media; Cyclophosphamide; Doxorubicin; Female; Gadolinium DTPA; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Retrospective Studies; Sensitivity and Specificity; Trastuzumab; Treatment Outcome | 2007 |
[A case of left breast cancer resulting in complete response by primary systemic therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Paclitaxel; Treatment Outcome | 2007 |
[A case of liver metastasis of breast cancer responding to trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for 30 months].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Trastuzumab; Treatment Outcome | 2007 |
Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1.
Topics: Breast Neoplasms; Drug Delivery Systems; Drug Design; Female; Humans; Paclitaxel; Peptides, Cyclic; Receptor, ErbB-2 | 2007 |
Patterns of care study of breast-conserving therapy in Japan: comparison of the treatment process between 1995 1997 and 1999 2001 surveys.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Japan; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Staging; Paclitaxel; Population Surveillance; Practice Patterns, Physicians'; Radiotherapy, Adjuvant; Tamoxifen; Vinblastine; Vincristine | 2007 |
Inhibition of paclitaxel-induced proteasome activation influences paclitaxel cytotoxicity in breast cancer cells in a sequence-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Death; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; Paclitaxel; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2007 |
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
Topics: Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genes, erbB-2; Humans; Paclitaxel; Retrospective Studies | 2007 |
Potential targeted therapy options in the management of basal cell subtype of breast carcinoma.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Breast Neoplasms; Caveolin 1; CD146 Antigen; Clinical Trials, Phase III as Topic; Dasatinib; Drug Delivery Systems; Female; Humans; Neoplasms, Basal Cell; Paclitaxel; Proto-Oncogene Proteins c-met; Pyrimidines; Thiazoles | 2007 |
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Line, Tumor; Etoposide; Female; Gene Expression Regulation; Humans; Paclitaxel; T-Lymphocytes | 2008 |
Breast-cancer therapy--looking back to the future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2007 |
A multi-fluorescent MDA435 cell line for mitosis inhibitor studies: simultaneous visualization of chromatin, microtubules, and nuclear envelope in living cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Chromatin; Female; Fluorescent Dyes; Green Fluorescent Proteins; Humans; Microscopy, Fluorescence; Microscopy, Video; Microtubules; Mitosis; Nuclear Envelope; Paclitaxel; Plasmids | 2007 |
[Two cases treated with trastuzumab as primary chemotherapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Paclitaxel; Trastuzumab | 2007 |
Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bentonite; Breast Neoplasms; Cell Line, Tumor; Humans; Lactic Acid; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Receptor, ErbB-2; Surface Properties; Temperature; Trastuzumab | 2008 |
NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ditiocarb; Female; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; NF-kappa B; Paclitaxel; Pyrrolidines; Sesquiterpenes; Spheroids, Cellular; Thiocarbamates; Time Factors; Xenograft Model Antitumor Assays | 2008 |
Histological features of breast cancer, highly sensitive to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel | 2007 |
In vitro evaluation of dose-response curve for paclitaxel in breast cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Evaluation Studies as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Tumor Cells, Cultured | 2007 |
Brain metastases after achieving local pathological complete responses with neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Doxorubicin; Female; Humans; Lymph Nodes; Magnetic Resonance Imaging; Mastectomy; Neoadjuvant Therapy; Paclitaxel; Remission Induction | 2007 |
Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Integrin alphaVbeta3; Microtubules; Neuregulin-1; Paclitaxel; Tubulin Modulators; Up-Regulation; Vincristine | 2007 |
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; British Columbia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Outcome | 2007 |
Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Laryngeal Nerves; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Vinblastine; Vinorelbine; Vocal Cord Paralysis | 2008 |
Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neutrophils; Paclitaxel; Treatment Outcome | 2008 |
Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Pregnancy; Pregnancy Complications, Neoplastic; Receptor, ErbB-2; Remission Induction | 2007 |
Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity.
Topics: Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clusterin; Dexamethasone; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; In Situ Nick-End Labeling; Oligonucleotides, Antisense; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transcription, Genetic; Up-Regulation | 2007 |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast Neoplasms; CD40 Antigens; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mastectomy; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; RNA, Messenger; Signal Transduction; Transcription, Genetic; Trastuzumab; Treatment Outcome; Up-Regulation | 2007 |
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Poly(ADP-ribose) Polymerases | 2008 |
Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitor of Differentiation Protein 1; Interleukin-6; NF-kappa B; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Subcellular Fractions; Time Factors; Tumor Suppressor Protein p53 | 2008 |
Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
Topics: Adult; Amenorrhea; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Cyclophosphamide; Estradiol; Female; Follicle Stimulating Hormone; Humans; Infertility, Female; Menstruation; Ovary; Paclitaxel; Prospective Studies; Risk Assessment; Time Factors | 2008 |
HER2 and response to paclitaxel in node-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2008 |
HER2 and response to paclitaxel in node-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2008 |
HER2 and response to paclitaxel in node-positive breast cancer.
Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen | 2008 |
HER2 and response to paclitaxel in node-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Paclitaxel; Receptor, ErbB-2; Risk; Trastuzumab | 2008 |
Taxane analogues against breast cancer: a quantitative structure-activity relationship study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Quantitative Structure-Activity Relationship; Taxoids; Thermodynamics | 2008 |
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrenes; Humans; Mice; Mice, Nude; Paclitaxel; Tubulin Modulators; Xenograft Model Antitumor Assays | 2008 |
Measuring the cost of chemotherapy is important, but it is not enough.
Topics: Antineoplastic Agents; Breast Neoplasms; Complementary Therapies; Cost of Illness; Cost-Benefit Analysis; Docetaxel; Drug Costs; Humans; Neutropenia; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Therapies, Investigational | 2008 |
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cytoprotection; Dexamethasone; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Dual Specificity Phosphatase 1; Dual Specificity Phosphatase 6; HeLa Cells; Humans; Mitogen-Activated Protein Kinase Phosphatases; Models, Biological; Naphthoquinones; Paclitaxel; Quinones; Reactive Oxygen Species; Tumor Cells, Cultured | 2008 |
Study finds that hormone status may predict chemotherapy's effectiveness on breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2008 |
Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Monitoring; Estrogens; Female; Fluorouracil; Follow-Up Studies; Humans; Japan; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Progesterone; Prognosis; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome | 2009 |
Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Proliferation; Dexamethasone; Down-Regulation; Drug Combinations; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Humans; Oncogene Protein v-akt; Paclitaxel; Phosphorylation; Trastuzumab; Tumor Cells, Cultured | 2008 |
Modeling resistance index of taxoids to MCF-7 cell lines using ANN together with electrotopological state descriptors.
Topics: Algorithms; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Female; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Neural Networks, Computer; Paclitaxel; Predictive Value of Tests; Principal Component Analysis; Quantitative Structure-Activity Relationship; Reproducibility of Results; Software; Taxoids | 2008 |
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Female; Glioma; Magnetic Resonance Imaging; Mice; Mice, Nude; Microtubules; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Tissue Distribution; Xenograft Model Antitumor Assays | 2008 |
Response to taxanes in triple negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Genes, BRCA1; Genes, erbB-2; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Receptors, Estrogen | 2008 |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Japan; Mastectomy; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2008 |
High energy shock waves (HESW) increase paclitaxel efficacy in a syngeneic model of breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Breast Neoplasms; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; Female; Gene Expression; High-Energy Shock Waves; In Situ Nick-End Labeling; Paclitaxel; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Genotype; Humans; Middle Aged; Paclitaxel; Polymorphism, Genetic; Receptor, ErbB-2; Receptors, IgG; Signal Transduction; Taxoids; Trastuzumab; Treatment Outcome | 2008 |
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bromodeoxyuridine; CD24 Antigen; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Phenotype | 2008 |
Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Delivery Systems; Female; Metabolic Clearance Rate; Mice; Mice, Nude; Oligopeptides; Organ Specificity; Paclitaxel; Radionuclide Imaging; Tissue Distribution | 2008 |
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Medical Oncology; MicroRNAs; Paclitaxel; RNA, Messenger; Treatment Outcome | 2008 |
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Doxorubicin; Female; Humans; Insurance Claim Review; Male; Medicare; Paclitaxel; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; ROC Curve; United States | 2008 |
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Folic Acid; Humans; Molecular Structure; Nanoparticles; Nanotechnology; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Spectrum Analysis; Vitamin E | 2008 |
Paclitaxel plus bevacizumab for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Humans; Paclitaxel; Quality of Life; Survival Analysis | 2008 |
Paclitaxel plus bevacizumab for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bias; Breast Neoplasms; Disease Progression; Humans; Paclitaxel; Research Design | 2008 |
A novel nanoparticle formulation for sustained paclitaxel delivery.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Emulsions; Female; Glycerides; Humans; Inhibitory Concentration 50; Kinetics; Microscopy, Electron, Transmission; Nanoparticles; Paclitaxel; Particle Size; Solubility; Surface Properties; Technology, Pharmaceutical; Time Factors | 2008 |
Evaluation of biological pathways involved in chemotherapy response in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; E2F3 Transcription Factor; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Signal Transduction; Treatment Outcome | 2008 |
Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Humans; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis | 2008 |
Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Exons; Female; Gene Deletion; Genetic Predisposition to Disease; Humans; Mothers; Mutation; Nuclear Family; Paclitaxel; Ubiquitin-Protein Ligases | 2008 |
Organic extracts of Larrea divaricata Cav. induced apoptosis on tumoral MCF7 cells with an higher cytotoxicity than nordihydroguaiaretic acid or paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Female; Flow Cytometry; Humans; Larrea; Masoprocol; Paclitaxel; Phytotherapy; Plant Extracts | 2008 |
[Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Collagen; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gels; Humans; Male; Paclitaxel; Taxoids | 2008 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Paclitaxel; Positron-Emission Tomography; Treatment Outcome | 2008 |
Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Humans; Neoplasm Metastasis; Paclitaxel | 1995 |
Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recombinant Proteins; Salvage Therapy | 1993 |
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Clinical Protocols; Drug Resistance; Etoposide; Genetic Vectors; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Informed Consent; Interleukin-3; Interleukin-6; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancytopenia; Recombinant Fusion Proteins; Recombinant Proteins; Retroviridae; Stem Cell Factor; Transplantation, Autologous; Vinblastine | 1994 |
Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel | 1995 |
Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain.
Topics: Astemizole; Bone and Bones; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Pain | 1995 |
Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Specimen Collection; Breast Neoplasms; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platelet Count; Thrombocytopenia; Transplantation, Homologous | 1995 |
Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials, Phase II as Topic; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Quality of Life; Surveys and Questionnaires; Survival Analysis | 1995 |
Paclitaxel in doxorubicin-resistant metastatic breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
An overview of phase II studies of docetaxel in patients with metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 1995 |
[ASCO 1995--highlights on breast and ovarian neoplasms].
Topics: Adult; Breast Neoplasms; Drug Resistance; Female; Humans; Mammography; Mass Screening; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1995 |
Innovative approaches to breast cancer treatment: the role of paclitaxel. Introduction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Paclitaxel; Survival Rate | 1995 |
Taxoids.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Paclitaxel (Taxol) induces cumulative mild neurotoxicity.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Nervous System; Paclitaxel; Prospective Studies; Vibration | 1994 |
Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Colony-Forming Units Assay; Creatinine; Drug Synergism; Female; Fluorescent Antibody Technique; Humans; Microtubules; Nocodazole; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1995 |
Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines.
Topics: Breast Neoplasms; Carcinoma; Cell Cycle; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Flow Cytometry; G2 Phase; Humans; Male; Mitosis; Paclitaxel; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured | 1995 |
Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Breast; Breast Neoplasms; Cell Line; Cell Survival; DNA Primers; Drug Resistance, Multiple; Epithelial Cells; Epithelium; Female; Gene Expression; Humans; Molecular Sequence Data; Paclitaxel; Polymerase Chain Reaction; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Vinblastine | 1995 |
Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Proteins; Breast Neoplasms; Carcinoma; Dialysis; Drug Resistance, Multiple; Estramustine; Gene Expression Regulation, Neoplastic; Humans; Orosomucoid; Paclitaxel; Protein Binding; Serum Albumin; Tritium; Tumor Cells, Cultured; Verapamil; Vinblastine | 1995 |
A Bayesian group sequential design for a multiple arm randomized clinical trial.
Topics: Bayes Theorem; Breast Neoplasms; Computer Simulation; Drug Administration Schedule; Humans; Paclitaxel; Probability; Randomized Controlled Trials as Topic; Sample Size; Time Factors | 1995 |
In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Tumor Cells, Cultured | 1995 |
Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Division; Cell Line; Enzyme-Linked Immunosorbent Assay; Humans; Kanamycin Kinase; Oncogene Proteins, Viral; Paclitaxel; Papillomaviridae; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Repressor Proteins; Transfection; Tumor Cells, Cultured | 1995 |
Clinical trials referral resource. Adjuvant therapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Paclitaxel; Tamoxifen | 1994 |
Antiproliferative activity of taxol on human tumor and normal breast cells vs. effects on cardiac cells.
Topics: Animals; Bradycardia; Breast; Breast Neoplasms; Cell Division; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Heart Rate; Humans; Microtubules; Myocardial Contraction; Myocardium; Paclitaxel; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 1995 |
Effects of the microtubule-disturbing agents docetaxel (Taxotere), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Kinetics; Neoplasm Proteins; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vincristine | 1994 |
Pneumonitis related to treatment with paclitaxel.
Topics: Adult; Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Paclitaxel; Pharmaceutical Vehicles; Pneumonia; Polyethylene Glycols | 1995 |
Preoperative taxol induces objective responses in primary breast cancer not responding to FEC treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Resistance, Multiple; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Paclitaxel; Premedication | 1994 |
Sudden death 7 days after paclitaxel infusion for breast cancer.
Topics: Breast Neoplasms; Death, Sudden; Female; Humans; Liver Neoplasms; Mastectomy; Middle Aged; Paclitaxel; Pulmonary Edema | 1993 |
Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.
Topics: Adenocarcinoma; Astrocytoma; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Glycerol; HeLa Cells; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1993 |
Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel | 1994 |
Evaluation of taxol cardiotoxicity in metastatic breast cancer.
Topics: Arrhythmias, Cardiac; Breast Neoplasms; Echocardiography; Female; Heart; Heart Conduction System; Heart Rate; Humans; Infusions, Intravenous; Neoplasm Metastasis; Paclitaxel | 1993 |
The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Cycle; DNA, Neoplasm; Female; Flow Cytometry; Glycerol; Humans; Lung Neoplasms; Mitotic Index; Paclitaxel; Pharmaceutical Vehicles; Photography; Tumor Cells, Cultured | 1994 |
Clinical trials referral resource. Clinical trials with paclitaxel in metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Metastasis; Paclitaxel | 1994 |
Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Kinetics; Models, Biological; Paclitaxel; Tumor Cells, Cultured | 1993 |
Thrombosis with paclitaxel.
Topics: Breast Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Thrombosis | 1994 |
Neurotoxicity as a possible manifestation of paclitaxel hypersensitivity reactions.
Topics: Breast Neoplasms; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
A mixed micellar formulation suitable for the parenteral administration of taxol.
Topics: Animals; Bile Acids and Salts; Breast Neoplasms; Cell Division; Drug Carriers; Drug Stability; Drug Storage; Humans; Liposomes; Mice; Micelles; Paclitaxel; Phospholipids; Polyethylene Glycols; Solubility; Tumor Cells, Cultured | 1994 |
Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Docetaxel; Drug Resistance; Drug Screening Assays, Antitumor; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1994 |
From the Food and Drug Administration.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drugs, Investigational; Food Labeling; Humans; Lung Neoplasms; Paclitaxel; Paraplegia; Prostheses and Implants; United States; United States Food and Drug Administration; Vinblastine; Vinorelbine | 1994 |
Optic nerve disturbances: a new form of paclitaxel neurotoxicity.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Optic Nerve Diseases; Paclitaxel | 1994 |
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2.
Topics: Breast Neoplasms; Female; Humans; Hypertension; Paclitaxel; Vision Disorders | 1994 |
Taxol and cisplatin inhibit proliferation of T47D human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cisplatin; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Tumor Cells, Cultured | 1994 |
Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity?
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases; Vinblastine; Vinorelbine | 1994 |
Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carrier Proteins; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Ethanol; Female; Glycerol; Humans; Membrane Glycoproteins; Neoplasm Proteins; Paclitaxel; Phenotype; Solvents; Tumor Cells, Cultured | 1994 |
Estramustine: a novel radiation enhancer in human carcinoma cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Estramustine; Female; Flow Cytometry; Glioma; HeLa Cells; Humans; Male; Microtubules; Neoplasms; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vinblastine | 1994 |
Cycloheximide inhibits the cytotoxicity of paclitaxel (Taxol).
Topics: Adenocarcinoma; Breast Neoplasms; Cell Cycle; Cell Death; Cycloheximide; DNA, Neoplasm; Drug Interactions; Flow Cytometry; Humans; Lung Neoplasms; Mitotic Index; Neoplasm Proteins; Paclitaxel; Tumor Cells, Cultured | 1994 |
Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Drug Administration Schedule; Drug Synergism; Gallium; Humans; Kinetics; Neoplastic Stem Cells; Paclitaxel; Tumor Cells, Cultured | 1994 |
Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Death; Cisplatin; DNA, Neoplasm; Drug Administration Schedule; Flow Cytometry; Humans; Lung Neoplasms; Melphalan; Paclitaxel; Thiotepa; Tumor Cells, Cultured | 1994 |
The management of cancer metastatic to bone.
Topics: Acetabulum; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Femur; Fractures, Spontaneous; Hip Prosthesis; Humans; Middle Aged; Paclitaxel; Pain; Tomography, X-Ray Computed | 1994 |
Use of Taxol (paclitaxel) in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1994 |
Taxotere shows significant antitumor activity in anthracycline-resistant breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance; Female; Humans; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Epirubicin; Female; Genital Neoplasms, Female; Humans; Paclitaxel; Tumor Cells, Cultured | 1994 |
Clinical trials referral resource. Update on taxol trials.
Topics: Acute Disease; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Leukemia, Myeloid; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Sarcoma | 1993 |
Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Cecal Diseases; Doxorubicin; Female; Humans; Inflammation; Lymphatic Metastasis; Middle Aged; Paclitaxel | 1993 |
Taxol and radiation recall dermatitis.
Topics: Adult; Breast Neoplasms; Female; Humans; Paclitaxel; Radiation Tolerance; Radiodermatitis | 1993 |
Is Cremophor EL, solvent for paclitaxel, cytotoxic?
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Glycerol; Humans; Paclitaxel; Solvents; Tumor Cells, Cultured | 1993 |
Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA, Neoplasm; Doxorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Flow Cytometry; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1993 |
Docetaxel: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Taxoids | 1995 |
Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
Topics: Adenocarcinoma; Aminopterin; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Synergism; Humans; Paclitaxel; Prospective Studies; Taxoids; Tumor Cells, Cultured | 1996 |
Growth inhibitory action of brefeldin A with taxol and tiazofurin in human breast carcinoma cells.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Brefeldin A; Cell Division; Cyclopentanes; Drug Synergism; Humans; Macrolides; Paclitaxel; Ribavirin; Tumor Cells, Cultured | 1995 |
Paclitaxel-induced cardiotoxicity. An ultrastructural study.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cardiomyopathies; Chemotherapy, Adjuvant; Female; Heart; Humans; Lymphatic Metastasis; Middle Aged; Myocardium; Paclitaxel | 1996 |
Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol.
Topics: Alkanes; Animals; Antineoplastic Agents; Breast Neoplasms; Burkitt Lymphoma; Calcium; Carbamates; Cell Division; Cell Line; Dose-Response Relationship, Drug; Female; Fluorescent Antibody Technique, Indirect; Guanosine Triphosphate; Humans; Kinetics; Lactones; Microscopy, Electron; Microtubule-Associated Proteins; Microtubules; Paclitaxel; Porifera; Pyrones; Time Factors; Tubulin; Tumor Cells, Cultured | 1996 |
Expedient liquid chromatographic assay for paclitaxel in plasma after its administration to cancer patients.
Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calibration; Chromatography, High Pressure Liquid; Computer Simulation; Female; Humans; Infusions, Intravenous; Nitrosamines; Paclitaxel; Spectrophotometry, Ultraviolet | 1995 |
Visual evoked potentials findings in course of paclitaxel doxorubicin combination chemotherapy. Report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Electrophysiology; Electroretinography; Evoked Potentials, Visual; Extremities; Female; Humans; Middle Aged; Paclitaxel; Peripheral Nerves | 1995 |
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line; Enzyme Activation; Female; HL-60 Cells; Humans; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1996 |
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.
Topics: Aged; Breast Neoplasms; Cisplatin; Female; Humans; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Ventricular Function | 1996 |
Paclitaxel-containing combination chemotherapy for metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Mitoxantrone; Paclitaxel; Vinblastine; Vinorelbine | 1996 |
Future developments for paclitaxel in the treatment of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluorouracil; Forecasting; Humans; Methotrexate; Paclitaxel | 1996 |
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Care Facilities; Cell Division; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Methotrexate; New York City; Paclitaxel; Randomized Controlled Trials as Topic | 1996 |
Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro.
Topics: Antineoplastic Agents; Ascorbic Acid; Breast Neoplasms; Cell Survival; Cisplatin; Doxorubicin; Drug Synergism; Female; Humans; Paclitaxel; Receptors, Estrogen; Tumor Cells, Cultured | 1996 |
Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Eruptions; Erythema Multiforme; Female; Humans; Hyperbilirubinemia; Hypercalcemia; Liver Neoplasms; Middle Aged; Mouth Diseases; Neoplasm Proteins; Paclitaxel; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Proteins; Vaginal Diseases | 1996 |
Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Eruptions; Female; Humans; Middle Aged; Paclitaxel; Skin Diseases, Vesiculobullous | 1996 |
Taxoids: new weapons against cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Microtubules; Molecular Structure; Neoplasms; Ovarian Neoplasms; Paclitaxel; Phytotherapy; Taxoids; Trees | 1996 |
Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Admission; Pilot Projects; Radiotherapy, Adjuvant | 1995 |
Paclitaxel: current developmental approaches of the National Cancer Institute.
Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Esophageal Neoplasms; Female; Germinoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Ovarian Neoplasms; Paclitaxel; Sarcoma, Kaposi; United States; Urinary Bladder Neoplasms | 1995 |
Paclitaxel and doxorubicin in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Heart Failure; Humans; Paclitaxel; Risk Factors | 1996 |
Effects of taxol on TNF-alpha and IL-6 production by human peripheral blood cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Interferon-gamma; Interleukin-6; Paclitaxel; Stimulation, Chemical; Tumor Necrosis Factor-alpha | 1996 |
Apoptosis susceptibility of human carcinoma and leukemia cell lines to taxol. Relationship with cell cycle and drug concentration.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Female; Flow Cytometry; Humans; Kinetics; Leukemia; Paclitaxel; Tumor Cells, Cultured | 1996 |
Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1995 |
Treatment of advanced breast cancer: How much chemotherapy is enough?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Mastectomy, Segmental; Methotrexate; Middle Aged; Paclitaxel; Tamoxifen | 1996 |
Response to dexamethasone in patients with fluid retention after docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Edema; Female; Glucocorticoids; Humans; Paclitaxel; Taxoids | 1996 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pilot Projects; Remission Induction; Sarcoma; Thrombocytopenia | 1996 |
Hypertensive reactions associated with paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Hypertension; Methotrexate; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1996 |
Paclitaxel-induced radiation recall dermatitis.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Radiotherapy | 1996 |
Vinorelbine/paclitaxel combination studied in treatment of metastatic breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 1995 |
Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel--a case report.
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Doxorubicin; Female; Humans; Mitomycin; Paclitaxel; Radiography; Recurrence; Treatment Failure; Vinblastine | 1996 |
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Docetaxel; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Death; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1996 |
Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Cycle; Cell Transformation, Neoplastic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Paclitaxel; Receptor, ErbB-2; Transfection; Tumor Cells, Cultured | 1996 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
Topics: Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genes, p53; Genes, Tumor Suppressor; Humans; Hyperplasia; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Research; Survival Rate | 1996 |
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Diseases; Breast Neoplasms; Carmustine; Cyclophosphamide; Defective Viruses; DNA, Complementary; DNA, Recombinant; Drug Resistance, Neoplasm; Ethics, Medical; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Interleukin-6; Mesna; Middle Aged; Paclitaxel; Pilot Projects; Recombinant Fusion Proteins; Retroviridae; Safety; Thiotepa | 1996 |
Thromboembolic events with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cerebral Infarction; Diphenhydramine; Female; Histamine H1 Antagonists; Humans; Intracranial Embolism and Thrombosis; Ovarian Neoplasms; Paclitaxel; Premedication; Seizures | 1996 |
Management of advanced breast cancer: patient needs, challenges and new treatment options. Introduction.
Topics: Aging; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Research; Taxoids | 1996 |
Conclusion: the place of docetaxel (Taxotere) in future therapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Humans; Paclitaxel; Taxoids | 1996 |
Fatal myocardial infarction potentially induced by paclitaxel.
Topics: Aged; Breast Neoplasms; Carcinoma; Fatal Outcome; Female; Humans; Myocardial Infarction; Neoplasm Staging; Paclitaxel | 1996 |
Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Female; Humans; Infusions, Intravenous; Middle Aged; Neuritis; Paclitaxel; Premenopause; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; United Kingdom | 1996 |
Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Doxorubicin; Female; Heart; Heart Failure; Humans; Infusions, Intravenous; Middle Aged; Muscular Diseases; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pain; Paresthesia; Remission Induction; Stroke Volume; Ventricular Function, Left; Vomiting | 1996 |
Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Heart; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Prospective Studies; Randomized Controlled Trials as Topic; Razoxane | 1996 |
An exploratory study of frequent pain measurement in a cancer clinical trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Longitudinal Studies; Middle Aged; New York City; Paclitaxel; Pain Measurement; Quality of Life; Recombinant Proteins | 1996 |
Paclitaxel-induced pancreatitis: a case report.
Topics: Acute Disease; Aged; Amylases; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diagnosis, Differential; Female; Humans; Lipase; Paclitaxel; Pancreatitis | 1997 |
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Corneal Neovascularization; Estradiol; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Transplantation; Paclitaxel; Tumor Stem Cell Assay | 1997 |
Two doses of paclitaxel and statistical analysis: try, try, try again.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Data Interpretation, Statistical; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
[Taxol].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1996 |
Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caffeine; Cell Cycle; Cisplatin; Cytarabine; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Doxorubicin; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Paclitaxel; Tumor Cells, Cultured | 1997 |
Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression.
Topics: Antineoplastic Agents, Phytogenic; Brain Chemistry; Breast Neoplasms; Depression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Paclitaxel; Recombinant Proteins; Suicide | 1996 |
[Chemotherapy of ovarian and breast cancer with Taxol].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel | 1996 |
Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Coloring Agents; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Paclitaxel; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Ascites; Breast Neoplasms; Docetaxel; Edema; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pleural Effusion; Taxoids; Treatment Failure; Treatment Outcome | 1997 |
Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions.
Topics: Administration, Oral; Anti-Asthmatic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cromolyn Sodium; Docetaxel; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1996 |
Fatal hepatic coma attributed to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Fatal Outcome; Female; Hepatic Encephalopathy; Humans; Middle Aged; Paclitaxel | 1997 |
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Interleukin-6; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Radioimmunotherapy; Transplantation, Heterologous; Yttrium Radioisotopes | 1997 |
Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; DNA Fragmentation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Tumor Cells, Cultured | 1997 |
Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Platelets; Blood Specimen Collection; Breast Neoplasms; Epirubicin; Female; Filgrastim; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocytes; Middle Aged; Paclitaxel; Recombinant Proteins; Treatment Outcome | 1997 |
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Humans; Middle Aged; Paclitaxel | 1997 |
Taxol inhibits opioid binding on T47D human breast cancer cells.
Topics: Amino Acid Sequence; Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Binding Sites; Binding, Competitive; Breast Neoplasms; Diprenorphine; Ethylketocyclazocine; Humans; Molecular Sequence Data; Paclitaxel; Receptors, Opioid; Receptors, Opioid, kappa; Sequence Alignment; Tubulin; Tumor Cells, Cultured | 1997 |
The taxanes: miracles for breast cancer treatment or just more chemotherapy?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Costs; Female; Humans; Paclitaxel | 1997 |
Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; Cell Death; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1997 |
Plasmin induces the formation of multicellular spheroids of breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Division; Doxorubicin; Fibrinolysin; Humans; Organoids; Paclitaxel; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1997 |
[Docetaxel in lymphangiosis carcinomatosa].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Tomography, X-Ray Computed | 1997 |
Docetaxel-induced subungual hemorrhage.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Breast Neoplasms, Male; Docetaxel; Female; Hemorrhage; Humans; Male; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 1997 |
Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
Topics: Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line; Down-Regulation; Drug Resistance; Gene Expression; Genes, erbB-2; Genetic Therapy; Genetic Vectors; Humans; Mice; Paclitaxel; Tumor Cells, Cultured | 1997 |
Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured | 1997 |
Paclitaxel (Taxol)-associated junctional tachycardia.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Tachycardia | 1997 |
Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Humans; Leukemia; Mitosis; Paclitaxel; Structure-Activity Relationship; Taxoids; Triterpenes; Tumor Cells, Cultured | 1997 |
Ataxia following docetaxel infusion.
Topics: Antineoplastic Agents, Phytogenic; Ataxia; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1997 |
Introduction: taxoids and the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1997 |
[Docetaxel symposium].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1997 |
Taxol-induced cellulitis after extravasation: a rarely reported event.
Topics: Aged; Antineoplastic Agents, Phytogenic; Blister; Breast Neoplasms; Catheters, Indwelling; Cellulitis; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Infusions, Intravenous; Paclitaxel | 1997 |
A mathematical model of breast and ovarian cancer treated with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow; Breast Neoplasms; Cell Cycle; Cell Division; Female; Humans; Mathematics; Models, Biological; Ovarian Neoplasms; Paclitaxel | 1997 |
Docetaxel: today's results and tomorrow's promises.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel chemotherapy induces transverse superficial loss of the nail plate.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Nail Diseases; Paclitaxel; Taxoids | 1997 |
Future directions of paclitaxel-based therapy of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel | 1997 |
Nurses should monitor cutaneous toxicity in chemotherapy regimens with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel; Skin Diseases | 1997 |
Synthesis and beta-lactamase-mediated activation of a cephalosporin-taxol prodrug.
Topics: Animals; Antineoplastic Agents, Phytogenic; beta-Lactamases; Biotransformation; Brain Chemistry; Breast Neoplasms; Cattle; Humans; Hydrolysis; Kinetics; Microtubules; Paclitaxel; Prodrugs; Recombinant Fusion Proteins; Taxoids; Tumor Cells, Cultured | 1995 |
The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 3: Breast Cancer. Puerto Rico, March 12-16, 1997. Proceedings.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Paclitaxel | 1997 |
Acute tumor lysis syndrome associated with paclitaxel.
Topics: Breast Neoplasms; Fatal Outcome; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Tumor Lysis Syndrome | 1997 |
Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line.
Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Female; Humans; Mitosis; Oligonucleotides, Antisense; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1997 |
Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma; Cisplatin; Confidence Intervals; Disease Progression; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Remission Induction; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Failure; Vinblastine; Vinorelbine | 1998 |
Optimization of the sulforhodamine B colorimetric assay.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Adhesion; Colorimetry; Culture Media; Drug Screening Assays, Antitumor; HeLa Cells; HT29 Cells; Humans; Mice; Microchemistry; Paclitaxel; Rhodamines; Tumor Cells, Cultured | 1997 |
Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Enzyme Activation; Humans; Paclitaxel; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1998 |
Ethics of randomized clinical trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Comprehension; Cyclophosphamide; Disclosure; Doxorubicin; Ethical Theory; Ethics, Medical; Female; Fluorouracil; Humans; Methotrexate; Paclitaxel; Patient Advocacy; Personal Autonomy; Physician-Patient Relations; Professional-Family Relations; Prognosis; Randomized Controlled Trials as Topic; Researcher-Subject Relations; Risk Assessment; Therapeutic Human Experimentation; Uncertainty | 1998 |
Another taxane takes center stage in San Antonio.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Mutation; Paclitaxel; Taxoids | 1998 |
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Bone Marrow; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Leukocyte Count; Models, Theoretical; Neutropenia; Neutrophils; Ovarian Neoplasms; Paclitaxel; Pharmacokinetics; Time Factors | 1998 |
The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells--preliminary comparisons to paclitaxel.
Topics: Alkanes; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carbamates; Diploidy; DNA Fragmentation; DNA, Neoplasm; Female; Humans; Lactones; Paclitaxel; Pyrones; Tumor Cells, Cultured | 1998 |
Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lewis X Antigen; Paclitaxel; Tumor Cells, Cultured | 1998 |
Paclitaxel in Breast Cancer: Putting the Evidence into Practice. Proceedings from the Pan European Interactive Forum. Lisbon, Portugal, June 28, 1997.
Topics: Antineoplastic Agents; Breast Neoplasms; Forecasting; Humans; Paclitaxel | 1998 |
Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Italy; Middle Aged; Paclitaxel; Pilot Projects | 1998 |
Paclitaxel plus vinorelbine in metastatic breast Ca patients with contraindications to receive anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Vinblastine; Vinorelbine | 1998 |
Metastatic breast cancer: experience with the combination paclitaxel plus epirubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 1998 |
Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carboplatin; Drug Therapy, Combination; Female; Humans; Middle Aged; Paclitaxel | 1998 |
Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Paclitaxel; Tumor Cells, Cultured | 1998 |
Prosaptide prevents paclitaxel neurotoxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line; Female; Nerve Growth Factors; Neural Conduction; Paclitaxel; Pain Threshold; PC12 Cells; Rats; Rats, Sprague-Dawley; Rats, Wistar | 1998 |
Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1998 |
Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytokines; Female; Gene Expression; Humans; Interleukin-1; Interleukin-8; Monocytes; Paclitaxel; RNA, Messenger; T-Lymphocytes; Tumor Cells, Cultured | 1998 |
Difluoromethylornithine antagonizes taxol cytotoxicity in MCF-7 human breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Drug Interactions; Eflornithine; Female; Humans; Paclitaxel; Tumor Cells, Cultured | 1997 |
Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, Drug; Genes, p53; Humans; Lymphoma; Mutation; Paclitaxel; Radiation, Ionizing; Tumor Cells, Cultured; Vincristine | 1998 |
[Breast cancer with liver metastasis responsive to docetaxel: case report].
Topics: Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1998 |
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Paclitaxel; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured | 1998 |
Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspases; Cyclic AMP-Dependent Protein Kinases; Cysteine Endopeptidases; DNA Damage; Enzyme Activation; Female; Humans; Male; Microtubules; Nocodazole; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Cells, Cultured; Vincristine | 1998 |
Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arachnoid; Blood-Brain Barrier; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Meningeal Neoplasms; Paclitaxel; Taxoids | 1998 |
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Topics: Antineoplastic Agents; Apoptosis; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Cell Cycle; Cell Division; Cell Survival; Doxorubicin; Female; Humans; Intercalating Agents; Mechlorethamine; Neoplasm Proteins; Paclitaxel; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured; Ultraviolet Rays; Vincristine | 1998 |
[Taxoids in ovarian and breast carcinoma: the role of the medical profession and the government].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Costs; Drug Utilization; Female; Guidelines as Topic; Humans; Paclitaxel; Physician's Role; Policy Making; Public Policy; Taxoids | 1998 |
[Provision of taxoids in 1996: inequality of care].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Budgets; Clinical Trials as Topic; Docetaxel; Drug Costs; Drug Utilization; Female; Health Care Rationing; Hospitals; Humans; Netherlands; Ovarian Neoplasms; Paclitaxel; Population Surveillance; Surveys and Questionnaires; Taxoids | 1998 |
In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Breast Neoplasms; Cisplatin; Cyclodextrins; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1998 |
Cardiac dysfunction in cancer patients receiving paclitaxel.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Female; Heart Failure; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Stroke Volume; Ventricular Dysfunction, Left | 1998 |
Genentech's anticancer Mab expected by November.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab; United States | 1998 |
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Proteins; Paclitaxel; Receptor, ErbB-2; Transplantation, Heterologous; Trastuzumab; Tumor Cells, Cultured | 1998 |
High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Transplantation, Autologous | 1998 |
Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calcitriol; Cell Division; Cisplatin; Female; Humans; Kidney; Liver; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Cytostatic and apoptotic effects of paclitaxel in human breast tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; DNA, Neoplasm; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Tumor Cells, Cultured | 1998 |
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Adhesion; Cell Division; Codon; Collagen; Culture Media, Conditioned; Female; Humans; Insulin-Like Growth Factor I; Laminin; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Point Mutation; Polymerase Chain Reaction; Precipitin Tests; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 1998 |
Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Survival; DNA Fragmentation; Drug Resistance, Multiple; Genes, MDR; Humans; Paclitaxel; Phenotype; Tumor Cells, Cultured | 1998 |
[Complete remission after salvage chemotherapy in metastatic breast carcinoma after failure of induction cycles of planned high dosage chemotherapy with stem cell support].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Mastectomy, Segmental; Neoplasm Staging; Paclitaxel; Pleural Neoplasms; Remission Induction; Salvage Therapy | 1998 |
Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Topics: beta 2-Microglobulin; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Paclitaxel; RNA, Antisense; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Vincristine | 1998 |
Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Estradiol; Female; Humans; Insulin-Like Growth Factor I; Interleukin-4; Ovarian Neoplasms; Paclitaxel; Receptors, Estrogen; Receptors, Interleukin-4; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1998 |
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Taxoids; Tubulin | 1998 |
[Yellow nails].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Hand Dermatoses; Humans; Middle Aged; Nail Diseases; Paclitaxel; Pigmentation Disorders; Taxoids | 1998 |
Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Microtubules; Middle Aged; Mitosis; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Tubulin | 1998 |
m-THPC-mediated photodynamic therapy (PDT) does not induce resistance to chemotherapy, radiotherapy or PDT on human breast cancer cells in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Mesoporphyrins; Necrosis; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Radiation Tolerance; Radiotherapy; Tumor Cells, Cultured | 1998 |
Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 1998 |
New regimen may increase chances of breast cancer cure.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Paclitaxel; Survival Analysis; Treatment Outcome | 1998 |
5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Drug Administration Schedule; Female; Fluorouracil; G1 Phase; Humans; KB Cells; Mitosis; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1997 |
Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Female; Genes, jun; Genes, myc; Humans; Paclitaxel; Tumor Cells, Cultured | 1996 |
Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Epirubicin; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Dose-intensified weekly paclitaxel induces multiple nail disorders.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Liver Neoplasms; Middle Aged; Nail Diseases; Paclitaxel | 1998 |
Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.
Topics: Animals; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Line; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA Fragmentation; Fibroblasts; Flow Cytometry; Humans; Kinetin; Mice; Oligonucleotides, Antisense; Paclitaxel; Protein Serine-Threonine Kinases; Purines; Receptor, ErbB-2; Transfection; Tumor Cells, Cultured; Up-Regulation | 1998 |
A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hearing Loss, Sensorineural; Humans; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 1998 |
Taxol induces apoptosis in various cancer cell lines: comparison among different methodological approaches.
Topics: Apoptosis; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1997 |
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Lactones; Leukemia P388; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Structure-Activity Relationship; Thiazoles; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Interactions; Epirubicin; Female; Humans; Mice; Paclitaxel; Taxoids | 1998 |
Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Taxoids | 1998 |
Is there a place for "dose-dense" weekly schedules of the taxoids?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Paclitaxel; Palliative Care; Taxoids | 1998 |
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Disease Progression; Docetaxel; Female; Humans; Markov Chains; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Taxoids; Western World | 1998 |
Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; Cell Cycle; Colchicine; Egtazic Acid; Enzyme Activation; Humans; Microtubules; Nocodazole; Paclitaxel; Podophyllotoxin; Tumor Cells, Cultured; Vincristine | 1999 |
Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Shc dominant negative disrupts cell cycle progression in both G0-G1 and G2-M of ErbB2-positive breast cancer cells.
Topics: Breast; Breast Neoplasms; Cell Cycle; Epithelial Cells; Female; G1 Phase; G2 Phase; Humans; Mitosis; Nocodazole; Paclitaxel; Phosphorylation; Receptor, ErbB-2; Resting Phase, Cell Cycle; src Homology Domains; Stem Cells; Tumor Cells, Cultured; Tyrosine | 1999 |
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Caspase 3; Caspases; Doxorubicin; Enzyme Activation; Fluorouracil; Glutathione Transferase; Humans; Melphalan; Membrane Glycoproteins; Paclitaxel; Recombinant Fusion Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1999 |
Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1999 |
Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Folic Acid Antagonists; Humans; Lung Neoplasms; Methotrexate; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1998 |
A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Drug Resistance, Multiple; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1999 |
Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis.
Topics: Alanine; Amino Acid Substitution; Apoptosis; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cytosol; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mitochondria; Mitogen-Activated Protein Kinases; Mutagenesis, Site-Directed; Paclitaxel; Phosphorylation; Point Mutation; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Sequence Deletion; Serine; Signal Transduction; Transfection; Tumor Cells, Cultured; Vincristine | 1999 |
Paclitaxel and docetaxel. Innovation, but at what cost?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Costs and Cost Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids | 1995 |
Cost utility in second-line metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Topics: Antineoplastic Agents; Breast Neoplasms; Cost-Benefit Analysis; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1999 |
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Division; Cetuximab; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Flow Cytometry; Humans; Oligonucleotides; Oligonucleotides, Antisense; Oligoribonucleotides, Antisense; Paclitaxel; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel | 1999 |
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Cycle; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Receptor, ErbB-2; Recombinant Proteins; Thiotepa; Topoisomerase II Inhibitors; Transplantation, Heterologous; Trastuzumab; Treatment Outcome; Vinblastine | 1999 |
Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis.
Topics: Affinity Labels; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Breast Neoplasms; Caspases; Cell Adhesion; Cell Cycle; Cytochrome c Group; Enzyme Activation; Epidermal Growth Factor; Fas Ligand Protein; Flow Cytometry; Floxuridine; Humans; Membrane Glycoproteins; Microscopy, Fluorescence; Paclitaxel; Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1999 |
Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Cell Nucleus; DNA; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Female; Gene Expression; Humans; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factor AP-1; Tumor Cells, Cultured; Up-Regulation; Vinblastine | 1999 |
Nail changes secondary to docetaxel (Taxotere).
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 1999 |
[Low-dose weekly administration of docetaxel for metastatic breast cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
The role of taxanes in the management of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Evidence-Based Medicine; Humans; Medical Oncology; Paclitaxel; Taxoids | 1999 |
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; DNA, Neoplasm; Drug Administration Schedule; Drug Antagonism; Fluorouracil; Humans; Paclitaxel; RNA, Neoplasm; Thymidylate Synthase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspases; CDC2 Protein Kinase; Cyclin B; Cyclin B1; Drug Interactions; Enzyme Activation; Flavonoids; Humans; Mitosis; Paclitaxel; Piperidines; Poly Adenosine Diphosphate Ribose; Retinoblastoma Protein; Stomach Neoplasms; Tumor Cells, Cultured | 1999 |
Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; CHO Cells; Cricetinae; Cyclic AMP-Dependent Protein Kinases; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Kinetics; Paclitaxel; Polymerase Chain Reaction; Recombinant Proteins; RNA, Messenger; Transcription, Genetic; Transfection | 1999 |
Feasibility of dose-intensified paclitaxel after chemotherapy-induced renal insufficiency in a patient with renal transplantation.
Topics: Acute Kidney Injury; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Kidney Transplantation; Middle Aged; Paclitaxel; Time Factors | 1999 |
[Cloning of genes associated with taxol-induced apoptosis of human breast cancer cells].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Breast Neoplasms; Cloning, Molecular; DNA, Complementary; Humans; Methionine Adenosyltransferase; Molecular Sequence Data; Paclitaxel; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid; Tumor Cells, Cultured | 1997 |
Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Carcinoma; Cell Count; Cell Division; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Female; Fluorouracil; Gene Expression; Humans; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Telomerase; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
[Multi-drug resistant breast cancer responding to chemotherapy with docetaxel (taxotere: TXT)].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Taxoids | 1999 |
[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pleural Neoplasms; Quality of Life; Taxoids | 1999 |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Survival Analysis; Treatment Outcome | 1999 |
The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration.
Topics: Apoptosis; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Microtubules; Mitosis; Necrosis; Paclitaxel; Spindle Apparatus; Tumor Cells, Cultured | 1999 |
Pharmacokinetic models for the saturable distribution of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Breast Neoplasms; Female; Humans; Paclitaxel | 1999 |
Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Administration Schedule; Fluorouracil; G1 Phase; Humans; Hydroxyurea; KB Cells; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; S Phase; Tumor Cells, Cultured | 1999 |
[Pharmacological study of weekly docetaxel in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 1999 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Time Factors; Tumor Cells, Cultured | 1999 |
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Middle Aged; Paclitaxel; Quality-Adjusted Life Years; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1999 |
Choroidal metastases. Case 1: breast cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Diagnosis, Differential; Eye; Female; Humans; Paclitaxel; Ultrasonography; Vision Disorders | 1999 |
New approach reduces side effects of high-dose chemotherapy for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Paclitaxel; Prognosis | 1999 |
[Facts and perspectives in the therapy of cancers of the breast, ovary and bronchi].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Bronchial Neoplasms; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Postoperative Care | 1999 |
Taxane-induced glaucoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Paclitaxel; Recurrence; Taxoids | 1999 |
Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Insulin-Like Growth Factor I; Paclitaxel; Tumor Cells, Cultured | 1999 |
Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1999 |
[Effectiveness of current chemotherapy in metastatic breast cancer resistant to anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Apoptotic cell death induced by baccatin III, a precursor of paclitaxel, may occur without G(2)/M arrest.
Topics: Alkaloids; Apoptosis; Breast Neoplasms; Cell Cycle; DNA Fragmentation; DNA, Neoplasm; Drugs, Chinese Herbal; Female; G2 Phase; Humans; KB Cells; Microtubules; Mitosis; Nucleosomes; Paclitaxel; Prohibitins; Taxoids; Tumor Cells, Cultured | 1999 |
FDA advisors recommend approval of taxol for node-positive breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Approval; Female; Humans; Lymphatic Metastasis; Paclitaxel; United States; United States Food and Drug Administration | 1999 |
[A case report: effective trans-arterial neoadjuvant chemotherapy with docetaxel for a local advanced breast cancer patient].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 1999 |
[A case of multiple liver metastases from breast cancer successfully treated with intra-arterial administration of docetaxel].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Middle Aged; Paclitaxel; Taxoids | 1999 |
[A case of hepatic arterial infusion chemotherapy with docetaxel for liver metastasis from breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 1999 |
Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Breast Neoplasms; Chromatography, High Pressure Liquid; Docetaxel; Drug Synergism; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 1999 |
[Administration of docetaxel in cases of recurrent breast carcinoma with malignant pleural effusion controlled by intrapleural administration of OK-432].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Picibanil; Pleura; Pleural Effusion, Malignant; Taxoids | 1999 |
Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Facial Paralysis; Female; Humans; Middle Aged; Paclitaxel; Risk Factors | 1999 |
Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Genes, erbB-2; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Trastuzumab | 1999 |
American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Drugs, Chinese Herbal; Flow Cytometry; Humans; Paclitaxel; Panax; Plants, Medicinal; Tamoxifen; Tumor Cells, Cultured | 1999 |
Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
Topics: Breast Neoplasms; Chemokine CCL2; DNA, Complementary; Doxorubicin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Interleukin-8; Ovarian Neoplasms; Paclitaxel; Phenotype; Tumor Cells, Cultured; Verapamil; Vincristine | 1999 |
Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Paclitaxel; Rats; Rats, Nude; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Breast Neoplasms; Carbazoles; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Glucosides; Humans; Indoles; Leukemia P388; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Time Factors | 1999 |
Taxing the taxanes: overused or undersold?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Synergism; Estramustine; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1999 |
Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Breast Neoplasms; Cell Cycle; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Polyglutamic Acid; Receptor, ErbB-2; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Topics: Adenocarcinoma; Adenoviruses, Human; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Drug Synergism; Female; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Pyridines; Teratocarcinoma; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Possible drug-associated pancreatitis after paclitaxel-cremophor administration.
Topics: Acute Disease; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Diagnosis, Differential; Female; Humans; Infusions, Intravenous; Paclitaxel; Pancreatitis; Pharmaceutical Vehicles; Polyethylene Glycols | 2000 |
Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Paclitaxel; Taxoids | 1999 |
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Culture Media, Serum-Free; Cyclophosphamide; Dendritic Cells; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-4; Leukapheresis; Leukocyte Count; Lymphocyte Culture Test, Mixed; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neutropenia; Paclitaxel; Taxoids | 1999 |
[A trial for neoadjuvant chemotherapy of transarterial infusion of docetaxel in locally advanced breast cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Topics: Anthropometry; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capillary Permeability; Carcinoma; Docetaxel; Double-Blind Method; Edema; Electronics, Medical; Female; Flavonoids; Humans; Leg; Lymphedema; Mastectomy; Optics and Photonics; Ovarian Neoplasms; Paclitaxel; Placebos; Randomized Controlled Trials as Topic; Taxoids; Venous Insufficiency; Weight Loss | 2000 |
Case problem: presenting conventional and complementary approaches for relieving nausea in a breast cancer patient undergoing chemotherapy.
Topics: Acupressure; Acupuncture Therapy; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Massage; Mastectomy, Modified Radical; Nausea; Paclitaxel; Phytotherapy; Plants, Medicinal; Prochlorperazine; Relaxation Therapy; Vomiting; Zingiber officinale | 2000 |
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
Glaucoma and paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Glaucoma; Humans; Intraocular Pressure; Middle Aged; Paclitaxel | 2000 |
Nail alterations secondary to pactitaxel [corrected] therapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Lymphatic Metastasis; Middle Aged; Nail Diseases; Neoplasm Recurrence, Local; Paclitaxel; Pigmentation Disorders | 2000 |
Complete regression of choroidal metastases from breast cancer after docetaxel-based systemic chemotherapy.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Choroid Neoplasms; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Taxoids; Treatment Outcome | 2000 |
Can HER2 status predict response to cancer therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Taxoids; Trastuzumab | 2000 |
Cutaneous fibrosis induced by docetaxel: a case report.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Eruptions; Female; Fibrosis; Humans; Paclitaxel; Skin; Taxoids | 2000 |
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Infections; Melphalan; Middle Aged; Mitoxantrone; Paclitaxel; Survival Rate; Thiotepa; Time Factors; Transplantation, Autologous | 2000 |
Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Biological Transport, Active; Breast Neoplasms; Deoxyglucose; Estradiol; Estrone; Female; Humans; Hydroxyestrones; Insulin; Kinetics; Paclitaxel; Tumor Cells, Cultured | 2000 |
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chi-Square Distribution; Cyclophosphamide; Doxorubicin; Feasibility Studies; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction | 2000 |
[Adjuvant therapy of breast cancer in the USA].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Paclitaxel; Prognosis; United States | 2000 |
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Cyclophosphamide; Docetaxel; Female; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Weight Loss | 2000 |
[Mechanism of taxol-induced apoptosis in human breast cancer cells].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; DNA Fragmentation; Female; Humans; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1997 |
Pseudomembranous colitis in a patient treated with paclitaxel for carcinoma of the breast: a case report.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Enterocolitis, Pseudomembranous; Female; Humans; Middle Aged; Paclitaxel | 2000 |
Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carboplatin; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Mitomycin; Neoplasm Proteins; Paclitaxel; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: surgical aspects.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Feasibility Studies; Female; Humans; Mastectomy, Modified Radical; Middle Aged; Paclitaxel; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Adjuvant; Treatment Outcome | 2000 |
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed | 2000 |
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prednisolone; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids; Tomography, Emission-Computed; Vincristine | 2000 |
1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.
Topics: Antineoplastic Agents; Breast Neoplasms; Calcitriol; Cell Survival; Doxorubicin; Drug Synergism; Female; Humans; Paclitaxel; Receptors, Calcitriol; Receptors, Estrogen; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Tretinoin; Tumor Cells, Cultured | 2000 |
Paclitaxel-epirubicin in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pilot Projects | 1999 |
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Leucovorin; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Skin Neoplasms; Taxoids | 2000 |
Herceptin in the adjuvant setting: phase III trials begin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Trastuzumab | 2000 |
[Chemosensitivity test for 170 human breast carcinoma samples].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Cyclosporine; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Tumor Cells, Cultured | 1998 |
Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Chromatography, High Pressure Liquid; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Leukopenia; Linear Models; Middle Aged; Paclitaxel; Platelet Count; Statistics, Nonparametric; Treatment Outcome | 2000 |
Impairment of heart rate variability during paclitaxel therapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervous System; Breast Neoplasms; Carcinoma; Circadian Rhythm; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Heart Conduction System; Heart Rate; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Risk Factors; Signal Processing, Computer-Assisted | 2000 |
Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cyclosporins; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Paclitaxel; Tumor Cells, Cultured | 2000 |
Taxane-based therapy for breast cancer: combination or sequential therapy?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Paclitaxel; Taxoids | 2000 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Remission of rheumatoid arthritis with taxol in a patient with breast carcinoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma; Female; Humans; Paclitaxel; Remission Induction | 2000 |
The pharmacokinetics of a 1-h paclitaxel infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Uterine Neoplasms | 2000 |
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Docetaxel; Enterocolitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Taxoids; Tomography, X-Ray Computed | 2000 |
Intra-arterial mitoxantrone and paclitaxel in a patient with Stewart-Treves syndrome: selection of chemotherapy by an ex vivo ATP-based chemosensitivity assay.
Topics: Adenosine Triphosphate; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Screening Assays, Antitumor; Female; Humans; Infusions, Intra-Arterial; Lymphangiosarcoma; Lymphedema; Mitoxantrone; Neoplasms, Radiation-Induced; Paclitaxel; Soft Tissue Neoplasms; Syndrome | 2000 |
Resistance to paclitaxel induces time-delayed multinucleation and DNA fragmentation into large fragments in MCF-7 human breast adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Female; Humans; Microscopy, Fluorescence; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2000 |
Colitis and docetaxel-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colitis; Diarrhea; Docetaxel; Estramustine; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2000 |
Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells.
Topics: Anisomycin; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line; DNA-Binding Proteins; Doxorubicin; Drug Resistance; Epidermal Growth Factor; ErbB Receptors; Humans; Immunoblotting; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Paclitaxel; Phenotype; Precipitin Tests; Proto-Oncogene Proteins c-fos; RNA, Messenger; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2000 |
Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; CHO Cells; Cricetinae; Drug Carriers; Drug Design; Endocytosis; Female; Growth Inhibitors; Humans; Ligands; Microscopy, Confocal; Models, Biological; Molecular Structure; Octreotide; Paclitaxel; Receptors, Somatostatin; Taxoids; Tubulin; Tumor Cells, Cultured | 2000 |
Phantom limb pain as a manifestation of paclitaxel neurotoxicity.
Topics: Adult; Aged; Amputation, Surgical; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Female; Hand; Humans; Leg; Lung Neoplasms; Male; Neurotoxins; Paclitaxel; Phantom Limb; Tendon Transfer; Ulnar Nerve | 2000 |
Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Cell Survival; Enzyme Inhibitors; Epidermal Growth Factor; Female; HL-60 Cells; Humans; Microtubules; Mitosis; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tetradecanoylphorbol Acetate; Tubulin; Tumor Cells, Cultured; Tyrphostins | 2000 |
Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Breast Neoplasms; Gastrointestinal Diseases; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Retrospective Studies; Suspensions; Transplantation, Autologous | 2000 |
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Rate; Ventricular Dysfunction, Left | 2000 |
[Paclitaxel (Tesu) as a single agent in the treatment of breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Leukopenia; Middle Aged; Paclitaxel; Remission Induction | 1997 |
[Effect of up-regulation of S-AdoMet synthetase on taxol-induced apoptosis in human breast cancer cells].
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Humans; Methionine Adenosyltransferase; Paclitaxel; Prohibitins; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 1998 |
[A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Hypercalcemia; Lymph Nodes; Lymphatic Metastasis; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Paclitaxel; Taxoids | 2000 |
[A case of head metastases of breast cancer successfully treated with radiation therapy and docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Mastectomy, Radical; Meningeal Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Skin Neoplasms; Skull Neoplasms; Taxoids | 2000 |
Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Diffusion; Drug Resistance, Neoplasm; Humans; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Mice; Mice, SCID; Neoplasm Transplantation; Paclitaxel; Time Factors; Tumor Cells, Cultured; Water | 1999 |
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antigens, Nuclear; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Docetaxel; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Paraffin Embedding; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Randomized Controlled Trials as Topic; Taxoids; Tumor Suppressor Protein p53 | 2000 |
Mesenteric venous thrombosis attributed to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Mesenteric Vascular Occlusion; Mesenteric Veins; Middle Aged; Osteolysis; Paclitaxel; Sternum; Taxoids; Venous Thrombosis | 2000 |
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Northern; Blotting, Western; Breast Neoplasms; Caenorhabditis elegans Proteins; DNA; DNA-Binding Proteins; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Inhibitor of Apoptosis Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Plants, Medicinal; Protein Binding; Proteins; Repressor Proteins; Sesquiterpenes; Superoxide Dismutase; TNF Receptor-Associated Factor 1; Tumor Cells, Cultured | 2000 |
[Effective chemotherapy with docetaxel in a patient with breast cancer who had progressed after high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2000 |
Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer.
Topics: Apoptosis; bcl-X Protein; Breast Neoplasms; Caspase 9; Caspases; Cell Membrane; Enzyme Precursors; Estradiol; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Recombinant Proteins; Transfection; Tumor Cells, Cultured; Ultraviolet Rays | 2000 |
Taxanes as adjuvant for breast cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Evidence-Based Medicine; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic | 2000 |
Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Humans; Immunotoxins; Iodine Radioisotopes; Lewis Blood Group Antigens; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Radioimmunotherapy; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; DNA Fragmentation; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Humans; Mitosis; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Recurrence; Taxoids | 2000 |
Mobilization and transplantation of peripheral blood stem cells.
Topics: Antigens, CD34; Blood Transfusion; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Cytokines; Erythrocytes; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Lymphoma, Non-Hodgkin; Paclitaxel; Platelet Transfusion; Regression Analysis; Retrospective Studies; Transplantation, Autologous | 1998 |
[A case of effective chemotherapy using CAF followed by docetaxel for advanced breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids | 2000 |
Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diterpenes; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Humans; Invertebrates; Lactones; Macrolides; Marine Biology; Paclitaxel; Plant Extracts; Plants, Medicinal; Pseudomonas; Structure-Activity Relationship; Tissue Extracts; Tumor Cells, Cultured | 2000 |
Docetaxel effectively mobilizes peripheral blood CD34+ cells.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; Blood Component Removal; Breast Neoplasms; Cell Count; Docetaxel; Drug Evaluation; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Time Factors | 2000 |
Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2000 |
Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Paclitaxel; Remission Induction; Salvage Therapy; Taxoids | 2000 |
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Time Factors | 2000 |
Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Caspases; Drug Synergism; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Paclitaxel; Tumor Cells, Cultured | 2000 |
[Antitumor activity of UFT and docetaxel on human breast carcinoma xenografts].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Paclitaxel; Succinate Dehydrogenase; Taxoids; Tegafur; Transplantation, Heterologous; Uracil; Xenograft Model Antitumor Assays | 2000 |
Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2000 |
[A case of locally advanced breast cancer successfully resected after selective intra-arterial chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Paclitaxel; Taxoids | 2000 |
Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Mitotic arrest of endometrial epithelium after paclitaxel therapy for breast cancer.
Topics: Adenocarcinoma; Adult; Antigens, Nuclear; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dilatation and Curettage; Doxorubicin; Endometrium; Epithelium; Female; Humans; Ki-67 Antigen; Menorrhagia; Mitosis; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tissue Embedding; Uterine Hemorrhage | 2000 |
Adjuvant chemotherapy for early breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Paclitaxel | 2000 |
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Paclitaxel; Pulmonary Edema; Radiography; Taxoids | 2000 |
Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Paclitaxel; Recombinant Proteins; Taxoids | 2001 |
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Humans; In Situ Nick-End Labeling; Mitosis; Paclitaxel; Time Factors; Treatment Outcome | 2000 |
Taxane evidence inconclusive in adjuvant setting.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Consensus Development Conferences, NIH as Topic; Disease-Free Survival; Europe; Evidence-Based Medicine; Female; Humans; Lymphatic Metastasis; Multicenter Studies as Topic; Paclitaxel; Survival Analysis; United States | 2001 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
Influences on oncologists' adoption of new agents in adjuvant chemotherapy of breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Models, Psychological; Paclitaxel; Practice Patterns, Physicians' | 2001 |
Changes in findings of mammography, ultrasonography and contrast-enhanced computed tomography of three histological complete responders with primary breast cancer before and after neoadjuvant chemotherapy: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Mammary | 2000 |
[Recurrent breast cancer successfully treated with a weekly dose of paclitaxel--a case report].
Topics: Antineoplastic Agents, Phytogenic; Axilla; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydrothorax; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pleural Effusion, Malignant | 2001 |
Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Inappropriate ADH Syndrome; Paclitaxel; Taxoids | 2000 |
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Child; Child, Preschool; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Taxoids | 2001 |
Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle Aged; Paclitaxel; Time Factors; Tomography, X-Ray Computed | 2001 |
Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Division; Doxorubicin; Drug Synergism; Female; Fluorouracil; Humans; Paclitaxel; Polyamines; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Designing and funding clinical trials of novel therapies.
Topics: Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Breast Neoplasms; Data Interpretation, Statistical; Female; Humans; Insurance, Health; Neurons; Paclitaxel; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design; Research Support as Topic; Sample Size; Survival Analysis; Therapies, Investigational; United States | 2001 |
Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cancer Vaccines; Cell Membrane; Cisplatin; Cloning, Molecular; Female; Flow Cytometry; Glioma; Immunohistochemistry; Macrophage Colony-Stimulating Factor; Macrophages; Necrosis; Neoplasm Transplantation; Paclitaxel; Rats; Rats, Inbred F344; Retroviridae; Time Factors; Transduction, Genetic; Transfection; Tumor Cells, Cultured | 2001 |
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Liver Neoplasms; Middle Aged; Paclitaxel; Soft Tissue Neoplasms; Thiotepa; Treatment Outcome | 2001 |
Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Female; gamma-Linolenic Acid; Humans; Oleic Acid; Paclitaxel; Tumor Cells, Cultured | 2001 |
Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Mammography; Middle Aged; Paclitaxel; Reproducibility of Results; Taxoids; Tomography, Emission-Computed | 2001 |
[Two cases of advanced and metastatic breast cancers treated by docetaxel in combination with intra-arterial infusion of adriamycin].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
[A case of breast cancer 5 cm in diameter treated with a breast preserving approach after preoperative intra-arterial chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Injections, Intra-Arterial; Middle Aged; Paclitaxel; Taxoids | 2001 |
[A case of recurrent breast cancer successfully treated with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2001 |
Clinical picture: nail changes secondary to docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Nail Diseases; Paclitaxel; Taxoids | 2001 |
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Count; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Mevalonic Acid; Paclitaxel; Time Factors; Tumor Cells, Cultured; Zoledronic Acid | 2001 |
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Models, Animal; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Paclitaxel; Taxoids; Thymidine Phosphorylase; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2001 |
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Female; Flavonoids; G2 Phase; Humans; Imidazoles; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Mitosis; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Protein Serine-Threonine Kinases; Pyridines; Rats; Receptor, ErbB-2; Retinoblastoma Protein; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
[A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2001 |
A new prodrug of paclitaxel: synthesis of Protaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Stability; Drug Tolerance; Female; Half-Life; Humans; Hydrogen-Ion Concentration; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Prodrugs; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Solubility; Taxoids; Xenograft Model Antitumor Assays | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Another reader shares experience with paclitaxel reactions.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Oncology Nursing; Paclitaxel | 2001 |
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Paclitaxel; Risk | 2001 |
Herceptin-taxol related hand and foot syndrome.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Paclitaxel; Syndrome; Trastuzumab | 2000 |
Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Volume; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukocyte Count; Male; Middle Aged; Paclitaxel; Time Factors | 2001 |
[Fulminant hepatocellular necrosis following administration of docetaxel].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Liver Failure; Middle Aged; Necrosis; Paclitaxel; Taxoids | 2001 |
BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Survival; Colonic Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Female; Humans; Infusions, Parenteral; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Sarcoma; Thiazoles; Tubulin; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2001 |
Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytoprotection; Electrophoresis, Polyacrylamide Gel; Fibroblasts; HeLa Cells; Humans; Melanoma; Mercaptoethylamines; Mice; NF-kappa B; NF-kappa B p50 Subunit; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Proto-Oncogene Proteins c-mdm2; Transcription Factor AP-1; Transcription Factors; Transcriptional Activation; Tumor Suppressor Protein p53 | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Hypertrophic osteoarthropathy associated with docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Docetaxel; Female; Humans; Lung Neoplasms; Mastectomy; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Paclitaxel; Taxoids | 2001 |
[Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer].
Topics: Alopecia; Anthracyclines; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2001 |
Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Doxorubicin; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ventricular Function, Left | 2001 |
Taxol-induced ceramide generation and apoptosis in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Ceramides; Female; Humans; Paclitaxel; Tumor Cells, Cultured | 2001 |
Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Chi-Square Distribution; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; RNA, Neoplasm; Taxoids; Transcription Factors | 2001 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Breast Neoplasms; Cell Survival; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Flow Cytometry; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunomagnetic Separation; Keratins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Risk Factors; Stem Cells; Taxoids; Time Factors; Tumor Cells, Cultured | 2001 |
The peripheral blood leukocyte phenotype in patients with breast cancer: effect of doxorubicin/paclitaxel combination chemotherapy.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Doxorubicin; Female; HLA-DR Antigens; Humans; Immunophenotyping; Lectins, C-Type; Leukocytes; Lipopolysaccharide Receptors; Lymphocyte Subsets; Middle Aged; Paclitaxel; Receptors, IgG | 2001 |
Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cdc20 Proteins; Cell Cycle Proteins; Enzyme Activation; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Mice; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Protein Biosynthesis; Proteins; RNA, Messenger; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Up-Regulation | 2001 |
[Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Neutropenia; Neutrophils; Paclitaxel; Retrospective Studies; Taxoids | 2001 |
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arthralgia; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Depression; Female; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Middle Aged; Mitoxantrone; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Transplantation, Autologous | 2001 |
Docetaxel induced cardiotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Skin Neoplasms; Taxoids; Ventricular Dysfunction, Left | 2001 |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; Paclitaxel | 2001 |
Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.
Topics: Adenoviridae; Animals; Apoptosis; Breast Neoplasms; Caspase 9; Caspases; Cell Division; Cisplatin; Combined Modality Therapy; Female; Genes, p53; Genetic Variation; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Colonic Neoplasms; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Immunotoxins; Inhibitory Concentration 50; Lewis Blood Group Antigens; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoquinones; Breast Neoplasms; Caspase 3; Caspase 9; Caspases; Cell Division; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mitosis; Paclitaxel; Retinoblastoma Protein; Rifabutin; Time Factors; Tumor Cells, Cultured | 2001 |
NF-kappa B-mediated chemoresistance in breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, Reporter; Humans; Inhibitory Concentration 50; Luciferases; NF-kappa B; Nitriles; Organic Chemicals; Paclitaxel; Sulfones; Tumor Cells, Cultured | 2001 |
Doxorubicin/paclitaxel combination does not expose breast cancer patients to excessive cardiac risk.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Heart Diseases; Humans; Paclitaxel | 2001 |
Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Bridged-Ring Compounds; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Fluorescence; Humans; Male; Paclitaxel; Taxoids; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon Type I; Interferon-Stimulated Gene Factor 3; Interferon-Stimulated Gene Factor 3, gamma Subunit; Microtubules; Paclitaxel; Signal Transduction; Transcription Factors; Transfection; Tumor Cells, Cultured; Uterine Neoplasms; Vinblastine | 2001 |
Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Adhesion; Cytochrome c Group; Drug Resistance, Neoplasm; Female; Humans; Integrin beta1; Mitochondria; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Cells, Cultured; Vincristine | 2001 |
Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines.
Topics: Animals; Breast Neoplasms; Chemokine CXCL10; Chemokine CXCL2; Chemokines; Chemokines, CXC; Coculture Techniques; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-1; Kinetics; Lipopolysaccharides; Macrophages; Mammary Neoplasms, Animal; Mice; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2001 |
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Epirubicin; Female; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids | 2001 |
[A case of breast cancer with bone marrow and liver metastases responding completely to low-dose weekly paclitaxel combined with toremifene].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Paclitaxel; Remission Induction; Toremifene | 2001 |
Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Heart Failure; Humans; Paclitaxel; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2001 |
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Blotting, Western; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Division; Cisplatin; DNA Damage; DNA, Complementary; Doxorubicin; GADD45 Proteins; Humans; Intracellular Signaling Peptides and Proteins; Microtubules; Mitosis; Paclitaxel; Phenotype; Proteins; Time Factors; Tumor Cells, Cultured; Vincristine | 2001 |
Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Cell Membrane; Collagen; Doxorubicin; Drug Combinations; G2 Phase; Laminin; Methotrexate; Mitosis; Nocodazole; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Phosphatidylcholines; Phospholipids; Phosphorus; Proteoglycans; Tumor Cells, Cultured; Vincristine | 2001 |
A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Nucleus; Cell Survival; Cysteine Proteinase Inhibitors; Female; Humans; Paclitaxel; Ploidies; Thymidine; Tumor Cells, Cultured | 2001 |
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
Topics: Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Paclitaxel; Proto-Oncogene Proteins c-jun; RNA, Catalytic; RNA, Messenger; Spindle Apparatus; Tumor Cells, Cultured; Vincristine | 2001 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Caspases; Cytosol; Enzyme Activation; Female; Humans; Paclitaxel; Transfection; Tumor Cells, Cultured | 2002 |
VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cyclic AMP; Disease Models, Animal; Doxorubicin; Drug Synergism; Female; Genes, fos; Humans; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Neurotensin; Paclitaxel; Protein Binding; Receptors, Vasoactive Intestinal Peptide; Recombinant Fusion Proteins; RNA, Messenger; Thymidine; Transplantation, Heterologous; Tumor Cells, Cultured; Vasoactive Intestinal Peptide | 2001 |
[Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel].
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
[A patient with recurrent breast cancer whose liver metastasis regressed following combined use of weekly docetaxel and MPA.5'-DFUR].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Paclitaxel; Taxoids | 2001 |
From the Food and Drug Administration.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Diethylhexyl Phthalate; Docetaxel; Female; Financing, Government; Fluorouracil; Heart Failure; Humans; Male; Orphan Drug Production; Pacemaker, Artificial; Paclitaxel; Spermatogenesis; Taxoids; Testis; United States; United States Food and Drug Administration | 2001 |
Salvage therapy with single-agent paclitaxel by three-hour infusion in metastatic breast cancer: an experience in Taipei Veterans General Hospital.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Salvage Therapy | 2001 |
Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Female; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Paclitaxel; Patient Selection; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2001 |
Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
[Therapeutic effect of multimodal therapy, such as cryosurgery, locoregional immunotherapy and systemic chemotherapy against far advanced breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Combined Modality Therapy; Cryosurgery; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Immunotherapy; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Picibanil; Taxoids | 2001 |
[Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Failure | 2001 |
[A case of locally advanced breast cancer successfully treated with wide resection and reconstruction of chest wall with A-O metallic plates].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Mastectomy; Middle Aged; Paclitaxel; Plastic Surgery Procedures; Quality of Life; Surgical Mesh; Survivors; Taxoids | 2001 |
[Local therapy for stage IV advanced breast cancer with brain metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Quality of Life; Radiosurgery; Tamoxifen; Taxoids | 2001 |
[Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Disease-Free Survival; Docetaxel; Female; Humans; Matched-Pair Analysis; Middle Aged; Paclitaxel; Palliative Care; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cachexia; Docetaxel; Drug Interactions; Female; Floxuridine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Paclitaxel; Taxoids; Tegafur; Thymidine Phosphorylase; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
[Cardiac conduction abnormalities after neoadjuvant chemotherapy with doxorubicin and docetaxel for primary breast carcinoma: a case report].
Topics: Aged; Anesthesia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Heart Block; Humans; Intraoperative Complications; Mastectomy, Segmental; Paclitaxel; Postoperative Complications; Taxoids | 2001 |
Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Breast Neoplasms; Calcineurin; Carcinoma; Caspases; DNA-Binding Proteins; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Humans; Jurkat Cells; Ligands; Membrane Glycoproteins; NFATC Transcription Factors; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2001 |
Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Humans; Mitogen-Activated Protein Kinase 1; Paclitaxel; Poly(ADP-ribose) Polymerases; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Burkitt Lymphoma; Cell Line; Cell Survival; Cricetinae; Cytochrome c Group; Dimerization; Fibroblasts; Humans; Kidney; Mesocricetus; Mitochondria; Paclitaxel; Phosphorylation; Protein Binding; Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Serine; Tumor Cells, Cultured | 2001 |
[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Ethanol; Fadrozole; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
[A case of breast cancer with multiple metastases effectively treated with long-term administration of docetaxel, aclarubicin and UFT].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Tegafur; Uracil | 2001 |
[Two cases of effective weekly paclitaxel administration for metastatic breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel | 2001 |
Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Female; Humans; Inflammation; Lung; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pneumonia; Radiation-Sensitizing Agents; Retrospective Studies; Time Factors; Treatment Outcome | 2001 |
Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dacryocystorhinostomy; Docetaxel; Drug Administration Schedule; Female; Glass; Humans; Infusions, Intravenous; Intubation; Lacrimal Duct Obstruction; Middle Aged; Nasolacrimal Duct; Paclitaxel; Silicone Elastomers; Taxoids; Tears | 2001 |
Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Survival; Doxorubicin; Drug Interactions; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, bcl-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Paclitaxel; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
Taxanes in the adjuvant treatment of breast cancer: why not yet?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Female; Follow-Up Studies; Humans; Meta-Analysis as Topic; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Taxoids | 2001 |
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Docetaxel; Female; Humans; Middle Aged; Mixed Function Oxygenases; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids | 2002 |
[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.
Topics: Adult; Anthracyclines; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Breast Neoplasms; Cell Separation; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infection Control; Infections; Inflammation; Melphalan; Middle Aged; Mitoxantrone; Mucous Membrane; Multivariate Analysis; Neutropenia; Paclitaxel; Patient Selection; Retrospective Studies; Risk; Taxoids; Thiotepa; Transplantation Conditioning | 2001 |
'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.
Topics: Actins; Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Nucleus; Cell Survival; Cytoskeleton; Docetaxel; Female; Humans; Immunohistochemistry; Microfilament Proteins; Microtubules; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
[A case of multiple liver metastases from breast cancer successfully treated with intra-arterial administration of paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Mastectomy, Modified Radical; Middle Aged; Paclitaxel | 2001 |
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Paclitaxel; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Tubulin Modulators; Tumor Cells, Cultured; Vinblastine | 2002 |
Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2001 |
Design, synthesis and biological activity of novel C2-C3' N-Linked macrocyclic taxoids.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Survival; Crystallography, X-Ray; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Indicators and Reagents; Molecular Conformation; Paclitaxel; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
[A 5'-DFUR + CPA + THP therapy that was effective for paclitaxel-refractory pulmonary metastasis of breast cancer--a case report].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Lung Neoplasms; Paclitaxel | 2002 |
[Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Feasibility Studies; Female; Histamine H2 Antagonists; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Ranitidine | 2002 |
Challenges in oncology. Case 2. Radiation recall associated with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Humans; Paclitaxel; Radiation Injuries; Radiotherapy; Skin; Taxoids | 2002 |
Docetaxel: new preparation. No first-line use in metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; France; Hormone Replacement Therapy; Humans; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2001 |
[Combination of taxotere and doxorubicin in chemotherapy of disseminated breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2001 |
Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Drug Administration Schedule; Female; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Taxoids; Treatment Outcome | 2000 |
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Coumarins; Cyclophosphamide; Drug Synergism; Endothelium, Vascular; Female; Fluorouracil; Growth Inhibitors; Humans; Isocoumarins; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2002 |
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Care Planning; Prospective Studies; Ultrasonography | 2001 |
Clinical experience of capecitabine in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2002 |
Severe interstitial pneumonitis associated with docetaxel administration.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Respiration, Artificial; Taxoids; Uterine Neoplasms | 2002 |
A systematic SAR study of C10 modified paclitaxel analogues using a combinatorial approach.
Topics: Animals; Breast Neoplasms; Chromatography, Thin Layer; Combinatorial Chemistry Techniques; Drug Resistance, Neoplasm; Fatty Acids; Humans; Hydrocarbons, Alicyclic; Hydrocarbons, Aromatic; Mass Spectrometry; Melanoma, Experimental; Mice; Nuclear Magnetic Resonance, Biomolecular; Paclitaxel; Solutions; Spectrometry, Mass, Fast Atom Bombardment; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
Massive cavitation of solid pulmonary metastatic lesions in a breast cancer patient: a case report.
Topics: Adult; Breast Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Lung; Lung Neoplasms; Paclitaxel; Taxoids | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Protocols; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Gene Expression; Genes, erbB-2; Humans; Middle Aged; Paclitaxel; Radiation-Sensitizing Agents; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2002 |
Combined modality radioimmunotherapy. Promise and peril.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Combined Modality Therapy; Disease Models, Animal; Female; Humans; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Mortality; Neoplasm Transplantation; Neoplasms, Experimental; Oligopeptides; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Radioimmunotherapy; Radiotherapy; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lacrimal Apparatus Diseases; Lacrimal Duct Obstruction; Middle Aged; Paclitaxel; Taxoids | 2002 |
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Paclitaxel; Taxoids | 2002 |
Clinical trials of new anticancer agents in recent years in China.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Clinical Trials as Topic; Colorectal Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Cytogenetic Analysis; Female; G2 Phase; Humans; Mitosis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Selection; Pilot Projects; Predictive Value of Tests; Preoperative Care; Prospective Studies; Time Factors; Treatment Outcome | 2000 |
Benefit of the addition of paclitaxel to standard chemotherapy with 5-fluorouracil/doxorubicin/cyclophosphamide in patients with operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Safety; Survival Rate | 2000 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Supercomputer-designed drug protects against chemotherapy toxicity.
Topics: Breast Neoplasms; Central Nervous System Diseases; Computer-Aided Design; Controlled Clinical Trials as Topic; Drug Design; Drug Interactions; Female; Humans; Mesna; Paclitaxel | 2000 |
Gastrointestinal pneumatosis after docetaxel chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Emphysema; Female; Humans; Middle Aged; Paclitaxel; Pneumatosis Cystoides Intestinalis; Stomach Diseases; Taxoids; Tomography, X-Ray Computed | 2002 |
Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Collagen; Cyclophosphamide; Docetaxel; Drug Screening Assays, Antitumor; Epirubicin; Female; Gels; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Taxoids | 2002 |
Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calcium-Binding Proteins; Cell Division; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Paclitaxel; Transfection; Tumor Cells, Cultured | 2002 |
Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Humans; Mastectomy, Radical; Paclitaxel; Radiotherapy Dosage | 2002 |
Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
[A case of effective paclitaxel therapy for adriamycin resistant metastatic breast cancer with brain metastases].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Radiation-Sensitizing Agents | 2002 |
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Chi-Square Distribution; Female; Genes, erbB-1; Humans; Immunohistochemistry; Neoplasm Metastasis; Paclitaxel; Predictive Value of Tests; Proliferating Cell Nuclear Antigen; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2002 |
Cardiotoxicity concerns prompt data review in breast cancer trial.
Topics: Advisory Committees; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Heart; Heart Diseases; Humans; Paclitaxel; Receptor, ErbB-2; Statistics as Topic; Trastuzumab | 2002 |
Gene expression profiling of epothilone A-resistant cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Epothilones; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Growth Substances; GTP Phosphohydrolases; HL-60 Cells; Humans; Interferons; Male; Microtubules; Neoplasm Proteins; Paclitaxel; Tumor Cells, Cultured | 2002 |
Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids; Treatment Failure; Treatment Outcome | 2002 |
Smoothing low-SNR molecular images via anisotropic median-diffusion.
Topics: Anisotropy; Breast Neoplasms; Computer Simulation; Humans; Image Enhancement; Models, Statistical; Paclitaxel; Phantoms, Imaging; Radiography; Reproducibility of Results; Sensitivity and Specificity; Spectrum Analysis, Raman; Stochastic Processes; Tissue Distribution | 2002 |
HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Immunoenzyme Techniques; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Up-Regulation | 2002 |
Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Caspase 9; Caspases; DNA Fragmentation; Enzyme Activation; Female; Humans; Ovarian Neoplasms; Paclitaxel; Transfection; Tumor Cells, Cultured | 2002 |
Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Clinical Trials as Topic; Dactinomycin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2002 |
[A case report of both CAF and docetaxel-resistant breast cancer responding to paclitaxel weekly therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids | 2002 |
[The antitumor activity of DPD inhibitory-fluoropyrimidine (DIF) and non-DIF alone or in combination with paclitaxel against orthotopically implanted human breast cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Floxuridine; Humans; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Oxidoreductases; Paclitaxel; Pyrimidines; Tegafur; Uracil | 2002 |
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast; Breast Neoplasms; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Cells, Cultured; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Fragmentation; Drug Resistance, Neoplasm; Female; Humans; In Situ Nick-End Labeling; Mitosis; Paclitaxel; Phosphorylation; Receptor, ErbB-2; Tumor Cells, Cultured; Tyrosine | 2002 |
PP1 phosphatase is involved in Bcl-2 dephosphorylation after prolonged mitotic arrest induced by paclitaxel.
Topics: Antineoplastic Agents; Breast Neoplasms; Cytosol; Enzyme Inhibitors; Female; Humans; Microcystins; Mitochondria; Mitosis; Paclitaxel; Peptides, Cyclic; Phosphoprotein Phosphatases; Phosphorylation; Precipitin Tests; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Sepharose; Tumor Cells, Cultured | 2002 |
Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Protein Isoforms; Tubulin; Tumor Cells, Cultured; Tyrosine | 2002 |
Acute transient encephalopathy after paclitaxel infusion: report of three cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Diseases; Breast Neoplasms; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Paclitaxel; Tomography, X-Ray Computed | 2002 |
[A case of liver metastasis of breast cancer successfully treated with paclitaxel infusion into the hepatic artery: an attempt of once weekly regimen].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Paclitaxel | 2002 |
G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells.
Topics: Breast Neoplasms; Colchicine; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Female; G1 Phase; G2 Phase; Humans; Microtubules; Nocodazole; Paclitaxel; Tumor Cells, Cultured; Vincristine | 2002 |
Clinical trials referral resource. Clinical trials with taxol.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1992 |
Selecting dose-intense drug combinations: metastatic breast cancer.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Leukocytes; Models, Biological; Neoplasm Metastasis; Organ Specificity; Paclitaxel | 1992 |
Taxol.
Topics: Adult; Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1992 |
Taxol improves outlook for lung, breast, and ovarian cancer.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel | 1992 |
Overview of new treatments for breast cancer.
Topics: Animals; Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Diseases; Breast Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Hormone Antagonists; Humans; Immunologic Factors; Paclitaxel; Pyrazoles; Pyrazolones; Survival Analysis; Vinblastine; Vinorelbine | 1992 |
National Cancer Institute making more taxol available for refractory ovarian, breast cancers.
Topics: Breast Neoplasms; Female; Humans; National Institutes of Health (U.S.); Ovarian Neoplasms; Paclitaxel; United States | 1992 |
Phase II studies: untreated breast cancer patients.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Paclitaxel | 1992 |
Taxol: twenty years later, the story unfolds.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1991 |
Anticancer activity and molecular mechanisms of α-conidendrin, a polyphenolic compound present in Taxus yunnanensis, on human breast cancer cell lines.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lignans; Taxus; Tetrahydronaphthalenes | 2020 |
Novel taxa-4(20),12-diene and 2(3→20)abeotaxane from needles of Taxus canadensis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Plant Extracts; Plant Leaves; Prostatic Neoplasms; Taxoids; Taxus; Treatment Failure; Uterine Cervical Neoplasms | 2011 |
Taxus baccata allergy in a breast cancer patient.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Immunologic; Drug Hypersensitivity; Female; Humans; Taxoids; Taxus | 2012 |
Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Flavanones; Flavonoids; Gene Expression Regulation, Neoplastic; HEK293 Cells; Herb-Drug Interactions; Humans; Humulus; Membrane Transport Proteins; Mitoxantrone; Neoplasm Proteins; Phytoestrogens; Propiophenones; Xanthones; Xenobiotics | 2014 |